Generated by All in One SEO Pro v5.0.1.1, this is an llms-full.txt file, used by LLMs to index the site.
# Zifo
When Science Meets Practical AI
## Pages
### [Home](https://zifo.com/)
**Published:** January 5, 2026
**Author:** Zifo_user
**Content:**
# When Science Meets
Practical AI
Zifo helps Science Leaders leverage Data, Technology Solutions, and Practical AI Services to turn ambitious goals into measurable business outcomes.
## Make Science + AI work for you
[ Connect With Us ](/contact-us-today/)
## Quantified Impact Across the Value Chain
By combining Scientific expertise and Informatics with Practical AI services, Zifo helps Scientific organizations move from data to decisive action, enabling measurable ROI across the value chain.
[ Click here ](#)
BioPharma Chemicals FMCG AgroTech Food & Bev
### DISCOVERY
Smarter AI-driven data integration for faster, reliable discovery
### PRODUCTIVITY
#### 2X
Increase in IND Candidates
### PRECLINICAL
Ethical benefits by deploying AI and reducing reliance on animal studies
### SPEED
#### 25%
Faster Candidate-to-IND Cycle Time
### CLINICAL
Faster recruitment, retention and data quality monitoring via AI
### EXECUTION
#### 85%
Adherence to Key Phase Milestones
### CMC
Accelerate Cycle Times with Connected CMC Data
### SPEED
#### 40%
AI-ready foundation
### OMICS
Harmonized multi-omics data improving target and biomarker validation
### ASSURANCE
#### 2X
Higher Confidence
### Manufacturing/ QC
Up to 25% cost savings from predictive process analytics and reduced deviations
### COMPLIANCE
#### 98%
On time Batch Release
### RESEARCH
Improved pipeline impact
### Conversion
#### >20%
Patent / Concept Conversion Rate
### DEVELOPMENT
Fuel growth and reinforce market differentiation
### Innovation
#### >25%
Revenue from New Products (RONP)
### MANUFACTURING
Lower cost and boost customer satisfaction
### Quality
#### >98%
First Pass Quality (FPQ) Rate
### RESEARCH
Turn consumer signals into winning propositions
### Insight
#### >60%
Consumer Insight-to-Concept Rate
### DEVELOPMENT
Preserve profitability and brand trust at scale
### Fidelity
#### >90%
Launch and Margin Fidelity
### MANUFACTURING
Protect consumer experience and reduce returns
### Consistency
#### >99.5%
End-of-Shelf-Life-Quality Adherence
### RESEARCH
Boost commercial pipeline and enterprise value
### Value
#### 2x
Net Present Value (NPV) Added to Commercial Pipeline annually
### DEVELOPMENT
Maximize returns on development spend
### ROI
#### 3x
Return on Every Dollar Spent in Development of New Products
### MANUFACTURING
Protect farmer outcomes and brand credibility
### Reliability
#### <0.5%
Field Failure Rate in the first year of launch
### RESEARCH
Capture trends before they peak
### Agility
#### 6-9
Months for Minor Product Extensions; <2 Years for New Product Lines
### DEVELOPMENT
Boost repeat purchase and reduce launch risk
### Adoption
#### >85%
Sensor Score Acceptance Rate
### MANUFACTURING
Cut waste and lift throughput
### Yield
#### >95%
First-Pass Yield
## Leading Partner for Enterprise Scientific Informatics
Wherever Science and technology are present, so is Zifo. We support a broad range of Science-driven companies with Strategic Business, Process & Data Consulting, and Specialist Scientific Informatics Services
### 1 in 3
Scientists
across Biopharma, Chemicals and FMCG industries enabled by Zifo
### 2,500+
#### Employees
### 13
#### Countries
### 30+
#### Nationalities
#### Since 2015
Specialist Scientific Informatics Services
### 20/25
#### Top Biopharma Companies
### 3/5
#### Top Chemicals Companies
### 4/6
#### Top FMCG Companies
are Zifo’s clients
### Rated 4.8/5
by end user Scientists vs. an industry average rating of 3.8
### 1 in 3Scientists
across Biopharma,
Chemicals and FMCG industries enabled by Zifo
### 2,500+
#### Employees
### 13
#### Countries
### 30+
#### Nationalities
#### Since 2015
### 18/20
#### Top Biopharma Companies
### 3/5
#### Top Chemicals Companies
### 4/6
#### Top FMCG Companies
are Zifo’s clients
### Rated 4.8/5
by end user Scientists
vs. an industry
average rating of 3.8
## Practical AI: Work with a Science-Led AI Partner
Scientific Organizations struggle to deliver real ROI from AI. Zifo’s **Practical AI framework** changes this by embedding AI into the fabric of science — whether you want to deploy a foundational model, make sense of mountains of data, or make automation and prompt engineering work for you, ensuring every initiative delivers tangible outcomes and lasting business value.
### Fragmented Knowledge
### Practical Ai3
### Science Knowledge Layer
### Fragmented Knowledge
Scattered Data
Sources
Manual Search
Effort
Redundant Work
Missed
Observations
### Practical Ai3
Now
Next
Future
### Science Knowledge Layer
Research &
Development
Clinical Trials
CMC
Omics
Manufacturing / QC
Research
Development
Manufacturing
Research
Development
Manufacturing
Research
Development
Manufacturing
Research
Development
Manufacturing
### Prompt Driven AI Outcomes
Faster, Improved
Answers
Harmonized
Target Biomarker
Confidence
Comprehensive Study
Data Traceability
Reliable
Transfers
Real-Time Quick
Release
Generative Molecular
Design
Virtual Formulation
Simulation
AI-Generated Quality
Insights
Trend Synthesis
Engine
Generative Recipe
Optimization
Dynamic Process
Narratives
Generative Crop
Modeling
Scenario-Based ROI
Forecasting
Predictive Reliability
Narratives
Flavor Concept
Generation
Synthetic Consumer
Testing
Generative Yield
Strategies
Return on
Investment
[ Contact Us ](/contact-us-today/)
[ Learn More ](/practical-ai-blueprints/)
## Read the Latest Edition of Zifo’s Curiosity Magazine!
[ Read Now ](/blogs/cmc-biopharmas-strait-of-hormuz/)
## Trusted by the Industry, Built for Science
Global Science leaders rely on Zifo to make their science come to life. Our Service Offerings and Solution Frameworks are validated in practice, ensuring compliance, scalability and measurable business impact
### Life Sciences
[ 
#### Large Pharma and Biotech
Integrated Excellence: Unifying R&D, Clinical, CMC, Manufacturing, and Quality
](/industries/pharmaceutical-informatics-and-consulting-services/) [ 
#### Small and Medium Biotech
Unlock novel therapies through better data integration and Practical AI Solutions
](/industries/biotech-informatics-and-consulting-services/) 
#### Diagnostic Laboratories
Improve test accuracy and turnaround time with AI-enabled automation
#### CROs
Win and retain sponsors by delivering faster, more reliable trial data with AI support
### Industries Powered by Science
[ 
#### AgroTech
Ensure Crop Success with Adaptable, High-Yield Strains
](/industries/agrotech-informatics-and-consulting-services/) [ 
#### Specialty Chemicals
Drive Product Margins via Resilient, Efficient Processes
](/industries/speciality-chemicals-informatics-and-consulting-services/) [ 
#### Fast-Moving Consumer Goods
Shorten Time-to-Revenue
with Regulated Efficiency
](/industries/fmcg-informatics-and-consulting-services/) 
#### Oil & Gas
Enhance safety, efficiency, and environmental compliance with AI-driven informatics
[ 
#### Food & Beverage
Drive Market Speed via
Verified Safety
](/industries/food-and-beverage-informatics-and-consulting-services/)
## Our Business is Our People
Zifo people are naturally curious and keen to make a difference in the world by helping to advance scientific discovery. We work hard to keep our people engaged and inspired, which is why we have one of the highest retention rates in our industry.
Together we can make a real difference
[ Our People ](/our-people/)
[ Join Team Zifo ](https://careers.zifo.com/)
Pointer Follower Ball Inside Div 
[ Our People ](/our-people/)
[ Join Team Zifo ](https://careers.zifo.com/)
---
### [Partners](https://zifo.com/partners/)
**Published:** October 29, 2025
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> Partners
# Our Partnerships
## As the scientific world has become increasingly specialised, Scientists need specific, hyper-specialised equipment, applications and services to support their work. Zifo has invested in building the world's largest scientific partner network to complement its deep knowledge of Science + Tech and decades of experience in connecting, integrating and enabling various Scientific technology platforms.
## Interested in partnering with Zifo?
[ Know More ](/contact-us-today)
## Our Partnerships and Experience
## Our expertise spans the whole spectrum of scientific informatics, and we're able to draw on a huge marketplace of partnerships and experience with scientific software & technology platform providers. So whatever is needed we'll provide an agnostic, unbiased, impartial and tailored approach to determining the best way forward for your situation.
All
AI & Semantics
Analytics & Search
Bioinformatics
Cheminformatics
Clinical Data Management
Data Infrastructure & Cloud
Data Integrity & QBD
Data Science
ELN Software
GxP Asset Management
Lab Efficiency & LIMS
Lab Instrument Data Management
MES & EBR
Pipelining & Orchestration
Product Lifecycle Management
Registration & Inventory
Robotics & Automation
SCADA & DCS
SDM with Chromatography Data Systems
Validation & Testing
Visualization
## AI & Semantics
Zifo provides vendor selection, configuration, integration, rollout, validation and managed services for many AI & Semantics platforms
- SciBite
- Smartlogic
- Nvidia
## Analytics & Search
Zifo provides vendor selection, configuration, integration, rollout, validation and managed services for many commercial and open-source analytics and search platforms
- Scieline
- Azure
- AWS
- Aveva
- Waters
- Scibite
- Chemaxon
- Ivention
- Chemotargets
- Scilligence
- Uncountable
- Optimistik
- Knime
- BSSN
- Entimo
- ACD Labs
- Smartlogic
- Fluxa
- QBD Vision
- Nvidia
- Synthace
- Starlims
- Certara
- Snowflake
- Genedata
- Eagle Genomics
- Labvantage
- BIOVIA
- Dotmatics
- Oracle
## Bioinformatics
Zifo provides vendor selection, pipeline development & configuration, integration, rollout, validation and managed services for many commercial and open source bioinformatics and omics analysis platforms
- TileDB
- Pure Starage
- Azure
- AWS
- Nextflow
- Biostrand
- Scilligence
- Genestack
- Knime
- CDD
- DNA Nexus
- Modul-Bio
- Nvidia
- Genedata
- Eagle Genomics
- Benchling
- L7 Informatics
- BIOVIA
- Sapio Sciences
- Revvity Signals
- Dotmatics
## Cheminformatics
The use of computational representations and techniques to support science is widespread. From the storage and search of chemical structures using chemical cartridges, and derivation of chemical properties through to more sophisticated structure modelling and simulation – there are many technologies and important science that is contained within the technologies that support this domain. Zifo provides vendor selection, configuration, integration, rollout, validation and managed services for many cheminformatics and modelling platforms.
- Azure
- AWS
- Scilligence
- Knime
- CDD
- ACD Labs
- Nvidia
- Genomics
- Benchling
- BIOVIA
- Sapio Sciences
- Revvity Signals
- Dotmatics
## Clinical Data Management
Zifo provides vendor selection, configuration, integration, rollout, validation and managed services for many Clinical Data Management platforms
- Entimo
- DNA Nexus
- Modul-Bio
- Certara
- Thermo Fisher
- Medidata
- Oracle
- CDISC
## Data Infrastructure & Cloud
Zifo provides vendor selection, configuration, integration, rollout, validation and managed services for many Data Infrastructure & Cloud platforms
- TileDB
- Pure Storage
- Azure
- AWS
- Biostrand
- Chemotargets
- Pega
- Uncountable
- Optimistik
- Genestack
- Snaplogic
- CDD
- ONQ Software
- Entimo
- ACD Labs
- DNA Nexus
- Smartlogic
- Fluxa
- Titan
- QBD Vision
- Modul-Bio
- Nvidia
- Sythace
- Starlims
- Certara
- Snowflake
- Agilab
- Genedata
- Eagle Genomics
- Thermo Fisher
- Labvantage
- Benchling
- L7 Informatics
- BIOVIA
- Sapio Sciences
- Revvity Signals
- Oracle
## Data Integrity & QBD
Zifo provides vendor selection, configuration, integration, rollout, validation and managed services for many Data Integrity & QBD platforms and approaches
- Fluxa
- QBD Vision
## Data Science
Zifo provides vendor selection, configuration, integration, rollout, validation and managed services for many commercial and open-source data science platforms
- Azure
- AWS
- Nextflow
- SciBite
- Uncountable
- Genestack
- Knime
- Snaplogic
- ACD Labs
- DNA Nexuc
- Smartlogic
- Fluxa
- QBD Vision
- Modul-Bio
- Nvidia
- Synthace
- Starlims
- Certara
- Snowflake
- Genedata
- Eagle Genomics
- Thermo Fisher
- Labvantage
- L7 Informatics
- BIOVIA
- Revvity Signals
## Electronic Lab Notebook (ELN) Software
Capturing all aspects of experiments in Electronic Laboratory Notebooks (ELNs) has become the norm in many laboratories. Zifo provides vendor selection, configuration, integration, rollout, validation and managed services support for ELNs, supported by strong partnerships with the majority of ELN providers.
- eLabNext
- LABII
- Scieline
- Chemaxon
- Ivention
- Scilligence
- Mestrelab
- Labguru - Biodata
- CDD
- ONQ Software
- Starlims
- Agilab
- Genedata
- Thermo Fisher
- Labvantage
- Benchling
- L7 Informatics
- BIOVIA
- Sapio Sciences
- Revvity Signals
- IDBS
- Dotmatics
- Alchemy Cloud
## GxP Asset Management
Managing inventory, commissioning, maintenance and entire lifecycle of physical assets (e.g. equipment, instruments, manufacturing machinery etc.) is a key requirement for manufacturing industries. The business application used for this is Enterprise Asset Management (EAM). For Life Sciences this is a key system because of its regulatory and GxP compliance.
Zifo provides vendor selection, configuration, integration, rollout, validation, and managed services for EAM systems. These services are supported by strategic partnership and experience with the industry leading EAM providers.
- Bluemountain
## Lab Efficiency & Laboratory Information Management Software (LIMS)
Tracking and managing the testing of samples in LIMS (Laboratory Information management Systems) and LES (Lab execution systems) is the norm in laboratories.
Setup, configuration, integration, validation and training are all required to effectively choose, use, and maintain LIMs & LES and associated laboratory environmental monitoring systems (metrology).
Zifo provides vendor selection, configuration, integration, rollout, validation and managed services for LIMS & LES and Metrology systems. These services are supported by strong and long-term partnerships and experience with the majority of LIMS, LES and metrology providers
- LABII
- Scieline
- Veeva
- Waters
- Ivention
- Scilligence
- Xybion
- Mestrelab
- Lab Operator
- CDD
- ONQ Software
- Starlims
- Agilab
- Genedata
- Thermo Fisher
- Labvantage
- Benchling
- L7 Informatics
- BIOVIA
- Sapio Sciences
- Revvity Signals
## Lab Instrument Data Management
Zifo provides vendor selection, configuration, integration, rollout, validation and managed services for many Lab Instrument Data Management platforms
- Scieline
- Aveva
- Honeywell
- Waters
- Ivention
- Xybion
- Mestrelab
- OSI PI - Aveva
- Genestack
- BSSN
- CDD
- ONQ Software
- ACD Labs
- Titan
- Modul-Bio
- Synthace
- Starlims
- Agilab
- Genedata
- Thermo Fisher
- Sapio Sciences
## MES & EBR
Manufacturing Execution Systems support the production environments of products through a combination of tracking, automation, process control, data management and reporting. Similarly, Electronic Batch Release leverages a similar set of approaches to ensure compliance and product specifications are met during the often complex product release processes. Zifo provides vendor selection, configuration, integration, rollout, validation and managed services for many MES & EBR platforms
- Thermo Fisher
- Labvantage
- L7 Informatics
## Pipelining & Orchestration
Zifo provides vendor selection, configuration, integration, rollout, validation and managed services for many data Science, Pipelining & Orchestration platforms
- Zontal
- Azure
- AWS
- Nextflow
- Chemotargets
- Pega
- Optimistik
- OSI PI - Aveva
- Knime
- BSSN
- Snaplogic
- DNA Nexus
- Smartlogic
- Fluxa
- QBD Vision
- Nvidia
- Synthace
- Snowflake
- Genedata
- Eagle Genomics
- L7 Informatics
- BIOVIA
- Revvity Signals
## Product Lifecycle Management
Zifo provides vendor selection, configuration, integration, rollout, validation and managed services for many Product Lifecycle Management platforms
## Registration & Inventory
Ensuring the tracking of all entities both physical and virtual is a core requirement for laboratories. Tracking of physical samples through processes allows association of test results and virtual registration allows tracking of IP and valuable knowledge. Reg systems need to be linked to inventory to track the physical location of any sample either at the laboratory or the corporate level – with many large systems incorporating robotics and automation to support the process. Zifo provides vendor selection, configuration, integration, rollout, validation and managed services for many registration, inventory and robotics platforms
- Chemaxon
- Ivention
- Scilligence
- Labguru - Biodata
- Lab Operator
- CDD
- ONQ Software
- Titian
- Modul-Bio
- Starlims
- Agilab
- Genedata
- Thermo Fisher
- Labvantage
- Benchling
- L7 Informatics
- BIOVIA
- Sapio Sciences
- Revvity Signals
- IDBS
## Robotics & Automation
Zifo provides vendor selection, configuration, integration, rollout, validation and managed services for many Robotics & Automation platforms.
- Automata
- Ivention
- Pega
- Xybion
- OSI PI - Aveva
- Lab Operator
- BSSN
- Snaplogic
- Titian
## SCADA & DCS
Supervisory Control and Data Acquisition (SCADA) and Distributed Control Systems (DCS) play critical roles in many process development, manufacturing and production environments. Zifo provides support across many SCADA and DCS platforms from setup and configurations, integration with instruments and sensors, to managed services and system validation and update.
- Aveva
- Honeywell
## Scientific Data Management with Chromatography Data Systems
Chromatography Data Systems (CDS) and Scientific Data Management Systems (SDMS) are an integral part of any analytical laboratory in development, manufacturing, and testing laboratories. Setup, configuration, integration, validation and regular qualification are required to ensure good accuracy and precision of test results. Zifo provides software and instrument commissioning, validation and support services in this area, supported by partnerships and experience with the majority of CDS and SDMS platforms.
- Honeywell
- Waters
- Starlims
- Thermo Fisher
- L7 Informatics
- Revvity Signals
- Dotmatics
## Validation & Testing
Zifo provides vendor selection, configuration, integration, rollout, validation and managed services for many regulatory guidelines & automated testing platforms
- Kneat
- Qualio
- Intelliqa
- Eggplant
## Visualization
Zifo provides vendor selection, configuration, integration, rollout, validation and managed services for many commercial and opensource visualisation and dashboarding platforms
- Chemaxon
- Scilligence
- OSI PI - Aveva
- Knime
- CDD
- Entimo
- ACD Labs
- DNA Nexus
- Fluxa
- Titian
- QBD Vision
- Modul-Bio
- Nvidia
- Synthace
- Certara
- Snowflake
- Genedata
- Eagle Genomics
- Labvantage
- L7 Informatics
- BIOVIA
- Revvity Signals
- Dotmatics
---
### [CMC Million Dollar Bottleneck Biopharma](https://zifo.com/cmc-million-dollar-bottleneck-biopharma/)
**Published:** July 27, 2026
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> CMC Million Dollar Bottleneck Biopharma
# CMC -- Biopharma’s billion-dollar bottleneck
## A strategic blueprint to reduce CMC cycle times by up to 40% and
build a scientist-centered operating model.
Discovery is accelerating and commercial manufacturing is scaling. Yet the pathway between them remains constrained by fragmented evidence, disconnected workflows, manual handoffs and technology that cannot carry scientific context from development to scale.
[ Download the Position Paper ](#access-positionpaper)
[ Join the Discussion ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjY5OTM3IiwidG9nZ2xlIjpmYWxzZX0%3D)
THE CMC CONSTRAINT
## The science has changed. The operating model has not.
Modern modalities generate levels of scientific, analytical and manufacturing complexity that legacy CMC environments were not designed to support. The result is not one isolated technology problem. It is a breakdown of continuity across data, decisions, samples, processes and teams.
INSIDE THE POSITION PAPER
## A diagnosis of the constraint and a blueprint for what comes next
The paper connects enterprise impact, scientific evidence,
workflow design, orchestration and technology transfer into one scientist-centered CMC operating model.
01
## Why CMC became the bottleneck
How complexity, organizational silos and fractured technology transfer created the rate-limiting constraint between discovery and launch.
02
## The enterprise cost of delay
How CMC friction affects commercialization timelines, scientific productivity, manufacturing readiness, patient access and lifetime asset value.
03
## Liberating trapped scientific evidence
How valuable information can be extracted, structured and reused from batch records, reports, PDFs and legacy test evidence.
04
## Rewiring DMTA
How Design, Make, Test and Analyze can evolve from a linear baton pass into a connected loop where context travels with every result and decision.
05
## Orchestrating the scientist experience
Why digital environments should adapt to scientific workflows instead of forcing scientists through rigid, application-defined paths.
06
## Making technology transfer continuous
How handoff by design can replace late-stage documentation exercises with persistent knowledge flows generated throughout development.
[ Explore the Position Paper ](#access-positionpaper)
THE FUTURE-STATE MODEL
## Six reinforcing moves for scientist-centered CMC
The model does not depend on a monolithic replacement
programme.
It prioritizes high-value evidence, targeted integrations, adaptive scientific workflows and rapid lighthouse implementations that can generate practical impact within existing brownfield environments.
From isolated systems to connected scientific context.
[ Access the Position Paper Blueprint ](#access-positionpaper)
EXECUTIVE INSIGHTS
## Four propositions that challenge the current CMC operating model
Each proposition reframes a familiar digital or operational problem as a breakdown in scientific continuity.
Talent
## Scientists are burdened with excessive manual data wrangling
The paper examines how manual cleanup, reconciliation and context reconstruction divert scientific capacity away from process understanding and optimization.
CONTEXT
## The problem is not simply that data is fragmented.
The deeper problem is that scientific context does not travel with the data across systems, functions and lifecycle stages.
WORKFLOW
## Digitizing a broken workflow does not create transformation.
It creates a faster version of the same constraint. Operating-model redesign must precede or accompany technology implementation.
HANDOFF
## Technology transfer should not begin at the point of handoff.
Knowledge, evidence and decisions should be captured continuously in forms that remain usable downstream.
PERSPECTIVE SHAPED IN PRACTICE
## A point of view built
across the science-
to-scale journey
Zifo works at the intersection of science, data, informatics and operations across research, development, CMC, manufacturing and quality.
This position paper reflects that cross-lifecycle perspective: where scientific context is lost, where evidence becomes trapped, where workflows fracture, and what it takes to reconnect decisions and execution from development through technology transfer.
[ About Zifo ](/about-zifo)
## 20 of 25
Leading global biopharma companies use
Zifo’s CMC services
## 2,500+
Employees supporting science-led organizations across 13 countries
## 190+
Science-focused organizations supported worldwide
READ THE POSITION PAPER
## CMC does not have to remain the bottleneck
Explore the operating-model, data and technology shifts required to create a faster, more connected and scientist-centered CMC value chain.
GET THE PAPER
## Access the Position Paper
Complete the form to receive the full paper via email
First name
Last name
Work email
Company
Job title
Acceptance I consent to receiving relevant communications from Zifo. I understand that I can unsubscribe at any time.
Download the Position Paper
Your details will be handled in accordance with Zifo’s [Privacy Policy](/privacy-policy/).
CONTINUE THE CONVERSATION
## Catalyst by Zifo
A curated practitioner community for senior leaders working across science, data,
informatics, AI and enterprise transformation.
[ Express Interest in Catalyst ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjY5OTM3IiwidG9nZ2xlIjpmYWxzZX0%3D)
FAQ
## About the
position paper
Who is this position paper intended for?
The paper is intended for senior leaders across CMC, pharmaceutical and process development, analytical development, MSAT, manufacturing, quality, regulatory, scientific informatics, data, AI and digital transformation.
Is the position paper free to access?
Yes. Complete the short form to access the full position paper.
What topics does the paper cover?
The paper examines the causes and enterprise impact of CMC bottlenecks and presents a scientist-centered future-state model covering scientific data continuity, DMTA transformation, orchestration, Scientific Language Models, technology transfer and hyper-agile execution.
---
### [Contact Us](https://zifo.com/contact-us-today/)
**Published:** December 19, 2025
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> Contact Us
# Contact Us
## Science-First. Always.
Please complete the form, and a member of our team will get in touch with you shortly to assist you further!
- Scalable global delivery model with local consulting across 13+ countries.
- Over 90% of the workforce holds a specialized scientific background.
- Powered by 2,500+ "Bilingual" Experts who speak Science and Tech.
Trusted by 25 out of 30 Top Companies across **Biopharma, Chemicals,** and **FMCG** Industries
Get in touch
First Name
Last Name
Email
Phone Number
Company
Designation
Enquiry Type
Enquiry Type Request for Zifo Services Product Partnership Job/Internship/Placement Enquiry Other
Message
Acceptance I consent to being contacted by an official Zifo representative
Submit
## Office Locations
## United States
## 500 Lake Cook Road,
Suite No.LL7,
Deerfield, IL 60015
[ Contact Now ](#form-scroll-cnr)
## United States
## 4000 Centregreen
Way
Suite 300
Cary, NC 27513
[ Contact Now ](#form-scroll-cnr)
## United States
## 245 Main St
3rd Floor
Cambridge, MA
02142
[ Contact Now ](#form-scroll-cnr)
## United Kingdom
## Office 7, 37-39,
Shakespeare Street,
Southport,
Merseyside,
PR8 5AB
[ Contact Now ](#form-scroll-cnr)
## France
## 24, rue René Boulanger,
75010 Paris,
France
[ Contact Now ](#form-scroll-cnr)
## Germany
## Tengstraße 27,
80798 Munich
Germany
[ Contact Now ](#form-scroll-cnr)
## Ireland
## C/O Crowley McCarthy,
West Cork Business Park,
Clonakilty,
Cork, Ireland
[ Contact Now ](#form-scroll-cnr)
## Singapore
## 10 Anson Road,
27-15 International,
Plaza,
Singapore 079903
[ Contact Now ](#form-scroll-cnr)
## Japan
## Humax Ebisu building,
7th floor,
Ebisu Minami 1-1-1,
Shibuya-Ku,
Tokyo 150-0022, +81 3 4405 4140
[ Contact Now ](#form-scroll-cnr)
## China
## Room 201, Building
A, NOVASIOT,
58 Xiangke Road.
Zhangjiang,
Shanghai 200120
[ Contact Now ](#form-scroll-cnr)
## Switzerland
## St Alban-Anlage 66,
4052 Basel,
Switzerland
[ Contact Now ](#form-scroll-cnr)
## Canada
## Suite 302,
7111 Syntex Drive,
Mississauga,
Ontario L5N 8C3.
[ Contact Now ](#form-scroll-cnr)
## India
## 6th Floor, Block 2,
DLF IT Park, 1/124,
Mount Poonamallee Road, Porur, Tamil Nadu,
India, 600089
[ Contact Now ](#form-scroll-cnr)
## Spain
## Carrer Ciutat de Granada 150,
3 Planta,
Barcelona, 08018
[ Contact Now ](#form-scroll-cnr)
## Mexico
## Paseo de la Reforma 296, Piso 39
Colonia Juarez, Cuauhtemoc,
CDMX, C.P. 06600
Mexico
[ Contact Now ](#form-scroll-cnr)
---
### [Curiosity](https://zifo.com/curiosity/)
**Published:** February 3, 2026
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> Curiosity
August 2026
## [CMC:
Biopharma's
Strait of Hormuz](/blogs/cmc-biopharmas-strait-of-hormuz/)
[ Read More ](/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](/blogs/cmc-biopharmas-strait-of-hormuz/)
[Edition 14 – JULY 2026](/blogs/beyond-the-rigidity-how-abbvies-platform-adapt-to-cmc-science/)
[  ](/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[Edition 13 – JULY 2026](/blogs/beyond-the-rigidity-how-abbvies-platform-adapt-to-cmc-science/)
[  ](/blogs/the-first-mile-of-lab-data-operationalizing-data-flow-in-heterogeneous-research-environments/)
[Edition 12 – JUNE 2026](/blogs/beyond-the-rigidity-how-abbvies-platform-adapt-to-cmc-science/)
[  ](/blogs/beyond-the-rigidity-how-abbvies-platform-adapt-to-cmc-science/)
[Edition 11 – JUNE 2026](/blogs/interview-stop-treating-lims-like-an-it-project-because-master-data-demands-science/)
[  ](/blogs/bilingual-scientists-faster-cures/)
[Edition 10 – MAY 2026](/blogs/interview-stop-treating-lims-like-an-it-project-because-master-data-demands-science/)
[  ](/blogs/interview-stop-treating-lims-like-an-it-project-because-master-data-demands-science/)
[Edition 09 – DECEMBER 2025](/blogs/2025-perspectives-in-ai-data-and-science/)
[  ](/blogs/2025-perspectives-in-ai-data-and-science/)
[Edition 08 – NOVEMBER 2025](/blogs/interview-ai-not-yet-a-miracle-worker-but-a-powerful-scientific-prompt-responder/)
[  ](/blogs/interview-ai-not-yet-a-miracle-worker-but-a-powerful-scientific-prompt-responder/)
[Edition 07 – SEPTEMBER 2025](/blogs/finding-our-google-maps-moment-in-translational-genomics/)
[  ](/blogs/finding-our-google-maps-moment-in-translational-genomics/)
[Edition 06 – SEPTEMBER 2025](/blogs/interview-tackling-ai-anxiety-and-technology-obsolescence-to-drive-better-science/)
[  ](/blogs/interview-tackling-ai-anxiety-and-technology-obsolescence-to-drive-better-science/)
[Edition 05 – AUGUST 2025](/blogs/interview-ai-by-itself-isnt-going-to-magically-deliver-a-drug-today/)
[  ](/blogs/interview-ai-by-itself-isnt-going-to-magically-deliver-a-drug-today/)
[Edition 04 – JULY 2025](/events/siee-2025on-demand-basel/)
[  ](/events/siee-2025on-demand-basel/)
[Edition 03 – JULY 2025](/blogs/a-strategic-guide-to-consolidation-in-scientific-informatics/)
[  ](/blogs/a-strategic-guide-to-consolidation-in-scientific-informatics/)
[Edition 02 – JUNE 2025](/blogs/beyond-the-hype-biopharmas-tech-transfer-process-needs-a-fundamental-reset/)
[  ](/blogs/beyond-the-hype-biopharmas-tech-transfer-process-needs-a-fundamental-reset/)
[Edition 01 – MAY 2025](/blogs/early-days-for-ai-but-scientific-data-management-gains-momentum/)
[  ](/blogs/early-days-for-ai-but-scientific-data-management-gains-momentum/)
---
### [Trainings & Workshops](https://zifo.com/chromatography-data-systems-and-solutions/trainings-workshops/)
**Published:** February 2, 2026
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> Trainings & Workshops
# Suitable trainings and individual
workshops for everyone.
# Trainings & Workshops
No two laboratories are alike.
We train Empower users individually
Every laboratory has its processes, objectives, challenges – and thus very individual training needs. As a leading provider of classroom training for Empower users in German-speaking countries, zifo responds to this with specific training plans that optimally fit the requirements profile of your laboratory. We offer all our Empower training modules in German and English in Germany and abroad.
Our training offers the optimal shoulder-to-shoulder connection between theory and practice. They are suitable for beginners as well as for system administrators. Our training spectrum ranges from beginner topics to special topics such as diode array options.
### EMPOWER® 3 INDIVIDUAL
For this training, we will put together a training plan that is tailored to your specific requirements. For example, would you like
[ Learn more here ](/chromatography-data-systems-and-solutions/trainings-workshops/empower3_individual/)
### EMPOWER® 3 DIODE ARRAY OPTION
This course gives you knowledge about the use of diode array detectors from Waters or Agilent. In practical exercises, you will learn the possibilities
[ Learn more here ](/chromatography-data-systems-and-solutions/trainings-workshops/empower3-diode-array-option/)
### EMPOWER® 3 REPORTING
In this training, you will learn the basics of report design and receive tips on layout and design using examples.
[ Learn more here ](/chromatography-data-systems-and-solutions/trainings-workshops/empower3-reporting/)
### EMPOWER® 3 CUSTOM FIELDS
This training is about custom fields, i.e. database fields that can be created by the user to implement user-defined calculations
[ Learn more here ](/chromatography-data-systems-and-solutions/trainings-workshops/empower3-custom-fields/)
### EMPOWER® 3 PROCESSING
In this training you will learn to use the possibilities that are in Empower: organizing samples in sample sets.
[ Learn more here ](/chromatography-data-systems-and-solutions/trainings-workshops/empower3-advanced-processing/)
### EMPOWER® 3 BASICS
In this two-day training course, you will learn the basics of operating Waters Empower 3. Using practical examples and under
[ Learn more here ](/chromatography-data-systems-and-solutions/trainings-workshops/empower3-basic/)
# Standard, Customized, Workshop.
You get what you need.
With our **standard training courses** ranging from **beginner training to intermediate and advanced training** to **special training,** we offer everything you need to enable your employees to make full use of the possibilities offered by laboratory data systems. Our training concepts are based on the many years of experience of our trainers, as well as the wishes of our customers and their own laboratory practice. This enables the trainers to impart knowledge from the user’s perspective.
If you would like to have your own SOPs or workflows mapped in training or work with your laboratory instruments, this is possible at any time within the scope of our **Customized Training.**
A **workshop** offers you an even higher level of knowledge transfer. Here, we work with a small group of your employees to develop a solution for an exemplary, customer-specific task. The aim is to enable your employees to solve similar tasks independently. We would be happy to create a customized concept for you. The basis for this offer is always a prior discussion about the level of knowledge of the participants and the individual goals of the workshop.
**Ask us. We will be happy to work with you to create a training concept tailored to your company.**
[ Request Training ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjQ3NjE5IiwidG9nZ2xlIjpmYWxzZX0%3D)
### NO TWO WORKOUTS ARE LIKE THE OTHER. THE ONLY THING THAT REMAINS CONSTANT IS OUR QUALITY.
Training takes place at different levels. For beginner’s training, you need a trainer who limits himself to the essentials and does not overload the participants with too much knowledge. For more advanced training, the trainer must not only understand the software but also how the user uses it. Industry experience is a must here!
After all, if you want to give your top employees a leg up in their area of expertise, the trainer must also be a top trainer.
We have divided our training and workshops into Basic, Advanced, Expert, and Specialized so that you always get the right trainer.
### ARE WE GOING TO YOU OR US? WE MEET, WHERE YOU WANT.
You don’t want to spend travel time for your employees? Then simply bring our trainer to your premises. You provide the room, the necessary hardware, and software, a projector – and you’re ready to go. If you don’t have the necessary technology, we’ll be happy to bring it along.
Do your employees work at different locations, or is there no room available? No problem! Then simply send your employees to us. Here they will get everything they need. And there’s something to drink and a little refreshment to keep them going, too.
Do you want to train your employees at the same level at different locations worldwide? Contact us: Our trainers are willing to travel. In many cases, it is possible to train your team on site.
### ONE-ON-ONE OR AUDITORIUM? THE CRITICAL MASS IS WHAT COUNTS.
It is important to us that your employees get something across. This works best if the group of participants is not too large and the participants have comparable experience with the application. Therefore, we recommend a maximum number of participants and reasonable prerequisites for all events. For workshops, we always agree on a maximum number of participants. After all, you should get the best value for your money.
Can’t you get enough participants together to make the training worthwhile for you? Just contact us – maybe we can find a solution together.
### INFORMATION TO TAKE AWAY.
For many pieces of training, we have accompanying material that we give to your participants. Participants also receive a discount when ordering our Empower 3 manual or our practical guide on the topic of custom fields in Empower 3. And otherwise, of course, taking notes is always allowed.
Our training brochure as a scrollable PDF:
Training and Workshop
# Your trainers
To ensure intensive learning and practical training, our experienced trainers teach GxP-compliant handling of the software in connection with HPLC or GC in didactically well-prepared learning units.
We will be happy to advise you in determining your training needs! Please contact us here.
## Arno Simon
is founder and managing director of zifo GmbH. As a consultant, trainer, and technical book author, he has been intensively involved with the Waters Empower laboratory data system for many years. He is a training partner of well-known pharmaceutical companies in Germany and abroad, where he has been training users and administrators in operation and configuration of Empower for many years. He supports customers in implementing and updating large Empower installations, including developing concepts and preparing validations. Until 1997, he worked as an employee of Waters GmbH in the areas of service, support, and sales.
## Matthias Gräser
was employed for more than five years in a pharmaceutical GxP laboratory in the area of analytical development with a focus on optimization and validation of chromatographic analytical methods. In addition to his main activities in liquid and gas chromatography, he also gained experience in spectroscopy and titration. During this time, he first used the Empower software as a user and then supported it as an administrator. Since 2017, he has been working for zifo as an administrator of a global Empower installation in the European region, in the Empower helpdesk, for the creation of customer-specific custom fields and report methods, and as a trainer for custom fields and reports.
## Fan Qiu
is a passionate Empower trainer with a lot of experience from everyday laboratory life, which she owes to her years of working as a laboratory technician in quality control. She is familiar with processes in the regulated pharmaceutical environment and supports international customers in Empower implementations. Especially with her Chinese language skills, she supports our Chinese customers in using the Empower software.
## Ralf Persuhn
has over 25 years of experience in pharmaceutical analytics and is well versed in chromatography and spectroscopy, among other things. He is familiar with the specific quality standards in the pharmaceutical laboratory and has extensive GxP knowledge. He started to support chromatographic data systems (CDS) as early as 1995 and participated in a wide variety of international projects for the selection, implementation, and validation of laboratory data systems. Eventually, he was the administrator of a global Empower installation with over 350 users at six sites. At zifo, he has been providing a helpdesk as well as customizations and training for Empower since 2011.
Get in touch
First Name
Last Name
Email
Phone Number
Company
Designation
Enquiry Type
Enquiry Type Request for Zifo Services Product Partnership Job/Internship/Placement Enquiry Other
Message
Acceptance I consent to being contacted by an official Zifo representative
Submit
---
### [Join Discussion Thank You](https://zifo.com/join-discussion-thank-you/)
**Published:** July 28, 2026
**Author:** Zifo_user
**Content:**
## Thank you for expressing your interest
Your expression of interest in Catalyst by Zifo has been received.
Catalyst is currently in beta and is being developed as a curated community for practitioners, scientists and senior leaders to discuss how data, informatics, technology and AI are reshaping science. The Zifo team will review your submission as we continue to shape the beta community and its initial practitioner cohort.
---
### [CMC Thank You](https://zifo.com/cmc-thank-you/)
**Published:** July 28, 2026
**Author:** Zifo_user
**Content:**
## Thank you. Your position paper is on its way.
We have emailed you a copy of The Billion-Dollar Bottleneck: Why CMC Is Strangling the Biopharma Pipeline as a PDF attachment.
**Did not receive the email?**
Some corporate email systems may block messages containing attachments. Check your spam, junk or quarantine folder first. If you still cannot locate the email, contact us at and request a digital copy of the position paper.
---
### [Leadership Team](https://zifo.com/leadership-team/)
**Published:** January 28, 2026
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> Leadership Team
# Leadership Team
Zifo’s global leadership positions the convergence of science, technology, data, and AI as a strategic enabler across the scientific value chain.
Hub Americas EMEA APAC Scientific Leadership Delivery Leadership
---
### [Practical AI Blueprints](https://zifo.com/practical-ai-blueprints/)
**Published:** January 10, 2026
**Author:** Zifo_user
**Content:**
Zifo AiDEATE
# Practical AI Blueprints
at the Intersection of Science
Driving real-world ROI through strategic AI adoption.
[ View Blueprints ](#blueprint-archive-container)
[ Contact Us ](/contact-us-today)
## The Agentic Science Value Chain
Autonomous agents driving value from Discovery to Manufacturing. Zifo can enable AI agents
across the value chain – below diagram is an indicator of what’s possible.
[ Click here ](#)
BioPharma Chemicals FMCG AgroTech Food & Bev
### DISCOVERY
Target Scouts mining omics
molecular data,
### Preclinical
Lab Auto-Pilots driving
Design-Make-Test cycles.
### CLINICAL
Sentinels monitoring safety
signals in real-time.
### CMC
Process Architects
optimizing synthesis routes.
### Omics
Bio-Code Readers decoding
complex biomarkers.
### Manufacturing / QC
Guardians automating
batch release validation.
### Research
Structure Scouts mining chemical space and property databases
### Development
Formulation Architects mining experimental records and process parameters.
### Manufacturing / QC
Process Sentinels mining real-time sensor streams and LIMS data.
### Research
Consumer Scouts mining social sentiment, market gaps, and ingredient trends.
### Development
Formula Architects mining stability data, sensory profiles, and packaging constraints.
### Manufacturing / QC
Batch Sentinels mining inline vision systems, sensor logs, and compliance records.
### Research
Trait Scouts mining genomic, phenotypic, and multi-omics data.
### Development
Cultivar Architects mining micro-climate trials, soil health, and yield data.
### Manufacturing / QC
Yield Sentinels mining satellite imagery, IoT sensor streams, and harvest logs.
### Research
Flavor Scouts mining sensory data, ingredient synergy, and consumer palates.
### Development
Recipe Architects mining nutritional targets, shelf-life kinetics, and cost-benefit ratios.
### Manufacturing / QC
Purity Sentinels mining inline contamination sensors, thermal logs, and batch consistency.
## The Industry Challenge
### Life Sciences companies are under pressure. The need to evolve is urgent.
#### Unlock Efficiency
70% of companies report the accessing scientific data for AI initiatives is difficult today. We break those silos
#### Navigate Data Deluge
AI provides essential tools to extract actionable intelligence and drive decision-making across the enterprise.
#### Drive Innovation
35% of companies say AI is not just about automation; it’s a powerful catalyst for scientific innovation.
## The Practical AI³ Framework
### A strategic approach designed for effective AI adoption.
#### Practical AI Now
Immediate value through our Hub of 100+
pre-built "Blueprints" focused on real- world ROI.
#### Practical AI Next
Client customized AI process maps for
incremental improvements leading to compounding benefits.
#### Practical AI Future
Setting the stage for long-term strategic
competitive advantage through deep AI integration.
## Blueprint Archive
### Select your area of interest to filter the blueprints.
All Blueprints Discovery Preclinical Clinical CMC Omics Manufacturing and Quality Data
## Completed
COMPLETED
DISCOVERY / OMICS
### AI Based Antibody Design
Accelerating Antibody Design with Zifo’s AI-powered Protein Language Models.
Click to Know More 
COMPLETED
DISCOVERY / LAB
### Scientist Voice Agent
Redefine Scientist Experience through AI Guided, Voice Based Contemporaneous Data Capture Agent.
Click to Know More 
COMPLETED
R&D
### Project Workbench
Chat interface with capabilities like web search, deep research and information retrieval.
Click to Know More 
COMPLETED
DATA
### Data Curation
Extraction from FDA labels and enrichment from DrugBank, ChEMBL, UniProt, etc.
Click to Know More 
COMPLETED
LIMS
### Agentic LIMS DevOps
Natural language business requirement analysis to generate configuration guides.
Click to Know More 
COMPLETED
LAB OPS
### LCS OS Upgrade
AI-powered compatibility analysis for seamless OS upgrades in lab environments.
Click to Know More 
COMPLETED
QUALITY / PRECLINICAL
### Assay Review Cycle Time
Zifo’s AI Solution speeds up deviation detection, ensures compliance, and validates hypotheses.
Click to Know More 
COMPLETED
CLINICAL / CMC
### No-Code AI Dashboard
Zifo’s AI-driven Conversational Interface to Visualize and Analyze Data for Instant Insights.
Click to Know More 
COMPLETED
REGULATORY
### Document Authoring
Infusing AI into creating CSRs and Investigator Brochures cuts first-draft timelines from days to hours.
Click to Know More 
COMPLETED
CLINICAL
### USDM Design
Transforming all study protocols into living, machine-actionable assets mapped to USDM.
Click to Know More 
COMPLETED
CLINICAL DATA
### BC Creation
Standardize, map, and create reusable Biomedical Concepts (BC) assets using AI/LLM.
Click to Know More 
COMPLETED
CLINICAL
### Clinical Data Lineage
Extracts and maps BCs across protocols, CRFs, and SDTM for semantic consistency.
Click to Know More 
COMPLETED
CLINICAL
### SDTM Automation
Leverages Agentic AI to reduce workload by Generating SDTM conversion R Programs.
Click to Know More 
COMPLETED
CMC
### Data Migration
AI-enabled data migration solution automates complex tasks while ensuring validated data transfer.
Click to Know More 
COMPLETED
DATA / OMICS
### Ontology Assistant
Reuses information from public ontologies to create a use-case specific ontology.
Click to Know More 
COMPLETED
VALIDATION
### Computer System Validation
AI-driven validation streamlines processes, boosts accuracy, and delivers upto 75%-time savings.
Click to Know More 
COMPLETED
MANUFACTURING
### CoA Automation
AI Solution to validate CoA data, Maintain Compliance and Accelerate Quality processes.
Click to Know More 
COMPLETED
COMPLIANCE
### 21 CFR Part 11 Solution
Transforms weeks of manual expert review into hours of analysis using AI.
Click to Know More 
COMPLETED
MANUFACTURING
### EHS Policy Update Engine
Proactively recommends updates to organizational EHS policies to align with regulations.
Click to Know More 
COMPLETED
SUPPORT
### Support Framework
AI-powered unified console for smart issue analysis and guided troubleshooting.
Click to Know More 
COMPLETED
QUALITY
### QC Harmonization
Compares multiple Test method execution variants to support harmonized & streamlined method creation in LIMS/LES.
Click to Know More 
COMPLETED
QUALITY
### Streamline Audit Trail Review
Automatically generating checklists and parsing audit logs can streamline and accelerate the audit trail process.
Click to Know More 
COMPLETED
QUALITY
### SOP Alignment
AI-driven compliance assistant that compares SOPs with FDA 483 findings and flags gaps.
Click to Know More 
COMPLETED
TRAINING
### Document Creation
Uses AI to analyze video content and generate structured, readable user manuals in minutes.
Click to Know More 
COMPLETED
QUALITY
### GxP User Management
Automates training validation, approval workflows, and escalations.
Click to Know More 
COMPLETED
DATA
### Ontology Assistant (AI)
Create scalable, interoperable ontologies using Zifo’s AI-enabled Ontology Assistant.
Click to Know More 
COMPLETED
QUALITY
### SOP Update Assistant
Identifies procedural gaps in current SOPs to recommend updates.
Click to Know More 
COMPLETED
DATA
### Database Summarization
Natural language-driven database summarization that transforms user questions into precise queries and delivers structured, context-aware insights.
Click to Know More 
COMPLETED
DATA
### Data Modelling Assistant
An engine to speed up data model creation for a specified use case.
Click to Know More 
COMPLETED
MANUFACTURING AND QUALITY
### Method Harmonization for QC Test
AI augmented QC Test Method Harmonization solution to accelerate enterprise-wide QC digitization initiatives.
Click to Know More 
COMPLETED
IT AND LAB COMPUTING SUPPORT, DISCOVERY, MANUFACTURING AND QC
### Lab Compute Automation
AI-powered software compatibility analysis to enable faster and reliable OS migration decisions.
Click to Know More 
COMPLETED
DISCOVERY / PRECLINICAL / DATA
### Experiment Insight Generation
This AI tool accelerates scientific analysis by automatically synthesizing experiment conclusions recorded by scientists into actionable insights.
Click to Know More 
COMPLETED
DATA / MANUFACTURING AND QUALITY
### AI Assisted Vendor Evaluation
This framework accelerates the shortlisting of laboratory system vendors by using AI to process vast amounts of workshop requirement data into quick, data-driven recommendations.
Click to Know More 
COMPLETED
MANUFACTURING AND QUALITY / CMC / CLINICAL
### SOP2Flow Generation
This solution significantly speeds up business process management by automatically converting text-based Standard Operating Procedures directly into actionable workflows.
Click to Know More 
COMPLETED
DATA / MANUFACTURING AND QUALITY
### Master Data Verification Support
This AI-driven tool streamlines data validation by generating comprehensive reports from master data spreadsheets, thereby reducing manual review efforts for creators and reviewers.
Click to Know More 
COMPLETED
DATA ORCHESTRATION PIPELINE: DATA / DISCOVERY / PRECLINICAL
### Symphor
Data Orchestration Pipeline: Symphor transforms lab operations by providing a unified, event-driven orchestration layer that connects all systems and enables seamless, hands-free, voice-guided workflows.
Click to Know More 
COMPLETED
CMC / MANUFACTURING AND QUALITY / PRECLINICAL
### DoE Assistant
This AI-powered assistant manages the entire Design of Experiments lifecycle for upstream bioprocessing, from initial literature searches and design space identification to execution and final analysis.
Click to Know More 
## In Progress
IN PROGRESS
COMMERCIAL
### Portfolio Support Engine
Decision support engine powered by patent expiry info and market research.
Click to Know More 
IN PROGRESS
CLINICAL
### Margin Analysis
Extracts information to compute equivalence or non-inferiority margins for study design.
Click to Know More 
IN PROGRESS
CLINICAL
### Edit Check Automation
Automated generation of JavaScript codes aligned with Viedoc 4 EDC standards.
Click to Know More 
IN PROGRESS
CMC
### ROS Scorecard
Ranking of Synthesis routes for Drug Substances based on customizable business logic.
Click to Know More 
IN PROGRESS
QUALITY
### Empower Peak Integration
AI assisted chromatographic peak integration resulting in faster processing.
Click to Know More 
IN PROGRESS
DATA
### System Profiler
This autonomous agent scans and maps your entire system landscape to deliver a comprehensive summary of schemas, relationships, configurations, and data quality.
Click to Know More 
IN PROGRESS
MANUFACTURING AND QUALITY / CLINICAL / CMC
### Regulatory Alerts
This autonomous workflow monitors major regulatory agency websites for critical updates and proactively alerts compliance teams to ensure timely procedural adaptations.
Click to Know More 
IN PROGRESS
DISCOVERY / DATA / OMICS
### Automated Template updates for schema changes - Benchling
This automated agent eliminates manual data entry by instantly revising relevant Benchling templates whenever underlying database schemas change, and generates a summary report of the updates.
Click to Know More 
IN PROGRESS
DISCOVERY / CMC
### Chembot
Chembot is an intelligent assistant that digitizes domain knowledge by interpreting molecular structures and performing complex chemical reasoning with expert-level proficiency.
Click to Know More 
Loading blueprints...
## Got an AI idea? Let’s Collaborate!
[ Submit idea ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjUyNTI5IiwidG9nZ2xlIjpmYWxzZX0%3D)
FAQ
## Curious how Zifo’s Practical AI Blueprints drive real-world ROI?
See how Zifo supports enable AI agents across the value chain — discovery to manufacturing.
[ Talk to an Expert ](https://zifo.com/practical-ai-blueprints/#contacts-form)
What are Zifo Practical AI Blueprints?
Zifo Practical AI Blueprints are structured frameworks that help life sciences organizations apply artificial intelligence to real scientific and operational challenges. These blueprints provide practical use cases and implementation approaches that demonstrate how AI can deliver measurable value in areas such as research, laboratory operations, and data analysis.
What is Zifo AiDEATE and how does it support Practical AI Blueprints?
Zifo AiDEATE is the platform behind Zifo’s Practical AI Blueprints initiative. It is designed to help science-focused organizations adopt AI effectively by providing practical implementation models and real-world solutions that can be applied across research, development, and manufacturing environments.
How does Zifo’s Practical AI³ framework support AI adoption?
Zifo’s Practical AI³ framework focuses on three stages of AI adoption: delivering immediate value through ready-to-use AI blueprints, enabling incremental improvements through customized AI processes, and building long-term strategic advantages through advanced AI capabilities. This staged approach helps organizations adopt AI in a practical and scalable way.
What types of AI solutions are included in Zifo Practical AI Blueprints?
Zifo Practical AI Blueprints cover a range of real-world applications, including AI-driven antibody design, AI-based conversational agents for scientists, automation of computer system validation processes, and AI tools that help reduce assay review cycle time in laboratory environments.
How do Zifo AI Blueprints help scientists and research teams?
Zifo AI Blueprints help scientists access and analyze large volumes of scientific data more efficiently. By integrating AI tools into research workflows, these blueprints enable faster data analysis, automated documentation, improved compliance monitoring, and better decision-making across scientific teams.
What new AI initiatives are Zifo currently developing?
Zifo continues to develop new AI Blueprints that address emerging scientific challenges. Examples include conversational dashboards that allow users to analyze data using natural language queries and AI solutions designed to automate certificate-of-analysis validation and quality processes.
How can organizations collaborate with Zifo on new AI ideas?
Organizations can collaborate with Zifo by submitting ideas for new AI use cases through the Practical AI Blueprints platform. Zifo works with partners to develop and implement AI solutions that address specific scientific or operational challenges in industries such as pharmaceuticals, biotechnology, and chemicals.
Get in touch
First Name
Last Name
Email
Phone Number
Company
Designation
Enquiry Type
Enquiry Type Request for Zifo Services Product Partnership Job/Internship/Placement Enquiry Other
Message
Acceptance I consent to being contacted by an official Zifo representative
Submit
---
### [CSR](https://zifo.com/csr/)
**Published:** January 27, 2026
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> CSR
# Corporate Social Responsibility
Zi-Foundation
For Zifo, Corporate Social Responsibility is not a social imperative. It has come to mean a way of giving back to society, adding value to the co-existence of our business and economic, social and environmental growth.
While charity, sponsorships or philanthropy contribute to growth, Zi-Foundation focuses on sustainable empowerment, striving for an aware and knowledgeable society that can recognize issues and demand for change.
CSR Committee members
- Raj Prakash G
- Vanchinathan S
CSR Budget Allocation for Financial Year 2025–26
CSR Project Thrust AreaExecution ModeBudget AllocationImpact AssessmentEducationDirect and / or Through Implementation Agencies98%As per CSR RulesMedical CareDirect and / or Through Implementation Agencies2%As per CSR Rules
---
### [Zifo Ikikata For Customers](https://zifo.com/zifo-ikikata-for-customers/)
**Published:** January 20, 2026
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> Zifo Ikikata For Customers
# Zifo Ikikata For Customers
---
### [Privacy Policy](https://zifo.com/privacy-policy/)
**Published:** April 4, 2025
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> Privacy Policy
# Privacy Policy
Zifo Technologies Private Limited respects your privacy and this privacy statement has been created to demonstrate our firm commitment to protect it. We understand that your privacy and your document security on the Internet are extremely important, and we handle your information with care and transparency.
If you believe our privacy policy has been violated or have any concerns, please send an email to or .
In general, using our site as a visitor may be considered anonymous. We do not engage in any activity that personally identifies visitors unless you voluntarily provide information through a contact form or communication with us.
We may collect limited technical information such as your IP address, browser type, operating system, referring URLs, and pages visited. This information helps us diagnose problems with our server, administer our website ([www.zifo.com](https://www.zifo.com/)), and identify the most used features so that we can improve the site. Your IP address may also be used to gather broad demographic information, but we do not link this to anything personally identifiable.
Information that you provide directly through forms or inquiries, such as your name, email address, company, or phone number, is used only to respond to your request or to improve our communication and services. Information collected through our website is stored on secure systems managed by us or our hosting partners, and access is limited to authorized personnel who need it for operational purposes.
We may share limited information with trusted service providers, such as hosting or analytics partners, who assist in the operation of our website under confidentiality obligations. We may also disclose information when required by law or to comply with legal processes. We do not sell or rent personal information, and we do not disclose it to third parties for marketing purposes.
Our website and services are not directed to children under 13 years of age, and we do not knowingly collect personal information from them. If we become aware that such information has been collected, we will delete it promptly.
## Links
This website contains links to other websites. Zifo Technologies is not responsible for the privacy practices or the contents of such websites, nor do we take any responsibility for the opinions of third parties expressed on or through our website.
## Correcting / Updating / Deleting / Deactivating Personal Information
If a user’s personally identifiable information changes (such as zip code, phone, email or postal address), or if a user no longer desires our service, we provide a way to access, correct, update or delete/deactivate users’ personally identifiable information. This can also be done by sending an email to . We will review and respond in accordance with applicable data protection requirements. Some information may need to be retained for legal or operational purposes.
## Compliance with Privacy and Communications Laws
We handle all personal and electronic communications data in accordance with applicable privacy, data protection, and communications laws in the regions where our website is accessed. We do not monitor or intercept communications except as permitted by law and only for the purpose of providing or improving our services.
## Cookies and Preferences
Our website uses cookies to understand how visitors use our site and to improve performance and functionality. Cookie preferences are managed through the Privacy Preference Center, which appears when you visit our website. You can review and change your cookie settings at any time.
We use:
**Strictly Necessary Cookies** that enable basic site functions and cannot be turned off.
**Performance Cookies** that measure visits and traffic sources to help us improve the site.
**Targeting Cookies** that may be set by our advertising partners to provide relevant content on other sites.
Performance cookies, and targeting cookies are activated only after you have provided consent through the Privacy Preference Center. Strictly necessary cookies that enable core site functionality remain active at all times. This consent-based approach ensures that no non-essential data is collected or shared before permission is given.
We use third-party tools, such as Leadinfo, to help identify business visits to our website based on IP addresses and related publicly available business information. These tools may also use first-party cookies or process domain information submitted through forms to support and improve their services. For more information, including available opt-out options, please email us at .
We also use third-party cookies such as Google Analytics to understand site usage and visitor demographics. All analytics data collected is aggregated and not used to personally identify visitors.
You can stop your browser from accepting cookies altogether by changing the browser’s cookie settings, usually found in the “options” or “preferences” menu. Disabling some cookies may affect certain site features, but essential functions will remain available.
## Contacting the Web Site
If you have any questions about this privacy statement, the practices of this site or your dealings with this website, you can contact us at
## Last updated: April 2026
---
### [Snowflake Antibody Engineering Documentation](https://zifo.com/snowflake-antibody-engineering-documentation/)
**Published:** January 22, 2026
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> Snowflake Antibody Engineering Documentation
# Snowflake Antibody Engineering Documentation
Click to Download Antibody Engineering Architecture Diagram
Click to Download Antibody Engineering Application Flow Diagram
Click to Download Zifo-Snowflake Antibody engineering - Documentation
Table of Contents
1\. Introduction
- 1.1. Why Snowflake?
- 1.2. Scope
- 1.3. Technologies involved
- 1.4. Scale
- 1.5. Value
- 1.5.1. Potential End Users & Applications
2\. Technical Architecture and Implementation of a Cloud-Native Generative AI Platform for Antibody Engineering
3\. System Components and Architecture
- 3.1. Data Store
- 3.2. Data Ingestion & Processing
- 3.3. Development & Model Integration
- 3.4. Model Training & Execution
- 3.5. Sequence Generation and Structure Generation
- 3.6. Snowflake Native Application
- 3.7. App Marketplace & Deployment
4\. Application Overview
5\. Navigating the Application
- 5.1. Native App – Main Page
- 5.1.1. Initial Setup
- 5.1.2. Activate Service
- 5.1.3. Native App – Settings Page
- 5.1.4. Native App – Support Page
- 5.1.5. Application – Home Page
- 5.1.6. Application – Fine-Tune Protein Models Page
- 5.1.7. Application – Generate Antibody Sequences Page
- 5.1.8. Application – Troubleshoot Page
1\. Introduction
In the rapidly evolving field of biologics and drug discovery, protein language models present a groundbreaking opportunity for accelerated antibody design. The Antibody Engineering application, a cloud-native AI solution, enables biopharmaceutical and biotech companies to generate antibody sequences, optimize proteins, and streamline drug discovery processes within the Snowflake ecosystem. By integrating state-of-the-art machine learning models, researchers can fine-tune and infer antibody sequences without moving data outside Snowflake, ensuring scalability, security, and compliance.
1.1 Why Snowflake?
This solution is particularly valuable to Snowflake customers because it leverages:
- Snowflake Native Apps & Snowpark Container Services (SPCS): Ensuring seamless deployment, security, and scalability within Snowflake’s managed environment.
- High-Performance AI Workloads: Trains and deploys AI models directly within Snowflake, removing dependency on external cloud services or on-prem infrastructure.
- No-Code & Low-Code Accessibility: Scientists and bioinformaticians can fine-tune protein models on custom datasets without requiring deep ML expertise.
By running AI-driven antibody sequence optimization directly in Snowflake’s scalable compute environment, organizations can accelerate drug discovery, optimize protein therapeutics, and enhance biologics manufacturing.
1.2 Scope
- Design and optimize antibodies using AI-driven protein language models (PLMs).
- Accelerating the antibody design by efficiently navigating the search space through generation of novel antibodies using generative models.
- Implement a complete end-to-end workflow:
- Finetuning Generative models for protein design Antibody sequence generation (contextual and non-contextual)
- Structure prediction
1.3 Technologies involved
- PLMs (ESM2, ProtGPT2, ) and Generative models like RoBERTa.
- Structure prediction tools (AbBodyBuilder2).
- Snowflake Native Apps for deployment.
1.4 Scale
Data and computational requirements:
- Requires large-scale model training and massive search space exploration.
- Support for Multi-modal inputs (sequence, structure, binding data).
- High-performance infrastructure (Snowflake, scalable compute).
Model types:
- ProtGPT2: Sequence design and property prediction.
- ESM2 (esm2\_t30\_150M\_UR50D): Structure prediction and protein representation.
- RoBERTa: Natural language-based metadata or annotation tasks.
Fine-tuning Modes:
- In-context learning (task-aware).
- Context-free learning (generalized generation).
1.5 Value
Scientific and commercial impact:
- Accelerates drug discovery by reducing time and cost in antibody development.
- Improves hit rate for high-affinity therapeutic antibodies.
- Enables rational antibody design at scale with high precision.
- Adaptable platform for multiple life science applications.
1.5.1 Potential End Users & Applications
Biopharma R&D Teams
Streamline antibody discovery by generating novel sequences and predicting binding affinities faster than traditional methods.
CDMOs & CROs
Offer AI-powered protein engineering as a service to clients developing therapeutic antibodies.
Academic & Research Institutions
Leverage advanced protein modeling tools to push the boundaries of computational biology and structural bioinformatics.
Clinical & Preclinical Development
Validate AI-generated antibodies with experimental data, expediting lead selection.
By addressing these use cases, Snowflake customers in biopharma, CROs, and biotech startups can integrate AI-driven protein modeling, antibody design, and sequence optimization within their secure Snowflake environment.
2\. Technical Architecture and Implementation of a Cloud-Native Generative AI Platform for Antibody Engineering
Technical Architecture – Provider
The proposed solution is a cloud-native, no-code generative AI platform built on Snowflake Native Apps and Snowpark Container Services to enable antibody engineering. The system integrates state-of-the-art AI models such as ProtGPT2, ESM2, and RoBERTa to facilitate real-time sequence generation and optimization using both context-free and in-context learning approaches. A simple user interface allows researchers and bioengineers to select models, fine-tune parameters, and generate optimized sequences and structures with ease.
3\. System Components and Architecture
The architecture of this platform is designed to leverage Snowflake’s scalability, security, and performance to handle antibody sequence data and model execution efficiently.
3.1 Data Store
The data store serves as the foundational layer containing essential datasets for antibody sequence analysis and optimization:
- OAS (Observed Antibody Space): Contains paired and unpaired antibody sequences.
3.2 Data Ingestion & Processing
- Snowflake Schema: Standardized schema for antibody data storage.
- Internal Stage & Data Table: Data is stored in Snowflake’s Internal Stage before processing.
3.3 Development & Model Integration
The development and model integration process involves multiple tools and repositories:
- Development Team Tools: GitHub, Jupyter, Docker, Hugging Face Hub.
- Model Deployment:
- Pre-trained protein models are pulled from Hugging Face Hub.
- Once fine-tuned, the models are saved to Snowflake’s internal stage.
- These staged models are then accessed by the app for downstream tasks such as antibody sequence generation and structure prediction.
- Model training is conducted using GPUs within Snowflake’s compute environment.
- The Image Registry maintains containerized model artifacts.
- Snowflake’s Internal Stage facilitates seamless data exchange between models and storage layers.
3.4 Model Training & Execution
- Model training occurs in Snowpark Container Services, which leverages accelerate library for multi-GPU enabled finetuning.
- Fine-tuning & Hyperparameter Selection: Users can configure and optimize models via the UI.
- AI Models Used:
- ProtGPT2: Context-free sequence generation.
- ESM (Evolutionary Scale Modeling): Sequence optimization with structural insights.
- RoBERTa: Antibody-specific language model for sequence design.
3.5 Sequence Generation and Structure Generation
- Fine-tuned models saved in Snowflake’s Internal Stage are used to generate novel antibody sequences through the app’s user interface.
- Users input sequence generation parameters (e.g., number of sequences, template chains), and the app utilizes the selected fine-tuned model to generate valid heavy and light chain sequences.
- The generated sequences are further analyzed using the ANARCI library, and the analysis is presented in a tabular form in the UI.
- For 3D structure prediction, the generated sequences are passed through AbodyBuilder2, a state-of-the-art tool for antibody structure modeling.
- Outputs include:
- Downloadable sequence files.
- PDB structure files.
- Visualizations with options like chain coloring and CDR (complementarity-determining region) annotations.
3.6 Snowflake Native Application
- The Snowflake Native App integrates with Streamlit UI to provide an interactive user experience.
- Features include:
- Model selection & configuration.
- Real-time sequence generation.
- Visualization of generated structures.
3.7 App Marketplace & Deployment
- The App Marketplace allows users to discover and install the application within Snowflake.
- App Consumers install and execute the Native App, leveraging Snowflake’s scalable infrastructure.
- Users upload sequence files to generate and analyze optimized antibody structures.
4\. Application Overview
The Antibody engineering application is a web-based tool that enables users to fine-tune antibody models and generate sequences using Snowflake’s computing power. The application integrates machine learning models with biological datasets to facilitate antibody structure generation and CDR analysis.
This document outlines:
- How the application is set up.
- Key navigation elements.
- Explanation of each page with screenshots.
5\. Navigating the Application
5.1 Native App - Main Page
The Main section of the Snowflake Native App serves as the central hub for managing the application setup, activation, and execution. It provides users with a structured workflow to initialize the environment, activate core services, and launch the antibody sequence generation interface.
5.1.1 Initial Setup
The Initial Setup process serves as the foundation for running the application by:
- Provisioning Snowpark Container Services with the necessary compute resources.
- Deploying and initializing AI models such as ProtGPT2, ESM2, and RoBERTa.
- Setting up the backend database schema and defining compute pools for model execution.
- Validating system readiness before activation.
Components of the Initial Setup Page
The setup process is divided into three key sections:
Displayed Information
- Compute Pool Name
- Status (e.g., STARTING)
- SMin/Max Nodes (e.g., min\_nodes=1, max\_nodes=5)
- Instance Family (e.g., GPU\_NV\_M)
- Number of Services Attached
Validation and Next Steps
- Once resources are initialized, users can proceed to Activate the Service.
- The system ensures that all configurations are correctly set up before proceeding to model selection and sequence generation.
User Actions:
- Wait for Compute Pool and Service Initialization – Status indicators display real-time progress.
- Click “Next” – Moves to the Activate Service stage once resources are ready.
Outcome of Initial Setup
Upon successful completion of this phase:
- The Snowflake environment is ready with allocated resources.
- AI model services are registered and mapped to the correct compute infrastructure.
- Users can proceed to activate and use the application for antibody sequence generation.
5.1.2 Activate Service
The Activate Service step initializes and starts the core AI model services required for antibody sequence generation. This ensures that the deployed models and dependencies are correctly installed and ready for execution.
Key Functions:
- Dependency Installation: The system installs necessary Python packages, AI models, and framework dependencies.
- Model Initialization: Services like ProtGPT2, ESM2, and RoBERTa are loaded, once the user selects a model and starts the finetuning.
- Log Monitoring: Real-time logs track installation progress, cloning of repositories, and model setup status.
- Health Check & Validation: Ensures that all services are successfully deployed and ready for sequence generation.
User Actions:
- Monitor Logs – Check real-time progress of package installation and model setup.
- Wait for Activation Completion – Ensure all components are properly initialized.
- Click “Next” – Proceed to Launch Application for sequence generation.
Application URL:
Key Functions:
- Application Access: Provides a direct URL to the deployed Streamlit interface within Snowflake.
- Interactive Model Selection: Users can choose from ProtGPT2, ESM, and RoBERTa for sequence generation.
- Sequence Analysis & Visualization: Enables real-time antibody structure visualization, CDR analysis, and sequence downloads.
User Actions:
- Click the Streamlit App URL – Opens the Zifo-Antibody Sequence Generator UI.
- Select an AI Model – Configure parameters for sequence generation.
- Generate & Analyze Sequences – View and download results in FASTA/PDB format.
5.1.3 Native App - Settings Page
The Settings page provides users with the ability to manage and control computational resources, ensuring flexibility and cost efficiency. It allows users to modify, suspend, resume, or drop resources as needed.
Key Functions:
- Modify Compute Pool
- Users can select a different compute pool to adjust the processing power of the application.
- This ensures optimal performance based on workload demands.
- Action: Click Update after selecting a new compute pool.
- Suspend Resources
- Temporarily suspends active resources, reducing computational usage.
- Ideal for pausing operations when no active jobs are running.
- Resume Resources
- Reactivates previously suspended compute resources.
- Ensures smooth continuation of model execution and data processing.
- Drop Resources
- Permanently removes assigned resources when they are no longer required.
- Helps in cost optimization by freeing up unused compute pools.
User Actions:
- Modify Compute Pool → Select a pool and click Update.
- Suspend or Resume Resources → Expand the section and confirm the action.
- Drop Resources → Use this option when compute resources are no longer needed.
5.1.4 Native App - Support Page
The Support page provides an interactive SQL Editor, allowing users to run queries directly on the Snowflake database. This feature is useful for validating data, testing query logic, and troubleshooting issues related to antibody sequence generation and optimization.
Key Functions:
- SQL Query Execution: Users can input and run custom SQL queries on Snowflake tables.
- Data Validation: Helps verify stored antibody sequence data and model-generated outputs.
- Debugging & Troubleshooting: Enables users to check system logs and diagnose issues.
User Actions:
- Enter a SQL Query – Type a valid SQL command (e.g., SELECT \* FROM table\_name WHERE condition).
- Click the Execute Button – Runs the query in the Snowflake environment.
- Review Results – Analyze the returned dataset to ensure correctness.
5.1.5 Application - Home Page
What’s on this page?
- Application Name & Description: Introduction to the tool.
- Features Overview: Quick guide on fine-tuning and sequence generation.
- Architecture Diagram: A high-level overview of the data flow and components.
How to Use?
Users can navigate to Fine-tune a Model or Generate Sequences from the sidebar.
5.1.6 Application - Fine-Tune Protein Models Page
The fine-tuning page allows users to train a machine learning model using their antibody sequence dataset.
Options Available:
- Model Selection: Choose from:
- ESM2 (Masked Language Model)
- ProtGPT (Causal Language Model)
- RoBERTa (Transformer-based Model)
- Data Input Options:
- Using default dataset – Sample OAS dataset in CSV format readily available
- Upload a CSV file (Max 200MB)
- Fetch tables directly from Snowflake
User Actions:
- Select the desired model.
- Choose an input method:
- Using default dataset
- Upload a sequence file
- Fetch antibody sequences from Snowflake.
- Select the Heavy and Light chain sequence columns
- Click “Start Fine-tuning”.
5.1.7 Application - Generate Antibody Sequences Page
The Generate Sequences page allows users to generate antibody sequences based on fine-tuned models.
Features:
- Protein language model selection: Choose from:
- ESM2 (Masked Language Model)
- ProtGPT (Causal Language Model)
- RoBERTa (Transformer-based Model)
- Model Selection: Choose a previously fine-tuned model which will be displayed in the dropdown.
- Masked Template Input: Users can enter a sequence template for both heavy and light chain.
- Adjust Sequence Count: Slider allows selecting the number of sequences to generate.
- Antibody Structure Visualization:
- Downloadable PDB files.
- Sidechain & Backbone Display.
- Color-coded structure visualization.
- CDR Results Table:
- Shows generated H1, H2, H3, L1, L2, L3 regions.
- Generated Antibody Sequences:
- Shows generated antibody sequences
User Actions:
- Protein language model selection: Choose from:
- ESM2 (Masked Language Model)
- ProtGPT (Causal Language Model)
- RoBERTa (Transformer-based Model)
- Select a pre-trained model.
- Enter a template sequence.
- Click “Generate Sequences”.
- View or download PDB files
- View or download CDR analysis results.
- View or download Session history
5.1.8 Application – Troubleshoot Page
The troubleshoot page allows users to execute code snippets for debug purposes.
Options Available:
- URL for jupyter notebook service
- Support team contact mail
- Downloading and viewing log file
User Actions:
- Click on Jupyter notebook hyperlink
- Enter Snowflake credentials
- Execute the existing debug scripts / write snippets to debug
- Click on button to download the streamlit logs for debugging
For further information and inquiries: Visit: [www.zifo.com](/) Email: , .
---
### [Solutions](https://zifo.com/chromatography-data-systems-and-solutions/solutions/)
**Published:** January 12, 2026
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> Solutions
# Get the most out of your system with
our software solutions
## Solutions
Learn more about our software solutions,
manuals, guides and pre-built packages
### Software solutions
Software and device drivers from zifo extend Waters Empower’s functions and meet the requirements of the pharmaceutical environment.
[ Find out more here ](#sectionSoftware)
### Document packages
Zifo has compiled digital info materials and rulebooks to guide and support you in using Empower.
[ Find out more here ](#sectionDocument)
### Document packages
Zifo has compiled digital info materials and rulebooks to guide and support you in using Empower.
[ Find out more here ](#sectionDocument)
## Software Solutions
Zifo develops its own software products and device drivers that extend
the functionality of Waters Empower® software and meet the
requirements of the regulated pharmaceutical
### CIQ – Customised Instrument Qualification
With the CIQ, the qualifications of all your chromatography instruments controlled by Empower or Chromeleon are performed uniformly and without additional validation effort. The decisive factor is the requirements of your laboratory.
[ Find out more here ](/chromatography-data-systems-and-solutions/solutions/ciq-customised-instrument/)
### Peakprovider 2.0 for Empower
Peakprovider is a small, easy-to-use tool. With great effect because it saves the error-prone and cumbersome transfer to third-party calculation programs.
[ Find out more here ](/chromatography-data-systems-and-solutions/solutions/peakprovider-2-0-for-empower/)
### Rhizomer
With Rhizomer, we developed a solution where LAC/E computers can be managed centrally from one location. Without the need to be on-site or to perform manual configurations.
[ Find out more here ](/chromatography-data-systems-and-solutions/solutions/rhizomer/)
### CLEAR – Efficient Empower3 Result- and Audit Trail-Reviews
Optimize and automate the review process in the laboratory with the CLEAR ToolKit.
[ Find out more here ](/chromatography-data-systems-and-solutions/solutions/clear-efficient-empower3-result/)
### CUT – Content Uniformity Template
Automatic assessment of content uniformity, taking full account of all regulatory aspects.
[ Find out more here ](/chromatography-data-systems-and-solutions/solutions/cut-content-uniformity/)
### LEI – LabX-Empower-Integration
LEI is the next step towards an efficient and paperless lab. It integrates the balance software LabX into Empower.
[ Find out more here ](/chromatography-data-systems-and-solutions/solutions/lei-labx-empower-integration/)
## Document Packages
The digital info materials and rulebooks have been compiled for you
by zifo to support and guide you in using Empower.
### SOP Box
A set of rules to operate the Empower software in a regulatory environment. Data integrity requirements require a risk-based set of rules to operate the Empower software in a regulated environment. Use this set of SOP templates in your organization to reduce time-consuming development and associated high costs.
[ Find out more here ](/chromatography-data-systems-and-solutions/solutions/sop-box/)
### CSV Box
Qualification documents for your Empower installation – Out of the Box. Before operating the Empower software, install it in a controlled manner and validate the installation. We have created a set of qualification documents for you, with which the CSV can be carried out according to the regulations and audit-stable.
[ Find out more here ](/chromatography-data-systems-and-solutions/solutions/csv-box/)
Get in touch
First Name
Last Name
Email
Phone Number
Company
Designation
Enquiry Type
Enquiry Type Request for Zifo Services Product Partnership Job/Internship/Placement Enquiry Other
Message
Acceptance I consent to being contacted by an official Zifo representative
Submit
---
### [Events](https://zifo.com/events/)
**Published:** March 5, 2026
**Author:** Zifo_user
**Content:**
On Demand, Zifo Signature Event
## SiEE Boston 2026
Sanofi, Takeda, AbbVie, Regeneron, Biogen, Eli Lilly, Novo Nordisk, J&J, and Broad Institute on what’s next for AI in Life Sciences
[ Watch Now ](https://zifo.com/event/siee-boston-2026-ondemand/)
Event Category Filter All Events
Industry Event
On Demand
Zifo Event
Zifo Signature Event
Sort by:
Sort... Date: Nearest First Date: Furthest First Name: A - Z
09
Apr
[On Demand](https://zifo.com/events/category/on-demand/),
[Zifo Signature Event](https://zifo.com/events/category/zifo-signature-event/)
SiEE Basel 2024
Basel, CH
[View Details →](https://zifo.com/event/siee-2024-basel/)
[Watch Video →](https://zifo.com/event/siee-2024-basel/)
[Register Now →](https://zifo.com/event/siee-2024-basel/)
07
Feb
[Industry Event](https://zifo.com/events/category/industry-event/)
SLAS 2026 International Conference & Exhibition
Boston, MA
[View Details →](https://zifo.com/event/slas-2026-international-conference-exhibition/)
[Watch Video →](https://zifo.com/event/slas-2026-international-conference-exhibition/)
[Register Now →](https://zifo.com/event/slas-2026-international-conference-exhibition/)
16
Oct
[On Demand](https://zifo.com/events/category/on-demand/),
[Zifo Signature Event](https://zifo.com/events/category/zifo-signature-event/)
SiEE Boston 2024
Boston, USA
[View Details →](https://zifo.com/event/siee-2024-on-demand-boston-oct-16/)
[Watch Video →](https://zifo.com/event/siee-2024-on-demand-boston-oct-16/)
[Register Now →](https://zifo.com/event/siee-2024-on-demand-boston-oct-16/)
17
Oct
[On Demand](https://zifo.com/events/category/on-demand/),
[Zifo Signature Event](https://zifo.com/events/category/zifo-signature-event/)
SiEE San Francisco 2023
San Francisco
[View Details →](https://zifo.com/event/siee-san-francisco/)
[Watch Video →](https://zifo.com/event/siee-san-francisco/)
[Register Now →](https://zifo.com/event/siee-san-francisco/)
10
Jun
[On Demand](https://zifo.com/events/category/on-demand/),
[Zifo Signature Event](https://zifo.com/events/category/zifo-signature-event/)
SiEE Basel 2025
Basel, CH
[View Details →](https://zifo.com/event/siee-2025on-demand-basel/)
[Watch Video →](https://zifo.com/event/siee-2025on-demand-basel/)
[Register Now →](https://zifo.com/event/siee-2025on-demand-basel/)
18
Apr
[On Demand](https://zifo.com/events/category/on-demand/),
[Zifo Signature Event](https://zifo.com/events/category/zifo-signature-event/)
SiEE Boston 2023
Boston, USA
[View Details →](https://zifo.com/event/siee-2023/)
[Watch Video →](https://zifo.com/event/siee-2023/)
[Register Now →](https://zifo.com/event/siee-2023/)
12
Feb
[On Demand](https://zifo.com/events/category/on-demand/),
[Zifo Signature Event](https://zifo.com/events/category/zifo-signature-event/)
Manufacturing Summit 2025
North Carolina, USA
[View Details →](https://zifo.com/event/manufacturing-summit-2025/)
[Watch Video →](https://zifo.com/event/manufacturing-summit-2025/)
[Register Now →](https://zifo.com/event/manufacturing-summit-2025/)
21
Apr
[Industry Event](https://zifo.com/events/category/industry-event/)
SmartLab USA
Philadelphia, USA
[View Details →](https://zifo.com/event/smartlab-usa/)
[Watch Video →](https://zifo.com/event/smartlab-usa/)
[Register Now →](https://zifo.com/event/smartlab-usa/)
27
Apr
[Industry Event](https://zifo.com/events/category/industry-event/)
Paperless Lab Academy | India 2027
Mumbai
[View Details →](https://zifo.com/event/paperless-lab-academy-india-2025/)
[Watch Video →](https://zifo.com/event/paperless-lab-academy-india-2025/)
[Register Now →](https://zifo.com/event/paperless-lab-academy-india-2025/)
02
Mar
[Industry Event](https://zifo.com/events/category/industry-event/)
Lab of the Future USA | 2026
The Sheraton Boston Hotel, USA
[View Details →](https://zifo.com/event/lab-of-the-future-usa-2026/)
[Watch Video →](https://zifo.com/event/lab-of-the-future-usa-2026/)
[Register Now →](https://zifo.com/event/lab-of-the-future-usa-2026/)
24
Mar
[Industry Event](https://zifo.com/events/category/industry-event/)
Analytica 2026 | Germany
Boston, USA
[View Details →](https://zifo.com/event/analytica-2026-germany/)
[Watch Video →](https://zifo.com/event/analytica-2026-germany/)
[Register Now →](https://zifo.com/event/analytica-2026-germany/)
29
Sep
[Industry Event](https://zifo.com/events/category/industry-event/)
BioTechX USA
Boston, USA
[View Details →](https://zifo.com/event/biotechx-usa-3/)
[Watch Video →](https://zifo.com/event/biotechx-usa-3/)
[Register Now →](https://zifo.com/event/biotechx-usa-3/)
23
Apr
[Zifo Event](https://zifo.com/events/category/zifo-event/)
Practical AI for Science Leaders: Platforms, Data, and Real Outcomes
Hamburg
[View Details →](https://zifo.com/event/zifo-sapio-sciences-lunch-learn-hamburg/)
[Watch Video →](https://zifo.com/event/zifo-sapio-sciences-lunch-learn-hamburg/)
[Register Now →](https://zifo.com/event/zifo-sapio-sciences-lunch-learn-hamburg/)
27
May
[Industry Event](https://zifo.com/events/category/industry-event/)
Future Labs Live | EMEA
Basel, CH
[View Details →](https://zifo.com/event/future-labs-live-emea/)
[Watch Video →](https://zifo.com/event/future-labs-live-emea/)
[Register Now →](https://zifo.com/event/future-labs-live-emea/)
06
May
[Industry Event](https://zifo.com/events/category/industry-event/)
London Labs Live | EMEA
London, UK
[View Details →](https://zifo.com/event/london-labs-live-emea/)
[Watch Video →](https://zifo.com/event/london-labs-live-emea/)
[Register Now →](https://zifo.com/event/london-labs-live-emea/)
24
Apr
[Industry Event](https://zifo.com/events/category/industry-event/)
2026 BPD Cell and Gene Therapy Symposium
North Carolina, USA
[View Details →](https://zifo.com/event/2026-bpd-cell-and-gene-therapy-symposium/)
[Watch Video →](https://zifo.com/event/2026-bpd-cell-and-gene-therapy-symposium/)
[Register Now →](https://zifo.com/event/2026-bpd-cell-and-gene-therapy-symposium/)
06
Oct
[Industry Event](https://zifo.com/events/category/industry-event/)
BioTechX EMEA
Basel, CH
[View Details →](https://zifo.com/event/biotechx-emea/)
[Watch Video →](https://zifo.com/event/biotechx-emea/)
[Register Now →](https://zifo.com/event/biotechx-emea/)
22
Sep
[Industry Event](https://zifo.com/events/category/industry-event/)
Lab of the Future EMEA | 2026
Amsterdam, NL
[View Details →](https://zifo.com/event/lab-of-the-future-emea-2026/)
[Watch Video →](https://zifo.com/event/lab-of-the-future-emea-2026/)
[Register Now →](https://zifo.com/event/lab-of-the-future-emea-2026/)
14
Apr
[On Demand](https://zifo.com/events/category/on-demand/),
[Zifo Signature Event](https://zifo.com/events/category/zifo-signature-event/)
SiEE Boston 2026
Boston, USA
[View Details →](https://zifo.com/event/siee-boston-2026-ondemand/)
[Watch Video →](https://zifo.com/event/siee-boston-2026-ondemand/)
[Register Now →](https://zifo.com/event/siee-boston-2026-ondemand/)
19
May
[Industry Event](https://zifo.com/events/category/industry-event/)
BioIT World
Boston, USA
[View Details →](https://zifo.com/event/bioit-world/)
[Watch Video →](https://zifo.com/event/bioit-world/)
[Register Now →](https://zifo.com/event/bioit-world/)
10
Aug
[Industry Event](https://zifo.com/events/category/industry-event/)
Bioprocessing Summit
Boston, USA
[View Details →](https://zifo.com/event/bioprocessing-summit/)
[Watch Video →](https://zifo.com/event/bioprocessing-summit/)
[Register Now →](https://zifo.com/event/bioprocessing-summit/)
07
Jul
[Zifo Event](https://zifo.com/events/category/zifo-event/)
From AI Promise to Real Impact in R&D
Paris
[View Details →](https://zifo.com/event/zifo_revvity_lunch_learn_paris/)
[Watch Video →](https://zifo.com/event/zifo_revvity_lunch_learn_paris/)
[Register Now →](https://zifo.com/event/zifo_revvity_lunch_learn_paris/)
18
Jun
[On Demand](https://zifo.com/events/category/on-demand/),
[Zifo Signature Event](https://zifo.com/events/category/zifo-signature-event/)
SiEE Basel 2026
[View Details →](https://zifo.com/event/siee-basel-2026-ondemand/)
[Watch Video →](https://zifo.com/event/siee-basel-2026-ondemand/)
[Register Now →](https://zifo.com/event/siee-basel-2026-ondemand/)
10
Aug
[Industry Event](https://zifo.com/events/category/industry-event/)
Harness the Power of AI in GxP East
Boston, USA
[View Details →](https://zifo.com/event/harness-the-power-of-ai-in-gxp-east/)
[Watch Video →](https://zifo.com/event/harness-the-power-of-ai-in-gxp-east/)
[Register Now →](https://zifo.com/event/harness-the-power-of-ai-in-gxp-east/)
23
Sep
[Industry Event](https://zifo.com/events/category/industry-event/)
Biomarkers, CDx & Precision Medicine
San Diego, CA
[View Details →](https://zifo.com/event/biomarkers-cdx-precision-medicine/)
[Watch Video →](https://zifo.com/event/biomarkers-cdx-precision-medicine/)
[Register Now →](https://zifo.com/event/biomarkers-cdx-precision-medicine/)
15
Oct
[Industry Event](https://zifo.com/events/category/industry-event/)
Benchtalk US
Boston, USA
[View Details →](https://zifo.com/event/benchtalk-us/)
[Watch Video →](https://zifo.com/event/benchtalk-us/)
[Register Now →](https://zifo.com/event/benchtalk-us/)
18
Oct
[Industry Event](https://zifo.com/events/category/industry-event/)
2026 ISPE Annual Meeting & Expo
Washington, DC
[View Details →](https://zifo.com/event/2026-ispe-annual-meeting-expo/)
[Watch Video →](https://zifo.com/event/2026-ispe-annual-meeting-expo/)
[Register Now →](https://zifo.com/event/2026-ispe-annual-meeting-expo/)
20
Oct
[Industry Event](https://zifo.com/events/category/industry-event/)
Veeva R&D Summit US
Boston, USA
[View Details →](https://zifo.com/event/veeva-rd-summit/)
[Watch Video →](https://zifo.com/event/veeva-rd-summit/)
[Register Now →](https://zifo.com/event/veeva-rd-summit/)
27
Oct
[Industry Event](https://zifo.com/events/category/industry-event/)
AiDDD Summit
San Diego, CA
[View Details →](https://zifo.com/event/aiddd-summit/)
[Watch Video →](https://zifo.com/event/aiddd-summit/)
[Register Now →](https://zifo.com/event/aiddd-summit/)
30
Jan
[Industry Event](https://zifo.com/events/category/industry-event/)
SLAS 2027
San Diego, CA
[View Details →](https://zifo.com/event/slas-2027/)
[Watch Video →](https://zifo.com/event/slas-2027/)
[Register Now →](https://zifo.com/event/slas-2027/)
09
Dec
[Industry Event](https://zifo.com/events/category/industry-event/)
CSV & CSA University
San Diego, CA
[View Details →](https://zifo.com/event/csv-csa-university/)
[Watch Video →](https://zifo.com/event/csv-csa-university/)
[Register Now →](https://zifo.com/event/csv-csa-university/)
01
Dec
[Industry Event](https://zifo.com/events/category/industry-event/)
Pharma Omics & AI
Orange County, CA
[View Details →](https://zifo.com/event/pharma-omics-ai/)
[Watch Video →](https://zifo.com/event/pharma-omics-ai/)
[Register Now →](https://zifo.com/event/pharma-omics-ai/)
15
Sep
[Industry Event](https://zifo.com/events/category/industry-event/)
REAL 2026: Readiness & Enablement for Automated Labs
Seaport, Boston
[View Details →](https://zifo.com/event/real-2026-readiness-enablement-for-automated-labs/)
[Watch Video →](https://zifo.com/event/real-2026-readiness-enablement-for-automated-labs/)
[Register Now →](https://zifo.com/event/real-2026-readiness-enablement-for-automated-labs/)
13
Apr
[Zifo Signature Event](https://zifo.com/events/category/zifo-signature-event/)
Scientific Informatics Experience Exchange (SiEE) | Boston April 13, 2027
Boston, MA
[View Details →](https://zifo.com/event/siee-boston-2027/)
[Watch Video →](https://zifo.com/event/siee-boston-2027/)
[Register Now →](https://zifo.com/event/siee-boston-2027/)
01
Jun
[Zifo Signature Event](https://zifo.com/events/category/zifo-signature-event/)
Scientific Informatics Experience Exchange (SiEE) | Basel June 1, 2027
Basel, CH
[View Details →](https://zifo.com/event/siee-basel-2027/)
[Watch Video →](https://zifo.com/event/siee-basel-2027/)
[Register Now →](https://zifo.com/event/siee-basel-2027/)
15
Oct
[Zifo Event](https://zifo.com/events/category/zifo-event/)
From In Silico to Molecule to Medicine: Every AI Journey Starts with Connected Science
San Francisco
[View Details →](https://zifo.com/event/insilicotomol/)
[Watch Video →](https://zifo.com/event/insilicotomol/)
[Register Now →](https://zifo.com/event/insilicotomol/)
16
Nov
[Zifo Event](https://zifo.com/events/category/zifo-event/)
Pharma 4.0 in Practice: Building AI-Ready, Connected and Compliant Manufacturing
Durham, NC
[View Details →](https://zifo.com/event/manufsummit2026/)
[Watch Video →](https://zifo.com/event/manufsummit2026/)
[Register Now →](https://zifo.com/event/manufsummit2026/)
---
### [Quality](https://zifo.com/quality/)
**Published:** January 28, 2026
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> Quality
# Quality at Zifo
The mantra of "do the right thing" and endeavouring to do this is part of our daily work practices. This means we live and breathe quality, encouraging risk-based thinking, support innovation and continual improvement and make it part of the company fabric. With a QMS and ISMS designed to support our business and backed by ISO 27001 & ISO 9001 accreditation, Zifo is well placed to meet the quality and regulatory requirements of your business.
## Our Commitment to Quality
ISO 27001 and ISO 9001 accreditation
[ Learn more >> ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjQxNjQ1IiwidG9nZ2xlIjpmYWxzZX0%3D)
Robust and mature QMS and ISMS
Compliant internal E-signature platform
Statement of Applicability ready to go
Flexibility - we can use customer QMS or Zifo QMS
Centralised project risk management & dashboarding
CAPA audits and quality training for all
Mature document retention policy
## Our Business is Our People
Zifo people are naturally curious and keen to make a difference in the world by helping to advance scientific discovery. We work hard to keep our people engaged, stretched and inspired, which is why we have one of the highest retention rates in our industry.
Together we can make a real difference
[ Our People ](/our-people/)
[ Join Team Zifo ](https://careers.zifo.com/)
Pointer Follower Ball Inside Div 
[ Our People ](/our-people/)
[ Join Team Zifo ](https://careers.zifo.com/)
## Our Capabilities
Our expertise spans the whole spectrum of scientific process applications, and we’re able to draw on a huge marketplace of partnerships with science technology providers, so whatever is needed to fix your current set-up. we’ll determine the best way forward.
Our People
Our people are our business and we invest and support their development and curiosity. We actively promote science in our daily work and over 90% of people in Zifo have a scientific background – meaning we speak & understand the language of science
Glocal
We have a GLOCAL (global & local) presence – meaning we engage with you in your language and time zone but leverage a global delivery support model to remain cost-effective, scalable and very reactive
Ecosystem
We focus on science and scientific process applications and informatics. This means we can provide expertise and domain knowledge without compromising quality, technical and service delivery excellence
Partnerships
Our huge marketplace of partnerships with science technology and informatics platform providers means you can rely on Zifo to be agnostic and advise on strategy, plan & deliver projects, and validate and maintain your scientific informatics environments
## Integrated Management System Policy
Zifo is fully committed to being the leading provider of Scientific Informatics Services across the entire spectrum of research, development and manufacturing.
We shall:
Maintain a people first culture that supports collaboration, growth and drives excellence;
Continuously strive to exceed customers' expectations on improving quality and timelines while ensuring confidentiality, integrity and availability.
Deliver great value by demonstrating curiosity for knowledge and blending technology skills, scientific knowledge and regulatory expertise, acting as consultants to our customers.
Communicate and satisfy applicable quality, information security and compliance requirements related to our company, people, customers, business partners and relevant interested parties.
Integrate Environmental, Social and Governance (ESG) expectations into our operations by promoting environmental sustainability, human‑rights protection, responsible procurement and ethical business conduct.
Adopt and govern responsible use of Artificial Intelligence (AI) technologies towards service excellence through robust data protection measures, continual risk management, adequate data governance and oversight with effective trainings and awareness to people.
We shall achieve this by adopting a strong quality, information security and regulatory culture across Zifo family, encouraging risk-based thinking, innovation and continual improvement.
## Raj Prakash, G
Chief Executive Officer
Get in touch
First Name
Last Name
Email
Phone Number
Company
Designation
Enquiry Type
Enquiry Type Request for Zifo Services Product Partnership Job/Internship/Placement Enquiry Other
Message
Acceptance I consent to being contacted by an official Zifo representative
Submit
---
### [Thank You Aideate](https://zifo.com/thank-you-aideate/)
**Published:** May 20, 2026
**Author:** Zifo_user
**Content:**
## Thank You
Your form has been submitted successfully. Our team will review your request, and get in touch with you soon.
In the meantime, feel free to continue exploring our website.
- [ Home Page ](https://zifo.com/)
- [ Services ](/services/)
- [ Industries ](/industries/)
- [ Events ](/events/)
- [ Blogs ](/blogs/)
- [ Contact ](/contact-us-today/)
Search
Search
---
### [Thank You](https://zifo.com/thank-you/)
**Published:** May 20, 2026
**Author:** Zifo_user
**Content:**
## Thank You
Your form has been submitted successfully. Our team will review your request, and get in touch with you soon.
In the meantime, feel free to continue exploring our website.
- [ Home Page ](https://zifo.com/)
- [ Services ](/services/)
- [ Industries ](/industries/)
- [ Events ](/events/)
- [ Blogs ](/blogs/)
- [ Contact ](/contact-us-today/)
Search
Search
---
### [Search Result](https://zifo.com/search-result/)
**Published:** December 8, 2025
**Author:** Zifo_user
**Content:**
# Search
Search
All
All (0) Service (0) Industry (0) Blog (0) Whitepapers (0) News (0)
0 Results Found
# Search
#### Industries we serve
[ Large Pharma and Biotech ](/industries/pharmaceutical-informatics-and-consulting-services/)
[ Specialty Chemicals ](/industries/speciality-chemicals-informatics-and-consulting-services/)
[ Diagnostic Laboratory ](#)
[ CRO ](#)
[ Fast-Moving Consumer Goods ](/industries/fmcg-informatics-and-consulting-services/)
[ Small and Medium Biotech ](/industries/biotech-informatics-and-consulting-services/)
[ Food & Beverage ](/industries/food-and-beverage-informatics-and-consulting-services/)
[ Oil & Gas ](#)
[ AgroTech ](/industries/agrotech-informatics-and-consulting-services/)
---
### [Services](https://zifo.com/services/)
**Published:** April 16, 2025
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> Services
Services
Where there is science, there is Zifo. Connecting every stage of the value chain through our specialized services.
Services White Papers Blogs News
Services
[  ](https://zifo.com/services/cmc-chemistry-manufacturing-controls/)
### [Manufacturing CMC Services](https://zifo.com/services/cmc-chemistry-manufacturing-controls/)
[ Read Now ](https://zifo.com/services/cmc-chemistry-manufacturing-controls/)
[  ](https://zifo.com/services/lab-compute-services/)
### [Lab Compute Services](https://zifo.com/services/lab-compute-services/)
[ Read Now ](https://zifo.com/services/lab-compute-services/)
[  ](https://zifo.com/services/scientific-application-managed-services/)
### [Scientific Application Managed Services](https://zifo.com/services/scientific-application-managed-services/)
[ Read Now ](https://zifo.com/services/scientific-application-managed-services/)
[  ](https://zifo.com/services/digital-transformation-consulting-services/)
### [Digital Transformation Consulting Services](https://zifo.com/services/digital-transformation-consulting-services/)
[ Read Now ](https://zifo.com/services/digital-transformation-consulting-services/)
[  ](https://zifo.com/services/manufacturing-and-mes-services/)
### [Manufacturing and Quality Informatics Services](https://zifo.com/services/manufacturing-and-mes-services/)
[ Read Now ](https://zifo.com/services/manufacturing-and-mes-services/)
[  ](https://zifo.com/services/product-development-and-design/)
### [Product Development and Design](https://zifo.com/services/product-development-and-design/)
[ Read Now ](https://zifo.com/services/product-development-and-design/)
White Papers
### [STREAMLINING PHARMA PRODUCT DEVELOPMENT THROUGH DIGITAL COACHING](https://zifo.com/?p=12737)
Mehnaz Husain
[ Read Now ](https://zifo.com/?p=12737)
### [The Role of Scientific Business Systems Analysts in Driving Science Forward](https://zifo.com/?p=12723)
Aishwarya Balajee
[ Read Now ](https://zifo.com/?p=12723)
[  ](https://zifo.com/?p=12718)
### [Informatics Vendor Evaluation Approach](https://zifo.com/?p=12718)
Uma Maheswari Adiseshan
[ Read Now ](https://zifo.com/?p=12718)
### [CDISC SEND FAIR data guide](https://zifo.com/?p=12702)
Aishwarya Balajee
[ Read Now ](https://zifo.com/?p=12702)
### [ePRO- Subject centric approach](https://zifo.com/?p=11809)
Amal Krishna Girish
[ Read Now ](https://zifo.com/?p=11809)
[  ](https://zifo.com/?p=11616)
### [ARTIFICIAL INTELLIGENCE IN THE PHARMACEUTICAL INDUSTRY PART 1 – Drug Discovery & Preclinical Development](https://zifo.com/?p=11616)
David Jackson
[ Read Now ](https://zifo.com/?p=11616)
Blogs
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
Sakthi Prasad T, Content Director
[ Read Now ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
Sakthi Prasad T, Content Director
[ Read Now ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
Shivani Vohra, Consulting Analyst
[ Read Now ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/the-first-mile-of-lab-data-operationalizing-data-flow-in-heterogeneous-research-environments/)
### [The “First Mile” of Lab Data: Operationalizing Data Flow in Heterogeneous Research Environments](https://zifo.com/blogs/the-first-mile-of-lab-data-operationalizing-data-flow-in-heterogeneous-research-environments/)
Sakthi Prasad T, Content Director
[ Read Now ](https://zifo.com/blogs/the-first-mile-of-lab-data-operationalizing-data-flow-in-heterogeneous-research-environments/)
[  ](https://zifo.com/blogs/design-of-experiments-labs-confront-the-challenge-of-capturing-experimental-intent/)
### [Design of Experiments: Labs Confront the Challenge of Capturing Experimental Intent](https://zifo.com/blogs/design-of-experiments-labs-confront-the-challenge-of-capturing-experimental-intent/)
Rahul Anil Babu, Scientific Application Consultant
[ Read Now ](https://zifo.com/blogs/design-of-experiments-labs-confront-the-challenge-of-capturing-experimental-intent/)
[  ](https://zifo.com/blogs/beyond-the-rigidity-how-abbvies-platform-adapt-to-cmc-science/)
### [Beyond the Rigidity: How AbbVie’s Platform Adapts to CMC Science](https://zifo.com/blogs/beyond-the-rigidity-how-abbvies-platform-adapt-to-cmc-science/)
Sakthi Prasad T, Content Director
[ Read Now ](https://zifo.com/blogs/beyond-the-rigidity-how-abbvies-platform-adapt-to-cmc-science/)
News
[  ](https://zifo.com/news/zifo-co-launches-real-2026-to-spotlight-the-next-generation-of-connected-ai-enabled-lab-environments/)
### [Zifo Co-Launches REAL 2026 to Spotlight the Next Generation of Connected, AI-Enabled Lab Environments](https://zifo.com/news/zifo-co-launches-real-2026-to-spotlight-the-next-generation-of-connected-ai-enabled-lab-environments/)
[ Read Now ](https://zifo.com/news/zifo-co-launches-real-2026-to-spotlight-the-next-generation-of-connected-ai-enabled-lab-environments/)
[  ](https://zifo.com/news/cmc-bottleneck-is-choking-biopharmas-drug-pipeline-says-zifo/)
### [CMC Bottleneck is Choking Biopharma’s Drug Pipeline, says Zifo](https://zifo.com/news/cmc-bottleneck-is-choking-biopharmas-drug-pipeline-says-zifo/)
[ Read Now ](https://zifo.com/news/cmc-bottleneck-is-choking-biopharmas-drug-pipeline-says-zifo/)
[  ](https://zifo.com/news/zifo-accelerates-lims-master-data-validation-with-new-ai-enabled-services-accelerator/)
### [Zifo Accelerates LIMS Master Data Validation with New AI-Enabled Services Accelerator](https://zifo.com/news/zifo-accelerates-lims-master-data-validation-with-new-ai-enabled-services-accelerator/)
[ Read Now ](https://zifo.com/news/zifo-accelerates-lims-master-data-validation-with-new-ai-enabled-services-accelerator/)
[  ](https://zifo.com/news/zifo-open-quiz-2026-draws-over-1200-quizzers-on-independence-day/)
### [Zifo Open Quiz 2026 Draws Over 1,200 Quizzers on Independence Day](https://zifo.com/news/zifo-open-quiz-2026-draws-over-1200-quizzers-on-independence-day/)
[ Read Now ](https://zifo.com/news/zifo-open-quiz-2026-draws-over-1200-quizzers-on-independence-day/)
[  ](https://zifo.com/news/change-management-strategies-elevating-digital-transformation-in-pharma/)
### [Conquering Biopharma’s ‘Mount Everest’: The Human Element of Digital Transformation](https://zifo.com/news/change-management-strategies-elevating-digital-transformation-in-pharma/)
[ Read Now ](https://zifo.com/news/change-management-strategies-elevating-digital-transformation-in-pharma/)
[  ](https://zifo.com/news/zifo-to-present-biobank-data-breakthrough-at-the-festival-of-genomics-boston/)
### [Zifo to Present Biobank Data Breakthrough at the Festival of Genomics Boston](https://zifo.com/news/zifo-to-present-biobank-data-breakthrough-at-the-festival-of-genomics-boston/)
[ Read Now ](https://zifo.com/news/zifo-to-present-biobank-data-breakthrough-at-the-festival-of-genomics-boston/)
---
### [Everest](https://zifo.com/scientific-it-service-delivery-everest-whitepaper/)
**Published:** March 17, 2026
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> Everest
Industry Whitepaper
# Embedding Scientific Expertise at the Core of Life Sciences IT Service Delivery
We are pleased to bring to you this Everest Group report
Discover why life sciences organizations must bridge the gap between Science and IT. This exclusive report breaks down the frameworks required to drive successful digital initiatives and measurable ROI.
Key risks associated with digital initiatives that are not grounded in scientific expertise.
Benefits of embedding scientific expertise into IT service delivery.
Sourcing considerations for IT service delivery in life sciences and other science-driven industries.
Blueprint for building a science-first digital enterprise.
## Download the Whitepaper
First Name
Last Name
Business Email
Company
By submitting this form, you agree to our [Privacy Policy](/privacy-policy/) and [Terms of Business.](/purchase/)
Get Instant Access
---
### [Our People](https://zifo.com/our-people/)
**Published:** January 10, 2026
**Author:** Zifo_user
**Excerpt:** People who join Zifo are naturally curious and keen to make a difference in the world by helping to advance scientific discovery for a better life, health
**Content:**
[Home](https://zifo.com "Home")> [About Zifo](https://zifo.com/about-zifo/ "About Zifo")> Our People
# Our People
## Curiosity Is In Our DNA
Discover the culture, stories, spirit, and curiosity that make Zifo a thriving global
community of scientific and technology experts
- [ Our Global Teams ](#our-people)
- [ Life at Zifo North America ](#zifo-north-america)
- [ Life at Zifo Europe ](#zifo-europe)
- [ Life at Zifo India ](#zifo-india)
- [ Employee Stories ](#employee-stories)
- [ Our Culture ](#ikikata-section)
- [ Careers ](#careers-section)
### Our Global Teams: Connecting Science and
Technology Worldwide
#### Multinational Expertise
Our teams span key locations globally, bringing together diverse skills and insights to drive scientific breakthroughs.
#### Seamless Collaboration
Cross-border teamwork is the cornerstone of our approach, fostering innovation through shared knowledge and cumulative experience.
#### Local Impact, Global Reach
From each region, we influence local markets while contributing to Zifo’s worldwide footprint and success.
### Life at Zifo: Where Culture Comes Alive
Be it Biriyani Day, Sports Day, or celebrating festivals and personal milestones with renewed vigor
and fervor, Zifo employees showcase the company culture in a colorful and vibrant way.
#### Zifo North America
At our U.S. offices, we thrive in a culture rooted in creativity, curiosity, and cultural awareness. We champion diverse perspectives and bold thinking in a fast-paced, results-driven environment. Whether working on-site or remotely, we prioritize collaboration and heart — ensuring every voice is valued and every success is celebrated.
##### Snacks
Our kitchen is always stocked with healthy options to keep the team fueled and focused throughout the day.
##### Fika
Inspired by the Swedish tradition, this weekly gathering is our time to unplug, enjoy coffee, and engage in meaningful conversation.
##### Monthly Events
From scavenger hunts to holiday celebrations, these gatherings bring the team together for laughter and bonding.
##### Culture Fest
A vibrant annual event where employees and their families celebrate our diverse heritage and cuisines.
#### Wellness Challenges
Engaging initiatives that support mental and physical health, focusing on everything from hydration to mindfulness.
#### Tea Talks
An open, honest forum for employees to share ideas and feedback directly with leadership over a cup of coffee or tea.
#### Celebrating Anniversaries
We honor every milestone, recognizing that each employee’s unique journey is vital to our collective success.
#### Zifo Europe
Zifo Europe is a vibrant tapestry of cultures spanning the UK, France, Germany, Switzerland, Spain, Ireland, and beyond. While our workforce is primarily remote, we bridge the distance through seamless digital collaboration and intentional face-to-face connection.
##### Europe-wide Events
Periodic large-scale gatherings, such as our recent event in Athens, bring together colleagues from across Europe.
##### Christmas Events
Regional teams gather locally to celebrate the holiday season. These events are a time to embrace diverse cultural traditions.
##### Steps Challenge
A collaborative wellness initiative where remote employees contribute their daily activity toward a shared distance goal.
##### Remote Bingo
A high-energy, virtual tradition that brings the team together for fun and friendly competition.
## Zifo India
At Zifo India, celebration is woven into our DNA. With a vibrant community of over 2,000 people, our workplaces reflect the rich diversity of India—from Kashmir to Tamil Nadu. We blend tradition with creativity, bringing our offices to life with festive décor, authentic cuisines, and traditional attire while ensuring a holistic and joyful work environment.
## CELEBRATION
Biriyani Day
A uniquely celebrated tradition that brings together diverse biriyani varieties from across India.
## ZiLeague
Our in-house sports league fuels teamwork and healthy competition across a variety of events, from cricket and badminton to e-sports.
## Boomerang
A TED-style platform where Zifoites share their journeys and ideas. This often includes “Musical Boomerang,” featuring performances by our talented in-house band.
## Tea Talks
Informal and engaging sessions with leadership, based on the belief that the best ideas emerge over a casual cup of tea or coffee.
## Wellness Programs
Holistic initiatives ranging from annual health camps and mindfulness webinars to laughter therapy sessions.
## The Festival Circuit
- **Deepavali:** The “Festival of Lights” celebrating victory of light over
darkness.
- Holi: “Festival of Colors” celebrated with a creative twist.
- **Pongal:** Harvest festival honoring prosperity and new beginnings.
- Onam: Celebrating the homecoming of King Mahabali.
- Christmas & Halloween: Global traditions embraced with equal fervor.
## Beat the Heat
To combat the intense summer, we unwind with seasonal local treats like mango popsicles and ice apples, or a refreshing break with a variety of ice cream scoops.
Employee Stories
INDIA
Christopher McClure
Director, Sales & BD
Have two twin brother dogs that love to run in the woods. Hiking is much more fun chasing them
INDIA
Niveda-Avinashilingam
Lead Consultant
Niveda enjoys experiencing the lovely local german culture and community. She also helped many large pharma companies with their scientific informatics strategies and delivery in both EU and India.
INDIA
Suchitra Ramaswamy (Suchi)
Client Partner
Suchi is often found volunteering in the local community. She has a passion for solving problems and has worked across different Zifo business areas including BD, Clinical and R&D informatics.
INDIA
Kristina Goncharenko
Cluster Lead
Kristina can often be found either on the ski slopes snowboarding or at the beach surfing, and has a background in Chemical Engineering and business development across many different market verticals
INDIA
Lisa Huguenin
Head of People Operations, Americas
People Operations (I love to bake and previously owned my own little cupcake business on the side)
INDIA
Nora Lapusnyik
Partner Success Manager
Nora has a passion for languages - speaking 4 languages, 3 fluently, and she is always learning new ones, and has a background in cheminformatics and and business development through partnering across many different market verticals
##### Our Culture-Ikikata
At Zifo, we believe in fostering a work environment that’s both collaborative and empowering.
#### Collaborative Spirit
Working together to achieve common goals through shared knowledge and mutual support.
#### Empowerment
Encouraging ownership, initiative, and personal growth in every role.
[ Know More ](/our-culture-ikikata/)
#### Zifo is more than just a company
It's a community built on collaboration, passion, and integrity. Join us and be part of something special!
[ Join the Team ](https://careers.zifo.com/)
---
### [Our Culture](https://zifo.com/our-culture-ikikata/)
**Published:** January 9, 2026
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> Our Culture
Our Culture-Ikikata
Where Collaboration and
Care Fuel Success
At Zifo, the philosophy of Care & Dare
shapes everything we do.
Rooted in our strategy of being **People First**, our values are more than principles – they are the
heart of our culture.
We call our cultural values as **Ikikata**, meaning **“Way of Life.”** Everyone in Zifo is bound to being a
custodian of Ikikata by living these values with our team and customers. And we all the more love it
when we have a shared demonstration with our customers.
- [1 One Zifo](#IkitatasectionOne)
- [2 ZAFE team](#IkitatasectionTwo)
- [3 3 Golden Habits](#IkitatasectionThree)
- [4 Curiosity](#IkitatasectionFour)
- [5 Integrity](#IkitatasectionFive)
One Zifo
One Zifo is about moving forward together, ensuring that every step we take brings us closer to **shared success**; by not creating imaginary boundaries.
ZAFE team
With ZAFE (Zeal for Winning and Psychological Safety), we value the **intent** behind every action, ensuring that every effort is appreciated for the **intensity** of action, and people are cared for while daring to unleash the potential. We play a team sport by demonstrating **Care & Dare**
3 Golden Habits
**Appreciation, Thanking and Celebration:** Small gestures make a significant difference. Whether it’s appreciating with immediacy and specificity, thanking for what truly matters, or cheering for one another’s success, our Golden Habits create a ripple effect of being together as a community.
Curiosity
**Fostering Learning and Listening:** Curiosity is in our DNA, where no question is dismissed, and every voice is valued. It encourages us to engage in constructive dissent, without the fear of judgment. With a focus on learning, listening, and **approachable leadership with humbled ego** , curiosity empowers innovation, with our team consultatively engaging with customers.
Integrity
Integrity for us means **doing the right thing even when no one is watching**. It’s about being conscious of what’s right and upholding our values in every rule and context, ensuring that decisions we make reflect integrity and compassion.
## Explore Opportunities with Zifo
It’s a community built on collaboration, passion, and integrity. Join us and be part of something special!
[ Join the Team ](https://careers.zifo.com/)
---
### [Survey](https://zifo.com/survey/)
**Published:** March 11, 2026
**Author:** Zifo_user
**Content:**
## 2026 Biopharma Agentic AI Readiness Survey
Assess your organization’s preparedness for the AI revolution. Your insights help
shape the future of Scientific Workflows.
0 / 9 Completed
↓ Keep scrolling
Section 1: Maturity Assessment
Question 01##### 1. How would you characterize your organization's engagement with "Agentic AI" (autonomous agents)?
A. Unexplored: We are still focused on standard Generative AI (Chat/Summarization).
B. Learning: We are actively evaluating the ROI thus far generated by GenAI and Agentic AI.
C. Experimenting: We have active internal POCs using agents for specific tasks.
D. Piloting: We are running bigger pilots with agents in certain workflows.
E. Production: We have deployed autonomous agents that execute tasks with minimal human oversight.
F. None of the Above. We are neither using AI nor Agentic AI.
Section 2: The Opportunity Landscape
Question 02##### 2. Which operational functions hold the highest potential for Agentic AI automation in the next 12-18 months?
(Multiple Selections Allowed) A. Lab Orchestration (Instrument control/Scheduling)
B. Regulatory Intelligence (Drafting/Verification/Submission)
C. Knowledge Management (Cross-departmental synthesis)
D. Pharmacovigilance / Safety
E. All of the Above
Question 03##### 3. Which stage of the Biopharma Value Chain do you feel holds the highest potential for Agentic AI?
(Multiple Selections Allowed) A. Discovery
B. Preclinical
C. Clinical
D. CMC (Chemistry, Manufacturing, and Controls)
E. Omics
F. Manufacturing / QC
G. All of the Above
Section 3: Strategy & Implementation
Question 04##### 4. How does your organization currently initiate new AI/Agentic projects?
A. Ad-hoc / Bottom-up: Individual scientists running isolated POCs and projects.
B. POC-First: We build rapid "Fail Fast" prototypes before deeper planning.
C. Blueprint-First: We require a strategic roadmap and architecture design before code is written.
D. Vendor-Led: We rely on external partners to demonstrate capabilities first.
E. AI strategy led: Centralised group aggregate project requests and provide delivery support
Question 05##### 5. What are the primary bottlenecks in moving your AI POCs (Proof of Concepts) into production environments?
(Multiple Selections Allowed) A. "Pilot Purgatory" (Successful tech, but no clear path to scale)
B. Data Governance (Data quality insufficient for autonomous agents)
C. Integration Complexity (Agents cannot reliably talk to legacy lab systems)
D. Cost / ROI Unclear (Potentially too expensive to run at scale)
E. Trust / Hallucination Risks (Safety / Regulatory concerns preventing deployment)
F. All of the Above
Section 4: Value Realization (ROI)
Question 06##### 6. How is the Return on Investment (ROI) for your current AI initiatives defined?
(Multiple Selections Allowed) A. Not Defined: Investment is driven by strategic necessity or is too early stage
B. Soft ROI: Measured by time saved or efficiency gains.
C. Hard ROI: Measured by direct cost reduction or headcount avoidance
D. Scientific ROI: Measured by novel discoveries or acceleration of pipeline milestones.
E. All of the Above
Section 5: Data Foundation & Partnerships
Question 07##### 7. How "Agent-Ready" is your current FAIR data implementation?
A. Human-Centric: Data is findable but often trapped in PDFs or proprietary formats.
B. Searchable but Siloed: Limited Metadata allows finding data, but access requires manual work.
C. Machine-Readable: Data is structured (JSON/Parquet) but lacks semantic context.
D. Agent-Native: Data is fully semantic and accessible via standardized APIs (Agents can "read" and "act" on it).
E. Data is not “Agent-Ready”
Question 08##### 8. What role do you expect external partners to play in your Agentic AI roadmap?
A. The Builder: Hands-on coding and integration.
B. The Architect: Strategy, blueprints, and roadmap design.
C. The Governor: Establishing safety, ethics, and validation frameworks.
D. The Accelerator: Providing pre-built agent templates or platforms.
E. All of the Above
Section 6: Final Thoughts
Question 09##### 9. Any specific challenges you foresee in scaling AI agents within your specific domain?
Submit Survey
✅
### Thank you for taking the time to complete this survey.
---
### [Empower3 Basic](https://zifo.com/chromatography-data-systems-and-solutions/trainings-workshops/empower3-basic/)
**Published:** February 2, 2026
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> Empower3 Basic
# Tailored training and individual
workshops for everyone.
# Empower® 3 Basics
In this two-day training, you will learn the basics of operating Waters Empower 3. Based on practical examples and using an HPLC system, you will create methods for data acquisition and evaluation. In all work steps, we take into account the requirements of a GxP laboratory for documentation and traceability.
[ Request Training ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjQ4MDI0IiwidG9nZ2xlIjpmYWxzZX0%3D)
- Overview of the structure of an Empower 3 system
- Login and Project Window- Overview Run Samples
- Instrumentation method: detailed description depending on the equipment used.
- Single injections and editing an instrument method
- Creating sample sets with
Bracketing
Definition of blind runs and control or system suitability samples
Application of custom fields
Shutdown method
- Sample Sets: Run – Edit – Abort
- The queue for sample sets
- Develop a processing method
- Verification of the calibration curve
- the essential components of the peak table
- Processing Method Parameters: Traditional or Apex Track Integration?
- practical exercises with different methods
### **Duration: 2 days**
### **Recommended number of participants: 5**
The training price includes a maximum of 5 training documentations: Empower 3 – Getting Started (59 pages)
[ Register for training ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjQ4MDI0IiwidG9nZ2xlIjpmYWxzZX0%3D)
# Trainings & Workshops
### EMPOWER® 3 INDIVIDUAL
For this training, we will put together a training plan that is tailored to your specific requirements. For example, would you like
[ Learn more here ](/chromatography-data-systems-and-solutions/trainings-workshops/empower3_individual/)
### EMPOWER® 3 DIODE ARRAY OPTION
This course gives you knowledge about the use of diode array detectors from Waters or Agilent. In practical exercises, you will learn the possibilities
[ Learn more here ](/chromatography-data-systems-and-solutions/trainings-workshops/empower3-diode-array-option/)
### EMPOWER® 3 REPORTING
In this training, you will learn the basics of report design and receive tips on layout and design using examples.
[ Learn more here ](/chromatography-data-systems-and-solutions/trainings-workshops/empower3-reporting/)
### EMPOWER® 3 CUSTOM FIELDS
This training is about custom fields, i.e. database fields that can be created by the user to implement user-defined calculations
[ Learn more here ](/chromatography-data-systems-and-solutions/trainings-workshops/empower3-custom-fields/)
### EMPOWER® 3 PROCESSING
In this training you will learn to use the possibilities that are in Empower: organizing samples in sample sets.
[ Learn more here ](/chromatography-data-systems-and-solutions/trainings-workshops/empower3-advanced-processing/)
### EMPOWER® 3 BASICS
In this two-day training course, you will learn the basics of operating Waters Empower 3. Using practical examples and under
[ Learn more here ](/chromatography-data-systems-and-solutions/trainings-workshops/empower3-basic/)
Get in touch
First Name
Last Name
Email
Phone Number
Company
Designation
Enquiry Type
Enquiry Type Request for Zifo Services Product Partnership Job/Internship/Placement Enquiry Other
Message
Acceptance I consent to being contacted by an official Zifo representative
Submit
---
### [About Zifo](https://zifo.com/about-zifo/)
**Published:** February 1, 2026
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> About Zifo
About Zifo
## Zifo is Bilingual
## We speak the language of science and technology. We are the leading global enabler of AI and data-driven enterprise informatics for science-focused organizations.
### Who We Are
We are a team of scientists, engineers, and consultants dedicated to bettering scientific outcomes. By combining deep domain expertise with advanced informatics, we help laboratories and science-focused organizations innovate for a better future.
**The Neutral Advantage:** Our approach is vendor-neutral, allowing us to draw on a vast marketplace of experience and partnerships with top technology providers.
#### Where There Are Scientists, There's Zifo
Innovating for a better future through specialist informatics services.
## Services We Deliver
- [ Digital Transformation ](/services/digital-transformation-consulting-services/)
- [ Business Analysis ](/services/business-analysis-consulting-services/)
- [ Program Management ](/services/project-management-service-company/)
- [ Managed Services ](/services/scientific-application-managed-services/)
- [ Validation & Compliance ](/services/validation-services-and-compliance-support/)
- [ Custom Development ](/services/custom-software-development-service-company/)
- [ Clinical Trials ](/services/clinical-trials-services/)
- [ Clinical Genomics ](/services/clinical-genomics/)
## Our Specialist Expertise
- [ AI and Agentic AI ](/practical-ai-blueprints/)
- [ Strategic Scientific Consulting ](/services/strategic-scientific-consulting-services/)
- [ Bioinformatics & Multiomics ](/services/bioinformatics/)
- [ Chemistry, Manufacturing, and Controls (CMC) ](/services/cmc-services-manufacturing/)
- [ Data Science & Machine Learning (ML) ](/services/data-science-and-consulting-services/)
- [ Cloud & HPC ](/services/scientific-cloud-computing-services/)
- [ Lab Compute ](/services/lab-compute-services/)
- [ Semantics & Ontology ](/services/biomedical-ontology-development-and-governance/)
## Our Reach
## Global Presence
Operating across Americas, Europe, Middle East and Asia.
## Trusted Partners
We are the partner of choice for over **190+ science-focused organizations**worldwide.
## Diverse Industries
Pharma, Biotech, Chemicals, Diagnostic Labs, Food & Beverage, Oil & Gas, and FMCG.
##### Together Science and Technology Can Change Our World
Our expertise spans the whole spectrum of scientific process applications, and we're able to draw on a huge marketplace of experience.
Get in touch
First Name
Last Name
Email
Phone Number
Company
Designation
Enquiry Type
Enquiry Type Request for Zifo Services Product Partnership Job/Internship/Placement Enquiry Other
Message
Acceptance I consent to being contacted by an official Zifo representative
Submit
Our Culture
###### Our Business is Our People
At Zifo, there is a real sense of being "in it together"— scientists working with scientists.
[ Join Our Team ](https://careers.zifo.com/)
---
### [Industries](https://zifo.com/industries/)
**Published:** January 14, 2026
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> Industries
Industries
Where science happens, Zifo is there — supporting the entire value chain of science-focused industries.
Services White Papers Blogs News
Industries
[  ](https://zifo.com/industries/biotech-informatics-and-consulting-services/)
### [Small and Medium Biotech](https://zifo.com/industries/biotech-informatics-and-consulting-services/)
[ Read Now ](https://zifo.com/industries/biotech-informatics-and-consulting-services/)
[  ](https://zifo.com/industries/agrotech-informatics-and-consulting-services/)
### [Agrotech](https://zifo.com/industries/agrotech-informatics-and-consulting-services/)
[ Read Now ](https://zifo.com/industries/agrotech-informatics-and-consulting-services/)
[  ](https://zifo.com/industries/speciality-chemicals-informatics-and-consulting-services/)
### [Specialty Chemicals](https://zifo.com/industries/speciality-chemicals-informatics-and-consulting-services/)
[ Read Now ](https://zifo.com/industries/speciality-chemicals-informatics-and-consulting-services/)
[  ](https://zifo.com/industries/pharmaceutical-informatics-and-consulting-services/)
### [Large Pharma and Biotech](https://zifo.com/industries/pharmaceutical-informatics-and-consulting-services/)
[ Read Now ](https://zifo.com/industries/pharmaceutical-informatics-and-consulting-services/)
[  ](https://zifo.com/industries/fmcg-informatics-and-consulting-services/)
### [Fast-Moving Consumer Goods](https://zifo.com/industries/fmcg-informatics-and-consulting-services/)
[ Read Now ](https://zifo.com/industries/fmcg-informatics-and-consulting-services/)
[  ](https://zifo.com/industries/food-and-beverage-informatics-and-consulting-services/)
### [Food & Beverage](https://zifo.com/industries/food-and-beverage-informatics-and-consulting-services/)
[ Read Now ](https://zifo.com/industries/food-and-beverage-informatics-and-consulting-services/)
White Papers
### [STREAMLINING PHARMA PRODUCT DEVELOPMENT THROUGH DIGITAL COACHING](https://zifo.com/?p=12737)
Mehnaz Husain
[ Read Now ](https://zifo.com/?p=12737)
### [The Role of Scientific Business Systems Analysts in Driving Science Forward](https://zifo.com/?p=12723)
Aishwarya Balajee
[ Read Now ](https://zifo.com/?p=12723)
[  ](https://zifo.com/?p=12718)
### [Informatics Vendor Evaluation Approach](https://zifo.com/?p=12718)
Uma Maheswari Adiseshan
[ Read Now ](https://zifo.com/?p=12718)
### [CDISC SEND FAIR data guide](https://zifo.com/?p=12702)
Aishwarya Balajee
[ Read Now ](https://zifo.com/?p=12702)
### [ePRO- Subject centric approach](https://zifo.com/?p=11809)
Amal Krishna Girish
[ Read Now ](https://zifo.com/?p=11809)
[  ](https://zifo.com/?p=11616)
### [ARTIFICIAL INTELLIGENCE IN THE PHARMACEUTICAL INDUSTRY PART 1 – Drug Discovery & Preclinical Development](https://zifo.com/?p=11616)
David Jackson
[ Read Now ](https://zifo.com/?p=11616)
Blogs
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
Sakthi Prasad T, Content Director
[ Read Now ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
Sakthi Prasad T, Content Director
[ Read Now ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
Shivani Vohra, Consulting Analyst
[ Read Now ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/the-first-mile-of-lab-data-operationalizing-data-flow-in-heterogeneous-research-environments/)
### [The “First Mile” of Lab Data: Operationalizing Data Flow in Heterogeneous Research Environments](https://zifo.com/blogs/the-first-mile-of-lab-data-operationalizing-data-flow-in-heterogeneous-research-environments/)
Sakthi Prasad T, Content Director
[ Read Now ](https://zifo.com/blogs/the-first-mile-of-lab-data-operationalizing-data-flow-in-heterogeneous-research-environments/)
[  ](https://zifo.com/blogs/design-of-experiments-labs-confront-the-challenge-of-capturing-experimental-intent/)
### [Design of Experiments: Labs Confront the Challenge of Capturing Experimental Intent](https://zifo.com/blogs/design-of-experiments-labs-confront-the-challenge-of-capturing-experimental-intent/)
Rahul Anil Babu, Scientific Application Consultant
[ Read Now ](https://zifo.com/blogs/design-of-experiments-labs-confront-the-challenge-of-capturing-experimental-intent/)
[  ](https://zifo.com/blogs/beyond-the-rigidity-how-abbvies-platform-adapt-to-cmc-science/)
### [Beyond the Rigidity: How AbbVie’s Platform Adapts to CMC Science](https://zifo.com/blogs/beyond-the-rigidity-how-abbvies-platform-adapt-to-cmc-science/)
Sakthi Prasad T, Content Director
[ Read Now ](https://zifo.com/blogs/beyond-the-rigidity-how-abbvies-platform-adapt-to-cmc-science/)
News
[  ](https://zifo.com/news/zifo-co-launches-real-2026-to-spotlight-the-next-generation-of-connected-ai-enabled-lab-environments/)
### [Zifo Co-Launches REAL 2026 to Spotlight the Next Generation of Connected, AI-Enabled Lab Environments](https://zifo.com/news/zifo-co-launches-real-2026-to-spotlight-the-next-generation-of-connected-ai-enabled-lab-environments/)
[ Read Now ](https://zifo.com/news/zifo-co-launches-real-2026-to-spotlight-the-next-generation-of-connected-ai-enabled-lab-environments/)
[  ](https://zifo.com/news/cmc-bottleneck-is-choking-biopharmas-drug-pipeline-says-zifo/)
### [CMC Bottleneck is Choking Biopharma’s Drug Pipeline, says Zifo](https://zifo.com/news/cmc-bottleneck-is-choking-biopharmas-drug-pipeline-says-zifo/)
[ Read Now ](https://zifo.com/news/cmc-bottleneck-is-choking-biopharmas-drug-pipeline-says-zifo/)
[  ](https://zifo.com/news/zifo-accelerates-lims-master-data-validation-with-new-ai-enabled-services-accelerator/)
### [Zifo Accelerates LIMS Master Data Validation with New AI-Enabled Services Accelerator](https://zifo.com/news/zifo-accelerates-lims-master-data-validation-with-new-ai-enabled-services-accelerator/)
[ Read Now ](https://zifo.com/news/zifo-accelerates-lims-master-data-validation-with-new-ai-enabled-services-accelerator/)
[  ](https://zifo.com/news/zifo-open-quiz-2026-draws-over-1200-quizzers-on-independence-day/)
### [Zifo Open Quiz 2026 Draws Over 1,200 Quizzers on Independence Day](https://zifo.com/news/zifo-open-quiz-2026-draws-over-1200-quizzers-on-independence-day/)
[ Read Now ](https://zifo.com/news/zifo-open-quiz-2026-draws-over-1200-quizzers-on-independence-day/)
[  ](https://zifo.com/news/change-management-strategies-elevating-digital-transformation-in-pharma/)
### [Conquering Biopharma’s ‘Mount Everest’: The Human Element of Digital Transformation](https://zifo.com/news/change-management-strategies-elevating-digital-transformation-in-pharma/)
[ Read Now ](https://zifo.com/news/change-management-strategies-elevating-digital-transformation-in-pharma/)
[  ](https://zifo.com/news/zifo-to-present-biobank-data-breakthrough-at-the-festival-of-genomics-boston/)
### [Zifo to Present Biobank Data Breakthrough at the Festival of Genomics Boston](https://zifo.com/news/zifo-to-present-biobank-data-breakthrough-at-the-festival-of-genomics-boston/)
[ Read Now ](https://zifo.com/news/zifo-to-present-biobank-data-breakthrough-at-the-festival-of-genomics-boston/)
---
### [CLEAR – Efficient Empower3 Result](https://zifo.com/chromatography-data-systems-and-solutions/solutions/clear-efficient-empower3-result/)
**Published:** January 30, 2026
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> CLEAR – Efficient Empower3 Result
# CLEAR - Efficient Empower3 Result- and Audit Trail-Reviews
## Optimize and automate the review process in the laboratory with the CLEAR ToolKit app.
[ See How ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjQ0NjM0IiwidG9nZ2xlIjpmYWxzZX0%3D)
### Developed by Empower experts to solve data integrity challenges!
CLEAR is the extension to your Empower 3 system that automates and digitizes the second person check and audit trail review.
### Replace your paper checklists!
CLEAR is more than the digital replacement of your old paper checklist. CLEAR guides the user through the review process and presents the necessary Empower data for each check point in such a way that a quick and reliable check is possible. No data to search and view filters to build, CLEAR shows what you need to see.
### Fully integrated into your existing CDS
But not only the implementation will convince you, the review process itself is also optimized and well thought out. Based on the required “risk-based approach” we examined what information is relevant and what is unimportant. The result is an efficient process that ensures the integrity of the Empower Results without taking up unnecessary time.
### Together with our SOP-Box we optimize your work processes!
CLEAR stores all review result in Empower. This means that the documentation of the review is always immediately available. The completion can then be confirmed in Empower by an electronic signature.
[ More Details ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjQ0NjM0IiwidG9nZ2xlIjpmYWxzZX0%3D)
## Your Advantages & Possibilities
Start CLEAR directly from Empower. As a toolkit app, CLEAR is fully integrated into Empower.
No administrative effort is necessary, since the Empower user administration is taken over by CLEAR.
CLEAR was developed for the pharmaceutical laboratory and meets regulatory requirements.
CLEAR optimally prepares the data to be reviewed and ensures an integral and efficient review.
CLEAR guides the user step-by-step through the defined review process. This avoids all errors and speeds up the review.
The data integrity of your analysis is thus ensured.
The many years of experience in supporting Empower installations and the deep knowledge of data integrity requirements have gone into the development of CLEAR. This resulted in a product that makes the review process extremely effective and compliant.
CLEAR ensures a paperless review, saving you time and resources in documentation.
Go confidently into every audit with CLEAR.
## Our Products
### Empower 3 manual
[ Find out more here ](/chromatography-data-systems-and-solutions/solutions/empower-3-manual/)
### Empower 3 Custom Fields Guide
[ Find out more here ](/chromatography-data-systems-and-solutions/trainings-workshops/empower3-custom-fields/)
### SOP box
[ Find out more here ](/chromatography-data-systems-and-solutions/solutions/sop-box/)
### CSV box
[ Find out more here ](/chromatography-data-systems-and-solutions/solutions/csv-box/)
### CIQ – Customized Instrument Qualification
[ Find out more here ](/chromatography-data-systems-and-solutions/solutions/ciq-customised-instrument/)
### Peakprovider 2.0 for Empower
[ Find out more here ](/chromatography-data-systems-and-solutions/solutions/peakprovider-2-0-for-empower/)
### Rhizomer
[ Find out more here ](/chromatography-data-systems-and-solutions/solutions/rhizomer/)
### CLEAR – Efficient Empower3 Result- and Audit Trail-Reviews
[ Find out more here ](/chromatography-data-systems-and-solutions/solutions/clear-efficient-empower3-result/)
### CUT – Content Uniformity Template
[ Find out more here ](/chromatography-data-systems-and-solutions/solutions/cut-content-uniformity/)
### LEI – LabX-Empower-Integration
[ Find out more here ](/chromatography-data-systems-and-solutions/solutions/lei-labx-empower-integration/)
Get in touch
First Name
Last Name
Email
Phone Number
Company
Designation
Enquiry Type
Enquiry Type Request for Zifo Services Product Partnership Job/Internship/Placement Enquiry Other
Message
Acceptance I consent to being contacted by an official Zifo representative
Submit
---
### [Empower3 Custom Fields](https://zifo.com/chromatography-data-systems-and-solutions/trainings-workshops/empower3-custom-fields/)
**Published:** February 3, 2026
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> Empower3 Custom Fields
# Tailored training and individual
workshops for everyone.
# Empower® 3 Custom Fields
This training is about custom fields, i.e., database fields that can be created by the user to implement user-defined calculations in Empower or to create space for additional inputs. The training uses real-world examples to illustrate how to set up Custom Fields The approaches presented are chosen to cover the most common use cases. Participants gain a solid understanding of the methodology and are thus enabled to use custom fields to map their own requirements in a meaningful way.
[ Register for training ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjQ3OTU4IiwidG9nZ2xlIjpmYWxzZX0%3D)
Step by step, requirements are described as they might arise from test specifications in the analytical laboratory. The trainers explain the concrete implementation using Empower Custom Fields and define the prerequisites for correct functioning.
**Prerequisite: Deep understanding of Empower 3 functionality and fields.**
**Duration: 1 day**
**Recommended number of participants: maximum 5**
The training price includes a maximum of 5 training documentations: Empower 3 – Practical Guide to Custom Fields (72 pages)
# Trainings & Workshops
### EMPOWER® 3 INDIVIDUAL
For this training, we will put together a training plan that is tailored to your specific requirements. For example, would you like
[ Learn more here ](/chromatography-data-systems-and-solutions/trainings-workshops/empower3_individual/)
### EMPOWER® 3 DIODE ARRAY OPTION
This course gives you knowledge about the use of diode array detectors from Waters or Agilent. In practical exercises, you will learn the possibilities
[ Learn more here ](/chromatography-data-systems-and-solutions/trainings-workshops/empower3-diode-array-option/)
### EMPOWER® 3 REPORTING
In this training, you will learn the basics of report design and receive tips on layout and design using examples.
[ Learn more here ](/chromatography-data-systems-and-solutions/trainings-workshops/empower3-reporting/)
### EMPOWER® 3 CUSTOM FIELDS
This training is about custom fields, i.e. database fields that can be created by the user to implement user-defined calculations
[ Learn more here ](/chromatography-data-systems-and-solutions/trainings-workshops/empower3-custom-fields/)
### EMPOWER® 3 PROCESSING
In this training you will learn to use the possibilities that are in Empower: organizing samples in sample sets.
[ Learn more here ](/chromatography-data-systems-and-solutions/trainings-workshops/empower3-advanced-processing/)
### EMPOWER® 3 BASICS
In this two-day training course, you will learn the basics of operating Waters Empower 3. Using practical examples and under
[ Learn more here ](/chromatography-data-systems-and-solutions/trainings-workshops/empower3-basic/)
Get in touch
First Name
Last Name
Email
Phone Number
Company
Designation
Enquiry Type
Enquiry Type Request for Zifo Services Product Partnership Job/Internship/Placement Enquiry Other
Message
Acceptance I consent to being contacted by an official Zifo representative
Submit
---
### [General Terms of Business](https://zifo.com/purchase/)
**Published:** January 23, 2026
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> General Terms of Business
# Zifo General Terms of Business
## Terms and Conditions
General
- Only the Purchase Order issued by Zifo, and duly signed, is valid order for supply.
- Absence of communication to Zifo Vendor Management Team () about any of these terms & conditions within 7 days from receipt of this order will constitute acceptance by the supplier. The supply of goods as per this order will constitute supplier’s acceptance of the terms & conditions of the order. These terms and conditions shall override any terms and conditions issued by supplier with his proposal, unless specifically agreed by Zifo in writing.
- Any terms and conditions rescinding, adding to or altering the terms of the Purchase Order subsequently shall always be in writing. All such additions, alterations or deletions shall be deemed to be incorporated herein and made part of the Purchase Order.
- In the event of any breach of these terms and conditions on the part of the Supplier, the Supplier agrees to compensate to us in such manner as may be reasonably determined.
- The Supplier shall not assign the Purchase Order to any other party.
- The Supplier is forbidden to offer any commission, brokerage or other gratification to any of our employees. This Purchase Order shall be governed and construed in accordance with the laws of India.
- It is agreed that any dispute arising in respect of this Purchase Order shall be decided by a competent Court in Chennai and shall be subject to the jurisdiction of Chennai Courts only.
Delivery & acceptance
- All materials ordered herein are to be supplied, carriage paid to the receiving address as specified in the Purchase Order, before 4 p.m. on working days. No charges for packing, boxing or carting will be accepted unless authorized by this Purchase Order. The goods are not to be insured for transit risk unless otherwise authorized by us.
- The services to be rendered at designated place only and shall be as per agreed conditions mentioned therein.
- Material shall be received (subject to inspection & approval) only if they are as per the agreed description, specification, as per latest approved samples and packing.
- The delivery challan, invoice/ bills should indicate our Order No. and date and should be submitted in DUPLICATE, failing which the deliveries are likely to be refused or payment delayed.
Rejection & cancellation
- The goods delivered after date specified in PO may be refused for acceptance and no payment shall be made for such rejected goods/services. The company reserves right of applying penalty for late delivery.
- Goods delivered in excess of the quantities ordered will be accepted as per discretion of Zifo and all charges resulting from such delivery will be held at the supplier’s risk and must be removed by the Supplier entirely at his expense.
- Rejected goods shall be held at the Supplier’s risk and must be removed by the Supplier entirely at his expense within seven days of our intimation and / or receipt of our rejection memo. We should be given disposal advice by the supplier; else we shall be free to dispose the goods after the due date & shall not be liable to compensate the supplier for any losses.
- Rejected goods bearing our trademark or emblems etc. would not be returned to the Supplier and would be destroyed at our end to avoid misuse.
- We reserve the right to cancel the PO if the service is deficient w.r.t agreed quality or specification. In such case, the payment shall be made on pro rata basis for the accepted part.
- We reserve the right to cancel or defer this Purchase Order or any part thereof during business interruption due to fire, flood, riot, ‘force majeure’ or from any other cause or causes beyond our control or from any changes in govt. rules / statutes.
Production, fabrication of goods / fulfillment of order
- All items manufactured by the Supplier according to our blueprints, drawings, designs, manufacturing data, specifications or information pertaining thereto furnished to the Supplier by us, shall not be utilized by the Supplier or anyone on his behalf for sale, manufacture or for any other purpose save as agreed by us in writing. All blueprints, drawings, designs, prototypes, blocks, etc. entrusted by us to the Supplier against our specific order/s shall be our property and are returnable to us on demand.
- We reserve the right at any time to make changes in drawings or specifications of the materials and /or work covered by this Purchase Order. In such event if any increase or decrease is caused in the cost of production, the price mentioned in this Purchase Order shall be equitably adjusted.
- The Supplier shall be responsible for compliance with all applicable laws, rules, regulations, central and/ or local, during performance of this Purchase Order and shall keep us indemnified against any liability on account of non-compliance.
- Any online print rejections which bear Zifo name, logo, product name, which is produced during the course of production/printing, shall not be disposed as scrap without defacing the company name, logo & product name. No such printed material shall be disposed in public place.
- Our authorized representatives shall be allowed to inspect the material ordered at any stage of their manufacture.
Supplier's obligations
The following conditions are binding on supplier upon acceptance of the order
- The Supplier shall treat any information relating to our products and / or business which may become available to him in the course of performance of this Purchase Order as strictly confidential and shall not disclose the same to any third party at any time. This obligation shall survive the fulfillment of this Purchase Order.
- The Supplier guarantees that the sale or use of his products will not infringe any Indian or Foreign patent, design or trade mark and undertakes to indemnify and keep us indemnified against any actions, judgment, decrees, costs, claims, demands and expenses resulting from any actual or alleged infringement. The Supplier further undertakes at his own expense to defend or assist in the defense of any suit or action which may be brought in this connection.
- Commitment to sustainable development: Zifo is committed to prefer suppliers who respect the principles of ‘Sustainable development, viz. human rights protection, environment friendly technology, right labor practices and non corruption. It is fully expected that the suppliers support these principles in course of their supply to us. The supplier must undertake to comply with existing laws w.r.t. environmental impacts & pollution, labor laws (no forced labor, child labor, social benefits etc.) and anti-corruption laws. Zifo reserves the rights to perform internal/external audit/checks to confirm the compliance to principles of sustainable development.
Billing & payment
- Bills to be submitted directly to the Accounts Payable dept () over an email with PDF copy as attachment.
- Bills must quote the Purchase Order reference number to be accepted for processing.
- Bill to be submitted to Zifo only after delivery of goods / completion of services/ as agreed with the Business Owner in Zifo
- All bills submitted in line with our guidelines will be processed as per the agreed payment terms with vendor.
Anti-bribery
- Supplier/Contractor represents and warrants that neither it nor any of Supplier/ Contractor’s personnel are officials, agents, representatives or employees of any government or political party or any international public organization where you/they may be in a position of official government authority able to use that position to help Supplier/ Contractor obtain or maintain business or obtain a business advantage.
- Supplier/ Contractor further represents and warrants that it has not made and agree that it shall not make any payment or any offer or promise for payment, either directly or indirectly, of money or other assets, or transfer anything of value, to government or political party officials, officials of international organizations, candidates for public office, or representatives of other businesses or persons acting on behalf of any of the foregoing for the purpose of influencing decisions or actions or where such payment or advantage would constitute violation of any applicable anti-bribery legislation, regulations and/or codes, both Local and State and/or national and foreign, including but not limited to the US Foreign Corrupt Practices Act and the UK Bribery Act (hereinafter and above designated by “Antibribery Provisions”).
- Supplier/ Contractor further represents and warrants that it has not accepted nor been offered any payment of money or other assets, or anything of value, for the purpose of influencing decisions or actions to help Supplier/ Contractor obtain or maintain business or obtain a business advantage where such payment or advantage would constitute violation of any applicable Anti-Bribery Provisions.
Conflict of interest
- Supplier/Contractor warrants that, to the best of its knowledge, it does not have, and is not likely to have, a conflict of interest in the performance of this Agreement.
- If a conflict or risk of conflict of interest arises during the term of this PO/ Agreement, Supplier/Contractor shall immediately give notice of the conflict of interest, or the risk of it, to Zifo.
- Supplier/ Contractor must:
- take all reasonable measures to ensure that its employees, agents, and subcontractors do not engage in any activity or obtain any interest which is in conflict with Supplier/ Contractor’s ability to provide the services to Zifo fairly and independently; and
- Immediately give notice of any Supplier/conflict of interest relating to the activities or interests of any of its employees, agents, or sub-contractors to Zifo.
- Upon receipt of such notice or upon Zifo otherwise identifying a conflict of interest, Zifo may elect to terminate this PO/ Agreement.
Confidential information
The Parties shall not at any time during or after the term of this Contract, divulge, to any person, any Confidential Information relating to the other Party (including, but not limited to, any information relating to the accounts, finance, trade secrets, knowhow, intellectual property, contractual arrangement, products, business or affairs of the parties) unless
- the said information comes in public domain without breach by either party,
- is already in the possession of the receiving Party at the time of disclosure, as evident from its files and record
- is obtained by the receiving Party from a third party without a breach of such third party’s obligations of confidentiality
- is independently developed by the receiving Party without use of or reference to the disclosing Party’s information as shown by documents and other evidence in the receiving Party’s possession Is required by law / applicable stock exchange listing rule, to be disclosed by the receiving Party, provided that the receiving Party gives the disclosing Party prompt written notice of such requirement prior to such disclosure and assists in obtaining an order protecting the information from disclosure.
Audit & Inspection
Zifo has the right to audit Supplier records to confirm compliance with the relevant provisions hereof and with applicable laws. Such audit may be either a documentary audit or otherwise, and will be performed at reasonable times and places, upon reasonable notice, and at Zifo’s sole expense, either with Zifo’s internal auditors or a third party nominated by Zifo. Supplier agrees to provide Zifo with access to relevant systems, documentation and individuals for the purposes of conducting the audit. Supplier shall permit any inspection of its processes, documents and premises by or on behalf of regulatory authorities, and shall have the resources available to address the requests of all inspectors, irrespective of which site or company of Suppler or which site or company in the Zifo group is concerned by the inspection. Documents maintained by Supplier must be ‘inspection-ready’. Supplier shall not charge Zifo for its time associated with assisting the authorities during such inspections. Supplier will take all appropriate measures to implement preventative and corrective actions for all issues detected during audits or inspections.
Withholding tax
- If the work is done through a permanent establishment/business connection in India then appropriate withholding tax will be deducted when making the payment the PO.
- Tax Certificate can be provided upon request for taxes withheld.
- The payment shall be made by cheque/bank transfer & dispatched/credited to supplier’s address/bank account (no hand delivery) OF PURCHASE ORDER
---
### [Modern Slavery Act Statement](https://zifo.com/modern-slavery-act-statement/)
**Published:** January 27, 2026
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> Modern Slavery Act Statement
# Modern Slavery Act Statement
Objective
Modern slavery is a heinous crime and a morally reprehensible act that deprives a person’s liberty and dignity for another person’s gain. It is a real problem for millions of people around the world. Every company is at risk of being involved in this crime through its own operations and its supply chain.
At Zifo and its affiliates operating in the jurisdictions as detailed on our website, we have a zero-tolerance approach to modern slavery and are fully committed to preventing slavery and human trafficking in our operation and supply chain. We have taken steps to tackle modern slavery, as outlined in our statement.
This statement sets out the actions that we have taken to understand all potential modern slavery risks related to our business, and to implement steps to prevent slavery and human trafficking during the financial year 2025/26.
This statement is published in line with:
- Section 54(1) of the Modern Slavery Act 2015.
- Article 5 of the European Union agency for Fundamental Rights **“Slavery / Forced Labour”.**
About Zifo
Zifo is the leading global enabler of AI and data driven enterprise informatics for science driven organizations. With extensive solutions and services expertise spanning research, development, manufacturing, and clinical domains, we serve a diverse range of industries, including Pharma, Biotech, Chemicals, Food and Beverage, Oil & Gas, and FMCG. Trusted by over 190 science-focused organizations worldwide, Zifo is the partner of choice for advancing digital scientific innovation.
Our Supply Chain
**Purchase of Physical Goods** Zifo does not require raw materials or purchase goods. Should we purchase from a supplier then we carry out due diligence to ensure compliance with our own standards and the respective national and international laws.
**Purchase of Services** Our subcontracting people needs are for highly scientific and motivated personnel. We use a very small number of subcontracting companies and we know each supplier well. As we onboard new suppliers we check their risk level and compliance with our standards and the law. We will never use a supplier where there is a risk of non-compliance.
Our other needs include travel and accommodation, legal and financial advisory services. These are purchased from reputable companies which have a very low risk of non-compliance.
At no time will Zifo enter into any agreement or contract with an organization where this is a likelihood that there is non-compliance with the law or this Statement.
Policies and Training
Zifo operates the following policies and training for identifying and preventing slavery and human trafficking in our operations:
- Whistleblowing Policy – we encourage all employees, customers and suppliers to report any suspicion of slavery or human trafficking without fear of retaliation.
- Ikikata – our code of conduct / values encourages employees to do the right thing by clearly stating the actions and behaviour expected of them when representing the business. We strive to maintain the highest standards of employee conduct and ethical behaviour when operating abroad and managing our supply chain.
- Statement Acknowledgement – all our people sign to say they have read and agree to this statement.
- Training – we offer e-learning courses to all employees throughout Zifo Technologies which covers various forms of modern slavery and human trafficking.
Embedding our ways
- By providing awareness training to our people and informing them of the appropriate action to take if they suspect a case of slavery or human trafficking we will achieve our objective.
- We continually ensure anyone involved in procurement activity are aware of and follow modern slavery procurement guidance set out in their country.
- Continuing to take action to embed a zero tolerance policy towards modern slavery.
Our Promise
As an equal opportunities employer, we strive to create a non-discriminatory and respectful working environment for our people. Our Ikikata include creating a **“Zafe Team”** with Integrity. We empower our people to expose wrongdoing without any risk to themselves.
Our recruitment and people management processes are designed to ensure that all prospective employees are legally entitled to work in the UK and other Country in which we operate and to safeguard our people from any abuse or coercion.
We will not enter into business with any organisation, in the UK or abroad, which knowingly supports or is found to be involved in slavery, servitude and forced or compulsory labour.
Approval
This statement has been approved by **Raj Prakash Govindarajan,** CEO for the financial year ending 31 March 2026.
**Raj Prakash Govindarajan**
**CEO**
---
### [Zifo’s Environmental Commitment](https://zifo.com/zec/)
**Published:** January 27, 2026
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> Zifo’s Environmental Commitment
# Zifo’s Environmental Commitment
We firmly believe in being environment-friendly and delivering our services of high quality in harmony with the environment. Since our operations are primarily centered around offering technological services to our customers, energy conservation and waste management are our key responsible areas.
We are committed to working continuously on our environmental practices in the key responsible areas and utilizing the opportunities to minimize the potential impacts as much as possible. We will incorporate environmental best practices in our operations across all our offices to ensure a sustainable environmental future.
Through our environmental practices, we will work towards:
Operations and Functions:
- Ensuring responsible usage of the resources in our daily operations.
- Minimizing the usage of environmentally unfriendly one-time/disposable products.
- Moving to a paperless recruitment process and electronic signature process to reduce the usage of papers.
- Creating awareness of our environmental commitment among our employees and other stakeholders.
Energy and Water Consumption:
- Committing to conserving energy through the usage of products like LED lights that reduce consumption and chiller plants for ACs to reduce greenhouse gas emissions.
- Committing to reducing water consumption by using water taps with aerators to restrict water outflow.
- Committing to reducing our carbon footprint by a mindful consumption of energy and resources.
Dry Waste and E-Waste Management:
- Segregation, disposal, and management of waste generated from our office premises.
- Monitoring e-waste created by our activities and disposing of the used devices with a government-authorized e-waste agency.
Reviews and Updates:
- Making efforts to continually improve our environmental sustainability practices aligned to the nature of our business.
- Reviewing and upgrading this commitment from time to time to stay relevant to the current conditions.
- Conducting refresher sessions for our employees as and when the environmental commitment goes through a series of major changes as part of upholding the awareness.
*The PDF report is embedded on this page. Please scroll to read or download it. Download option button is available below the PDF embed*
Click here to Download the ESG Report
---
### [Empower3 Reporting](https://zifo.com/chromatography-data-systems-and-solutions/trainings-workshops/empower3-reporting/)
**Published:** February 16, 2026
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> Empower3 Reporting
# Tailored training and individual
workshops for everyone.
# Empower®3 Reporting
Reports in Empower offer a variety of options for presenting results and are the basis for exporting data. In this training, you will learn the basics of report design and receive tips on layout and design. Using the example of a single and a summary report, you will create report methods for the output of a result set.
[ Request for Training ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjU4OTc0IiwidG9nZ2xlIjpmYWxzZX0%3D)
- Report Publisher Overview
- Generating a single report
- Basics of report creation
- Layout and design tips
- Generating a summary report with
Filtering of data
Grouping of data
- Chromatograms and charts
- Manage reports
**Prerequisite: Participation in the training “Empower 3 Basics” or corresponding basic knowledge.**
**Duration: 1 day**
**Recommended number of participants: maximum 5**
The training price includes a maximum of 5 training documentations: Empower 3 – Reporting (55 pages)
# Trainings & Workshops
### EMPOWER® 3 INDIVIDUAL
For this training, we will put together a training plan that is tailored to your specific requirements. For example, would you like
[ Learn more here ](/chromatography-data-systems-and-solutions/trainings-workshops/empower3_individual/)
### EMPOWER® 3 DIODE ARRAY OPTION
This course gives you knowledge about the use of diode array detectors from Waters or Agilent. In practical exercises, you will learn the possibilities
[ Learn more here ](/chromatography-data-systems-and-solutions/trainings-workshops/empower3-diode-array-option/)
### EMPOWER® 3 REPORTING
In this training, you will learn the basics of report design and receive tips on layout and design using examples.
[ Learn more here ](/chromatography-data-systems-and-solutions/trainings-workshops/empower3-reporting/)
### EMPOWER® 3 CUSTOM FIELDS
This training is about custom fields, i.e. database fields that can be created by the user to implement user-defined calculations
[ Learn more here ](/chromatography-data-systems-and-solutions/trainings-workshops/empower3-custom-fields/)
### EMPOWER® 3 PROCESSING
In this training you will learn to use the possibilities that are in Empower: organizing samples in sample sets.
[ Learn more here ](/chromatography-data-systems-and-solutions/trainings-workshops/empower3-advanced-processing/)
### EMPOWER® 3 BASICS
In this two-day training course, you will learn the basics of operating Waters Empower 3. Using practical examples and under
[ Learn more here ](/chromatography-data-systems-and-solutions/trainings-workshops/empower3-basic/)
Get in touch
First Name
Last Name
Email
Phone Number
Company
Designation
Enquiry Type
Enquiry Type Request for Zifo Services Product Partnership Job/Internship/Placement Enquiry Other
Message
Acceptance I consent to being contacted by an official Zifo representative
Submit
---
### [Empower3 diode array option](https://zifo.com/chromatography-data-systems-and-solutions/trainings-workshops/empower3-diode-array-option/)
**Published:** February 3, 2026
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> Empower3 diode array option
# Tailored training and individual
workshops for everyone.
# Empower 3 Diode Array Option
[ Register for training ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjQ4MzEzIiwidG9nZ2xlIjpmYWxzZX0%3D)
**Prerequisite: Participation in the training “Empower 3 Basics” or corresponding basic knowledge.**
**Duration: 1 day**
**Recommended number of participants: maximum 5**
The training price includes a maximum of 5 training documentations: Empower 3 – Diode Array (43 pages)
# Trainings & Workshops
### EMPOWER® 3 INDIVIDUAL
For this training, we will put together a training plan that is tailored to your specific requirements. For example, would you like
[ Learn more here ](/chromatography-data-systems-and-solutions/trainings-workshops/empower3_individual/)
### EMPOWER® 3 DIODE ARRAY OPTION
This course gives you knowledge about the use of diode array detectors from Waters or Agilent. In practical exercises, you will learn the possibilities
[ Learn more here ](/chromatography-data-systems-and-solutions/trainings-workshops/empower3-diode-array-option/)
### EMPOWER® 3 REPORTING
In this training, you will learn the basics of report design and receive tips on layout and design using examples.
[ Learn more here ](/chromatography-data-systems-and-solutions/trainings-workshops/empower3-reporting/)
### EMPOWER® 3 CUSTOM FIELDS
This training is about custom fields, i.e. database fields that can be created by the user to implement user-defined calculations
[ Learn more here ](/chromatography-data-systems-and-solutions/trainings-workshops/empower3-custom-fields/)
### EMPOWER® 3 PROCESSING
In this training you will learn to use the possibilities that are in Empower: organizing samples in sample sets.
[ Learn more here ](/chromatography-data-systems-and-solutions/trainings-workshops/empower3-advanced-processing/)
### EMPOWER® 3 BASICS
In this two-day training course, you will learn the basics of operating Waters Empower 3. Using practical examples and under
[ Learn more here ](/chromatography-data-systems-and-solutions/trainings-workshops/empower3-basic/)
Get in touch
First Name
Last Name
Email
Phone Number
Company
Designation
Enquiry Type
Enquiry Type Request for Zifo Services Product Partnership Job/Internship/Placement Enquiry Other
Message
Acceptance I consent to being contacted by an official Zifo representative
Submit
---
### [Empower3 Advanced Processing](https://zifo.com/chromatography-data-systems-and-solutions/trainings-workshops/empower3-advanced-processing/)
**Published:** February 2, 2026
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> Empower3 Advanced Processing
# Tailored training and individual workshops for everyone.
## Empower® 3 Advanced Processing
In this training, you will learn to use the possibilities that Empower offers: organizing samples into sample sets and
using integration events, peak grouping, and suitability functions with the help of real-life case studies.
[ Register for training ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjQ4NDU2IiwidG9nZ2xlIjpmYWxzZX0%3D)
- Parameters of the Processing Method
- Comparison traditional vs. ApexTrack integration
- Parameters of the Component Table: Application by means of examples
- The processing of channels with different processing methods
- Peak Grouping and System Suitability Functions
- Manual integration and reprocessing of results
- ICH Impurity Function
- Audit trail functions
**Prerequisite: Participation in the training “Empower 3 Basics” or corresponding basic knowledge.**
**Duration: 1 day**
**Recommended number of participants: maximum 5**
The training price includes a maximum of 5 training documentations: Empower 3 – Advanced Processing (60 page)
# Trainings & Workshops
### EMPOWER® 3 INDIVIDUAL
For this training, we will put together a training plan that is tailored to your specific requirements. For example, would you like
[ Learn more here ](/chromatography-data-systems-and-solutions/trainings-workshops/empower3_individual/)
### EMPOWER® 3 DIODE ARRAY OPTION
This course gives you knowledge about the use of diode array detectors from Waters or Agilent. In practical exercises, you will learn the possibilities
[ Learn more here ](/chromatography-data-systems-and-solutions/trainings-workshops/empower3-diode-array-option/)
### EMPOWER® 3 REPORTING
In this training, you will learn the basics of report design and receive tips on layout and design using examples.
[ Learn more here ](/chromatography-data-systems-and-solutions/trainings-workshops/empower3-reporting/)
### EMPOWER® 3 CUSTOM FIELDS
This training is about custom fields, i.e. database fields that can be created by the user to implement user-defined calculations
[ Learn more here ](/chromatography-data-systems-and-solutions/trainings-workshops/empower3-custom-fields/)
### EMPOWER® 3 PROCESSING
In this training you will learn to use the possibilities that are in Empower: organizing samples in sample sets.
[ Learn more here ](/chromatography-data-systems-and-solutions/trainings-workshops/empower3-advanced-processing/)
### EMPOWER® 3 BASICS
In this two-day training course, you will learn the basics of operating Waters Empower 3. Using practical examples and under
[ Learn more here ](/chromatography-data-systems-and-solutions/trainings-workshops/empower3-basic/)
Get in touch
First Name
Last Name
Email
Phone Number
Company
Designation
Enquiry Type
Enquiry Type Request for Zifo Services Product Partnership Job/Internship/Placement Enquiry Other
Message
Acceptance I consent to being contacted by an official Zifo representative
Submit
---
### [EMPOWER® 3 MANUAL](https://zifo.com/chromatography-data-systems-and-solutions/solutions/empower-3-manual/)
**Published:** February 2, 2026
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> EMPOWER® 3 MANUAL
# The compact Empower® 3 manual
## Manual Empower 3
More than just online help. The compact Empower 3 manual for end-users
The manual provides HPLC and GC analysis users with the essential knowledge of the software in an easy-to-understand manner. It describes the functions and operation of the software based on Empower® Build 3471 Feature Release 2, equipped with the PDA and System Suitability options.
I already know the Empower Handbook 3 and would also like to express great praise at this point – it is the only comprehensible literature on this program.” (Quote from a customer
[ Request a quote ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjQ4MTExIiwidG9nZ2xlIjpmYWxzZX0%3D)
### Your interface between laboratory and software This is how we support our customers in manufacturing safe products. That is our mission.
- Training, consulting and development.
- We solve problems. At any time and uncomplicated.
- Individual support. According to your needs.
## Our Products
### Empower 3 manual
[ Find out more here ](/chromatography-data-systems-and-solutions/solutions/empower-3-manual/)
### Empower 3 Custom Fields Guide
[ Find out more here ](/chromatography-data-systems-and-solutions/trainings-workshops/empower3-custom-fields/)
### SOP box
[ Find out more here ](/chromatography-data-systems-and-solutions/solutions/sop-box/)
### CSV box
[ Find out more here ](/chromatography-data-systems-and-solutions/solutions/csv-box/)
### CIQ – Customized Instrument Qualification
[ Find out more here ](/chromatography-data-systems-and-solutions/solutions/ciq-customised-instrument/)
### Peakprovider 2.0 for Empower
[ Find out more here ](/chromatography-data-systems-and-solutions/solutions/peakprovider-2-0-for-empower/)
### Rhizomer
[ Find out more here ](/chromatography-data-systems-and-solutions/solutions/rhizomer/)
### CLEAR – Efficient Empower3 Result- and Audit Trail-Reviews
[ Find out more here ](/chromatography-data-systems-and-solutions/solutions/clear-efficient-empower3-result/)
### CUT – Content Uniformity Template
[ Find out more here ](/chromatography-data-systems-and-solutions/solutions/cut-content-uniformity/)
### LEI – LabX-Empower-Integration
[ Find out more here ](/chromatography-data-systems-and-solutions/solutions/lei-labx-empower-integration/)
Get in touch
First Name
Last Name
Email
Phone Number
Company
Designation
Enquiry Type
Enquiry Type Request for Zifo Services Product Partnership Job/Internship/Placement Enquiry Other
Message
Acceptance I consent to being contacted by an official Zifo representative
Submit
---
### [CSV Box](https://zifo.com/chromatography-data-systems-and-solutions/solutions/csv-box/)
**Published:** February 2, 2026
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> CSV Box
# Our document box of system validation
### Validation/qualification: Why is qualification of the Empower system not enough?
The CSV box contains detailed document templates for planning, implementing and documenting a computer system validation. These include:
- Validation plan
- User Requirements Specification
- Functional specification
- Risk Analysis
- Supplier Assessment Waters
- System Design Specification
- Configuration specification
- Installation Qualification Plan
- Operational Qualification Plan
- User Acceptance Test (UAT) plan
- Installation Qualification Report
- Operational Qualification Report
- User Acceptance Test (UAT) Report
- Trace Matrix
- Validation report
- System Release Document
In addition to the documents as a Word template, the package includes 10 days of support from a zifo CVS specialist who will use his experience to give you valuable information on configuring and setting up your Empower system. He will work with you to adapt the templates to your needs and environment.
Upon request and for a separate charge, he will also carry out the validation.
[ Get an offer ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjQ3OTE3IiwidG9nZ2xlIjpmYWxzZX0%3D)
## Our Products
### Empower 3 manual
[ Find out more here ](/chromatography-data-systems-and-solutions/solutions/empower-3-manual/)
### Empower 3 Custom Fields Guide
[ Find out more here ](/chromatography-data-systems-and-solutions/trainings-workshops/empower3-custom-fields/)
### SOP box
[ Find out more here ](/chromatography-data-systems-and-solutions/solutions/sop-box/)
### CSV box
[ Find out more here ](/chromatography-data-systems-and-solutions/solutions/csv-box/)
### CIQ – Customized Instrument Qualification
[ Find out more here ](/chromatography-data-systems-and-solutions/solutions/ciq-customised-instrument/)
### Peakprovider 2.0 for Empower
[ Find out more here ](/chromatography-data-systems-and-solutions/solutions/peakprovider-2-0-for-empower/)
### Rhizomer
[ Find out more here ](/chromatography-data-systems-and-solutions/solutions/rhizomer/)
### CLEAR – Efficient Empower3 Result- and Audit Trail-Reviews
[ Find out more here ](/chromatography-data-systems-and-solutions/solutions/clear-efficient-empower3-result/)
### CUT – Content Uniformity Template
[ Find out more here ](/chromatography-data-systems-and-solutions/solutions/cut-content-uniformity/)
### LEI – LabX-Empower-Integration
[ Find out more here ](/chromatography-data-systems-and-solutions/solutions/lei-labx-empower-integration/)
Get in touch
First Name
Last Name
Email
Phone Number
Company
Designation
Enquiry Type
Enquiry Type Request for Zifo Services Product Partnership Job/Internship/Placement Enquiry Other
Message
Acceptance I consent to being contacted by an official Zifo representative
Submit
---
### [SOP Box](https://zifo.com/chromatography-data-systems-and-solutions/solutions/sop-box/)
**Published:** February 2, 2026
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> SOP Box
# Our document box of performance
## The Empower SOP Box
Creating SOPs for operating Empower requires a lot of experience in using the software. In addition to understanding how Empower works, the processes in the laboratory and the regulatory requirements provide the framework.
### The box contains templates for the following SOPs:
- SOP1 application of Empower
- SOP2 double check in Empower plus checklist
- SOP3 Operational Audit Trail Review in Empower plus Checklist
- SOP4 Validation of Empower Reports
- SOP5 Validation of Empower Custom Fields
- SOP6 Administration by Empower
[ Get an offer ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjQ3NTA3IiwidG9nZ2xlIjpmYWxzZX0%3D)
## Our Products
### Empower 3 manual
[ Find out more here ](/chromatography-data-systems-and-solutions/solutions/empower-3-manual/)
### Empower 3 Custom Fields Guide
[ Find out more here ](/chromatography-data-systems-and-solutions/trainings-workshops/empower3-custom-fields/)
### SOP box
[ Find out more here ](/chromatography-data-systems-and-solutions/solutions/sop-box/)
### CSV box
[ Find out more here ](/chromatography-data-systems-and-solutions/solutions/csv-box/)
### CIQ – Customized Instrument Qualification
[ Find out more here ](/chromatography-data-systems-and-solutions/solutions/ciq-customised-instrument/)
### Peakprovider 2.0 for Empower
[ Find out more here ](/chromatography-data-systems-and-solutions/solutions/peakprovider-2-0-for-empower/)
### Rhizomer
[ Find out more here ](/chromatography-data-systems-and-solutions/solutions/rhizomer/)
### CLEAR – Efficient Empower3 Result- and Audit Trail-Reviews
[ Find out more here ](/chromatography-data-systems-and-solutions/solutions/clear-efficient-empower3-result/)
### CUT – Content Uniformity Template
[ Find out more here ](/chromatography-data-systems-and-solutions/solutions/cut-content-uniformity/)
### LEI – LabX-Empower-Integration
[ Find out more here ](/chromatography-data-systems-and-solutions/solutions/lei-labx-empower-integration/)
Get in touch
First Name
Last Name
Email
Phone Number
Company
Designation
Enquiry Type
Enquiry Type Request for Zifo Services Product Partnership Job/Internship/Placement Enquiry Other
Message
Acceptance I consent to being contacted by an official Zifo representative
Submit
---
### [Empower3 Individual](https://zifo.com/chromatography-data-systems-and-solutions/trainings-workshops/empower3_individual/)
**Published:** February 3, 2026
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> Empower3 Individual
# Tailored training and individual
workshops for everyone.
# Empower 3 Individual
This course provides you with knowledge on the application of Waters or Agilent diode array detectors. In practical exercises, you will learn about the possibilities and special features of data acquisition and evaluation. In addition to the basics of photodiode array detection, the creation of instrument methods and spectra libraries will be demonstrated. Contents of the course are also the spectra determination as well as the handling of the peak purity detection.
[ Register for training ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjQ4MTkxIiwidG9nZ2xlIjpmYWxzZX0%3D)
Here are some examples of customer requests from practice:
**Audit Trail**
- Selection of suitable parameters for a compact audit trail expression
- Determination of the audit trail layout and protection of the layout
- Measures for securing audit trail data: protection against deletion, overwriting, etc.
**Working with Empower 3**
- Use of view filters
- Organization of data (project structure and custom fields)
**Evaluation of chromatograms**
- Integration of complex chromatograms
- Sensible procedure for manual postprocessing of integrations
- New in Empower 3: ICH Impurity
**Report generation**
- Adaptation of existing reports
- Dependencies between report expression and method, sequence as well as rights management
- How “dynamic” can a predefined report be?
- A sensible selection of data fields in a GxP report: header, calibration, Sample, and statistical data.
- Creation of Custom Fields
- Choice of significant decimal places in the calculation: traceability for GxP auditors
- Protection of reports against changes/manipulations
- Suggestions for structured data storage of measurement data, methods, and reports in the application program
[ Register for training ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjQ4MTkxIiwidG9nZ2xlIjpmYWxzZX0%3D)
# Trainings & Workshops
### EMPOWER® 3 INDIVIDUAL
For this training, we will put together a training plan that is tailored to your specific requirements. For example, would you like
[ Learn more here ](/chromatography-data-systems-and-solutions/trainings-workshops/empower3_individual/)
### EMPOWER® 3 DIODE ARRAY OPTION
This course gives you knowledge about the use of diode array detectors from Waters or Agilent. In practical exercises, you will learn the possibilities
[ Learn more here ](/chromatography-data-systems-and-solutions/trainings-workshops/empower3-diode-array-option/)
### EMPOWER® 3 REPORTING
In this training, you will learn the basics of report design and receive tips on layout and design using examples.
[ Learn more here ](/chromatography-data-systems-and-solutions/trainings-workshops/empower3-reporting/)
### EMPOWER® 3 CUSTOM FIELDS
This training is about custom fields, i.e. database fields that can be created by the user to implement user-defined calculations
[ Learn more here ](/chromatography-data-systems-and-solutions/trainings-workshops/empower3-custom-fields/)
### EMPOWER® 3 PROCESSING
In this training you will learn to use the possibilities that are in Empower: organizing samples in sample sets.
[ Learn more here ](/chromatography-data-systems-and-solutions/trainings-workshops/empower3-advanced-processing/)
### EMPOWER® 3 BASICS
In this two-day training course, you will learn the basics of operating Waters Empower 3. Using practical examples and under
[ Learn more here ](/chromatography-data-systems-and-solutions/trainings-workshops/empower3-basic/)
Get in touch
First Name
Last Name
Email
Phone Number
Company
Designation
Enquiry Type
Enquiry Type Request for Zifo Services Product Partnership Job/Internship/Placement Enquiry Other
Message
Acceptance I consent to being contacted by an official Zifo representative
Submit
---
### [Rhizomer](https://zifo.com/chromatography-data-systems-and-solutions/solutions/rhizomer/)
**Published:** January 31, 2026
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> Rhizomer
# Rhizomer 2.0 brings your software to the lab
## What advantages does Rhizomer offer?
### Central administration
Reduce your administrative effort and costs. You need fewer qualified staff on site and save on training and travel costs.
### Save time
Updating a LAC/E does not take long, around 20 minutes is typical for current computers. This allows e.g. B. Updates can be implemented without a major impact on laboratory operations. This means you can quickly introduce new device series or functions in the laboratory and increase your productivity. Even if a LAC/E computer is defective, it can be restored very quickly. The downtime in the laboratory is significantly reduced.
### Rollback on errors
Mistakes happen! Unfortunately, Empower does not allow you to easily uninstall an update. In fact, if an error occurs, a new installation must always be carried out. This is a time-consuming step that must be initiated manually. Rhizomer includes a rollback feature that takes you back to the previous version in a few seconds.
### Documentation
Rhizomer allows continuous monitoring of the LAC/E computers. A clear dashboard shows the status of the LAC/E computers and allows you to retrieve the current configuration. If you make changes, they will be recorded and documented in the Rhizomer Audit Trail. Thanks to an electronic device LOG, you can reach the next level on the path to a paperless laboratory.
### Individually customizable
Rhizomer is compatible with all custom environments. Different regions or laboratories can also be configured individually in the global networks. This provides the necessary flexibility and can reduce your network traffic. Rhizomer provides the infrastructure for your installation without limiting you. You can install any software you want. This means Rhizomer also fits into your company network.
### Securing your configuration
The LAC/E computer also stores information about the configuration of your instrument network, your connected devices and their configuration locally. In the event of a failure or a new installation, these must be laboriously restored. To avoid this, Rhizomer regularly backs up this information and is therefore able to fully restore a LAC/E configuration in the event of a failure.
### Future-proof
Before each update, did you have to spend a lot of time thinking about how the software should be rolled out, the process documented and the installation validated? By switching to rhizomer, you receive a comprehensive concept that frees you from this task. Every rollout with Rhizomer works according to the same principle, regardless of whether it is a simple driver update or a switch to a new operating system.
### Still open questions?
Read our bilingual brochure “How to bring software to the lab” to learn more about Rhizomer. If you have any questions about Rhizomer 2, please feel free to contact us.
[ More Details ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjQ0NzMwIiwidG9nZ2xlIjpmYWxzZX0%3D)
## Our Products
### Empower 3 manual
[ Find out more here ](/chromatography-data-systems-and-solutions/solutions/empower-3-manual/)
### Empower 3 Custom Fields Guide
[ Find out more here ](/chromatography-data-systems-and-solutions/trainings-workshops/empower3-custom-fields/)
### SOP box
[ Find out more here ](/chromatography-data-systems-and-solutions/solutions/sop-box/)
### CSV box
[ Find out more here ](/chromatography-data-systems-and-solutions/solutions/csv-box/)
### CIQ – Customized Instrument Qualification
[ Find out more here ](/chromatography-data-systems-and-solutions/solutions/ciq-customised-instrument/)
### Peakprovider 2.0 for Empower
[ Find out more here ](/chromatography-data-systems-and-solutions/solutions/peakprovider-2-0-for-empower/)
### Rhizomer
[ Find out more here ](/chromatography-data-systems-and-solutions/solutions/rhizomer/)
### CLEAR – Efficient Empower3 Result- and Audit Trail-Reviews
[ Find out more here ](/chromatography-data-systems-and-solutions/solutions/clear-efficient-empower3-result/)
### CUT – Content Uniformity Template
[ Find out more here ](/chromatography-data-systems-and-solutions/solutions/cut-content-uniformity/)
### LEI – LabX-Empower-Integration
[ Find out more here ](/chromatography-data-systems-and-solutions/solutions/lei-labx-empower-integration/)
Get in touch
First Name
Last Name
Email
Phone Number
Company
Designation
Enquiry Type
Enquiry Type Request for Zifo Services Product Partnership Job/Internship/Placement Enquiry Other
Message
Acceptance I consent to being contacted by an official Zifo representative
Submit
---
### [LEI-LabX Empower Integration](https://zifo.com/chromatography-data-systems-and-solutions/solutions/lei-labx-empower-integration/)
**Published:** January 12, 2026
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> LEI-LabX Empower Integration
# LEI - LabX-Empower-Integration
## LabX Empower Integration (LEI) integrates
the scale software into Empower.
You no longer want to transfer numbers manually? We’ll
show you how!
[ See How ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjQ0MzU0IiwidG9nZ2xlIjpmYWxzZX0%3D)
### Every chromatography requires weighing.
That means anyone using Waters Empower needs to weigh standards and samples. A process with extensive documentation and above all: lots of numbers!
### More than just a transfer of values: the zifo LabX-Empower-Integration
More than just a transfer of values: the zifo LabX-Empower-Integration
### Zifo LabX-Empower-Integration does the double check!
With one mouse click, the LabX-Empower-Integration compares the values used against the LabX database and provides the Empower result with a pass/fail statement. One look is enough and the review step is done.
### Bring your Waters Empower System and LabX by Mettler-Toledo together
Already using Sample Set Methods in Empower? Great! The LabX-Empower-Integration (LEI) creates the appropriate weighing tasks in LabX for you. And after the weighing process, transfers the values back into the correct fields of your Empower Sample Set Metho
We would be happy to show you what your optimized
laboratory process looks like.
[ More Details ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjQ0MzU0IiwidG9nZ2xlIjpmYWxzZX0%3D)
## Your Advantages & Possibilities
Launch LabX-Empower-Integration directly from Empower. As a ToolKit, LEI is fully integrated into Empower.
There is no administrative effort necessary, as the Empower user administration is taken over by LEI.
The LabX-Empower-Integration is designed for the pharmaceutical lab and is compliant with regulatory requirements.
The LEI process is practical and intuitive. Supported by a detailed manual, every Empower user is immediately able to carry out an analysis independently.
All data is automatically transferred between LabX and Empower through LEI. Banish manual data transfers and save yourself time-consuming double checks.
Speed up your analytics and avoid errors. LEI creates Sample Set Methods and LabX Tasks for you independently.
Take the next step towards the paperless lab.
## Our Services
#### Implement
Project support during
implementation
Training
Training of administrators and lab staff on how to use the LabX-Empower-Integration
Support
Support for creating the Master Sample Set Methods
Integration
Ongoing support for LabX-Empower-Integration
[ Know more ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjQ0MzU0IiwidG9nZ2xlIjpmYWxzZX0%3D)
## Our Products
### Empower 3 manual
[ Find out more here ](/chromatography-data-systems-and-solutions/solutions/empower-3-manual/)
### Empower 3 Custom Fields Guide
[ Find out more here ](/chromatography-data-systems-and-solutions/trainings-workshops/empower3-custom-fields/)
### SOP box
[ Find out more here ](/chromatography-data-systems-and-solutions/solutions/sop-box/)
### CSV box
[ Find out more here ](/chromatography-data-systems-and-solutions/solutions/csv-box/)
### CIQ – Customized Instrument Qualification
[ Find out more here ](/chromatography-data-systems-and-solutions/solutions/ciq-customised-instrument/)
### Peakprovider 2.0 for Empower
[ Find out more here ](/chromatography-data-systems-and-solutions/solutions/peakprovider-2-0-for-empower/)
### Rhizomer
[ Find out more here ](/chromatography-data-systems-and-solutions/solutions/rhizomer/)
### CLEAR – Efficient Empower3 Result- and Audit Trail-Reviews
[ Find out more here ](/chromatography-data-systems-and-solutions/solutions/clear-efficient-empower3-result/)
### CUT – Content Uniformity Template
[ Find out more here ](/chromatography-data-systems-and-solutions/solutions/cut-content-uniformity/)
### LEI – LabX-Empower-Integration
[ Find out more here ](/chromatography-data-systems-and-solutions/solutions/lei-labx-empower-integration/)
Get in touch
First Name
Last Name
Email
Phone Number
Company
Designation
Enquiry Type
Enquiry Type Request for Zifo Services Product Partnership Job/Internship/Placement Enquiry Other
Message
Acceptance I consent to being contacted by an official Zifo representative
Submit
---
### [Blogs New](https://zifo.com/blogs/)
**Published:** November 13, 2025
**Author:** Zifo_user
**Content:**
Resources
A collection of stories about our people, our capabilities, our research, and the ever-changing face of our industry.
## Resource Type
Blogs Whitepapers Webinars Casestudies
Blogs
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
Sakthi Prasad T, Content Director
[ Read Now ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
Sakthi Prasad T, Content Director
[ Read Now ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
Shivani Vohra, Consulting Analyst
[ Read Now ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/the-first-mile-of-lab-data-operationalizing-data-flow-in-heterogeneous-research-environments/)
### [The “First Mile” of Lab Data: Operationalizing Data Flow in Heterogeneous Research Environments](https://zifo.com/blogs/the-first-mile-of-lab-data-operationalizing-data-flow-in-heterogeneous-research-environments/)
Sakthi Prasad T, Content Director
[ Read Now ](https://zifo.com/blogs/the-first-mile-of-lab-data-operationalizing-data-flow-in-heterogeneous-research-environments/)
[  ](https://zifo.com/blogs/design-of-experiments-labs-confront-the-challenge-of-capturing-experimental-intent/)
### [Design of Experiments: Labs Confront the Challenge of Capturing Experimental Intent](https://zifo.com/blogs/design-of-experiments-labs-confront-the-challenge-of-capturing-experimental-intent/)
Rahul Anil Babu, Scientific Application Consultant
[ Read Now ](https://zifo.com/blogs/design-of-experiments-labs-confront-the-challenge-of-capturing-experimental-intent/)
[  ](https://zifo.com/blogs/beyond-the-rigidity-how-abbvies-platform-adapt-to-cmc-science/)
### [Beyond the Rigidity: How AbbVie’s Platform Adapts to CMC Science](https://zifo.com/blogs/beyond-the-rigidity-how-abbvies-platform-adapt-to-cmc-science/)
Sakthi Prasad T, Content Director
[ Read Now ](https://zifo.com/blogs/beyond-the-rigidity-how-abbvies-platform-adapt-to-cmc-science/)
White Papers
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
Sakthi Prasad T, Content Director
[ Read Now ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
Sakthi Prasad T, Content Director
[ Read Now ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
Shivani Vohra, Consulting Analyst
[ Read Now ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/the-first-mile-of-lab-data-operationalizing-data-flow-in-heterogeneous-research-environments/)
### [The “First Mile” of Lab Data: Operationalizing Data Flow in Heterogeneous Research Environments](https://zifo.com/blogs/the-first-mile-of-lab-data-operationalizing-data-flow-in-heterogeneous-research-environments/)
Sakthi Prasad T, Content Director
[ Read Now ](https://zifo.com/blogs/the-first-mile-of-lab-data-operationalizing-data-flow-in-heterogeneous-research-environments/)
[  ](https://zifo.com/blogs/design-of-experiments-labs-confront-the-challenge-of-capturing-experimental-intent/)
### [Design of Experiments: Labs Confront the Challenge of Capturing Experimental Intent](https://zifo.com/blogs/design-of-experiments-labs-confront-the-challenge-of-capturing-experimental-intent/)
Rahul Anil Babu, Scientific Application Consultant
[ Read Now ](https://zifo.com/blogs/design-of-experiments-labs-confront-the-challenge-of-capturing-experimental-intent/)
[  ](https://zifo.com/blogs/beyond-the-rigidity-how-abbvies-platform-adapt-to-cmc-science/)
### [Beyond the Rigidity: How AbbVie’s Platform Adapts to CMC Science](https://zifo.com/blogs/beyond-the-rigidity-how-abbvies-platform-adapt-to-cmc-science/)
Sakthi Prasad T, Content Director
[ Read Now ](https://zifo.com/blogs/beyond-the-rigidity-how-abbvies-platform-adapt-to-cmc-science/)
Webinars
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
Sakthi Prasad T, Content Director
[ Read Now ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
Sakthi Prasad T, Content Director
[ Read Now ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
Shivani Vohra, Consulting Analyst
[ Read Now ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/the-first-mile-of-lab-data-operationalizing-data-flow-in-heterogeneous-research-environments/)
### [The “First Mile” of Lab Data: Operationalizing Data Flow in Heterogeneous Research Environments](https://zifo.com/blogs/the-first-mile-of-lab-data-operationalizing-data-flow-in-heterogeneous-research-environments/)
Sakthi Prasad T, Content Director
[ Read Now ](https://zifo.com/blogs/the-first-mile-of-lab-data-operationalizing-data-flow-in-heterogeneous-research-environments/)
[  ](https://zifo.com/blogs/design-of-experiments-labs-confront-the-challenge-of-capturing-experimental-intent/)
### [Design of Experiments: Labs Confront the Challenge of Capturing Experimental Intent](https://zifo.com/blogs/design-of-experiments-labs-confront-the-challenge-of-capturing-experimental-intent/)
Rahul Anil Babu, Scientific Application Consultant
[ Read Now ](https://zifo.com/blogs/design-of-experiments-labs-confront-the-challenge-of-capturing-experimental-intent/)
[  ](https://zifo.com/blogs/beyond-the-rigidity-how-abbvies-platform-adapt-to-cmc-science/)
### [Beyond the Rigidity: How AbbVie’s Platform Adapts to CMC Science](https://zifo.com/blogs/beyond-the-rigidity-how-abbvies-platform-adapt-to-cmc-science/)
Sakthi Prasad T, Content Director
[ Read Now ](https://zifo.com/blogs/beyond-the-rigidity-how-abbvies-platform-adapt-to-cmc-science/)
Case Studies
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
Sakthi Prasad T, Content Director
[ Read Now ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
Sakthi Prasad T, Content Director
[ Read Now ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
Shivani Vohra, Consulting Analyst
[ Read Now ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/the-first-mile-of-lab-data-operationalizing-data-flow-in-heterogeneous-research-environments/)
### [The “First Mile” of Lab Data: Operationalizing Data Flow in Heterogeneous Research Environments](https://zifo.com/blogs/the-first-mile-of-lab-data-operationalizing-data-flow-in-heterogeneous-research-environments/)
Sakthi Prasad T, Content Director
[ Read Now ](https://zifo.com/blogs/the-first-mile-of-lab-data-operationalizing-data-flow-in-heterogeneous-research-environments/)
[  ](https://zifo.com/blogs/design-of-experiments-labs-confront-the-challenge-of-capturing-experimental-intent/)
### [Design of Experiments: Labs Confront the Challenge of Capturing Experimental Intent](https://zifo.com/blogs/design-of-experiments-labs-confront-the-challenge-of-capturing-experimental-intent/)
Rahul Anil Babu, Scientific Application Consultant
[ Read Now ](https://zifo.com/blogs/design-of-experiments-labs-confront-the-challenge-of-capturing-experimental-intent/)
[  ](https://zifo.com/blogs/beyond-the-rigidity-how-abbvies-platform-adapt-to-cmc-science/)
### [Beyond the Rigidity: How AbbVie’s Platform Adapts to CMC Science](https://zifo.com/blogs/beyond-the-rigidity-how-abbvies-platform-adapt-to-cmc-science/)
Sakthi Prasad T, Content Director
[ Read Now ](https://zifo.com/blogs/beyond-the-rigidity-how-abbvies-platform-adapt-to-cmc-science/)
---
### [White papers](https://zifo.com/white-papers/)
**Published:** December 1, 2025
**Author:** Zifo_user
**Content:**
Resources
A collection of stories about our people, our capabilities, our research, and the ever-changing face of our industry.
## Resource Type
Whitepapers Blogs News
White Papers
### [STREAMLINING PHARMA PRODUCT DEVELOPMENT THROUGH DIGITAL COACHING](https://zifo.com/?p=12737)
Mehnaz Husain
[ Read Now ](https://zifo.com/?p=12737)
### [The Role of Scientific Business Systems Analysts in Driving Science Forward](https://zifo.com/?p=12723)
Aishwarya Balajee
[ Read Now ](https://zifo.com/?p=12723)
[  ](https://zifo.com/?p=12718)
### [Informatics Vendor Evaluation Approach](https://zifo.com/?p=12718)
Uma Maheswari Adiseshan
[ Read Now ](https://zifo.com/?p=12718)
### [CDISC SEND FAIR data guide](https://zifo.com/?p=12702)
Aishwarya Balajee
[ Read Now ](https://zifo.com/?p=12702)
### [ePRO- Subject centric approach](https://zifo.com/?p=11809)
Amal Krishna Girish
[ Read Now ](https://zifo.com/?p=11809)
[  ](https://zifo.com/?p=11616)
### [ARTIFICIAL INTELLIGENCE IN THE PHARMACEUTICAL INDUSTRY PART 1 – Drug Discovery & Preclinical Development](https://zifo.com/?p=11616)
David Jackson
[ Read Now ](https://zifo.com/?p=11616)
Blogs
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
Sakthi Prasad T, Content Director
[ Read Now ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
Sakthi Prasad T, Content Director
[ Read Now ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
Shivani Vohra, Consulting Analyst
[ Read Now ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/the-first-mile-of-lab-data-operationalizing-data-flow-in-heterogeneous-research-environments/)
### [The “First Mile” of Lab Data: Operationalizing Data Flow in Heterogeneous Research Environments](https://zifo.com/blogs/the-first-mile-of-lab-data-operationalizing-data-flow-in-heterogeneous-research-environments/)
Sakthi Prasad T, Content Director
[ Read Now ](https://zifo.com/blogs/the-first-mile-of-lab-data-operationalizing-data-flow-in-heterogeneous-research-environments/)
[  ](https://zifo.com/blogs/design-of-experiments-labs-confront-the-challenge-of-capturing-experimental-intent/)
### [Design of Experiments: Labs Confront the Challenge of Capturing Experimental Intent](https://zifo.com/blogs/design-of-experiments-labs-confront-the-challenge-of-capturing-experimental-intent/)
Rahul Anil Babu, Scientific Application Consultant
[ Read Now ](https://zifo.com/blogs/design-of-experiments-labs-confront-the-challenge-of-capturing-experimental-intent/)
[  ](https://zifo.com/blogs/beyond-the-rigidity-how-abbvies-platform-adapt-to-cmc-science/)
### [Beyond the Rigidity: How AbbVie’s Platform Adapts to CMC Science](https://zifo.com/blogs/beyond-the-rigidity-how-abbvies-platform-adapt-to-cmc-science/)
Sakthi Prasad T, Content Director
[ Read Now ](https://zifo.com/blogs/beyond-the-rigidity-how-abbvies-platform-adapt-to-cmc-science/)
News
[  ](https://zifo.com/news/zifo-co-launches-real-2026-to-spotlight-the-next-generation-of-connected-ai-enabled-lab-environments/)
### [Zifo Co-Launches REAL 2026 to Spotlight the Next Generation of Connected, AI-Enabled Lab Environments](https://zifo.com/news/zifo-co-launches-real-2026-to-spotlight-the-next-generation-of-connected-ai-enabled-lab-environments/)
[ Read Now ](https://zifo.com/news/zifo-co-launches-real-2026-to-spotlight-the-next-generation-of-connected-ai-enabled-lab-environments/)
[  ](https://zifo.com/news/cmc-bottleneck-is-choking-biopharmas-drug-pipeline-says-zifo/)
### [CMC Bottleneck is Choking Biopharma’s Drug Pipeline, says Zifo](https://zifo.com/news/cmc-bottleneck-is-choking-biopharmas-drug-pipeline-says-zifo/)
[ Read Now ](https://zifo.com/news/cmc-bottleneck-is-choking-biopharmas-drug-pipeline-says-zifo/)
[  ](https://zifo.com/news/zifo-accelerates-lims-master-data-validation-with-new-ai-enabled-services-accelerator/)
### [Zifo Accelerates LIMS Master Data Validation with New AI-Enabled Services Accelerator](https://zifo.com/news/zifo-accelerates-lims-master-data-validation-with-new-ai-enabled-services-accelerator/)
[ Read Now ](https://zifo.com/news/zifo-accelerates-lims-master-data-validation-with-new-ai-enabled-services-accelerator/)
[  ](https://zifo.com/news/zifo-open-quiz-2026-draws-over-1200-quizzers-on-independence-day/)
### [Zifo Open Quiz 2026 Draws Over 1,200 Quizzers on Independence Day](https://zifo.com/news/zifo-open-quiz-2026-draws-over-1200-quizzers-on-independence-day/)
[ Read Now ](https://zifo.com/news/zifo-open-quiz-2026-draws-over-1200-quizzers-on-independence-day/)
[  ](https://zifo.com/news/change-management-strategies-elevating-digital-transformation-in-pharma/)
### [Conquering Biopharma’s ‘Mount Everest’: The Human Element of Digital Transformation](https://zifo.com/news/change-management-strategies-elevating-digital-transformation-in-pharma/)
[ Read Now ](https://zifo.com/news/change-management-strategies-elevating-digital-transformation-in-pharma/)
[  ](https://zifo.com/news/zifo-to-present-biobank-data-breakthrough-at-the-festival-of-genomics-boston/)
### [Zifo to Present Biobank Data Breakthrough at the Festival of Genomics Boston](https://zifo.com/news/zifo-to-present-biobank-data-breakthrough-at-the-festival-of-genomics-boston/)
[ Read Now ](https://zifo.com/news/zifo-to-present-biobank-data-breakthrough-at-the-festival-of-genomics-boston/)
---
### [News](https://zifo.com/news/)
**Published:** December 2, 2025
**Author:** Zifo_user
**Content:**
Resources
A collection of stories about our people, our capabilities, our research, and the ever-changing face of our industry.
## Resource Type
News Whitepapers Blogs
News
[  ](https://zifo.com/news/zifo-co-launches-real-2026-to-spotlight-the-next-generation-of-connected-ai-enabled-lab-environments/)
### [Zifo Co-Launches REAL 2026 to Spotlight the Next Generation of Connected, AI-Enabled Lab Environments](https://zifo.com/news/zifo-co-launches-real-2026-to-spotlight-the-next-generation-of-connected-ai-enabled-lab-environments/)
[ Read Now ](https://zifo.com/news/zifo-co-launches-real-2026-to-spotlight-the-next-generation-of-connected-ai-enabled-lab-environments/)
[  ](https://zifo.com/news/cmc-bottleneck-is-choking-biopharmas-drug-pipeline-says-zifo/)
### [CMC Bottleneck is Choking Biopharma’s Drug Pipeline, says Zifo](https://zifo.com/news/cmc-bottleneck-is-choking-biopharmas-drug-pipeline-says-zifo/)
[ Read Now ](https://zifo.com/news/cmc-bottleneck-is-choking-biopharmas-drug-pipeline-says-zifo/)
[  ](https://zifo.com/news/zifo-accelerates-lims-master-data-validation-with-new-ai-enabled-services-accelerator/)
### [Zifo Accelerates LIMS Master Data Validation with New AI-Enabled Services Accelerator](https://zifo.com/news/zifo-accelerates-lims-master-data-validation-with-new-ai-enabled-services-accelerator/)
[ Read Now ](https://zifo.com/news/zifo-accelerates-lims-master-data-validation-with-new-ai-enabled-services-accelerator/)
[  ](https://zifo.com/news/zifo-open-quiz-2026-draws-over-1200-quizzers-on-independence-day/)
### [Zifo Open Quiz 2026 Draws Over 1,200 Quizzers on Independence Day](https://zifo.com/news/zifo-open-quiz-2026-draws-over-1200-quizzers-on-independence-day/)
[ Read Now ](https://zifo.com/news/zifo-open-quiz-2026-draws-over-1200-quizzers-on-independence-day/)
[  ](https://zifo.com/news/change-management-strategies-elevating-digital-transformation-in-pharma/)
### [Conquering Biopharma’s ‘Mount Everest’: The Human Element of Digital Transformation](https://zifo.com/news/change-management-strategies-elevating-digital-transformation-in-pharma/)
[ Read Now ](https://zifo.com/news/change-management-strategies-elevating-digital-transformation-in-pharma/)
[  ](https://zifo.com/news/zifo-to-present-biobank-data-breakthrough-at-the-festival-of-genomics-boston/)
### [Zifo to Present Biobank Data Breakthrough at the Festival of Genomics Boston](https://zifo.com/news/zifo-to-present-biobank-data-breakthrough-at-the-festival-of-genomics-boston/)
[ Read Now ](https://zifo.com/news/zifo-to-present-biobank-data-breakthrough-at-the-festival-of-genomics-boston/)
White Papers
### [STREAMLINING PHARMA PRODUCT DEVELOPMENT THROUGH DIGITAL COACHING](https://zifo.com/?p=12737)
Mehnaz Husain
[ Read Now ](https://zifo.com/?p=12737)
### [The Role of Scientific Business Systems Analysts in Driving Science Forward](https://zifo.com/?p=12723)
Aishwarya Balajee
[ Read Now ](https://zifo.com/?p=12723)
[  ](https://zifo.com/?p=12718)
### [Informatics Vendor Evaluation Approach](https://zifo.com/?p=12718)
Uma Maheswari Adiseshan
[ Read Now ](https://zifo.com/?p=12718)
### [CDISC SEND FAIR data guide](https://zifo.com/?p=12702)
Aishwarya Balajee
[ Read Now ](https://zifo.com/?p=12702)
### [ePRO- Subject centric approach](https://zifo.com/?p=11809)
Amal Krishna Girish
[ Read Now ](https://zifo.com/?p=11809)
[  ](https://zifo.com/?p=11616)
### [ARTIFICIAL INTELLIGENCE IN THE PHARMACEUTICAL INDUSTRY PART 1 – Drug Discovery & Preclinical Development](https://zifo.com/?p=11616)
David Jackson
[ Read Now ](https://zifo.com/?p=11616)
Blogs
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
Sakthi Prasad T, Content Director
[ Read Now ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
Sakthi Prasad T, Content Director
[ Read Now ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
Shivani Vohra, Consulting Analyst
[ Read Now ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/the-first-mile-of-lab-data-operationalizing-data-flow-in-heterogeneous-research-environments/)
### [The “First Mile” of Lab Data: Operationalizing Data Flow in Heterogeneous Research Environments](https://zifo.com/blogs/the-first-mile-of-lab-data-operationalizing-data-flow-in-heterogeneous-research-environments/)
Sakthi Prasad T, Content Director
[ Read Now ](https://zifo.com/blogs/the-first-mile-of-lab-data-operationalizing-data-flow-in-heterogeneous-research-environments/)
[  ](https://zifo.com/blogs/design-of-experiments-labs-confront-the-challenge-of-capturing-experimental-intent/)
### [Design of Experiments: Labs Confront the Challenge of Capturing Experimental Intent](https://zifo.com/blogs/design-of-experiments-labs-confront-the-challenge-of-capturing-experimental-intent/)
Rahul Anil Babu, Scientific Application Consultant
[ Read Now ](https://zifo.com/blogs/design-of-experiments-labs-confront-the-challenge-of-capturing-experimental-intent/)
[  ](https://zifo.com/blogs/beyond-the-rigidity-how-abbvies-platform-adapt-to-cmc-science/)
### [Beyond the Rigidity: How AbbVie’s Platform Adapts to CMC Science](https://zifo.com/blogs/beyond-the-rigidity-how-abbvies-platform-adapt-to-cmc-science/)
Sakthi Prasad T, Content Director
[ Read Now ](https://zifo.com/blogs/beyond-the-rigidity-how-abbvies-platform-adapt-to-cmc-science/)
---
### [Resources](https://zifo.com/resources/)
**Published:** December 1, 2025
**Author:** Zifo_user
**Content:**
Resources
A collection of stories about our people, our capabilities, our research, and the ever-changing face of our industry.
## Resource Type
Blogs Whitepapers News Services
Blogs
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
Sakthi Prasad T, Content Director
[ Read Now ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
Sakthi Prasad T, Content Director
[ Read Now ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
Shivani Vohra, Consulting Analyst
[ Read Now ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/the-first-mile-of-lab-data-operationalizing-data-flow-in-heterogeneous-research-environments/)
### [The “First Mile” of Lab Data: Operationalizing Data Flow in Heterogeneous Research Environments](https://zifo.com/blogs/the-first-mile-of-lab-data-operationalizing-data-flow-in-heterogeneous-research-environments/)
Sakthi Prasad T, Content Director
[ Read Now ](https://zifo.com/blogs/the-first-mile-of-lab-data-operationalizing-data-flow-in-heterogeneous-research-environments/)
[  ](https://zifo.com/blogs/design-of-experiments-labs-confront-the-challenge-of-capturing-experimental-intent/)
### [Design of Experiments: Labs Confront the Challenge of Capturing Experimental Intent](https://zifo.com/blogs/design-of-experiments-labs-confront-the-challenge-of-capturing-experimental-intent/)
Rahul Anil Babu, Scientific Application Consultant
[ Read Now ](https://zifo.com/blogs/design-of-experiments-labs-confront-the-challenge-of-capturing-experimental-intent/)
[  ](https://zifo.com/blogs/beyond-the-rigidity-how-abbvies-platform-adapt-to-cmc-science/)
### [Beyond the Rigidity: How AbbVie’s Platform Adapts to CMC Science](https://zifo.com/blogs/beyond-the-rigidity-how-abbvies-platform-adapt-to-cmc-science/)
Sakthi Prasad T, Content Director
[ Read Now ](https://zifo.com/blogs/beyond-the-rigidity-how-abbvies-platform-adapt-to-cmc-science/)
White Papers
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
Sakthi Prasad T, Content Director
[ Read Now ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
Sakthi Prasad T, Content Director
[ Read Now ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
Shivani Vohra, Consulting Analyst
[ Read Now ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/the-first-mile-of-lab-data-operationalizing-data-flow-in-heterogeneous-research-environments/)
### [The “First Mile” of Lab Data: Operationalizing Data Flow in Heterogeneous Research Environments](https://zifo.com/blogs/the-first-mile-of-lab-data-operationalizing-data-flow-in-heterogeneous-research-environments/)
Sakthi Prasad T, Content Director
[ Read Now ](https://zifo.com/blogs/the-first-mile-of-lab-data-operationalizing-data-flow-in-heterogeneous-research-environments/)
[  ](https://zifo.com/blogs/design-of-experiments-labs-confront-the-challenge-of-capturing-experimental-intent/)
### [Design of Experiments: Labs Confront the Challenge of Capturing Experimental Intent](https://zifo.com/blogs/design-of-experiments-labs-confront-the-challenge-of-capturing-experimental-intent/)
Rahul Anil Babu, Scientific Application Consultant
[ Read Now ](https://zifo.com/blogs/design-of-experiments-labs-confront-the-challenge-of-capturing-experimental-intent/)
[  ](https://zifo.com/blogs/beyond-the-rigidity-how-abbvies-platform-adapt-to-cmc-science/)
### [Beyond the Rigidity: How AbbVie’s Platform Adapts to CMC Science](https://zifo.com/blogs/beyond-the-rigidity-how-abbvies-platform-adapt-to-cmc-science/)
Sakthi Prasad T, Content Director
[ Read Now ](https://zifo.com/blogs/beyond-the-rigidity-how-abbvies-platform-adapt-to-cmc-science/)
News
[  ](https://zifo.com/news/zifo-co-launches-real-2026-to-spotlight-the-next-generation-of-connected-ai-enabled-lab-environments/)
### [Zifo Co-Launches REAL 2026 to Spotlight the Next Generation of Connected, AI-Enabled Lab Environments](https://zifo.com/news/zifo-co-launches-real-2026-to-spotlight-the-next-generation-of-connected-ai-enabled-lab-environments/)
[ Read Now ](https://zifo.com/news/zifo-co-launches-real-2026-to-spotlight-the-next-generation-of-connected-ai-enabled-lab-environments/)
[  ](https://zifo.com/news/cmc-bottleneck-is-choking-biopharmas-drug-pipeline-says-zifo/)
### [CMC Bottleneck is Choking Biopharma’s Drug Pipeline, says Zifo](https://zifo.com/news/cmc-bottleneck-is-choking-biopharmas-drug-pipeline-says-zifo/)
[ Read Now ](https://zifo.com/news/cmc-bottleneck-is-choking-biopharmas-drug-pipeline-says-zifo/)
[  ](https://zifo.com/news/zifo-accelerates-lims-master-data-validation-with-new-ai-enabled-services-accelerator/)
### [Zifo Accelerates LIMS Master Data Validation with New AI-Enabled Services Accelerator](https://zifo.com/news/zifo-accelerates-lims-master-data-validation-with-new-ai-enabled-services-accelerator/)
[ Read Now ](https://zifo.com/news/zifo-accelerates-lims-master-data-validation-with-new-ai-enabled-services-accelerator/)
[  ](https://zifo.com/news/zifo-open-quiz-2026-draws-over-1200-quizzers-on-independence-day/)
### [Zifo Open Quiz 2026 Draws Over 1,200 Quizzers on Independence Day](https://zifo.com/news/zifo-open-quiz-2026-draws-over-1200-quizzers-on-independence-day/)
[ Read Now ](https://zifo.com/news/zifo-open-quiz-2026-draws-over-1200-quizzers-on-independence-day/)
[  ](https://zifo.com/news/change-management-strategies-elevating-digital-transformation-in-pharma/)
### [Conquering Biopharma’s ‘Mount Everest’: The Human Element of Digital Transformation](https://zifo.com/news/change-management-strategies-elevating-digital-transformation-in-pharma/)
[ Read Now ](https://zifo.com/news/change-management-strategies-elevating-digital-transformation-in-pharma/)
[  ](https://zifo.com/news/zifo-to-present-biobank-data-breakthrough-at-the-festival-of-genomics-boston/)
### [Zifo to Present Biobank Data Breakthrough at the Festival of Genomics Boston](https://zifo.com/news/zifo-to-present-biobank-data-breakthrough-at-the-festival-of-genomics-boston/)
[ Read Now ](https://zifo.com/news/zifo-to-present-biobank-data-breakthrough-at-the-festival-of-genomics-boston/)
Services
[  ](https://zifo.com/services/cmc-chemistry-manufacturing-controls/)
### [Manufacturing CMC Services](https://zifo.com/services/cmc-chemistry-manufacturing-controls/)
[ Read Now ](https://zifo.com/services/cmc-chemistry-manufacturing-controls/)
[  ](https://zifo.com/services/lab-compute-services/)
### [Lab Compute Services](https://zifo.com/services/lab-compute-services/)
[ Read Now ](https://zifo.com/services/lab-compute-services/)
[  ](https://zifo.com/services/scientific-application-managed-services/)
### [Scientific Application Managed Services](https://zifo.com/services/scientific-application-managed-services/)
[ Read Now ](https://zifo.com/services/scientific-application-managed-services/)
[  ](https://zifo.com/services/digital-transformation-consulting-services/)
### [Digital Transformation Consulting Services](https://zifo.com/services/digital-transformation-consulting-services/)
[ Read Now ](https://zifo.com/services/digital-transformation-consulting-services/)
[  ](https://zifo.com/services/manufacturing-and-mes-services/)
### [Manufacturing and Quality Informatics Services](https://zifo.com/services/manufacturing-and-mes-services/)
[ Read Now ](https://zifo.com/services/manufacturing-and-mes-services/)
[  ](https://zifo.com/services/product-development-and-design/)
### [Product Development and Design](https://zifo.com/services/product-development-and-design/)
[ Read Now ](https://zifo.com/services/product-development-and-design/)
---
## Blogs
### [CMC: Biopharma's Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
**Published:** September 1, 2026
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/ "CMC: Biopharma’s Strait of Hormuz")
'); } // Special validation for email fields if ($input.attr('type') === 'email' && value && !emailPattern.test(value)) { isValid = false; $input.addClass('error'); // Remove previous error message if exists $input.next('.error-message').remove(); $input.after('Enter a valid email address.
'); } }); // If form is valid, trigger download if (isValid) { // Add timestamp to prevent browser from re-downloading on refresh let timestamp = new Date().getTime(); let downloadUrl = "https://zifo.com/wp-content/uploads/2025/12/AI-Pharma-Drug.pdf?t=" + timestamp; // Method 1: Direct link click (most reliable) let link = document.createElement("a"); link.href = downloadUrl; link.download = "AI-Pharma-Drug.pdf"; document.body.appendChild(link); link.click(); // Method 2: Iframe backup setTimeout(function() { let iframe = document.createElement('iframe'); iframe.style.display = 'none'; iframe.src = downloadUrl; document.body.appendChild(iframe); }, 100); // Clean up setTimeout(function() { if (link.parentNode) { document.body.removeChild(link); } // Clear form values after successful download clearForm(); }, 1000); } } function clearForm() { // Clear all input values $('.elementor-down-pdf-form input[type="text"], .elementor-down-pdf-form input[type="email"]').val(''); // Remove floating-active class from all fields $('.elementor-down-pdf-form .elementor-field-group').removeClass('floating-active'); // Remove any error classes $('.elementor-down-pdf-form input').removeClass('error'); // Clear any remaining error messages $('.error-message').remove(); } /* ------------------------------------- REAL-TIME VALIDATION Remove error when user starts typing --------------------------------------*/ $(document).on('input', '.elementor-down-pdf-form input[type="text"], .elementor-down-pdf-form input[type="email"]', function() { var $input = $(this); var $errorMessage = $input.next('.error-message'); if ($input.val().trim() !== '' && $errorMessage.length) { $input.removeClass('error'); $errorMessage.remove(); } }); /* ------------------------------------- PREVENT BROWSER FROM AUTO-DOWNLOADING ON REFRESH --------------------------------------*/ // Clear any previous download triggers if (window.history.replaceState) { window.history.replaceState(null, null, window.location.href); } // Remove any existing download elements $('iframe[src*="AI-Pharma-Drug.pdf"], a[href*="AI-Pharma-Drug.pdf"]').remove(); });
## CMC: Biopharma’s Strait of Hormuz
Sakthi Prasad T, Content Director
Sep 01, 2026
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20CMC%3A%20Biopharma%27s%20Strait%20of%20Hormuz%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Fcmc-biopharmas-strait-of-hormuz%2F "Share on Email")
- [](https://x.com/intent/post?text=CMC%3A%20Biopharma%27s%20Strait%20of%20Hormuz&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fcmc-biopharmas-strait-of-hormuz%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=CMC%3A+Biopharma%5C%26%23039%3Bs+Strait+of+Hormuz&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fcmc-biopharmas-strait-of-hormuz%2F "Share on LinkedIn")
Biopharma has invested billions in modernizing drug discovery and commercial manufacturing. AI, machine learning, high-throughput experimentation, and advanced production capabilities are transforming both ends of the value chain. Yet between these sophisticated endpoints sits a historically underfunded vulnerability: Chemistry, Manufacturing, and Controls (CMC).
CMC has become the industry’s proverbial “Strait of Hormuz,” a narrow and often unpredictable checkpoint through which every therapy must pass before reaching patients. The consequences are significant. CMC deficiencies have contributed to 74% of FDA Complete Response Letters, often because of fragmented evidence, unresolved site observations, weak manufacturing readiness, or incomplete proof of commercial-scale control.
Solving this challenge requires more than isolated technology deployments. By connecting scientific data, redesigning workflows, and applying agentic orchestration and AI-enabled process intelligence, biopharma companies could reduce overall cycle times by up to 40% and accelerate individual phases by as much as 60%.
*The PDF report is embedded on this page. Please scroll to read or download it. Download option button is available below the PDF embed*
[ Click Here to Download the Report ](#)
GET YOUR FREE COPY
First Name
Last Name
Email
Company
Job Title
Acceptance I consent to being contacted by an official Zifo representative
Submit
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
**Categories:** Pre-Built Solutions and Blueprints
---
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
**Published:** September 11, 2026
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/ "Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration")
'); } // Special validation for email fields if ($input.attr('type') === 'email' && value && !emailPattern.test(value)) { isValid = false; $input.addClass('error'); // Remove previous error message if exists $input.next('.error-message').remove(); $input.after('Enter a valid email address.
'); } }); // If form is valid, trigger download if (isValid) { // Add timestamp to prevent browser from re-downloading on refresh let timestamp = new Date().getTime(); let downloadUrl = "https://zifo.com/wp-content/uploads/2025/12/AI-Pharma-Drug.pdf?t=" + timestamp; // Method 1: Direct link click (most reliable) let link = document.createElement("a"); link.href = downloadUrl; link.download = "AI-Pharma-Drug.pdf"; document.body.appendChild(link); link.click(); // Method 2: Iframe backup setTimeout(function() { let iframe = document.createElement('iframe'); iframe.style.display = 'none'; iframe.src = downloadUrl; document.body.appendChild(iframe); }, 100); // Clean up setTimeout(function() { if (link.parentNode) { document.body.removeChild(link); } // Clear form values after successful download clearForm(); }, 1000); } } function clearForm() { // Clear all input values $('.elementor-down-pdf-form input[type="text"], .elementor-down-pdf-form input[type="email"]').val(''); // Remove floating-active class from all fields $('.elementor-down-pdf-form .elementor-field-group').removeClass('floating-active'); // Remove any error classes $('.elementor-down-pdf-form input').removeClass('error'); // Clear any remaining error messages $('.error-message').remove(); } /* ------------------------------------- REAL-TIME VALIDATION Remove error when user starts typing --------------------------------------*/ $(document).on('input', '.elementor-down-pdf-form input[type="text"], .elementor-down-pdf-form input[type="email"]', function() { var $input = $(this); var $errorMessage = $input.next('.error-message'); if ($input.val().trim() !== '' && $errorMessage.length) { $input.removeClass('error'); $errorMessage.remove(); } }); /* ------------------------------------- PREVENT BROWSER FROM AUTO-DOWNLOADING ON REFRESH --------------------------------------*/ // Clear any previous download triggers if (window.history.replaceState) { window.history.replaceState(null, null, window.location.href); } // Remove any existing download elements $('iframe[src*="AI-Pharma-Drug.pdf"], a[href*="AI-Pharma-Drug.pdf"]').remove(); });
## Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration
Sakthi Prasad T, Content Director
Sep 11, 2026
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Agentic%20AI%20Survey%3A%20Early%20Days%20as%20Industry%20Focuses%20on%20ROI%20and%20Lab%20Orchestration%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Fagentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration%2F "Share on Email")
- [](https://x.com/intent/post?text=Agentic%20AI%20Survey%3A%20Early%20Days%20as%20Industry%20Focuses%20on%20ROI%20and%20Lab%20Orchestration&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fagentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Agentic+AI+Survey%3A+Early+Days+as+Industry+Focuses+on+ROI+and+Lab+Orchestration&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fagentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration%2F "Share on LinkedIn")
The biopharma industry is currently navigating a paradigm shift. Just last year, the core of the digital transformation conversation revolved almost entirely around Gen AI applications and basic data readiness. But much water has flowed under the bridge since then, and the industry’s focus has evolved from basic AI readiness sharply toward “Agentic AI” – autonomous agents capable of reasoning, orchestrating, and executing complex scientific workflows. While the hype around Agentic AI is deafening right now, our recent survey – gathering insights from nearly 500 respondents belonging to over 125 companies — reveals that the industry is very much still at the starting line.
Of course, things are evolving quiet rapidly in this segment. While the goal is always driving better scientific and patient outcomes, the immediate wins organizations are hunting for revolve around efficiency, massive time savings, and unlocking cross-departmental knowledge synthesis. But progress is shadowed by substantial, understandable anxieties.
*The PDF report is embedded on this page. Please scroll to read or download it. Download option button is available below the PDF embed*
[ Click Here to Download the Report ](#)
GET YOUR FREE COPY
First Name
Last Name
Email
Company
Job Title
Acceptance I consent to being contacted by an official Zifo representative
Submit
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
---
### [Early Days For AI But Scientific Data Management Gains Momentum](https://zifo.com/blogs/early-days-for-ai-but-scientific-data-management-gains-momentum/)
**Published:** May 28, 2025
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [Early Days For AI But Scientific Data Management Gains Momentum](https://zifo.com/blogs/early-days-for-ai-but-scientific-data-management-gains-momentum/ "Early Days For AI But Scientific Data Management Gains Momentum")
'); } // Special validation for email fields if ($input.attr('type') === 'email' && value && !emailPattern.test(value)) { isValid = false; $input.addClass('error'); // Remove previous error message if exists $input.next('.error-message').remove(); $input.after('Enter a valid email address.
'); } }); // If form is valid, trigger download if (isValid) { // Add timestamp to prevent browser from re-downloading on refresh let timestamp = new Date().getTime(); let downloadUrl = "https://zifo.com/wp-content/uploads/2025/12/AI-Pharma-Drug.pdf?t=" + timestamp; // Method 1: Direct link click (most reliable) let link = document.createElement("a"); link.href = downloadUrl; link.download = "AI-Pharma-Drug.pdf"; document.body.appendChild(link); link.click(); // Method 2: Iframe backup setTimeout(function() { let iframe = document.createElement('iframe'); iframe.style.display = 'none'; iframe.src = downloadUrl; document.body.appendChild(iframe); }, 100); // Clean up setTimeout(function() { if (link.parentNode) { document.body.removeChild(link); } // Clear form values after successful download clearForm(); }, 1000); } } function clearForm() { // Clear all input values $('.elementor-down-pdf-form input[type="text"], .elementor-down-pdf-form input[type="email"]').val(''); // Remove floating-active class from all fields $('.elementor-down-pdf-form .elementor-field-group').removeClass('floating-active'); // Remove any error classes $('.elementor-down-pdf-form input').removeClass('error'); // Clear any remaining error messages $('.error-message').remove(); } /* ------------------------------------- REAL-TIME VALIDATION Remove error when user starts typing --------------------------------------*/ $(document).on('input', '.elementor-down-pdf-form input[type="text"], .elementor-down-pdf-form input[type="email"]', function() { var $input = $(this); var $errorMessage = $input.next('.error-message'); if ($input.val().trim() !== '' && $errorMessage.length) { $input.removeClass('error'); $errorMessage.remove(); } }); /* ------------------------------------- PREVENT BROWSER FROM AUTO-DOWNLOADING ON REFRESH --------------------------------------*/ // Clear any previous download triggers if (window.history.replaceState) { window.history.replaceState(null, null, window.location.href); } // Remove any existing download elements $('iframe[src*="AI-Pharma-Drug.pdf"], a[href*="AI-Pharma-Drug.pdf"]').remove(); });
## Early Days For AI But Scientific Data Management Gains Momentum
Paul Denny-Gouldson, Chief Scientific Officer | Sakthi Prasad T, Content Director
May 28, 2025
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Early%20Days%20For%20AI%20But%20Scientific%20Data%20Management%20Gains%20Momentum%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Fearly-days-for-ai-but-scientific-data-management-gains-momentum%2F "Share on Email")
- [](https://x.com/intent/post?text=Early%20Days%20For%20AI%20But%20Scientific%20Data%20Management%20Gains%20Momentum&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fearly-days-for-ai-but-scientific-data-management-gains-momentum%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Early+Days+For+AI+But+Scientific+Data+Management+Gains+Momentum&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fearly-days-for-ai-but-scientific-data-management-gains-momentum%2F "Share on LinkedIn")
Zifo’s recently concluded “Data Readiness Survey,” which saw participation of scientists and informaticians from over 30 global companies, shows that scientifically driven companies (Pharma, Biotech, Chemicals, F&B, FMCG, Agrotech etc.) are beginning to seriously invest in AI and ML across the entire R&D, Manufacturing and Trials value chain, and a lot of the initial effort is going into the basics — making sure data is of good enough quality i.e. there are proper standards, and that everyone’s on the same page with things like metadata, ontologies, master data etc.
*The PDF report is embedded on this page. Please scroll to read or download it. Download option button is available below the PDF embed*
[ Click Here to Download the Report ](#)
GET YOUR FREE COPY
First Name
Email
Company
Designation
Submit
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
**Categories:** Bioinformatics, Clinical Genomics, Clinical Trials Services, Pre-Built Solutions and Blueprints, RnD Informatics Services, Scientific Application Managed Services, Scientific Cloud Computing Services, Strategic Scientific Consulting Services, Validation Service and Compliance Support
---
### [Conquering Biopharma's 'Mount Everest': Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
**Published:** July 10, 2026
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/ "Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation")
## Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation
Shivani Vohra, Consulting Analyst
Jul 09, 2026
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Conquering%20Biopharma%27s%20%27Mount%20Everest%27%3A%20Why%20People%20Matter%20Most%20in%20Digital%20Transformation%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Faccelerating-digital-transformation-with-strategic-change-management-in-pharma%2F "Share on Email")
- [](https://x.com/intent/post?text=Conquering%20Biopharma%27s%20%27Mount%20Everest%27%3A%20Why%20People%20Matter%20Most%20in%20Digital%20Transformation&url=https%3A%2F%2Fzifo.com%2Fblogs%2Faccelerating-digital-transformation-with-strategic-change-management-in-pharma%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Conquering+Biopharma%5C%26%23039%3Bs+%5C%26%23039%3BMount+Everest%5C%26%23039%3B%3A+Why+People+Matter+Most+in+Digital+Transformation&url=https%3A%2F%2Fzifo.com%2Fblogs%2Faccelerating-digital-transformation-with-strategic-change-management-in-pharma%2F "Share on LinkedIn")
As the biopharma industry adopts advanced technologies at breakneck speed, organizations are encountering a surprising roadblock: it isn’t the technology — it’s human behavior. While AI and other emerging innovations promise to accelerate scientific capabilities at unprecedented scale and speed, the industry’s biggest challenge is no longer implementing technology but helping people embrace and adapt to it. This was the central theme of a recent Zifo virtual panel discussion, **“***Change Management Strategies Elevating Digital Transformation in Pharma***,”** where Zifo experts explored why technology investments often fall short of expectations — and why effective change management is the key to turning digital transformation into lasting business success.
**Core Themes & Key Takeaways from the discussion:**
**1. Macro Vision vs. Micro Execution**
Successful digital transformation requires a balanced approach. While leadership must set a clear, long-term strategic “North Star” (the macro vision), the ability to realize this vision falls short unless leaders actively address the granular, day-to-day workflow frictions (the micro execution) that scientists face at the bench.
Harsha Nirmal Kumar emphasized how true transformation requires balancing the boardroom’s “why” with the bench scientist’s daily “how.”
**2. Understanding Change Resistance**
Rather than viewing user pushback as behavioral sabotage, the speakers reframe it as a vital health check. As the discussion highlighted, “Resistance is not troublemaking; rather, it is a signal that a piece of the adoption puzzle is missing.” Understanding what is driving the resistance is an important first step in figuring out how to best support the scientists through the transition.
Shari Bickford shared a case study of a lab team fiercely resisting a new digital rollout. By digging deeper via a focus group, the project team discovered the resistance stemmed from a poorly managed past software transition that left the scientists stuck with unresolved workarounds for years. The team was then able to proactively establish supports for the team to make this transition smoother for them.
**3. Governance vs. Operationalization**
Governance frameworks (policies, compliance charters, and audit readiness) act as essential enterprise guardrails. However, these blueprints would remain hollow without the human element for operationalization: building user habits, setting up governance council, and using adaptive tools (like Jira and Confluence) to make adoption seamless.
Harsha outlined this as an intersection of people and policies, noting that terms like COMPLIANCE shouldn’t frighten users; he also emphasized: “Policies should be guardrails that guide people. They should not impede your progress.”
**4. The Transformation Toolkit**
To successfully pull high-stakes digital initiatives out of “pilot purgatory” and scale them globally, organizations need agile, tactical frameworks. Shari highlighted models like vision & value workshops (what the transition is fundamentally intended to accomplish and how does the organization define concrete metrics of success beyond technical deployment), dynamic stakeholder mapping (knowing how to reach all segments of the audience through balancing user buy-in against enterprise influence), and the CDV (Communicate, Demonstrate, Validate) framework to support leaders in knowing how to best drive change.
**Summary:**
Technology alone does not drive transformation and, in fact, in isolation is likely to fail. Technology is no longer the bottleneck; rather workforce enablement is now the biggest hurdle. Well-designed and executed change management will help to drive implementation in a more sustainable manner, ensuring a people-first approach. Bringing along the community during the transition will lead to better adoption, in turn driving overall success.
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
---
### [The "First Mile" of Lab Data: Operationalizing Data Flow in Heterogeneous Research Environments](https://zifo.com/blogs/the-first-mile-of-lab-data-operationalizing-data-flow-in-heterogeneous-research-environments/)
**Published:** June 24, 2026
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [The “First Mile” of Lab Data: Operationalizing Data Flow in Heterogeneous Research Environments](https://zifo.com/blogs/the-first-mile-of-lab-data-operationalizing-data-flow-in-heterogeneous-research-environments/ "The “First Mile” of Lab Data: Operationalizing Data Flow in Heterogeneous Research Environments")
## The “First Mile” of Lab Data: Operationalizing Data Flow in Heterogeneous Research Environments
Sakthi Prasad T, Content Director
Jul 01, 2026
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20The%20%27First%20Mile%27%20of%20Lab%20Data%3A%20Operationalizing%20Data%20Flow%20in%20Heterogeneous%20Research%20Environments%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Fthe-first-mile-of-lab-data-operationalizing-data-flow-in-heterogeneous-research-environments%2F "Share on Email")
- [](https://x.com/intent/post?text=The%20%27First%20Mile%27%20of%20Lab%20Data%3A%20Operationalizing%20Data%20Flow%20in%20Heterogeneous%20Research%20Environments&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fthe-first-mile-of-lab-data-operationalizing-data-flow-in-heterogeneous-research-environments%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=The+%5C%26%23039%3BFirst+Mile%5C%26%23039%3B+of+Lab+Data%3A+Operationalizing+Data+Flow+in+Heterogeneous+Research+Environments&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fthe-first-mile-of-lab-data-operationalizing-data-flow-in-heterogeneous-research-environments%2F "Share on LinkedIn")
**Speaker: Chris Perkins, Director of Lab IT and Operations, Broad Institute**
***Zifo’s SiEE event 2026***
**The Ultimate Mission: Navigating Lab IT in a Highly Heterogeneous Academic Environment**
In a presentation on operationalizing data flow, Chris Perkins, Director of Lab IT and Operations at the Broad Institute, highlighted the monumental task of managing IT assets and data pipelines in a decentralized, academic environment. Transitioning from industry to academia, Chris discovered that instead of top-down corporate mandates, the Broad operates more like a collection of “fiefdoms” where researchers dictate their own funding, hardware, and networks.
The ultimate goal for his team is to move away from messy, disconnected data practices toward highly structured, interoperable datasets — the necessary foundation for AI models like AlphaFold. In this presentation, Chris explores the delicate balance of building a metadata-first culture, driving standardization without authority, and creating practical lab interventions that prioritize the researchers’ immediate scientific needs.
**Key Takeaways from the Presentation**
- **Building a “Metadatism” Culture:** You cannot simply shove data into an LLM and expect revolutionary results. Cultivating a culture-like “metadatism” means capturing metadata at every step using structured schemas. Critically, systems must be designed so scientists never have to enter metadata more than once, minimizing the administrative burden at the bench.
- **The “Sneakernet” Reality and Tactical Solutions:** Because scientists often face heavy security friction when trying to move data to the cloud, they frequently rely on USB drives or buying private servers. Rather than fighting this directly, Chris’s team meets users where they are. They implement “mule architectures” (jump boxes) to safely extract data from older lab computers and use automated background scripts that mimic the simplicity of a USB transfer, quietly routing data directly to the cloud.
- **Financial Transparency and Cloud Trust:** To address researchers’ fear of unpredictable cloud fees, Chris uses his business background to present a clear cost comparison over three years. He walks them through the true cost of buying and maintaining a local NAS drive — including the reality of having to purchase another one once it fills up — versus a Cloud subscription. This transparency is part of an ongoing effort to rebuild trust in cloud storage after past instances of unexpected bills left scientists wary of the technology.
- **The Carrot Over the Stick for Standardization:** In an environment with zero central ELN or LIMS mandates, IT cannot simply force compliance. To drive the adoption of uniform data platforms, IT must build exceptional workflows that generate a “fear of missing out” (FOMO). By automating data ingestion directly at the instrument, IT removes the manual data entry barrier, encouraging natural adoption.
- **Balancing Security and Science:** IT teams are sometimes viewed as hostile invaders who get in the way of science. Chris emphasizes that the IT mindset must pivot from immediate control to collaborative support. By physically sitting side-by-side with scientists in the lab to solve problems, IT builds necessary trust, ultimately proving that good security and good science can coexist.
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
---
### [Design of Experiments: Labs Confront the Challenge of Capturing Experimental Intent](https://zifo.com/blogs/design-of-experiments-labs-confront-the-challenge-of-capturing-experimental-intent/)
**Published:** June 18, 2026
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [Design of Experiments: Labs Confront the Challenge of Capturing Experimental Intent](https://zifo.com/blogs/design-of-experiments-labs-confront-the-challenge-of-capturing-experimental-intent/ "Design of Experiments: Labs Confront the Challenge of Capturing Experimental Intent")
## Design of Experiments: Labs Confront the Challenge of Capturing Experimental Intent
Rahul Anil Babu, Scientific Application Consultant
Jun 18, 2026
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Design%20of%20Experiments%3A%20Labs%20Confront%20the%20Challenge%20of%20Capturing%20Experimental%20Intent%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Fdesign-of-experiments-labs-confront-the-challenge-of-capturing-experimental-intent%2F "Share on Email")
- [](https://x.com/intent/post?text=Design%20of%20Experiments%3A%20Labs%20Confront%20the%20Challenge%20of%20Capturing%20Experimental%20Intent&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fdesign-of-experiments-labs-confront-the-challenge-of-capturing-experimental-intent%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Design+of+Experiments%3A+Labs+Confront+the+Challenge+of+Capturing+Experimental+Intent&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fdesign-of-experiments-labs-confront-the-challenge-of-capturing-experimental-intent%2F "Share on LinkedIn")
Image reference: / source
At the core of every chemical synthesis and formulation improvement is systematic testing and optimizing reaction and formulation parameters through a series of experiments. The experiments they run are not random; rather, they are structured attempts to understand how different reaction factors influence outcomes such as yield, purity, stability or efficacy.
And yet, despite this structure, a familiar frustration often persists in the lab: results that don’t quite add up, patterns that remain just out of reach, and iterations that feel necessary but not always illuminating.
Traditionally, experimental design has relied heavily on scientific expertise and domain intuition leading to incremental trial-and-error of altering one variable at a time and studying its impacts on a reaction (OVAT – **O**ne **V**ariable **A**t a **T**ime). While this approach has led to many breakthroughs, it can also be slow and inefficient, especially when greater than three factors are involved. More importantly, it risks overlooking how variables interact — often where the most critical insights lie.
This led to the emergence of Design of Experiments (DoE), which is a structured methodology that helps scientists learn more from fewer experiments.
*Figure 1: Decision workflow for reaction optimization Design of Experiments adapted from Wall et al. (2025).*
**What is Design of Experiments (DoE)?**
**Design of Experiments** is a branch of applied statistics that helps to systematically plan experiments so that multiple variables can be studied simultaneously. DoE represents a shift from **ad hoc experimentation** to **intentional experimental design** by prompting the following questions:
- Which factors might matter?
- What ranges should we test?
- How can we combine them efficiently to understand both individual effects and interactions?
This shift is subtle, but powerful — it moves experimentation from sequential exploration to structured discovery.
Let’s consider a simple hypothetical study to identify conditions that improve the yield of a reaction. Based on prior knowledge and scientific domain expertise, a few factors would be identified as critical:
- **Temperature:** Low / High
- **Reaction Time:** Short / Long
- **Catalyst Amount:** Low / High
While other variables may exist, they are excluded as unlikely to influence yield based on previous knowledge and understanding. This highlights that DoE can be used as a powerful tool to improve efficiency and accelerate experimentation, but not as a substitute for scientific judgement.
At the same time, it also introduces an important caveat: the quality of a DoE is only as good as the assumptions that guide it.
If a lab employs DoE before studying all key variables, the result can be misleading. For example, if humidity wasn’t recognized as a meaningful variable before designing the DoE, an unexpected yield at a particular factor combination might be misinterpreted. The deviation could simply be due to uncontrolled ambient humidity rather than the factors under study.
**The hypothetical DoE matrix for this example study is shown below:**
Experimental ConditionTemperature (°C)Temperature (°C)Catalyst (mol %)160300.5260302.0370601.25460900.5560902.0670601.25780300.5880302.0980900.51080902.01170601.251270601.25
There are many aspects that could be understood through employment of DoE. One such aspect that helps in understanding whether observed variation in results is due to true chemical effects or simply the natural variability of the experimental system is **Center Point Replicates.**
In practice, this answers a deceptively simple but critical question: *are we observing a real signal, or just noise?*
As seen above, each factor has a defined range in a designed experiment. The **center point** is simply the midpoint of every factor simultaneously: in this case, 70°C, along with the midpoints of reaction time and catalyst loading. Runs 3, 6, 11, and 12 are considered center point replicates which help in understanding the variability of the experiment.
The repetition is deliberate. When a scientist runs the same conditions three times and obtains yields of 74%, 76%, and 75%, the results suggest that the experimental system has roughly 1% natural variability. This matters enormously because without that baseline, it is difficult to assert whether a factor actually affects yield or whether the effect is just noise.
What may appear as an improvement — or degradation — can sometimes simply be randomness in disguise.
As such, center point replicates can validate the validity and reproducibility of results to auditors and reviewers in downstream reports.
As such, center point replicates can validate the validity and reproducibility of results to auditors and reviewers in downstream reports.
**Why Design of Experiments?**
Design of Experiments offers multiple benefits in the scientific realm. Within the context of chemical formulations and synthesis reactions, let’s focus on some of the benefits to understand its importance.
Beyond efficiency, DoE fundamentally improves the quality of decisions derived from experimental data. It enables scientists to surface interactions, explore experimental spaces more effectively, and draw conclusions with greater confidence.
But this raises a less obvious question: *What happens to that insight once the experiment is over?*
DoE doesn’t just change how experiments are run — it changes what needs to be remembered.
**Evolving DoE design through Cross-Reaction Pattern Recognition**
DoE studies are often designed by utilizing existing knowledge to decide which factors to include, what ranges to explore, and how many runs to allocate.
If yield is observed to consistently plateau above 75°C across multiple studies for a particular compound class, the next design would be better designed by narrowing the temperature for finer resolution. If reaction time is observed to have negligible impacts across multiple studies, then it frees up runs to introduce a new variable like solvent ratio.
Each of these becomes a more informed design decision — not just based on intuition, but on accumulated evidence.
This is only possible if DoE data is captured in a structured manner that makes it easily accessible and comparable across experiments — and crucially, if the *intent of those experiments* is preserved alongside the results.
**Predictive Modelling and Advanced Analytics**
Every data-point captured in a DoE study carries meaning beyond individual experiments. Collectively, these structured data points reveal trends, boundaries, and relationships that single experiments could fail to give.
However, the value of this data depends not just on what was recorded, but *how completely the experimental context was captured.*
This is where a well thought-out, DoE-integrated data capture design in ELN/LIMS systems becomes critical — not as an add-on, but as the natural continuation of DoE thinking.
When this structured data accumulates over time, it becomes the foundation upon which predictive models and advanced analytics are built.
A machine learning model trained on hundreds of structured DoE datasets from an ELN can predict the probability of a reaction succeeding before a single additional experiment is run.
Instead of starting from a blank slate, scientists can begin with direction.
**Integrating DoE Thinking into ELNs and LIMS**
This gap — between what was observed and what was intended in an experiment — becomes especially visible in how experimental data is captured in ELNs and LIMS.
Minimum viable product requirements are often based out of the data capture needs such as recording recipes, inputs, outputs, and associated calculations. This structure works well for documenting what went into each batch, but it completely misses the experimental considerations taken to arrive at the formulation recipe.
In effect, the results are remembered, but the reasoning that led to them is not.
Not every component in a formulation is a variable under study, and not every variable is a formulation component.
Temperature, reaction time, and catalyst loading could be factors a scientist intentionally varies in understanding how they influence yield. A standard reaction record can tell you that run 1 was executed at 60°C, 30 minutes, and 0.5 mol% catalyst.
What this record doesn’t specify is that these three factors were chosen as DoE factors, that 60°C was the low level of a deliberately set temperature range, or that runs 1 and 7 were placed at opposite ends of that range in order to estimate the temperature effect on yield.
This DoE awareness can be factored into an ELN/LIMS by introducing a separate definition table and a design run table that sit between the formulation, process parameters, and results. These tables explicitly define which variables are being studied, what ranges or levels they take, and how they are combined across planned runs.
This is what makes the difference between documenting experiments and *learning from them.*
This in turn could be leveraged by LLMs or AI models to uncover hidden patterns and generate meaningful recommendations for scientists starting on new projects.
Instead of a scientist starting from a blank page, an AI-enabled system might be able to open a new ELN entry and immediately suggest:
*“Based on similar crystallization steps, a fractional factorial design with these four factors is likely to give you the most insight,”*
or
*“For this type of tablet formulation, a mixture DoE with these excipient constraints has historically produced robust design spaces.”*
**Capturing What Experiments Actually Teach Us**
Introducing DoE awareness into your ELN/LIMS system will not only aid in elevating your data quality, but also can set a foundation for a smarter, AI-augmented scientific workflow.
More importantly, it shifts experimentation from a series of isolated trials to a connected system of learning — where every experiment not only answers a question but also contributes to a growing body of reusable knowledge.
And that is the real promise of DoE: not just better experiments, but experiments whose value extends far beyond a single run.
**Where Experimental Design Meets Institutional Memory**
As DoE adoption grows, the conversation is naturally shifting from how experiments are designed to how their insights are preserved.
Designing better experiments is only part of the equation. The real value lies in ensuring that the intent behind those experiments — the factors considered, the ranges explored, and the structure of the design — is captured in a way that can be reused and built upon.
In practice, however, this is not a trivial shift. Most ELN and LIMS implementations are built around recording experimental inputs and outputs, not the reasoning that shaped them. Retrofitting these systems to capture DoE intent requires not just changes in data models, but also alignment across scientists, workflows, and organizational priorities. What to capture, how consistently to capture it, and how much structure is “enough” are decisions that rarely have straightforward answers.
**This raises a few important questions for modern labs:**
- At what point does additional structure begin to add more value than friction?
- How can experimental intent be captured without slowing down the scientist at the bench?
- And how do organizations ensure that this data remains usable — not just stored — as systems and teams evolve?
When this intent is lost, experiments remain isolated outcomes. When it is preserved, they become part of a larger system of learning.
In that sense, DoE is not just a methodology for improving individual studies — it is a foundation for creating experiments that continue to generate value beyond a single run. And when thoughtfully integrated with ELNs and LIMS, it enables a shift from experimentation as a sequence of trials to experimentation as an accumulating, compounding source of insight.
Because the real advantage isn’t just in running better experiments — it’s in remembering them well enough to not have to start from scratch.
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
---
### [A Strategic Guide To Consolidation In Scientific Informatics](https://zifo.com/blogs/a-strategic-guide-to-consolidation-in-scientific-informatics/)
**Published:** July 8, 2025
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [A Strategic Guide To Consolidation In Scientific Informatics](https://zifo.com/blogs/a-strategic-guide-to-consolidation-in-scientific-informatics/ "A Strategic Guide To Consolidation In Scientific Informatics")
'); } // Special validation for email fields if ($input.attr('type') === 'email' && value && !emailPattern.test(value)) { isValid = false; $input.addClass('error'); // Remove previous error message if exists $input.next('.error-message').remove(); $input.after('Enter a valid email address.
'); } }); // If form is valid, trigger download if (isValid) { // Add timestamp to prevent browser from re-downloading on refresh let timestamp = new Date().getTime(); let downloadUrl = "https://cdn.zifo.com/2026/01/Streamlining-Scientific-Informatics.pdf?t=" + timestamp; // Method 1: Direct link click (most reliable) let link = document.createElement("a"); link.href = downloadUrl; link.download = "Streamlining-Scientific-Informatics.pdf"; document.body.appendChild(link); link.click(); // Method 2: Iframe backup setTimeout(function() { let iframe = document.createElement('iframe'); iframe.style.display = 'none'; iframe.src = downloadUrl; document.body.appendChild(iframe); }, 100); // Clean up setTimeout(function() { if (link.parentNode) { document.body.removeChild(link); } // Clear form values after successful download clearForm(); }, 1000); } } function clearForm() { // Clear all input values $('.elementor-down-pdf-form input[type="text"], .elementor-down-pdf-form input[type="email"]').val(''); // Remove floating-active class from all fields $('.elementor-down-pdf-form .elementor-field-group').removeClass('floating-active'); // Remove any error classes $('.elementor-down-pdf-form input').removeClass('error'); // Clear any remaining error messages $('.error-message').remove(); } /* ------------------------------------- REAL-TIME VALIDATION Remove error when user starts typing --------------------------------------*/ $(document).on('input', '.elementor-down-pdf-form input[type="text"], .elementor-down-pdf-form input[type="email"]', function() { var $input = $(this); var $errorMessage = $input.next('.error-message'); if ($input.val().trim() !== '' && $errorMessage.length) { $input.removeClass('error'); $errorMessage.remove(); } }); /* ------------------------------------- PREVENT BROWSER FROM AUTO-DOWNLOADING ON REFRESH --------------------------------------*/ // Clear any previous download triggers if (window.history.replaceState) { window.history.replaceState(null, null, window.location.href); } });
## A Strategic Guide To Consolidation In Scientific Informatics
Suchitra Ramaswamy, Strategic Advisor | Paul Denny-Gouldson, Chief Scientific Officer
Jul 08, 2025
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20A%20Strategic%20Guide%20To%20Consolidation%20In%20Scientific%20Informatics%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Fa-strategic-guide-to-consolidation-in-scientific-informatics%2F "Share on Email")
- [](https://x.com/intent/post?text=A%20Strategic%20Guide%20To%20Consolidation%20In%20Scientific%20Informatics&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fa-strategic-guide-to-consolidation-in-scientific-informatics%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=A+Strategic+Guide+To+Consolidation+In+Scientific+Informatics&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fa-strategic-guide-to-consolidation-in-scientific-informatics%2F "Share on LinkedIn")
Modern scientific informatics relies on a vast ecosystem of specialized software, including ELNs, LIMS, and CDS. Large R&D and manufacturing organizations, particularly in healthcare and pharma, often manage hundreds of these applications. This proliferation leads to fragmentation, data silos, and high maintenance. By synthesizing insights from Zifo’s Customer Advisory Board (CAB) meeting — in collaboration with select Zifo customers — we have developed a cohesive solution to help organizations understand and implement consolidation strategies.
*The PDF report is embedded on this page. Please scroll to read or download it. Download option button is available below the PDF embed*
[ Click Here to Download the Report ](#)
## Download Survey Report
Name
Email
Company
Designation
Submit
GET YOUR FREE COPY
First Name
Email
Company
Designation
Submit
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
**Categories:** Bioinformatics, Chromatography Systems Services, Clinical Genomics, Clinical Trials Services, Data Science and Consulting Services, Digital Transformation Consulting, Lab Compute Services, Manufacturing and Quality Informatics Services, Pre-Built Solutions and Blueprints, Product Development and Design Services, RnD Informatics Services, Scientific Application Managed Services, Scientific Cloud Computing Services, Strategic Scientific Consulting Services, Validation Service and Compliance Support
---
### [Fire Side Chat : Navigating The Translational Genomics Landscape](https://zifo.com/blogs/fire-side-chat-navigating-the-translational-genomics-landscape/)
**Published:** October 28, 2025
**Author:** Zifo_user
**Content:**
' ); } }); } }); /* ------------------------------------- FORM VALIDATION (INLINE MESSAGES) Updated to work with Elementor form --------------------------------------*/ jQuery(document).ready(function($) { // Prevent default form submission $('.elementor-down-pdf-form form').on('submit', function(e) { //e.preventDefault(); // validateForm(); }); // Also attach to button click $('.elementor-down-pdf-form .elementor-button').on('click', function(e) { // e.preventDefault(); //validateForm(); }); }); function validateForm() { // Clear previous errors jQuery(".error-message").remove(); jQuery('.elementor-down-pdf-form input').removeClass('error'); // Get form values - using Elementor field IDs let firstname = jQuery("#form-field-name").val().trim(); let lastname = jQuery("#form-field-field_f313a9e").val().trim(); let email = jQuery("#form-field-email").val().trim(); let company = jQuery("#form-field-field_cf8f855").val().trim(); let jobtitle = jQuery("#form-field-field_c49cb5f").val().trim(); let checkbox = jQuery('.elementor-down-pdf-form input[type="checkbox"]'); let consentChecked = checkbox.is(":checked"); let isValid = true; let emailPattern = /^[^\s@]+@[^\s@]+\.[^\s@]+$/; function showError(inputElement, message) { inputElement.addClass('error'); // Insert error message after the input field inputElement.after('' + message + '
'); } // Validate First Name if (firstname === "") { showError(jQuery("#form-field-name"), "Please fill this field."); isValid = false; } // Validate Last Name if (lastname === "") { showError(jQuery("#form-field-field_f313a9e"), "Please fill this field."); isValid = false; } // Validate Email if (email === "") { showError(jQuery("#form-field-email"), "Please fill this field."); isValid = false; } else if (!emailPattern.test(email)) { showError(jQuery("#form-field-email"), "Enter a valid email address."); isValid = false; } // Validate Company if (company === "") { showError(jQuery("#form-field-field_cf8f855"), "Please fill this field."); isValid = false; } // Validate Job Title if (jobtitle === "") { showError(jQuery("#form-field-field_c49cb5f"), "Please fill this field."); isValid = false; } // Validate Checkbox if (!consentChecked) { checkbox.addClass('error'); checkbox.closest('.elementor-field-subgroup').after( 'Please fill this field
' ); isValid = false; } // If form is valid, trigger download if (isValid) { // Close form popup $('.download-survey-report-container').removeClass('is-open'); // ✅ SHOW VIDEO SECTION AGAIN $('.video-hover-button-section').removeClass('is-close'); // Optional: scroll to video $('html, body').animate({ scrollTop: $('.video-hover-button-section').offset().top - 100 }, 600); // Clear form clearForm(); return true; } return false; } /* ------------------------------------- CLEAR FORM FUNCTION --------------------------------------*/ function clearForm() { // Clear all input values jQuery('.elementor-down-pdf-form input[type="text"]').val(''); jQuery('.elementor-down-pdf-form input[type="email"]').val(''); // Reset checkbox to checked jQuery('.elementor-down-pdf-form input[type="checkbox"]').prop('checked', true); // Remove floating-active class from all fields jQuery('.elementor-down-pdf-form .elementor-field-group').removeClass('floating-active'); // Remove any error classes jQuery('.elementor-down-pdf-form input').removeClass('error'); // Clear any remaining error messages jQuery('.error-message').remove(); } /* ------------------------------------- REAL-TIME VALIDATION Remove error when user starts typing --------------------------------------*/ jQuery(document).ready(function($) { $('.elementor-down-pdf-form input[type="text"], .elementor-down-pdf-form input[type="email"]').on('input', function() { var $input = $(this); var $errorMessage = $input.next('.error-message'); if ($input.val().trim() !== '' && $errorMessage.length) { $input.removeClass('error'); $errorMessage.remove(); // For email field, also validate format if ($input.attr('type') === 'email' && $input.val().trim() !== '') { var emailPattern = /^[^\s@]+@[^\s@]+\.[^\s@]+$/; if (!emailPattern.test($input.val().trim())) { $input.addClass('error'); $input.after('Enter a valid email address.
'); } } } }); }); document.addEventListener('DOMContentLoaded', function () { const STORAGE_KEY = 'fire_side_video_unlocked'; const form = document.querySelector('.elementor-down-pdf-form form'); const videoWrapper = document.getElementById('fire-side-video'); const video = videoWrapper ? videoWrapper.querySelector('video') : null; const hoverSection = document.querySelector('.video-hover-button-section'); const overlay = document.querySelector('.overlay'); const registerBtn = document.querySelector('.regiter-to-view-btn'); const el = document.querySelector('.download-survey-report-container'); //After page reload: unlock video if (localStorage.getItem(STORAGE_KEY) === 'yes') { if (form) { form.style.display = 'none'; } if (hoverSection) hoverSection.classList.remove('is-close'); if (overlay) overlay.style.display = 'none'; if (registerBtn) registerBtn.style.display = 'none'; } //Capture form submit (plain JS) if (form) { form.addEventListener('submit', function () { localStorage.setItem(STORAGE_KEY, 'yes'); if (hoverSection) hoverSection.classList.remove('is-close'); if (overlay) overlay.style.display = 'none'; if (registerBtn) registerBtn.style.display = 'none'; if (el) el.classList.remove('is-open'); }); } });
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [Fire Side Chat : Navigating The Translational Genomics Landscape](https://zifo.com/blogs/fire-side-chat-navigating-the-translational-genomics-landscape/ "Fire Side Chat : Navigating The Translational Genomics Landscape")
## Fire Side Chat : Navigating The Translational Genomics Landscape
Oct 28, 2025
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Fire%20Side%20Chat%20%3A%20Navigating%20The%20Translational%20Genomics%20Landscape%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Ffire-side-chat-navigating-the-translational-genomics-landscape%2F "Share on Email")
- [](https://x.com/intent/post?text=Fire%20Side%20Chat%20%3A%20Navigating%20The%20Translational%20Genomics%20Landscape&url=https%3A%2F%2Fzifo.com%2Fblogs%2Ffire-side-chat-navigating-the-translational-genomics-landscape%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Fire+Side+Chat+%3A+Navigating+The+Translational+Genomics+Landscape&url=https%3A%2F%2Fzifo.com%2Fblogs%2Ffire-side-chat-navigating-the-translational-genomics-landscape%2F "Share on LinkedIn")
Image reference: / source
In this video, experts discuss the transformative impact of AI and biobank data on translational research. They explore the challenges of managing large and diverse datasets –ranging from the lack of standards to the need for scalable storage and advanced analytics. The session also highlights success stories, including the use of genetics in drug discovery for Alzheimer’s, Parkinson’s, and cardiovascular diseases. Emphasizing the importance of longitudinal and digital health data, the experts underscore how integrating multi-omics data and fostering collaboration across academia, industry, and IT can accelerate the future of genomic research.
**PANEL MEMBERS**
**Simonne Longerich**
Principal Consultant, Early Discovery Genetics | Ex-Merck, Biogen
**Chris DeBoever**
Associate Director, Human Genetics | Maze Therapeutics
**Hector Rodriguez**
Vice President, New Targets | Kardigan Therapeutics
**Peter Bossier**
Principal Data Architect | Zifo
**MODERATORS & ORGANIZERS**
**Sandor Szalma**
Scientific Advisor | Zifo
**Ragavi Shanmugam**
Data Strategy Consultant | Zifo
**Adi Ghosh**
Commercial Lead & Alliance – Innovation | Zifo
[ Register to view ](#)
Watch Video
Name
Email
Company
Designation
Acceptance I consent to being contacted by an official Zifo representative
Submit
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
---
### [Beyond the Rigidity: How AbbVie's Platform Adapts to CMC Science](https://zifo.com/blogs/beyond-the-rigidity-how-abbvies-platform-adapt-to-cmc-science/)
**Published:** June 10, 2026
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [Beyond the Rigidity: How AbbVie’s Platform Adapts to CMC Science](https://zifo.com/blogs/beyond-the-rigidity-how-abbvies-platform-adapt-to-cmc-science/ "Beyond the Rigidity: How AbbVie’s Platform Adapts to CMC Science")
## Beyond the Rigidity: How AbbVie’s Platform Adapts to CMC Science
Sakthi Prasad T, Content Director
Jun 10, 2026
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Beyond%20the%20Rigidity%3A%20How%20AbbVie%27s%20%20Platform%20Adapts%20to%20CMC%20Science%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Fbeyond-the-rigidity-how-abbvies-platform-adapt-to-cmc-science%2F "Share on Email")
- [](https://x.com/intent/post?text=Beyond%20the%20Rigidity%3A%20How%20AbbVie%27s%20%20Platform%20Adapts%20to%20CMC%20Science&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fbeyond-the-rigidity-how-abbvies-platform-adapt-to-cmc-science%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Beyond+the+Rigidity%3A+How+AbbVie%5C%26%23039%3Bs++Platform+Adapts+to+CMC+Science&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fbeyond-the-rigidity-how-abbvies-platform-adapt-to-cmc-science%2F "Share on LinkedIn")
**Speaker: Diana Bowley, Director Digital Strategy, AbbVie**
***Zifo’s SiEE event 2026***
**The Ultimate Mission: Treating Data Like an Asset to Serve Patients Faster**
In a presentation on digital transformation in bioprocess labs, Diana, a digital strategy leader with AbbVie, who had earlier worked in the company’s Bioprocess CMC Development organization, emphasized that the true driver behind upgrading lab tech isn’t just modernizing software — it’s about accelerating the delivery of life-saving biologics to patients.
Before their transformation journey, CMC development labs were dealing with immense amounts of siloed information. Scientists were burdened by stacks of thermal printouts, manual transcription on clipboards, and scattered Excel spreadsheets. Diana shared her team’s multi-year journey of shifting the organization toward a “fit-for-science integrated digital ecosystem,” treating CMC data as a highly structured, contextualized asset capable of being used for immediate insights and reused seamlessly for commercial filings (like a BLA).
In this presentation, she explores the delicate balance of building custom digital architectures and managing human readiness to achieve massive efficiency gains.
**Key Takeaways from the Presentation**
**Data “Assets” Before Digital Transformation**
- **Moving Beyond the Clipboard:** True digital transformation isn’t just about digitizing paper; it’s about simplifying workflows and changing how scientists work. Moving away from manual transcriptions in basic Electronic Lab Notebooks (ELNs) ensures data is captured structurally, directly from the source.
- **The “Fit-for-Science” Ecosystem:** Instead of forcing scientists into rigid legacy platforms, the goal is to find the right digital tools for the specific experimental science being done. Once identified, IT must deeply integrate those systems so data flows seamlessly from high-throughput instruments to data warehouses, and finally to visualization tools like Spotfire.
**The “Espresso” Solution: A Choose-Your-Own-Adventure Platform**
- **Custom Solution:** Because CMC process development is an exploratory science lacking the rigid, repetitive workflows of commercial manufacturing, traditional linear software often fails. To solve this, the team built a custom solution dubbed “Espresso.”
- **Streamlined Data Collection:** Espresso heavily reduces data silos between lab automation and instruments. Scientists now design their experiments in Espresso first, allowing them to export sample IDs to take to the instruments. While not fully automated end-to-end, this allows for a semi-automated pull of data back into Espresso, vastly reducing manual transcription errors.
**Real ROI: Shrinking Timelines from Months to Days**
- **Slashing Documentation Time:** By creating a seamless integration loop between instruments, data platforms, and visualizations, the time scientists spend simply documenting a standard two-week bioreactor experiment dropped drastically – from consuming roughly 50% of their working hours down to just 15%.
- **Aggregating and Reviewing Data:** Aggregating and reviewing 100% of the data points across multiple instances used to take at least a month. Thanks to the new automated data architecture, this timeline has been condensed to just days, freeing up scientist time.
**The Secret Sauce: Organizational Readiness**
- **Waiting for the Right Moment:** Sometimes the best deployment strategy is patience. Diana revealed that she delayed a major rollout by a full year because the scientific team was overwhelmed and lacked the bandwidth to absorb the change. Transformation requires true “co-ownership” between IT and lab SMEs.
- **The 80/20 Rule & The Skateboard:** Perfection is the enemy of progress in digital labs. Diana championed delivering an 80% solution and utilizing continuous feedback to co-evolve the technology alongside the science, with scientists playfully reminding each other, “remember we’re on the skateboard but we’re learning.”
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
---
### [When Digital Transformation in Pharma Breaks, Look at the Business Analyst](https://zifo.com/blogs/when-digital-transformation-in-pharma-breaks-look-at-the-business-analyst/)
**Published:** June 2, 2026
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [When Digital Transformation in Pharma Breaks, Look at the Business Analyst](https://zifo.com/blogs/when-digital-transformation-in-pharma-breaks-look-at-the-business-analyst/ "When Digital Transformation in Pharma Breaks, Look at the Business Analyst")
## When Digital Transformation in Pharma Breaks, Look at the Business Analyst
Pavithra Ulagappan, Scientific informatics Specialist, Consulting
Jun 02, 2026
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20When%20Digital%20Transformation%20in%20Pharma%20Breaks%2C%20Look%20at%20the%20Business%20Analyst%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Fwhen-digital-transformation-in-pharma-breaks-look-at-the-business-analyst%2F "Share on Email")
- [](https://x.com/intent/post?text=When%20Digital%20Transformation%20in%20Pharma%20Breaks%2C%20Look%20at%20the%20Business%20Analyst&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fwhen-digital-transformation-in-pharma-breaks-look-at-the-business-analyst%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=When+Digital+Transformation+in+Pharma+Breaks%2C+Look+at+the+Business+Analyst&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fwhen-digital-transformation-in-pharma-breaks-look-at-the-business-analyst%2F "Share on LinkedIn")
Image reference: / source
Digital transformation in Pharma R&D rarely fails because the technology is inadequate. Platforms are powerful, cloud infrastructure is mature, and tooling continues to evolve faster than most organizations can absorb.
And yet, many initiatives still stall, underdeliver, or quietly lose momentum once systems go live.
The root cause is often less visible — and far more structural.
It sits at the intersection between science, technology, and business decision-making. Specifically, in how organizations define and enable the Business Analyst role in scientific environments.
**The Limits of the Traditional BA Model**
Historically, Business Analysts have been positioned as translators. They gather requirements from business stakeholders, convert them into functional specifications, and work with IT teams to drive implementation.
This model works reasonably well in transactional or process-driven domains and industries. It breaks down, however, when applied unchanged to science-focussed industries such as Biotech, Pharma, Chemicals, Food & Beverage and so on.
In lab environments, requirements are rarely static, fully articulated, or even consciously understood by the people performing the work. Critical steps live in muscle memory. Metadata dependencies are inherited from legacy practices. Workarounds evolve to protect experimental integrity, not to satisfy process diagrams.
When a BA approaches this landscape without scientific context, several things tend to happen:
- Scientists feel misunderstood or oversimplified
- Requirements surface late, if at all
- Systems reflect “how work should happen,” not how it actually does
- Adoption becomes an exercise in change management rather than trust
The result isn’t failure in a dramatic sense. It’s something quieter and more costly: partial usage, parallel workflows, and gradual erosion of confidence in digital systems.
**A Common Pattern in Advanced Research Domains**
This tension becomes especially visible in data-intensive areas such as proteomics and multi-omics research.
The priorities entering a digital initiative are often divergent:
- Scientists focus on data accuracy, reproducibility, and experimental nuance
- IT teams prioritize scalability, stability, and architectural coherence
- Business stakeholders seek visibility, standardization, and insight across studies
None of these objectives are inherently incompatible. The problem arises when they are interpreted independently, without a unifying layer of scientific understanding during requirement discovery and design.
In these situations, the BA is expected to mediate alignment — yet without fluency in the science itself, that mediation is limited to surface-level translation. Important assumptions remain implicit. Risk is identified late. Decisions are made without fully understanding their impact on downstream science.
**From Translation to Interpretation**
What these environments require is not simply better documentation or more stakeholder meetings. They require a different posture from the BA role altogether.
The most effective BAs operating in scientific informatics settings act less as translators and more as interpreters. They understand enough of the underlying science to ask meaningful “why” questions. They recognize when a seemingly minor workflow step carries regulatory or experimental significance. They know when a request for flexibility is a request for scientific protection.
This science-first approach changes the nature of discovery:
- Requirements are grounded in real experimental workflows, not idealized process maps
- Edge cases surface early, before they become rework
- IT teams receive context, not just specifications
- Business leaders gain visibility into trade-offs without compromising scientific rigor
Lately, science-first approach is beginning to gain prominence in the life sciences industry as well. Nearly 8 in 10 pharma leaders anticipate that scientific expertise will carry greater weight in sourcing evaluations over the next three years, with 4 in 10 already viewing it as a key future differentiator, as per Everest Group in a report titled “Embedding Scientific Expertise at the Core of Life Sciences IT Delivery”.
Hence, scientific context becomes extremely critical in business analysis.
When scientific context is embedded early in business analysis, the effects are visible across multiple dimensions of delivery. Across complex R&D digital initiatives, a consistent set of outcome patterns tends to emerge.
**Observed Impact of Science‑First Business Analysis in R&D Digital Programs**
Impact AreaWhat Changes When Scientific Context Is EmbeddedRequirements AccuracyFewer late‑stage surprises as tacit lab workflows are surfaced early and translated into implementable requirementsImplementation TimeReduced rework due to early identification of scientific edge cases and constraintsUser AdoptionFaster, organic uptake driven by workflows that feel familiar rather than imposedScientific ConfidenceGreater trust in data pipelines as validation logic aligns with experimental rigorStakeholder AlignmentEarlier convergence between science, IT, and business through shared understanding rather than negotiation
**Seeing the Full Workflow**
One of the most consistent blind spots in digital R&D initiatives is the assumption that workflows begin and end within systems.
In reality, data journeys in the lab are fragmented. They pass through instruments, spreadsheets, notebooks, interim scripts, emails, and human handoffs. Informal documentation fills gaps left by formal tools.
When BAs rely primarily on interviews or pre-existing SOPs, much of this reality remains invisible. It is only through close observation — watching how experiments are actually run, how exceptions are handled, and how trust is built around data — that unspoken requirements emerge.
These requirements are rarely dramatic. They are often small: a metadata field that must remain editable, a review step that cannot be automated, a naming convention that encodes historical meaning. But collectively, they determine whether a system feels usable or intrusive.
**Rethinking Vendor and Platform Evaluation**
The same science-aligned lens applies when evaluating platforms.
Vendor demonstrations frequently showcase breadth of features. What they rarely expose is how a system behaves under the strain of real experimental complexity.
More effective evaluations stress-test platforms using authentic scenarios:
- Non-ideal data sets
- Incomplete or evolving metadata
- Workflow deviations that reflect real lab behavior
- Regulatory expectations that extend beyond checkbox compliance
When evaluation criteria are grounded in scientific reality rather than abstract capabilities, decision-making shifts. Platforms are chosen not for how impressive they appear, but for how resilient they are in practice.
**Adoption Without Resistance**
One of the clearest indicators of alignment is what happens after go-live.
Systems designed with scientific empathy tend to see a different adoption pattern. Training feels familiar rather than imposed. Users recognize their own workflows in the interface. Resistance gives way to cautious trust — and eventually to advocacy.
This does not happen because scientists suddenly enjoy new tools. It happens because the systems respect the logic of their work.
**Two Models of the BA Role in Scientific Informatics**
Across pharma and biotech, two broad models of business analysis continue to coexist:
**Process-first BA models** emphasize consistency, standardization, and functional completeness. They often struggle with scientific nuance and generate downstream rework.
**Science-First BA models** prioritize understanding the experimental reality before formalizing requirements. They surface risk early, reduce iteration, and create systems that feel credible to scientific users.
The difference between the two is not talent. It is orientation.
**Two Approaches to Business Analysis in Scientific Informatics**
Without Science-First BAWith Science-First BAScientists feel ignoredScientists become active partners because the BA speaks their languageRequirements need reworkRequirements land right the first timeTools don’t fit realityWorkflows mirror true lab practice – the BA ensures workflows reflect real-world practices, not just theoretical designs.Resistance to adoptionSystem advocacy from within — adoption accelerates as the BA champions usability, minimizes friction, and frames benefits in terms scientists care about.Oversold vendor featuresDecisions are grounded in evidence because the BA designs evaluations using authentic sample sets and tests vendor claims under real conditions.
**A Role Evolution, Not a Niche Skillset**
As R&D organizations continue to digitize, the need for science-first BAs will only increase. This is not a call for every BA to become a scientist. It is a recognition that in scientific environments, digital success depends on contextual fluency.
Effective BAs in these settings consistently demonstrate:
- Strong scientific literacy
- Comfort navigating ambiguous workflows
- Awareness of regulatory implications
- Strong listening and observational skills
Most importantly, they understand that science is not just another business process. It is a knowledge-generating activity, and digital systems must be designed to protect that purpose.
**Closing Reflection**
Digital transformation in pharma is often discussed in terms of platforms, data strategies, and operating models. Less attention is paid to the roles that translate ambition into execution.
The Business Analyst — when grounded in scientific context — becomes one of the most consequential of those roles.
Because when systems honor how science actually works, change does not need to be forced. It is accepted, adopted, and sustained.
And that is where transformation becomes real.
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
---
### [Can AI Cut the 13-Year Wait? Inside the Drive to Halve Time-to-Market](https://zifo.com/blogs/bilingual-scientists-faster-cures/)
**Published:** May 26, 2026
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [Can AI Cut the 13-Year Wait? Inside the Drive to Halve Time-to-Market](https://zifo.com/blogs/bilingual-scientists-faster-cures/ "Can AI Cut the 13-Year Wait? Inside the Drive to Halve Time-to-Market")
## Can AI Cut the 13-Year Wait? Inside the Drive to Halve Time-to-Market
Sakthi Prasad T, Content Director
May 25, 2026
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Can%20AI%20Cut%20the%2013-Year%20Wait%3F%20Inside%20the%20Drive%20to%20Halve%20Time-to-Market%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Fbilingual-scientists-faster-cures%2F "Share on Email")
- [](https://x.com/intent/post?text=Can%20AI%20Cut%20the%2013-Year%20Wait%3F%20Inside%20the%20Drive%20to%20Halve%20Time-to-Market&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fbilingual-scientists-faster-cures%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Can+AI+Cut+the+13-Year+Wait%3F+Inside+the+Drive+to+Halve+Time-to-Market&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fbilingual-scientists-faster-cures%2F "Share on LinkedIn")
**The New Scientific Method: Today’s Digital Lab Revolution**
**Speaker: Leah O’Brien, VP Global Head Digital Lab and Plant Operations, Sanofi**
***Zifo’s SiEE event 2026***
**The Ultimate Mission: Halving Time-to-Market with AI**
**Leah emphasizes that at Sanofi,** the true driver behind digital lab revolution program is accelerating the delivery of life-saving innovations to patients. She notes that currently, **the industry average for a new drug to go from discovery to a patient’s hands is 13 years. However, Leah shares Sanofi’s ambitious goal: to cut this timeline in half over the next few years using AI.**
In this insightful presentation, Leah explores the delicate balance between pushing the boundaries of futuristic AI labs to achieve this goal, while ensuring the foundational “basics” of data management are set up for success.
Here are the key takeaways from the speech:
**The “Lab of the Future” is Frictionless**
- **Ambient Capture Over Keyboards:** The future lab replaces manual data entry with ambient data capture, disrupting traditional Electronic Lab Notebooks (ELNs) and LIMS freeing up scientists’ time.
- **“Lab in the Loop”:** Wet labs and dry labs are becoming so deeply integrated that predictive models guide bench tests, while real-time results from the bench continuously refine the models.
- **Adaptive Robotics:** Leah says the company is moving away from brittle, rigid automation toward “physical AI” and robots that evolve seamlessly alongside the science.
**The Scientist of the Future is “Bilingual”**
- **AI Superpowers:** Tomorrow’s scientists will leverage AI to assist with experimental design, automate protocol authoring, and generate predictive hypotheses out of billions of data points.
- **Fluency in Both Science and AI:** The future scientific workforce will be “bilingual”—fluent in both core sciences and AI tools (such as simulation, modeling, and data visualization).
**Data “Vegetables” Before AI “Ice Cream”**
- AI requires perfectly structured foundations. As Leah playfully notes, quoting Julie Huxley Jones, the VP at Vertex: *“You can’t have your AI ice cream until you eat your data vegetables.”* Achieving AI-ready, FAIR data is no longer an afterthought, but a heavily funded priority.
**Transforming Infrastructure: Edge Computing & Scaling**
- **Edge Compute in the Lab:** With massive data-generating instruments (like Cryo-EM) and the demands of a 24/7 “Lab in the Loop,” running analytics purely in the cloud causes latency issues. Leah says the company is seeing a critical shift toward heavy edge computing right inside the physical lab.
- **Change Management:** Successfully scaling AI pilots isn’t just a technology problem; human-centered design and effective business change management are more important than ever to drive real adoption.
- **Biggest Opportunities for Speed:** According to value framework mapping, the biggest current opportunities to shave off development time reside in optimizing clinical trials, regulatory reporting, and CMC (Chemistry, Manufacturing, and Controls) processes.
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
---
### [Biopharma Companies Discover AI’s Weak Spot: Scientific Context](https://zifo.com/blogs/biopharma-companies-discover-ais-weak-spot-scientific-context/)
**Published:** April 15, 2026
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [Biopharma Companies Discover AI’s Weak Spot: Scientific Context](https://zifo.com/blogs/biopharma-companies-discover-ais-weak-spot-scientific-context/ "Biopharma Companies Discover AI’s Weak Spot: Scientific Context")
## Biopharma Companies Discover AI’s Weak Spot: Scientific Context
Marilyne Labasque, PhD – Data Stewardship Practice Lead
Apr 15, 2026
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Biopharma%20Companies%20Discover%20AI%E2%80%99s%20Weak%20Spot%3A%20Scientific%20Context%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Fbiopharma-companies-discover-ais-weak-spot-scientific-context%2F "Share on Email")
- [](https://x.com/intent/post?text=Biopharma%20Companies%20Discover%20AI’s%20Weak%20Spot%3A%20Scientific%20Context&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fbiopharma-companies-discover-ais-weak-spot-scientific-context%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Biopharma+Companies+Discover+AI%E2%80%99s+Weak+Spot%3A+Scientific+Context&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fbiopharma-companies-discover-ais-weak-spot-scientific-context%2F "Share on LinkedIn")
Image reference: / source
Biopharma organizations and other science-driven industries are at a pivotal moment. Investments in AI are accelerating across discovery, development, and manufacturing, and expectations are rising just as quickly. However, the data that should power these ambitions is often fragmented, inconsistently managed, and missing the context needed for meaningful and responsible use. AI, whether powered by agentic systems or machine learning models, does not fall short because of the technology itself. It falls short when the basics are missing. Without the minimum stewardship and contextualization that automation and reproducibility depend on, AI cannot deliver. The hard truth remains, no matter how advanced the technology becomes, it will not create value if knowledge and data are not shared.
In an AI‑native landscape, not all information can or should be fully structured. What matters is that it is discoverable, well described, and handled in ways that preserve scientific context and ethical use. The cost of falling short shows up every day as rework, repeated experiments, stalled data initiatives and digital programs, alongside increasing scrutiny around traceability, integrity, and reproducibility.
In this context, stewardship gains renewed significance. As AI increases the scale, speed, and reach of data use, the cost of ambiguity, inconsistency, and lost context rises sharply. Decisions that were once recoverable through expert memory or manual review become opaque when automated systems operate on poorly described data. Stewardship provides the discipline needed to preserve scientific intent as data moves across experiments, systems, and analytical uses. By embedding clarity, traceability, and accountability into everyday data practices, stewardship enables organizations to scale analytics and AI with confidence rather than compounding risk.
**Why Stewardship Matters Now**
Scientific data today forms an intricate ecosystem: multimodal assay outputs, instrument files, electronic lab notebook (ELN) records, laboratory information management system (LIMS) entries, in vivo study data, and chemistry, manufacturing and controls (CMC) packages. Each domain evolves at its own pace. Without stewardship, coherence depends on what individuals remember, where an experiment ran, how an instrument was configured, which field captured the real scientific meaning. Even large platform investments struggle when local conventions and inconsistent practices shape how data is captured, interpreted, and shared.
Expectations across the industry now go far beyond correctness. Teams need auditable lineage, validated processing, robust description, reproducible results, and analytics they can explain with confidence. Stewardship turns these expectations into daily practice. It clarifies meaning, harmonizes descriptions, curates context, strengthens traceability, and makes reuse the rule rather than the exception. Applied systematically, stewardship shortens the time scientists spend searching for information or reconstructing decisions, slows data decay, prevents drift between silos, and lays the foundation for AI that can be trusted.
**Stewardship as an Operational Capability**
Much of the literature describes what stewardship should be. Fewer address what stewardship looks like in practice, within the constraints of real scientific environments. Effective stewardship requires working across roles – scientists, data owners, architects, and engineers – so that decisions reflect how experiments are designed, how instruments are used, and how results are consumed. The outcome is practical change that improves how data is captured, described, and reused, without adding friction to scientific work.
Stewardship efforts are most effective when informed by scientific depth and operational consistency. Across data domains such as biospecimen, assay, omics, biologics, CMC, and clinical data, stewardship decisions must reflect real experimental practice rather than theoretical assumptions. Leaders also need a clear view of where they stand and what to address first. Structured diagnostic approaches and capability assessments can provide visibility into current stewardship maturity and help prioritize the most impactful improvements.
Stewardship operating models vary by organization and context. Some functions are embedded within scientific teams, others operate as shared responsibility models, and some are centralized. Regardless of structure, successful efforts follow a consistent pattern: diagnosis of current practices, deliberate design of standards and workflows, development of enabling processes, and sustained delivery and improvement. When approached this way, stewardship holds up in real laboratories and scientific programs.
**The Layered Model for AI‑Ready Scientific Data**
Becoming AI‑ready requires more than cleaner data. It requires a layered foundation that connects scientific defensibility with machine‑actionable design and responsible use. At the base is trusted data: information that is accurate, attributable, traceable, and handled with the discipline expected in scientific settings. This ensures every data point has a clear origin and every transformation can be explained.
Above that are FAIR‑driven enhancements: semantic alignment, richer description, standardized terminologies, interoperable formats, and normalization practices. These ensure data is understandable to people and usable by automation and machine‑learning pipelines. Without this layer, even high‑quality data remains largely invisible to AI.
Finally, the human layer ensures accountability over time. Data stewards and data owners monitor drift, guide lifecycle management, and safeguard ethical use as new assays, instruments, and workflows emerge.
When these layers work together, organizations create datasets that are not only usable but also suitable for analytics and AI that must be explainable and defensible.
**FAIR, Data Quality, and Stewardship: A Unified Perspective**
A persistent misconception is that FAIR and data quality measure the same thing. They do not. FAIR – standing for Findable, Accessible, Interoperable, and Reusable – describes how well data and its description support discovery and reuse, especially by machines (1). Data quality focuses on characteristics such as accuracy, completeness, consistency, and timeliness. A dataset may excel at quality yet fail FAIR if its description is sparse or identifiers are not machine‑actionable. The reverse can also be true.
Both dimensions are essential for AI readiness, and stewardship is the discipline that brings them together. With trained evaluators, structured scoring rubrics, and aligned maturity models, FAIR and quality assessments can reinforce one another rather than duplicate effort. This integration makes FAIR durable, preventing the drift that occurs when assessments are infrequent, inconsistent, or detached from daily practice.
**Real‑World Impact: A Practical Example**
A large pharmaceutical organization sought to resolve longstanding issues in its CMC equipment reference and master data. Thousands of equipment records had accumulated across sites, each with different naming conventions and inconsistent descriptions. Scientists struggled to select the appropriate record, integrations frequently broke, and teams could not rely on a single, authoritative view of the equipment used in critical CMC processes.
Working across CMC, IT, and digital teams, legacy records were standardized and harmonized, and a dynamic data collection template was introduced to ensure new entries were captured consistently at creation. This effort reconciled thousands of records, established clear naming and de‑duplication rules, and introduced preventive checks so issues were identified at source rather than downstream.
Within months, the organization gained a unified equipment data model across multiple CMC data environments, with improved FAIR characteristics and reliable interoperability. Scientists and engineers could find and reuse equipment information in hours rather than days, integration issues decreased, and longstanding traceability gaps were closed. The result was not only cleaner and more reliable data, but a sustainable way of working that supported future analytics and model‑driven CMC initiatives.
**Assessing Stewardship Capability**
Structured stewardship assessments offer a way to understand how scientific data is managed in practice. Adapted from existing stewardship maturity approaches and aligned with FAIR and established quality principles, these assessments evaluate both individual datasets and the conditions surrounding their management (2).
Key components – preservability, accessibility, usability, preventive quality practices, lifecycle monitoring, transparency, integrity, and sustainability – create an evidence‑based view of current capability and the most impactful next steps (2, 3). Clear maturity levels provide a progression path, and alignment with FAIR maturity indicators ensures that improvements support both human understanding and machine‑actionable reuse (4).
**Evidence That Matters to Executives**
Stewardship must demonstrate tangible impact. Indicators such as reduced time‑to‑find, increased reuse, faster remediation turnaround, shorter analytics cycles, and stronger audit outcomes translate stewardship from concept to performance. These measures connect stewardship to outcomes executives care about: productivity, risk reduction, and return on scientific and digital investments.
Organizations that begin in one domain, demonstrate value, and then expand to adjacent areas often experience faster returns and more durable improvement, as teams build confidence and adopt new ways of working. Over time, the foundation strengthens and AI initiatives progress beyond isolated pilots.
**The Leadership Mandate**
AI‑ready data cannot be bolted onto the end of a project. It must be designed, curated, managed, and monitored from the outset. Leaders who expect AI to play a strategic role must treat stewardship as a core enabler: establish repeatable assessment practices, ensure stewards and related roles receive formal training, embed stewardship into the broader scientific data foundation, and make value visible through shared metrics.
Stewardship is not optional for organizations that aim for scientific excellence. It is the operational backbone that turns data into a durable, strategic asset, supporting innovation, compliance confidence, and AI at scale.
**References**
1. Wilkinson MD et al., The FAIR Guiding Principles for scientific data management and stewardship. Sci Data. 2016 Mar 15;3:160018. doi: 10.1038/sdata.2016.18. Erratum in: Sci Data. 2019 Mar 19;6(1):6. DOI: 10.1038/s41597-019-0009-6
2. Peng G et al., Crosswalks among stewardship maturity assessment approaches promoting trustworthy FAIR data and repositories. Sci Data. 2022 Sep 21;9(1):576. DOI: 10.1038/s41597-022-01683-x
3. Peng G et al., Practical Application of a Data Stewardship Maturity Matrix for the NOAA OneStop Project, 2019, Data Science Journal, DOI: 10.5334/dsj-2019-041
4. [FAIR Maturity Matrix | An organisational maturity model of FAIR implementation](https://pistoiaalliance.github.io/FAIRMaturityMatrix/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
---
### [Interview: Stop Treating LIMS Like an IT Project Because Master Data Demands Science](https://zifo.com/blogs/interview-stop-treating-lims-like-an-it-project-because-master-data-demands-science/)
**Published:** May 12, 2026
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [Interview: Stop Treating LIMS Like an IT Project Because Master Data Demands Science](https://zifo.com/blogs/interview-stop-treating-lims-like-an-it-project-because-master-data-demands-science/ "Interview: Stop Treating LIMS Like an IT Project Because Master Data Demands Science")
## Interview: Stop Treating LIMS Like an IT Project Because Master Data Demands Science
Sakthi Prasad T – Content Director
May 11, 2026
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Interview%3A%20Stop%20Treating%20LIMS%20Like%20an%20IT%20Project%20Because%20Master%20Data%20Demands%20Science%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Finterview-stop-treating-lims-like-an-it-project-because-master-data-demands-science%2F "Share on Email")
- [](https://x.com/intent/post?text=Interview%3A%20Stop%20Treating%20LIMS%20Like%20an%20IT%20Project%20Because%20Master%20Data%20Demands%20Science&url=https%3A%2F%2Fzifo.com%2Fblogs%2Finterview-stop-treating-lims-like-an-it-project-because-master-data-demands-science%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Interview%3A+Stop+Treating+LIMS+Like+an+IT+Project+Because+Master+Data+Demands+Science&url=https%3A%2F%2Fzifo.com%2Fblogs%2Finterview-stop-treating-lims-like-an-it-project-because-master-data-demands-science%2F "Share on LinkedIn")
Image reference: / source
Walk into a modern biopharma lab today. You will see robotics, sleek monitors, and humming centrifuges. It looks like the future.
But what you don’t see is the invisible architecture holding it all together. You don’t see the master data.
For decades, the Biopharma industry has treated the implementation of Laboratory Information Management Systems (LIMS) as a standard IT project. Buy the software. Install it. Plug it in. Go live. It’s a costly illusion, and one that **Marc De Luca** has spent his entire career dismantling.
**Marc, currently a Director, Business Development Lead, and Chief of Staff at Bayer**, has lived at the turbulent intersection of bench science and scientific informatics for over 35 years. He knows what happens when software developers try to code a laboratory without understanding the science that happens inside it.
“You can make up for a lot of bad choices in your LIMS development if you have got solid master data,” Marc told Zifo in an exclusive interview. “But the inverse is a nightmare. A perfectly coded software ecosystem built on sloppy data that lacks scientific context is just a dumb system. Garbage in, Garbage out,” he adds.
To understand why labs across the globe struggle with digital transformation, one has to understand the delicate, nuanced, and frequently misunderstood relationship between the code on the screen and the science at the bench.
**Decoding Master Data**
To the uninitiated, “master data” sounds like corporate jargon. But without it, a laboratory is paralyzed.
Marc’s journey into the weeds of data architecture began out of necessity. Graduating as a chemist in the mid-1990s during a brutal Canadian recession, jobs were scarce. He landed at a startup that automated standard USP laboratory tests — like fluoride testing and biological oxygen demands (BOD) in water. His team built the backend software to connect best in breed solutions such as auto-samplers, pumps, and probes to a LIMS.
When you move a product out of early R&D — a phase Marc affectionately refers to as the “Wild West” where scientists are creating the science necessary for development as they go — and transition it into commercial manufacturing, everything suddenly locks down. The flexibility vanishes. Strict adherence to Good Manufacturing Practices (GMP) takes over, and the master data becomes the literal law of the land. And it was there Marc had an epiphany. “I started early in my career to realize early in that process the importance of the alignment of your master data,” he recalls. For all these disparate instruments and applications to interoperate, they desperately needed a standard language.
Marc strips away the jargon. Master data isn’t just a list of names. It is the literal digitisation of the lab’s physical reality. “Master data to me is the fundamental building blocks of the system,” he explains. Before a scientist can even touch a sample, the software needs a roadmap. “You are actually digitising the instructions on how to execute your analysis,” he notes. “This would be your test methods, this would be your calculations, this would be your parameters… and you are digitalising it within your system”.
“Theoretically, a lab could lose its entire LIMS overnight and still function if it possessed a perfect, paper-based master data rulebook. The software is just the vessel. The master data is the absolute truth,” Marc says.
**The Illusion of the Five-Day Fix**
Despite the critical nature of Master Data Management, corporate leadership routinely underestimates the sheer human effort required to build it — and, at times, dubs it as “transcription activity”. And that’s where most problems arise.
Before joining Bayer, Marc spent five years as a senior program manager at LabVantage, operating on the vendor side of the fence. He spent his days delivering software to clients who harboured wild misconceptions about digital readiness.
“I remember having a discussion with a client where they figured in 5 days they could install the LIMS software and just start using it,” he says. “And I kept iterating to them how important it was to ensure that the master data was created… and it takes time in order to correctly develop all the master data”.
Companies will happily spend massive budgets to purchase a “Bugatti version” of a LIMS or an integrated quality management system. But if they rush the foundational data mapping, the system fails. Conversely, using agile development to launch a highly stripped-down Minimum Viable Product (MVP) can yield immediate, massive returns — provided the master data is pristine.
**“The Process is the Product”: Why Biotech Breaks Standard IT**
The friction between IT and science becomes explosive in the realm of biotechnology. It is here that generic software solutions go to die.
Marc transitioned to the manufacturing side of the industry at Bayer’s massive Berkeley, California site. The sprawling 7-acre campus handles 60% of their quality control testing, with the remaining 40% conducted at a separate facility two kilometres away.
In traditional small molecule pharmaceutical manufacturing, the physical environment is largely forgiving. “If you look at tablet making, outside factors that don’t affect the small molecule industry can have a big impact in biotech; if it gets really super-hot outside, large daily humidity swings and tablets still get made,” Marc explains. An active pharmaceutical ingredient (API) like in an over the counter pill isn’t living. “I can make my API, and it can sit on the shelf for years before being made into tablets in sometimes unfavourable conditions, and I can still use it for final product manufacturing. It doesn’t matter”.
However, biotech is an entirely different beast. The cells are alive. They require a gruelling muti-day / month manufacturing cycle involving constant feeding, precise temperature controls, and delicate extractions. “If any cog in the 16-step phase doesn’t go according to plan, the process breaks, the product breaks,” he warns. Marc always says, “sneeze in the wrong direction, or open the door and let in a draft at the wrong time, and the cells can die”, that’s how sensitive the process is.
In biotech, Marc states unequivocally: “The process is the product”.
This unforgiving reality demands software that bends to the science, not the other way around. He recalls a software vendor pitching an automated scheduling tool for the lab. The pitch sounded great in a boardroom. At the bench, it was a disaster.
The lab was dealing with cold-chain reactions. Once a sample was prepped, scientists had a strict, shrinking two-hour window to execute potency testing across four different instruments. If an instrument went down, vials had to be manually re-routed to a different machine within 15 minutes.
The vendor’s highly touted software? It only refreshed its scheduling logic in hourly intervals.
“I don’t have hourly intervals to refresh and be able to plan and stuff,” Marc notes. The software was fundamentally blind to the physical realities of a living, degrading biological sample. The team had to build a custom module within their LIMS to allow for real-time, drag-and-drop sample routing — a feat only possible because their master data accurately mapped the physical capabilities and statuses of every instrument on the floor.
**Why Science Knowledge is the Ultimate Master Key**
IT knows code. Scientists know cells. The gap between them is exactly where millions of dollars in software investments go to die.
You simply can’t automate what you don’t understand. Marc lived this frustration early in his LIMS career. He remembers constantly hitting a wall when he approached implementations as a pure tech exercise. “I was originally told, look, you are the expert, you go in, you tell him how it’s gonna be done,” he recalls.
It was a spectacularly ineffective approach. “I used to bang my head against the wall all the time because it wouldn’t make any sense,” he admits.
Everything changed the moment he stopped acting like an omniscient software developer and started leaning on his roots as a chemist. “Once I started to use my knowledge of how things worked at the bench… I was able to say, okay, I would design this a whole different way,” he notes.
The reality is that LIMS implementation is not a tech project. It is a science project enabled by tech. He estimates the ideal project split is 60% science and 40% plug-and-play IT. “If you just go out to the universities and start hiring Java programmers, they can come in and they can code, of course,” Marc says. But there is a fatal catch. If those developers lack practical laboratory or scientific knowledge, “they are never going to understand how to correctly develop a LIMS”.
This is where fluent science knowledge changes the entire trajectory of a build. In his own experience, when lab teams talked to him about a pH calibration, he didn’t need a basic chemistry tutorial. He already knew they were standardizing the probe. He knew the exact sequence in which the buffers had to be run. When they mentioned linear regression, he instantly understood why they were running those calculations.
That knowledge of science is a superpower. “Having that baseline knowledge just expedites everything,” he explains. “It gets the master data and the development exactly where they need to be.”
A pure IT professional cannot successfully design a LIMS in a vacuum. The classic example of poor master data understanding arises if an IT developer simply asks a business user i.e., a bench scientist for a list of parameters for a 96-well ELISA plate, the developer might literally create a single, inefficient list of 96 rows, Marc opined. A scientist, however, knows that a 96-well plate is broken into specific physical zones. Grouping the master data by these zones allows for vastly more efficient testing and downstream calculations. Marc said this is one such example among hundreds, which emphasizes the knowledge of science for a successful implementation of Master Data and LIMS.
“When bench scientists realize the IT architect sitting across the table understands the science, the walls come down. The friction evaporates. They stop demanding hyper-customized, impossible software builds and start genuinely collaborating. Without that foundational scientific context, the software will always just be a clumsy overlay forced onto a highly delicate process,” Marc said.
**Egos, Turf Wars**
When LIMS projects fail, the root cause is rarely the code itself. The failure is cultural. It’s a clash of egos.
Marc’s advice to informatics teams is blunt: “Go hang out in the lab for a couple days. See what they are doing. Follow the sample”. Understanding the physical chain of custody — knowing that out of 10 vials, exactly six are staying in Building One while four are shipped two kilometers away — dictates how the master data and LIMS workflows must be structured.
However, he notes that, at times. the business side is equally culpable in these turf wars. Scientists spend years perfecting an assay. It becomes deeply personal. “Sometimes I find on the business side of things, they have spent so much time designing and developing their assay, it’s their baby, right?” Marc observes. Understanding these specialisations, requires that you understand and can empathise with them, which brings you credibility that you will deliver the solution they need for them.
The magic happens when both sides drop their defences. As Marc says, “When the end user community can see that you truly understanding their pain, I’ve seen smiles on peoples’ faces and their body language opens up to the possibilities of what could be”. The philosophy must be: “Business driven and IT enabled, meaning the business tells us what they need and we tell them how it’s going to be done”.
**The Blueprint: Five Pillars of a LIMS Master Data Strategy**
So, how does a global enterprise avoid these traps? Based on decades of hard-won experience, Marc highlights a foundational playbook for any LIMS deployment:
- **Resource for the Long Haul, Not Just the Go-Live:** Organisations frequently treat LIMS as a one-and-done project. They fail to realise that master data is a living, breathing entity. As a new drug moves through its lifecycle, specifications inevitably tighten. New reagents are constantly introduced. “Every time you change the specification, you have to change the master data,” Marc says. The business must staff permanent roles to manage this constant evolution. “It’s always a shock to them. We tell them at the beginning of each project… and then when it’s time for them to do it, then there’s always a panic”.
- **Standardize the Low-Hanging Fruit:** In a massive matrix network like Bayer — where an API made in Spain is shipped to Italy for processing, and then to the U.S. for packaging — standardisation is survival. If different sites use different naming conventions, data interoperability is impossible. Short-term employee assignments become logistical nightmares because scientists spend three months just figuring out the local nomenclature. Marc advises standardising common tests early. “If you can standardise the top 20 tests across the enterprise, why do you need pH tests 500 different ways?” he asks. “You are doing the same test. Loss on drying is done only one way, so why do you have 10 different versions of it? There might be local nuances, but if you start with a standard, you can move on from there”.
- **Demand Automation Testing:** Moving master data between Development, Quality, and Production environments manually is a soul-crushing, error-prone endeavour. He recalls past projects lacking an import/export utility, forcing teams to manually recreate and re-document massive data sets in every environment. “If you can have automation testing with respect to your master data management, that’s going to just speed up the process,” he emphasizes.
- **Establish a Governance Board:** You cannot maintain data integrity through good intentions, Marc opined. A formalized governance board is required to enforce naming conventions, approve new standards, and prevent digital bloat. This board decides whether a parameter requires a global standard or if a local site-specific nuance is justified. Without them, you end up with “4 different versions of millilitres”.
- **Leverage Data for “Quality by Design (QbD)”:** A robust master data strategy is the ultimate defence during a regulatory audit. When an organisation can clearly demonstrate how its data dictates its process, it proves total operational control. “Having that level of control is going to bring credibility… and it’s going to really stop a lot of the questions coming your way,” Marc says. It is the literal manifestation of building quality into the product by design.
**The AI Horizon: Hope and Fear at the Bench**
As AI aggressively permeates the tech sector, its role in laboratory master data remains surprisingly nascent.
Currently, Marc sees the immediate potential for AI to ingest dense Standard Operating Procedures (SOPs), interpret the parameters, and automatically generate basic master data drafts. It could also scan enterprise databases to identify existing test methods, preventing scientists from needlessly duplicating work and creating “copies of copies”.
But the true prize — the leap that would fundamentally change lab informatics — remains elusive. With the speed of AI’s evolution, Marc believes the industry could be turned on it’s head within the next 12 to 18 months.
“The sweet spot from my perspective right now would be if it could create all the calculations for me,” Marc admits. He isn’t talking about basic addition. He is talking about the heavy, nuanced math required in biotech: calculating coefficients of variance, tracking parallelism, and mapping linear regressions. “Right now, AI is not doing that. At least I have not seen anything in the market that’s doing that”.
Down at the bench level, the sentiment regarding AI is a complicated mix of exhaustion and anxiety. Scientists desperately want AI to automate the soul-draining, manual administrative tasks that pull them away from actual science. Yet, there is a lingering, quiet dread about the concept of the “lights out” laboratory — a fully autonomous facility running in the dark.
“A lot of people are scared of lights out chemistry, right?” Marc notes. “They are anxious about job losses”.
For now, the human element remains irreplaceable. AI cannot feel the physical constraints of a freezing California lab. A software developer cannot code a workflow they have never observed. The laboratory operates at the messy, unpredictable junction of biology, chemistry, and human execution.
If companies want to truly digitize their operations, they must stop viewing their systems as mere IT installations. They must recognize them as the central nervous system of the enterprise.
“I was told on a number of occasions,” Marc reflects, summing up a lifetime in the digital trenches. “LIMS, on some level, is almost more complicated to install and configure than SAP”.
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
---
### [Interview: AI Not Yet A Miracle Worker, But A Powerful Scientific Prompt Responder](https://zifo.com/blogs/interview-ai-not-yet-a-miracle-worker-but-a-powerful-scientific-prompt-responder/)
**Published:** November 11, 2025
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [Interview: AI Not Yet A Miracle Worker, But A Powerful Scientific Prompt Responder](https://zifo.com/blogs/interview-ai-not-yet-a-miracle-worker-but-a-powerful-scientific-prompt-responder/ "Interview: AI Not Yet A Miracle Worker, But A Powerful Scientific Prompt Responder")
## Interview: AI Not Yet A Miracle Worker, But A Powerful Scientific Prompt Responder
Sakthi Prasad T – Content Director
Nov 11, 2025
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Interview%3A%20AI%20Not%20Yet%20A%20Miracle%20Worker%2C%20But%20A%20Powerful%20Scientific%20Prompt%20Responder%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Finterview-ai-not-yet-a-miracle-worker-but-a-powerful-scientific-prompt-responder%2F "Share on Email")
- [](https://x.com/intent/post?text=Interview%3A%20AI%20Not%20Yet%20A%20Miracle%20Worker%2C%20But%20A%20Powerful%20Scientific%20Prompt%20Responder&url=https%3A%2F%2Fzifo.com%2Fblogs%2Finterview-ai-not-yet-a-miracle-worker-but-a-powerful-scientific-prompt-responder%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Interview%3A+AI+Not+Yet+A+Miracle+Worker%2C+But+A+Powerful+Scientific+Prompt+Responder&url=https%3A%2F%2Fzifo.com%2Fblogs%2Finterview-ai-not-yet-a-miracle-worker-but-a-powerful-scientific-prompt-responder%2F "Share on LinkedIn")
Image reference: / source
Tech giant Google in collaboration with Yale University released an AI model known as Cell2Sentence-Scale 27B (C2S-Scale), a new 27 billion parameter foundation model designed to understand the language of individual cells. Built on Google’s Gemma family of open models, C2S-Scale represents a new frontier in single-cell analysis.
Given this scenario, and even as **AI fever grips Biopharma and other science-focused industries,** along with its fair share of disillusionment, we spoke with **Paul Denny-Gouldson, Zifo’s Chief Scientific Officer,** to make sense of what Google’s announcement means for AI in science and for scientists.
***Google announced this partnership with Yale, and their AI model has generated a cancer hypothesis. This, of course, is the initial stage of research, and the company says they achieved in vitro success, which then requires testing and confirmation in vivo. Firstly, what are your thoughts on this development? Secondly, what does it truly mean for an AI model to generate a scientific hypothesis, and why is that significant? I am asking this because I want to know: is this a ‘Sputnik moment’ for AI, or is that an exaggeration?***
Firstly, I would like to congratulate the Google and Yale team for achieving this impressive breakthrough. The first thing we have to consider is **what this thing that’s been created actually is:** it’s a **model of a single cell** that enables it to answer questions a scientist asks. For instance, they might ask, “Can you find me this?” or “Can you tell me about this?”
The model’s power lies in the **vast volume of different, multimodal data types** used to build it. **This essentially creates a statistical model of how the single cell will behave.** The data types include imaging, biochemical, and phenotypic data, all merged with open-source information on pathways, genes, and proteins.
This specific development is a **single-cell model for cancer,** making it disease-specific. The paper discusses the concept of developing similar models for other diseases and cell types. By linking different data types, the model offers predictions. **However, we must be careful about calling it an “AI” in the sense of an independent creator; it is a model that is only as good as the data used to create it.**
The authors themselves discuss extending the model with more data types to increase the fidelity of the information and the model’s ability to offer alternatives or predict things. **But it always comes down to the question you ask of the model. The model itself won’t just create something out of nothing regarding potential treatments or outcomes for the disease in question. It responds to a prompt like, “I am investigating this; can you find me an alternative or something that works with this?”**
That is why it’s so **important to really distinguish this from the de novo creation of a hypothesis by the model or the AI on its own.**
**Back to the question —** is this a Sputnik moment — maybe, maybe not. I am not sure. My healthy scepticism has me thinking if this has been done before, but behind “closed doors” — so in that way it may not be the “first”. There is no doubt, however, it will fuel the research into this space as it shows what’s possible — and being open-source means others can build on it, which is the best way to accelerate development. So, in this way, it is just like Sputnik — it will incentivise and challenge others to build on it and do better, like getting a man on the moon, or in this case, even Mars.
***Okay, this is fantastic. They built a model, applied a “specialised LLM” trained on a multimodal corpus of over 50 million cells and associated text on top of it, and the scientists used a highly structured, computational query to interact with the model. Hence, this isn’t a classic LLM query like “Hey C2S, what drug combination works for cold tumors?”***
Yes, that’s correct. Now, let’s be clear: this is a **very, very large model.** While I don’t know if private organizations have produced bigger ones, the sheer number of parameters they used — in the billions — means it can accommodate a vast variety of different questions. This is because all **cell behavior is interlinked,** and the model’s main function is to map all those links.
The power of having such a large model to describe the overall behavior of an **individual cell** — remember, this is a single-cell model — is its ability to find relationships that a human cannot see or even contemplate. We can only actively manipulate perhaps two or three parameters in our minds at once; whereas this model has billions.
That is the true power I see in this methodology: building a model using **the highest quality and largest volume of data possible. This allows the model to be used effectively to test or generate hypotheses.**
***Now that the model has come up with the hypothesis, the scientists will still have to test it as the next step, through experiments.***
Yes, now that the model has come up with the hypothesis, the normal process goes on. Now we have the classic **design, make, test, analyze (DMTA) cycle. What the Goole-Yale model offers is the ability to generate ideas for testable hypotheses in the lab, all derived from a vast pool of quality data.**
This brings us back to the issue of **good data: if the data used to create the model is not trustworthy or high-quality, the model will inherently be flawed.** Regardless, the scientist, organization, or lab environment still needs to proceed with **testing that hypothesis.**
The fascinating aspect here lies in the **cost and subsequent cycle.** The investment to build and train this model is significant — likely multiple millions, if not tens of millions of dollars, factoring in compute power, personnel, and data curation. This endeavor is a real showcase of what is possible with major investment from partners like Google and Yale.
Now that the model exists, as we go through the **design, make, test, analyze cycle** in the lab — the “wet work” — and generate new data, that data can be used to **augment and retrain the model.** If an experimental result confirms the model’s prediction, the model’s trust in that relationship is **enhanced.** If the experiment result “fails”, the significance of that perceived relationship is **lowered.**
**This entire cycle must continue: you continually add new information based on the hypotheses the model generated.** This process is called **reinforcement** or checking of the model. As you conduct more testing, the model becomes progressively better, because you are exploring, extending and validating the entire “cell process space” that exists within the model.
***Okay, so how was this hypothesis being validated? I am asking because we are so used to the consumerization of LLM models. People can ask ChatGPT or any other LLM any question, and it throws out an answer, but we don’t know if it’s true or if it’s just hallucinating, and so on. From the paper, were you able to deduce any guardrails that Google and Yale put in place to ensure that the hypothesis generated by the model is actually validated, and not just hallucinating? How do they ensure that?***
**There are different ways to reduce the risk of hallucination.** One is ensuring the data used is of **good quality. This alone is a labor-intensive problem, requiring knowledgeable people to validate the data. However, a number of automated and other tools can be used to check the data for consistency.**
**As for the guardrails, this is where the concept of a data foundation comes in.** Beyond the raw data, the critical piece is the ontology used to govern the relationship between all the entities. **You can start with a gene, a pathway, a hormone, or a metabolite and traverse the relationships between all those entities.**
The ontology is critical; they used and curated a number of external ontologies to ensure they had a good definition of all the relationships and terminology. This ontology can then be used to **check the data.** It asks: “Does this new data fit the ontology, or does it suggest claims or relationships that are either new or contradict existing information?” If a contradiction arises, scientists must go in and examine the data to see if it was tagged incorrectly or produced inconsistently.
**The large language model (LLM) itself also needs guardrails to prevent it from making incorrect assumptions or stating that two things are related when they are not. The ontology helps serve as the quality checker or QC element to support the LLM.** The final piece, of course, is that you cannot trust anything without **experimental testing and checking.**
***What excites you about this AI model?***
The exciting part here is using this concept of a model to empower scientists to **explore hypotheses.** The next step would be to have an agent that can take that hypothesis and turn it into an **experimental design —** for example, “I can help you design an experiment to test the relationship between this gene-pathway-protein-disease”. This could then be executed by another agent that controls an automated robotics laboratory — and a third agent could pull all that data and analysis together for the scientists, before pushing it back into the model after the scientist intervention.
This creates a **virtuous cycle** of support. As you add more data from successful or failed experimental studies, the model is continually refined through **reinforcement.** If something works, it enhances the trust in that relationship. If it doesn’t, it lowers the significance of that potential relationship. **The more testing conducted, the better the model becomes, because you are exploring and validating the entire experimental space.**
Playing this forward, the ultimate goal is to have a whole set of models that mimic a human, starting at the cell level, scaling up to an organ, linked organs, and eventually the entire system — a human — the **“moon shot”** perhaps. **Previous attempts at this were small-scale, and while useful, they are limited. The power of this new wave of large compute is that it enables us to build much better, larger-scale models.**
***Okay, moving on, Paul. As a scientist yourself, how important do you think scientists are in the current day, now that these AI models are slowly emerging, and what makes their job so important?***
I think it’s really interesting talking to fellow scientists. As I do most weeks, many of them are a little **distrustful of AI** generally, mainly because of the **hype** and the **outlandish claims** some people have made about what it can do. I think it’s all about being very thoughtful and employing a **healthy scepticism —** and that’s exactly what I see with my science colleagues and believe myself.
**There are some scientists who are “all in” and pursuing it aggressively, and others who are completely against it.** But the biggest group is that middle band utilizing healthy scepticism and asking, **“What’s in it for me? How will this help me do my science?”**
You have to imagine there are so many different types of scientists and problems that scientifically driven organizations are trying to solve. The example with Google and Yale **— a single-cell cancer model — is perhaps only applicable to 0.1% of the scientific community.** This is where the hype has taken over a little: the declaration that “we have done this, and it’s amazing” isn’t relevant if you talk to chemists, food scientists, or people who don’t work in cancer or cells. **These other scientists are asking, “I need something that will help me.”**
I think having **healthy scepticism** is very good. The job now for all organizations is to determine what kind of support will work for each specific scientist or scientific group. Will it be a “model” like this, or a different concept of how machine learning or an LLM-based search interface can interrogate information?
Fundamentally, there is a whole host of different scientific problems to solve. Whether it is physics, chemistry, biology, or material science, all have their own unique issues. The key is to put the **scientist at the center** and determine how we can help them do their job: **help them ask questions they perhaps didn’t think of** and **see patterns they can’t see.** This is the ultimate power of LLM interrogation of big models: surfacing patterns, links, and relationships that are impossible for a human being to perceive.
***The hypothesis that Google generated for a single-cell cancer model — does this qualify as a discovery? And with AI entering the process, does that generation itself qualify as a discovery?***
**Personally, I don’t believe it qualifies as discovery.** Discovery is the **finding of proof** of something — being able to definitively state, “We now know this behaves this way and this is a new discovery.”
What Google’s single-cell model has done is create an **environment** for people to ask questions they perhaps couldn’t have asked and to generate hypotheses, or “multipaths,” that then need to be tested. Until that relationship is **proven in the lab — both in vitro, which they have successfully done, and then in vivo, which they are currently working on — it does not qualify as a discovery for me.**
**The model didn’t just tell the scientists there’s a relationship “out of the blue.” You had to apply their scientific knowledge of disease biology and pathways to formulate the initial queries —** as they describe in the paper — to build up the investigation. **Only then is the model able to suggest a potential link and the treatment regime for the specific problem.**
It’s an interesting journey through the **semantics** of what constitutes discovery. **I believe these models, at this stage, will support scientists in exploring areas and relationships they had never seen before — but the scientist still must prompt and interrogate the model.**
***All of the scientific AI we hear about at the moment is, so to speak, primarily focused on the discovery side –specifically drug discovery — which is arguably the most glamorous part. However, discovery alone is not all of science, right? There is a whole host of processes involved in bringing a drug to the market, and currently, all AI efforts are concentrated on discovery.***
***It’s becoming a bit like a fairy tale where some people claim, “Oh, I just need to ask GPT to find the next prototype for paracetamol, or whatever, and it gives me an answer.” Do you think there is too much focus on the discovery side because it’s obviously glamorous — the idea of just finding the next magical drug?***
***The chatter suggests that drug discovery might move from wet labs to computation. I know these are very far-fetched, futuristic pronouncements, but we shouldn’t dismiss them either, as we don’t know how technology will evolve.***
***As a scientist for a long time, Paul, when you hear such pronouncements, what comes to your mind? What do you think is going to happen?***
You are absolutely right; the **discovery topic is the one that grabs the headlines.** However, behind the scenes, **at all the scientifically driven organizations I talk to in Pharma-Biotech, FMCG, Speciality Chemicals, Food & Beverage, Agrotech etc., their understanding of AI is evolving very rapidly. They are looking at how AI can impact all parts of the lifecycle: not just discovery, but also research, development, manufacturing, and product trials.**
They are exploring concepts like **AI augmentation, decision support, pattern recognition,** and workflow support to enable things they couldn’t do before. Crucially, the time to value is often faster the further up the chain we go toward development and manufacturing.
This is because there are many problems in those stages that are manual and stepwise: creating documentation, checking data quality, and so on. These tasks are perfectly suited to well-trained models and AI and Agentic concepts. Furthermore, the amount of money you need to spend to address these issues is **much lower.** The problems are more **discreet and defined —** you can precisely put a box around them. For example, if the goal is to create an Investigational New Drug (IND) application, you can work backward, mapping all the required data sources, variables, and parameters. This process can then be monitored and augmented with AI.
In contrast, the **discovery problems are massive.** Look at the investment required to get a single-cell model to partially describe one disease type: **multiple millions to tens of millions of dollars,** plus the cost of aggregating data from many different places. **These discovery problems are so hard, yet they dominate the headlines.**
We have seen many **startups in this drug discovery space that require a huge amount of capital that haven’t succeeded yet despite spending heavily on aggregating old data and generating new data.**
I feel we are definitely heading toward, or are already in, the **trough of disillusionment** in this space. The **actual wins we are seeing** are in more **process-oriented, stepwise concepts** for AI, and that success will build trust.
But who knows? We could eventually see multiple massive models — a “model of the heart,” a “model of the lungs” — each described at this huge scale. Models exist now that describe these organs, but they aren’t built on these massive datasets. The interesting future question will be to compare the massive models with the smaller ones and determine how much better they are versus how much more money you have to spend to build them.
***And, personally, what do you think is the importance of a scientist in this age of AI?***
I think we are heading toward a state where these AI models will adopt the **co-pilot concept —** an assistant that is simply a part of our life as scientists. How fast we get there, I don’t know, but we are already seeing it. Product companies are implementing it, and organizations are building their own support tools.
This raises many questions: How do I know that a product-embedded AI is **compatible** with my own corporate AI strategy and models, or any orchestration layer I am using? Can I leverage its functionality, but turn it off if I want to use my own AI models in the scientist workflow?
This is because you have to **trust the AI.** You must trust the model, how it’s been developed, the data it was created on, and its output. Without that trust, it’s like a game of Russian roulette; you don’t know if you’ll get the right answer. This brings us back to: **How do we avoid or pick up hallucinations and ensure the AI is giving a quality, proper result or inference?**
Then we enter the realm of **governance — AI** governance, model governance, and the concepts of **AIOps** and **GenAIOps,** similar to DevOps in many ways. I believe this will become highly connected to the **quality groups** within organizations, as they are responsible for the quality of the final product. **If we are using tools that directly impact that quality, there will be a much bigger emphasis on governance.**
**Organizations are not fully there yet;** some are just beginning to build this concept. It all comes back to: **How do I build trust? The answer is: I need really good, trustworthy data. This is where the scientific data foundations become essential again —** they must be in place to deliver reliable data for the models to consume and provide quality inference or hypothesis support.
**What does it take to be a scientist in the age of AI? I think it’s all down to being a scientist — healthy scepticism with an equal amount of curiosity and willingness to learn and try new things.** Applying the DMTA cycle to AI in the same way we typically use it to our chosen area of science. Embracing the technology will help us in finding new ways to work that let us explore new innovative approaches, speed up current things, increase precision and accuracy or enable more capacity. All of these will add value to the scientists, helping us be better scientists, all thanks in part to our scientific AI assistants.
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
---
### [Advancements And Challenges In Genomic Medicine](https://zifo.com/blogs/variant-classification-advancements-and-challenges-in-genomic-medicine/)
**Published:** February 8, 2024
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [Advancements And Challenges In Genomic Medicine](https://zifo.com/blogs/variant-classification-advancements-and-challenges-in-genomic-medicine/ "Advancements And Challenges In Genomic Medicine")
## Advancements And Challenges In Genomic Medicine
Radesh Nattamai Malli P.
Feb 08, 2024
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Advancements%20And%20Challenges%20In%20Genomic%20Medicine%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Fvariant-classification-advancements-and-challenges-in-genomic-medicine%2F "Share on Email")
- [](https://x.com/intent/post?text=Advancements%20And%20Challenges%20In%20Genomic%20Medicine&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fvariant-classification-advancements-and-challenges-in-genomic-medicine%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Advancements+And+Challenges+In+Genomic+Medicine&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fvariant-classification-advancements-and-challenges-in-genomic-medicine%2F "Share on LinkedIn")
Image reference: / source
Fig.1 – Ref: ****
Some say that we should admit that genes are no longer the blueprint of life –; however, understanding their importance and impact on disease should not be downplayed. We need to know how all the other factors and “life” elements interact and manifest healthy versus unhealthy systems – but we can also still learn a lot about the genetic impacts.
Were you aware that on the level of base pairs, your genome shares 99.9 per cent similarity with the genomes of other humans around you? (Fig.1). However, within that 0.1 per cent variation, many distinctive traits that make you unique can be found!.
Genetic variants are alterations in the DNA sequence that make individuals unique. The human genome, the complete set of genetic material, consists of about 3 billion base pairs of DNA organized into chromosomes. Genetic variants can occur at the level of a single nucleotide (single nucleotide polymorphisms or SNPs), or they can involve more significant segments of DNA. There are several types of genetic variants ranging from a single base pair change (SNPs) to structural variants involving larger DNA segments.
Genetic variants play a crucial role in the diversity of traits and disease susceptibility. Some variants are associated with specific characteristics or conditions, while others appear currently to have no apparent effect. Additionally, genetic variants can interact with environmental factors, influencing an individual’s overall phenotype. Understanding genetic variants is essential in the fields of genetics, genomics, and personalized medicine. Advances in technology, such as high-throughput sequencing, have facilitated the identification and analysis of genetic variants on a large scale. This knowledge has implications for disease risk assessment, drug development, and personalized treatment strategies based on an individual’s genetic makeup.
Variant classification is a critical component of clinical decision-making in a diagnostic setting. It involves the interpretation and evaluation of genetic variants to determine their potential pathogenicity. The American College of Medical Genetics and Genomics (ACMG) has recommended five variant classification categories: pathogenic, likely pathogenic, uncertain significance, likely benign, and benign.
Genomic medicine has revolutionized healthcare by providing insights into an individual’s genetic makeup. Variant classification, a crucial aspect of genomic analysis, involves the interpretation of genetic variations to determine their significance in health and disease. The evolution in Bioinformatics techniques and genomic data analytics has facilitated the development of custom workflows which automate the variant analysis & classification process. Below is a sample high-level variant analysis & classification workflow.
Fig2. Variant analysis and classification workflow.
Advances in variant classification have propelled precision medicine forward, but they also bring forth challenges that necessitate continuous research and innovation. Below is the overview for some of the topics in advancements and challenges in variant classification.
**Advancements in Variant Classification:**
**1. High-Throughput Sequencing Technologies**
- **Recent years have witnessed remarkable advancements in high-throughput sequencing technologies, such as Next-Generation Sequencing (NGS). These technologies enable the rapid and cost-effective analysis of large genomic datasets, allowing clinicians to identify a wide array of genetic variants.**
**2. Public Databases and Resources**
- **The availability of extensive public databases, like the Genome Aggregation Database (gnomAD) and ClinVar, has significantly enhanced variant classification. These repositories provide a wealth of genetic data, facilitating the comparison of newly discovered variants with existing knowledge, aiding in their classification.**
**3. Machine Learning and Artificial Intelligence**
- **Machine learning algorithms and artificial intelligence (AI) have emerged as powerful tools in variant classification. These technologies can analyze complex genomic data patterns, identify subtle correlations, and predict the functional impact of genetic variants. The integration of AI into variant interpretation processes has expedited analysis and improved accuracy.**
**4. Functional Studies and In Silico Tools**
- **Advances in functional genomics and in silico prediction tools have contributed to a more comprehensive understanding of the biological effects of genetic variants. Functional studies help validate the impact of variants on gene function, while in silico tools predict the potential pathogenicity of variants based on computational models.**
Variant classification and analysis involve a combination of tools and software that leverage bioinformatics, statistical methods, and computational algorithms. Here are some key tools and software commonly used in variant classification in a tabular format.
**Table 1: Tools & Software applied in Variant analysis.**
These models, tools, databases, and software (Table 1.) collectively contribute to the development of robust and accurate machine learning-based variant analysis and classification pipelines. The choice of specific tools depends on the nature of the data, the scale of the analysis, and the goals of the study.
**Challenges in Variant Classification:**
**1. Variant of Unknown Significance (VUS)**
- **A significant challenge in variant classification is the presence of variants with unknown significance. VUS poses difficulties in providing clear clinical guidance, making it crucial to improve our understanding of these variants through further research and functional studies.**
**2. Ethnic Diversity and Population-Specific Variants**
- **Genomic studies have revealed the existence of population-specific genetic variants. However, the lack of diversity in existing databases can lead to challenges in accurately classifying variants, particularly in individuals from underrepresented populations.**
**3. Complexity of Polygenic Traits**
- **Many diseases are polygenic, involving multiple genetic factors. Classifying variants associated with complex traits requires sophisticated analytical methods and a deeper understanding of the interplay between various genetic factors.**
**4. Clinical Implementation and Interpretation**
- **Translating genomic data into actionable clinical insights remains a challenge. Clinicians must interpret genetic information accurately and communicate findings to patients effectively. This necessitates ongoing education and collaboration between geneticists, clinicians, and other healthcare professionals.**
Apart from these challenges listed, there are others which are lack of standardization in variant classification systems and the sheer volume of variants that need to be classified.
Variant classification is a complex process that requires expertise and computational power. With the rapid advances in sequencing technology, clinical diagnostic laboratories are identifying an increasing number of novel variants. This makes it difficult to keep up with the latest research and to classify variants accurately and consistently. The interpretation of genetic variants requires expertise and computational power, which can be a challenge for some laboratories.
**If you’re interested in variant calling, analysis, classification, research, and development, contact us by email at , and we are eager to collaborate and discuss further.**
**Happy Discovery from Zifo Global Bioinformatics Team!**
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
---
### [Exploring The NIS2 Directive: Strengthening Cybersecurity Measures Throughout The European Union](https://zifo.com/blogs/exploring-the-nis2-directive-strengthening-cybersecurity-measures-throughout-the-european-union/)
**Published:** July 23, 2025
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [Exploring The NIS2 Directive: Strengthening Cybersecurity Measures Throughout The European Union](https://zifo.com/blogs/exploring-the-nis2-directive-strengthening-cybersecurity-measures-throughout-the-european-union/ "Exploring The NIS2 Directive: Strengthening Cybersecurity Measures Throughout The European Union")
## Exploring The NIS2 Directive: Strengthening Cybersecurity Measures Throughout The European Union
Tript Srivastava, Engagement Lead
Jul 23, 2025
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Exploring%20The%20NIS2%20Directive%3A%20Strengthening%20Cybersecurity%20Measures%20Throughout%20The%20European%20Union%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Fexploring-the-nis2-directive-strengthening-cybersecurity-measures-throughout-the-european-union%2F "Share on Email")
- [](https://x.com/intent/post?text=Exploring%20The%20NIS2%20Directive%3A%20Strengthening%20Cybersecurity%20Measures%20Throughout%20The%20European%20Union&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fexploring-the-nis2-directive-strengthening-cybersecurity-measures-throughout-the-european-union%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Exploring+The+NIS2+Directive%3A+Strengthening+Cybersecurity+Measures+Throughout+The+European+Union&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fexploring-the-nis2-directive-strengthening-cybersecurity-measures-throughout-the-european-union%2F "Share on LinkedIn")
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Stories
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
The Network and Information Security Directive (NIS2) represents a major enhancement over NIS1, aiming to strengthen cybersecurity throughout the European Union. As cyber threats continue to evolve, the EU has recognized the need for more robust and comprehensive measures to protect critical infrastructure and essential services. This blog will delve into the details of the NIS2 regulation, highlighting its key components and how it differs from its predecessor, NIS1.
**Introduction to NIS2**
Directive (EU) 2022/2555, commonly referred to as the NIS2 Directive, was adopted on December 14, 2022, and became effective on January 16, 2023. The directive aims to enhance cybersecurity across the European Union by requiring entities that manage critical infrastructure and essential services to adopt appropriate security practices and report incidents to designated authorities. EU Member States were required to integrate the directive into national law by October 17, 2024.
**Key components of NIS2**
**1. Broader scope of covered entities**
NIS2 expands its coverage from 7 to 15 sectors, now including areas such as postal and courier services, chemical and food production, manufacturing, digital service providers, and public sector organizations. This broader scope ensures that more entities vital to societal and economic stability are subject to the directive’s cybersecurity requirements.
**2. New classification of organizations**
NIS2 establishes a standardized classification system for organizations, dividing them into two groups: Essential Entities and Important Entities. This distinction allows for tailored cybersecurity obligations based on the criticality of the entity’s role in society and the economy. Essential Entities face more stringent requirements and closer supervision, whereas Important Entities are subject to less intensive oversight.
**3. Enhanced risk management obligations**
Organizations are required to implement robust cybersecurity practices, which include conducting formal risk assessments, performing regular penetration tests and audits, securing their supply chains, and using encryption to protect sensitive data.
**4. Tightened incident reporting protocols**
NIS2 defines clear expectations for incident reporting: an initial alert must be submitted within 24 hours, followed by a detailed report within 72 hours, and a final report with full analysis and corrective actions.
**5. Increased penalties for non-compliance**
Entities that fail to meet NIS2 requirements may face substantial fines of up to €10 million or 2% of their global annual revenue, particularly for those classified as essential.
**Differences between NIS1 and NIS2**
AspectNIS1NIS2ScopeLimited to sectors like energy, transport, and healthcareExpanded to include additional industries, such as postal services, chemical and food industries, manufacturing, digital technology providers, and public administrationClassificationMember States had flexibility in defining covered entitiesUniform classification into Essential Entities and Important EntitiesRisk managementBasic risk management measuresAdvanced risk management measures, including mandatory risk assessments, regular audits, supply chain security, and encryptionIncident reportingGeneral guidelines for incident reportingClearly defined timelines for incident reporting include: an initial alert within 24 hours, a comprehensive follow-up within 72 hours, and a final submission detailing the full analysis and mitigation stepsPenaltiesLower penalties for non-complianceEssential Entities may face significantly higher penalties for non-compliance, including fines reaching up to €10 million or 2% of their total global annual revenue
**How organizations can comply with NIS2**
To comply with NIS2, organizations must adhere to the cybersecurity risk management measures outlined in Article 21. These measures include:
**1. Risk analysis and system security policies**
Organizations should establish structured policies for evaluating risks and securing their information systems.
**2. Incident response procedures**
Clear protocols must be in place to manage and respond to cybersecurity incidents effectively.
**3. Continuity planning**
Entities should develop strategies for data backup, disaster recovery and managing crises to ensure operational resilience.
**4. Securing the supply chain**
Security measures must extend to relationships with suppliers and service partners to mitigate third-party risk.
**5. Secure system lifecycle management**
Security should be embedded throughout system acquisition, development and maintenance, including handling and disclosing vulnerabilities.
**6. Evaluating control effectiveness**
Cybersecurity controls and risk management practices should be reviewed regularly to ensure they remain effective.
**7. Cyber hygiene and awareness**
Promoting basic cybersecurity practices and providing regular ongoing training to staff helps maintain a secure environment.
**8. Use of encryption and cryptography**
Sensitive data should be protected using appropriate cryptographic techniques and encryption standards.
**9. Workforce security measures**
Access controls and asset management policies should be applied to safeguard systems and data from internal threats.
**10. Authentication and secure communication**
Multi-factor authentication, secure communication channels and emergency communication systems should be implemented to protect against unauthorized access and ensure reliability during incidents.
**Conclusion**
The NIS2 Directive marks a vital advancement in bolstering cybersecurity throughout the European Union. By expanding the scope of covered entities, introducing uniform classifications, enhancing risk management measures, and imposing stricter penalties, NIS2 aims to create a more resilient and secure digital environment. Organizations must take a meticulous approach to compliance to ensure they meet the new requirements and protect their critical infrastructure and essential services.
As cyber threats continue to evolve, the NIS2 Directive offers a robust framework to protect the EU’s digital environment, ensuring the security and continuity of essential services.
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Stories
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
---
### [Cdisc Clinical Trails](https://zifo.com/blogs/cdisc-clinical-trials/)
**Published:** April 25, 2022
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [Cdisc Clinical Trails](https://zifo.com/blogs/cdisc-clinical-trials/ "Cdisc Clinical Trails")
## Cdisc Clinical Trails
Sreelekha Pasupuleti
Apr 25, 2022
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Cdisc%20Clinical%20Trails%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Fcdisc-clinical-trials%2F "Share on Email")
- [](https://x.com/intent/post?text=Cdisc%20Clinical%20Trails&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fcdisc-clinical-trials%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Cdisc+Clinical+Trails&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fcdisc-clinical-trials%2F "Share on LinkedIn")
Image reference: / source
**INTRODUCTION**
Clinical data should be in standardized format in accordance with submission to FDA. Data Integrity is the key element for review by regulatory bodies. And, CDISC has paved “n” ways for validating clinical data to ensure the submission quality. Regardless, there are still high potential programming/data issues observed in clinical data. Many of these issues are not comprehensible when a programmer converts raw data to SDTM. But, if we miss squaring the clinical data conformance, we may undergo defective clinical data submission.
A clinical SAS programmer/CDISC SDTM expert can have the skill set for capturing a lot more programming/data issues since he/she plays with clinical data on a day to day basis. But aren’t we in high time to automate the reliability of the data conformance in the aspect of regulatory review?
Yes! Guess what – A SAS macro does that!
Here comes CDISC Checks!!!
It can ensure the data conformance and CDISC standard verification for the FDA submission.
**Would it be impossible to expect such help in the real world?**
A clinical SAS programmer can notify the data management team during study-live, thereby helping to re-investigate data issues.
Programmers get a consolidated list of critical errors in the SDTM package, so chances of sponsor finding are reduced.
When issues in SDTM are identified, programmers are supported in such a way that enables traceability of the data collected. So what can be achieved?
**Contribute to a better assessment of the quality of clinical data**
**To comply with CDISC/ FDA guidelines**
**To perform the checks which are yet to be integrated to Pinnacle 21 Validator**
**Skills:**
Has a strong understanding of SDTM and data compliance.
Not a wallflower- but also user friendly
Expertise in various skills: \[Structure Compliance, Cross-domain verification, cross variables verification, data/terminology\]
Can distinguish between the programming error/data issue and the criticality of the issue.
Can draw a distinction between pinnacle vs non-pinnacle checks, which are mainly CDISC/SDTM IG 3.2 compliance checks.
Can be integrated with all kinds of SAS environments and set-ups.
Can highlight the issues in a detailed manner like the SDTM domain, its variable, and the value within it where the issue occurred.
Can help in the traceability of data collected from EDC, to ensure data integrity.
Can be a great input for documenting the issues that needs to be addressed in Reviewer’s guide.
Can capture more issues with Low detection limit.
**How it works?**
Once the SDTM dataset is clinically evaluated by the CDISC Checks, Open CDISC Validator/Pinnacle 21 won’t surprise the SAS programmer about the quality of SDTM domains.
**FUTURE GOALS**
What does the next level look like?
Expand the knowledge in incorporating the therapeutic area-specific checks.
Checks corresponding to all regulators (eg: FDA/EMEA/PMDA)
Compliance checks for ADaM conformance.
Compliance checks for Non-clinical data (SEND)
To find out more about how Zifo can help with your clinical biometrics please email us directly at
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
**Categories:** Clinical Trials Services
---
### [Decentralized Clinical Trials](https://zifo.com/blogs/decentralized-clinical-trial/)
**Published:** May 16, 2023
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [Decentralized Clinical Trials](https://zifo.com/blogs/decentralized-clinical-trial/ "Decentralized Clinical Trials")
## Decentralized Clinical Trials
Amal Krishna Girish, Bhooma Sridharan, Prasanna Lakshmi Oggu
May 16, 2023
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Decentralized%20Clinical%20Trials%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Fdecentralized-clinical-trial%2F "Share on Email")
- [](https://x.com/intent/post?text=Decentralized%20Clinical%20Trials&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fdecentralized-clinical-trial%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Decentralized+Clinical+Trials&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fdecentralized-clinical-trial%2F "Share on LinkedIn")
Image reference: / source
**What comes to mind when you think of the term ‘Clinical trial’?**
Pretty sure it’s a large hospital site having all the subjects enrolled in the study, physicians interacting with the subject, and lots of things going on in the background. So, what if this hospital – site centric is called the traditional approach? And what does the future hold for clinical trials without a site?
That’s what a “decentralized” clinical trial is all about – a clinical trial with no site.
In 2011, the first ever Decentralized Clinical Trial (DCT) was initiated, and today’s biometrics technology has evolved to support remote subject data collection.
It is well known that retaining subjects through a trial is more demanding than getting subjects to enrol in the first place. So, What matters in a clinical trial is the subject’s comfort.
**Speed Up recruitment, Ensure retention. Drive greater engagement**
The COVID-19 pandemic has significantly influenced the growth of decentralized clinical trials. As the pandemic intensified, patient access to clinical sites became very limited due to travel restrictions. And since more than 70 % of the potential participants lived more than two hours away this caused a big problem. Surveys1 show that between the months of January 2020 and April 2020, the number of monthly trials reduced by 50 %.
To keep the trials going, sponsors had to find an alternate solution, and that was “telemedicine”.
Looking back at the pre covid era, we can see that to a certain degree, decentralized clinical trials had existed before. The pandemic has accelerated the increase in numbers of decentralized clinical trials.
In a survey2 conducted in 2020, up to 98 % of the clinical trial subjects reported satisfaction with telemedicine, and 72 % of the physicians favoured remote engagements in comparison with in-person visits.
**DCT VS HYBRID**
Even though decentralised clinical trials sounds theoretically reliable, it is not suitable for all types of clinical trials. A hybrid approach that brings together the best of both centralised and decentralised clinical trials is then the best approach. In a hybrid trial, technology is utilized wherever possible to reduce the need for in-person site visits. For instance, smartwatches can record their vitals periodically and notify the site – meaning the patient does not travel to the site for this routine event.
So we see, to achieve decentralised clinical trials, a platform for the exchange of information is mandatory.
In addition to the smartwatches mentioned – devices such as blood glucose monitors, blood pressure monitors, pedometers (which displays number of steps walked and the the calories burned propotional to that activity) will aid as a medium for the exchange of information.
**Challenges**
Regardless of the benefits associated with DCTs, there are challenges.
For CROs, the top 3 challenges stated are the effectiveness of study execution at the patient’s residence, clear regulatory guidance, and the ability to integrate data into the existing clinical trial data management (CTDM) ecosystems.
**Other pressing challenges are,**
- Drug distribution and management must be done with utmost care, security and regulatory compliance.
- The use of technology requires identifying modern technology vendors adhering to study compliance.
1. Technology vendors should be available always to provide guidance and solve the technical issues faced.
2. For cases where patients might not be aware of using technical devices, healthcare professionals or caregivers should be appointed and trained.
- Caregivers should be trained properly about administering study drugs or tests to patients, especially for persons with severe health conditions or the elderly.
1. Since the data is collected electronically, there should be multiple layers of security followed to avoid data breaches.
Despite these challenges, DCTs are on their way to becoming part of the future of drug discovery and development assisted by modern technology.
**Conclusion**
DCT is a rapidly growing field and data from EY-Parthenon3 of 69 sponsors and contract research organisation (CRO) decision makers indicates that 50 % of the clinical trials will be hybrid or decentralised by 2024.
The Covid-19 pandemic and it’s after effects has demonstrated that DCTs are critical and effective. History often shows us that technology and innovation often grows exponentially when a major need is present – -and in the COVID 19 case this was the case – “adversity is the mother of innovation” a quote attribute to Einsten.
It seems that further adoption of a DCT approach will be driven by regulatory approval/guidance and advancements in data integration. Many CROs and CTDM vendors across the globe are taking the necessary steps to fill in the gaps.
**References:**
1\. [Clinical trial recovery from COVID-19 disruption](https://www.nature.com/articles/d41573-020-00150-9)
2\. [Helping US healthcare stakeholders understand the human side of the COVID-19 crisis: McKinsey Consumer Healthcare Insights](https://www.mckinsey.com/industries/healthcare/our-insights/helping-us-healthcare-stakeholders-understand-the-human-side-of-the-covid-19-crisis)
3\. [How biopharma and CROs can create value in a shift to decentralized trials](https://www.ey.com/en_us/life-sciences/how-biopharma-and-cros-can-create-value-in-a-shift-to-decentralized-trials#:~:text=An%20EY-Parthenon%20poll%20of%2069%20sponsor%20%28pharmaceutical%20or,be%20either%20hybrid%20or%20completely%20decentralized%20by%202024.)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
**Categories:** Clinical Trials Services
---
### [Computer Vision](https://zifo.com/blogs/ai-computer-vision/)
**Published:** February 23, 2022
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [Computer Vision](https://zifo.com/blogs/ai-computer-vision/ "Computer Vision")
## Computer Vision
Mohamed Ben Hamoudine
Feb 23, 2022
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Computer%20Vision%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Fai-computer-vision%2F "Share on Email")
- [](https://x.com/intent/post?text=Computer%20Vision&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fai-computer-vision%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Computer+Vision&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fai-computer-vision%2F "Share on LinkedIn")
Image reference: / source
**How can computer vision help science industries?**
This article takes a look at the widely used machine learning application: computer vision. While it is used heavily in many market verticals, we will focus on its usage in the R&D-driven pharmaceutical and related industries. To remove any ambiguity, machine vision is part of the larger computer vision domain. We use computer vision because we discuss algorithms to work with image data, as we will discuss here.
Zifo’s approach has been to acquire an in-depth knowledge of AI/ML applications/solutions already in use and focusing on the science. We are here to deliver solutions and bring innovations because that is the place from which transformational impacts derive.
So, let us take a critical look at the pharmaceutical and biotech industries’ state and related “science-centric” industries like Chemicals, Food, Fast Moving Consumer Goods, Agro-tech, and Oil & Gas’s use of this technology.
**What computer vision brings?**
One pharmaceutical industry activity is assessing products and packaging to guarantee optimum quality and deliver traceability via the supply chain. Many other examples can be quoted, such as contamination measurement, cap integrity or code validation. This product tracking and quality assurance is not just a Pharma problem; it spans all the industries mentioned above – albeit perhaps in different terminologies.
Pharmaceutical companies oversee supply tracing and manufacturer data with all their products. Computer vision solutions can improve to identify that information and deliver it across networks during many steps of the shipping process.
The quality and quantity of the data have a precise effect on the consistency of the predictions provided by machine learning algorithms. Data is the fuel for data science, it has many features, such as instructions regarding medication or expiration dates, and this information is essential for distribution and consumption.
In brief, computer vision is one of the many machine learning applications that can bring efficiency benefits within strict quality demands. I can cite you our RPA (Robotic Process Automation) application named qcKen, a hyper automatization for Master Data Management, and an interface incorporated for values configuration. Our solution uses computer vision to help optimise the accuracy of the paper document ingestion.
**What’s the future impact of computer vision?**
Computer vision is growing fast and will impact all our futures as a part of improving all operations requiring human eyes — even activities in which human interface is needed, such as machine maintenance and manual quality assurance. Currently, the primary use of computer vision is “digitising” forms and spreadsheets. Here, computer vision models can significantly accelerate text recognition and data capture whilst monitoring quality and “automating the human” interaction, e.g. in our solution qcKen.
We currently know how to robotically extract data from “paper” documents, making it accessible in a central system. Globally it helps digitise clinical trial documents, patient reports containing historical clinical data or historical medical records and even historical lab notebooks. AI (Artificial Intelligence), and especially ML (Machine Learning), still needs human control since its mostly statistics and probabilities at the root. It would be reckless to let algorithms do sales target setting and business strategy by themselves without a human involved, and so there needs to be a a complementary flow and interaction.
For the future, the industry needs people to configure and experiment with these new technologies and optimise their use. In other words, computer vision is not meant to replace people but to augment and support their performance, as seen in image-based disease diagnostics case studies.
In conclusion, science-driven industries will modernise and deliver citizen health benefits by using AI/ML because everyone wants to ensure speed and accuracy is at the forefront of their research and development. With this in mind, a digital transformation is the only real option that can help them compete, innovate, and efficiently comply with legislation.
To find out more about how Zifo can help with AI, ML, Deep Learning, and scientific Data Sciences, please email us directly at
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
---
### [Rolling Out An Eln](https://zifo.com/blogs/eln-rollout/)
**Published:** April 22, 2022
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [Rolling Out An Eln](https://zifo.com/blogs/eln-rollout/ "Rolling Out An Eln")
## Rolling Out An Eln
Srimathi Krishna Kumar
Apr 22, 2022
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Rolling%20Out%20An%20Eln%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Feln-rollout%2F "Share on Email")
- [](https://x.com/intent/post?text=Rolling%20Out%20An%20Eln&url=https%3A%2F%2Fzifo.com%2Fblogs%2Feln-rollout%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Rolling+Out+An+Eln&url=https%3A%2F%2Fzifo.com%2Fblogs%2Feln-rollout%2F "Share on LinkedIn")
Image reference: / source
**A DIGITAL SCIENCE CONUNDRUM**
Like any other sector, digitalization has also influenced the pharma industry, with many moving towards Pharma 4.0, aiming at simplified regulatory compliance, enhanced security of data, and ease of collaboration. The market value of ELN was around $505 million in 2018, and is expected to reach around $726 million in 2026. The recent COVID crisis has accelerated this process, with industries targeting shorter timelines and effective transitions to the digital style, with effective collaboration and accelerated research.
Recently, we had a chance to interact with one of our customers, who was having a hard time moving to an ELN platform. They said that they were keen to move into ELN as the first step in their digitalization lifecycle to reap its benefits over the traditional paper-based lab notebooks. But they found the process to be such a nightmare that they are now second-guessing their decision.
**HOW TO SEAMLESSLY ADOPT AN ELN**
Our curiosity grew, and we wanted to find possible reasons behind this feeling. After a quick analysis, we observed the following bottlenecks to be reasons for their difficulties in adapting to ELN:
**The Selected ELN system is incompatible with the research area.**
Different ELN systems are designed for different domains of research. Hence, it is important to consider the research domain of the group while selecting an ELN. If an appropriate ELN is chosen after considering the research domain, the functionalities of the system can be used at the maximum level to benefit the users.
**ELN is used for just storing the data and not configured to make it usable elsewhere.**
This happens when the data retrieval systems, such as searches, are not configured properly, or in cases when the data stored in ELN cannot be seen in the data visualization tools currently being used. In such cases, initially, the users will use the system just to dump in data, and eventually stop using it entirely when they realize they cannot do anything with the data stored there. Hence it is very important to set up appropriate data retrieval systems and ensure that ELN is linked to the data visualization tools that are currently in use.
**Users feel ELN systems are complex and time-consuming to enter data daily.**
This happens when the chosen ELN system is very complex and requires intensive training to understand how to use it. Hence, ease of use should also be considered as one of the key aspects while selecting an ELN. Also, the implementation of the ELN system should be in a gradual and phased manner, so that users have time to get accustomed to the system at each phase and have a smooth transition.
With these points in mind, we proposed a methodology that would address all their current perceptions/concerns, and eventually ensure this transition is seamless.
With the proposed solution, we saw several customers going ahead with rolling out ELN, overcoming the reservations that they had in the initial stages. Eventually, the ELN was successfully rolled out in a phased process.
**KEY TAKEAWAYS**
The following concerns of our customer regarding the traditional paper lab notebooks were addressed in this process of digitization:
**Searchability**
**Before ELN.** Manual searching is tedious; key facts may be missed out in the process.
**After ELN Rollout**. Searches are automated; easier with fewer chances of errors.
**Security.**
**Before ELN.** Anyone with access to the notebook can view the data and modify it.
**After ELN Rollout.** Access to view and edit the data can be restricted, to allow only specific users to edit or view the data.
**Data collaboration.**
**Before ELN.** Collaboration across different sites is difficult and time-consuming; the chances of a data breach cannot be ignored in this process.
**After ELN Rollout.** Collaboration of data across sites is much easier and safer.
**Uniformity.**
**Before ELN.** It may not be in a uniform format across different users, because of which important data may be missed or not captured.
**After ELN Rollout.** A predefined format will be designed for capturing data in a uniform and easily readable manner.
**Calculations.**
**Before ELN.** Must be done manually; time-consuming. High chances of errors
**After ELN Rollout.** Can be automated; takes less time. Chances of errors are minimal.
**Audit Trail.**
**Before ELN.** Difficult to maintain; not foolproof always.
**After ELN Rollout.** Can be configured to comply with regulatory requirements
Any “Change Management” process is sensitive to people’s emotions and is done with utmost care to take people along.
A thorough analysis of the user needs, selecting the correct platform, and following a gradual, phased approach with adequate end-user training will make this transition smooth and comfortable until many more user groups adopt ELN.
To find out more about how Zifo can help with your ELN and Digitalisation, please email us at
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
---
### [Streamlining Bioprocess](https://zifo.com/blogs/streamlining-bioprocess/)
**Published:** April 22, 2022
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [Streamlining Bioprocess](https://zifo.com/blogs/streamlining-bioprocess/ "Streamlining Bioprocess")
## Streamlining Bioprocess
Janani Muralikrishnan & Pavithra Ulagappan
Apr 22, 2022
Image reference: / source
**WHAT IS BIOPROCESS?**
Bioprocess is the process of translating biological science into bio-based products, processes, or systems. It plays a major role in the production of biotherapeutics, vaccines, speciality chemicals, biochemicals and enzymes. This involves a series of upstream and downstream processes, which are interdependent and connected to each other, mostly in a linear manner.
The market for bioprocess derived products is steadily increasing. However, only 21 biologics were approved by the FDA in 2018, 22 in 2019, and 8 in 2020\[1\].
Incorporating Quality-by-Design (QbD) into the process and building it into the product is being actively pursued to innovate, improve development strategies, and enhance the success rate of drugs towards the final stages of development. Automation in bioprocessing has been one of the significant contributors to ensuring QbD in different stages of drug development.
**WHATS THE FUTURE?**
**In bioprocess, the channelling of data from one step to another plays an integral and crucial part in the process.**
Informatics platforms like ELN, LIMS etc., can play a significant role in pipelining data transfer in these processes. They enable automation of the workflow, collaboration with multiple systems and users, parallelizing data capture and analysis, and documentation of data\[2\]. In other words, digitalization of the processes ensures streamlining of data across different experiments while also maintaining source data credibility and traceability.
Other platforms such as SDMS, LIS, Instrument Integrations, Registration systems etc., can integrate to establish a digital footprint of the entire lab.
Bioprocess can be broadly classified into two stages – upstream and downstream processing.
The **upstream processing** is the phase in which cell lines are generated and biomass is produced at an appreciable scale.
The **downstream processing**, on the other hand, is the phase that deals with the extraction or separation of desired products from the biomass (developed in upstream processing). The image shows the processes involved in the upstream phase.
Digitalization of the upstream processes ensures transparency and traceability. It can function as an integrated bioprocess execution system, with the following advantages\[2\]:
Scientific and laboratory informatics platforms aid in the following:
1. Enable system integrations and facilitate data transfer among systems.
2. Provide a secure repository for data handling.
3. Flexible to create or amend lab processes and procedures.
4. Enforce lab protocols, regulatory processes, and business standards.
These digital platforms hence prevent common laboratory and documentation errors, thus building QbD from the very initial stages of bioprocesses. Informatics platforms provide continuous feedback that supports the entire process lifecycle, facilitating its evolution and optimization.
Process efficiency, achievable cell densities and product titres in cell culture processes can be increased enormously through the application of innovative technologies.
Automated cell culture systems, single-use bioreactors, integrated online biomass measurement and other latest applications help bioprocess move towards better performance.
**WHATS NEXT?**
Significant progress can be achieved by integrating workflows. With newer advances in processes and technology, adaptation to informatics platforms proves to be the most suitable option. These platforms and solutions are constantly updated and upgraded to support and meet the emerging trends in bioprocess studies.
Stay tuned to know more about the influence of digitalization on downstream processing…
**References:**
1. [Biologics Approvals](https://www.fda.gov/vaccines-blood-biologics/development-approval-process-cber/biological-approvals-year)
2. [Bioprocess Development Automation](https://www.genengnews.com/sponsored/securecell-empowering-biopharma-for-full-bioprocess-development-automation/)
3. [Bioprocess Execution System Support Process Lifecycle](https://bioprocessintl.com/2011/how-can-you-improve-your-bioprocess-efficiency-by-40-320192/#:~:text=The%20Bioprocess%20Execution%20System%20is,supports%20the%20entire%20process%20lifecycle.)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
---
### [Microbiome Research - Don't Forget The Data](https://zifo.com/blogs/microbiome-research-dont-forget-to-look-after-your-data/)
**Published:** March 17, 2023
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [Microbiome Research – Don’t Forget The Data](https://zifo.com/blogs/microbiome-research-dont-forget-to-look-after-your-data/ "Microbiome Research – Don’t Forget The Data")
## Microbiome Research – Don’t Forget The Data
Ragavi Shanmugam
Mar 17, 2023
Image reference: / source
Microorganisms (microbes) are found in every environment on earth, including air, water, soil, plants, and animals. A “microbiome” is a collection of microorganisms (microbes) living in a specific environment that can include bacteria, viruses, fungi, and other microorganisms. Human Gut Microbiome refers to all the microorganisms\[ 1 \] living inside the human gut.
By studying a microbiome, scientists can better understand the impact of human activities or any other external factors on that environment. For example, by investigating the microbes in soil and on say crop growth, scientists can better understand and improve crop yields, potentially reduce the need for pesticides, and perhaps create more sustainable farming practices. Furthermore, many studies have shown that changes in the human gut microbiome are associated with several diseases, such as inflammatory bowel disease, type 2 diabetes, and obesity \[ 1 \]\[ 2 \].
In the area of human health, microbiome related products are available that alter the microbiome in each environment to achieve the desired outcome. With better understanding of the impacts of microbiome on health, the demand for microbiome products such as probiotics/prebiotics has grown significantly over the last decade. Microbiome therapeutics is now evolving rapidly and has shown promising results to treat\[ 3 \] and certain mental health disorders \[ 4 \]\[ 5 \]. The applications of microbiome-based products can now be found in the food, agriculture, fermentation, cosmetic and wellbeing/fitness industries. Given the fast-moving nature of this research, the focus is now on how to effectively capture, analyze and leverage microbiome-based data to support research and product development.
**Microbiome Data:** Microbiome studies typically start with the study of the genetic material, such as DNA /RNA of the microbiome. The genetic material is extracted and sequenced from the microbiome sample. There are various approaches used to gather the molecular genetic data of a microbiome.
**16S rRNA sequencing:**This technique is commonly used to study microbiomes. It identifies and classifies bacteria based on their 16S rRNA gene sequence. This is a cost-effective and rapid method for characterizing microbiome, allowing for the identification of different bacterial genus. However, it has limited taxonomic resolution and cannot distinguish between closely related species or strains. It could miss rare or low-abundance taxa that are important for understanding the overall microbiome function. This technique is also prone to sequencing errors.
**Shotgun metagenomics:** This technique sequences the entire genome of all the microbes in a sample. It provides more detailed information when compared to 16S rRNA sequencing, but it is more expensive. Unlike traditional methods that focus on one organism at a time, metagenomics sequencing allows researchers to simultaneously analyze the DNA of thousands of microbe species and strains in a single run. Metagenomics is now an essential technique for understanding the complex interactions between different microorganisms and their roles in maintaining the health and stability of the ecosystems the inhabit.
**Metatranscriptomics:** This technique analyzes the RNA molecules being produced by the microbes at a given time. The time and transcription information provides insights into not only which genes are being expressed but how they are being regulated – either up or down compared to the past. This gives much more information about the state of the microbiome at a point in time and what are the active/participating pathways and genes in the microbe population. When compared to analyzing only genomic DNA the meta transcriptomics approach can tell scientists how the microbiome reacts to changes in environment and exposure to external factors such as pollutants, different types of food etc.
All the above techniques require the same key steps:
- Sample collection
- Extracting the genetic material
- Sequencing
- Sequence data analysis
- Interpretation
Once the data is gathered from the sequencer, the processing of raw data also varies by the nature of the study. After examining the DNA/RNA to get the taxonomy composition/functional abundance or gene expression profile of the microbiome, the output is then analyzed using a various statistical or AI/ML methods to examine a hypothesis.
**Challenges**
A proper microbiome sequence data analysis pipeline and robust data storage are crucial for ensuring the accuracy and reproducibility of a microbiome study. There are many challenges in the analysis and interpretation phase due to the huge amounts of data these studies and sequencing instruments produce. Figure 1. explains the challenges at each major step of a metagenomics study:
As researchers increasingly turn to microbiome data to answer complex scientific questions, it’s important to have a good data management and analysis strategy and infrastructure in place. Here are some key things to do and some considerations:
**Computational Environment:** set up computational environment and evaluate the need for cloud services.
This may include evaluating the cost and scalability of cloud services, as well as ensuring compliance with relevant regulations. Consider which cloud service provider to use, such as Google Cloud or AWS, and compare the cost and features of each.
**Bioinformatics Processing:** Identify and set up the data processing workflow so it is both reproducible and scalable.
It is common for Bioinformaticians to rely on open-source workflows or pipelines that are published as Github repositories. These resources have their own advantages and disadvantages that researchers should be aware of before deciding to use them for research. There are several advantages to open-source resources: flexibility to customize, cost efficiency, collaboration with the community, transparency, and reproducibility. But the open-source tools/resources have their own set of disadvantages, such as lack of maintenance, compatibility issues with in-house applications or environments, open bug issues and security vulnerabilities.
**Data Storage:** Define where you will store and manage data processing outputs and bioinformatics specific file formats.
Bioinformatics processing involves various steps including base calling, read counts, taxonomic classifications, and functional annotations. These outputs require a strategy on how to efficiently model and store the memory intensive file formats such as FASTQ, BAM, and tab-delimited tables. The data will quickly become disorganized and expensive to store without proper storage solutions.
**Data Integration:** Ensure all data is in one place.
Define how you will integrate sample/subject metadata from the LIMS/clinical systems with the outputs of bioinformatics analysis pipeline. This is crucial in ensuring that the metadata is properly recorded, and the relationships are established between various data entities. Having the right approach to integrate outputs from data processing with public databases (Eg. KEGG), enables different analysis possible. For any downstream analysis such as network, Graph DB, statistical modeling, or AI/ML, relational data modelling is also necessary.
**Data Visualization:** Understand how best to visualise your data.
Data visualization is highly subjective and specific to the use case, so you must pick whether to go with static plots, interactive visualizations, or other tooling. There are some good open-source genomics tools, such as IGV, UCSC genome browser etc., that can be integrated with a database and embedded with your R-shiny/Python Dash applications for better usage.
**Data governance:** Ensure the data in properly managed and curated overtime.
Organizations must carefully consider how to store the microbiome data long-term and have strategies for version control, data backup, and data archiving. Evaluate the need for a centralized data repository and if needed, which repository to use. The specialist nature of data governance calls for roles such as data stewards with deep domain knowledge and experience with data-sharing policies such as GDPR, HIPPA, etc.
So, we can see it is important to have all the right pieces in the right place to deliver conducted effective microbiome research and development. Each step of the process is very important and ensuring you have a reproducible bioinformatics workflow is a core part of this. The potential challenge here, though is you need knowledge and multiple domains – scientific, data, cloud, and analytics to perform due diligence and make informed decisions for your microbiome research and development informatics support.
**Webinar:**
Zifo and Boost Biomes is going to jointly expand on the above challenges and approaches to tackle them in this webinar: [Register here for the webinar on Mar 29,2023](https://www.zifo.com/event/the-microbiome-data-journey-navigating-challenges-to-model-and-store-key-insights/)
**Case Study 1:**
**Hunt for fit-for-purpose tools:**
Metagenomics requires several tools for processing and analyzing raw sequencing data. There are many open-source workflows, such as SqueezeMeta, MetaVelvet, etc., and open-source data resources, such as HMP, KEGG, GTDB, etc. While this is helpful, it can also be overwhelming for scientists to determine which tools/resources to use and how they compare to each other.
A data management plan should include strategies to address the disadvantages or limitations of the open-source resources described above in the bioinformatics processing step.
Zifo was approached to help benchmark and choose fit-for-purpose tools. Our Bioinformatics team recognized the need for benchmarking to help compare the performance of different metagenomics data processing tools. Popular and commonly used tools were evaluated for each processing step, such as quality control, assembly, taxonomy, and functional annotation. The nf-core/mag pipeline was enhanced by including these tools to make it a benchmarking pipeline. The benchmarking pipeline is published on GitHub for usage by the broad scientific community.
You can read more and try out this pipeline here: [MetaBP pipeline on GitHub](https://github.com/zifornd/metaBP)
**Case Study 2:**
**Stitch together your microbiome data:**
Microbiome data comes in different shapes and sizes and as technology advances, scientists need to combine various types of microbiome data together to understand the real picture. Our Team was asked to design and develop a microbiome database by combining various microbiome data such as 16S, WGS and sample metadata. The main challenge was in modeling the data and figuring out the relationships between different entities. The bioinformatics processing methods of 16S and WGS were different, and it posed its own challenges during integration. Our team also modelled KEGG, RHEA and PATRICK public databases to make sure the annotation information was available in standardized formats for downstream analysis. The public sources have plenty of important information, but the lack of a common genomic standard ontology makes it difficult to digest the data. We overcame these challenges by carefully filtering only the data that supported the end goal.
We picked technologies that are both efficient and user friendly. The database was successfully built and deployed, and now delivers a centralized platform for managing all microbiome sequencing data from multiple studies and projects. Scientists are now able to query their data using a simple search, and the database now provides a working framework for conducting comparative analysis across different projects.
To find out more about how Zifo can help with your Microbiome informatics and analysis needs please email us directly at
**References:**
1\. Gomaa E. Z. (2020). Human gut microbiota/microbiome in health and diseases: a review. Antonie van Leeuwenhoek, 113(12), 2019–2040.
2\. Dominguez-Bello, M. G., Godoy-Vitorino, F., Knight, R., & Blaser, M. J. (2019). Role of the microbiome in human development. Gut, 68(6), 1108–1114.
3\. Arbel, L. T., Hsu, E., & McNally, K. (2017). Cost-Effectiveness of Fecal Microbiota Transplantation in the Treatment of Recurrent Clostridium Difficile Infection: A Literature Review. Cureus, 9(8), e1599.
4\. Peirce, J. M., & Alviña, K. (2019). The role of inflammation and the gut microbiome in depression and anxiety. Journal of Neuroscience Research, 97(10), 1223–1241.
5\. Malan-Muller, S., Valles-Colomer, M., Raes, J., Lowry, C. A., Seedat, S., & Hemmings, S. M. J. (2018). The Gut Microbiome and Mental Health: Implications for Anxiety- and Trauma-Related Disorders. Omics: a journal of integrative biology, 22(2), 90–107. h.
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
**Categories:** Uncategorized
---
### [5 Steps To Data Integrity Remediation](https://zifo.com/blogs/5-steps-to-perform-a-data-integrity-remediation/)
**Published:** May 15, 2023
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [5 Steps To Data Integrity Remediation](https://zifo.com/blogs/5-steps-to-perform-a-data-integrity-remediation/ "5 Steps To Data Integrity Remediation")
## 5 Steps To Data Integrity Remediation
Loganathan Kumarasamy
May 15, 2023
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%205%20Steps%20To%20Data%20Integrity%20Remediation%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2F5-steps-to-perform-a-data-integrity-remediation%2F "Share on Email")
- [](https://x.com/intent/post?text=5%20Steps%20To%20Data%20Integrity%20Remediation&url=https%3A%2F%2Fzifo.com%2Fblogs%2F5-steps-to-perform-a-data-integrity-remediation%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=5+Steps+To+Data+Integrity+Remediation&url=https%3A%2F%2Fzifo.com%2Fblogs%2F5-steps-to-perform-a-data-integrity-remediation%2F "Share on LinkedIn")
Image reference: / source
Wondering how to perform a Data Integrity Remediation exercise at your firm? We have a tried and tested method that walks us through the entire exercise.
**Here’s what we do:**
We also have a checklist that can help you figure out how to identify gaps, analyse impact & risks and whether a mitigation plan is required. Click [here](https://cdn.zifo.com/2026/02/DI_Remediation_Checklist-1.pdf) to download our free checklist!
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
---
### [COVID 19 Strikes – Would Cloud Services Boom In The Scientific RnD World?](https://zifo.com/blogs/covid-19-strikes-would-cloud-services-boom-in-the-scientific-rnd-world/)
**Published:** May 15, 2023
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [COVID 19 Strikes – Would Cloud Services Boom In The Scientific RnD World?](https://zifo.com/blogs/covid-19-strikes-would-cloud-services-boom-in-the-scientific-rnd-world/ "COVID 19 Strikes – Would Cloud Services Boom In The Scientific RnD World?")
## COVID 19 Strikes – Would Cloud Services Boom In The Scientific RnD World?
Radhika Govindarajan
May 15, 2023
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20COVID%2019%20Strikes%20%E2%80%93%20Would%20Cloud%20Services%20Boom%20In%20The%20Scientific%20RnD%20World%3F%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Fcovid-19-strikes-would-cloud-services-boom-in-the-scientific-rnd-world%2F "Share on Email")
- [](https://x.com/intent/post?text=COVID%2019%20Strikes%20–%20Would%20Cloud%20Services%20Boom%20In%20The%20Scientific%20RnD%20World%3F&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fcovid-19-strikes-would-cloud-services-boom-in-the-scientific-rnd-world%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=COVID+19+Strikes+%E2%80%93+Would+Cloud+Services+Boom+In+The+Scientific+RnD+World%3F&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fcovid-19-strikes-would-cloud-services-boom-in-the-scientific-rnd-world%2F "Share on LinkedIn")
Image reference: / source
Ever since the announcement of the novel coronavirus as a pandemic, all that I got to hear was about the significant toll of the COVID-19 outbreak all over the world with positive cases expanding more than 3.6 million and 2,50,000 deaths as of May 5, 2020.
If there was something that seemed to prevail among all societal groups irrespective of any discrimination, then it was fear, anxiety and uncertainty and of course I was no exception. I turned more anxious when the health crisis started to take shape as a social and economic crisis as well, which led around 175 countries across the globe announce a nation-wide lockdown to mitigate the spread.
Running across headlines on how global trade of essential commodities like oil were drastically affected, leading to the sharp fall of prices, sounded like a warning towards economic recession. Working in the Scientific RnD Informatics sector and having crossed almost 50 days of remote work lifestyle, made me curious to know as to how sectors like us are coping up with the shutdown and what is awaiting us in the post pandemic run. Surprisingly, I happened to witness a spurt of growth in the business of cloud technology providers such as Amazon, Microsoft and Google especially during these times and analysis show that they are expected to emerge as the champions at the end of this phase for several reasons.
- IT and RnD sectors are trying their maximum to time-box the impact of the virus, by rapidly switching into “Work from home” mode which has caused the availability of data services to turn into a necessity.
- Organizations that have already migrated to cloud seem to be at less pressure than those having traditional data centers that require people to do the setup on the premise and find it difficult to operate remotely. This has also reduced the risk of exposing the human resources involved in the maintenance and operation of the in-house servers to the virus.
- While there were many ambiguities all these years on cloud capacity, security and applicability to real-time usage, the COVID-19 crisis has proved to be a case study breaking all the ambiguities.
Similarly, AWS has put in place several disaster recovery policies and provides confidence to handle the spike in demands during the period.
With regards to environmental issues, many arguments were raised stating that the construction of data centers would lead to an increase in the warmth of the planet and hence questioning the eco-friendliness of cloud computing. But, according to recent studies, it may be seen that the increase in data centers of public cloud due to their sharing abilities in terms of computing and storage, have lower carbon emissions and energy consumption when compared to individual on-premise data centers.
Also, looking back at what can be learnt from earlier times during similar pandemics, it is evident that pharma and healthcare sectors were those who continued to operate with even more rigor. Returning to normal conditions has happened only with the discovery of a vaccine. Unlike any other companies which proceed with inventing and selling better versions of their products, pharmaceutical and biotech companies undergo a lot more of procedures and trials to achieve the same with respect to a drug/vaccine, since they are bound by a set of regulatory and compliance guidelines.
The drug development process in general involves several phases of experimental studies and clinical trials which require diverse data collection, processing and analysis of huge chunks of data in collaboration with laboratories across the globe.
*As of today, with the list of completed and ongoing COVID-19 studies registered in the WHO database amounts up to 1,042 and “time” being the essence of success in the pharma & biotech sectors, a solution is required to accelerate the process with limited/no movement.*
When I was chatting with our Digital Transformation, Cloud Services and HPC teams, they said **cloud computing seems to have received the attention of quite a few pharma and biotech companies as an avid jump into digital transformation and cloud migration might help them in terms of recording, storage, processing and analysis of humongous data from anywhere in the world. Moreover, adopting HPC based cloud services might provide a whole lot of advantage in terms of faster computation and simulation resulting in improved performance**. Also, cloud services over time have come up with various features to be secure and compliant with the regulatory guidelines.
With all these considered, a huge surge in the demand for cloud services are expected at the end of the COVID -19 pandemic. Would it make it an essential infrastructure?
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
---
### [Enhancing User Experience In Scientific Informatics Support](https://zifo.com/blogs/enhancing-user-experience-in-scientific-informatics-support/)
**Published:** May 15, 2023
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [Enhancing User Experience In Scientific Informatics Support](https://zifo.com/blogs/enhancing-user-experience-in-scientific-informatics-support/ "Enhancing User Experience In Scientific Informatics Support")
## Enhancing User Experience In Scientific Informatics Support
Abhinav Balakumar
May 15, 2023
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Enhancing%20User%20Experience%20In%20Scientific%20Informatics%20Support%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Fenhancing-user-experience-in-scientific-informatics-support%2F "Share on Email")
- [](https://x.com/intent/post?text=Enhancing%20User%20Experience%20In%20Scientific%20Informatics%20Support&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fenhancing-user-experience-in-scientific-informatics-support%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Enhancing+User+Experience+In+Scientific+Informatics+Support&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fenhancing-user-experience-in-scientific-informatics-support%2F "Share on LinkedIn")
Image reference: / source
**Understanding scientific informatics support**
First Rule of Customer Support: Be responsive.
Second Rule: Do not talk (much) to your customers!
Sounds ironic? Not actually.
We’ve been preaching this rule to our scientific application support analysts and it’s starting to work wonders with our user experience.
We are supporting 25000 scientists/statisticians/analysts and over 110 applications across the spectrum of discovery, R&D and clinical studies, and this rule holds good for every request/issue we resolve.
*Every contact we have with a customer influences whether or not they’ll come back. We have to be great every time or we’ll lose them. – Kevin Stirtz, marketing expert and author. But how?*
We’ve come to realise that scientific application support is characterized by 3 distinct attributes. We fondly call it the trichotomy of 3 Ps.
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
---
### [The Good, The Bad And The Ugly – Impact Of COVID-19 On Scientific Research And Informatics](https://zifo.com/blogs/the-good-the-bad-and-the-ugly-impact-of-covid-19-on-scientific-research-and-informatics/)
**Published:** May 15, 2023
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [The Good, The Bad And The Ugly – Impact Of COVID-19 On Scientific Research And Informatics](https://zifo.com/blogs/the-good-the-bad-and-the-ugly-impact-of-covid-19-on-scientific-research-and-informatics/ "The Good, The Bad And The Ugly – Impact Of COVID-19 On Scientific Research And Informatics")
## The Good, The Bad And The Ugly – Impact Of COVID-19 On Scientific Research And Informatics
Sujeegar Jeevanandam
May 15, 2023
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20The%20Good%2C%20The%20Bad%20And%20The%20Ugly%20%E2%80%93%20Impact%20Of%20COVID-19%20On%20Scientific%20Research%20And%20Informatics%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Fthe-good-the-bad-and-the-ugly-impact-of-covid-19-on-scientific-research-and-informatics%2F "Share on Email")
- [](https://x.com/intent/post?text=The%20Good%2C%20The%20Bad%20And%20The%20Ugly%20–%20Impact%20Of%20COVID-19%20On%20Scientific%20Research%20And%20Informatics&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fthe-good-the-bad-and-the-ugly-impact-of-covid-19-on-scientific-research-and-informatics%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=The+Good%2C+The+Bad+And+The+Ugly+%E2%80%93+Impact+Of+COVID-19+On+Scientific+Research+And+Informatics&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fthe-good-the-bad-and-the-ugly-impact-of-covid-19-on-scientific-research-and-informatics%2F "Share on LinkedIn")
Image reference: / source
On the other day, I was speaking to my friend who works in process development for a chip manufacturer in New Mexico. Being a jolly person in general, hearing him speak this time around was miserable.
He described how his organization was re-purposing its manufacturing line and shelved his role as non-essential for the time being. At the end of our conversation (in which I was only a patient listener), referring to me, he remarked how working in scientific research at this time was a boon.
I would have corrected him, but the poor fellow was already beaten worse. Moreover, what he said was only the common (mis)perception I was encountering all around. Though it is true that biotech and healthcare stocks are expected to perform better than those of other sectors in the ongoing circumstances, the reality is not all biotech stocks across the industry are performing well.
For instance, some clinical-stage biotech companies are seeing delayed drug pipelines due to quarantine measures and this is keeping their stocks extremely volatile.
As a R&D informatics solutions provider to a wide range of scientific organizations across the world, we at Zifo are at a vantage point to observe and understand how the life sciences industry is working to address this pandemic and how the pandemic has affected Scientists, Researchers, Vendors focused on Drug Discovery & Development.
The following are few intimate observations that try to capture the ground situation in large Pharma companies and small Biotechs.
**\#WFH**
Securing employee and patient safety is being the priority now. As a side effect, most of our pharma and biotech customers’ laboratories are either shut or operated with bare minimum occupancy. This has plunged R&D plans and timelines into uncertainty.
We regularly partner with and provide services to a scientific informatics solution provider based in Japan. They are committed to personally implementing completed projects at their customers’ sites. This however is not going to be a possibility in the near future. Because of this, the projects that we completed a few months back have not been officially closed.
If we ignore such hiccups, there are a few turns that have marked improvements and innovative workarounds to note. For instance,
- In our engagement with an American biotechnology company, even though we had not adopted agile approach for projects, we decided to hold daily stand-up calls to avoid any miscommunication until Zifo team members are able to meet the scientists at customer’s organization in person.
- One of our other customers from Japan who has always insisted on couriering wet-signed hard copies of business contracts (which has stretched projects and implementations), is now comfortable with digital records executed in a matter of minutes. This has encouraged early understanding of business challenges and solution principles and saved days spent in unnecessary logistics. Bye-bye to paperwork!
**Moving the goalposts**
Reprioritization is essential when times are challenging and unpredictable.
One of Zifo’s partners is a research lab operating under the government of India. They have now repurposed their genomics lab to a PCR-RT testing lab for COVID-19.
Similarly, one of our UK-based customers has shifted their project leads to work with Cambridge University to build an emergency COVID-19 testing laboratory. This temporary shift has also freed up laboratory research funds which our customer has now reallocated for other projects that could be done remotely in the meantime, including business consulting.
Another curious case of facing the heat and cold at once was seen in our customer who is a global leader in laboratory instruments, consumables, and software.
They cater to a range of laboratories from pharmaceutical and chemical to food and beverages and oil and natural gas. Because each of these sectors have reacted differently and by varying degrees to the pandemic, our customer is relooking at their portfolio and conducting weekly evaluations to ensure their teams are operational and sufficiently allocated.
One of their customers, a Dutch brewing company, is seeing extensive demand for beer and is looking to revitalize their manufacturing landscape with our customer’s scientific informatics tools to meet the demand. But another of their customers who comes from the oil and natural gas industry has pulled the plug on many agreed deals.
A positive mentality to change management can go a long way, neatly exemplified by an American life sciences company and a Swiss company we work with.
At the German site of the American company, production of medical devices and equipment is in full swing. Team members who are not a part of this are working from home and identifying SOPs/forms that have not yet been automated (paper-on-glass) and passing onto us for workflow or templates development.
Interestingly, they are doing this by creating detailed Visio diagrams of all laboratory SOPs and connecting them to arrive at the overall process flow of all their German laboratories. This has helped them in easier identification and tracking of automated and non-automated processes.
Scientists at the Swiss company are avoiding isolation blues by using their time to test and enhance the prepared automation workflows that they could not work on erstwhile. Our team recently experienced a surge of automation requests and enhancements with enthusiastic turnaround timelines.
**One pixel at a time**
An interesting fact: Netflix has [more than doubled](https://www.theguardian.com/media/2020/apr/21/netflix-new-subscribers-covid-19-lockdown) the number of new subscribers from February to April as more people were settling down to work, study, or holiday at home. Confined, people who did not need Netflix earlier were adopting digital entertainment as a solution to lift up their spirits.
We also saw how [work-from-home was driving digital ](/blogs/covid-19-strikes-would-cloud-services-boom-in-the-scientific-rnd-world/)adoption in terms of executing and exchanging contracts and records digitally.
Similarly, the need to work remotely and the restrictions on face-to-face contact have compelled physicians in charge of disrupted clinical trials to adopt more digital platforms – a move that industry observers thought would take years combined with immense persuasion and investments. Truly, necessity is the mother of all invention.
(For trial sponsors who are in the grey area regarding the general continuity of clinical trials. [We have come up with an FAQ ](/blogs/answered-most-burning-questions-on-clinical-trials-due-to-covid-19-2/) that deals with how disruptions in clinical trials can be handled according to industry guidelines.)
We recently designed a virtual trial simulation to study the challenges and possibilities in a decentralized digital clinical trial.
The research is a registry study running in South America with 50 subjects and 2 sites. The subjects come to the site once every month and provide data and also blood samples.
In the next stage, the pandemic affects this routine and subjects are not able to travel to the sites and the sites are also not able to focus on clinical trials due to other priorities. The study is due to get over in 3 months and they are thinking of closing down the study as the last option.
At this stage, Zifo evaluates options and comes up with a solution where the CRFs are built in ePRO that can be accessed via mobile phones. The data part is taken care of, but blood sample is a showstopper. Luckily, this study does not need a centralized lab and so we tie up with a lab vendor around the sites who could do home visits and collect blood samples.
However, we cannot rely on the subjects to enter data and there are issues with internet connection. So we configure the mobile app to enable offline data entry. We train the lab vendor to collect data in offline mode so that it will sync with the database once it latches on to an active connection.
For years, we have been championing the use of digital technologies including AI, ML, IoT, etc., to accelerate R&D processes, ensure compliance and reduce costs, and to see digital adoption gaining favour now is great news.
COVID-19 has surely opened Pandora’s box. We have seen both setbacks and leaps, blessings and curses in the scientific research industry. Being an important stakeholder in global R&D, we are adapting ourselves to this new normal. We are redefining our approach and methodologies to be flexible to support R&D organizations that are taking cautious, slow and steady steps as well as those that want to make full use of this situation to overhaul their processes and informatics landscapes.
(On that note, we are offering our services free of cost for COVID-19 programs and will ensure that these projects will be handled on the highest priority. You can read about this and contact us [here](/contact-us-today/).)
While these turbulent times are impacting different people and organizations differently, there is no doubt that together we will cross this period emerging stronger.
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
---
### [Natural Language Processing For Reliability In Business](https://zifo.com/blogs/natural-language-processing-for-reliability-in-business/)
**Published:** May 15, 2023
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [Natural Language Processing For Reliability In Business](https://zifo.com/blogs/natural-language-processing-for-reliability-in-business/ "Natural Language Processing For Reliability In Business")
## Natural Language Processing For Reliability In Business
Mohamed Ben Hamdoune
May 15, 2023
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Natural%20Language%20Processing%20For%20Reliability%20In%20Business%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Fnatural-language-processing-for-reliability-in-business%2F "Share on Email")
- [](https://x.com/intent/post?text=Natural%20Language%20Processing%20For%20Reliability%20In%20Business&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fnatural-language-processing-for-reliability-in-business%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Natural+Language+Processing+For+Reliability+In+Business&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fnatural-language-processing-for-reliability-in-business%2F "Share on LinkedIn")
Image reference: / source
In our last article, we saw applications concerning image data analysis, and in this one, we will discuss one other primary type of data – text. We will explore applications trying to understand how to treat human language – a domain called Natural Language Processing (NLP).
At Zifo, our experts work with different stakeholders on these challenges and to stay competitive, more companies will include NLP models in their solutions. We are here to enable you to stay at the forefront of innovative technologies that are coming out with AI. It is not only about being efficient but also how to be more reliable as our “data resource” is continually growing.
**HOW CAN NLP IMPACT YOUR BUSINESS ACTIVITIES?**
NLP models are suitable to help your business in many ways. One example is from a very topical COVID-19 situation: NLP usage to improve the patient’s life in hospitals by having a vocal assistant that can help with communications between patient and staff. We can add that the health sector has profound specificities (financial, regulatory, organisational), where the concepts of patients and practitioners replace those of consumers and employees are mostly in need of reliability, and it is also essential to consider the highly confidential nature of health data in that case. It is important to remember for your business that this notion of confidentiality depends on the geography.
Other area, R&D, by definition, is about innovation & speed to market, and this can be supported in part with NLP models applied to large databases. Indeed, we create text data every day, and models are used to identify unnoticed relationships between certain notions, and it is possible thanks to semantic analysis on large volumes of scientific publications.
Other sources of data are summaries of clinical trials or internal research papers, used to identify new biomarkers and phenotypes or to detect relationships of antibiotic resistance.
R&D-driven organisations producing a large mass of textual reports then following a particular terminology use NLP model with these documents to help lessen the time to market of a cure, which is why many laboratories reduce the drafting time, allowing experts to focus on the phase of conclusion and validation of reports.
Simply, whether there is an unstructured text document or structured, there is a path to explore using AI/ML to unearth future development opportunities, unseen relationships, and options to reduce waste by not “repeating the same mistake again”.
**LET’S ASK AN AI**
We asked a GPT-3 based model, what does it think by giving it only the title on this blog as a topic as a seed.
**Here is the answer – entirely derived by the model:**
*Knowledge and information are not the same thing, yet they are often confused. Knowledge is empirical data that can be proven to be true by observation or experimentation, whereas information is data that may or may not have been verified as true empirically. Information in many fields of study has no set standard for what counts as factually correct knowledge. The only way to prove something people believe is accurate according to this definition of knowledge would be through mutual agreement among a group of people who share the same observations and experiences about their environment.*
*In regards to Natural Language Processing, it is technology used in computing and Artificial Intelligence research that gives computer systems the ability to understand human speech. It allows computers to recognise spoken words as well as written text input from a user and then translate those words into machine-readable data.*
*In the field of artificial intelligence, Natural Language Processing is an important part of developing systems that can mimic human thought processes and reasoning. For example, IBM’s Watson system uses natural language processing to understand natural conversational speech as it analyses massive amounts of data from many sources simultaneously. It then produces a potential answer for a question by using statistical analysis on its information.*
*In business, Natural Language Processing is used in customer service call centers for processing and answering questions from customers. For example, if a customer calls the tech support number of their internet or cable provider to ask when they can expect to have services back up and running following an outage, the computer system will be able to understand what the customer is asking for.*
*In this way, Natural Language Processing can be used in many different fields of business and technology. It is a useful tool when dealing with large amounts of data that need to be processed quickly and efficiently.*
*In closing, I hope this response was helpful to you. Thank you for the opportunity to participate in this project.*
I am sure you will agree – quite impressive!
It is the original without any changes, to know more, read [Philosopher AI – Natural Language Processing for reliability in your business](https://philosopherai.com/philosopher/natural-language-processing-for-reliability-in-you-f07bd4)
To find out more about how Zifo can help with AI, ML, Deep Learning, and scientific Data Sciences, please email us at
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
**Categories:** Data Science and Consulting Services
---
### [Webinar - Data Integrity Remediation: It Is NOT A One-Time Activity!](https://zifo.com/blogs/data-integrity-remediation-it-is-not-a-one-time-activity/)
**Published:** May 15, 2023
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [Webinar – Data Integrity Remediation: It Is NOT A One-Time Activity!](https://zifo.com/blogs/data-integrity-remediation-it-is-not-a-one-time-activity/ "Webinar – Data Integrity Remediation: It Is NOT A One-Time Activity!")
## Webinar – Data Integrity Remediation: It Is NOT A One-Time Activity!
info@zifo.com
May 15, 2023
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Webinar%20%26%238211%3B%20Data%20Integrity%20Remediation%3A%20It%20Is%20NOT%20A%20One-Time%20Activity%21%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Fdata-integrity-remediation-it-is-not-a-one-time-activity%2F "Share on Email")
- [](https://x.com/intent/post?text=Webinar%20–%20Data%20Integrity%20Remediation%3A%20It%20Is%20NOT%20A%20One-Time%20Activity!&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fdata-integrity-remediation-it-is-not-a-one-time-activity%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Webinar+%E2%80%93+Data+Integrity+Remediation%3A+It+Is+NOT+A+One-Time+Activity%21&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fdata-integrity-remediation-it-is-not-a-one-time-activity%2F "Share on LinkedIn")
Image reference: / source
With the release of Data Integrity guidelines from regulatory bodies across the globe, data integrity compliance received limelight across the industry since 2015. Looking at the trend of increase in warning letters on Data Integrity non-compliance, the industry jumped immediately into Remediation exercises to achieve compliance with the Data Integrity requirements.
Will one time exercise of Data Integrity Remediation be sufficient to demonstrate compliance?
Let us discuss in this webinar to see how Periodic Review, a critical step in Data Integrity Monitoring helps to achieve overall compliance. Join us on Oct 29, 2020 at 11 am EST. Click [here](https://kenx.org/register/?event=https://attendee.gotowebinar.com/register/5312908764963992843) to register!
**Checklist!**
We’ve put together a comprehensive Periodic Review checklist which would help in carrying out Periodic Review exercises successfully.
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
---
### [AI, ML, DL… How Does It Matter?](https://zifo.com/blogs/ai-ml-dl-how-does-it-matter-part-2-of-our-data-sciences-series/)
**Published:** May 15, 2023
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [AI, ML, DL… How Does It Matter?](https://zifo.com/blogs/ai-ml-dl-how-does-it-matter-part-2-of-our-data-sciences-series/ "AI, ML, DL… How Does It Matter?")
## AI, ML, DL… How Does It Matter?
Mohamed Ben Hamdoune
May 15, 2023
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20AI%2C%20ML%2C%20DL%E2%80%A6%20How%20Does%20It%20Matter%3F%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Fai-ml-dl-how-does-it-matter-part-2-of-our-data-sciences-series%2F "Share on Email")
- [](https://x.com/intent/post?text=AI%2C%20ML%2C%20DL…%20How%20Does%20It%20Matter%3F&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fai-ml-dl-how-does-it-matter-part-2-of-our-data-sciences-series%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=AI%2C+ML%2C+DL%E2%80%A6+How+Does+It+Matter%3F&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fai-ml-dl-how-does-it-matter-part-2-of-our-data-sciences-series%2F "Share on LinkedIn")
Image reference: / source
In our last article, we discussed practical delivery of Data Science by Zifo and clarified what Data Science is in our opinion. To give you a more precise idea of what you could achieve, we will now discuss different project types existing and that can be made successful by Artificial Intelligence.
As with any new area, buzzwords and opinions are abound. Is AI the same as ML, and what is Deep Learning? All are topics existing within the bucket of data science and are about exploitation of data?
We can describe the most common three terms as follows:
**Artificial Intelligence (AI)**
The idea of modern artificial intelligence appears to have originated in the 1950s when Alan Turing wondered if a machine can “think”. In the article “Computing Machinery and Intelligence”, Turing studies this dilemma and suggests conducting a test (now called the Turing test) seeking to find if a machine could become “mindful”.
**Machine Learning (ML)**
In the 1980s, machine learning was developed, notably with the renaissance of connectionism. The computer begins to deduce “rules to follow” by analysing only data. We can see machine learning as a field of study of artificial intelligence which is based on mathematical and statistical approaches to give computers the capacity to “learn” from data.
**Deep Learning (DL)**
In practical terms, deep learning is just a subset of machine learning, attempting to model with a high level of data abstraction. In other words, it will be learning how your data is composed, for example, in the context of cat images classification: shapes, textures, colours, poses and background. Deep learning models are composed of layers of neurons.
Artificial Intelligence captivates, challenges and perhaps even scares our society due to the extensive use of the term in sci-fi movies. It does, however, deliver benefits and is crucial in sectors such as healthcare, manufacturing, retail, transportation, health, energy, logistics and finance. During the 1980s and 90s, there were several false starts with companies promising AI and ML-based regression of data. A significant error was the assumption that with enough data, we can perform a regression to predict outside of what the data describes. This is a total fallacy.
For practical use of AI or ML in our science domains there needs to be an in-depth knowledge and understanding of the area of science or its application. Treating the problem or question purely as a mathematical problem will lead to incorrect and non-reproducible conclusions. Taking a straightforward example, you could take a litre of water and apply heat to it. As heat is added, you could measure the change in temperature from 20°C to 30°C then 40° C. A regression would then predict a linear increase in temperature as the heat increases, but we know that at 100°C the water boils. There is a discontinuity, and the temperature does not increase in the same way as the earlier temperatures.
Whilst this is a crude and straightforward example, it is an excellent example of applying machine learning without having enough data – a flawed model – which makes extrapolation dangerous. This learning is applicable across our more complex domains and illustrates why we need a highly skilled team to make sense of data. The latest innovations are showing there are practical solutions and business-driven reasons to apply these data science techniques. A significant bottleneck now is the number of people who have the range of skills which are necessary. Zifo’s mission today is to provide scalable data science services to meet the needs of our global customers and help them to exploit their “renewable data”.
So – we see that data science is the marriage of different skills. Without the right balance of skills and knowledge, we can reach incorrect decisions and inferences, which we refer as the “Danger Zone“. Zifo’s advantage is that we have been working in the scientific domain for over ten years so have a depth of knowledge in our company to help avoid the “Danger Zone”.
**DATA SCIENCE IS ABOUT RESOLVING PROBLEMS AND ANSWERING QUESTIONS – IT’S NOT ABOUT TECHNOLOGY**
Data Science is a combination of disciplines, and without all elements, there are risks.
The three circles represent what is required when we want to work correctly and succeed in data science. It is not only about having skills in mathematics and computer science but also the knowledge on the subject you want to resolve – domain expertise.
The applications of Data Science are endless. However, three concrete objectives are commonly expected from Data Science.
The first application is to achieve robotic process automation. It is the most advanced automation technique, and which allows, for example, reading and analysing of contract and legal documents to extract possible constraints or anomalies. Robotic Process Automation (RPA) is the most comfortable and cheapest form of AI to set up.
The second most common and well-known form is the analysis of information and the extraction of value from a large volume of data (Big Data) for descriptive or predictive purposes. Data analysis can be done, for example, to identify possible frauds in banking or insurance systems or health systems. The most developed techniques of Machine Learning, known as Deep Learning, make it possible to perform functions such as voice or image recognition (Computer Vision projects) or even Natural Language Processing (NLP).
The third form is to engage the end-user (employee or customer) in the process of interacting with the machine to gather information or provide a service. An example would be building intelligent chatbots.
In summary, the implementation of data science projects faces many obstacles; organisational, financial, technological, and strategic – but with a right, experienced and innovative partner these hurdles can be managed and their impact minimised. In the next article, we will explain how a data science team can be efficiently put in place and how it works in a company.
To find out more about how Zifo can help with AI, ML, Deep Learning and scientific Data Sciences, please email us at
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
---
### [Global Data Integrity Guidelines](https://zifo.com/blogs/global-data-integrity-guidelines/)
**Published:** May 16, 2023
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [Global Data Integrity Guidelines](https://zifo.com/blogs/global-data-integrity-guidelines/ "Global Data Integrity Guidelines")
## Global Data Integrity Guidelines
Loganathan Kumarasamy
May 16, 2023
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Global%20Data%20Integrity%20Guidelines%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Fglobal-data-integrity-guidelines%2F "Share on Email")
- [](https://x.com/intent/post?text=Global%20Data%20Integrity%20Guidelines&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fglobal-data-integrity-guidelines%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Global+Data+Integrity+Guidelines&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fglobal-data-integrity-guidelines%2F "Share on LinkedIn")
Image reference: / source
Complying with different regulatory agency guidelines for data integrity can be tricky, given the nuances of each agency in terms of its focus and expectations. Let’s take a quick look at where the three major global regulatory agencies stand with respect to their data integrity guidelines:
**US FDA:**
The FDA has focused exclusively on the GMP process and has placed special emphasis on the importance of validating individual workflows as opposed to validating just the core product. For example, validating the Manufacturing Execution System (MES) alone is not enough; the individual workflows utilized must be validated as well.
The pharmaceutical industry is fast adopting paperless labs using technology such as Electronic Lab Notebooks (ELN) for batch records, production and control records. The FDA data integrity framework mandates that the individual workflows created within these systems (e.g.: ELNs) are also validated to ensure that they fulfil the intended purpose. This is a gap area that we have also noticed in our Data Integrity Assessments of various labs.
The FDA’s guidelines are published in an easy-to-understand Q&A format, and primarily focus on:
1. Audit Trail and Reviews
2. Security and Restricted Access to Data
3. Paper Records and Electronic Records Storage and Retrieval
**EU EMA:**
Like the FDA, the EMA has also focused on the GMP industry, but has approached it from a risk-based methodology – to foresee risks, analyse them and take measures to avoid them. It is important that we do not confuse this with system or functional risk assessment; it is rather a data risk assessment for reducing the risk and leveraging the available risk based methodologies to ensure data integrity. The EMA data integrity framework mandates the validation of third-party products, services and service providers. For example, calibration devices / services and their providers also need to be reviewed and qualified to achieve data integrity compliance with the EMA.
The EMA’s guidelines primarily focus on:
1. Assessing Data Risks and Data Criticality
2. Review of Data Life Cycle
3. Risk-based Decisions for Review of Data
**UK MHRA:**
The MHRA’s data integrity guidelines are more comprehensive and holistic, and focus on the complete spectrum of the GxP industry – in fact, the FDA and EMA guidelines can be seen as a subset of the MHRA guidelines. Interestingly, the MHRA has included a special focus on hybrid approaches, wherein the process includes both paper-based and paperless methods of data management. This has been a welcome move to the pharmaceutical industry which is transitioning to paperless labs, and is increasingly working on hybrid models in the process.
The MHRA’s guidelines primarily focus on:
1. Data Risks, Lifecycle and Review
2. Electronic Signatures
3. Audit Trail and Reviews
4. Security and Restricted Access to Data
Validation of Systems Deployed in the GxP Space
Understanding the different guidelines and translating those to ground-level checklists is a difficult but critical task. One of the pharma companies from the US, selling their products in EU and UK was discussing with us on how to take this forward and perform a Data integrity assessment.
Interestingly, we had to take the best of all to accommodate global compliance and we call it “[Global Data Integrity Checklist](https://cdn.zifo.com/2026/01/Periodic-Review-Checklist-1.pdf)“. Have a look at our [easy-to-use checklist](https://cdn.zifo.com/2026/01/Periodic-Review-Checklist-1.pdf) and address the Data Integrity gaps in your firm today!
Have any thoughts or questions on this? Please email us at !
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
---
### [How Personal Data Can Be Processed During A Pandemic](https://zifo.com/blogs/how-personal-data-can-be-processed-during-a-pandemic/)
**Published:** May 16, 2023
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [How Personal Data Can Be Processed During A Pandemic](https://zifo.com/blogs/how-personal-data-can-be-processed-during-a-pandemic/ "How Personal Data Can Be Processed During A Pandemic")
## How Personal Data Can Be Processed During A Pandemic
Aishwarya Lakshmi Narasimhan
May 16, 2023
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20How%20Personal%20Data%20Can%20Be%20Processed%20During%20A%20Pandemic%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Fhow-personal-data-can-be-processed-during-a-pandemic%2F "Share on Email")
- [](https://x.com/intent/post?text=How%20Personal%20Data%20Can%20Be%20Processed%20During%20A%20Pandemic&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fhow-personal-data-can-be-processed-during-a-pandemic%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=How+Personal+Data+Can+Be+Processed+During+A+Pandemic&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fhow-personal-data-can-be-processed-during-a-pandemic%2F "Share on LinkedIn")
Image reference: / source
It’s always in the news. It’s trending on social media. Above all, it has sent half of humanity back home and sealed the doors. Yes, it’s the nCOVID-19 virus. It has been spreading fear ever since it started travelling across continents. The world is slowly coming to a standstill and we still don’t have the complete picture in the context of dealing with this.
With the current situation, we can see an exponential growth in the number of cases where it is essential for public and private organisations to process a huge amount of personal data, without an individual’s consent.
During this time, we are faced with a pressing question:
**Which do you think should take priority?**
Protection of pandemic victim’s identity to safeguard their dignity
**or**
Identifying the potential victims who might have faced exposure, by processing the pandemic victim’s personal data
European Data Protection Board (EDPB) clarifies that no ordinance will be an obstacle to the medical mitigation during a pandemic.
They adopted a policy on 19 Mar 2020 easing the data protection burden amidst the battle against the COVID-19 pandemic, while the data processor and controller must continue to ensure the protection of personal data of data subjects, the victim.
**Let’s walk through highlights of the policy:**
**Health officials**
- GDPR is a broad legislation which takes care of epidemic situation, which gives the liberty to the public health authorities to process personal data without relying on the consent of individuals in accordance to the nation law and rules applicable to them.
- In addition to GDPR, ePrivacy Directive must be followed when electronic data such as location are to be processed. Under the provisions of this Directive, the Member States can introduce emergency legislative measures to safeguard public security under the criteria it’s a necessary, appropriate and proportionate measure within a democratic society.
- Under this directive and GDPR, the public authorities should first attempt to process the electronic data by anonymous means. For instance, mobile phone towers can be used to trace the distribution of mobile devices such that whenever crowding takes place, the officials are alerted based on this information. This way, the information is processed anonymously. As this is anonymized data, data protection rules do not apply.
- In case, when processing of anonymized data is not adequate, under ePrivacy Directive, Member States are mandated to put in place adequate safeguard measures (right to judicial remedy) as a part of the emergency legislation before processing non-anonymized electronic communication data, for instance, emails, messenger data etc., is processed.
- Invasive measures of “tracking” of individuals could be taken in proportion to the risk and need where an exceptional case can be considered.
- Any measures adopted in the event of emergency must be documented appropriately
- These emergency legislative measures will become obsolete after the pandemic event subsides as controllable.
**Employers**
In a workplace when any individual is infected, the employers could proceed to analyse and evaluate the personal data of the affected employees, without compromising on the privacy of an individual’s personal data. So here,
- The overall idea is that competent employers, who can ensure data integrity at all levels of processing, can process the special categories of data like health data of the employees without individual’s consent for the obligations of safety of the workplace and control of spread of the disease.
- While the personal data processing without prior consent is allowed, it’s the responsibility of the data processor to ensure that it does not reach any unauthorized parties.
- The personal data must be processed for specific and explicit objectives. If the data subjects, employees in this case, demand to know the details of processing activities, they should receive clear and accessible information on the activities in plain language on demand.
- The employer should weigh the risk against need and ensure minimal data is obtained, particularly when collecting health information in the context of COVID-19.
- The employer can perform medical check-ups on their employees only under the legal obligations of the nation.
- An employer must inform the staff about the COVID-19 cases and can reveal their name and no more information than what is deemed necessary.
In a nutshell, if we need to process personal data to aid in mitigation, we can do so without compromising on an individual’s dignity. This is intended to help the direct and indirect touch-point organisations who need to be compliant yet execute a swift mitigation plan.
To find out more about how Zifo can help please email us at
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
---
### [Gxp Saas Vendors](https://zifo.com/blogs/gxp-saas-vendors/)
**Published:** April 25, 2022
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [Gxp Saas Vendors](https://zifo.com/blogs/gxp-saas-vendors/ "Gxp Saas Vendors")
## Gxp Saas Vendors
Vivekram Apparsundaram
Apr 25, 2022
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Gxp%20%20Saas%20Vendors%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Fgxp-saas-vendors%2F "Share on Email")
- [](https://x.com/intent/post?text=Gxp%20%20Saas%20Vendors&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fgxp-saas-vendors%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Gxp++Saas+Vendors&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fgxp-saas-vendors%2F "Share on LinkedIn")
Image reference: / source
**INTRO**
With cloud-based solutions dominating global workspaces, we now have a myriad of SaaS vendors taking interest in the Scientific R&D IT space. The promise of accessibility, scalability and simplicity over something as common as a stable internet connection has been a great driving force in the shift towards the cloud.
Among the many pieces of the jigsaw puzzle that SaaS Application validation is, responsibility is one chunk. Is it the user’s responsibility to validate the solution? Or should the vendor take up that task?
In reality, the answer is almost never a binary and falls in the middle ground.
**SaaS VENDORS RESPONSIBLITIES**
**Extent of qualification.** The vendor should perform an Installation Qualification (IQ) and an Operational Qualification (OQ) and these documents must be shared with the user. Based on the coverage of testing and a suitable package, the user would be able to understand the extent of the qualification already performed.
**Audit-ready.** The procedures followed, along with the evidence must be made available for an audit. Specifically, the software development life cycle, change control process for upgrades, and cases, where there might be the automated deployment of configurations in the cloud, should be presented for a customer audit.
**Customizations.**
SaaS products are like ice cream cones. Each user might want custom-built add-ons and integrations to suit their taste or, in all probability, their purpose. These could be API extensions or any suitable solution offered by the vendor. Do you think these should be qualified by the vendor or the user?
**Provision of multiple instances for end-user.**
To support the end user’s validation and exclusive cloud environment needs for any customizations or configurational changes, the vendor must provide separate development, validation and production instances.
**Performance Testing.**
The vendor would see how the application performs on the cloud in terms of how quickly it can be accessed, used and queried. A combination of timed and automated tests is usually done for this, to verify the performance of the application.
**Security!**
Among the many apprehensions of an end-user, cloud security is one of the biggest. A solution that comes with a security feature will be preferred over one that does not. Providing visibility in terms of stats, metrics and insights into the services used would be of great help for an end-user. For instance, AWS Security Hub is a collection of CloudTrail (a compliance-governing service), CloudWatch (a performance monitoring tool), Firewall Manager, etc. This way, Security Hub monitors and manages the overall cloud security aspects.
Based on a couple of recent consulting exercises, our cloud qualification and validation team assessed the above key aspects and interestingly, in several discussions, the end-users were happy ticking away these parameters until it came to one more KEY aspect.
While evaluating to purchase a suitable cloud-based solution, is it enough if a vendor checks all the above boxes? Can a simple checklist decide whether you are going to go all-in?
Absolutely Not!
**END USER RESPONSIBLITIES**
**Validation!**
Despite a qualification exercise performed by the vendor, the product must be verified for its intended use. From drafting User Requirements, and Validation Planning to closing out a Validation Summary Report, with documented qualification for the end-user configurations and a re-assuring traceability matrix, the end-user needs to validate the cloud-based solution.
The healthcare space has been a vast field with regulations laying down impermeable boundaries. With remarkable innovations changing global businesses, responsible use of systems may also require adopting an innovative strategy, without compromising on regulatory standards.
To find out more about how Zifo can help with SaaS and on-premise informatics systems and hardware validation, please email us directly at
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
---
### [Validation Of Cloud-Based Solutions](https://zifo.com/blogs/validation-of-cloud-based-solutions/)
**Published:** May 16, 2023
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [Validation Of Cloud-Based Solutions](https://zifo.com/blogs/validation-of-cloud-based-solutions/ "Validation Of Cloud-Based Solutions")
## Validation Of Cloud-Based Solutions
Harini Raghavan
May 16, 2023
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Validation%20Of%20Cloud-Based%20Solutions%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Fvalidation-of-cloud-based-solutions%2F "Share on Email")
- [](https://x.com/intent/post?text=Validation%20Of%20Cloud-Based%20Solutions&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fvalidation-of-cloud-based-solutions%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Validation+Of+Cloud-Based+Solutions&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fvalidation-of-cloud-based-solutions%2F "Share on LinkedIn")
Image reference: / source
E-mails. Sensitive patient data. Dense droplets of water.
What’s common between them, you ask? At first glance, absolutely nothing. But let me break it down for you. E-mails are stored in the servers of your e-mail service vendor, which is in turn hosted on the cloud. Patient information, when added to a health app, is stored in the servers of the application developer, which is stored in the cloud. Dense droplets of water are stored in the cloud. Okay maybe not the same cloud, but what about the first two?
With a [surge in cloud-based services across global businesses](/blogs/covid-19-strikes-would-cloud-services-boom-in-the-scientific-rnd-world/), it’s already a tad late to take notice. Cloud computing offers easy deployment, unlimited scope for scalability, high speed and affordable pricing. Either through e-mail solutions or personal device storage, you might have already marked your footprint on the cloud.
Let’s zoom into the picture and take a long look at healthcare. With regulations laying tough boundaries, migrating to the cloud might seem like a difficult task. This is what we’re trying to break down in the upcoming sections.
**What’s common**
Current industry practices that follow the waterfall model for SDLC essentially talk about three aspects to qualify for validating a system: the infrastructure (IQ), the system as a whole (OQ), and the system for its intended use (PQ). We adopt a similar approach for validation cloud-based solutions.
**What’s different**
The structure of a cloud-based product is slightly different from that of an on-premise software. Unlike the latter, these products are hosted on a cloud infrastructure which varies for each use-case. Qualifying this is the most influential aspect of qualifying a service hosted on the cloud. The following sections talk about the key features to look out for in a cloud infrastructure setup.
**Security**
The most vital concern! Ensuring that sufficient physical and virtual security measures like firewalls, back-up storage, anti-virus software and encryption are in place is necessary for qualification. While doing so, cross-check whether the settings are in tandem with data privacy and security regulations applicable for the particular demography and sector. If the cloud vendor has certifications and audit results that suggest compliance with the above-mentioned regulations, put a big tick-mark for security as these display a high level of data security practices followed by the vendor.
**Back-up, storage & retrieval**
Suitable data back-up procedures should be documented by the vendor. Additionally, proper storage of data and ease of retrieval must also be achieved.
**Reliability**
Ideally, the end-user must ensure that the system deployed in their environment is compliant with applicable regulations and guidelines. However, some vendors ensure GxP compatibility in their solutions. Ensure that you give their white papers a read! This would tell you the extent of validation that is achieved by the system, with which you can gauge the scope of validation that is necessary from your end.
Remember ‘CIA’ – to comply, not to spy. Evaluate whether the vendor exhibits Confidentiality, Integrity and Availability in their processes. In case of third-party services being added on, ensure that appropriate SLAs (Service Level Agreements) are laid down.
Remember ‘CIA’ – to comply, not to spy. Evaluate whether the vendor exhibits Confidentiality, Integrity and Availability in their processes. In case of third-party services being added on, ensure that appropriate SLAs (Service Level Agreements) are laid down.
The utopian model of validating a system might seem far-fetched, but with certain tools we can get closer to it.
We’ve put together a [checklist](https://cdn.zifo.com/2026/01/Cloud-Vendor-Assessment-Checklist-1.pdf) you can use to help in assessing a cloud-based product for your business. If you’d like any assistance on this matter, clicking any of the buttons on this page would get us one step closer to you. If not, [download our curated checklist](https://cdn.zifo.com/2026/01/Cloud-Vendor-Assessment-Checklist-1.pdf) and tick away!
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
---
### [Single Cell Sequencing](https://zifo.com/blogs/atlas-rise-cell-biology/)
**Published:** September 5, 2022
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [Single Cell Sequencing](https://zifo.com/blogs/atlas-rise-cell-biology/ "Single Cell Sequencing")
## Single Cell Sequencing
James Ashmore
Sep 05, 2022
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Single%20Cell%20Sequencing%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Fatlas-rise-cell-biology%2F "Share on Email")
- [](https://x.com/intent/post?text=Single%20Cell%20Sequencing&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fatlas-rise-cell-biology%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Single+Cell+Sequencing&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fatlas-rise-cell-biology%2F "Share on LinkedIn")
Image reference: / source
**MAPPING CONTINENTS AND CELLS**
This week I was thinking about how maps were drawn in the ancient world. If I were given the challenge of drawing a map of my local area without using today’s technology, how would I do it? Would I walk around sketching my surroundings with a pencil and paper? Would I try to be clever and use a standard length of string to measure the distance between features on my street? This question led me to reading about the long and fascinating history of cartography – the art and science of graphically representing a geographical area, usually on a flat surface such as a map or chart.
It’s hard to overstate how effective maps are at displaying complex information in a simple way. They allow us to comprehend the shapes and sizes of areas, the location of features, and the distances between places. It comes as no surprise then that life science researchers have seized upon the idea and started making maps of their own. However, these maps don’t describe geographical areas, instead, they illustrate the cellular landscape of tissues from a single organism. These maps are probably better described as atlases, given they aim to describe the entire organism akin to the earth’s globe.
Quickly going back to the question at the beginning, how did the ancient world create maps? It turns out a mathematical method called triangulation allowed them to precisely determine the location of a point using an array of different tools. In fact, this method is still widely used today, albeit with the help of more advanced technology like satellites. So, what about these maps life science researchers are producing? What tools and methods do they use? The advent of single-cell gene expression technology allowed researchers to isolate and record the gene expression profile of millions of individual cells. Using machine learning algorithms, cells can be placed on a so-called map based on the similarity of their expression profiles. Once drawn, biologists and other domain experts can annotate and curate the atlas to produce a highly informative visualization of the cellular landscape of an organism.
**SO HOW DO MAPS HELP IN BIOLOGY?**
So, what sorts of questions can we answer with an expression atlas? Really, the number of questions is only limited by two things: the ingenuity of the researcher and the quality of the data. Usually, we are interested in cataloguing all the different types of cells, measuring what genes are uniquely expressed in one cell type but not the other, modelling the developmental relationship between cells, and identifying what genes or cells are disrupted by a given disease state. A fantastic example of the insights which can be achieved with this technology comes from the Human Cell Atlas project, a herculean effort to chart the cell types in the healthy body across time from development to adulthood and eventually to old age. See below for an example of an expression atlas taken from the project website.
If you’re interested in creating an expression atlas for a tissue or disease state you’re studying, get in touch with us by email at and we can discuss the design and implementation.
James Ashmore
Lead Bioinformatician (Europe)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
---
### [Practical Delivery Of Data Science](https://zifo.com/blogs/practical-delivery-of-data-science/)
**Published:** May 15, 2023
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [Practical Delivery Of Data Science](https://zifo.com/blogs/practical-delivery-of-data-science/ "Practical Delivery Of Data Science")
## Practical Delivery Of Data Science
Mohamed Ben Hamdoune
May 15, 2023
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Practical%20Delivery%20Of%20Data%20Science%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Fpractical-delivery-of-data-science%2F "Share on Email")
- [](https://x.com/intent/post?text=Practical%20Delivery%20Of%20Data%20Science&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fpractical-delivery-of-data-science%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Practical+Delivery+Of+Data+Science&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fpractical-delivery-of-data-science%2F "Share on LinkedIn")
Image reference: / source
Our world is full of data, but how do we extract value from it? The challenge today is not how to capture data – but how to harness that data to generate business value. How can we use our data to support innovation, stimulate discovery and accelerate delivery – the answer is Data Science.
Data Science is two things – it is about developing and expanding the skills required to gain value from data. But it is also a cross-discipline team approach which combines a deep understanding of the field of application (scientific domain) as well as the technical skills of data management and in-depth knowledge of data analysis. Despite this relatively simple description, the current challenge remains to bring together these multi-functional “data science teams” fast enough and with enough capacity to meet the demands and solve the constant flow of scientific business questions and challenges.
Zifo’s approach to all things, including data sciences, starts with acquiring an in-depth knowledge of research-led industries and a focusing on their science. Our people are scientists – biologists, chemists, process engineers – who work with leading research organisations across many verticals around the globe. We are now focusing specifically to bring together these technical experts to deliver Data Science services to our clients globally. We are developing our understanding and applications at an exponential rate and possess the abilities to adjust, execute, and fulfil business requirements of our customers more effectively.
In this first article and the series to follow, we will explore all things Data Science to give you a background and some ideas for the path forward; we will discuss what we can deliver today and how that can help your business. This first article sets out our vision and capabilities to delivery Data Science to our customers.
**A SCIENTIFIC DATA SERVICES LANDSCAPE VISION**
To remain competitive, we always require more robust and more effective solutions which manage the data, to facilitate and accelerate scientific discoveries as well as promote other benefits such as reduced costs. It is within a context of new analysis techniques and methods which are opening new fields of research. Within Zifo, we embrace a culture of curiosity and innovation which drives us to take up the challenge to work with our customers to explore these new opportunities.
“Data is the New Oil” is a commonly stated phrase. Perhaps we should re-phrase this as “**Data is the new Renewable Energy**” as the allusion to fossil fuels could mean data is finite, while data is constantly evolving and renewing. There is an overwhelming growth of public and private data being constantly developed in both quantity and quality. Our industry is more frequently emerging onto many more journeys with Artificial Intelligence (AI) and Machine Learning (ML). We help our customers by allowing them to use established algorithmic methods already used globally to solve similar problems.
Whilst both concepts – AI and ML have been discussed for decades; it is the rapid expansion of available data. Together with advances in computing power and data storage which mean we can now realise innovation in real-world scientific challenges. Zifo’s history of embracing new technologies, understanding, and managing scientific data together with our scientific knowledge means we are well prepared to meet the needs of our customers across the scientific spectrum in Pharma, Oil and Gas, Food, and Chemicals.
Within the pharmaceutical, biotech and chemical industries, we have many sources of data: some internal and some external. With outsourcing, partner networks, and a continually moving landscape as compounds and companies are purchased and divested, the sources of data become fluid and interconnected. Zifo comes with a strong knowledge in many of these areas, having delivered services and solutions for over ten years in this market.
The challenge for companies now is not only to **make effective use of data** but to **make this capability scalable**. To realise the full potential, Data Science needs to be applied consistently across the enterprise. It is not sustainable to have a Data Science strategy based on a small group of superheroes. While this will prove concepts, it fails to realise the potential and deliver continued value. The management, operation, and governance requirements all need to be considered from the beginning. There is also a further challenge in the form of change management. How to demonstrate success and engage our organisations, so everyone embraces the opportunities that Data Science offers?
Most companies in research-led sectors are investing in the delivery of data-driven strategies. They are embarking on a marathon of Data Science and Artificial Intelligence projects, hoping to gain the benefits of new technologies and data. Zifo’s experience helps companies identify successful Data Science initiatives, including AI and ML, to assist in the change management process to ensure effective and scalable deployment.
In summary, we discussed our vision of Data Science and our capabilities to deliver AI/ML for your business. In the next article, we will provide an in-depth look at machine learning and deep learning and how you can incorporate these methods into your projects.
To find out more about how Zifo can help with AI, ML, Deep Learning and scientific Data Sciences, please email us at
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
---
### [Deciphering Audit Trail Review](https://zifo.com/blogs/deciphering-audit-trail-review/)
**Published:** May 15, 2023
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [Deciphering Audit Trail Review](https://zifo.com/blogs/deciphering-audit-trail-review/ "Deciphering Audit Trail Review")
## Deciphering Audit Trail Review
Poorani Karunanidhi
May 15, 2023
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Deciphering%20Audit%20Trail%20Review%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Fdeciphering-audit-trail-review%2F "Share on Email")
- [](https://x.com/intent/post?text=Deciphering%20Audit%20Trail%20Review&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fdeciphering-audit-trail-review%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Deciphering+Audit+Trail+Review&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fdeciphering-audit-trail-review%2F "Share on LinkedIn")
Image reference: / source
Although software providers are demonstrating efforts to comply with data integrity requirements, reviewing audit trails as part of routine monitoring is still the responsibility of the organization using the software.
Deciding what to look out for during an audit trail depends on many factors such as GxP applicability, data criticality, system complexity and control mechanisms.
Are you confused whether your organization is doing too much or too little audit trail review? Click [here](https://cdn.zifo.com/2026/01/Audit-Trail-Review-Checklist.pdf) to download our free checklist that can help you find the right balance.
For any questions, please contact
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
---
### [Cloud Infrastructure Qualification](https://zifo.com/blogs/cloud-infrastructure-qualification/)
**Published:** May 15, 2023
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [Cloud Infrastructure Qualification](https://zifo.com/blogs/cloud-infrastructure-qualification/ "Cloud Infrastructure Qualification")
## Cloud Infrastructure Qualification
Radhika Govindarajan
May 15, 2023
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Cloud%20Infrastructure%20Qualification%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Fcloud-infrastructure-qualification%2F "Share on Email")
- [](https://x.com/intent/post?text=Cloud%20Infrastructure%20Qualification&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fcloud-infrastructure-qualification%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Cloud+Infrastructure+Qualification&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fcloud-infrastructure-qualification%2F "Share on LinkedIn")
Image reference: / source
Life science industries generally face several challenges in adopting to the technological advances considering the regulatory impacts and tedious processes involved. But with the alluring benefits provided by cloud based solutions and the need to globalize R&D, moving to cloud has become the “New Normal”. Though adoption of cloud, means the vendor would qualify, maintain and administer the services, it does not spare the end user from their ultimate responsibility to ensure that the applications in cloud are validated and comply with the regulations, in which in turn is complete only with the qualification of underlying infrastructure.
Wondering how to formulate an approach to qualify cloud infrastructure? Here it is:
**Vendor Assessment:**
A thorough selection process and ongoing oversight about the following is required to determine the supplier quality and reliability and there by the extent of qualification:
- Their capability to deliver the service as per your requirements
- The level of compliance with different regulatory requirements and standards to be followed
- Presence of quality management system and procedural controls to ensure confidentiality, integrity and availability
**Determine Qualification Scope and Infrastructure Layer**
- List down all the infrastructure components
- Identify those having an impact on current industry’s regulations and business operations at your organization and this will serve as the major input to the risk assessment process
- Each infrastructure component identified in scope for qualification can be categorized based on the GAMP 5 Categorization of Hardware and Software and also into subsequent infrastructure layers depending on the function or service they provide.
- The Qualification activities to be performed will differ for each such layer.
**Perform Risk Assessment**
- On determining the scope, a documented risk assessment must be conducted, to identify the possible risks associated with each infrastructure component, likelihood of its occurrence and its impact to business
- Any possible threats to data privacy and data security must be considered and evaluated
Qualification activities must be tightly controlled in such a way to minimize those risks
Let us consider a server for instance, the results of risk assessment would be as follows:
**Qualification Deliverables**
The qualification deliverables required in general include the following:
- Risk Assessment Report
- Qualification Plan
- Design Specification
- Qualification Protocol
- Qualification Summary Results
**Plan Qualification Activities and level of qualification**
Considering the components in scope, layer to which they belong to, the results of the risk assessment and reliability of the supplier, a qualification plan must be formulated detailing the level of qualification required followed by the creation of qualification deliverables.
**Infrastructure Layers**
*Here is a comprehensive checklist listing down the points to be verified when qualifying cloud infrastructure, and qualify any solution of your choice with it!*
*Confused about which deliverable is applicable for which infrastructure layer, who should take responsibility for which activities? Don’t worry, we’ve got it covered for you!*
Take a quick glance at these helpers-
[Deliverables Matrix for Infrastructure Layers](https://cdn.zifo.com/2026/01/Deliverable-Matrix-for-each-Infrastructure-Layer.pdf)
[RACI Matrix for Qualification Activities and Deliverables](https://cdn.zifo.com/2026/01/RACI-Matrix-for-Deliverables.pdf)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
---
### [Automated Clinical Trial Safety Reporting Systems](https://zifo.com/blogs/automated-safety-reporting-system/)
**Published:** May 17, 2023
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [Automated Clinical Trial Safety Reporting Systems](https://zifo.com/blogs/automated-safety-reporting-system/ "Automated Clinical Trial Safety Reporting Systems")
## Automated Clinical Trial Safety Reporting Systems
Srija Sridhar
May 17, 2023
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Automated%20Clinical%20Trial%20Safety%20Reporting%20Systems%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Fautomated-safety-reporting-system%2F "Share on Email")
- [](https://x.com/intent/post?text=Automated%20Clinical%20Trial%20Safety%20Reporting%20Systems&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fautomated-safety-reporting-system%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Automated+Clinical+Trial+Safety+Reporting+Systems&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fautomated-safety-reporting-system%2F "Share on LinkedIn")
Image reference: / source
In Clinical trials, objectives, outcomes, evaluation, sponsors, efficacy, endpoints, analysis, etc., – all these matters. But you know what, SAFETY takes the front seat.
**Webisode 1 of Bots automate Clinical Data Management**
Safety events reporting and monitoring is always considered meticulous in every clinical trial as well in epidemiology studies. There are a bunch of regulatory-specific guidelines put forth by the controllers such as FDA, DCGI, EMA, PMDA, TGA, CDSCO etc.
Regulations toward safety reporting are rigid and deviations from it come with very less tolerance. This always remains a headache for the pharma companies conducting clinical trials. Usually a large investment of time and effort is made in reporting and filing the reports to regulators.
Data to these safety events eventually come from the sites conducting the clinical trials. When we refer to site, it usually denotes the physicians / investigators treating the subject in the clinical trial who are involved in the critical task of reporting.
Subject safety is an untold primary objective and this makes serious adverse event reporting even more critical in the progress of clinical trials. SAE/AESI also demands the timely reporting and follow-ups as defined in the study protocol. Given all these constraints, one need not depend extensively on human intervention. This provides scope for automation.
Though automation might complicate the process if not developed user friendly, we chose to take the brave step of automating the SAE Reporting. With the checks and balances, risks and criticality assessment, we were able to arrive at a hybrid solution which will accelerate the reporting process.
**Key features of the system:**
**Overview of the process:**
**Interfaces**:
**Electronic data capture (EDC)**
Electronic Data Capture involves the system where the study is configured as per the protocol. All the eCRFs including the safety forms (Adverse Events, Serious Adverse Events, Adverse Events of Special Interest), Medical history and medications data are captured and will reside in EDC.
**Automated reporting solution**
Custom application developed to support the automated reporting of safety events to Pharmacovigilance team (PV).
**Mailbox**
Mailbox of the PV, investigators and monitors, used for receiving the safety reports generated by the automated reporting solution.
**Process Flow:**
Let us know your take on handling SAE Reporting. Drop your thoughts / questions on this to us at
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
---
### [Advantages Of Using A LIMS Managed Services Provider](https://zifo.com/blogs/advantages-of-using-a-lims-managed-services-provider/)
**Published:** February 21, 2024
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [Advantages Of Using A LIMS Managed Services Provider](https://zifo.com/blogs/advantages-of-using-a-lims-managed-services-provider/ "Advantages Of Using A LIMS Managed Services Provider")
## Advantages Of Using A LIMS Managed Services Provider
Hannah Laidly
Feb 21, 2024
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Advantages%20Of%20Using%20A%20LIMS%20Managed%20Services%20Provider%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Fadvantages-of-using-a-lims-managed-services-provider%2F "Share on Email")
- [](https://x.com/intent/post?text=Advantages%20Of%20Using%20A%20LIMS%20Managed%20Services%20Provider&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fadvantages-of-using-a-lims-managed-services-provider%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Advantages+Of+Using+A+LIMS+Managed+Services+Provider&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fadvantages-of-using-a-lims-managed-services-provider%2F "Share on LinkedIn")
Image reference: / source
**Introduction**
In the dynamic landscape of laboratories, efficiency, accuracy, and compliance are paramount. Laboratory Information Management Systems (LIMS) play a crucial role in streamlining processes, but managing these systems can be a complex task. This is where LIMS managed services step in, offering a range of benefits to ensure seamless operations.
LIMS serve as the backbone of modern laboratories, managing testing data, samples, and workflows. However, the maintenance of LIMS requires specialized knowledge and resources. A good LIMS resource has knowledge of the application being used, laboratory workflows, and GxP requirements. LIMS managed services provide a solution by offering comprehensive support throughout the lifecycle of a system. In this blog, we explore the benefits of LIMS managed services.
**Key Benefits of LIMS Managed Services**
- **Master Data Management:** Even after a system has reached a steady state, there will always be a need for updating existing master data and for the creation of new master data. As processes are improved and new products and tests are introduced, your managed services provider can assist with changes to test methods, specifications, reagents, and more.
- **System Enhancements:** Requests for improvements to LIMS will increase as end users become more familiar with the system. A managed services provider can provide solutions for these enhancements, such as modification and creation of queries, system page configuration, dashboards, labels, and reports. These enhancements increase the efficiency and ease of use of the system.
- **System Validation Documentation:** As master data and system enhancement changes are implemented in LIMS, documentation such as SOPS, work instructions, and requirements documents need to be updated as well to comply with regulatory standards. Managed services will assist with drafting and revising these documents related to your LIMS system, as they are the ones making the changes to the system.
- **System Support:** Technical issues can arise at any time. LIMS managed services aid end users with everything from routine user account management to incident troubleshooting. Support tickets go through three levels of support, where Level I are fixes for basic issues such as a user being locked out of the system. Level II support provides technical support for troubleshooting system issues and making system configuration changes, and Level III support is for advanced issues handling for customizations. Another benefit centers around when a bug is potentially detected in the system, your managed services team can investigate it, log the issue with the vendor, and deploy the patch for the fix.
**Conclusion**
In the fast-paced world of laboratories, embracing LIMS managed services is a strategic move. It not only ensures the efficient functioning of critical systems but also allows laboratories to focus on their core mission – advancing scientific research. When organizations no longer have to worry about maintaining their LIMS, their scientists have more time to perform analyses and research instead. By partnering with a science focused managed services team for LIMS management, laboratories can unlock a new level of productivity, compliance, and innovation.
To find out more about how Zifo can help with your LIMS implementation, please contact us at
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
**Categories:** Lab Compute Services, Scientific Application Managed Services
---
### [Supporting Laboratory IT And Scientific Applications](https://zifo.com/blogs/supporting-laboratory-it-and-scientific-applications/)
**Published:** August 16, 2023
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [Supporting Laboratory IT And Scientific Applications](https://zifo.com/blogs/supporting-laboratory-it-and-scientific-applications/ "Supporting Laboratory IT And Scientific Applications")
## Supporting Laboratory IT And Scientific Applications
Paul Denny-Gouldson
Aug 16, 2023
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Supporting%20Laboratory%20IT%20And%20Scientific%20Applications%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Fsupporting-laboratory-it-and-scientific-applications%2F "Share on Email")
- [](https://x.com/intent/post?text=Supporting%20Laboratory%20IT%20And%20Scientific%20Applications&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fsupporting-laboratory-it-and-scientific-applications%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Supporting+Laboratory+IT+And+Scientific+Applications&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fsupporting-laboratory-it-and-scientific-applications%2F "Share on LinkedIn")
Image reference: / source
**The Critical Role of Scientific Knowledge When Supporting Laboratory IT and Scientific Informatics**
Laboratories in science-driven industries such as Pharma & Biotech, Speciality Chemicals, Food, FMCG (Fast Moving Consumer Goods), Agro Tech etc., have leveraged computers and software since they became routinely available over the past 50 years. The recent drive for Digital transformation of laboratories and science is now demanding “software and IT” in science crucial. Without them, all the benefits of the digital transformation to build a digital science value chain through efficiency, quality, FAIR data, and innovation are impossible. Information technology (IT) and scientific applications have grown from peripheral necessities to core components of laboratory functions, enabling automation, data collection, and advanced analysis. But, the successful deployment and maintenance of these systems require not only traditional IT skills but a deep understanding of the science these systems are meant to facilitate.
From a high-level perspective, IT professionals are experts in software and hardware components, networking, troubleshooting, and various other technical aspects. However, an additional dimension must be accounted for when operating in the laboratory setting – the science behind the research or analytical testing being conducted. Understanding the scientific principles at play and how they influence the design and use of laboratory IT systems can make a substantial difference in both the efficacy of these systems and the results produced by the lab.
Typically, when generic IT service providers deliver scientific informatics and lab IT support –scientists are left “doing their own support,” and the time taken to “get the problem fixed” is far longer than is needed – this leads to a slowdown of the scientists and significant frustration and lost opportunity. Tickets are raised, but L1 support does not have the tools or scientific knowledge to help fix the issue, so it goes to L2 support, who have a little more understanding. The support process is then long, with tickets typically ending up at L3 support. So why not do it differently – why not get the science and informatics knowledge at L1 and L2? Why not allow the scientists to get “real scientific support” that helps them with IT and informatics issues and supports their science? Why not provide Lab IT support for the scientists in their local language onsite in their lab?
**Why is scientific knowledge vital for Scientific Informatics and Lab IT?**
Laboratory informatics includes elements such as Laboratory Information Management Systems (LIMS), Electronic Lab Notebooks (ELN), registration systems, robotics control systems, scientific data management systems, and laboratory instrument systems such as CDS (Chromatography Data Systems). Each application serves a distinct purpose and requires a specific understanding of the scientific workflow and context to be set up and operate optimally.
For instance, a LIMS manages samples and their associated data. This system must adhere to protocols related to sample handling, storage, and testing, which can be vastly different depending on whether you’re in a pharmaceutical, forensics, or food testing lab. Knowledge of the scientific processes ensures the LIMS is structured and configured correctly, facilitating efficient lab workflow and reliable data management.
Lab IT support is all the support required to network instruments and associated hardware, updating instrument firmware and software locally – essentially ensuring all lab “infrastructure” elements are working correctly. So when automating laboratory processes, a deep understanding of the scientific process being automated is essential to ensure success for the scientists. Without such knowledge, automation may fail, not serve the intended purpose or lead to errors that impact the integrity of results. Understanding the scientific principles behind these processes ensures that the lab’s IT and automation is accurately and effectively implemented.
A great example where generic IT skills are not sufficient is connecting a lab sample label printer to a LIMS system in the lab. This is not a common task and is not covered by the standard IT policies, managed services and processes. It is specific to the situation:
- the particular lab, e.g. in a clean room;
- the laboratory software, e.g. a specific version of CDS software;
- the particular label printer type, e.g. a Zebra ZD200 series printer and;
- the type of work conducted in the lab, e.g. -80 long-term storage sample prep.
This is not the same as connecting the standard corporate printer to the network in an open-plan office – it needs scientific understanding and experience.
Local language support for the scientists is another aspect that makes this area more complex. Scientific and laboratories are technical environments – with precise and domain-centric language. Ensuring the scientists are supported with their local AND scientific language is a critical success factor in ensuring customer satisfaction for an IT group within a scientific organization. In many cases, Lab IT support is only conducted in English – meaning the scientists have to explain their issues in English – which can be time-consuming and problematic when English is not your first language.
In many cases, IT managed service and support services are measured with KPIs – the customer, aka the scientists’ satisfaction, is a significant part of the delivery measurement. The combination of the abovementioned issues leads to these “support KPIs” often not being met. This leads to frustration and lost time for the scientists.
**How scientific knowledge enhances laboratory informatics and IT support?**
By understanding the scientific methods and principles, support professionals can better communicate with the lab staff, which is crucial in troubleshooting and optimizing lab systems. This understanding helps the lab informatics and Lab IT support staff see from the scientist’s perspective, identifying potential issues or bottlenecks and providing solutions that align with the specific scientific workflows.
Moreover, regulatory compliance is a crucial issue in many laboratories. Whether HIPAA in medical labs, GLP in pharmaceutical labs, or ISO standards in testing labs, the lab informatics and IT must be designed and managed to ensure compliance. Knowledge of the scientific context helps IT professionals to comprehend these workflows and standards and implement them efficiently and accurately. We often see that the informatics service provider, if properly experienced and understanding of the science, can provide added value and insights to help optimize the scientific workflow efficiency, increase the data’s worth, and support the scientists’ innovation and effectiveness.
**Conclusion**
In conclusion, while traditional IT skills remain crucial, scientific knowledge has become an equally indispensable asset for Lab IT and scientific informatics managed services support. By understanding the scientific processes and principles, systems can be continually optimized to support efficient, accurate, and compliant scientific research and testing. This combination of skills will likely be even more important as laboratories continue leveraging technology to push scientific boundaries. The successful marriage of IT expertise and science is paramount to enabling digital science, affirming the irreplaceable role of scientific knowledge in modern laboratory informatics setup and support.
If you would like to know more about Zifo’s market-leading scientific informatics and laboratory IT managed services, please get in touch with us at
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
**Categories:** Lab Compute Services, Scientific Application Managed Services
---
### [Preparing For A Successful LIMS Implementation](https://zifo.com/blogs/preparing-for-a-successful-lims-implementation/)
**Published:** January 23, 2024
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [Preparing For A Successful LIMS Implementation](https://zifo.com/blogs/preparing-for-a-successful-lims-implementation/ "Preparing For A Successful LIMS Implementation")
## Preparing For A Successful LIMS Implementation
Ken Alves
Jan 23, 2024
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Preparing%20For%20A%20Successful%20LIMS%20Implementation%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Fpreparing-for-a-successful-lims-implementation%2F "Share on Email")
- [](https://x.com/intent/post?text=Preparing%20For%20A%20Successful%20LIMS%20Implementation&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fpreparing-for-a-successful-lims-implementation%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Preparing+For+A+Successful+LIMS+Implementation&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fpreparing-for-a-successful-lims-implementation%2F "Share on LinkedIn")
Image reference: / source
**Introduction**
If your organization has made the strategic and financial commitments to implement a Laboratory Information Management System (LIMS) to better improve the quality and efficiency of your laboratories, then you should be aware of the impact of not properly preparing for this implementation by your organization could have. Implementing a LIMS is a huge undertaking and not being properly prepared could have drastic impacts on timeline, budget, scope, and user adoption of the system. This blog assumes you have already decided on the LIMS system you will be implementing, but before you allow the implementation vendor to come in and start the implementation, deciding on all the below points will set you up for implementation and user adoption success.
**Team**
Having an experienced team is the most important part of a successful implementation. Your team should consist of the people listed below. Keep in mind that some of the functions could be combined into one resource.
**Implementation Team**
- **Project Manager (PM)** – Your PM will keep your project on track for time, scope and budget and be the point person for overall communication to management. An experienced LIMS PM brings a wealth of knowledge to your implementation and is aware of the pitfalls that can lead to an unsuccessful implementation.
- **Scientific Business Analyst (SBA)** – A SBA that understands both LIMS and laboratory processes is one of the most valuable members of your team. Being able to translate your workflows into LIMS requirements and being able to push-back on the business for unnecessary configurations and customizations will ensure that your lab users get a system that truly meets the business’s needs.
- **Change Management Lead** – Having a person dedicated to user adoption of the new system is critical to success. This lead will plan out the activities and training needed for the business so that when your system is ready to go live, they are ready to use it and they will not be experiencing any surprises to their job.
- **Master Data Lead** – One of the most underestimated items in a LIMS implementation is the amount of master data that a company has. Master data is the data that needs to be in the system so that the end users can use the system as intended. This includes the tests they will be doing, the products and sample types they will be testing, and much more. Having a lead who is responsible for pulling together lists of all the master data that needs to be created and formulating a plan on how it will all get created and approved before go-live will ensure that the system is ready for use.
- **SOP Lead** – If your company works in a regulated environment, then having a lead who is responsible for identifying all the existing SOPs that need updating due to the new LIMS and deciding on new SOPs that will need to be created for the LIMS is a must. This lead will also be responsible for putting together a plan for who will be responsible for updating or creating the SOPs and when they will get done.
- **Validation/Testing Lead** – Having a lead responsible for all aspects of your validation or testing will ensure the system is ready for use. This person is responsible for all aspects including what documents need to be produced, what needs to be tested and the schedule that will be followed.
- **Developers** – If you decide to not use the LIMS vendor to implement the system, then having a development team with experience in your system of choice is valuable. They will be able to translate the requirements into what is needed in the system.
**Subject Matter Experts (SMEs)**
Dedicating business users to the team is important. They will serve roles throughout the implementation including LIMS Administrators, Super Users, and trainers and testing functionality for acceptance. You need to consider that this is adding work to their schedule, and you need to adjust for that. You cannot just expect that they will be able to fulfill both duties. They are needed on the team for things such as being in workshops to decide the future to-be workflows, answering questions, being in demos and the list goes on and on.
**Management Team**
Having management buy-in and involvement is crucial to the success of the implementation. At the very least you should have dedicated the below list to make sure that the implementation is always moving forward and to help resolve issues and conflicts that may arise.
- **Project Sponsor** – Has the overall responsibility of the project and is the first level to escalate issues to when they arise.
- **Steering Committee** – Meets at least monthly to be informed of the progress and help resolve any issues that the Project Sponsor has not resolved.
**User Requirements and As-Is Workflows**
Considering that you have already chosen your LIMS system, these should have been part of the vendor selection, but if they were not, now is the time to produce these. Use your SBA to produce detailed workflows of how you do every laboratory process today, that you expect to implement in the LIMS. From these workflows produce a set of user requirements for the LIMS. These requirements should be grouped by process and function and state if they are ‘Must Haves’ or ‘Nice to Have.’ This document will be used for generating your To-Be workflows and functional requirements during the implementation and will become the basis of your final user acceptance testing.
If you have multiple labs and/or sites doing the same workflows, generate these As-Is workflows and user requirements for each site. These can then be used as a basis for harmonizing your To-Be processes across the labs and sites during the requirements gathering phase of the implementation.
**Implementation Plan**
A best practice in LIMS implementations is to implement what has come to be known as the Minimum Viable (or Valuable) Product (MVP). This involves implementing the minimum amount of functionality to get your user base to start using and becoming familiar with the LIMS. The best part is that implementing the MVP increases user adoption of the system. Use the items below to produce an implementation plan that you will use to implement the MVP for your laboratory.
- **Sites** – How many sites will be using the LIMS. Consider staggering the go-lives for the sites to better understand the user adoption and to deal with any initial issues before moving on to the next site.
- **Products** – How many products are being created at each site. Consider using a pilot in which a smaller number of Products are initially captured in LIMS and have a plan to bring on the other Products.
- **Tests** – Similar to Products. Consider a pilot in which a subset of the tests you perform are initially captured in LIMS and have a plan to bring on the other Tests you perform.
- **Workflows and Modules** – Once your LIMS is fully implemented, what functionality will it have? From that, start with basic functionality to get your user base accustomed to using it and add additional workflows and modules over time.
- **Timeline** – What is your timeline and what is it based on? Be realistic on the timeline and what functionality can be implemented in that period using the budget you have allocated.
SDLC – Waterfall, agile, a mix. Decide which way you will implement the LIMS.
**Plans and Other Documents**
With the above taken care of, the next recommendation is to get your plans in place and approved. Having these in place will allow you to know where you are going, how you will get there and how to deal with issues when they arise.
- **Project Charter** – The formal document that approves and project and describes the essential elements of it like, initial scope, team members, implementation plan (based on above section), budget, etc.
- **Initial Project Plan** – Based on the implementation plan. At this point, it should be high-level and updated at the end of the requirements gathering phase.
- **Scope Change** – A document that will deal with how requests to scope change and requirements changes will be handled after the initial approval of all functional requirements.
- **Organizational Change Management** – A plan on what activities and timelines for the end user base to get them trained and ready for the new system.
- **Stakeholder** – A plan on who the stakeholders are and how they will be involved. Most important for the SMEs chosen to work on the project.
- **Communication** – A plan of all communications that will be either socialized by email or in person through meetings. Includes frequency and purpose of the communications.
- **Risk** – A plan for how the implementation team will define risks and handle them if they emerge as issues.
- **Testing/Validation** – A plan to gather, create and test all master data for the implemented system.
Master Data – A plan of all testing/validation deliverables and what the testing/validation workflow will look like.
- **SOP** – A plan to determine which SOPs need to be updated or created.
**Infrastructure Needs**
Based on the system you have selected, make sure you plan and procure everything from an infrastructure perspective. Everything from servers if you plan to host on premise, to space in the cloud to all user licenses that will be needed. Also look at hardware needs, everything from additional workstations in the laboratories, label printers that may be needed and networking connections in the laboratory for adding these workstations and instruments to your network. Don’t overlook things that may be needed such as bar code scanners and development environments of other software that you may be interfacing to the LIMS, such as your ERP or chromatography data system (CDS).
**Summary**
If you follow the above recommendations, the next steps in the implementation process, such as the functional requirements gathering, the builds and demos, handling scope changes and issues that arise will go much smoother.
To find out more about how Zifo can help with your LIMS implementation, please contact us at
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
---
### [Oxford Nanopore Technology (ONT) For Whole Genome Sequencing (WGS) SNP Typing Of Pathogenic Bacterial Strains](https://zifo.com/blogs/loxford-nanopore-technology-ont-for-whole-genome-sequencing-wgs-snp-typing-of-pathogenic-bacterial-strains/)
**Published:** March 21, 2025
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [Oxford Nanopore Technology (ONT) For Whole Genome Sequencing (WGS) SNP Typing Of Pathogenic Bacterial Strains](https://zifo.com/blogs/loxford-nanopore-technology-ont-for-whole-genome-sequencing-wgs-snp-typing-of-pathogenic-bacterial-strains/ "Oxford Nanopore Technology (ONT) For Whole Genome Sequencing (WGS) SNP Typing Of Pathogenic Bacterial Strains")
## Oxford Nanopore Technology (ONT) For Whole Genome Sequencing (WGS) SNP Typing Of Pathogenic Bacterial Strains
Sai Sharadhaa T G, Bioinformatics Analyst | Sinrasu A, Bioinformatics Analyst | Ahkam Saddam S H, Bioinformatics Analyst
Mar 21, 2025
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Oxford%20Nanopore%20Technology%20%28ONT%29%20For%20Whole%20Genome%20Sequencing%20%28WGS%29%20SNP%20Typing%20Of%20Pathogenic%20Bacterial%20Strains%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Floxford-nanopore-technology-ont-for-whole-genome-sequencing-wgs-snp-typing-of-pathogenic-bacterial-strains%2F "Share on Email")
- [](https://x.com/intent/post?text=Oxford%20Nanopore%20Technology%20(ONT)%20For%20Whole%20Genome%20Sequencing%20(WGS)%20SNP%20Typing%20Of%20Pathogenic%20Bacterial%20Strains&url=https%3A%2F%2Fzifo.com%2Fblogs%2Floxford-nanopore-technology-ont-for-whole-genome-sequencing-wgs-snp-typing-of-pathogenic-bacterial-strains%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Oxford+Nanopore+Technology+%28ONT%29+For+Whole+Genome+Sequencing+%28WGS%29+SNP+Typing+Of+Pathogenic+Bacterial+Strains&url=https%3A%2F%2Fzifo.com%2Fblogs%2Floxford-nanopore-technology-ont-for-whole-genome-sequencing-wgs-snp-typing-of-pathogenic-bacterial-strains%2F "Share on LinkedIn")
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Stories
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
**1. Abstract**
Advancements in whole-genome sequencing (WGS) technologies have revolutionized the study of pathogenic microbes, offering detailed insights into their genetic composition and transmission patterns. This study explores the use of Oxford Nanopore Technology (ONT) for WGS-based single nucleotide polymorphism (SNP) typing of Francisella tularensis subsp. Holarctica, Brucells suis, and Bacillus anthracis. We compare data from ONT R9 and R10 flow cells with Illumina short-read sequencing to evaluate performance across multiple metrics, including read quality, assembly contiguity, SNP detection, and phylogenetic clustering. Our findings highlight both the benefits of ONT—such as long-read capacity for resolving repetitive regions—and its current limitations, including challenges in homopolymer resolution and species-specific DNA modifications. We also discuss workflow adjustments and emerging tools that may further improve ONT
accuracy in microbial genomic analysis. This work provides practical guidelines for researchers considering ONT for pathogen genome characterization and underscores the need for application-specific approaches when selecting sequencing technologies.
**2. Introduction**
Whole-genome sequencing (WGS) has become a cornerstone in understanding microbial pathogens, enabling precise identification of genetic variants and the reconstruction of outbreak dynamics. Short-read sequencing technologies, such as Illumina, have traditionally dominated this space owing to their high accuracy and cost-effectiveness. However, limitations in resolving repetitive regions and larger structural variants have prompted researchers to explore alternative platforms, including Oxford Nanopore Technology (ONT). ONT’s portable devices offer long-read sequencing capabilities and have gained increasing attention for field-based and point-of-care applications.
Despite the promise of ONT, its performance can vary significantly across different microbial species and experimental conditions. To address these concerns, we conducted a comparativestudy of ONT (R9.4.1 and R10.4 flow cells) and Illumina sequencing platforms for the whole-genome analysis of three pathogenic bacteria: Francisella tularensis subsp. holarctica, Brucella suis, and Bacillus anthracis. We specifically focused on SNP typing and phylogenetic inference to assess the impact of technology choice on downstream analyses.
In the sections that follow, we review the current literature on ONT’s application to microbial genomics (Section 3) and discuss the latest updates in ONT flow cells and basecalling (Section 4). We then highlight the advantages and limitations of ONT for de novo assembly and variant detection (Section 5). Subsequently, we present our dataset, analysis workflow, and results (Sections 6–8), including assembly metrics, SNP calls, and phylogenetic trees. Finally, we discuss the challenges and limitations observed in this study (Section 9) and suggest avenues for further research.
**3. Oxford Nanopore sequencing technology and microbial analysis**
*Having established the motivation for exploring ONT in pathogen genomics, we now turn to a review of Oxford Nanopore sequencing technology and its applications in microbial analysis.*
Various studies have investigated Oxford Nanopore sequencing technology for its potential applications in microbial analysis. Research has explored its capacity to address particular challenges associated with short-read sequencing methods. Studies have examined the long-read capability of the technology, particularly in resolving repetitive regions and structural variants (Amarasinghe et al., 2020). Investigations into GC bias patterns in Nanopore sequencing have been conducted, comparing them with those observed in some short-read platforms (Laver et al., 2015). Additionally, the potential of Nanopore sequencing for generating contiguous microbial genome assemblies has been a focus of research (Wick et al., 2017). While some researchers have considered Oxford Nanopore as an option for microbial genomic analysis, its efficacy depends on specific applications and experimental conditions (Tyler et al., 2018). Further research may be required to fully understand the strengths and limitations of this technology across different microbial analysis contexts.
**4. ONT – Current trends and updates**
*While the long-read capabilities of ONT have addressed some limitations of short-read sequencing, recent updates in ONT hardware and basecalling software continue to shape its performance. The next section highlights current technological advancements and trends.*
Recent developments in ONT over the past years have shown advancements in library preparation methods and the transition from R9 to R10 series flow cells. The R9 series, particularly the R9.4.1 flow cells, have been widely used in various applications, while the newer R10 series, including R10.3 and R10.4, have been introduced to improve sequencing accuracy (Nurk et al., 2022). Research suggests that the R10.4 flow cell, with its improved sequencing accuracy and reduced error rates, may offer enhanced performance in homopolymer resolution compared to R9.4.1. However, comparative analyses suggest that each type may have specific strengths depending on the application (Sereika et al., 2022). For basecalling, which converts raw electrical signals to nucleotide sequences, efforts to improve accuracy and speed through updated algorithms and software have been ongoing, with regular updates to tools like Guppy and Bonito (Wick et al., 2022). ONT has also introduced a Nanopore-Only Microbial Isolate Sequencing Solution, described as an end-to-end workflow for microbial genome sequencing (Oxford Nanopore Technologies, 2023). This development potentially offers a streamlined approach for the infectious disease research community, though its efficacy across various research contexts remains a subject of ongoing investigation.
**5. Advantages of ONT**
*Building on these recent developments in ONT library preparation and basecalling, we now outline the key advantages that ONT offers for microbial genome assembly and variant detection.*
Studies investigating ONT’s utility in de novo genome assembly have reported the relative ease of assembly processes compared to short-read technologies (Tange et al., 2021). A variety of genome assembly tools optimized for ONT data have been developed and evaluated, including software such as Flye and Canu, each with reported strengths and limitations (Kolmogorov et al., 2019; Koren et al., 2017). Further, exploration of the capacity of ONT long reads to span repetitive regions has revealed potential benefits in resolving complex genomic structures (Charalampous et al., 2019). Additionally, research into ONT’s ability to detect structural variations suggests improved sensitivity for certain types of variants (Sedlazeck et al., 2018). The portability of ONT devices has also been noted in several studies, with researchers examining their potential for field-based or point-of-care applications (Jain et al., 2016). However, comparisons of genome assembly quality between ONT and other sequencing platforms have produced varied results, largely depending on the organisms and methodologies used (Wick et al., 2019). Therefore, it is important to note that the performance and advantages of ONT technology can vary depending on the specific application, experimental design, and analytical approach. For example, data generated using R10.4 sequencing enzyme with the latest Q20+ chemistry, compared to data generated with R9.4.1 chemistry, improved ONT’s SNV detection capabilities and yielded comparable results for SV and overall methylation detection (Ni et al., 2023).
**6. Datasets**
*Having discussed the overall advantages and potential utility of ONT for microbial genomics, we next describe the datasets and workflows used in our comparative study.*
The data used for the analysis were publicly available from BioProject (ID: **PRJEB59317**). The analysis workflow (**Figure 1**) performed was adapted from an already published study with certain modifications to meet the objectives (Linde et al., 2017). For short reads, we followed a standard workflow using short-read–specific tools until the assembly step of the workflow. After the assembly step, we used the same tools for downstream analysis of both short reads and long ONT reads. The ONT dataset was readily available as FASTQ files. We took a subset of samples and proceeded with our analysis. The raw ONT files were converted to FASTQ files using Guppy (v6.0.1) basecaller utilizing the dna\_r9.4.1\_450bps\_sup model for R9ONT and dna\_r10.4\_e8.1\_sup.Cfg model for R10ONT. The same basecaller tool was also used for demultiplexing and trimming of the barcodes.
**Table 1: Sample information for input data. The selected species include *Francisella tularensis subsp. holarctica* (yellow), *Brucella suis* (blue), and *Bacillus anthracis* (green). Nine samples from each species were analyzed using various sequencing technologies, including Illumina, R9ONT, and R10ONT amounting to a total of 27 samples.**
Run IDsBioSampleStrain IDsGenomic Size (MB)SpotsLibrary LayoutTechnologySpeciesERR10820717SAMEA11237082508T00132341056616PAIREDILLUMINAFrancisella tularensisERR10828745SAMEA11237082508T001326516654SINGLEONT – R9Francisella tularensisERR10828751SAMEA11237082508T001328026447SINGLEONT – R10Francisella tularensisERR10820719SAMEA11237082710T0192211940770PAIREDILLUMINAFrancisella tularensisERR10828747SAMEA11237082710T019235927010SINGLEONT – R9Francisella tularensisERR10828753SAMEA11237082710T019227429877SINGLEONT – R10Francisella tularensisERR10820721SAMEA11237082915T0012172726495PAIREDILLUMINAFrancisella tularensisERR10828749SAMEA11237082915T001264849200SINGLEONT – R9Francisella tularensisERR10828755SAMEA11237082915T001217324958SINGLEONT – R10Francisella tularensisERR10820711SAMEA11237083108RB2802253692799PAIREDILLUMINABrucella suisERR10828733SAMEA11237083108RB280232561974SINGLEONT – R9Brucella suisERR10828739SAMEA11237083108RB280211024041SINGLEONT – R10Brucella suisERR10820714SAMEA11237083408RB3701265817936PAIREDILLUMINABrucella suisERR10828736SAMEA11237083408RB370129758803SINGLEONT – R9Brucella suisERR10828742SAMEA11237083408RB370110824712SINGLEONT – R10Brucella suisERR10820716SAMEA11237083615RB2242258796321PAIREDILLUMINABrucella suisERR10828738SAMEA11237083615RB224230757178SINGLEONT – R9Brucella suisERR10828744SAMEA11237083615RB224214030436SINGLEONT – R10Brucella suisERR10820686SAMEA11237083712RA19443531304222PAIREDILLUMINABacillus anthracisERR10828757SAMEA11237083712RA1944997123183SINGLEONT – R9Bacillus anthracisERR10828763SAMEA11237083712RA194422933303SINGLEONT – R10Bacillus anthracisERR10820687SAMEA11237083812RA19453361281935PAIREDILLUMINABacillus anthracisERR10828758SAMEA11237083812RA19452074230225SINGLEONT – R9Bacillus anthracisERR10828764SAMEA11237083812RA194560979516SINGLEONT – R10Bacillus anthracisERR10820690SAMEA11237084114RA59153381326955PAIREDILLUMINABacillus anthracisERR10828761SAMEA11237084114RA59151752206807SINGLEONT – R9Bacillus anthracisERR10828767SAMEA11237084114RA591531043146SINGLEONT – R10Bacillus anthracis
***Figure 1: Analysis workflow comparing ONT R9 vs. ONT R10 vs. Illumina short reads.***
**7. Preprocessing**
*With an overview of the samples and sequencing technologies in place, we now detail our data preprocessing methods, including quality control and assembly strategies.*
**7.1 Quality control and filtering**
For adapter trimming, we used the *Porchop\_abi* (v0.5.0) tool, and for quality control, we used *NanoQC*. In terms of quality filtering, we tested *Chopper* (v0.8.0), *Filtlong* (v0.2.1) and *Japsa* (v1.9). Chopper showed promising results based on several metrics:
- **Number of reads:** Number of quality-filtered reads is almost equal to number of raw reads.
- **Mean read length** remains almost equal to the read length of raw reads.
- **Mean quality score:** Improved quality score compared to raw reads.
The sequence quality indicated that coverage for ONT reads was lower than that of the short reads. The mean read length of ONT reads was about 11kbp, with a difference of 20kbp in read length between R9 ONT and R10 ONT. The overall mean quality score of the reads was higher for R10ONT (Q14-Q17) compared to R9ONT (Q10-Q12). A negligible number of reads were observed to pass a quality score of Q20 and Q30 in ONTR9 and ONTR10, respectively.
**7.2 Assembly**
After quality trimming of ONT reads, the reads were assembled using the *Flye* (v2.9.3) assembler, followed by an initial round of polishing with the Racon (v1.5.0) tool and an additional round of polishing with the *Medaka* (v1.11.3) tool. Prior to Racon polishing, the reads were mapped to the assembly using the Minimap2 (v2.28) tool. We used two basecalling models for *Medaka* polishing: *r941\_min\_fast\_g303\_model.hdf5* (R9ONT) and *r1041\_e82\_400bps\_sup\_v4.3.0* (R10ONT). Assembly metrics were compared between the assembled contigs of raw ONT (*Flye* assembly only), polished ONT and short-read technologies using *QUAST* (v5.2.0) tool and the results are shown in **Tables 2-4**. The color scheme in the tables represents the respective technologies applied (Illumina – light orange, R9ONT – blue, R10ONT – green).
The average number of contigs in ONT assemblies (1-3 contigs) was lower than that in short-read technology (50-102 contigs), suggesting that the largest assembled contig size (N50) from ONT can encompass the entire genome. The number of base mismatches and misassembled contigs was higher in ONT compared to short-read technology. Additionally, reduced N50 values, exhibiting a difference of 3-fold to 7-fold, were associated with a significant number of misassemblies. Interestingly, assembly metrics were better for microbial species with low GC content compared to those with higher GC content. The number of mismatch bases ranged from approximately 150-300bp in species with low GC content, while in species with high GC content, this figure was around 4000-5000 bp.
**Table 2: QUAST assembly metrics for Bacillus anthracis and their respective strains across different sequencing technologies.**
PlatformSampleGenome fraction (%)Genomic featuresTotal aligned lengthNGA50MisassembliesMismatches\# contigsLargest contigN50GC (%)IlluminaERR1082068699.0911531 + 58 part5456126331382004762073433138235.11ERR1082068799.03411524 + 65 part54525752893410055134552628934135.11ERR1082069099.03311513 + 65 part54524542891380059129024428913835.11ONT-R9ERR1082876199.89411634 + 12 part55031795233104324925233511523351135.22ERR1082875899.9911643 + 9 part55082415231265019535233940523394035.22ERR1082875799.9911644 + 10 part55103235233390011935233821523382135.21ONT-R10ERR1082876799.98111644 + 10 part55024645227951223935228559522855935.25ERR1082876499.98411638 + 16 part55046135227854020435230670523067035.24ERR1082876399.98411641 + 13 part55115505228363012345229060522906035.24
**Table 3: QUAST assembly metrics for **Brucella suis** strains across different sequencing technologies.**
PlatformSampleGenome fraction (%)Genomic featuresTotal aligned lengthNGA50MisassembliesMismatches\# contigsLargest contigN50GC (%)IlluminaERR1082071698.8816558 + 42 part3278999170185248973453180717033957.21ERR1082071498.8816556 + 46 part3278588155908248883153179915600957.24ERR1082071198.8786559 + 39 part3278434170010248823153180918442857.24ONT-R9ERR1082873899.4976603 + 19 part329971140431516495821928723192872357.21ERR1082873699.4976603 + 19 part329958440430316496221928579192857957.21ERR1082873399.4976601 + 21 part330575845059714495322133781213378157.21ONT-R10ERR1082874499.1266574 + 32 part33052972820651851498140027886683657.21ERR1082874299.2416592 + 23 part329690240405616519921928926192892657.2ERR1082873999.4936600 + 22 part330199845020314513922133013213301357.21
**Table 4: QUAST assembly metrics for **Francisella tularensis** strains across different sequencing technologies.**
PlatformSampleGenome fraction (%)Genomic featuresTotal aligned lengthNGA50MisassembliesMismatches\# contigsLargest contigN50GC (%)IlluminaERR1082071794.298–1788588256150153101882392698832.17ERR1082072194.276–178741425350173099884212698732.17ERR1082071994.224–1787054256231854102876802662232.17ONT-R9ERR1082874599.801–18937491890286321311895619189561932.13ERR1082874799.617–1888518781455994611892668189266832.14ERR1082874999.801–18909351658707788111895765189576532.13ONT-R10ERR1082875199.528–18866811566868120821571931157193132.16ERR1082875397.371–184923141703181083765751055833932.21ERR1082875594.885–1829187180907410531732821228990332.14
**8. Downstream analysis**
*Following the preprocessing and assembly steps, we proceed to evaluate the assembled genomes through downstream analyses such as SNP typing, ANI calculation, and phylogenetic inference.*
Several downstream analyses were performed for the polished ONT-assembled reads:
- **Calculating Average Nucleotide Identity (ANI):** ANI was calculated using the fastANI (v1.32) tool. This metric measures the similarity between the assembled genome and the reference genome. Results indicated that the nucleotide identity was 99.8% for all three species across all sequencing technologies.
- **Identification of virulence biomarkers:** Virulence genes were identified for two species using the Abricate (v1.0.1) tool. Most of the virulent genes were identified for all the technologies with a few exceptions in ONT.
- **Plasmid identification:** Plasmid identification was performed using the plasmidfinder ([kcri-tz/plasmidfinder (github.com)](https://github.com/kcri-tz/plasmidfinder)) tool. This analysis focused solely on a single species, and the plasmid was accurately identified in the genome assembly across various technologies.
- **Multi-Locus Sequence Typing (MLST):** MLST was performed using mlst (v2.23.0). The sequence type was correctly identified for only one of the three species resulting from the R10ONT-assembled genome (with a few exceptions), whereas it was not identified in the R9ONT assembly.
- **Single Nucleotide Polymorphism Typing (SNP typing):** Identification of SNP using the Snippy (v4.6.0) tool was performed by comparing ONT-based assemblies against the reference genome of the respective species. Similarly, we compared the assembly contigs against the reference genome of the corresponding species for short reads. Following SNP identification, we proceeded with core genome SNP typing for both ONT- and short-read—based assembly contigs.
**8.1 Core genome SNP typing**
Core genome SNP typing, a standard method to construct phylogenies for closely related microbes, was performed with the *Snippy* (v4.6.0) tool using standard settings. The pairwise distances of SNPs were calculated using the *snp-dists* (v0.8.2) tool based on cgSNP alignment, for the reconstruction of phylogenetic trees using Randomized AxeleratedMaximimum Likelihood (*RAxML* v1.2.2). The resulting phylogenetic trees were visualized with the interactive Tree of Life (iTOL v6.9.1) web tool.
The number of cgSNPs identified by ONT was higher than that of short-read technology for *Br. suis*, but the number of cgSNPs for R10 ONT was lower than that of short reads for *F. tularensis* and *B. anthracis*, indicating possible bias from the reference genome built using short-read technology (Figure 2).
**Figure 2: Venn diagrams indicating the SNPs identified across all the technologies for all three species: *Francisella tularensis* (a), *Brucella suis* (b), *Bacillus anthracis* (c).**
Phylogenetic trees were generated from SNP distance for all three species across various sequencing methods. The number of cgSNPs for R10 ONT was smaller compared to R9 ONT and short reads for *F. tularensis* (Figure 3). The phylogenetic tree for *Br. suis* (Figure 4 shows clustering according to strains, independent of the sequencing technology. For *B. anthracis*, the phylogenies observed were clustered based on outbreak year, independent of the sequencing technology (Figure 5).
**Figure 3: Phylogenetic tree constructed for *Francisella tularensis* from SNP distance for all three strains, comparing assemblies of different technologies and the reference genome. The colors highlighting the run IDs represent different strain IDs (08T0013 – yellow, 10T0192 – green, 15T0012 – blue).**
**Figure 4: Phylogenetic tree constructed for *Brucella suis* from SNP distance for all three strains, comparing assemblies of different technologies and the reference genome. The colors highlighting the run IDs represent different strain IDs (08RB2802 – yellow, 08RB3701 – green, 15RB2242 – blue).**
**Figure 5: Phylogenetic tree constructed for *Bacillus anthracis* from SNP distance for all three strains, comparing assemblies of different technologies and the reference genome. The colors highlighting the run IDs represent different strain IDs (12RA1944 – yellow, 12RA1945 – green, 14RA5915 – blue).**
**9. Challenges and limitations**
*Our findings show that ONT can provide robust phylogenetic clustering, though certain discrepancies remain. In the next section, we discuss the challenges and limitations encountered during our analyses, along with potential improvements.*
ONT has shown very promising results for clustering based on phylogenetic trees; however, considering the number of cgSNPs, differences were observed for specific species. The number of cgSNPs observed across technologies was comparable for Francisella tularensis and Bacillus anthracis. However, for Brucella suis, the cgSNPs identified with ONT R10 differed compared to those obtained with short reads and ONT R9. The resulting variation observed between microbial species for the same ONT sequencing technology could be primarily due to certain factors.
One well-known issue is the decrease in ONT accuracy in homopolymer regions. Although errors within homopolymer regions have improved with the ONT R10.4.1 library compared to the ONT R9.4.1 library, very long homopolymers can still cause problems with accuracy. Another possible factor leading to systematic errors within the assembly could be ascribed to DNA modification specific to the microbial species (Forde et al., 2015; Beauchamp et al., 2015). The species-specific modification and motifs not included in the basecaller training set could cause errors with ONT for that specific species. A basecalling model trained and fine-tuned on specific species, including species-specific modified bases in all possible motifs, could be a promising solution to narrow down the observed assembly error for specific species. For example, using a tuned model for Brucella suis could reduce the errors encountered with ONT. Other factors, such as GC content and coverage specific to ONT R10, also cannot be ruled out.
Many ONT-specific tools are released frequently, particularly for assembly methods. In addition to Flye, other assemblers like Canu and Trycycler exist. Canu, though somewhat slower, can produce better assembly than Flye, and both assemblers require minimal manual effort to complete a genome. However, Trycycler has been shown to produce better assemblies than either Canu or Flye, requiring a more complex process involving human judgment and intervention. Exploring other assembly tools beyond Flye could potentially improve the assembly quality for specific species.
In addition, our analysis has some limitations that may influence the observed results. First, we used publicly available FASTQ files generated with the Guppy basecaller, rather than Dorado. Dorado is currently the official Nanopore basecaller and has been shown to be more efficient than Guppy in methylation calling with the 5-hydroxymethylcytosine group (5hmCG) (Dittforth et al., 2023). This newer official basecalling tool could have further improved results for species such as Brucella suis.
Moreover, the tool we used for core genome SNP typing, Snippy, is not specifically optimized for ONT long reads; it relies on Freebayes for SNP calling, whose assumptions may not fully apply to ONT data. We opted for Snippy because no ONT-specific variant caller capable of performing cgSNP analysis was available or optimized for bacterial genomes. Testing ONT-specific tools that do not rely on a reference file—and instead use a pre-trained dataset—could improve results for challenging strains like Brucella suis.
If you would like to know more about any of the topics in this review, please reach out to us at [info@zifo.com.](mailto:info@zifo.com)
**References:**
Amarasinghe, S. L., Su, S., Dong, X., Zappia, L., Ritchie, M. E., & Gouil, Q. (2020). Opportunities and challenges in long-read sequencing data analysis. Genome Biology, 21(1), 30.
Beauchamp, J. M., Leveque, R. M., Dawid, S., & DiRita, V. J. (2017). Methylation-dependent DNA discrimination in natural transformation of Campylobacter jejuni. *Proceedings of the National Academy of Sciences*, 114(38), E8053-E8061.
Charalampous, T., Kay, G. L., Richardson, H., Aydin, A., Baldan, R., Jeanes, C., Rao, D., Marque, S., Cordeil, N., Larkin, J., Matuszewski, D. J., Otter, J. A., Parkhill, J., Peacock, S. J., Loose, M., & O’Grady, J. (2019). Nanopore metagenomics enables rapid clinical diagnosis of bacterial lower respiratory infection. Nature Biotechnology, 37(7), 783-792.
Dittforth, S., Ozturk, D., & Mueller, M. (2023, May 18). *Benchmarking the Oxford Nanopore Technologies basecallers on AWS*. Benchmarking Oxford Nanopore basecaller on AWS. November 5, 2024,
Forde BM, Phan M, Gawthorne JA, Ashcroft MM, Stanton-Cook M, Sarkar S, Peters KM, Chan K, Chong TM, Yin W, Upton M, Schembri MA, Beatson SA. 2015. Lineage-Specific Methyltransferases Define the Methylome of the Globally Disseminated Escherichia coli ST131 Clone. mBio 6:10.1128/mbio.01602-15. [https://doi.org/10.1128/mbio.01602-15](https://journals.asm.org/doi/10.1128/mbio.01602-15)
Kolmogorov, M., Yuan, J., Lin, Y., & Pevzner, P. A. (2019). Assembly of long, error-prone reads using repeat graphs. Nature Biotechnology, 37(5), 540-546. https://doi.org/10.1038/s41587-019-0072-8
Koren, S., Walenz, B. P., Berlin, K., Miller, J. R., Bergman, N. H., & Phillippy, A. M. (2017). Canu: scalable and accurate long-read assembly via adaptive k-mer weighting and repeat separation. Genome Research, 27(5), 722-736. [https://doi.org/10.1101/gr.215087.116](https://www.nature.com/articles/s41587-019-0072-8)
Laver, T., Harrison, J., O’Neill, P. A., Moore, K., Farbos, A., Paszkiewicz, K., & Studholme, D. J. (2015). Assessing the performance of the Oxford Nanopore Technologies MinION. Biomolecular Detection and Quantification, 3, 1-8.[ https://doi.org/10.1016/j.bdq.2015.02.001](http://doi.org/10.1016/j.bdq.2015.02.001)
Linde, J., Brangsch, H., Hölzer, M. et al. Comparison of Illumina and Oxford Nanopore Technology for genome analysis of Francisella tularensis, Bacillus anthracis, and Brucella suis. BMC Genomics **24**, 258 (2023). [https://doi.org/10.1186/s12864-023-09343-z](https://link.springer.com/article/10.1186/s12864-023-09343-z)
Ni Y, Liu X, Simeneh ZM, Yang M, Li R. Benchmarking of Nanopore R10.4 and R9.4.1 flow cells in single-cell whole-genome amplification and whole-genome shotgun sequencing. Comput Struct Biotechnol J. 2023 Mar 24;21:2352-2364. doi: 10.1016/j.csbj.2023.03.038. PMID: 37025654; PMCID: PMC10070092.
Nurk, S., Walenz, B. P., Rhie, A., Vollger, M. R., Logsdon, G. A., Grothe, R., Miga, K. H., Eichler, E. E., Phillippy, A. M., & Koren, S. (2022). HiCanu: accurate assembly of segmental duplications, satellites, and allelic variants from high-fidelity long reads. Genome Research, 32(9), 1917-1932.
Oxford Nanopore Technologies. (2023). Nanopore-Only Microbial Isolate Sequencing Solution.
Sedlazeck, F. J., Rescheneder, P., Smolka, M., Fang, H., Nattestad, M., von Haeseler, A., & Schatz, M. C. (2018). Accurate detection of complex structural variations using single-molecule sequencing. Nature Methods, 15(6), 461-468. [https://doi.org/10.1038/s41592-018-0001-7](http://doi.org/10.1038/s41592-018-0001-7)
Sereika, M., Kirkpatrick, J. M., Bobonis, J., Depta, G. B., Leidel, S. A., & Butter, F. (2022). Oxford Nanopore R10.4 long-read sequencing enables near-perfect de novo assemblies of a diploid yeast genome. Molecular Systems Biology, 18(7), e11159.
Tange, O., Blythe, A. J., & Swift, J. (2021). Nanopore sequencing of RNA and DNA from marine organisms. Marine Genomics, 57, 100825.
Tyler, A. D., Mataseje, L., Urfano, C. J., Schmidt, L., Antonation, K. S., Mulvey, M. R., & Corbett, C. R. (2018). Evaluation of Oxford Nanopore’s MinION Sequencing Device for Microbial Whole Genome Sequencing Applications. Scientific Reports, 8(1), 10931. [https://doi.org/10.1038/s41598-018-29334-5](https://www.nature.com/articles/s41598-018-29334-5)
Wick, R. R., Judd, L. M., Gorrie, C. L., & Holt, K. E. (2017). Unicycler: Resolving bacterial genome assemblies from short and long sequencing reads. PLOS Computational Biology, 13(6), e1005595.
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Stories
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
**Categories:** Bioinformatics
---
### [Lab Informatics Projects: Handling Dynamic Requirements With Grace](https://zifo.com/blogs/lab-informatics-projects-handling-dynamic-requirements-with-grace/)
**Published:** January 24, 2024
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [Lab Informatics Projects: Handling Dynamic Requirements With Grace](https://zifo.com/blogs/lab-informatics-projects-handling-dynamic-requirements-with-grace/ "Lab Informatics Projects: Handling Dynamic Requirements With Grace")
## Lab Informatics Projects: Handling Dynamic Requirements With Grace
Melody Hendricks
Jan 24, 2024
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Lab%20Informatics%20Projects%3A%20Handling%20Dynamic%20Requirements%20With%20Grace%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Flab-informatics-projects-handling-dynamic-requirements-with-grace%2F "Share on Email")
- [](https://x.com/intent/post?text=Lab%20Informatics%20Projects%3A%20Handling%20Dynamic%20Requirements%20With%20Grace&url=https%3A%2F%2Fzifo.com%2Fblogs%2Flab-informatics-projects-handling-dynamic-requirements-with-grace%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Lab+Informatics+Projects%3A+Handling+Dynamic+Requirements+With+Grace&url=https%3A%2F%2Fzifo.com%2Fblogs%2Flab-informatics-projects-handling-dynamic-requirements-with-grace%2F "Share on LinkedIn")
Image reference: / source
**Introduction**
Lab Informatics project requirements are living and breathing as much as the people working to meet them. Amongst other reasons, requirements may change to account for updated lab processes, priority changes, or additional process data collected. While geared specifically towards laboratory informatics, this guide may also be applied to any software-based project that faces changing requirements. Changing requirements pose a challenge for customers and consultants alike. Effectively navigating them together properly can help provide users with the best possible end-product. Here are key considerations to maintain momentum and foster a cohesive team.
**Understanding the Request**
As requirements expand or pose risks to the system, proactive team members play a crucial role in pushing back. This dynamic, while challenging, fosters the development of well-configured systems. To push through the shaping of requirements, you should expect your developers to be able to help bridge the gap to find the best path forward.
**Clarifying Intent and Vision**
Team members need to be able to listen first and strive to understand the driving need for the requirement. As the customer, you may need to provide examples of your expectations for process inputs and your vision for the end-result. Including flowcharts, mockup forms, or an outline of the current and desired process is extremely helpful. Open communication ensures that interpretations align, with follow-up questions serving as bridges to mutual understanding.
**Tapping into your Consultant’s Knowledge**
Consultants are more than problem solvers; they are educators, empowering customers with information and distilling relevant functionality. As a customer, you should feel empowered to request additional training or knowledge transfer for your product. A quality consultant excels as both a diligent learner and an effective teacher, elucidating reasons behind recommendations or limitations.
**Do alternatives exist?**
While your vision may not be possible or recommended, your consultant may suggest alternative solutions. A quality consultant should guide you through the logic for alternative solutions and be open to outside ideas for resolution. Stepping back into a learning mindset, ask any questions you can think of to help keep traction towards a potential solution. Active listening and solutioning from all parties at this step is extremely helpful. If several potential alternatives are considered, leaving the consultant with high-level expectations ensures a focused investigation into potential solutions.
**Is there additional investigation required?**
Allowing your consultant to take the conversation offline can provide them with the opportunity to identify alternatives and organize information. This is an iterative step where the consultant should provide an email, other written communications, or may set up another meeting to provide you with the investigation results. For each iteration of communication, you should expect to feel closer to a satisfactory solution where the goal is to achieve mutual understanding that emphasizes a quality workable solution. A quality consultant may use one or multiple of the following tools to help guide choosing an alternative.
- **Numbered alternatives complete with an evaluation of the benefits and drawbacks for each option**
- **Visual aids such as screenshots, wireframes, or mockups**
- **Light development or configuration for displaying examples**
- **A plain language logic outline for the process**
- **A visual flowchart of the proposed solution(s)**
**Conclusion: How do we move forward?**
Although some of the earlier questions may be irrelevant, I feel that this is the most important aspect of handling changing requirements within a project. When determining the answer to this question, your consultant should ensure that all parties are supportive of the chosen path and effectively communicate clear and achievable expectations for success. If the result of this process includes performing no action or development, you should feel heard and satisfied with that result. If an alternative is chosen, then the expectations have been inherently defined, and your team should have a clear path to success.
**To find out more, please contact us at **
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
**Categories:** Product Development and Design Services
---
### [Integrating Elns And Lims](https://zifo.com/blogs/integrating-elns-and-lims-best-practice/)
**Published:** May 23, 2023
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [Integrating Elns And Lims](https://zifo.com/blogs/integrating-elns-and-lims-best-practice/ "Integrating Elns And Lims")
## Integrating Elns And Lims
Paul Denny-Gouldson
May 23, 2023
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Integrating%20Elns%20And%20Lims%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Fintegrating-elns-and-lims-best-practice%2F "Share on Email")
- [](https://x.com/intent/post?text=Integrating%20Elns%20And%20Lims&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fintegrating-elns-and-lims-best-practice%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Integrating+Elns+And+Lims&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fintegrating-elns-and-lims-best-practice%2F "Share on LinkedIn")
Image reference: / source
**BACKGROUND**
Integrating Electronic Laboratory Notebooks (ELNs) and Laboratory Information Management Systems (LIMS) can streamline data management and enhance efficiency in a laboratory setting. Here are some best practices for ELN and LIMS integrations that Zifo recommend.
**KEY CONSIDERATIONS**
1. Define integration goals: Clearly define your integration objectives and identify the specific functionalities and data that need to be shared between the ELN and LIMS. This will help you design an integration strategy that aligns with your laboratory’s needs.
2. Evaluate compatibility: Ensure that your chosen ELN and LIMS platforms are compatible and offer integration capabilities. Review the technical requirements, compatibility documentation, and APIs (Application Programming Interfaces) provided by both systems. Consider a data integration and orchestration platform so you are not integrating everything to everything and end up with spaghetti code everywhere – making it super hard to maintain and debug when things go wrong. Integrate to a common data backbone (data fabric) this will give you options and flexibility in the future to change the ELN and LIMS and adapt as your your lab changes and grows.
3. Data mapping: Identify the data elements that need to be synchronized between the ELN and LIMS. Define a consistent data model and mapping strategy to ensure that data is correctly transferred and mapped between the two systems. This includes fields such as sample IDs, test results, metadata, and timestamps.
4. Establish data synchronization rules: Determine the rules and frequency for data synchronization between the ELN and LIMS. Decide whether data should be synchronized in real-time or on a scheduled basis. Consider factors such as data volume, system performance, and the importance of up-to-date information.
5. Ensure data integrity and security: Data integrity and security are crucial when integrating ELNs and LIMS. Implement robust encryption methods, access controls, and user authentication mechanisms to protect sensitive data. Regularly backup data to prevent loss or corruption. Evaluate the use of BPMN tools versus custom code to define system integration architecture. BPMN often provide robust and scalable integration at low cost and provide easy updates, monitoring, failover support and future development.
6. Build, Test and Validate the integration: Perform thorough testing to ensure the integration works as expected. Test various scenarios, data types, and system interactions to identify and resolve any issues or discrepancies. Validate the integration with a diverse set of sample data. Build DEVOPs for integration services (best approach is hosted integrations if using SaaS ELNs and LIMS or a mixture on prem/SaaS) to ensure stability, security and maintainability. Build in system monitoring and fault detection to reduce impacts of potential system failures (BPMN offers good capabilities).
7. Provide user training and support: Educate laboratory staff about the integrated ELN and LIMS system. Offer training sessions to familiarize users with the new workflows, data entry procedures, and access to integrated functionalities. Establish a support mechanism to address user questions and troubleshoot any integration-related problems.
8. Monitor and maintain the integration: Continuously monitor the integration to ensure its smooth operation. Regularly review system logs, error reports, and performance metrics. Stay updated with the latest releases and updates from both the ELN and LIMS vendors to address compatibility issues or take advantage of new features.
9. Document the integration process: Maintain comprehensive documentation that outlines the integration setup, configuration, and workflows. Document troubleshooting steps, known issues, and resolutions to facilitate future maintenance or upgrades.
**KEY TAKEAWAYS**
Remember, the specific integration requirements may vary based on the ELN and LIMS platforms you’re using, as well as the unique needs of your laboratory workflows. Zifo have extensive experience with many ELN and LIMS systems currently on the market and can provide support for the full process detailed above from ideation and design, through build and test, to validation and ongoing managed services.
Please contact us at if you have any questions or would like to know more.
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
---
### [Delivering Value With Spatial Transcriptomics](https://zifo.com/blogs/delivering-value-with-spatial-transcriptomics/)
**Published:** November 8, 2024
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [Delivering Value With Spatial Transcriptomics](https://zifo.com/blogs/delivering-value-with-spatial-transcriptomics/ "Delivering Value With Spatial Transcriptomics")
## Delivering Value With Spatial Transcriptomics
Radesh Nattamai Malli Pooranachandhiran, Senior Bioinformatician
Nov 08, 2024
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Delivering%20Value%20With%20Spatial%20Transcriptomics%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Fdelivering-value-with-spatial-transcriptomics%2F "Share on Email")
- [](https://x.com/intent/post?text=Delivering%20Value%20With%20Spatial%20Transcriptomics&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fdelivering-value-with-spatial-transcriptomics%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Delivering+Value+With+Spatial+Transcriptomics&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fdelivering-value-with-spatial-transcriptomics%2F "Share on LinkedIn")
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Stories
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
Spatial transcriptomics is revolutionizing our understanding of gene expression patterns and disease states. However, harnessing the full potential of this technique requires careful consideration of a few critical elements, such as input data types and file formats, computational challenges, and the all-important downstream visualization.
**Input Data: A Diverse Spectrum of Data Types and Formats**
Spatial transcriptomics leverages a wide range of data types, each with unique characteristics.
Common types include:
- **Spatial RNA sequencing (spRNA-seq):** Generates gene expression count matrices for individual cells or spots within a tissue.
- **In situ sequencing (ISS):** Produces high-resolution images of gene expression patterns within cells.
- **Slide-seq:** Captures gene expression profiles on a spatially barcoded slide.
Understanding the specific data type and characteristics of your data is crucial for selecting appropriate analysis tools and methods, requiring the following steps:
- **Data preprocessing:** Cleaning, filtering, and normalizing the data to remove noise and artifacts.
- **Spatial domain identification:** Identifying biologically meaningful spatial regions or compartments within the tissue.
- **Cell type annotation:** Assigning cell types to different spatial locations based on gene expression profiles.
- **Cell-cell interaction analysis:** Inferring interactions between cells based on their spatial proximity and gene expression patterns.
Table 1 lists the files which are commonly available or required as input to a spatial transcriptomics analysis pipeline.
TypeNameDescriptionH5 Fileraw\_feature\_bc\_matrix.h5Contains raw feature-barcode matrixJSON Filescalefactors\_json.jsonContains scale factors for image alignmentPNG Imagetissue\_hires\_image.pngHigh-resolution tissue imagetissue\_lowres\_image.pngLow-resolution tissue imageCSV Filetissue\_positions\_list.csvList of tissue positionsgene\_graph\_clusters.csvClustering results from SpaceRangerparameters.csvMetadata about the experimentTIFF Imagewsi.tifHigh-resolution whole slide imageGeoJSON Fileannotations.geojson (optional)Defines regions of interestHTML Fileweb\_summarySummary of the experiment
Table 1: Commonly available input files, format and description utilized by spatial transcription pipelines.
**Computational Challenges: A Complex Maze**
Analyzing spatial transcriptomics data presents significant computational challenges due to the large volume and complexity of the data. Key challenges include the need for specialized computational tools and pipelines, which are essential for effective data processing.
A critical computational requirement is the availability of High-Performance Computing (HPC) infrastructure with a combination of GPUs + CPUs (Figure 1). Additionally, sufficient RAM and storage (cloud-based S3 or on-premise server storage) are needed for efficient execution of any spatial transcriptomics pipeline.
In addition, other key considerations for the computational requirements of Spatial Omics include:
- **Data storage and processing:** ST datasets can be large, requiring significant computational resources for storage and analysis. High-performance computing infrastructure may be necessary for efficient processing and analysis.
- Algorithm complexity: Many ST analysis algorithms are computationally intensive, especially for large datasets or complex spatial patterns. Developing efficient algorithms is crucial for practical applications.
- Docker networking & API interface (plumber):
- **Plumber API** deployed in different containers.
- Interaction between containers via sending request and receiving response.
- **Python packages (Hydra and Metaflow):**
- **Metaflow** was used to build and design the pipeline workflow.
- **Hydra** used to generate dynamic configuration capabilities.
Figure 1: A typical high performance computational (HPC) system with GPU + CPU for executing spatial transcriptomics pipelines.
**Downstream Visualization: A Clear Picture**
Visualization of spatial transcriptomics results is critical for understanding gene expression patterns within a tissue. Researchers can identify spatial domains, cell types, and gene-gene interactions by combining spatial information with gene expression data. This enables a deeper understanding of biological processes and disease mechanisms.
Creating informative and visually appealing representations of spatial gene expression patterns is essential. Visualizing spatial transcriptomics data is crucial for understanding and communicating biological insights. Effective visualization techniques include:
- **Heatmaps**: Representing gene expression levels across different cells or spatial regions.
- **Spatial plots:** Displaying gene expression patterns within the tissue context.
- **3D visualizations:** Creating three-dimensional representations of spatial gene expression data.
- **Interactive tools:** Allowing users to explore and analyze data interactively.
Choosing the right visualization methods depends on specific research questions and the nature of the data.
Figure 2 shows a typical visualization of the spatial data results using Tissuumaps, an open-source tool that helps view different aspects of the results.
Figure 2: Spatial transcriptomics visualization of results used for downstream analysis using Tissuumaps.
In addition to this open-source tool, custom visualization options require developing R Shiny applications that provide data visualization spanning initial data processing, cell clustering, annotation and UMAP plots for deeper insights. Figure 3 shows a custom R Shiny app displaying UMAP data, ready for analysis.
Figure 3: Custom R Shiny app depicting spatial omics data ready for analysis.
**Conclusion**
Spatial transcriptomics offers immense potential for advancing our understanding of biological processes. However, navigating the challenges associated with input data, computational analysis, and downstream visualization is essential for extracting meaningful insights.
If you are interested in spatial omics, data ingestion, algorithm development, or visualization development, please contact .
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Stories
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
**Categories:** Bioinformatics
---
### [Unlocking The Power Of Posit In Pharma : Use Cases And Architecture Best Practices](https://zifo.com/blogs/unlocking-the-power-of-posit-in-pharma-use-cases-and-architecture-best-practices/)
**Published:** April 23, 2025
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [Unlocking The Power Of Posit In Pharma : Use Cases And Architecture Best Practices](https://zifo.com/blogs/unlocking-the-power-of-posit-in-pharma-use-cases-and-architecture-best-practices/ "Unlocking The Power Of Posit In Pharma : Use Cases And Architecture Best Practices")
## Unlocking The Power Of Posit In Pharma : Use Cases And Architecture Best Practices
Hariram Jayaram, Scientific Application Consultant | Jeya Priya Senthilkumaran, Senior Scientific DevOps Analyst
Apr 23, 2025
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Unlocking%20The%20Power%20Of%20Posit%20In%20Pharma%20%3A%20Use%20Cases%20And%20Architecture%20Best%20Practices%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Funlocking-the-power-of-posit-in-pharma-use-cases-and-architecture-best-practices%2F "Share on Email")
- [](https://x.com/intent/post?text=Unlocking%20The%20Power%20Of%20Posit%20In%20Pharma%20%3A%20Use%20Cases%20And%20Architecture%20Best%20Practices&url=https%3A%2F%2Fzifo.com%2Fblogs%2Funlocking-the-power-of-posit-in-pharma-use-cases-and-architecture-best-practices%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Unlocking+The+Power+Of+Posit+In+Pharma+%3A+Use+Cases+And+Architecture+Best+Practices&url=https%3A%2F%2Fzifo.com%2Fblogs%2Funlocking-the-power-of-posit-in-pharma-use-cases-and-architecture-best-practices%2F "Share on LinkedIn")
Image reference: / source
**Introduction**
The pharmaceutical industry is undergoing a data revolution. From early drug discovery to clinical trial submissions, data science is playing a pivotal role in accelerating research, improving decision-making, and meeting regulatory requirements.
At the heart of this transformation lies Posit (formerly RStudio), a powerful platform that enables open-source data science workflows with R and Python. In regulated environments like pharma, where reproducibility, compliance and scalability are essential, Posit offers a reliable and secure foundation for end-to-end analytics.
In this blog, we explore the key use cases of Posit in pharmaceutical research and walk through architectural best practices to help you get the most out of your investment.
**The Posit Ecosystem – At a Glance**
Posit provides an integrated suite of tools designed to cover the full data science lifecycle:
- **Posit Workbench:** A central development environment supporting R and Python, with integrations for multiple IDEs (Jupyter/VS Code), designed for collaboration and scalability.
- **Posit Connect:** A publishing platform that allows researchers to securely share reports, dashboards, APIs and models (multi-framework supported, from Shiny to Gradio/Bokeh).
- **Posit Package Manager:** Enables governance by controlling package access, managing internal repositories, and freezing versions through repo snapshots for reproducibility.
Together, these tools enable scientific teams to go from data to decision—securely, reproducibly, and collaboratively.
**Key Use Cases of Posit in Pharma**
**a. Clinical trial data analysis**
Pharmaceutical companies can rely on Posit for preparing CDISC-compliant datasets such as SDTM and ADaM, and for generating TLFs (Tables, Listings, and Figures) required in clinical study reports. Analysts use R Markdown or Quarto to integrate code, data, and interpretation in a single document—ensuring transparency and traceability.
**b. Drug discovery and bioinformatics**
R and Python packages for genomics, transcriptomics, and cheminformatics (e.g., Bioconductor, tidyverse, scikit-learn) are widely used for target identification and lead optimization. Posit Workbench supports these workflows with scalable compute and secure storage integrations.
**c. Interactive dashboards for clinical monitoring**
Using Shiny or Plotly Dash, teams can build web-based dashboards to monitor trial metrics, track patient recruitment, visualize adverse events, and more. These dashboards can be securely published on Posit Connect for real-time collaboration.
**d. Risk-based quality assessment**
R packages like riskmetric help assess the risk of open-source R packages. Pharma companies are extending these ideas to internal packages and tools to ensure validation readiness.
**e. Integrations with ELN, SDMS, and LIMS**
Posit integrates well with existing scientific data systems, enabling analysis pipelines. Reports and summaries can be auto-published to internal portals or email lists via Connect.
**Architecting Posit for Pharma: Best Practices**
To get the most out of Posit, the platform must be thoughtfully architected for performance, compliance, and usability.
**a. Scalable and flexible infrastructure**
- Deploy Posit on cloud platforms like AWS, Azure, or GCP—or in hybrid setups.
- Use scalable clusters (e.g., Kubernetes or AWS ParallelCluster) for heavy computation.
- Integrate with file systems like Lustre, EFS, or object stores (e.g., S3).
**b. Security and compliance**
- Integrate with enterprise authentication (SSO via Azure AD, Okta).
- Enable encrypted connections, audit logging, and workspace isolation.
- Ensure compliance with GxP, 21 CFR Part 11, and internal SOPs.
- Use Infrastructure Qualification (IQ), Operational Qualification (OQ), and Performance Qualification (PQ) templates.
**c. Package governance**
- Use Posit Package Manager to mirror and curate CRAN/PyPI packages.
- Take monthly snapshots and enforce reproducibility across projects.
- Create validated package sets for different stages of the research lifecycle.
**d. Multi-tenant setup and access controls**
- Organize users by therapeutic areas or project teams.
- Use project folders, ACLs, and scoped publishing in Connect.
- Enable resource isolation between business groups.
**e. CI/CD and automation**
- Integrate Git-based workflows for version control.
- Automate the deployment of Shiny apps, reports, and APIs using the Connect publishing API.
- Parameterize reports for dynamic generation across multiple studies or regions.
**Reference Architecture**
While Posit Suite provides a one-stop data analytics solution, building a well-oiled platform with the necessary integrations and scalability is the key to unlocking its full potential.
The following must be considered when designing such a platform:
1. Compute power and scalability.
2. Storage integrations.
3. Data source integrations.
4. Different IDE integrations.
Decisions around these considerations should be made based on the business use case.
The ideal enterprise-scale Posit platform uses essential components of a reference architecture. The Workbench serves as the entry point for developers and can be powered by various compute environments such as Kubernetes (EKS), HPC (Slurm cluster), or a single server. Based on business case analysis, one or more compute environments should be selected. It is recommended to maintain flexibility by integrating different IDEs, such as Jupyter, VS Code, Positron or RStudio IDE, into the Workbench to support diverse user needs. Additionally, the Workbench can be integrated with Databricks clusters for parallel data analysis using Spark (optional).
Content created in the Workbench (e.g., Shiny apps, Streamlit apps, APIs, Markdown Reports, Quarto Reports) is intended to be hosted on the Posit Connect platform. While direct deployment is straightforward, a Git-based deployment with unit testing is recommended for controlled releases. Both Workbench and Connect can connect to a wide variety of data sources (e.g., Redshift, Oracle, Postgres, MongoDB) to support robust analysis.
Multiple versions of R and Python can be configured in both Workbench and Connect, giving developers flexibility when migrating code from local environments. However, it’s essential to manage the risks of open-source software by controlling the repositories and packages used. This is achieved through careful configuration of the Package Manager for both R and Python packages. While it’s important to configure the platform for flexibility across use cases, performance is equally critical. Hosting the platform in the cloud offers scalability and processing power for enterprise-wide analytics. Choosing the right services, compute resources, network configurations, and storage options is vital to creating a robust data analytics architecture.
**Embracing R and Python Together**
Modern pharmaceutical analytics is no longer limited to a single language. Posit supports both R and Python seamlessly, allowing teams to leverage the best tools for each task.
- Analysts can use reticulate to combine R and Python in a single notebook.
- Python support in Posit Workbench includes JupyterLab, VS Code, and terminal-based workflows.
- Machine learning models built in scikit-learn or TensorFlow can be deployed and monitored alongside R-based models.
This multi-language capability empowers diverse teams to collaborate without barriers.
**Conclusion**
Posit is more than an IDE—it’s a complete platform for modern, reproducible, and compliant data science in pharma. From clinical trial analytics to bioinformatics, it provides the tools to drive insights while meeting the demands of a regulated environment.
By thoughtfully architecting your Posit environment with the right infrastructure, governance, and automation, you can empower your scientific teams and accelerate drug development timelines.
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
**Categories:** Data Science and Consulting Services, Scientific Cloud Computing Services
---
### [Why Science Is Protesting For Data Democracy And We Must Listen](https://zifo.com/blogs/why-science-is-protesting-for-data-democracy-and-we-must-listen/)
**Published:** May 17, 2023
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [Why Science Is Protesting For Data Democracy And We Must Listen](https://zifo.com/blogs/why-science-is-protesting-for-data-democracy-and-we-must-listen/ "Why Science Is Protesting For Data Democracy And We Must Listen")
## Why Science Is Protesting For Data Democracy And We Must Listen
Abhinav Balakumar,Sanjanaa Jeevandass
May 17, 2023
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Why%20Science%20Is%20Protesting%20For%20Data%20Democracy%20And%20We%20Must%20Listen%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Fwhy-science-is-protesting-for-data-democracy-and-we-must-listen%2F "Share on Email")
- [](https://x.com/intent/post?text=Why%20Science%20Is%20Protesting%20For%20Data%20Democracy%20And%20We%20Must%20Listen&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fwhy-science-is-protesting-for-data-democracy-and-we-must-listen%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Why+Science+Is+Protesting+For+Data+Democracy+And+We+Must+Listen&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fwhy-science-is-protesting-for-data-democracy-and-we-must-listen%2F "Share on LinkedIn")
Image reference: / source
In a rapidly transforming world where data is termed the new oil, we are surrounded by conversations about why data is important, the wonders we unearth each day with data and how it is transforming and invading our lives. Perhaps the oil analogy is not quite right – we do transform data as we do oil – but data is not a fixed resource and will not run out – it will continue to grow and develop over time – making it more valuable than oil.
This continuous overpowering creation of information, insights and knowledge is often characterized as uncontrolled, confounding and largely under-utilized. Global industries are now going through a revolution in digitization, digital technologies, automation and AI among other “buzz-word” worthy concepts. However, the foundation of any of or all these technologies is…… Data.
The life sciences industry has often been criticized for playing catch-up with other industries such as FINTECH etc.. While other industries are becoming data and analytics-ready, and even data-driven in some cases – the life sciences industry has yet to realise the true potential of the data stockpile they are sitting on.
**More Data, More Problems:**
Data generation has never been a problem in the life sciences industry. Labs have been producing enormous amounts of data for many years and it is only increasing thanks to recent technology advances in multi-omics and image based analytical techniques.
Our data requirements have always been intensive and are only getting more complicated thanks to such fields as omics (genomics, transcriptomics, proteomics, metabolomics etc.), biomarker analysis, clinical statistics to name a few.
The time spent and complexity of managing data is becoming increasingly cumbersome compared to our data generation capacity. Scientists are often faced with insurmountable challenges in accessing, cleaning and managing data, rather than spending their time on analysing and inferring from it.
The most common problems faced by scientists are:
**Availability:**
The availability and accessibility of data for business and exploratory needs are perhaps the foremost problems faced by scientists working in data-siloed organizations. Data is often stored in native or custom formats specific to each instrument or scientific application niche to a business process. Scientists often hit roadblocks when trying to search for related data from their processes or running behind “data owners” to get access to relevant data.
**Lack of Data Standards:**
Data exchange is often seen necessary for driving innovation between organizations and within organizations, but it’s always impeded by the lack of data standards among instruments, labs, business units, and entire organizations. The need for data standards was clearly understood during the [ Ebola outbreak](https://www.manufacturingchemist.com/news/article_page/Data_standards_the_key_to_making_the_lab_of_the_future_dream_a_reality/163825) of 2014, when data sharing helped scientists trace the origins of the virus and control the endemic. The need is reiterated in the current COVID-19 pandemic, with the [WHO defining data sharing and reporting protocols](https://www.who.int/bulletin/volumes/98/3/20-251561/en/). In spite of defining a protocol, the COVID-19 pandemic has [ clearly highlighted](https://www.healthcareitnews.com/news/covid-19-emergency-shows-limitations-nationwide-data-sharing-infrastructure) how lack of data sharing standards in real world scenario exposes the shortcomings of any data infrastructure, and in turn the health infrastructure.
**Ownership and usage:**
Most organizations do not have clearly defined owners for their data, and often the IT teams that manage the applications end up as de facto owners. This leads to scientists and research teams being dependent on IT teams to access and analyse data.
There’s also the unwanted evolution of the IT team into a common data analytics team, performing [ ETL operations](https://towardsdatascience.com/a-data-engineers-perspective-on-data-democratization-a8aed10f4253) on behalf of the data users.
Lack of Self-service Analytical tools or knowledge leads to dependency on data scientists to perform ETL and create inferences without complete knowledge about the data process. Organizations often end up having to hire generalist data scientists who work across business functions without the scientific focus required for drug discovery research.
**Data Democratization:**
Data democratization is the process of making data accessible to everyone. There would be no gatekeepers creating bottlenecks at the data gateway. Democratization is not limited to just access. It requires that the accessed data is understandable, and teams have a way to analyse and function using said data. The earliest proponents of large scale Data Democratization, [AirBnB](https://medium.com/airbnb-engineering/how-airbnb-democratizes-data-science-with-data-university-3eccc71e073a) have made a stellar proof of concept for organizations to follow.
In order to understand how democratized data is within an organization, asking yourself a few simple questions would help:
Can you….
- directly access all data relevant to your position
- search for datasets and inferences made by other teams related to your position
- access unprocessed data to perform exploratory analysis
- create new datasets, that can be added to a central repository
- set up new experiments with the existing models and data
- access metadata information related to all datasets
If even one of these questions is answered No, then your organization needs to work on democratizing their data.
Consider an example of a batch control process in a bioprocess lab where your scientist is trying to improve the batch-end quality.
Usually Quality Analysis is performed at the end of each batch process by performing full factorial tests on measured variables. Data for analyses must be gathered from quality parameter sensors in order to identify accurate changes to the input. This is usually done with an open- loop control, which does not happen in real-time.
Instead, if you can enable the entire process to be data-centric, with data-driven models, allowing your team to access and analyse data at every step, including the end result, it allows scientists and engineers to work on controlling and optimizing the batch performance.
Business units are always in need of data from different sources for optimization and decision-making. Enabling them to be data-centric can help achieve a paradigm shift in labs and industries of the future.
**How do you democratize Data?**
**Set up data infrastructure:**
Create/set up data storage, platforms and analytical tools depending on your end-use with the core components of democratization in mind. Apply [FAIR ](https://www.go-fair.org/fair-principles/) (findability, accessibility, interoperability, and reusability) principles to all data over time.
**Restructure your team:**
Move towards a decentralized data team, where any team has the ability/knowledge to perform the role of a data scientist
**Implement Metadata Hubs:**
A Metadata Hub is part of your infrastructure that goes a long way in enabling your data to be democratized. Metadata Hubs help in enabling data to be accessible by indexing datasets, contents of tables, and its connection to other data. Using semantics, this allows any data user to understand the origin, context and historical use of a data source before they decide to work with it.
**Quality checks and data stewards:**
One of the biggest challenges in decentralizing data is maintaining quality of the datasets created by different teams and ensuring consistency. Open data formats, in-house QC tools and automated checks and anomaly detectors go a long way in helping with quality checks. Data stewards can help in implementing data governance standards for democratized data to ensure quality of content and metadata.
**Realigning focus by training your team on ETL:**
Having a decentralized team helps users perform Extract, Transform and Load operations on their own data, instead of having to rely on IT teams and Data Engineers. This reduces the burden of data engineers who can work towards more organizationally relevant ideas of improving and maintaining data infrastructure. It creates an agile process for business units to have analysis-ready data whenever they need it.
“Democracy is the art of thinking independently together”- Alexander Meiklejohn
Data Democratization allows life sciences and healthcare organizations to uncover opportunities from research data thus expediting decision-making and in turn allowing solutions to reach patients faster.
A data democratized organization has teams that are data-centric and empowered through a connected ecosystem and knowledge of handling and analysing data.
Numerous hidden patterns and undiscovered insights can come to light leading to accelerated drug discovery and development from existing data.
Have any thoughts or questions on this? Please email us at
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
**Categories:** Data Science and Consulting Services, Digital Transformation Consulting
---
### [Telemedicine: Then, Now And The Future](https://zifo.com/blogs/telemedicine-then-now-and-ahead/)
**Published:** May 23, 2023
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [Telemedicine: Then, Now And The Future](https://zifo.com/blogs/telemedicine-then-now-and-ahead/ "Telemedicine: Then, Now And The Future")
## Telemedicine: Then, Now And The Future
Amal Krishna Girish
May 23, 2023
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Telemedicine%3A%20Then%2C%20Now%20And%20The%20Future%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Ftelemedicine-then-now-and-ahead%2F "Share on Email")
- [](https://x.com/intent/post?text=Telemedicine%3A%20Then%2C%20Now%20And%20The%20Future&url=https%3A%2F%2Fzifo.com%2Fblogs%2Ftelemedicine-then-now-and-ahead%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Telemedicine%3A+Then%2C+Now+And+The+Future&url=https%3A%2F%2Fzifo.com%2Fblogs%2Ftelemedicine-then-now-and-ahead%2F "Share on LinkedIn")
Image reference: / source
What comes to your mind when you hear “**Telemedicine**“?
One might think that Telemedicine is all about the internet, video calling, and wearable devices, etc., but it’s not limited to just those things.
We all know that Telemedicine revealed its real potential amidst the Covid-19 pandemic when it became a necessity, and the medical industry could not proceed without!
Although Telemedicine has become widely popular in recent times, proof of its existence goes back to ancient Greek and Roman civilizations around 500 B.C. It includes Smoke, Fire, and Loud sounds by drums or other means – and were used to signify events such as birth, death, or disease outbreaks.
The more recent incarnation of Telemedicine as we know it now, came in April 1924 in a radio news magazine titled “***The Radio Doctor – Maybe***!” where it showed patients interacting with doctors via a television like screen and a microphone – it also showed a few ECG graphs getting printed out from the device. The remarkably interesting thing here is that television wasn’t invented in 1927!
Although it was a very wild prediction – it is quite surprising that has taken almost one hundred years for the world to start to leverage Telemedicine to its full potential.
**Telemedicine Amidst Covid-19 times**
There is little doubt that the Covid pandemic hastened the growth of Telemedicine.
Data shows that use of Telemedicine hiked from 11 % to 76 % from 2019 to 2022.
So, one clear beneficiary of the COVID-19 outbreak is Telemedicine. The progress of Hybrid/Decentralized clinical trials is streamlined through Telemedicine. Data indicates that shares of the company Zoom are up more than 150 % since the start of 2020 and shares of Microsoft \[Which owns skype\] are up more than 14% since the start of 2020. Some of this increase might also be due to the increase in remote working due to COVID, but it is likely some is due to Telemedicine.
Telemedicine not only reduces costs, but also time. For instance, it is estimated that on average, a person takes almost 2 Hours for an in-person physician/doctor visit2. Breaking down this 2 Hours:
- Travelling takes around 37 minutes,
- Waiting and filling out paperwork takes 63 minutes, and
- Actual time spent face-to-face with a doctor: 20 minutes.
According to a study conducted by CISCO, over **74%** of patients favour simple remote access to medical care services over in-person interactions3. An important factor when we consider any clinical trial is that it should be delivered in a patient- centric fashion. From the patient’s point of view, it is way better in terms of cost and time not having to take a 2 -3 hour break from work for a doctor’s appointment.
Plus, patients don’t have to invest a lot of time waiting, and for all the procedures associated with an in-person visit.
**BENEFITS**
Upon close examination, there are clear benefits of using Telemedicine in clinical trials for all stakeholders – shown by the infographic.
**Future of Telemedicine**
**Artificial intelligence**
AI powered technologies can serve as an anchor in automatic interactions with patients.
AI-based healthcare systems could detect symptoms and give information on medications, treatment, appointments etc., and there are many examples of these “monitoring” type applications in the news.
AI supported systems could also potentially improve the speed, accuracy, and precision of the process.
FDA approved the first AI based diagnostic device – which uses a self-optimizing algorithm based on deep learning to diagnose diabetic retinopathy. This algorithm enables a neural network to learn and execute a particular task through repetition and self-correction.
It is reported that this algorithm was trained with almost 0.12 million high-quality human-graded fundus images, which helped it to correct and learn how to diagnose diabetic retinopathy.
What’s fascinating is the doctor’s words on this technology –
- In 87% of the given cases, this disorder was precisely detected by the AI, and 90 % of the time, it correctly identified individuals without the disorder.
- It lessens the burden on the doctor as well as playing a key role in Hybrid, Decentralized clinical trials.
- We can’t conclude that ‘AI’ replaces the doctor’s intelligence. In fact, it’s going to filter out the patients with real disease who need real treatments.
**Virtual reality / Augmented reality**
Along with AI, **VR/AR** is also aiding in educating and training health care professionals and planning medical procedures. For visits, patients see and talk to their doctors as if they are standing nearby. Because, at the end of the day, humans are humans, and we need to interact with each other. The kind of engagement that happens when interaction happens face-to-face is entirely different to the remote version. In a clinical trial where everything is decentralized, VR/AR can aid with this “engagement” to an extent.
**Conclusion**
It’s no doubt that Telemedicine is here, adding value and being used but, still a few concerns exist.
The fundamental necessity of Telemedicine is the internet. In a recent survey done by Statista, more than 50 % of Indians don’t have access to internet4. And, even with internet access, bandwidth issues typically cause problems in video calls/consultations.
From a clinical trial point of view, patients need a proper private place to communicate with their doctors, lack of this will undoubtably affect the trial.
Even though Telemedicine allows doctors to examine their patients without the constraints of time and place, face-to-face interaction is always different. A physical touch, an eye-to-eye conversation aids in improving the mood of the patient and helps with diagnosis – which cannot be substituted by any technology.
However, it is highly likely that these hurdles with current Telemedicine will be overcome for the betterment of human health and the clinical trials industry.
If you would like to talk to us about this topic – please email us at info@zifo.com
**References**
1.
2.
3.
4.
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
---
### [Role Of ELNs In Drug Metabolism And Pharmacokinetics (DMPK) Studies](https://zifo.com/blogs/role-of-elns-in-drug-metabolism-and-pharmacokinetics-dmpk-studies/)
**Published:** May 17, 2023
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [Role Of ELNs In Drug Metabolism And Pharmacokinetics (DMPK) Studies](https://zifo.com/blogs/role-of-elns-in-drug-metabolism-and-pharmacokinetics-dmpk-studies/ "Role Of ELNs In Drug Metabolism And Pharmacokinetics (DMPK) Studies")
## Role Of ELNs In Drug Metabolism And Pharmacokinetics (DMPK) Studies
Tript Srivastava
May 17, 2023
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Role%20Of%20ELNs%20In%20Drug%20Metabolism%20And%20Pharmacokinetics%20%28DMPK%29%20Studies%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Frole-of-elns-in-drug-metabolism-and-pharmacokinetics-dmpk-studies%2F "Share on Email")
- [](https://x.com/intent/post?text=Role%20Of%20ELNs%20In%20Drug%20Metabolism%20And%20Pharmacokinetics%20(DMPK)%20Studies&url=https%3A%2F%2Fzifo.com%2Fblogs%2Frole-of-elns-in-drug-metabolism-and-pharmacokinetics-dmpk-studies%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Role+Of+ELNs+In+Drug+Metabolism+And+Pharmacokinetics+%28DMPK%29+Studies&url=https%3A%2F%2Fzifo.com%2Fblogs%2Frole-of-elns-in-drug-metabolism-and-pharmacokinetics-dmpk-studies%2F "Share on LinkedIn")
Image reference: / source
A fitting Drug Metabolism and Pharmacokinetic (DMPK) profile remains a challenge to reduce risks and improve efficiency in pharmaceutical R&D, leading to major drug failure cases. Compounds with optimal DMPK results seem to be efficacious and safe when choosing the same for drug development.
For the last 32 years, pharmaceutical industries have witnessed the vital role of DMPK and the science behind it, supporting and facilitating drug discovery and development process. Its predominant contribution is identifying the best drug candidates in Lead Identification and Optimization phases to enter Development phase. DMPK studies in preclinical phase can be broadly classified into in vitro DMPK and in vivo DMPK studies.
Nowadays, Electronic Laboratory Notebooks (popularly known as an ELNs) take huge credits for supporting DMPK studies. No wonder that this software system, which has been specially fabricated for scientific studies, has played a tremendous role in accelerating the preclinical studies by capturing, calculating, organizing, interacting, storing, searching and reporting scientific data across the scientific spectrum. Being a cloud-based software, it helps scientists to go paper-free.
In *in vitro* DMPK study there are a few sets of highly qualified assays which ensure the safety and efficacies of the drugs tested. These assays are configured as workflows in ELNs from High-throughput Screening to Lead Optimization phases. ELN assists the in vitro DMPK profile by providing a broad platform for the interaction and integrations of number of databases, instruments and other scientific setups which facilitate the process.
**Physicochemical screening Assays**
**Purpose of the Assay**
- Aids in the reduction of lipophilicity
- Modifies solubility
- Screens the best suited physicochemical properties of the desirable drug
**Instruments**
- LC-MS/MS
**Role of ELN**
- Performs all physicochemical calculations
- Batch file generation feature – sends data to plate readers or sophisticated instruments (e.g. LC-MS)
- Imports LC-MS exports (Excel or CSV files) for final solubility assessment of drugs
**Drug-transporter interaction Assays**
**Purpose of the Assay**
- Helps to understand the compound’s absorption potential by assessing membrane permeability with transformed human intestinal enterocytes (CaCo2 cells) / Madin-Darby canine kidney (MDCK) cells / Parallel artificial membrane permeability assay (PAMPA)
**Instruments**
- Nanoelectrospray MS/MS
**Role of ELN**
- Calculates Permeability coefficient (Papp) and Efflux ratio
- Knocks out unexpected values for further calculations
**Transporter screening Assays**
**Purpose of the Assay**
- Activation or inhibition of a drug transporter protein that involves in the ADME and toxicity of a drug (could have considerable clinical effects ranging from lowering drug efficacy to compromising safety)
**Instruments**
- Fluorescence and Radioactivity probes
- Fluorescence spectrometers coupled with LC/MS
**Role of ELN**
- Determines IC50 values
- Generates reports by consolidating experiments (created in ELN)
- Allows consolidation of results for future reference or investigational new drug application
**Metabolic Stability Assays**
**Purpose of the Assay**
- Metabolic Stability assays establish the percentage of compound’s metabolism over time using microsomes or hepatocytes
- Helps to compare and assess the compound’s metabolic rate and metabolites generated across species to fetch the PK values
**Instruments**
- LC-MS/MS is regarded as the best biological analytical method for the Metabolic Stability assays
**Role of ELN**
- Calculates intrinsic clearance of tested drugs
- Senior scientist can review the experiments done, if necessary
- Helps in considering only reviewed and approved experiments for further studies
**Metabolite identification Assays**
**Purpose of the Assay**
- Metabolite Identification assays optimize the chemical structure based on propensity to metabolic activation.
- This may increase or decrease the chances of unfavorable protein interactions
**Instruments**
- High Resolution Mass Spectrometry (HRMS)
**Role of ELN**
- CView chemical structure of any registered drug in the database
- Create chemical structures and perform chemical reactions in order to identify the desired and unwanted metabolites
**In-vitro CYP450 inhibition and induction screens Assays**
**Purpose of the Assay**
- Used to assess the potential of the compound towards drug-drug interactions
- Cytochrome P450 induction assay recognizes whether the test compounds have the potential to induce CYP1A2, CYP2B6 or CYP3A4 in cultured human hepatocytes by assessing mRNA levels
- P450 Inhibition assay, a reduction in the generation of the metabolites is examined
**Instruments**
- LC-MS for quantification of CYP proteins
- qRT-PCR is used for capturing relative mRNA expression levels for CYP1A2, CYP2B6 and CYP3A4
**Role of ELN**
- Easily compares assay’s fold induction data that is normalized to vehicle control: positive control responses
- Calculates IC50, EC50 and Emax
**Plasma Protein Binding (PPB) and Blood Partitioning Assays**
**Purpose of the Assay**
- Helps to understand how binding to plasma impacts the distribution of a drug into various tissues in the body
- Used to evaluate the blood to plasma ratio which determines the concentration of the drug in whole blood compared to plasma and gives an indication of drug binding capacity to erythrocytes
**Instruments**
- Equilibrium dialysis combined with LC-MS for measurement of PPB in drug discovery
- Lab on chip (LOC) is recommended to carry micro fluids management
**Role of ELN**
- Determines a value of the fraction of compound unbound to proteins (another essential parameter to be explored in-vitro)
- Calculates blood to plasma ratio
- Generates and prints labels to deal with many samples and differentiate the same
**The hepatotoxicity and cytotoxicity Assays**
**Purpose of the Assay**
- Measures cell death due to the cytotoxic effect of a test compound
**Instruments**
- Cytotoxicity is assessed using MTT technique (calorimetric assay)
**Role of ELN**
- Heat map configuration assists interpretation of these assays based on varied color range
**WANT TO KNOW MORE?**
If you would like to find out more about how Zifo can help with ELN, LIMS, Data Management, Invitro and Invivo sciences, please email us at
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
---
### [RNA & Protein Folding - Intricacies & Challenges](https://zifo.com/blogs/rna-protein-folding-intricacies-challenge/)
**Published:** September 21, 2023
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [RNA & Protein Folding – Intricacies & Challenges](https://zifo.com/blogs/rna-protein-folding-intricacies-challenge/ "RNA & Protein Folding – Intricacies & Challenges")
## RNA & Protein Folding – Intricacies & Challenges
Radesh Nattamai Malli P.
Sep 21, 2023
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20RNA%20%26%20Protein%20Folding%20%26%238211%3B%20Intricacies%20%26%20Challenges%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Frna-protein-folding-intricacies-challenge%2F "Share on Email")
- [](https://x.com/intent/post?text=RNA%20%26%20Protein%20Folding%20–%20Intricacies%20%26%20Challenges&url=https%3A%2F%2Fzifo.com%2Fblogs%2Frna-protein-folding-intricacies-challenge%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=RNA+%26+Protein+Folding+%E2%80%93+Intricacies+%26+Challenges&url=https%3A%2F%2Fzifo.com%2Fblogs%2Frna-protein-folding-intricacies-challenge%2F "Share on LinkedIn")
Image reference: / source
**Introduction**
RNA and protein folding can have significant drug discovery and development application as they aid in understanding molecular structures, dynamics, and interactions.
In a drug discovery context, RNA sequence analysis tools can aid in identifying potential drug targets or regulatory elements in disease-related RNA sequences. The MicroRNA target prediction tool from ViennaRNA helps in understanding post-transcription regulation, which can be relevant in diseases such as cancer, where microRNA dysregulation is common.
Protein folding tools are crucial in understanding the three-dimensional structure of proteins, which are in turn essential for rational drug design. By studying the folding pathways and dynamics of target proteins, researchers can identify potential binding sites and design drugs that specifically interact with disease-related proteins. There are several large-scale computational projects such as Rosetta@Home, Folding@Home, Foldit which are focusing on protein folding. In addition the application of Artificial Intelligence (AI) on computational problems has resulted in the development of AlphaFold, by DeepMind & EMBL, which performs protein structure predictions using deep learning. This whole area will be a topic in a future blog
Protein folding tools can also help guide site-directed mutagenesis experiments to engineer proteins with desired properties. This has applications in biotechnology, such as the development of enzymes with enhanced catalytic activity or increased stability. In infectious diseases, understanding the three-dimensional structure of viral or bacterial proteins is crucial for designing effective vaccines. In this case, protein folding tools can assist in predicting antigenic regions and developing vaccines that elicit a robust immune response.
Here’s a workflow that combines ViennaRNA and protein folding tools to predict the secondary structure of an RNA sequence followed by modelling the 3D structure of the associated protein.
Figure 1. A simple workflow which combines RNA and protein sequences tools for modelling and analysis.
Below is the description of the tools listed in the workflow (Figure 1) with each step describing the tools required, the URL of the tools and a high-level overview of executing the tool.
**Step 1: Predict RNA Secondary Structure using ViennaRNA**
- **Install ViennaRNA:** Download and install ViennaRNA package from the official website [**(https://www.tbi.univie.ac.at/RNA/)** ](https://www.tbi.univie.ac.at/RNA/)or use the appropriate package manager.
- **Prepare RNA Sequence:** Obtain the RNA sequence you want to analyze. Save it in a plain text file, e.g., “rna\_sequence.txt”. The format should be in a FASTA file format.
- **Run RNAfold:** Use the ViennaRNA “RNAfold” command to predict the secondary structure of the RNA sequence. Open a terminal and execute the following command:
**code:**
“RNAfold < rna\_sequence.txt > rna\_structure.txt”.
This command will output the predicted secondary structure in “rna\_structure.txt” along with the calculated minimum free energy (MFE) and ensemble free energy.”
**Step 2: Obtain Protein Sequence and 3D Structure Prediction**
- **Obtain Protein Sequence:** If you don’t have the protein sequence already, you can obtain it from publicly available databases or predict it using tools like BLAST or PSI-BLAST. The NCBI is the best place to learn more about downloading and installing BLAST suite of tools.
- **Predict Protein 3D Structure:** Use a protein structure prediction tool such as I-TASSER [**(https://zhanglab.ccmb.med.umich.edu/I-TASSER/)** ](https://aideepmed.com/I-TASSER/)or Rosetta **[(https://www.rosettacommons.org/software)](https://rosettacommons.org/software/)** or SWISS-MODEL **[(https://swissmodel.expasy.org/)](https://swissmodel.expasy.org/)** to predict the 3D structure of the protein based on its sequence.
**Step 3: Mapping RNA and Protein Structures**
- **Identify RNA-Protein Interactions:** Use RNA-protein interaction prediction tools like RPISeq [**(http://pridb.gdcb.iastate.edu/RPISeq/)**](http://pridb.gdcb.iastate.edu/RPISeq) or RPI-SE **[(https://github.com/haichengyi/RPI-SE/)](https://github.com/haichengyi/RPI-SE/)** to identify potential RNA-binding sites on the protein.
- **Visualization:** Use molecular visualization software like PyMOL **[(https://pymol.org/)](https://pymol.org/)** or ChimeraX **[(https://www.cgl.ucsf.edu/chimerax/)](https://www.cgl.ucsf.edu/chimerax/)** or VMD [**(https://www.ks.uiuc.edu/Research/vmd/)** ](https://www.ks.uiuc.edu/Research/vmd/)to visualize both the predicted RNA secondary structure and the modeled protein 3D structure. You can superimpose the structures to analyze potential RNA-protein interactions.
**Optional steps**
**Docking of RNA and Protein**
- **Docking Prediction:** Use a molecular docking tool like ClusPro **[(https://cluspro.bu.edu/)](https://cluspro.bu.edu/login.php)** or HADDOCK **[(https://www.bonvinlab.org/software/haddock2.4/)](https://www.bonvinlab.org/software/haddock2.4/)** to perform the docking of the RNA secondary structure (from Step 1) with the protein structure (from Step 2).
- **Analyze Docking Results:** Analyze the output of the docking simulation to identify potential RNA-protein binding sites and evaluate the interactions.
**Molecular Dynamics Simulation**
If you want to study the dynamics of the RNA-protein complex, you can perform molecular dynamics (MD) simulations using tools like GROMACS [(**https://www.gromacs.org/)**](https://www.gromacs.org/) or AMBER **[(https://ambermd.org/)](https://ambermd.org/)**.
RNA folding tools are crucial for predicting the secondary structure of RNA, which is essential for understanding their function and interactions. To achieve accurate results, data preprocessing is a critical step. Some important considerations in data preprocessing for RNA folding experiments are: sequence format conversion, sequence length Normalization, identification & handling of pseudoknots, data augmentation, secondary structure parsing and large dataset handling.
Downstream analysis of RNA folding results involves the examination and interpretation of the predicted RNA secondary structure obtained from RNA folding algorithms. These predictions are typically represented in various formats, such as dot-bracket notation, which describes the base-pairing interactions in the RNA molecule.
The downstream analysis of RNA folding results is a multi-faceted process that combines computational predictions with experimental data and functional annotations to gain a deeper understanding of the RNA’s structure and function. There are several factors such as identifying structural motifs, energy analysis, conservation analysis, interaction prediction, functional analysis and visualization which all combine to provide a deep understanding of the results generated.
Remember that predicting protein 3D structures is a challenging task and may not always be accurate. Additionally, the reliability of RNA-protein interaction predictions can vary depending on the tools and parameters used. Therefore, it’s essential to interpret the results with caution and validate the findings through experimental techniques if possible.
If you’re interested in RNA & Protein folding & sequence analysis or other bioinformatics specialties, please contact us at
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
---
### [Revitalizing Variant Calling With RNA-Seq Data](https://zifo.com/blogs/revitalizing-variant-calling-with-rna-seq-data/)
**Published:** August 3, 2023
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [Revitalizing Variant Calling With RNA-Seq Data](https://zifo.com/blogs/revitalizing-variant-calling-with-rna-seq-data/ "Revitalizing Variant Calling With RNA-Seq Data")
## Revitalizing Variant Calling With RNA-Seq Data
Radesh Nattamai Malli P.
Aug 03, 2023
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Revitalizing%20Variant%20Calling%20With%20RNA-Seq%20Data%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Frevitalizing-variant-calling-with-rna-seq-data%2F "Share on Email")
- [](https://x.com/intent/post?text=Revitalizing%20Variant%20Calling%20With%20RNA-Seq%20Data&url=https%3A%2F%2Fzifo.com%2Fblogs%2Frevitalizing-variant-calling-with-rna-seq-data%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Revitalizing+Variant+Calling+With+RNA-Seq+Data&url=https%3A%2F%2Fzifo.com%2Fblogs%2Frevitalizing-variant-calling-with-rna-seq-data%2F "Share on LinkedIn")
Image reference: / source
**Introduction**
RNA-Seq variant calling provides a powerful approach for uncovering genetic variations, understanding gene regulation, and identifying potential disease-associated variants. Its ability to capture transcriptome-wide information makes it a valuable tool for basic research and clinical applications. RNA-Seq variant calling offers several advantages, making it a useful tool for genomic research and clinical applications. SNP detection by RNA-seq is particularly interesting for various species since whole genome sequencing is expensive and exome sequencing tools are unavailable. In addition, applying **deep-learning techniques to RNA-seq variant calling** has dramatically increased the chances of identifying variants from RNA-seq data \[1\].
Zifo Bioinformatics team has experience in working on RNA-seq variant calling, which has applications in diverse fields such as:
- **Cancer Genomics**
- **Nephrological Disease Analysis**
- **Training RNA-Seq Variant Calling**
- **Custom RNA-Seq Pipeline Development, Enhancement and Customization**
**RNA-Seq Variant calling – Challenges and considerations:**
Some of the key challenges and considerations in RNA-seq pipeline building are given below, all of which the Zifo bioinformatics team has handled.
- **Alignment accuracy**
- **Differentiating sequencing errors from true variants**
- **Low expression levels and coverage**
- **Detection of structural variants**
- **Allelic imbalance and allele-specific expression**
- **Transcript isoforms identification**
- **False positives and false negatives**
- **Annotation and interpretation**
Addressing these challenges requires specialized bioinformatics tools, careful quality control measures, validation using independent methods, and consideration of the specific characteristics of RNA-Seq data.
Based on Zifo’s experience and knowledge derived from working on multiple projects we see the cost of RNA-Seq can range from a few hundred dollars to several thousand dollars per sample. As technology advances and economies of scale improve, the price of RNA-Seq has decreased over time. It is crucial to consult with sequencing service providers or core facilities to obtain accurate cost estimates tailored to your specific project requirements. They can provide detailed information on sequencing platforms, library preparation options, and associated costs.
In addition, the Zifo BIO team can help in RNA-seq pipeline development (Figure 1.) related to **Preprocessing (quality control, reads alignment), post-processing, variant calling (selecting RNA-Seq variant callers and parameter customization)** and reporting. Furthermore, **Metrics Capture** during pipeline execution is an additional service performed by the Zifo BIO team. It provides valuable data to the scientific team and the IT department, and the infrastructure teams.
Figure 1. RNA-seq pipeline workflow starting from library construction, sequencing, Bioinformatics pipeline (development and execution) finally ending with reporting, data analysis and results visualization. \[Image credit: www.bio-rad.com\].
**Zifo’s experience in the field of RNA-Seq Variant calling in Cancer and Normal samples**
RNA-Seq variant calling in cancer and normal samples can provide valuable insights into somatic mutations specific to cancer cells. Here are some considerations when performing variant calling with cancer and normal RNA-Seq samples:
- **Sample selection**
- **Data preprocessing**
- **Alignment and variant calling**
- **Filtering Germline variants**
- **Filtering artefacts & sequencing errors**
- **Annotation and prioritization**
- **Validation**
- **Downstream analysis**
Since the normal sample contains germline variants in the patient’s genome, it is important to filter out these variants from the variant calling results. Tools like GATK’s “MuTect” or “VarScan” offer specific options for identifying somatic variants by filtering out germline variants in the normal sample..
It’s important to note that RNA-Seq variant calling in cancer samples may have additional complexities due to tumour heterogeneity, sub-clonal mutations, and variations in gene expression levels. These challenges may require specialized methods for accurate variant calling and interpretation. Overall, performing variant calling with cancer and normal RNA-Seq samples can provide insights into the somatic mutations specific to cancer cells, enabling a better understanding of the genetic alterations underlying cancer development and progression.
If you’re interested in RNA-Seq variant calling design, custom enhancement, research, and development, contact us by email at , and we are eager to collaborate and discuss further.
**Reference:**
\[1\]. (A deep-learning-based RNA-seq germline variant caller) [https://academic.oup.com/bioinformaticsadvances/article/3/1/vbad062/7197031?login=false#409987722](https://academic.oup.com/bioinformaticsadvances/article/3/1/vbad062/7197031?login=false#409987722%22)
**Happy Discovery from Zifo Global Bioinformatics Team !**
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
---
### [Maintaining Data Integrity During EHR-EDC Integrations](https://zifo.com/blogs/maintaining-data-integrity-during-ehr-edc-integrations/)
**Published:** May 16, 2023
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [Maintaining Data Integrity During EHR-EDC Integrations](https://zifo.com/blogs/maintaining-data-integrity-during-ehr-edc-integrations/ "Maintaining Data Integrity During EHR-EDC Integrations")
## Maintaining Data Integrity During EHR-EDC Integrations
Loganathan K, Compliance Consultant
May 16, 2023
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Maintaining%20Data%20Integrity%20During%20EHR-EDC%20Integrations%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Fmaintaining-data-integrity-during-ehr-edc-integrations%2F "Share on Email")
- [](https://x.com/intent/post?text=Maintaining%20Data%20Integrity%20During%20EHR-EDC%20Integrations&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fmaintaining-data-integrity-during-ehr-edc-integrations%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Maintaining+Data+Integrity+During+EHR-EDC+Integrations&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fmaintaining-data-integrity-during-ehr-edc-integrations%2F "Share on LinkedIn")
Image reference: / source
Integrating Electronic Health Record (EHR) systems with Electronic Data Capture (EDC) systems in clinical trials can save time, effort and cost. However, ensuring data integrity and security during such an integration can be tricky.Here is a simple explainer, breaking down the guideline, “Use of Electronic Health Record Data in Clinical Investigations”. There are three key requirements to ensure data integrity and data security in line with the FDA guideline:
**1. Validation and Part 11:**
- Have a validation package for the EDC system and the EHR-EDC integration ready, and make sure it is in accordance with 21 CFR Part 11
- Assess the EDC system thoroughly and set in place a clear process for compliance
**2. Documentation and Change Control:**
- Have appropriate procedures and design documentation in place. This must cover all the requirements for the integration
- If you have multiple integrations for various EHR systems, make sure you appropriately define, validate and document the cross integrations
- Set in place a suitable change control process. Make sure that this outlines any updates to the integration and EDC system
- Ensure that any updates made to the EDC system do not impact the integrity of the EHR data
**3. Data Integrity and Data Security:**
- Make sure you comply with HIPAA requirements to ensure data integrity and data security
- Conduct periodic checks to review the integration logs for any errors to identify and address potential data security gaps
At the exciting prospect of health records and EDC systems coming together, this is an approach that could ensure that data integrity is fulfilled.
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
---
### [Leveraging Open-Source & Public Bioinformatics Data Repositories](https://zifo.com/blogs/leveraging-open-source-public-bioinformatics-data-repositories/)
**Published:** July 13, 2023
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [Leveraging Open-Source & Public Bioinformatics Data Repositories](https://zifo.com/blogs/leveraging-open-source-public-bioinformatics-data-repositories/ "Leveraging Open-Source & Public Bioinformatics Data Repositories")
## Leveraging Open-Source & Public Bioinformatics Data Repositories
Radesh Nattamai Malli P.
Jul 13, 2023
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Leveraging%20Open-Source%20%26%20Public%20Bioinformatics%20Data%20Repositories%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Fleveraging-open-source-public-bioinformatics-data-repositories%2F "Share on Email")
- [](https://x.com/intent/post?text=Leveraging%20Open-Source%20%26%20Public%20Bioinformatics%20Data%20Repositories&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fleveraging-open-source-public-bioinformatics-data-repositories%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Leveraging+Open-Source+%26+Public+Bioinformatics+Data+Repositories&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fleveraging-open-source-public-bioinformatics-data-repositories%2F "Share on LinkedIn")
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Stories
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
**Introduction**
In bioinformatics, the availability of open-source software and resources has been a game-changer. Researchers can now access and analyze vast amounts of biological data using powerful, freely available computational tools. This has democratized the field and allowed researchers from all over the world to collaborate and contribute to the advancement of biological knowledge.
This document will discuss the benefits of leveraging open-source bioinformatics resources and provide examples of how researchers can use them to enhance their research.
Leveraging open-source bioinformatics databases can be incredibly valuable for various research and analysis purposes in biology and genetics. These databases provide access to vast amounts of biological data, allowing researchers to explore and interpret information related to genes, proteins, genomes, pathways, and more.
Some of the key databases are NCBI, Ensembl, TCGA, GEO (Gene expression Omnibus), which are used widely by researchers and scientists worldwide and are being updated with increased frequency. These databases, among many others, serve as valuable resources for scientists and bioinformaticians. Leveraging these open-source bioinformatics databases can aid in data analysis, hypothesis generation, and gaining insights into biological processes, ultimately advancing research and discovery in bioinformatics.
Open-source bioinformatics repositories provide a wealth of information that can be used in biological research. Here are some strategies for effectively using these resources:
1. **Identify the right resource:** With the plethora of open-source bioinformatics resources available, it is important to identify the right tool /data that suits your research needs. It is important to understand the nature of your research problem and the type of data you are working with to identify the right resource. For example, if you are working with next-generation sequencing data, tools like Galaxy, NCBI BLAST, and Bioconductor can be useful.
2. **Familiarize yourself with the resource:** Once you have identified the right resource, familiarize yourself with it. Learn about its features, functionalities, and limitations. Take advantage of online tutorials and documentation to better understand the tool/data.
3. **Collaborate with others:** Collaborating with other researchers using similar resources can be helpful and can be achieved through online forums, mailing lists, and social media. Collaborating with others can provide valuable insights and solutions to problems that you may encounter.
4. **Keep up-to-date:** Bioinformatics resources are constantly evolving. Keeping up-to-date with the latest developments and updates is important to ensure you use the most current and accurate information.
5. **Participate in the community:** Participating in the open-source Bioinformatics community can provide valuable feedback and insights.
**Description of ASD**
Autism Spectrum Disorder \[Mendelian inheritance in man \[(MIM) 209850\], commonly referred to as ASD is a cluster of neurodevelopmental and neuropsychiatric abnormalities which manifest in individuals with deficiencies in social interactions, communications, repetitive behaviour and developmental issues which arises early (first two years) in the life of an individual. ASD is categorized as syndromic if the affected individual is associated with another neurological disorder and non-syndromic if ASD occurs without any other neurological disorder.
ASD is now prevalent in many countries and is present in 1% of the children population. Individuals with ASD are afflicted with cognitive function impairments, language development and intellectual disability (ID). The term spectrum points to a cluster of wide-ranging symptoms and disorders exhibited by individuals with ASD. The symptoms can be clinical and behavioural, which are ingused for diagnostic purposes.
Figure 1. ASD prevalence around the world. \[source: \]
The figure above (Figure 1.) shows the prevalence of ASD around the world. The figure is one of the best examples of merging public data sources with genetics data to show the distribution of the disease in various countries.
**Open-Source Bioinformatics & ASD resources**
The research done on ASD for the past 10 years with the advent of the ‘Omics’ era has generated a huge volume of data both metadata and bioinformatics data which includes, potential list of genes, gene sequences, ASD data repositories, bioinformatics analysis tools which have the power and versatility to handle large volume of data. Another simple data analysis shows the trend of discovery in ASD. The analysis was done using publicly available research which are housed in public data repositories such NCBI, EBI and other publicly funded databases.
Figure 2. Literature analysis from the year 1975 till 1996. \[source : NCBI – Keyword used: ASD\]
The figure (Figure 2.) shows that only a handful of researchers were working on ASD simply based on the publication history from 1970 – 1996 for which data was sourced from NCBI and also other public data sources. In contrast, from 1996 till the year 2022, the below figure (Figure 3.) shows the explosion of research which was generated due to the availability of Bioinformatics & “Omics” data. Almost ~1500 research papers were published within this time frame which again is due to the omics data generated due to the advancement in sequencing technologies and public funding to make the data available to the public and research.
Figure 3. Literature analysis from the year 1996 till 2022. \[source : NCBI – add parameters \]
The public & open-source data repositories available for ASD research are given below, with URL’s provided for easy reference and access. The 1st table (Table 1) has links to Bioinformatics data repositories which also contain information regarding ASD. The 2nd table is specific to ASD-related data sources, which are helpful to ASD researchers (Table 2).
Table 1: **Open-Source Bioinformatics data repositories and databases**
S.NoNameURL1NCBI – National Center for Bioinformatics information2EBI – European Bioinformatics Institute3GEO – Gene Expression Omnibus4DECIPHER –5GTex – Genotype -Tissue Expression Portal6OpenTargets7OmicsDI
Table 2: **Open-source Autism specific data repositories and databases**
S.NoNameURL1SFARI – Simons Foundation Autism Research Initiative2AutDB – Autism Database3NDAR – National Database of Autism Research4Autism Chromosomal Rearrangement Database5CNV database for Autism Research6Varicarta
The generation of genome level data for ASD patients and families has added another dimension in the data realm. Publicly available WGS samples (individual/family) along with tissue and organ specific Omics data has made ASD research more insightful and has provided more in-depth results in the field of ASD.
The most common source is the various databases of NCBI which house the largest collection of public sequence data for analysis. There is a search capability and advanced parameters which help in filtering the required data.In addition, other public datasets such as gnomAD at the Broad Institute are accessible to researchers for analysis. gnomAD data is available for download through Google Cloud Public Datasets, the Registry of Open Data on AWS, and Azure Open Datasets.
The NDAR database listed above contains multidisciplinary biomolecular data, including exome sequencing, brain imaging, and clinical diagnostic data. The level of heterogeneity in ASD research is unprecedented and can provide a better understanding of this complex disease. The Aut10K is a genome mapping study database which uses Google Cloud to manage, analyze, and disseminate its data, which provides new opportunities for broader public access.
The availability of WGS data has provided an additional dimension in regard to ASD research which is the study of structural variation analysis in ASD. The DECIPHER database hosted at the Sanger center for genome sequencing, another genetic resource, provides additional information about the CNV loci associated with ASD. It’s a web-based interactive database which Wellcome Trust Sanger Institute maintains. More than 1,100 entries are available when the DECIPHER database is searched with the keyword “Autism”. The database can be accessed at [http://decipher.sanger.ac.uk/.](http://decipher.sanger.ac.uk/)
**Conclusion**
Open-source bioinformatics resources can be valuable tools for biological research, providing access to a wealth of information and computational power. Before starting any project, it is important to identify the appropriate bioinformatics resources for your specific research question. Open-source bioinformatics resources are constantly evolving, and new updates are frequently released. A FAIR (Findability, Accessibility, Interoperability, and Reuse) approach to the databases is also helping researchers access the data more efficiently. The availability of open-access bioinformatics data repositories ranging from all-encompassing NCBI, EBI to specialized ASD databases and genomic resources has been a game changer for researchers who now can leverage bioinformatics data and tools to perform research on a simple laptop.
If you’re interested in open-source bioinformatics data repositories design, custom enhancement, research, and development, contact us by email at , and we can discuss further.
**Happy Discovery from Zifo Global Bioinformatics Team !**
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Stories
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
---
### [ELN Upgrade: Influencing Factors And Strategies](https://zifo.com/blogs/eln-upgrade-influencing-factors-and-strategies/)
**Published:** May 17, 2023
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [ELN Upgrade: Influencing Factors And Strategies](https://zifo.com/blogs/eln-upgrade-influencing-factors-and-strategies/ "ELN Upgrade: Influencing Factors And Strategies")
## ELN Upgrade: Influencing Factors And Strategies
Saurav Yadav,Pranaov Ravindrababu
May 17, 2023
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20ELN%20Upgrade%3A%20Influencing%20Factors%20And%20Strategies%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Feln-upgrade-influencing-factors-and-strategies%2F "Share on Email")
- [](https://x.com/intent/post?text=ELN%20Upgrade%3A%20Influencing%20Factors%20And%20Strategies&url=https%3A%2F%2Fzifo.com%2Fblogs%2Feln-upgrade-influencing-factors-and-strategies%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=ELN+Upgrade%3A+Influencing+Factors+And+Strategies&url=https%3A%2F%2Fzifo.com%2Fblogs%2Feln-upgrade-influencing-factors-and-strategies%2F "Share on LinkedIn")
Image reference: / source
22 years ago, when the world was figuring out how to handle the [Y2K Paradigm](https://en.wikipedia.org/wiki/Year_2000_problem) life science industry was probably least bothered given the maturity of the computer systems it had invested in then. Back then, scientific data was still being recorded in paper and would be looked up manually from the archive rooms. More than 2 decades later , the industry is now in the center of digitalization and is attempting to harness the potential of machine learning and artificial intelligence.
The transition period saw the phenomenal rise of two concepts in computer systems – **Electronic Lab Notebook (ELN) and Laboratory Information Management System (LIMS).**
Today, there are more makers of ELN in the market than the makers of android phone – clearly underpinning the market potential. However, not all ELN makers sustain in the market – primarily because of their inability to keep up with the innovative but disruptive scientific methodologies towards drug discovery, development, and commercialization.
Given the wild run to cure diseases being at its highest than ever before, the drug makers are now looking for ELN systems that allow them to focus on research rather than recording the research data i.e., they are looking for systems that can automate data capture.
The product vendors are all ears to this and are in constant work to better their products but there is one practical problem – **making technology meet its actual need** i.e., understanding the unsaid / unexpressed needs of the lab analysts (the actual users of ELN) and deploying / upgrading the system in a way it meets these needs.
Since the last decade, both big pharmaceutical and small biotech organizations have been constantly overhauling their informatics landscape to have ELN system that caters to all their changing needs.
From our experience with our customers, **one critical step** that alleviates the constant re-work is to understand the unsaid needs, pain points, and / or challenges for Business and IT stakeholders with the current ELN system.
When these unsaid needs were overlapped with the vision / strategy of the organization, we were able to render sustainable plan for the implementation / upgrade of ELN system. We call this exercise **“Phase 0 Evaluation.”**
And it includes other systemic tasks like evaluating current state usage independently of business emotions. Though this exercise may sound simple, we learnt over a period that it requires a specific skill to do it right – following are some of the key items.
- **Knowledge of the capabilities of legacy, current and upcoming versions** of ELN system (from whichever product vendor)
- **Experience of assessing informatics landscape** and proposing solutions to address gaps
- **Understanding infrastructure constrains** and network architecture of the organization
- **Understanding business process** across different functional unites and their usage of **ELN**
- **Empathy towards business users to understand pain points** with current ELN version
- **Knowledge of other ELN systems in the market** and what value they may bring to the business
- **Experience with proposing upgrade plans** along with risk identification and mitigation
- Overseeing upgrade with ability to manage needs of various parties (including product vendors)
The implementation of above in a phased manner for upgrade of ELN plays a key role in filling the gap between the usual approach and an economic approach (that Zifo prefers). This can be understood through the following infographic.
Ensuring inclusion of all the steps in the recommended approach increases the chances of better assimilation of upgrades, addressing business needs and providing good user experience – one of the primary objectives of any upgrade, isn’t it?
Have any thoughts or questions on this? Please email us at !
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
---
### [Unlocking The Potential Of Data For AI](https://zifo.com/blogs/unlocking-the-potential-of-data-for-ai/)
**Published:** November 12, 2024
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [Unlocking The Potential Of Data For AI](https://zifo.com/blogs/unlocking-the-potential-of-data-for-ai/ "Unlocking The Potential Of Data For AI")
## Unlocking The Potential Of Data For AI
Fabio Urbina – AIML Solutions Architect, Sashank Yakkali – Data Engineer, Atul Kakrana – Head Of Data Science
Nov 12, 2024
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Unlocking%20The%20Potential%20Of%20Data%20For%20AI%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Funlocking-the-potential-of-data-for-ai%2F "Share on Email")
- [](https://x.com/intent/post?text=Unlocking%20The%20Potential%20Of%20Data%20For%20AI&url=https%3A%2F%2Fzifo.com%2Fblogs%2Funlocking-the-potential-of-data-for-ai%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Unlocking+The+Potential+Of+Data+For+AI&url=https%3A%2F%2Fzifo.com%2Fblogs%2Funlocking-the-potential-of-data-for-ai%2F "Share on LinkedIn")
Image reference: / source
**Data Readiness**
Your organization has decided to embark on a new journey and implement AI and ML solutions. However, you notice many blockers related to the state of your data: Data lies in personal accounts, instrument-attached computers, inaccessible cloud drives, the LIMS systems, and fragmented across different devices. Worse, the context of the data is unclear, with different versions and file-types, and lacks information on how the data was generated. Even if the data is accessible, another crucial question remains: will my data even be useful for generating valuable AI/ML solutions? Without knowledge of what data exists or what state it’s in, it is impossible to propose, let alone evaluate, value-driven AI/ML solutions.
These questions lead back to a single initial thought: where do we start? Despite the importance of data in driving AI-value, many organizations find themselves struggling with data readiness. Most biopharmaceutical organizations are not ready for AI deployment. Figure 1 shows common issues with data usability including data silos (Figure 1A), data quality (Figure 1B), whether the data is meaningful for downstream use-cases or not (Figure 1C), and data management (Figure 1D). **Enabling Data Readiness at your organization is the critical first step for developing key strategic AI applications.**
Figure 1. Common problems encountered when evaluating a Data Read strategy at biopharmaceutical organizations.
**Achieving Data Readiness**
The potential of an AI/ML solution to generate value depends heavily on the data that powers it. **Every dollar spent on data generation is an investment in future downstream applications, but without Data Readiness, the return on investment is unclear and at risk.** The fundamental concepts of Data Readiness are data integration, data quality, observability, and metadata lineage.
**Data Quality and Observability**
To determine if AI/ML can generate value for your organization, the first question that needs to be answered is “Is my data useful or not?” AI is only as good as the data it is trained with. Enabling Data Quality and Observability is required to answer this critical question, giving an indicator of the data’s value and relevance. Data Quality is a complex concept, with multiple factors including accuracy, consistency, and reliability of data. Some common attributes of Data Quality include the following:
- Completeness: How much missing or incomplete data is there?
- Accuracy: How error-free is the data?
- Timeliness: How outdated is the data?
- Comprehensive: How much does the data cover the question being asked?
Data Quality metrics give a general view of the value and useability of data for downstream data science or AI/ML applications. In addition to answering “Is this data is useful”, Data Quality can help uncover and monitor biases that may exist in the data, preventing decision-making headaches down the road. **Data Observability is defined as the ability to gain comprehensive insights into the behavior, performance, and quality of data systems, processes, and workflows across the data production ecosystem.** It serves as an indicator for what downstream applications can be developed and timely alerts to data problems when they occur. In absence of data observability, the data issues can go undetected for months, leading to inaccurate models and lost value.
Figure 2: Several Core Concept are required to support Data Readiness.
**Data Integration and Data Availability**
Data must be available in its desired format for downstream AI/ML applications. This requires data extracted and integrated into a common data model or a form amenable to AI/ML applications. Timeliness of data availability is also a core concept of data readiness. **Data is being generated constantly, and the time-to-value of this new data depends on how soon data is integrated into current AI/ML solutions. Data that takes months to integrate would not be considered “available”, and constantly outdated AI applications would be less valuable.** Another way to think about it is like this: The sooner your data is integrated into an AI/ML solution, the sooner the data is generating value.
**Data Lineage and Metadata Management**
Data Lineage and Metadata management ties closely to the Data Observability. Data Lineage provides a snapshot of data’s history, from source to the current version. This includes tracking every time data is changed. Data Observability and metadata management together enable data reusability, thus empowering organizations for secondary applications and other potential AI solutions.
**Data Readiness is synonymous with AI/ML Readiness**
Data is the key component for quality, consistency, and value of AI-driven solutions. With a data-centric model of AI/ML solutions, the concept of Data Readiness has emerged to become the key factor in generating value from AI. We have discussed here key components of Data Readiness which we highly encourage organizations adopt to be ready for future AI and ML applications and solutions development. Data Readiness enables data to meet the FAIR principles of Findability, Accessibility, Interoperability, and Reusability. **A Data Ready organization will find themselves in an advantageous position for new AI technology of the future.** We at Zifo are dedicated to unlocking the value for AI/ML and it starts with Data Readiness.
This is the first article of a three-part series. It introduces the concept of Data Readiness. The next articles will focus on Data Observability and Data Products.
If you would like to know more about our experience, please contact .
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
---
### [Understanding The MRA](https://zifo.com/blogs/understanding-the-mra/)
**Published:** May 16, 2023
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [Understanding The MRA](https://zifo.com/blogs/understanding-the-mra/ "Understanding The MRA")
## Understanding The MRA
Loganathan K, Compliance Consultant
May 16, 2023
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Understanding%20The%20MRA%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Funderstanding-the-mra%2F "Share on Email")
- [](https://x.com/intent/post?text=Understanding%20The%20MRA&url=https%3A%2F%2Fzifo.com%2Fblogs%2Funderstanding-the-mra%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Understanding+The+MRA&url=https%3A%2F%2Fzifo.com%2Fblogs%2Funderstanding-the-mra%2F "Share on LinkedIn")
Image reference: / source
As a compliance consultant, I have always wondered why the same facility or site is inspected by multiple agencies even though the audit reports from the first inspection has demonstrated compliance.
After years of contemplation, a big step was achieved last month towards this question where U.S. FDA and EU signed a Mutual Recognition Agreement to effectively perform the site inspections and rely on inspection reports of each other. It is important to understand this agreement was established in 2017 where EU has confirmed that US FDA has capabilities to conduct the inspections to that of EU. However, it took around 2 years for FDA to confirm this capability on each EU member states and within the last three months, Luxembourg, Netherlands, Germany and Slovakia have been added into this confirmation list. Let us examine what it means to your drug manufacturing sites and import sites.
**No more import testing**
Currently, human medicines imported into EU requires an import testing. With this MRA in place, such import testing is no longer required provided each batch / lots manufactured in US has a batch certificate to indicate compliance with marketing requirements. This reduces the cost and process burden associated with import testing for pharmaceutical companies.
**No more multiple audits**
So far, there were several instances where U.S. FDA and EU will audit a site on the same year even though the site has demonstrated compliance and successfully cleared the first audit. With MRA in place, agencies will rely on each other’s report and will divert their focus on sites that have not been inspected. This means, less audit to the sites and QA / Auditing groups will not have to prepare multiple times!
**Exclusion**
Not all drug products are included in the scope of MRA at this point. The MRA excludes Veterinary products, Human Vaccines and Plasma-derived products but these are expected to be included within July 2022. If you are supporting such manufacturing or import testing sites, sorry you will have to bear the pain of import testing and repeated audits for another 3 years!
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
---
### [Adopting To The Latest Technologies As A Part Of The Digital Transformation Journey.](https://zifo.com/blogs/adopting-to-the-latest-technologies/)
**Published:** December 6, 2023
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [Adopting To The Latest Technologies As A Part Of The Digital Transformation Journey.](https://zifo.com/blogs/adopting-to-the-latest-technologies/ "Adopting To The Latest Technologies As A Part Of The Digital Transformation Journey.")
## Adopting To The Latest Technologies As A Part Of The Digital Transformation Journey.
Tript Srivastava, Lakshmi Nallaperumal
Dec 06, 2023
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Adopting%20To%20The%20Latest%20Technologies%20As%20A%20Part%20Of%20The%20Digital%20Transformation%20Journey.%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Fadopting-to-the-latest-technologies%2F "Share on Email")
- [](https://x.com/intent/post?text=Adopting%20To%20The%20Latest%20Technologies%20As%20A%20Part%20Of%20The%20Digital%20Transformation%20Journey.&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fadopting-to-the-latest-technologies%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Adopting+To+The+Latest+Technologies+As+A+Part+Of+The+Digital+Transformation+Journey.&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fadopting-to-the-latest-technologies%2F "Share on LinkedIn")
Image reference: / source
**Introduction**
To stay competitive in today’s constantly changing scientific landscape, laboratories must adopt digital transformation. By adopting cutting-edge informatics solutions, labs can optimise operations, streamline workflows, prioritise data management, and fuel innovation. This article delves into digital transformation within the laboratory, providing real-world examples of how informatics solutions can give a significant edge in the competitive scientific arena.
**The Need for Digital Transformation**
Conventional laboratory procedures often depend on manual processes, paper-based documentation, and standalone instruments. However, these current practices hinder efficiency, data integrity, and collaboration. For example, a lab conducting drug discovery may struggle with managing vast amounts of experimental data, resulting in delays and potential errors.
Digital transformation offers a pathway to overcome these challenges and unlock the full potential of laboratory operations.
**1. Streamlining Workflows with Lab Informatics:**
Lab informatics solutions streamline workflows by automating data capture, analysis, and reporting.
For instance, a pharmaceutical lab implementing an **Electronic Laboratory Notebook** (ELN) can enable real-time research collaboration, ensuring seamless knowledge sharing and version control. **Laboratory Information Management Systems** (LIMS) can help a diagnostics lab track samples, manage inventory, and schedule experiments efficiently, optimizing resource utilization.
**2. Enhancing Data Management and Analysis:**
Digital transformation can enable labs to manage vast amounts of data efficiently. Informatics solutions offer centralized data repositories, capabilities for integrating data, and advanced analytics tools.
For example, a genomics lab can leverage informatics solutions to integrate and analyse large-scale genomic datasets, identifying patterns and potential therapeutic targets faster and more accurately.
**3. Leveraging Automation and Robotics:**
Automation and robotics play a vital role in digital transformation within the lab. Robotic process automation (RPA) handles repetitive tasks like sample manipulation, liquid handling, and data input, thus allowing researchers more time for higher-value activities.
For instance, a lab that implements robotic systems for high-throughput screening can accelerate the identification of potential drug candidates and improve research productivity.
**4. Embracing IoT and Sensor Technologies:**
Lab operations are being impacted by the Internet of Things (IoT) and sensor technologies. IoT devices and sensors can monitor environmental conditions, equipment performance, and sample storage, ensuring ideal conditions for experiments.
For example, a labs can utilize IoT sensors to monitor temperature and humidity in storage facilities, maintaining sample integrity and reducing the risk of experimental failure.
**5. Enabling Collaborative Research:**
Digital transformation fosters collaboration among researchers, both within and across organizations. Cloud-based collaboration platforms and virtual research environments facilitate the seamless sharing of data, protocols, and insights.
For instance, a multi-site project can leverage cloud-based informatics solutions to enable real-time collaboration, data sharing, and joint analysis, enhancing research efficiency and enabling breakthrough discoveries.
**6. Driving Innovation and Intellectual Property Management:**
Digital transformation drives innovation by facilitating rapid experimentation, data integration, and knowledge sharing. Informatics solutions enable effective **Intellectual Property** (IP) management, ensuring data security and compliance with IP regulations.
For example, scientists can utilize informatics tools to capture research findings, streamline patent filing processes, and safeguard valuable innovations.
**7. Ensuring Regulatory Compliance:**
Digital transformation can help labs maintain regulatory compliance by automating data integrity controls, audit trails, and documentation processes. Informatics solutions provide a robust framework for meeting regulatory requirements, including **Good Laboratory Practice** (GLP), **Good Manufacturing Practice** (GMP), and **21 CFR Part 11**.
For instance, a validated labs can implement informatics solutions to ensure data integrity, traceability, and compliance with industry regulations, reducing the risk of compliance violations and associated penalties.
**Conclusion:**
Digital transformation has become an essential strategy for laboratories seeking a competitive advantage in the scientific landscape. Labs can optimize workflows, enhance data management, drive collaboration, and foster innovation by adopting informatics solutions. By fully harnessing technology, labs can proactively remain at the forefront by adopting such digital approaches.
If you’re interested in digital transformation technologies and laboratory process transformation, please get in touch with us at
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
---
### [A Bench Scientist’s Venture Into Lab Informatics](https://zifo.com/blogs/a-bench-scientists-venture-into-lab-informatics/)
**Published:** March 19, 2024
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [A Bench Scientist’s Venture Into Lab Informatics](https://zifo.com/blogs/a-bench-scientists-venture-into-lab-informatics/ "A Bench Scientist’s Venture Into Lab Informatics")
## A Bench Scientist’s Venture Into Lab Informatics
Curtis Wriston
Mar 19, 2024
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20A%20Bench%20Scientist%E2%80%99s%20Venture%20Into%20Lab%20Informatics%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Fa-bench-scientists-venture-into-lab-informatics%2F "Share on Email")
- [](https://x.com/intent/post?text=A%20Bench%20Scientist’s%20Venture%20Into%20Lab%20Informatics&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fa-bench-scientists-venture-into-lab-informatics%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=A+Bench+Scientist%E2%80%99s+Venture+Into+Lab+Informatics&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fa-bench-scientists-venture-into-lab-informatics%2F "Share on LinkedIn")
Image reference: / source
**A Bench Scientist’s Venture into Lab Informatics**
So, your organization is undergoing a Laboratory Information Management System (LIMS) implementation, now what? You may have found yourself here because you or a member of your team have been asked to be a Subject Matter Expert (SME) on the project or you may even be soon transitioning from a Bench Scientist into a LIMS Administrator for your company. Although this transition may be intimidating, as a seasoned Bench Scientist, you have more knowledge of Lab Informatics than you may think. From industry regulations to daily lab processes, your knowledge of these areas will allow you to excel in a LIMS Admin role. Below are some examples where your experience will help you succeed.
**Knowledge of Industry Regulations**
**What You Know**
Some of the most important knowledge that Bench Scientists possess are the ins-and-outs of regulated industries. From Food and Drug’s Current Good Manufacturing Practice (CGMP) to Petrochemical’s National Emission Standards for Hazardous Air Pollutants (NESHAP), and everything in between, you understand the importance of following these Federal requirements. Additionally, you understand that the data and results you enter are what demonstrate compliance with these strict guidelines. Unfortunately, inadvertent typos can occur, which skews results and causes your company to appear out of compliance. This is where a LIMS application can help you keep your laboratory compliant.
**What LIMS does for You**
Configurations such as product specifications and audit trails function to track data modifications. Your limits for in-spec or out-of-spec results are applied through product specifications and can be defined even further into release or stability products. When a product fails to meet these requirements, it will be automatically flagged as out-of-spec. This is where audit trails become a necessity. When a result is changed, the audit trail captures this change with details such as user account, time/date, original and modified result values, as well as a reason for the modification if required by your organization. LIMS applications can also integrate with instruments and software to eliminate transcription errors, thus improving data integrity.
**Takeaway**
Your direct insight of rules and regulations will ensure that your company is compliant within its industry. By configuring and maintaining your LIMS application with the features mentioned above, your laboratory’s data will be accurate and readily available in the case of an internal or external audit.
**Understanding the Laboratory**
**What You Know**
- **Key Data Elements:** By understanding the laboratory, you understand that data is the foundation of its functionality. Data is used in every aspect of the laboratory, from sample information to test results, from user accounts to instruments. Details such as locations and result units play a major role when configuring a LIMS. Your knowledge will allow you to outline the data for the developers to ensure that LIMS is configured accurately and appropriately for your lab’s needs
- **Processes and Workflows:** A great example of your knowledge transitioning perfectly into Informatics is through the understanding of laboratory processes. You use these processes daily and that inside perspective can help streamline functionality in LIMS applications. By mapping out the processes prior to development, they can be more easily transitioned into LIMS. This also enables you to find gaps or bottlenecks in your processes which can then be improved in LIMS to increase efficiency and compliance.
- **Stock Management:** As a scientist, you have firsthand exposure to which reagents and buffers are most frequently used and which are used less frequently. This may seem like a small piece of the puzzle, but any scientist understands the disappointment when you are out of a necessary reagent, and your experiment is delayed until more can be ordered.
**How LIMS works for you**
- **Key Data Elements:** LIMS applications break down your data into Static and Dynamic data. Static data such as user accounts, test methods, and storage locations are configured during development and allow your LIMS to function smoothly. Dynamic data such as test results and audit trails are created during use of the application. Historical data can also be migrated into LIMS for trending reports and audit readiness.
- **Processes and Workflows:** Your point of view as a scientist can be directly translated into how the application is configured for your laboratory. LIMS workflows are configured based on the specific processes of your laboratory to make work smoother and more productive, a true win-win for both the scientists and the company. Your lab processes knowledge will also enable you to quickly and efficiently perform any workflow maintenance that is needed, further reducing downtime.
- **Stock Management:** During development you can provide invaluable insights into the setup and maintenance of the stock management modules that many Informatics systems offer. Also, by maintaining stock quantities inside your LIMS application, users will have access to the current quantities as well as the ability to trigger an email to the appropriate party when orders need to be placed.
**Takeaway**
As a LIMS Administrator having a high understanding of the data, processes, workflows, and components of your laboratory will guarantee that any modifications necessary in your LIMS application can be made in a timely fashion to prevent any downtime or loss of production.
**Familiarity with LIMS Applications**
**What You Know**
Many Bench Scientists, like you, have or will work in many different laboratories throughout their careers. Multiple laboratories typically equates to using multiple LIMS applications which gives you a diverse amount of end user experience. The major benefit from your variety of experience is seeing what works well and what doesn’t work well when it comes to LIMS applications and different system layouts.
**How LIMS works for you**
End user experience gives you a head start when learning the inner workings of the application because you have used similar functions to the ones that you will be maintaining. You know when something isn’t working correctly and can more easily find a solution. That specific knowledge benefits the entire lab because you understand how to setup the application to best suit the functions of your laboratory.
**Takeaway**
As a veteran scientist, you have insider knowledge from working with other LIMS applications. This experience will aid you during the initial development and continued maintenance of your system.
**Summary**
The above factors as well as many others give you a head start in successfully transitioning into Lab Informatics. Your laboratory background will give you vital insight into how a LIMS application should look and function, and when used correctly will lead your company to more streamlined and increased productivity.
To find out more about how Zifo can help you and your company, please contact us at
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
---
### [The Power Of Data Modeling In Scientific Research: From Lab Informatics To Real-World Applications](https://zifo.com/blogs/the-power-of-data-modeling-in-scientific-research-from-lab-informatics-to-real-world-applications/)
**Published:** May 8, 2025
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [The Power Of Data Modeling In Scientific Research: From Lab Informatics To Real-World Applications](https://zifo.com/blogs/the-power-of-data-modeling-in-scientific-research-from-lab-informatics-to-real-world-applications/ "The Power Of Data Modeling In Scientific Research: From Lab Informatics To Real-World Applications")
## The Power Of Data Modeling In Scientific Research: From Lab Informatics To Real-World Applications
Tript Srivastava, Engagement Lead | Nishkala Ramesh, Senior Scientific Application Analyst
May 08, 2025
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20The%20Power%20Of%20Data%20Modeling%20In%20Scientific%20Research%3A%20From%20Lab%20Informatics%20To%20Real-World%20Applications%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Fthe-power-of-data-modeling-in-scientific-research-from-lab-informatics-to-real-world-applications%2F "Share on Email")
- [](https://x.com/intent/post?text=The%20Power%20Of%20Data%20Modeling%20In%20Scientific%20Research%3A%20From%20Lab%20Informatics%20To%20Real-World%20Applications&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fthe-power-of-data-modeling-in-scientific-research-from-lab-informatics-to-real-world-applications%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=The+Power+Of+Data+Modeling+In+Scientific+Research%3A+From+Lab+Informatics+To+Real-World+Applications&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fthe-power-of-data-modeling-in-scientific-research-from-lab-informatics-to-real-world-applications%2F "Share on LinkedIn")
Image reference: / source
In our data-driven era, the significance of precisely capturing, organizing, and utilizing scientific data is immense. Over the past few decades, laboratory informatics tools like Electronic Laboratory Notebooks (ELN) and Laboratory Information Management Systems (LIMS) have changed how data is captured, stored and managed in scientific laboratories. However, the real magic begins with data modeling—a critical process that guides how raw data should be structured and stored, enabling it to be transformed into meaningful and valuable insights.
**The Art of Data Modeling in Lab Informatics**
Data modeling involves creating a structured representation of the data gathered. In the context of ELN and LIMS, this consists of defining data entities, their attributes and their relationships. The goal is to create a model that accurately reflects the experimental data, ensuring it can be easily queried, analyzed, and interpreted.
Here’s a detailed breakdown of the data modeling process:
**Step 1. Requirement Gathering**
Understand the specific requirements of the laboratory. What kind of data needs to be captured? How is the data planned to be used and what are the objectives? This involves close collaboration with scientists and stakeholders to define the scope of the model. Additionally, understanding how the data is captured, including business and technical rules, is a crucial part of requirement gathering.
*Case Study:* A pharmaceutical company needed to streamline its data management for clinical trials. The data modeling team collaborated with scientists and stakeholders to understand the types of data to be captured, such as patient demographics, treatment protocols, and outcome measures. They also identified business and technical rules, ensuring the model would support regulatory compliance and data integrity.
**Step 2. Data Entity Identification**
Identify the primary data entities. These could include samples, tests, instruments, reagents, results etc. Each entity represents a distinct piece of information within the scientific domain.
*Case Study:* In a genomics research lab, the primary data entities identified included samples, sequencing runs, instruments and results. Each entity represented a distinct piece of information crucial for tracking the entire sequencing process from sample collection to data analysis.
**Step 3. Attribute Definition**
Add detail to the entities. For example, a “Sample” entity might have attributes like sample ID, source, collection date and storage conditions, etc. Entity attributes (or properties) provide the necessary detail to describe each entity fully.
*Case Study:* For a “Sample” entity in a microbiology lab, attributes were defined such as sample ID, source, collection date and storage conditions. These attributes provided detailed information necessary for tracking and managing samples throughout various experiments.
**Step 4. Relationship Mapping**
Define how the entities are related within the domain. For example, a “Sample” might be related to a “Test” entity, indicating that the sample was subjected to a specific test. This step is essential to ensure that data can be tracked throughout the experimental process and that all data is connected.
*Case Study:* In a chemical testing lab, the relationship between “Sample” and “Test” entities was mapped.Each sample was subjected to multiple tests and the results were linked back to the specific sample. This mapping ensured that all data could be traced through the testing process, maintaining a clear connection between samples and their test results.
**Step 5. Normalization and Schema Design**
Assess the data model to determine the degree of normalization required, balancing the need to eliminate redundancy and ensure data integrity with the potential benefits of denormalization. This involves designing a schema that defines the entities, attributes and relationships, then organizing the data into tables (in relational database design) or other structures (e.g., NoSQL databases) that efficiently store and aid retrieval of data.
*Case Study:* A library system required a robust database schema. The data model was normalized to eliminate redundancy and ensure data integrity. Entities such as books, authors and patrons were organized into tables, with relationships defined to support efficient data retrieval and management.
**Step 6. Validation and Refinement**
Conduct use case simulations and iterative prototyping. Feedback from domain experts and scientists is used to refine the model, ensuring it meets practical needs and performs as expected in real-world scenarios.
*Case Study:* A manufacturing company used iterative prototyping to validate and refine its data model for a new production tracking system. Feedback from engineers and production managers was incorporated to ensure the model accurately represented real-world processes and performed well under various scenarios.
**Step 7. Implementation**
Deploy the data model within the system. In many cases, the data already exists in ELNs, LIMS, etc., and the data model is implemented in a data aggregation system where data from the source systems is transformed and stored centrally. This often includes a critical step where the data capture systems (ELN, LIMS etc.) are configured to ensure data is captured according to the defined data model, ensuring consistency, integrity and quality.
*Case Study:* A biotech firm implemented its data model within an integrated data aggregation system. Data from existing ELNs and LIMS was transformed and centrally stored. The data capture systems were configured to align with the new model, ensuring consistency, integrity and quality across all data sources.
**Step 8. Continuous Monitoring**
Continuously monitor the data model to ensure it remains effective and accurate. This involves regularly reviewing and updating the model to accommodate new data types, changes in data capture processes and evolving business requirements. Continuous monitoring helps identify and address any issues promptly, ensuring the data model continues to meet the needs of the organization.
*Case Study:* Case Study: A leading biotech company implemented continuous monitoring for its laboratory environments to ensure optimal conditions for sensitive experiments. The company used advanced sensors and automated systems to track temperature, humidity and air quality in real time. This continuous monitoring allowed the company to quickly detect and address any deviations from the required conditions, preventing potential disruptions to their research.
**The Future of Data Modeling in Science**
As science continues to evolve, so will the sophistication of data modeling. Integrating artificial intelligence (AI), big data and cloud computing is already enhancing ELN and LIMS systems’ capabilities, requiring even more powerful data models.
In the future, we will see automated data models that can adapt and evolve as new entities and variables appear, offering dynamic insights that keep pace with rapid advancements in science. Additionally, data modeling will continue to help embed global data standards, such as Identification of Medicinal Products (IDMP), Health Level Seven (HL7), General Data Protection Regulation (GDPR), ISO/IEC 27001 and Clinical Data Interchange Standards Consortium (CDISC).
**Conclusion**
Data modeling is a cornerstone of modern science, providing the structure and framework needed to turn raw experimental data into actionable insights. From enhancing the efficiency of laboratory processes to supporting regulatory compliance and driving innovation, the impact of data modeling extends far beyond the lab bench. As we continue to push the boundaries of what’s possible in science, data modeling will remain a key enabler of progress, unlocking new frontiers in our understanding of the world around us.
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
**Categories:** Data Science and Consulting Services, Scientific Cloud Computing Services
---
### [Navigating AI Regulations In GxP: A Comparative Look At EU AI Act, EU Annex 22 & FDA AI Guidance](https://zifo.com/blogs/navigating-ai-regulations-in-gxp-a-comparative-look-at-eu-ai-act-eu-annex-22-fda-ai-guidance/)
**Published:** October 22, 2025
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [Navigating AI Regulations In GxP: A Comparative Look At EU AI Act, EU Annex 22 & FDA AI Guidance](https://zifo.com/blogs/navigating-ai-regulations-in-gxp-a-comparative-look-at-eu-ai-act-eu-annex-22-fda-ai-guidance/ "Navigating AI Regulations In GxP: A Comparative Look At EU AI Act, EU Annex 22 & FDA AI Guidance")
## Navigating AI Regulations In GxP: A Comparative Look At EU AI Act, EU Annex 22 & FDA AI Guidance
Tript Srivastava, GxP Compliance Associate Manager
Oct 22, 2025
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Navigating%20AI%20Regulations%20In%20GxP%3A%20A%20Comparative%20Look%20At%20EU%20AI%20Act%2C%20EU%20Annex%2022%20%26%20FDA%20AI%20Guidance%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Fnavigating-ai-regulations-in-gxp-a-comparative-look-at-eu-ai-act-eu-annex-22-fda-ai-guidance%2F "Share on Email")
- [](https://x.com/intent/post?text=Navigating%20AI%20Regulations%20In%20GxP%3A%20A%20Comparative%20Look%20At%20EU%20AI%20Act%2C%20EU%20Annex%2022%20%26%20FDA%20AI%20Guidance&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fnavigating-ai-regulations-in-gxp-a-comparative-look-at-eu-ai-act-eu-annex-22-fda-ai-guidance%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Navigating+AI+Regulations+In+GxP%3A+A+Comparative+Look+At+EU+AI+Act%2C+EU+Annex+22+%26+FDA+AI+Guidance&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fnavigating-ai-regulations-in-gxp-a-comparative-look-at-eu-ai-act-eu-annex-22-fda-ai-guidance%2F "Share on LinkedIn")
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Stories
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
As artificial intelligence increasingly transforms the life sciences landscape, regulatory clarity is more and more critical—particularly in GxP-regulated environments. The incorporation of AI into drug development, production, and quality systems requires not just innovation but careful control to guarantee patient safety and data integrity. As global regulators move to set limits and expectations, comprehension of the subtleties of new AI frameworks is no longer a nicety—it’s mandatory for compliance professionals and technology planners both.
This blog represents a comprehensive comparative analysis of the three most important AI regulation realized so far **—EU AI Act (finalized), EU GMP Annex 22 (draft), and FDA AI Draft Guidance – Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products (draft) —**with a key focus on their significance to GxP-regulated environments and implementation-viewpoint insights.
This blog represents a comprehensive comparative analysis of the three most important AI regulation realized so far **—EU AI Act (finalized), EU GMP Annex 22 (draft), and FDA AI Draft Guidance – Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products (draft) —**with a key focus on their significance to GxP-regulated environments and implementation-viewpoint insights.
Implementation AreaEU AI ActEU GMP Annex 22FDA AI Draft Guidance1Intended Use DefinitionAcknowledge documented intended use and register in EU database for high-risk AI systems.Detail intended use, including characteristics and limitations of input data. SME approval prior to testingDefine the question of interest and context of use (COU). Clarify role of model and scope in decision-making.2Risk Classification & Model TypeCategorize AI systems as high-risk on the grounds of impact on health, safety, and basic rights. Emotion recognition in work environment and predictive profiling are the prohibited practices.Static deterministic models permitted in mission-critical GMP applications only. Dynamic/adaptive models and probabilistic outputs are not permitted.Measure model risk by model influence × decision consequence. Utilize risk matrix for establishment of credibility assessment rigor.3Testing & ValidationHigh-risk AI products need conformity assessment (third-party or internal). CE marking and post-market surveillance are required.Establish test measures (e.g., F1 score, accuracy, sensitivity, specificity). Acceptance levels need to be at least as good as replaced process. Record test plan, deviations, and keep all records.Provide performance measures with confidence limits. Specify evaluation techniques, test data independence, and consistency with observed data.4Data GovernanceTraining/validation/testing data should be high quality, representative, and bias-reduced. Special categories of personal data can be processed under strong protections.Use representative, stratified, validated test data. Generative data should be avoided unless warranted. Data independence and audit trails must be ensured.Data has to be fit-for-use: applicable, trustworthy, traceable. Document data management practices and bias reduction.5Explainability & TransparencyUser instructions need to contain system capabilities, limitations, risks, and control mechanisms. Transparency needed in synthetic content and biometric systems.Feature attribution with SHapley Additive exPlanations (SHAP), Local Interpretable Model-agnostic Explanations (LIME), or heatmaps. Explain why features are relevant.Write down model architecture, features, training reasons. Add uncertainty quantification and explainability tools.6Human OversightMandatory human oversight for high-risk AI. Biometric systems require dual human verification unless legally exempt.HITL required for non-critical applications. Operator training and performance monitoring mandatory.Human-AI team performance must be evaluated. Oversight roles and responsibilities must be defined.7Lifecycle Management & Change ControlChange control and post-market surveillance necessary. Significant changes initiate reassessment.Adopt change and configuration control. Keep track of performance drift and sample space of input. Retest if there are changes.Lifecycle maintenance necessary. Retrain/revalidate in case of change in performance. Document changes according to regulatory guidelines.8Regulatory EngagementInteract with AI Office and federal authorities. Apply regulatory sandboxes for testing and innovation.No formal engagement processes established; follows Annex 11 principles.Early interaction highly recommended. Apply Pre-IND, CID, ISTAND, and other FDA initiatives.9Documentation & TraceabilityKeep technical documentation, EU declaration of conformity, and register systems on EU database.Keep all test documentation, access control logs, and audit trails.Prepare credibility assessment report. Cover model development, evaluation, and deviations.10Confidence & ThresholdsSpecify thresholds for high-risk AI forecasts. Employ confidence scores to ascertain reliability.Store confidence scores. Utilize thresholds to mark undecided results.Estimate uncertainty and confidence levels. Incorporate into performance measures.11Personnel Qualification & TrainingProviders and deployers must ensure that personnel who take part in the operation of AI systems are AI literate and trained.All personnel working on AI lifecycle should have their roles defined and appropriate qualifications.Personnel working on model development and monitoring should be trained and qualified.12SME & Innovation SupportSMEs and start-ups receive priority access to sandboxes, simplified QMS, reduced fees, and standard templates.Not specifically mentioned.Not specifically mentioned.13Real-World TestingReal-world testing allowed under close control; requires testing plan, consent, supervision, and registration.Not applicable; testing must be controlled and documented.Real-world monitoring of performance encouraged as part of lifecycle maintenance.14Biometric & Emotion Recognition SystemsEmotion recognition in educational/work environment not allowed; judicial approval and double human endorsement required for biometric systems.Not applicable; emotion recognition and biometric categorization excluded.If used, justification and tested for bias and risk required.15Fundamental Rights Impact AssessmentCompulsory for public deployers and private deployers of high-risk AI in high-concern domains (e.g., healthcare, education, law enforcement). Optional.Optional.Risk-based credibility testing involves ethics.16Adversarial Testing & RobustnessSuppliers of general-purpose AI models with systemic risk are obliged to perform adversarial testing (internal or external) before market launch.Not clearly mentioned but robustness is implied through validation and performance tracking.Sponsors ought to test model robustness and resilience to input variation and overfitting.17Cybersecurity & Model ProtectionCybersecurity controls required for high-risk and systemic-risk models, including model leakage protection, access control, and tampering.Configuration control and detection of unauthorized change required.Sponsors must ensure model integrity and security throughout lifecycle, especially in production.18Environmental Sustainability & Ethical DesignVoluntary codes of conduct promoted for energy-efficient AI, inclusive design, and ethical development.Not mentioned.Ethics are part of credibility assessment but not specifically linked to sustainability.19Stakeholder Participation & Inclusive DevelopmentEncourages participation of civil society, academia, and various development teams in AI system design.Requires SME, QA, IT, and data scientist collaboration.Sponsors need to have subject matter experts included for model development and risk evaluation.20Voluntary Codes of Conduct for Non-High-Risk AINon-high-risk AI system providers and deployers should voluntarily adopt high-risk requirements (e.g., transparency, oversight, documentation).Principles may be applied to non-critical GMP uses with HITL.No official voluntary scheme, but sponsors may apply credibility principles to non-regulatory AI application.21Transition Periods & Legacy SystemsMarket-placed AI systems before Aug 2026 must be compliant if significantly modified. Public sector systems must comply by Dec 2030New systems only; legacy systems may potentially need revalidation if AI is introduced.No transition period is provided, but changes during the lifecycle must be documented and justified.22Serious Incident ReportingProviders shall report serious events (e.g., harm to health, disruption of infrastructure, infringement of rights) to the competent authorities.Deviations and failures shall be logged and investigated.Sponsors shall track and report side effects associated with the application of AI models.
**Final Insights for GxP Professionals**
**EU GMP Annex 22:** Provides straightforward validation guidelines for static AI models deployed in GMP production environments. It emphasizes documentation, explainability, and human oversight to ensure product quality and patient safety.
**FDA Draft Guidance:** Provides a framework for credibility to make AI models credible in regulatory submissions. It applies a risk-based methodology with context of use and early collaboration with the FDA.
**EU AI Act:** Requires lawfulness for high-risk and general-purpose AI, with emphasis on safety, transparency, and regulation. It brings strict obligations to providers, such as risk management and technical documentation.
**Conclusion:**
Yet the regulatory landscape for AI is far from settled. While the EU AI Act is finalized, the EU GMP Annex 22 and the FDA AI Draft Guidance are still in draft form. Both are open to revisions on the basis of industry input, advancements in technology, and shifting risk views. Organizations therefore need to remain adaptable and up-to-date—because draft today may become policy tomorrow.
Stay tuned for Part 2 of this blog, where we’ll explore updates as these drafts evolve, and dive deeper into practical implementation strategies for GxP environments.
**Reference:**
1\. The EU AI Act – [https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=OJ:L\_202401689](https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=OJ:L_202401689)
2\. EU GMP Annex 22: Artificial Intelligence – [https://health.ec.europa.eu/document/download/5f38a92d-bb8e-4264-8898-ea076e926db6\_en?filename=mp\_vol4\_chap4\_annex22\_consultation\_guideline\_en.pdf](https://health.ec.europa.eu/document/download/5f38a92d-bb8e-4264-8898-ea076e926db6_en?filename=mp_vol4_chap4_annex22_consultation_guideline_en.pdf)
3\. FDA – Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products –
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Stories
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
**Categories:** Validation Service and Compliance Support
---
### [Mastering LIMS Validation: Best Practices For Ensuring Compliance And Data Integrity](https://zifo.com/blogs/mastering-lims-validation-best-practices-for-ensuring-compliance-and-data-integrity/)
**Published:** July 30, 2025
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [Mastering LIMS Validation: Best Practices For Ensuring Compliance And Data Integrity](https://zifo.com/blogs/mastering-lims-validation-best-practices-for-ensuring-compliance-and-data-integrity/ "Mastering LIMS Validation: Best Practices For Ensuring Compliance And Data Integrity")
## Mastering LIMS Validation: Best Practices For Ensuring Compliance And Data Integrity
Poorani Karunanidhi, Associate Consultant
Jul 30, 2025
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Mastering%20LIMS%20Validation%3A%20Best%20Practices%20For%20Ensuring%20Compliance%20And%20Data%20Integrity%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Fmastering-lims-validation-best-practices-for-ensuring-compliance-and-data-integrity%2F "Share on Email")
- [](https://x.com/intent/post?text=Mastering%20LIMS%20Validation%3A%20Best%20Practices%20For%20Ensuring%20Compliance%20And%20Data%20Integrity&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fmastering-lims-validation-best-practices-for-ensuring-compliance-and-data-integrity%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Mastering+LIMS+Validation%3A+Best+Practices+For+Ensuring+Compliance+And+Data+Integrity&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fmastering-lims-validation-best-practices-for-ensuring-compliance-and-data-integrity%2F "Share on LinkedIn")
Image reference: / source
**Abstract**
Laboratory Information Management Systems (LIMS) are critical tools for managing laboratory workflows, ensuring regulatory compliance and maintaining data integrity in sectors such as pharmaceuticals, biotechnology and clinical diagnostics. Owing to their high degree of customization and system complexity, validating LIMS poses unique challenges. This article outlines the major obstacles to effective LIMS validation—including complex configurations, frequent updates and varied user roles—and offers best practices for achieving compliance, data integrity and operational efficiency. By adopting a risk-based, modular and cross-functional approach, laboratories can validate their systems with precision and sustainability.
**Introduction**
Laboratory Information Management Systems (LIMS) have become indispensable tools across scientific and industrial laboratories, supporting everything from workflow automation to regulatory compliance. Their ability to handle complex data, support customized workflows and integrate with diverse instruments makes them essential in regulated environments such as pharmaceuticals, biotechnology, clinical diagnostics and environmental testing.
However, while LIMS offers powerful capabilities, its validation presents significant challenges. The very features that make LIMS so adaptable—such as customization, integration and scalability—also make it complex to validate. This article explores the unique aspects that complicate LIMS validation and provides actionable recommendations for managing these challenges effectively.
**Unique challenges of LIMS validation**
**1. Extensive Configuration and Customization**
LIMS platforms are rarely used “out of the box.” Laboratories routinely configure and customize their systems to reflect specific workflows, testing protocols and reporting needs. These changes, though necessary, must be individually validated.
**Workflow configuration:** For example, a pharmaceutical lab might customize its LIMS to track a drug sample’s lifecycle, including data fields for storage conditions, multi-step approvals, and alerts. Each configuration must be verified to ensure compliance with GMP standards and functional requirements.
**Custom reporting:** Many labs require tailored reports and dashboards to support unique decision-making or regulatory needs. These must be validated for accuracy, formatting and consistency with regulatory standards.
**Instrument and System Integrations:** LIMS often connects with instruments (e.g., spectrometers, chromatography systems) and software (e.g., ELNs, ERP systems). Each integration, especially when custom-coded, poses risks for data corruption or loss and must be validated thoroughly to preserve data integrity.
**2. Support for Complex, Industry-Specific Workflows**
Each lab operates differently and LIMS must support workflows that vary in complexity, data handling and compliance requirements across industries.
**Pharmaceuticals/biotech:** Sample management, stability testing, GMP traceability
**Clinical diagnostics:** Sensitive patient data, HIPAA compliance, complex testing
**Environmental testing:** Field sampling, EPA reporting, sensor integration
Validation must account for the breadth and specificity of workflows across industries.
**3. Targeted Validation: Identifying Critical Configurations**
A common and often overlooked challenge in LIMS validation is determining which configurations are critical to validate and which can be treated as low-risk or standard behavior.
- Extensive validation of low-risk configurations always leads to unnecessary resource expenditure, extended project timelines, and validation fatigue.
- On the other hand, failing to validate critical configurations, such as custom approval workflows, automated data transformations, or specific system triggers, can introduce compliance risks along with system failures.
Properly scoping validation activities allows organizations to maintain compliance without overburdening validation teams.
**4. Multiple User Roles with Varying Access Needs**
LIMS typically supports a wide range of users, each with distinct responsibilities:
- Technicians perform routine testing and data entry.
- Supervisors approve results and oversee workflow accuracy.
- QA personnel audit the system for compliance.
- Regulatory officers rely on audit trails and reports to demonstrate adherence to regulations.
- Administrators manage configuration and user access control.
Each user role must have appropriate access levels, and validation must confirm that permissions are enforced correctly to protect data integrity and confidentiality.
**5. Validation of Critical System Paths**
LIMS validation must ensure that all critical workflows—commonly referred to as “critical paths”—operate reliably and in compliance with regulations.
Examples of critical paths include:
**Sample Login and Tracking:** Ensuring samples are logged correctly and traceable throughout their lifecycle.
**Data Entry and Analysis:** Validating that data is captured, analyzed, and stored according to laboratory SOPs.
**Reporting and Electronic Signatures:** Ensuring reports meet regulatory formatting and security standards (e.g., 21 CFR Part 11 compliance), and that electronic signatures are properly authenticated and timestamped.
**6. Compliance with Multiple Regulatory Frameworks**
Depending on the type of lab, LIMS must comply with various regulatory frameworks:
**FDA 21 CFR Part 11:** Governs electronic records and signatures, requiring validated systems for all data handling and approval workflows.
**GLP/GMP:** Requires systems to support reliable, auditable data for regulated processes in research and manufacturing.
**ISO/IEC 17025:** Laboratories involved in testing and calibration must validate systems to meet ISO standards for technical competence and data reliability.
HIPAA: Clinical labs handling patient data must enforce strict privacy and security controls, including encryption and role-based access.
**7. Frequent Software Updates**
LIMS vendors frequently release patches, upgrades and new features. While these updates can bring performance improvements or new capabilities, they also introduce a risk of inadvertently disrupting validated functions.
- Even minor changes—such as UI tweaks or bug fixes—can affect workflow behavior or data processing.
- Each update must undergo an impact assessment, followed by partial or full revalidation as needed to confirm that core functionalities remain intact and compliant.
- Failing to revalidate after updates may jeopardize regulatory compliance and data integrity.
**8. Ensuring Data Integrity (ALCOA+)**
Data integrity is a central pillar of regulatory compliance in GxP environments. Authorities such as the FDA and EMA expect adherence to ALCOA+ principles. LIMS validation must confirm that data throughout the system lifecycle, from acquisition and processing to storage and retrieval, remains secure, traceable and unaltered. Key areas to validate include:
- Audit trails that link data to user actions
- Electronic signatures that meet 21 CFR Part 11 requirements
- System controls that prevent overwriting, backdating, or unauthorized edits
- Long-term data storage and availability for inspections or audits
**Best practices for LIMS validation**
**1. Establish a Risk-Based and Modular Validation Strategy**
A strong validation approach begins with prioritizing efforts based on risk and breaking the system into manageable components.
- Follow GAMP 5 guidelines: Focus validation activities on high-risk components that impact data integrity, product quality, or patient safety. Use software classification (e.g., Category 3–5 systems) to determine the required depth of testing, particularly for Commercial Off-The-Shelf (COTS) systems.
- Validate custom features with risk focus: Prioritize validation of critical customizations, such as fields affecting data integrity (e.g., reagent expiration tracking), while minimizing testing for low-risk features (e.g., cosmetic UI changes).
- Modularize validation efforts: Validate core functionalities, custom configurations, instrument integrations and reporting tools separately. This approach simplifies maintenance, facilitates updates and avoids extensive validation.
**2. Define a Robust Validation Master Plan (VMP)**
Your VMP acts as the blueprint for the entire validation process. It should include:
- Scope, objectives and validation strategy
- Defined roles and responsibilities
- System components and interfaces
- Documentation structure and review process
- Approach to change control and periodic review
**3. Perform End-to-End Testing and Verification**
Testing should cover all phases of system qualification and reflect real-world usage.
- Qualification phases:
- IQ (Installation Qualification): Verify proper installation.
- OQ (Operational Qualification): Confirm the system operates according to specifications.
- PQ (Performance Qualification): Simulate actual workflows to ensure the system performs reliably under routine and edge-case conditions.
- Real-world scenario testing: Include day-to-day operational scenarios, exception handling and error paths to validate system robustness.
- Integration testing: For example, confirm seamless and accurate data transfer between LIMS and instruments, such as HPLC or mass spectrometers.
**4. Implement Strong Configuration and Change Management**
Effectively managing configuration changes helps prevent both under- and over-validation.
- Identify critical configurations: Conduct risk assessments to classify configurations as GxP-impacting or standard. Prioritize validation for those influencing data integrity, compliance, or business decisions.
- Control configuration baselines: Define which configurations are locked, monitored and require change control.
- Change control process: All updates or changes—whether to configuration, workflows, or software—should undergo documented impact assessment and, if necessary, partial or full revalidation.
**5. Ensure Cross-Functional Collaboration**
Validation success depends on early and sustained input from all stakeholders:
- Involve IT, QA, laboratory staff and regulatory affairs early and throughout the process.
- Leverage team expertise to define meaningful test cases, configuration needs and regulatory interpretations.
**6. Maintain Comprehensive and Compliant Documentation**
Accurate documentation supports audit readiness, traceability and knowledge transfer. Required documentation includes:
- URS (User Requirements Specification)
- FS/DS (Functional and Design Specifications)
- IQ/OQ/PQ protocols and reports
- Traceability matrix
- Validation summary report
- Audit trails and change logs
**7. Leverage Automation for Efficiency**
Use automated testing tools, particularly for:
- Regression testing during software updates
- Repetitive functional testing across multiple configurations or test cases
- Accelerating validation cycles in agile or iterative deployment models
- Accelerating validation cycles in agile or iterative deployment models
- Automation improves test accuracy and reduces manual effort during revalidation or large-scale updates.
**8. Train Users and Maintain SOPs**
Validation is only as effective as its implementation.
- User training: Ensure all roles understand how to use the system as validated, including procedures for data entry, error resolution and reporting.
- Standard Operating Procedures (SOPs): Maintain up-to-date SOPs aligned with system functionalities and regulatory expectations. SOPs should cover:
- Data management protocols
- Error handling
- Use of system integrations
- Compliance and audit processes
**Conclusion**
Validating LIMS is not just a regulatory formality, it’s a strategic investment in quality, compliance and operational resilience. The complexity of LIMS systems, driven by their high configurability and integration requirements, demands a thoughtful and risk-based validation strategy.
By understanding and managing the unique challenges—such as regulatory compliance, frequent software updates and varying user needs—and adopting best practices in planning, documentation and automation, laboratories can ensure that their LIMS delivers accurate, traceable and compliant data throughout its lifecycle.
Ultimately, a well-validated LIMS not only satisfies auditors but also empowers laboratories to operate more efficiently, make informed decisions and maintain scientific and operational integrity in a rapidly evolving regulatory landscape.
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
---
### [Smarter Science, Lower Costs: Why Pharma Needs Centralized Modeling & Simulation Services](https://zifo.com/blogs/smarter-science-lower-costs-why-pharma-needs-centralized-modeling-simulation-services/)
**Published:** July 23, 2025
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [Smarter Science, Lower Costs: Why Pharma Needs Centralized Modeling & Simulation Services](https://zifo.com/blogs/smarter-science-lower-costs-why-pharma-needs-centralized-modeling-simulation-services/ "Smarter Science, Lower Costs: Why Pharma Needs Centralized Modeling & Simulation Services")
## Smarter Science, Lower Costs: Why Pharma Needs Centralized Modeling & Simulation Services
Hariram Jayaram, Technical Specialist
Jul 23, 2025
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Smarter%20Science%2C%20Lower%20Costs%3A%20Why%20Pharma%20Needs%20Centralized%20Modeling%20%26%20Simulation%20Services%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Fsmarter-science-lower-costs-why-pharma-needs-centralized-modeling-simulation-services%2F "Share on Email")
- [](https://x.com/intent/post?text=Smarter%20Science%2C%20Lower%20Costs%3A%20Why%20Pharma%20Needs%20Centralized%20Modeling%20%26%20Simulation%20Services&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fsmarter-science-lower-costs-why-pharma-needs-centralized-modeling-simulation-services%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Smarter+Science%2C+Lower+Costs%3A+Why+Pharma+Needs+Centralized+Modeling+%26+Simulation+Services&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fsmarter-science-lower-costs-why-pharma-needs-centralized-modeling-simulation-services%2F "Share on LinkedIn")
Image reference: / source
**Modeling and Simulation (M&S)** tools have become essential to modern pharmaceutical R&D. From simulating protein-ligand interactions to optimizing dosing strategies, M&S supports faster, more informed decisions across every stage of drug development.
Yet in many pharma organizations, M&S capabilities are still fragmented, siloed across departments, built on redundant infrastructure, and supported by duplicated licenses. The result? Rising IT costs, poor reproducibility and missed opportunities for collaboration.
It’s time for a change.
**How M&S tools power the drug development lifecycle**
Modeling and Simulation tools enable scientists to test hypotheses, simulate drug behavior, and predict clinical outcomes, often before stepping into a lab. They reduce experimental burden, accelerate decision-making, and improve translatability across discovery and development. Multiple specialized tools are used at different stages, from structural modeling in early discovery to PK/PD and QSP simulations in clinical development.
Fig: Different M&S tools used in different phases of drug discovery
**Limitations of fragmented scientific modeling ecosystems**
Today, individual scientific teams often manage their own modeling tools and infrastructure.
While this provides short-term flexibility, it leads to:
- Multiple teams buying the same software licenses (e.g., Schrödinger, NONMEM, CryoSPARC).
- Redundant infrastructure setups, increasing support burden.
- Inconsistent environments, hurting reproducibility.
- Scientists spending time on tool setup instead of science.
**A better way: centralized M&S as a scientific service**
Rather than building a one-size-fits-all platform, organizations can deliver Modeling & Simulation as a centralized service, operated by a team with both scientific domain knowledge and technology expertise.
This model gives research teams easy access to validated tools, standardized environments, compute resources and automation workflows, without each team needing to reinvent the wheel.
Implementing M&S as a centralized, shared service offers clear advantages:
- **Up to 40% reduction in IT and licensing costs** through pooled tools and infrastructure.
- Faster onboarding of scientists with preconfigured, ready-to-use environments.
- Standardization and reproducibility across teams and studies.
- Less time managing environments, more time generating insights.
- A scalable, future-ready foundation for model-informed drug development.
This model doesn’t restrict flexibility, it amplifies it by making high-quality environments available faster, cheaper and more consistently.
**What should this service include?**
A strong M&S service model includes:
- Provisioning of validated, domain-specific tools (e.g., for QSP, PK/PD, structure-based design).
- Scalable HPC/cloud compute with workflow orchestration.
- Containerized or modular tool delivery to support flexibility.
- Usage tracking for cost visibility and license optimization.
- Centralized knowledge sharing, model libraries, and scientific support.
By centralizing Modeling & Simulation services, not just infrastructure but also the people and processes behind them, pharma companies can reduce operational complexity, unlock cost savings and give their scientists what they need most: the freedom to explore, iterate and discover.
**Smarter science. Faster insight. Lower cost.** That’s the promise of a centralized M&S service model and it’s well within reach.
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
---
### [Data Science Workflows](https://zifo.com/blogs/data-science-workflows/)
**Published:** February 23, 2022
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [Data Science Workflows](https://zifo.com/blogs/data-science-workflows/ "Data Science Workflows")
## Data Science Workflows
Mohamed Ben Hamoudine
Feb 23, 2022
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Data%20Science%20Workflows%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Fdata-science-workflows%2F "Share on Email")
- [](https://x.com/intent/post?text=Data%20Science%20Workflows&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fdata-science-workflows%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Data+Science+Workflows&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fdata-science-workflows%2F "Share on LinkedIn")
Image reference: / source
**INTRODUCTION**
As we discussed in our last articles, Data Science is a “recent” industry term and trend. As the industry is in its infancy, this likely means you will have some difficulties defining the right team setup and project tools for your new “data science” projects. In this blog, we will begin to talk about the best practices that you can use. At Zifo, our data science experts are here to provide you with help and solutions for your Data Science projects.
Regarding your project structure, we recommend that you set up auto-documentation processes and a retrospective of the good and bad points at the end of the project. One of the main mistakes we see is focusing on technologies and tools rather than proactively evaluating and optimising algorithms and methods.
This focus on outcomes will be one of the main differences between a company that leads in AI/ML from those that “just play”. It is a great aim to create a “perfect model”, but the fact is this will limit the impact and benefits. Nevertheless, it is best to keep in mind how your information quality and capability bring you the most business value – in essence, we need a balance.
We see nine main steps when working with a Data Science project:
UNDERSTAND >> AQUIRE >> CLEAN >> EXPLORE >> MODEL >> EVALUATE >> COMMUNICATE >> DEPLOY >> MONITOR
**WHAT ARE THE MAIN IDEAS BEHIND THE “WORKFLOW”**
The first step that is vital and must not be skipped for every project is understanding the question being posed and the objective of the question by asking … you guessed it – lots of questions. Without a deep understanding of the domain, context, data landscape and expectations, we risk missing the point and not delivering.
Since we are working on a Data Science project, we are more often willing to obtain the maximum amount of data to help build our analysis.
Once we have the maximum amount of data, the next challenge is to prepare the data for our purpose. Not all data is equivalent – some may be of high quality, FAIR in all aspects (Findable, Accessible, Interoperable, and Reusable), but life is not that simple. You will need support from data engineers and analysts to gather the data from various systems. Do not expect all data to be available – you may need to change the business processes to collect the data required.
Once we have the data collected, how do we get an overview of our data? It is by exploration; this involves building various visualisation methods and using simple statistics to get an excellent holistic perspective of your dataset. Having this global idea of our dataset can help us tune parameter(s) of the chosen model.
**SOME THINGS TO REMEMBER**
The construction of the model should be an incremental process, which starts with a simple model that adds complexity if needed after reviewing metric evaluations (the more complexity you add, the more your model will “cost” (time and C/GPU) you to perform).
As the model evolves, communicate results in many ways, like writing reports of different steps and plots that show metrics results coming with a demonstration with a test dataset, perhaps run workshops to help educate and gather feedback from your business partners. This direct interaction allows the teams to understand what is being done, and what is needed next time and develops more in-depth organisational knowledge and capacity.
Now that we have confirmed our model can deliver robust and reliable results, we might want to deploy it on the cloud or directly included it in an application running on any eligible device. Choosing where and how needs to be thought through and planned – ensuring the organisation is ready, and change management has been used to help smooth the deployment. Part of this is done a few steps back – engaging with the business with interactive sessions during model development.
Finally, we have now delivered this super, exciting solution’s development and deployment, we must facilitate updates and incorporate future changes easily. This again needs planning and consideration. One benefit of models and data science is as you collect more data and new insights, they can be incorporated into the model to enhance its efficiency, accuracy, and value.
To conclude, the backbone of data science in your company should be maintaining an agile and collaborative environment and researching technical topics for future challenges that you might confront.
To find out more about how Zifo can help with AI, ML, Deep Learning, and scientific Data Sciences, please email us directly at
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
---
### [Eln Upgrade](https://zifo.com/blogs/eln-upgrade/)
**Published:** April 22, 2022
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [Eln Upgrade](https://zifo.com/blogs/eln-upgrade/ "Eln Upgrade")
## Eln Upgrade
Saurav Yadav & Pranaov Ravindrababu
Apr 22, 2022
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Eln%20Upgrade%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Feln-upgrade%2F "Share on Email")
- [](https://x.com/intent/post?text=Eln%20Upgrade&url=https%3A%2F%2Fzifo.com%2Fblogs%2Feln-upgrade%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Eln+Upgrade&url=https%3A%2F%2Fzifo.com%2Fblogs%2Feln-upgrade%2F "Share on LinkedIn")
Image reference: / source
**BACKGROUND**
22 years ago, when the world was figuring out how to handle the Y2K Paradigm life science industry was probably the least bothered given the maturity of the computer systems it had invested in then. Back then, scientific data was still being recorded on paper and would be looked up manually from the archive rooms. More than 2 decades later, the industry is now in the centre of digitalization and is attempting to harness the potential of machine learning and artificial intelligence.
The transition period saw the phenomenal rise of two concepts in computer systems – Electronic Lab Notebook (ELN) and Laboratory Information Management System (LIMS).
Today, there are more makers of ELN in the market than the makers of android phones – clearly underpinning the market potential. However, not all ELN makers sustain in the market – primarily because of their inability to keep up with the innovative but disruptive scientific methodologies towards drug discovery, development, and commercialization.
**WHAT ARE THE MAIN IDEAS BEHIND THE “APPROACH”**
Given the wild run to cure diseases being at its highest than ever before, the drug makers are now looking for ELN systems that allow them to focus on research rather than recording the research data i.e., they are looking for systems that can automate data capture.
The product vendors are all ears to this and are in constant work to better their products but there is one practical problem – making technology meet its actual need i.e., understanding the unsaid / unexpressed needs of the lab analysts (the actual users of ELN) and deploying/upgrading the system in a way it meets these needs.
Since the last decade, both big pharmaceutical and small biotech organizations have been constantly overhauling their informatics landscape to have ELN system that caters to all their changing needs.
From our experience with our customers, one critical step that alleviates the constant re-work is to understand the unsaid needs, pain points, and/or challenges for Business and IT stakeholders with the current ELN system.
When these unsaid needs overlapped with the vision/strategy of the organization, we were able to render a sustainable plan for the implementation/upgrade of the ELN system. We call this exercise “Phase 0 Evaluation.”
And it includes other systematic tasks like evaluating current state usage independently of business emotions.
Though this exercise may sound simple, we learnt over a period that it requires a specific skill to do it right – following are some of the key items.
1. Knowledge of the capabilities of legacy, current and upcoming versions of ELN system (from whichever product vendor)
2. Experience in assessing informatics landscapes and proposing solutions to address gaps
3. Understanding infrastructure constrains and network architecture of the organization
4. Understanding business processes across different functional units and their usage of ELN
5. Empathy towards business users to understand pain points with the current ELN version
6. Knowledge of other ELN systems in the market and what value they may bring to the business
7. Experience with proposing upgrade plans along with risk identification and mitigation
8. Overseeing upgrades with the ability to manage the needs of various parties (including product vendors)
**KEY TAKEAWAYS**
The implementation of the above in a phased manner for the upgrade of ELN plays a key role in filling the gap between the usual approach and an economic approach (that Zifo prefers). The infographic takes each step in turn.
Ensuring inclusion of all the steps in the recommended approach increases the chances of better assimilation of upgrades, addressing business needs and providing good user experience – one of the primary objectives of any upgrade, isn’t it?
To find out more about how Zifo can help with your ELN and Digitalisation, please email us at
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
---
### [User Experience (UX)](https://zifo.com/blogs/user-experience-ux/)
**Published:** April 22, 2022
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [User Experience (UX)](https://zifo.com/blogs/user-experience-ux/ "User Experience (UX)")
## User Experience (UX)
Abhinav Balakumar
Apr 22, 2022
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20User%20Experience%20%28UX%29%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Fuser-experience-ux%2F "Share on Email")
- [](https://x.com/intent/post?text=User%20Experience%20(UX)&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fuser-experience-ux%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=User+Experience+%28UX%29&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fuser-experience-ux%2F "Share on LinkedIn")
Image reference: / source
**UNDERSTANDING SCIENTIFIC INFORMATICS SUPPORT**
**First Rule of Customer Support:** Be responsive.
**Second Rule**: Do not talk (much) to your customers!
Sounds ironic? Not actually. We’ve been preaching this rule to our scientific application support analysts and it’s starting to work wonders with our user experience. We are now supporting in excess of 25000 scientists/statisticians/analysts and over 110 applications across the spectrum of discovery, R&D and clinical studies, and this rule holds good for every request/issue we resolve. Every contact we have with a customer influences whether or not they’ll come back. We have to be great every time or we’ll lose them. – Kevin Stirtz, marketing expert and author. But how?
**RUNNING A COUNTERINTUITIVE EXPERIMENT**
We’ve come to realise that scientific application support is characterized by 3 distinct attributes. We fondly call it the trichotomy of the 3 Ps.
Navigating this landscape isn’t a walk in the park. Our service delivery methodology has been fine-tuned constantly to tame this trichotomy, keeping in mind the diverse aspects involved. It required a multi-faceted approach that includes creating/adopting new technologies, adding to our scientific repertoire, redesigning our processes with a user-centric design and maintaining the security robustness of the scientific applications.
The obvious focus in any application support is to measure and meliorate User Experience. Following this, we started with the traditional approach of obtaining periodic feedback from users, developing a standardized form that compiles 14 key aspects of any project, and an overall score. Listening to scientists and other end-users from across the globe over a period of 4 years, we gathered a lot of information, emotions, appreciations and concerns.
This allowed us to read between the customer’s responses and gain insights into their experience and the quality of our support.
Beyond the 14 points standardized for any project model, we decided to take things up a notch to see how we can put the customer-centric approach to scientific application support so that at every opportunity, we give them more than what they expect.
And, based on the data we gleaned from our feedback score, we were able to arrive at a fascinating metric that influences a user’s support experience:
**Number of Interactions**
Identifying this metric made us realise that we need to look beyond the measurable data that we had in terms of feedback scores and delve deeper into a user’s interaction with our teams and how it influences their experience.
We decided to conduct a Social Experiment with our Scientific Support Analysts with the intention of tracking the number of iterations a user goes through before their issue is resolved by our team.
Consciously measuring the number of iterations led to two improvements.
The first was foreseen – The less time users spent talking about their issues, the happier they were at the time of resolution.
The unexpected improvement was that our analysts were striving to keep the number of iterations down, and this led to a more science-driven and focused approach to delivering scientific application support seamlessly.
Analysts spent more time per request on examining the situation clinically, empathizing with the scientist or end-user. Our scientific background allowed us to speak the user’s language and to analyse the request comprehensively before reaching out to the user for inputs.
**KEY TAKEAWAYS**
The satisfaction of scientific curiosity that comes when an experiment results in an insight is only matched by the eagerness to move to the next experiment. We have a few more experiments lined up for our analysts and would love to share them, but those are for another day!
P.S: Still curious? Think Natural Language Processing… 😉
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
---
### [AI vs ML vs Data Science](https://zifo.com/blogs/ai-ml-dl-why-does-it-matter-data-science/)
**Published:** April 25, 2022
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [AI vs ML vs Data Science](https://zifo.com/blogs/ai-ml-dl-why-does-it-matter-data-science/ "AI vs ML vs Data Science")
## AI vs ML vs Data Science
Mohamed Ben Hamoudine
Apr 25, 2022
Image reference: / source
**INTRODUCTION**
In our last article, we discussed the practical delivery of Data Science by Zifo and clarified what Data Science is in our opinion.
To give you a more precise idea of what you could achieve, we will now discuss different project types existing and that can be made successful by Artificial Intelligence.
**WHAT DOES IT ALL MEAN?**
As with any new area, buzzwords and opinions are abound. Is AI the same as ML, and what is Deep Learning? All are topics existing within the bucket of data science and are about the exploitation of data?
We can describe the most common three terms as follows:
**Artificial Intelligence (AI)**
The idea of modern artificial intelligence appears to have originated in the 1950s when Alan Turing wondered if a machine can “think”. In the article “Computing Machinery and Intelligence”, Turing studies this dilemma and suggests conducting a test (now called the Turing test) seeking to find if a machine could become “mindful”.
**Machine Learning (ML)**
In the 1980s, machine learning was developed, notably with the renaissance of connectionism. The computer begins to deduce “rules to follow” by analysing only data. We can see machine learning as a field of study of artificial intelligence which is based on mathematical and statistical approaches to give computers the capacity to “learn” from data.
**Deep Learning (DL)**
In practical terms, deep learning is just a subset of machine learning, attempting to model with a high level of data abstraction. In other words, it will be learning how your data is composed, for example, in the context of cat images classification: shapes, textures, colours, poses and background. Deep learning models are composed of layers of neurons.
Artificial Intelligence captivates, challenges and perhaps even scares our society due to the extensive use of the term in sci-fi movies. It does, however, deliver benefits and is crucial in sectors such as healthcare, manufacturing, retail, transportation, health, energy, logistics and finance.
During the 1980s and 90s, there were several false starts with companies promising AI and ML-based regression of data. A significant error was the assumption that with enough data, we can perform a regression to predict outside of what the data describes.
**This is a total fallacy.**
For practical use of AI or ML in our science domains there needs to be an in-depth knowledge and understanding of the area of science or its application. Treating the problem or question purely as a mathematical problem will lead to incorrect and non-reproducible conclusions. Taking a straightforward example, you could take a litre of water and apply heat to it. As heat is added, you could measure the change in temperature from 20°C to 30°C then 40° C. A regression would then predict a linear increase in temperature as the heat increases, but we know that at 100°C the water boils. There is a discontinuity, and the temperature does not increase in the same way as the earlier temperatures.
Whilst this is a crude and straightforward example, it is an excellent example of applying machine learning without having enough data – a flawed model – which makes extrapolation dangerous. This learning is applicable across our more complex domains and illustrates why we need a highly skilled team to make sense of data. The latest innovations are showing there are practical solutions and business-driven reasons to apply these data science techniques. A significant bottleneck now is the number of people who have the range of skills which are necessary. Zifo’s mission today is to provide scalable data science services to meet the needs of our global customers and help them to exploit their “renewable data”.
So – we see that data science is the marriage of different skills. Without the right balance of skills and knowledge, we can reach incorrect decisions and inferences, which we refer to as the “Danger Zone“. Zifo’s advantage is that we have been working in the scientific domain for over ten years so have a depth of knowledge in our company to help avoid the “Danger Zone”.
**DATA SCIENCE IS ABOUT RESOLVING PROBLEMS AND ANSWERING QUESTIONS – IT’S NOT ABOUT TECHNOLOGY**
Data Science is a combination of disciplines, and without all elements, there are risks.
The three circles represent what is required when we want to work correctly and succeed in data science. It is not only about having skills in mathematics and computer science but also the knowledge of the subject you want to resolve – domain expertise.
The applications of Data Science are endless. However, three concrete objectives are commonly expected from Data Science.
The **first** application is to achieve robotic process automation. It is the most advanced automation technique, which allows, for example, reading and analysing contract and legal documents to extract possible constraints or anomalies. Robotic Process Automation (RPA) is the most comfortable and cheapest form of AI to set up.
The **second** most common and well-known form is the analysis of information and the extraction of value from a large volume of data (Big Data) for descriptive or predictive purposes. Data analysis can be done, for example, to identify possible frauds in banking or insurance systems or health systems. The most developed techniques of Machine Learning, known as Deep Learning, make it possible to perform functions such as voice or image recognition (Computer Vision projects) or even Natural Language Processing (NLP).
The **third** form is to engage the end-user (employee or customer) in the process of interacting with the machine to gather information or provide a service. An example would be building intelligent chatbots.
In summary, the implementation of data science projects faces many obstacles; organisational, financial, technological, and strategic – but with the right, experienced and innovative, partner these hurdles can be managed and their impact minimised. In the next article, we will explain how a data science team can be efficiently put in place and how it works in a company.
To find out more about how Zifo can help with AI, ML, Deep Learning and scientific Data Sciences, please email us directly at
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
---
### [How Data Science Teams Work](https://zifo.com/blogs/data-science-teams/)
**Published:** April 25, 2022
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [How Data Science Teams Work](https://zifo.com/blogs/data-science-teams/ "How Data Science Teams Work")
## How Data Science Teams Work
Mohamed Ben Hamoudine
Apr 25, 2022
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20How%20Data%20Science%20Teams%20Work%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Fdata-science-teams%2F "Share on Email")
- [](https://x.com/intent/post?text=How%20Data%20Science%20Teams%20Work&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fdata-science-teams%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=How+Data+Science+Teams+Work&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fdata-science-teams%2F "Share on LinkedIn")
Image reference: / source
**INTRODUCTION**
Welcome to another article in our data science series. We will discuss the challenge that companies are facing right now. We already know that artificial intelligence is gaining budget in companies and a part of it goes into creating a team. But after that, the team is released into the wild in the hope that they will produce expected results when, in reality, failure is almost unavoidable with this approach.
At Zifo, our expert team has provided recommendations and consulting to a variety of research-based organizations. Therefore, this is what we will discuss today around a simple question: What team to create internally to carry out your data projects? It is indeed worth asking how companies can, in a thoughtful way, make data teams that are genuinely productive.
**FINDING THE RIGHT CREW**
The term “Data Scientist” has received relatively recent media coverage. This function existed before this appellation, wherever data needed to be managed and analysed. So, if you want to build a specific data team, you must know that it is not just a matter of hiring the best data scientists. It is also about making the best use of the skills of the employees who are already present in the company, whether they have received dedicated training in data science or otherwise. They can add their knowledge of processes and people to guide the team and ensure that it remains in direct contact with all business lines and real business goals.
One question now may come to mind: How do we hire the right people?
As we develop machine learning skills, we must ensure that the group and people do not become disconnected from the business. We are looking for people who will produce “the magic” and help develop a data-driven project mindset. Still, we must ensure that the people involved do not “innovate” in the wrong direction and work in areas that are not of value to the rest of the organisation.
After having taken care of this potential problem, it is then all about getting the right balance. In general, the most successful data science teams – and one could even say, in general, the people who are most successful in their professional life – know how to find a harmonious balance between the pleasure of doing the work and the concrete expression of their creativity, while carefully weighing the risks and rewards involved in such an approach.
**BRINGING A DATA CULTURE**
Part of the success of young and motivated data teams can be attributed to their enthusiasm and agility. They are willing to win and are still small enough in number to maintain the required flexibility and know-how to think outside the box. But these powerful data teams can also fall into an unproductive trap, which consists of focusing too much on the “fun” and creative aspect and lacking discipline.
The consequence will be that the team will come up with risky solutions that undermine the company or the sector activity they are supposed to help.
One leading solution to help with this matter is to adopt a data culture in your company. Spreading the data culture and making data-driven decisions is a responsibility shared by everyone within the company (and not just the data team’s responsibility). It can eventually manifest itself in the development of a “self-service” data team.
Automation, predictive analytics, machine learning, and artificial intelligence are essential and positive business developments. In other words, it does not mean cutting jobs or taking responsibilities away from other people.
To find out more about how Zifo can help with AI, ML, Deep Learning, and scientific Data Sciences, please email us directly at
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
---
### [Covid Impact On Clinical Trails](https://zifo.com/blogs/covid-impact-on-clinical-trials/)
**Published:** April 25, 2022
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [Covid Impact On Clinical Trails](https://zifo.com/blogs/covid-impact-on-clinical-trials/ "Covid Impact On Clinical Trails")
## Covid Impact On Clinical Trails
Divya Suryanarayanan
Apr 25, 2022
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Covid%20Impact%20On%20Clinical%20Trails%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Fcovid-impact-on-clinical-trials%2F "Share on Email")
- [](https://x.com/intent/post?text=Covid%20Impact%20On%20Clinical%20Trails&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fcovid-impact-on-clinical-trials%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Covid+Impact+On+Clinical+Trails&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fcovid-impact-on-clinical-trials%2F "Share on LinkedIn")
Image reference: / source
**INTRO**
COVID-19 pandemic has left sponsors with many questions and decisions to take regarding the continuity or adaptation of the ongoing clinical trials. Our blog explores some of our experiences in a Q&A format.
**Sponsor:** Yes, I do have a lot of questions.
**Zifo:** Have you gotten around to reading the “FDA Guidance on Conduct of Clinical Trials of Medical Products during COVID-19 Public Health Emergency” yet?
**Sponsor:** No, I haven’t yet. I wish I could skim through the guideline quickly.
**Zifo:** Ask away any questions you may have, and I will try to help you.
**CLINICAL TRIALS PROTOCOL AMENDMENTS & DEVIATIONS**
**Sponsor (Q):** I need to make amendments to the protocol specified procedures to avoid potential exposure of subjects to COVID-19 infection. Patient safety will be compromised if we wait for the amendment to be approved by IRB/IEC. What shall I do?
**Zifo (A):** Protocol amendments having a significant impact on the safety of subjects can be implemented prior to IRB/IEC approval! But do ensure that the approval can and should be obtained post-facto.
**Sponsor (Q):** In order to ensure that the subjects enrolled in the trial are not infected by COVID-19 while the study is ongoing, it is mandatory to perform Screening Assessments related to COVID-19 during enrolment. I don’t think I can wait till the protocol amendment is done.
**Zifo (A):** No, it is not necessary that you need to wait. COVID-19 related Screening Assessments can be performed in the trial without amending the protocol.
**Sponsor(Q):** After a lot of deliberations we decided to proceed with the first follow-up through a telephonic visit. This has worked out well with Adverse Events but not much luck with Vital Signs and ECG. Should we capture this deviation at the study level or subject level?
**Zifo (A):** Any deviation from the planned course of study due to COVID-19 needs to be recorded at the subject level, summarized and submitted to FDA. Moreover, capturing the deviation at the study level is not advisable, since it can only be listed and not summarized at the subject level.
**INFORMED CONSENT & TECHNOLOGY**
**Sponsor (Q):** The ICF process requires oral communication with the subject and signed consent for study participation. In this case, we would have to call the subjects to the clinical site, discuss with them and get the ICF signed. How to proceed with the ICF signature process with the subject during this quarantine?
**Zifo (A):** Avoid requesting subjects/participants to visit sites, instead you can use other sources to send the ICF document to the client and get their signature. If needed, Video conferencing of ICF explanation involving the subject, investigator and a third-party witness to authenticate the ICF signature is recommended.
**Sponsor (Q):** We started a Phase III trial on neuropathic pain, and we are in the recruitment phase. Due to the ongoing COVID-19 pandemic, it is not possible to get the ICF signed from the new subjects. How can we proceed with this?
**Zifo (A):** Yeah, ICF is highly critical for subjects to participate in any clinical trial. If the Informed consent form (ICF) cannot be sent to the site, the photo of the attested and signed ICF can be used as a valid ICF document. It is not mandated to comply with the conventional methods for obtaining ICF. There is ‘n’, a number of validated platforms, where we can get the electronic consent signed by subjects. We can use these systems to get the e-consents signed by the subjects directly from their home.
**Technology in Clinical Trials**
**Sponsor (Q):** We have ongoing trials in which several subjects are in the treatment phase. Sites are closed, and it is not always possible for the subjects to come to the clinic for IMP refills. How do we ensure treatment compliance during this pandemic?
**Zifo (A):** Home delivery of IMP from sites using online logistics systems can be used. Note that, IMP from sites can be shipped only if it does not require specific storage and handling conditions.
**Sponsor / Monitoring CRO (Q):** Few of our studies are approaching Database Lock next week. However, there are travel restrictions due to the COVID-19 lockdown, and source documents are unable to be transported. Also, the monitoring team could not commute to the site to perform Source Data Verification. This could delay our submission timelines. How can we perform SDV in this scenario?
**Zifo (A):** The delay due to SDV completely makes sense. But you can request the sites to support remote monitoring – including remote clinical review and SDV by transferring the source documents electronically with general safety practices. Hope this helps to meet the timelines.
**Sponsor (Q):** With the current COVID-19 situation, it is unfeasible for subjects to come to the site for visits within the protocol specified window. Is there an alternative to conducting these visits seamlessly?
**Zifo (A):** Virtual Video Visits using HIPPA-certified online meeting rooms can be used. And, there are a few features worth exploring. For instance, you can link the visit dates with the online meeting rooms which will serve as reminders.
To find out more about how Zifo can help with your clinical biometrics please email us directly at
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
---
### [Data Democratisation Part 2](https://zifo.com/blogs/data-democratisation-part-2/)
**Published:** April 25, 2022
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [Data Democratisation Part 2](https://zifo.com/blogs/data-democratisation-part-2/ "Data Democratisation Part 2")
## Data Democratisation Part 2
Abhinav Balakumar & Sanjanaa Jeevandass
Apr 25, 2022
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Data%20Democratisation%20Part%202%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Fdata-democratisation-part-2%2F "Share on Email")
- [](https://x.com/intent/post?text=Data%20Democratisation%20Part%202&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fdata-democratisation-part-2%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Data+Democratisation+Part+2&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fdata-democratisation-part-2%2F "Share on LinkedIn")
Image reference: / source
**BACKGROUND**
In the first blog in this series, we looked at why data democratisation is important. In this blog, we look at how to decide if you need it.
Data democratization is the process of making data accessible to everyone. There would be no gatekeepers creating bottlenecks at the data gateway. Democratization is not limited to just access. It requires that the accessed data is understandable, and teams have a way to analyse and function using said data. The earliest proponents of large scale Data Democratization, AirBnB have made a stellar proof of concept for organizations to follow.
**WHAT TO ASK YOURESLF TO SEE IF YOU NEED DEMOCRATISATION**
In order to understand how democratized data is within an organization, asking yourself a few simple questions would help.
**Can you….**
Directly access all data relevant to your position?
Search for datasets and inferences made by other teams related to your position?
Access unprocessed data to perform exploratory analysis?
Create new datasets, that can be added to a central repository?
Set up new experiments with the existing models and data?
Access metadata information related to all datasets?
If even one of these questions is answered No, then your organization needs to work on democratizing its data.
Consider an example of a batch control process in a bioprocess lab where your scientist is trying to improve the batch-end quality.
Usually, Quality Analysis is performed at the end of each batch process by performing full factorial tests on measured variables. Data for analyses must be gathered from quality parameter sensors in order to identify accurate changes to the input. This is usually done with open-loop control, which does not happen in real-time.
Instead, if you can enable the entire process to be data-centric, with data-driven models, allowing your team to access and analyse data at every step, including the end result, it allows scientists and engineers to work on controlling and optimizing the batch performance.
Business units are always in need of data from different sources for optimization and decision-making. Enabling them to be data-centric can help achieve a paradigm shift in labs and industries of the future.
**WHATS NEXT?**
Stay tuned to know more about how to democratise data in our third blog in this series
To find out more about **how** Zifo can help with your data management needs please email us directly at
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
---
### [Data Democratisation Part 1](https://zifo.com/blogs/data-democratisation-part-1/)
**Published:** April 25, 2022
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [Data Democratisation Part 1](https://zifo.com/blogs/data-democratisation-part-1/ "Data Democratisation Part 1")
## Data Democratisation Part 1
Abhinav Balakumar & Sanjanaa Jeevandass
Apr 25, 2022
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Data%20Democratisation%20Part%201%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Fdata-democratisation-part-1%2F "Share on Email")
- [](https://x.com/intent/post?text=Data%20Democratisation%20Part%201&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fdata-democratisation-part-1%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Data+Democratisation+Part+1&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fdata-democratisation-part-1%2F "Share on LinkedIn")
Image reference: / source
**WHY SCIENCE IS PROTESTING FOR DATA DEMOCRACY**
In a rapidly transforming world where data is termed the new oil, we are surrounded by conversations about why data is important, the wonders we unearth each day with data and how it is transforming and invading our lives. Perhaps the oil analogy is not quite right – we do transform data as we do oil – but data is not a fixed resource and will not run out – it will continue to grow and develop over time – making it more valuable than oil.
This continuous overpowering creation of information, insights and knowledge is often characterized as uncontrolled, confounding and largely under-utilized. Global industries are now going through a revolution in digitization, digital technologies, automation and AI among other “buzz-word” worthy concepts. However, the foundation of any of or all these technologies is…… Data.
The life sciences industry has often been criticized for playing catch-up with other industries such as FINTECH etc. While other industries are becoming data and analytics-ready, and even data-driven in some cases – the life sciences industry has yet to realise the true potential of the data stockpile they are sitting on.
**MORE DATA, MORE PROBLEMS:**
Data generation has never been a problem in the life sciences industry. Labs have been producing enormous amounts of data for many years and it is only increasing thanks to recent technological advances in multi-omics and image-based analytical techniques.
Our data requirements have always been intensive and are only getting more complicated thanks to such fields as omics (genomics, transcriptomics, proteomics, metabolomics etc.), biomarker analysis, and clinical statistics to name a few.
The time spent and complexity of managing data is becoming increasingly cumbersome compared to our data generation capacity. Scientists are often faced with insurmountable challenges in accessing, cleaning and managing data, rather than spending their time on analysing and inferring from it.
**The most common problems faced by scientists are:**
**Availability:**
The availability and accessibility of data for business and exploratory needs are perhaps the foremost problems faced by scientists working in data-siloed organizations. Data is often stored in native or custom formats specific to each instrument or scientific application niche to a business process. Scientists often hit roadblocks when trying to search for related data from their processes or running behind “data owners” to get access to relevant data.
**Lack of Data Standards:**
Data exchange is often seen as necessary for driving innovation between organizations and within organizations, but it’s always impeded by the lack of data standards among instruments, labs, business units, and entire organizations. The need for data standards was clearly understood during the Ebola outbreak of 2014 when data sharing helped scientists trace the origins of the virus and control the endemic. The need is reiterated in the current COVID-19 pandemic, with the WHO defining data sharing and reporting protocols. In spite of defining a protocol, the COVID-19 pandemic has clearly highlighted how the lack of data sharing standards in real-world scenarios exposes the shortcomings of any data infrastructure, and in turn the health infrastructure.
**Ownership and usage:**
Most organizations do not have clearly defined owners for their data, and often the IT teams that manage the applications end up as de facto owners. This leads to scientists and research teams being dependent on IT teams to access and analyse data.
There’s also the unwanted evolution of the IT team into a common data analytics team, performing ETL operations on behalf of the data users.
Lack of Self-service Analytical tools or knowledge leads to dependency on data scientists to perform ETL and create inferences without complete knowledge about the data process. Organizations often end up having to hire generalist data scientists who work across business functions without the scientific focus required for drug discovery research.
**WHATS NEXT?**
Stay tuned to know more about the **questions** that can be used to decide if you need to your democratise data in our second blog in this series
To find out more about how Zifo can help with your data management needs please email us directly at
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
---
### [Data Democratisation Part 3](https://zifo.com/blogs/data-democratisation-part-3/)
**Published:** April 25, 2022
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [Data Democratisation Part 3](https://zifo.com/blogs/data-democratisation-part-3/ "Data Democratisation Part 3")
## Data Democratisation Part 3
Abhinav Balakumar & Sanjanaa Jeevandass
Apr 25, 2022
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Data%20Democratisation%20Part%203%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Fdata-democratisation-part-3%2F "Share on Email")
- [](https://x.com/intent/post?text=Data%20Democratisation%20Part%203&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fdata-democratisation-part-3%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Data+Democratisation+Part+3&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fdata-democratisation-part-3%2F "Share on LinkedIn")
Image reference: / source
**BACKGROUND**
In the first blog in this series we looked at what is data democratisation, and in the second we looked at what questions should you ask to see if you need it.
In this third and final blog in the series, we look at how can you democratise your data.
**HOW DO YOU DEMOCRATISE YOUR DATA?**
**Set up data infrastructure:**
Create/set up data storage, platforms and analytical tools depending on your end usage with the core components of democratization in mind. Apply FAIR (findability, accessibility, interoperability, and reusability) principles to all data over time.
**Restructure your team:**
Move towards a decentralized data team, where any team has the ability/knowledge to perform the role of a data scientist
**Implement Metadata Hubs:**
A Metadata Hub is part of your infrastructure that goes a long way in enabling your data to be democratized. Metadata Hubs help in enabling data to be accessible by indexing datasets, contents of tables, and their connection to other data. Using semantics allows any data used to understand the origin, context and historical use of a data source before they decide to work with it.
**Quality checks and data stewards:**
One of the biggest challenges in decentralizing data is maintaining the quality of the datasets created by different teams and ensuring consistency. Open data formats, in-house QC tools and automated checks and anomaly detectors go a long way in helping with quality checks. Data stewards can help in implementing data governance standards for democratized data to ensure the quality of content and metadata.
**Realigning focus by training your team on ETL:**
Having a decentralized team helps users perform Extract, Transform and Load operations on their own data, instead of having to rely on IT teams and Data Engineers. This reduces the burden on data engineers who can work toward more organizationally relevant ideas for improving and maintaining data infrastructure. It creates an agile process for business units to have analysis-ready data whenever they need it.
**“Democracy is the art of thinking independently together”- Alexander Meiklejohn**
Data Democratization allows scientific and process-driven organizations to uncover opportunities from research data thus expediting decision-making and in turn allowing solutions to reach the market faster.
A data democratized organization has teams that are data-centric and empowered through a connected ecosystem and knowledge of handling and analysing data. Numerous hidden patterns and undiscovered insights can come to light leading to accelerated drug discovery and development from existing data.
To find out more about how Zifo can help with your data management needs please email us directly at
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
---
### [Cloud And Covid Research](https://zifo.com/blogs/covid-and-cloud-based-research-services/)
**Published:** April 27, 2022
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [Cloud And Covid Research](https://zifo.com/blogs/covid-and-cloud-based-research-services/ "Cloud And Covid Research")
## Cloud And Covid Research
Radhika Govindarajan
Apr 27, 2022
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Cloud%20And%20Covid%20Research%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Fcovid-and-cloud-based-research-services%2F "Share on Email")
- [](https://x.com/intent/post?text=Cloud%20And%20Covid%20Research&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fcovid-and-cloud-based-research-services%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Cloud+And+Covid+Research&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fcovid-and-cloud-based-research-services%2F "Share on LinkedIn")
Image reference: / source
**COVID 19 STRIKES – WILL CLOUD SERVICES BOOM?**
Ever since the announcement of the novel coronavirus as a pandemic, all that I got to hear was about the significant toll of the COVID-19 outbreak all over the world with positive cases expanding to more than 3.6 million and 2,50,000 deaths as of May 5, 2020.
If there was something that seemed to prevail among all societal groups irrespective of any discrimination, then it was fear, anxiety and uncertainty and of course, I was no exception. I turned more anxious when the health crisis started to take shape as a social and economic crisis as well, which led around 175 countries across the globe to announce a nationwide lockdown to mitigate the spread.
Running across headlines on how global trade of essential commodities like oil was drastically affected, leading to the sharp fall of prices, sounded like a warning toward economic recession. Working in the Scientific RnD Informatics sector and having crossed almost 50 days of remote work lifestyle, made me curious to know how sectors like us are coping with the shutdown and what is awaiting us in the post-pandemic run.
Surprisingly, I happened to witness a spurt of growth in the business of cloud technology providers such as Amazon, Microsoft and Google, especially during these times and analysis shows that they are expected to emerge as the champions at the end of this phase for several reasons.
**WHY WILL CLOUD SERVICES GROW IN A PANDEMIC?**
IT and RnD sectors are trying their maximum to time-box the impact of the virus, by rapidly switching into “Work from home” mode which has caused the availability of data services to turn into a necessity.
Organizations that have already migrated to the cloud seem to be under less pressure than those having traditional data centres that require people to do the set-up on the premise and find it difficult to operate remotely.
This has also reduced the risk of exposing the human resources involved in the maintenance and operation of the in-house servers to the virus. While there were many ambiguities all these years on cloud capacity, security and applicability to real-time usage, the COVID-19 crisis has proved to be a case study breaking all the ambiguities.
Similarly, AWS has put in place several disaster recovery policies and provides confidence to handle the spike in demands during the period.
With regards to environmental issues, many arguments were raised stating that the construction of data centres would lead to an increase in the warmth of the planet and hence questioning the eco-friendliness of cloud computing. But, according to recent studies, it may be seen that the increase in data centres of public cloud due to their sharing abilities in terms of computing and storage have lower carbon emissions and energy consumption when compared to individual on-premise data centres.
Also, looking back at what can be learnt from earlier times during similar pandemics, it is evident that the pharma and healthcare sectors were those who continued to operate with even more rigour. Returning to normal conditions has happened only with the discovery of a vaccine.
Unlike any other companies which proceed with inventing and selling better versions of their products, pharmaceutical and biotech companies undergo a lot more procedures and trials to achieve the same with respect to a drug/vaccine, since they are bound by a set of regulatory and compliance guidelines.
The drug development process, in general, involves several phases of experimental studies and clinical trials which require diverse data collection, processing and analysis of huge chunks of data in collaboration with laboratories across the globe.
**WHAT NOW?**
As of today, with the list of completed and ongoing COVID-19 studies registered in the WHO database amounts up to 1,042 and “time” is the essence of success in the pharma & biotech sectors, a solution is required to accelerate the process with limited/no movement.
When I was chatting with our Digital Transformation, Cloud Services and HPC teams, they said cloud computing seems to have received the attention of quite a few pharma and biotech companies as an avid jump into digital transformation and cloud migration might help them in terms of recording, storage, processing and analysis of humongous data from anywhere in the world. Moreover, adopting HPC based cloud services might provide a whole lot of advantages in terms of faster computation and simulation resulting in improved performance. Also, cloud services over time have come up with various features to be secure and compliant with the regulatory guidelines.
With all these considered, a huge surge in the demand for cloud services are expected at the end of the COVID -19 pandemic. Would it make it an essential infrastructure?
To find out more about how Zifo can help with your cloud, digital transformation and HPC needs please email us directly at
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
---
### [The Data Science Workflow](https://zifo.com/blogs/the-data-science-workflow/)
**Published:** May 17, 2023
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [The Data Science Workflow](https://zifo.com/blogs/the-data-science-workflow/ "The Data Science Workflow")
## The Data Science Workflow
Mohamed Ben Hamdoune
May 17, 2023
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20The%20Data%20Science%20Workflow%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Fthe-data-science-workflow%2F "Share on Email")
- [](https://x.com/intent/post?text=The%20Data%20Science%20Workflow&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fthe-data-science-workflow%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=The+Data+Science+Workflow&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fthe-data-science-workflow%2F "Share on LinkedIn")
Image reference: / source
As we discussed in our last articles, Data Science is a “recent” industry term and trend. As the industry is in its infancy, this likely means you will have some difficulties defining the right team setup and project tools for your new “data science” projects. In this blog, we will begin to talk about the best practices that you can use. At Zifo, our data science experts are here to provide you with help and solutions for your Data Science projects.
Regarding your project structure, we recommend that you set up auto-documentation processes and a retrospective of the good and bad points at the end of the project. One of the main mistakes we see is focusing on technologies and tools rather than proactively evaluating and optimising algorithms and methods.
This focus on outcomes will be one of the main differences between a company that leads in AI/ML from those that “just play”. It is a great aim to create a “perfect model”, but the fact is this will limit the impact and benefits. Nevertheless, it is best to keep in mind how your information quality and capability bring you the most business value – in essence, we need a balance.
We see nine main steps when working with a Data Science project:
The first step that is vital and must not be skipped for every project is understanding the question being posed and the objective of the question by asking … you guessed it – lots of questions. Without a deep understanding of the domain, context, data landscape and expectations, we risk missing the point and not delivering.
Since we are working on a Data Science project, we are more often willing to obtain the maximum amount of data to help build our analysis.
Once we have the maximum amount of data, the next challenge is to prepare the data for our purpose. Not all data is equivalent – some may be of high quality, FAIR in all aspects (Findable, Accessible, Interoperable, and Reusable), but life is not that simple. You will need support from data engineers and analysts to gather the data from various systems. Do not expect all data to be available – you may need to change the business processes to collect the data required.
Once we have the data collected, how do we get an overview of our data? It is by exploration; this involves building various visualisation methods and using simple statistics to get an excellent holistic perspective of your dataset. Having this global idea of our dataset can help us tune parameter(s) of the chosen model.
The construction of the model should be an incremental process, which starts with a simple model that adds complexity if needed after reviewing metric evaluations (the more complexity you add, the more your model will “cost” (time and C/GPU) you to perform).
As the model evolves, communicate results in many ways, like writing reports of different steps and plots that show metrics results coming with a demonstration with a test dataset, perhaps run workshops to help educate and gather feedback from your business partners. This direct interaction allows the teams to understand what is being done, what is needed next time and develops more in-depth organisational knowledge and capacity.
Now that we have confirmed our model can deliver robust and reliable results, we might want to deploy it on the cloud or directly included it in an application running on any eligible device. Choosing where and how needs to be thought through and planned – ensuring the organisation is ready, and change management has been used to help smooth the deployment. Part of this is done a few steps back – engaging with the business with interactive sessions during model development.
Finally, we have now delivered this super, exciting solution’s development and deployment, we must facilitate updates and incorporate future changes easily. This again needs planning and consideration. One benefit of models and data science is as you collect more data and new insights, they can be incorporated into the model to enhance its efficiency, accuracy, and value.
To conclude, the backbone of data science in your company should be maintaining an agile and collaborative environment and researching technical topics for future challenges that you might confront.
To find out more about how Zifo can help with AI, ML, Deep Learning, and scientific Data Sciences, please email us at
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
---
### [Accelerating Lab Data Transformation With LDAS](https://zifo.com/blogs/accelerating-lab-data-transformation-with-ldas/)
**Published:** August 20, 2025
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [Accelerating Lab Data Transformation With LDAS](https://zifo.com/blogs/accelerating-lab-data-transformation-with-ldas/ "Accelerating Lab Data Transformation With LDAS")
## Accelerating Lab Data Transformation With LDAS
Zifo
Aug 20, 2025
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Accelerating%20Lab%20Data%20Transformation%20With%20LDAS%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Faccelerating-lab-data-transformation-with-ldas%2F "Share on Email")
- [](https://x.com/intent/post?text=Accelerating%20Lab%20Data%20Transformation%20With%20LDAS&url=https%3A%2F%2Fzifo.com%2Fblogs%2Faccelerating-lab-data-transformation-with-ldas%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Accelerating+Lab+Data+Transformation+With+LDAS&url=https%3A%2F%2Fzifo.com%2Fblogs%2Faccelerating-lab-data-transformation-with-ldas%2F "Share on LinkedIn")
Image reference: / source
Modern labs face challenges like fragmented data, manual workflows, and the growing need to make data FAIR and AI-ready. Zifo’s accelerator, Lab Data Automation Solution (LDAS), addresses these by breaking down silos, streamlining integration, and enabling scalable automation and AI-driven insights.
LDAS combines Zifo’s informatics expertise with pre-built accelerators to fast-track implementation. Whether you’re managing diverse instrument outputs or preparing for AI initiatives, LDAS ensures your data is structured, contextualized, and ready to scale — making it a strategic enabler for digital transformation
**Explore case studies** to see how LDAS is applied across pharma domains—from Research, Development to Manufacturing QA/QC : [https://zifo.com/services/lab-data-automation-solution-ldas/](/services/lab-data-automation-solution-ldas/)
**Browse our parser library** to explore instrument parsers built using AI for faster development and easier integration. If your instrument isn’t listed, it’s either in our roadmap or can be added quickly—just reach out and help us expand the community library : [https://zifo.com/services/instrument-and-system-agents-parser/](/services/instrument-and-system-agents-parser/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
---
### [2025 Perspectives In AI, Data And Science](https://zifo.com/blogs/2025-perspectives-in-ai-data-and-science/)
**Published:** December 16, 2025
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [2025 Perspectives In AI, Data And Science](https://zifo.com/blogs/2025-perspectives-in-ai-data-and-science/ "2025 Perspectives In AI, Data And Science")
## 2025 Perspectives In AI, Data And Science
Sakthi Prasad T, Content Director
Dec 16, 2025
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%202025%20Perspectives%20In%20AI%2C%20Data%20And%20Science%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2F2025-perspectives-in-ai-data-and-science%2F "Share on Email")
- [](https://x.com/intent/post?text=2025%20Perspectives%20In%20AI%2C%20Data%20And%20Science&url=https%3A%2F%2Fzifo.com%2Fblogs%2F2025-perspectives-in-ai-data-and-science%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=2025+Perspectives+In+AI%2C+Data+And+Science&url=https%3A%2F%2Fzifo.com%2Fblogs%2F2025-perspectives-in-ai-data-and-science%2F "Share on LinkedIn")
AI sits at a crossroads in biopharma. While Google’s Gemma model successfully identified a cancer pathway, the industry faces a reality check. Meanwhile, Translational genomics is drowning in data without clear navigation, and Gartner places Gen AI in the “Trough of Disillusionment” due to unmet promises.
Zifo’s Data Readiness Survey confirms this tension: companies are investing heavily, but most work remains foundational — cleaning data and aligning standards. Real value lies in balancing flashy breakthroughs with the essential, behind-the-scenes work that drives science.
*The PDF report is embedded on this page. Please scroll to read or download it. Download option button is available below the PDF embed*
[ Click Here to Download the Report ](#)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
---
### [Operational Excellence in Lab IT Using Splunk: Beyond SIEM, Into Scientific Enablement](https://zifo.com/blogs/operational-excellence-in-lab-it-using-splunk-beyond-siem-into-scientific-enablement/)
**Published:** April 1, 2026
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [Operational Excellence in Lab IT Using Splunk: Beyond SIEM, Into Scientific Enablement](https://zifo.com/blogs/operational-excellence-in-lab-it-using-splunk-beyond-siem-into-scientific-enablement/ "Operational Excellence in Lab IT Using Splunk: Beyond SIEM, Into Scientific Enablement")
## Operational Excellence in Lab IT Using Splunk: Beyond SIEM, Into Scientific Enablement
Karthikeyan Selvaraj – Tech Solutions Consultant
Apr 01, 2026
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Operational%20Excellence%20in%20Lab%20IT%20Using%20Splunk%3A%20Beyond%20SIEM%2C%20Into%20Scientific%20Enablement%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Foperational-excellence-in-lab-it-using-splunk-beyond-siem-into-scientific-enablement%2F "Share on Email")
- [](https://x.com/intent/post?text=Operational%20Excellence%20in%20Lab%20IT%20Using%20Splunk%3A%20Beyond%20SIEM%2C%20Into%20Scientific%20Enablement&url=https%3A%2F%2Fzifo.com%2Fblogs%2Foperational-excellence-in-lab-it-using-splunk-beyond-siem-into-scientific-enablement%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Operational+Excellence+in+Lab+IT+Using+Splunk%3A+Beyond+SIEM%2C+Into+Scientific+Enablement&url=https%3A%2F%2Fzifo.com%2Fblogs%2Foperational-excellence-in-lab-it-using-splunk-beyond-siem-into-scientific-enablement%2F "Share on LinkedIn")
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Stories
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
When people hear “Splunk,” they often think of a **SIEM tool** used for cybersecurity. But in the context of **pharmaceutical R&D labs**, Splunk is much more — it’s a **data intelligence platform that** empowers Lab IT teams to achieve **operational excellence** through real-time visibility, automation, and actionable insights.
**Why Lab IT Needs a Smarter, Unified Approach**
Pharma R&D labs are high-stakes environments where instrument uptime, data integrity, and workflow efficiency directly impact innovation timelines. Lab IT teams manage:
- A diverse mix of instruments (e.g., HPLC, GC, spectrometers)
- Scientific applications (LIMS, ELN, CDS)
- Network infrastructure and middleware
- Compliance with GxP and data integrity standards
Traditional monitoring tools often fall short in providing **end-to-end visibility**, leading to delays, inefficiencies, and audit risks.
**Splunk in Lab IT: A Strategic Enabler**
Splunk ingests and correlates machine data from across the lab ecosystem, enabling Lab IT teams to monitor, analyse, and act in real time.
**Instrument Log Monitoring & Availability**
Splunk collects logs and performance data from lab instruments to track uptime, detect anomalies, and ensure availability. Lab managers can instantly identify which instruments are online, idle, or experiencing issues—reducing downtime and improving lab throughput.
**Real-Time Dashboards on Lab TVs**
Splunk dashboards can be displayed on large screens across the lab floor, showing:
- Instrument status
- Experiment throughput
- System usage trends
- Network health
This fosters transparency, faster decision-making, and a culture of continuous improvement.
**Experiment & System Usage Statistics**
Splunk aggregates data from scientific applications and infrastructure to provide insights into:
- Number of experiments run per day/week
- Resource utilization across instruments and systems
- User activity and workflow bottlenecks
These metrics help optimize lab scheduling, improve capacity planning, and support data-driven budgeting.
**Automated Incident & Request Ticket Creation**
Splunk integrates with ITSM platforms like **ServiceNow**, **Jira**, or **BMC Remedy** to automate ticketing:
-
- Detects issues (e.g., instrument errors, network failures) in real time
-
- Automatically creates incident or request tickets with detailed diagnostics
-
- Routes tickets to appropriate support teams for faster resolution
This reduces manual effort, improves response times, and ensures consistent issue tracking.
**Built-in Compliance Monitoring for GxP Environments**
Regulated pharma labs must meet ALCOA+, 21 CFR Part 11, and EU Annex 11 requirements. Splunk becomes a strategic enabler by:
- **Consolidating audit trails** from instruments, CDS/LIMS/ELN systems, and infrastructure into a tamper‑resistant repository
- Providing **real-time monitoring** for data integrity anomalies, timestamp mismatches, unauthorized configuration changes, and missing audit entries
- Generating **automated compliance reports** for QA, audits, and periodic reviews
- Supporting **CSV validation** (IQ/OQ/PQ) for dashboards, alerts, and data flows
This makes Splunk a compliance accelerator, not just an operational tool.
**Simplifying Integration Across a Highly Heterogeneous Lab Ecosystem**
Lab IT landscapes are inherently complex—diverse instruments, proprietary log formats, middleware, data brokers, and segmented networks. Splunk becomes a strategic enabler by:
- Normalizing log formats from legacy instruments, modern devices, and scientific software
- Integrating multi-hop data flows through SDMS, LES, and file-transfer middleware
- Handling high-volume scientific logging with scalable indexing and retention strategies
- Maintaining secure connectivity across segmented lab networks, DMZs, and firewalls
This turns Splunk into the central nervous system connecting all parts of the lab ecosystem.
**Splunk Features That Drive Lab IT Excellence**
Splunk’s core features make it a powerful ally for Lab IT:
- **Dashboards**: Customizable views for instrument health, experiment stats, and system performance
- **Alerts**: Real-time notifications for anomalies, failures, or compliance breaches
- **Reports**: Scheduled or on-demand reports for audits, KPIs, and operational reviews
- **Integrations**: Seamless connectivity with ITSM tools, security platforms, and lab systems
These capabilities help Lab IT teams move from reactive support to proactive enablement.
**Business Impact for Pharma Leaders**
By adopting Splunk in Lab IT, pharma organizations can achieve:
- **30–50% reduction in instrument downtime as per Zifo estimate.**
- **Faster root cause analysis and issue resolution**
- **Improved audit readiness and compliance**
- **Greater lab productivity and scientific throughput**
Operational excellence in Lab IT isn’t just about technology—it’s about enabling science, accelerating innovation, and delivering better outcomes for patients.
**Conclusion**
Splunk is not just a SIEM tool—it’s a **strategic platform for operational intelligence**. In pharma R&D labs, it empowers Lab IT teams to ensure instrument availability, streamline workflows, and automate support processes. The result? A smarter, faster, and more resilient lab environment.
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Stories
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
---
### [2026 GxP Regulatory Outlook: What Will Meaningfully Change](https://zifo.com/blogs/2026-gxp-regulatory-outlook-what-will-meaningfully-change/)
**Published:** March 17, 2026
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [2026 GxP Regulatory Outlook: What Will Meaningfully Change](https://zifo.com/blogs/2026-gxp-regulatory-outlook-what-will-meaningfully-change/ "2026 GxP Regulatory Outlook: What Will Meaningfully Change")
## 2026 GxP Regulatory Outlook: What Will Meaningfully Change
Tript Srivastava, GxP Compliance Associate Manager
Mar 16, 2026
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%202026%20GxP%20Regulatory%20Outlook%3A%20What%20Will%20Meaningfully%20Change%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2F2026-gxp-regulatory-outlook-what-will-meaningfully-change%2F "Share on Email")
- [](https://x.com/intent/post?text=2026%20GxP%20Regulatory%20Outlook%3A%20What%20Will%20Meaningfully%20Change&url=https%3A%2F%2Fzifo.com%2Fblogs%2F2026-gxp-regulatory-outlook-what-will-meaningfully-change%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=2026+GxP+Regulatory+Outlook%3A+What+Will+Meaningfully+Change&url=https%3A%2F%2Fzifo.com%2Fblogs%2F2026-gxp-regulatory-outlook-what-will-meaningfully-change%2F "Share on LinkedIn")
Image reference: / source
Regulators across the US, EU, and UK are entering 2026 with a more mature and coordinated regulatory posture. Digital governance, data integrity, AI accountability, ISMS modernization, and device QMS harmonization through ISO 13485 (via the US QMSR) will collectively shape inspection expectations through 2026–2029. The year marks a shift from procedural compliance toward governance‑driven, data‑centric assurance.
**1) GDPR & Global Privacy: 2026 as the Year of Transparency**
The EDPB has selected transparency and information obligations (GDPR Arts. 12–14) as its theme for the 2026 Coordinated Enforcement Framework, meaning DPAs will conduct coordinated inquiries, questionnaires, and investigations throughout the year.
The UK will simultaneously implement its updated clinical‑trials transparency rules in 2026, with broader UK privacy reforms progressing in parallel.
**Implication:**
For any GxP environment processing personal data: clinical, safety, RWD, pharmacovigilance, or laboratory, 2026 requires embedding GDPR‑grade transparency, RoPA traceability, and disclosure readiness directly within validation, configuration, and change‑control activities.
**2) ISO 9001: New Edition Expected September–October 2026**
The ISO/DIS 9001 has been released, with publication targeted for September–October 2026, followed by a three‑year transition (pending IAF confirmation). Key thematic directions include strengthened quality culture, ethical considerations, clarified risk opportunity planning, and integration of the 2024 climate amendment.
**Implication:**
Organizations integrating enterprise quality with the PQS should begin embedding culture‑and‑ethics metrics, leadership accountability, and risk/opportunity differentiation into dashboards and management‑review inputs to avoid reactive transitions post‑release.
**3) ISO/IEC 27001:2022—Full Enforcement from 2026**
The IAF transition window closed on 31 October 2025, rendering ISO/IEC 27001:2013 certificates expired. Beginning 2026, auditors will uniformly assess against ISO/IEC 27001:2022, including its expanded control set: threat intelligence, security monitoring, and configuration management.
**Implication:**
For cloud and hybrid GxP systems, harmonize Annex 11 and data‑integrity controls with ISMS requirements (IAM, backup/restore, supplier governance). A unified control mapping streamlines inspections and demonstrates end‑to‑end governance.
**4) EU GMP Modernization: Annex 11 Revision + New Annex 22 (AI)**
Following the July–October 2025 public consultation, the European Commission is expected to release updated texts for Chapter 4 (Documentation), Annex 11 (Computerised Systems), and the new Annex 22 (AI) in 2026. Drafts emphasize elevated data governance, audit‑trail expectations, hybrid documentation rules, and validated, monitored AI restricting adaptive behavior for systems involved in GMP‑critical decisions.
**Implication:**
Organizations should complete a structured Annex 11/22 gap assessment addressing:
- clarified roles and responsibilities,
- supplier oversight,
- audit‑trail review procedures,
- AI lifecycle governance (datasets, drift monitoring, retraining controls),
- human‑in‑the‑loop checkpoints.
**5) Clinical Trials: EU CTR Fully Operational; UK Regime Live by April 28, 2026**
The EU CTR is now fully enforced (new CTAs through CTIS; legacy migrations completed January 31, 2025), with operational refinements continuing into 2026.
The UK MHRA’s amended Clinical Trials Regulations enter into force on April 28, 2026, completing a 12‑month rollout emphasizing efficiency and transparency.
**Implication:**
Harmonize governance across EU/UK processes: CTIS versus UK national routes prioritizing consistency in auditability, data integrity, and transparency obligations.
**6) Devices & Diagnostics: US QMSR in 2026; EU MDR/IVDR & EUDAMED Milestones**
The US QMSR becomes effective February 2, 2026, integrating ISO 13485:2016 into federal regulation and updating combination‑product references in 21 CFR Part 4.
ISO 13485:2016 remains stable (reconfirmed).
Under EU MDR/IVDR, transitional provisions continue, with EUDAMED’s first four modules mandatory by May 28, 2026.
**Implication:**
US: Execute a QSR→QMSR gap assessment, anticipating broader FDA access to internal QMS records (e.g., internal audits, management review).
EU: Establish a structured 2026 EUDAMED plan and meet conditional MDR/IVDR milestones to maintain certificate continuity.
**7) ICH Updates with 2026 Operational Impact**
ICH Q9(R1) (bias mitigation, formality, effective risk‑based decisions) is now fully adopted.
ICH M10 continues to have significant operational implications, particularly regarding cross‑validation, endogenous analytes, and parallelism expectations.
**Implication:**
Integrate Q9(R1) formality levels and M10 rigor into data‑governance, method‑validation, and digital‑system assurance programs. These align naturally with Annex 11/22 expectations and FDA’s CSA‑aligned approach.
**8) AI Governance Across GxP and Privacy**
The EU AI Act phases in major obligations through 2025–2027, with most high‑risk system requirements applying from August 2, 2026, and embedded high‑risk product obligations by August 2, 2027. Core themes include risk management, dataset governance, human oversight, documentation, monitoring, and transparency (e.g., labeling synthetic content).
**Implication:**
For any AI touching quality, manufacturing, PV, or clinical functions: define intended use, control training data lineage, monitor models for drift, document constraints on retraining, integrate human oversight, and align GDPR transparency with AI‑related explanations in notices and SOPs.
**9) Computer Software Assurance (CSA): FDA Re‑issues Final Guidance Aligned to QMSR**
On February 3, 2026, FDA issued the revised Computer Software Assurance for Production and Quality Management System Software guidance, replacing the September 2025 version. The CSA principles remain unchanged, but terminology and citations now align with QMSR/ISO 13485 (e.g., ISO 13485 4.1.6, 7.5.6, 7.6).
On February 4, 2026, FDA also reissued its medical‑device cybersecurity guidance with parallel QMSR/ISO 13485 citation updates.
**Implication:**
CSA frameworks do not require redesign; only SOPs, templates, and citation updates are needed. Continue applying risk‑based scripted/unscripted testing, leveraging vendor evidence, and capturing digital records.
**Conclusion**
2026 marks a structural shift in how regulators expect organizations to govern data, digital systems, and quality processes. GDPR transparency obligations, ISO‑aligned ISMS controls, ISO 9001’s renewed emphasis on culture and risk‑based thinking, ISO 13485 alignment through the US QMSR, the EU’s Annex 11/22 digital and AI expectations, full CTR operationalization, and the maturity of ICH Q9/M10 collectively raise the threshold for demonstrable governance.
Regulators are moving beyond documentation‑heavy compliance toward evidence of consistent, end‑to‑end governance across quality, data, security, and digital systems. Organizations that cannot show integrated control over their data flows, software lifecycle, AI usage, and system assurance will face heightened scrutiny, irrespective of how much validation documentation they generate.
TimeframeMonth / PeriodRegulatory Change / Event2026January 2026ISO/IEC 27001:2022 baseline in audits2026February 2026US FDA QMSR, CSA, and Cybersecurity Guidance reissue2026April 2026UK Clinical Trials Regulations amended2026May 2026EUDAMED mandatory use of first four modules2026August 2026EU AI Act high-risk AI and transparency obligations apply2026September–October 2026ISO 9001:2026 new edition publication window2026Throughout 2026GDPR EDPB Coordinated Enforcement Framework (Transparency focus)2026Throughout 2026ICH Q9(R1) & M10 inspection expectations
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
**Categories:** Validation Service and Compliance Support
---
### [Rethinking Animal Management: A Move Towards Technological Innovation](https://zifo.com/blogs/rethinking-animal-management-a-move-towards-technological-innovation/)
**Published:** May 31, 2024
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [Rethinking Animal Management: A Move Towards Technological Innovation](https://zifo.com/blogs/rethinking-animal-management-a-move-towards-technological-innovation/ "Rethinking Animal Management: A Move Towards Technological Innovation")
## Rethinking Animal Management: A Move Towards Technological Innovation
Karan Khatter, Lead Consultant
Mar 31, 2024
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Rethinking%20Animal%20Management%3A%20A%20Move%20Towards%20Technological%20Innovation%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Frethinking-animal-management-a-move-towards-technological-innovation%2F "Share on Email")
- [](https://x.com/intent/post?text=Rethinking%20Animal%20Management%3A%20A%20Move%20Towards%20Technological%20Innovation&url=https%3A%2F%2Fzifo.com%2Fblogs%2Frethinking-animal-management-a-move-towards-technological-innovation%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Rethinking+Animal+Management%3A+A+Move+Towards+Technological+Innovation&url=https%3A%2F%2Fzifo.com%2Fblogs%2Frethinking-animal-management-a-move-towards-technological-innovation%2F "Share on LinkedIn")
Image reference: / source
**Introduction:**
Animals are routinely used in the pre-clinical development phase of pharmaceutical development, with the industry accounting for approximately one-third of animal research in the UK. Many current informatics systems, initially designed to support now outdated lab processes, play a crucial role in managing animal health & welfare but face numerous scientific and technological challenges. With the advent of technologies like Machine Learning (ML) and Artificial Intelligence (AI), there’s potential to reduce the reliance on in-vivo testing for regulatory approvals. This paper explores transformative changes in business processes and technologies that could reduce the need for animal studies in the development of new medicines and treatments.
**Business Process:**
Organizations adhere to diverse business processes in animal research operations, yet standard practices emerge across most big pharma companies. This process typically unfolds in three sequential steps:
- **Ethical considerations:** Focus is on using animals only when necessary and ensuring ethical treatment. The Animal Welfare and Ethical Review Body (AWERB) in the UK, akin to the Institutional Animal Care and Use Committees (IACUC) in the USA, enhances scientific and animal welfare and fosters a culture of care while improving public accountability. In the UK, The Animals (Scientific Procedures) Act 1986, enforced by the Home Office’s Science Regulation Unit, mandates project authorization and ethical review. Whilst similar committees exist worldwide, regulatory frameworks can vary. The key responsibilities of AWERBs in the UK include:
- **Forum for ethical discussion:** Provide a platform for discussing and developing ethical advice related to animal welfare, care and use, which helps inform decisions by the establishment license holder.
- **Promotion of animal welfare:** Raise awareness of animal welfare principles and the 3R’s (Reduction, Replacement and Refinement), which guide the ethical use of animals in research.
- **Support for staff:** Offer support to named persons and other staff members who handle animals, addressing any animal welfare and ethical concerns.
- **Cultural promotion:** Foster a ‘Culture of Care’ within research establishments, ensuring that welfare considerations are integrated into daily practices and decision-making.
- **Animal procurement:** Animals are ordered only after AWERB approval. Modern IT systems should seamlessly handle all related tasks—from reviewing study requirements and detailing the procedures needed to be performed on the animal by scientists or vets, to managing procurement and integrating financial processes—ensuring accuracy and efficiency throughout.
- **Health management of animals:** Scientists and veterinary staff are responsible for the ongoing health management of the animals, maintaining all treatment plans and recordingincidents/surgeries within the IT system.
Image 1: **This image depicts the typical animal management business process in pharmaceutical and research organizations.**
Despite the efficiency of current IT systems in managing various tasks related to animal management in pharmaceutical and research industries, significant challenges persist, which will be explored in the following section.
**Challenges with the Current In Vivo Testing Process and IT Systems**
Several issues continue to undermine the effectiveness of existing protocols and systems:
- **Independence and oversight:** AWERB, while subject to Home Office audits, lacks a defined audit frequency and functions non-independently within organizations, potentially resulting in biased decisions when specific drug research is conducted. Primarily, AWERB offers recommendations on reducing, replacing, and refining the use of animals rather than halting their use in research, thus limiting its oversight capabilities and the visibility of potential biases. This issue is common to internal bodies and committees within many organizations.
- **Financial Systems Integration:** Many organizations lack robust financial integration with IT systems, leading to inefficiencies such as bulk ordering of animals without precise need estimates.
- **Animal Health Records:** Inadequate health histories for animals can result in improper treatment plans, akin to a clinician prescribing medication without knowledge of a patient’s medical history. This oversight can lead to unforeseen drug interactions or, in cases where animals are unsuitable or allergic to certain medications, severe distress or euthanasia.
- **IT system reliability:** Reliance on IT systems to manage treatment plans and scheduled events, such as surgeries or medication times for animals, can lead to critical delays or omissions in care if the system fails, adversely affecting the animals’ quality of life.
- **Integration and accuracy:** Poor integration and data management within IT systems can lead to errors, such as assigning too many animals to a study, and may result in unnecessary animal suffering and loss. In the worst IT systems, reliance on manual processes persists, further compounding the potential for errors.
- **Costs for utilizing animals in studies:** The cost of using animals in research is substantial, impacting not only the lives of the animals but also the financial budgets of R&D organizations. Significant resources are wasted when animal studies do not yield successful outcomes, making cost one of the most significant yet overlooked challenges in the entire business process.
These issues underscore critical concerns related to animal welfare. Beyond this, there are numerous other challenges, such as discrepancies between the actual and recorded number of animals, poorly managed animal identification, and inconsistent animal health data. Next, we will explore how AI could revolutionize the current landscape of animal research.
**How AI Could Revolutionize Animal Research**
Artificial Intelligence (AI) offers transformative potential for animal research, with capabilities spanning complex problem-solving across various scientific and medical disciplines. By reducing reliance on animal testing, AI could usher in methods that are not only humane but also more efficient and less costly.
**Understanding AI’s Role in Research**
Artificial Intelligence (AI) and Machine Learning (ML) involve the development of intelligent systems that perform tasks typically requiring human intelligence. These systems are adept at learning from data to support informed decisions, a crucial feature for modeling biological responses without physical testing. Some key concepts include Machine Learning, Deep Learning, Neural Networks, Natural Language Processing (NLP) and computer vision.
**Key AI Processes in Animal Research**
- **Data Collection:** AI systems analyze extensive data from previous studies, including drug responses and genetic information, to predict outcomes without animal testing. For example, data on how mice respond to Meloxicam can forecast reactions in new tests. Data extends beyond mere observations of animal behavior; it encompasses genetic profiles, physiological measurements, and histopathological images, among others. The criticality of this data lies in its relevance and representation of the specific challenges AI systems are designed to address. In this context, the goal is to predict an animal’s or species’ reaction to a drug without actual exposure. This approach of predictive modeling is equally applicable to and valuable in human medical research.
- **Data preprocessing:** Before AI algorithms can effectively process the data, it undergoes essential preprocessing steps. This process includes cleansing the data to remove inaccuracies, eliminating noise or outliers, and normalizing or scaling the data for consistency. Additionally, the data is transformed into a format suitable for detailed analysis. For instance, in the case of Meloxicam, preprocessing is critical due to the potential presence of duplicate data from multiple pharmacokinetics and pharmacodynamics (PK/PD) studies with similar results. Such duplicity must be resolved, and the data enriched and reformatted into a standardized variable ontology or catalog as necessary.
- **Algorithm selection:** The choice of AI algorithms is determined by the specific task and data characteristics. Selection is strategically aligned with the problem at hand and the desired outcomes. For example, in studies involving Meloxicam, the initial goal is to predict its effect on rats without actual drug administration. A general machine learning algorithm may suffice for this. However, if the objective extends to understanding health outcomes in mice that received Meloxicam and subsequently died, a different, more specialized algorithm might be necessary to detect patterns or causative factors in their health histories that contributed to their death.
- **Model training:** During this stage, the chosen AI algorithm is trained using the prepared “training” data. The algorithm learns from the input data by discerning patterns, correlations, or features relevant to the research objectives. This training phase involves adjusting the algorithm’s internal parameters to optimize its performance based on a defined objective or loss function. For instance, in the context of Meloxicam studies, the algorithm is tailored to detect and learn from data patterns, correlations, and features that are relevant to the disease and drug/treatment response.
- **Model evaluation:** Once training is complete, the performance of the AI model is assessed using separate test data that was not utilized during training. This evaluation measures how effectively the model generalizes to new, unseen data and assesses metrics such as accuracy, precision, recall, or other pertinent criteria. In our Meloxicam study, for instance, this evaluation phase will help researchers determine the model’s reliability in making predictions about animal health, disease progression, treatment efficacy, as well as drug response.
- **Model deployment:** Once the model is validated, researchers can leverage its capabilities to screen and evaluate potential drug candidates; for example, predicting how healthy mice might respond to Meloxicam without actual administration. Moreover, by inputting information about specific animal health history and habits, the AI model should be able to predict reactions to the drug based on the data gathered from historical animal models.
**Impact of AI on Animal Testing:**
The integration of AI into research protocols can dramatically decrease the need for animal subjects by identifying the most promising drug candidates early in the research process. This not only streamlines development but also enhances ethical standards by minimizing animal use. With computer vision and reliable datasets, AI models can save the lives of millions of animals. It is one of the alternatives to in-vivo testing and could show enormous promise for producing dependable and safe drug discovery outcomes. As a result, there would be significantly reduced or even no need to use animal testing.
**Existing Alternatives to Animal Testing:**
Minimizing animal testing in drug development is not only a humane and ethical pursuit but also shortens and reduces the costs of the drug development process. This approach alleviates the burden of extensive animal testing on researchers. Several organizations are already pioneering these alternative methods, as highlighted below:
- **VeriSIM Life** is building AI-enabled biosimulation models. Animal testing is slow, ethically questionable, and doesn’t act as much of a filter. VeriSIM’s solution is to create disease-specific biosimulation models, which allow researchers at pharma companies to model in software how a drug will interact in animals. This allows researchers to test 1000x more potential candidates in the same unit of time, ensuring that drugs that do make it to (human) clinical trials are far more likely to work, and therefore saving millions in annual costs.
- **Quris AI** (with operations in Israel and Boston) is advancing toward clinical trials its first fully AI-designed drug for treating fragile X syndrome, a rare autism-associated condition. The company utilizes its Bio-AI Clinical Prediction Platform, which uses simulated organs to predict drug interactions. This innovative approach has the potential to obfuscate the need for mice in pre-clinical safety trials, thereby decreasing both the time and financial costs associated with unsuccessful experiments.
- **Exscientia** have automated drug design and have AI-designed molecules entering clinical trials. By generating and analyzing their own data using advanced AI algorithms, Exscientia significantly shortens the pre-clinical drug discovery process, substantially accelerating the transition to clinical testing phases.
Significant opportunities remain to innovate and transform the landscape of in-vivo studies and experiments through advancements in study designs and experimental methodologies.
**Conclusion**
It is possible to predict the attributes of new potential drug molecules using the data we already have about past tests and experiments. In some instances, toxicity predictions for tens of thousands of unknown chemicals, based on previous studies, are now more accurate and reliable than the results from actual animal studies. Despite these advances, animal testing remains necessary for compounds with no historical data. This white paper explores how AI could revolutionize the current animal testing process, benefitting animal welfare and enhancing the efficiency, cost-effectiveness and productivity of pharmaceutical research.
**References:**
1\.
2\.
3\.
For questions or clarifications:
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
---
### [A Comparison Of ACMG/AMP And ACGS Guidelines For Variant Interpretation](https://zifo.com/blogs/a-comparison-of-acmg-amp-and-acgs-guidelines-for-variant-interpretation/)
**Published:** September 30, 2024
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [A Comparison Of ACMG/AMP And ACGS Guidelines For Variant Interpretation](https://zifo.com/blogs/a-comparison-of-acmg-amp-and-acgs-guidelines-for-variant-interpretation/ "A Comparison Of ACMG/AMP And ACGS Guidelines For Variant Interpretation")
## A Comparison Of ACMG/AMP And ACGS Guidelines For Variant Interpretation
Jeanette Mccarthy, Principal Consultant – Variant Interpretation
Sep 30, 2024
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20A%20Comparison%20Of%20ACMG%2FAMP%20And%20ACGS%20Guidelines%20For%20Variant%20Interpretation%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Fa-comparison-of-acmg-amp-and-acgs-guidelines-for-variant-interpretation%2F "Share on Email")
- [](https://x.com/intent/post?text=A%20Comparison%20Of%20ACMG%2FAMP%20And%20ACGS%20Guidelines%20For%20Variant%20Interpretation&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fa-comparison-of-acmg-amp-and-acgs-guidelines-for-variant-interpretation%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=A+Comparison+Of+ACMG%2FAMP+And+ACGS+Guidelines+For+Variant+Interpretation&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fa-comparison-of-acmg-amp-and-acgs-guidelines-for-variant-interpretation%2F "Share on LinkedIn")
Image reference: / source
Sequence variant interpretation is at the heart of delivering clinical genetic test results for hereditary diseases. The first widely adopted [guidelines](https://www.nature.com/articles/gim201530) for variant interpretation came in 2015 from the American College of Medical Genetics and Genomics (ACMG) and the Association for Molecular Pathology (AMP). Since then, ClinGen has recommended many modifications to the ACMG/AMP guidelines and is working on a new version (V4), expected to be released in the coming years. A separate set of guidelines for the interpretation of copy number variants (CNV) was introduced by [ACMG/ClinGen in 2020](https://pmc.ncbi.nlm.nih.gov/articles/PMC7313390/). Meanwhile, in the UK, the Association for Clinical Genomic Science (ACGS) developed its own guidelines in 2017, which are deeply rooted in the ACMG guidelines and updated biennially.
With the most recent publication of the ACGS 2024 variant classification guidelines, laboratories may wonder what the differences are between the ACGS and ACMG/AMP guidelines.
Below, we highlight some of the tangible differences that labs should be aware of.
**Overall improvements**
ACGS combines guidelines for SNVs, CNVs and intronic variants in a single document, while separate guidelines are available from ACMG/AMP/ClinGen. One benefit of this approach is that ACGS addresses scenarios regarding when to apply SNV versus CNV guidelines for intragenic CNVs.
For CNV guidelines, ACGS offers options for genes that either do not or cannot qualify as haploinsufficient, offering a path for interpreting CNVs for recessive disorders. For example, when a gene lacks evidence for haploinsufficiency, ACGS permits the use of evidence of loss of function mechanisms from G2P (absent gene product) or other compelling evidence.
ACGS guidelines explicitly address the mutually exclusive attributes. For example, using the same evidence for PM1, PM5 and PP2 should be avoided as it can result in circular evidence. Also, PS1 and PM4 should not be attributed together.
**Attribute level**
ACGS guidelines provide a comprehensive breakdown of attributes, offering examples to clarify their use.
**PM2/PP3/BP4**
One major difference in the ACGS guidelines is the retention of the moderate strength of the allele frequency attribute PM2, aligning with the original ACMG/AMP guidelines, rather than the current ClinGen recommendation to downgrade it to supporting strength. This decision is based on the maintenance of the computational scores—PP3/BP4—at supporting strength. It was thoroughly analyzed and concluded upon a mini-impact assessment by ACGS. Although ACGS applies these strengths to PM2 and PP3, it also indicates that this implementation is subject to the forthcoming ACMG/AMP V4 guidelines.
**PS4**
ACGS also provides clarity on case control study counts, which are not mentioned in ACMG/AMP guidelines and only available for a few gene-specific guidelines from ClinGen. It recommends attributing PS4 at a supporting level even when one proband is reported for the variant and at a moderate level when two or more probands are reported with the appropriate phenotype. The attribute can be used at a stronger strength when the variant has an odds ratio. Odds ratios can also be calculated with cases available in a paper, and gnomAD data can be used as controls. ACGS also provides the flexibility to attribute PS4 in the absence of PM2 when a considerable number of probands are reported for the variant.
**PM4**
ACMG/AMP uses the PM4 attribute for all stop-loss variants that disrupt protein function, whereas ACGS aptly suggests attributing stop-loss variants using either PM4 or PVS1. For variants undergoing Non-stop mediated decay (NSD), in the absence of an in-frame termination codon in the 3’UTR, ACGS recommends using PVS1 at a very strong strength. This exhibits strong logical consistency. Conversely, the stop-loss not undergoing NSD can be attributed PM4.
**BP7**
The ACMG guidelines for BP7 consider silent variants for which splicing prediction algorithms predict no impact on splicing. The ACGS guidelines explicitly mention the application of BP7 to different types of silent variants: synonymous, UTR and intronic variants. In addition to using algorithmic prediction to evaluate potential impact on splicing (using BP7 at a supporting level when there is no evidence of splice impact), ACGS allows the use of laboratory evidence of no splice impact from RNA splicing assays to invoke BP7 at a strong level.
**Scoring**
ACGS has already shifted to a point-based system for the calculation of final pathogenicity, while current ACMG/AMP guidelines still utilize combinations of supporting/moderate/strong/very strong attributes (Note: V4 of ACMG/AMP guidelines will be based on a point-based system as well).
One advantage of this is that the point-based system provides a straightforward way of dealing with conflicting evidence, which the ACMG/AMP 2015 guidelines do not adequately address.
Because of the different scoring mechanisms, the final pathogenicity might differ when ACGS guidelines are followed versus ACMG/AMP guidelines, but these differences may disappear once ACMG/AMP V4 guidelines come out. For example, it is much easier to reach a classification of Likely Benign with the point-based system. The equivalent of one supporting attribute will get you there with the point-based system, whereas two supporting attributes are needed in the current ACMG/AMP guidelines.
**Conclusion**
In short, we find that the ACGS variant interpretation guidelines differ in only a few meaningful ways from ACMG/AMP guidelines and they provide some much-needed clarification on the application of different attributes. It is likely that ACGS and ACMG/AMP V4 will be even more closely aligned.
In the meantime, while it is tempting to combine the best of both guidelines when drafting your own SOPs for variant interpretation, caution should be exercised as modifications to some attributes are balanced by modifications to other attributes.
The ACGS guidelines represent a significant step forward in variant interpretation, promoting consistency, accuracy, and uniformity among variant scientists. These guidelines not only help to streamline interpretation processes but also facilitate good clinical practice, ultimately benefiting patient care and outcomes.
If you have any questions or if you would like to know more, please contact us at .
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
**Categories:** Clinical Genomics
---
### [Unlocking The Transformative Flavor Of DIGITAL In The Food & Beverage Industry](https://zifo.com/blogs/unlocking-the-transformative-flavor-of-digital-in-the-food-beverage-industry/)
**Published:** October 21, 2024
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [Unlocking The Transformative Flavor Of DIGITAL In The Food & Beverage Industry](https://zifo.com/blogs/unlocking-the-transformative-flavor-of-digital-in-the-food-beverage-industry/ "Unlocking The Transformative Flavor Of DIGITAL In The Food & Beverage Industry")
## Unlocking The Transformative Flavor Of DIGITAL In The Food & Beverage Industry
Anisa Heck and Dinesh Agaram
Oct 21, 2024
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Unlocking%20The%20Transformative%20Flavor%20Of%20DIGITAL%20In%20The%20Food%20%26%20Beverage%20Industry%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Funlocking-the-transformative-flavor-of-digital-in-the-food-beverage-industry%2F "Share on Email")
- [](https://x.com/intent/post?text=Unlocking%20The%20Transformative%20Flavor%20Of%20DIGITAL%20In%20The%20Food%20%26%20Beverage%20Industry&url=https%3A%2F%2Fzifo.com%2Fblogs%2Funlocking-the-transformative-flavor-of-digital-in-the-food-beverage-industry%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Unlocking+The+Transformative+Flavor+Of+DIGITAL+In+The+Food+%26+Beverage+Industry&url=https%3A%2F%2Fzifo.com%2Fblogs%2Funlocking-the-transformative-flavor-of-digital-in-the-food-beverage-industry%2F "Share on LinkedIn")
Image reference: / source
In the Food & Beverage business, where flavors meld and trends simmer, the emergence of digital transformation has been akin to discovering a secret ingredient that elevates every dish. That being said, the Food & Beverage industry is rapidly catching on. For example, in 2020, already 88% of food companies in the European Union were fully aware of the advantages of digital transformation.1
The number of food & beverage companies beginning a digital transformation journey increases significantly every year. *Why might that be?*
The Food & Beverage industry faces unique challenges, such as rapidly changing consumer preferences, seasonal changes, demand for innovation, improved sustainability, traceability, food safety, and increasingly complex regulatory restrictions, making it well-suited for digitalization. Not only that, but production in the food industry is often artisanal and characterized by empirical knowledge. This applies not only to artisanal cheeses, for example, but also extends into various aspects of research and development (R&D), manufacturing, quality control (QC), and more. This drives a culture of hidden and non-shared knowledge, making digital transformation even more challenging and, at the same time, more valuable.
In short, if you haven’t started yet, it’s time to get moving, or you risk being left behind!
**A Recipe for Digital Success**
Digital transformation is not just about adopting new technologies—it’s about creating a cohesive strategy that aligns with the specific needs of your business. Just like crafting a new recipe, it requires understanding your ingredients (data and processes) and knowing how to blend them harmoniously. By carefully integrating digital tools and platforms, companies can unlock unprecedented levels of efficiency, innovation, and competitiveness.
Imagine your organization as a kitchen. The goal is to streamline operations, optimize resources, and continuously improve the quality of the end product. The process of digitalization enables you to gather and analyze data, leading to better decision-making, enhanced product quality, and greater customer satisfaction. Whether it’s automating routine tasks, enhancing data accuracy, or predicting trends, digital tools are essential for staying competitive in today’s fast-paced market.
**Blending Tradition with Innovation**
In the diverse landscape of the Food & Beverage industry, digital transformation offers a unique opportunity to blend tradition with innovation. From artisanal producers who rely on empirical knowledge to global conglomerates with complex supply chains, the potential for digitalization to drive value is vast. Companies are increasingly recognizing the importance of integrating digital tools into their operations to maintain a competitive edge.
Many companies generate and collect substantial amounts of data. However, the ability to use this data intelligently is often hindered by limited integration—that is where the real value lies: using the data to further a company’s key goals. Data-driven decision-making is widespread within global conglomerates, often focusing on staying ahead of market trends and consumer preferences. Two key components of this include tools for R&D data collection, e.g., laboratory information management systems (LIMS) and electronic laboratory notebooks (ELNs), along with predictive analytics, often involving artificial intelligence (AI) and machine learning (ML) techniques. That being said, factors that often hold larger companies back from fully realizing digital transformation include the complexity of integrating disparate systems and legacy infrastructure, as well as cultural challenges.
**Not Sure Where to Start?**
Moving forward without understanding your current digital state can result in unanticipated roadblocks, akin to unexpected flavor profiles that disrupt the harmony of a food product. This can derail even the most detailed plans, resulting in additional costs—not to mention lost time. A thorough assessment of digital and data maturity is essential to ensure successful initiatives that bring value to the business. Additionally, developing a long-term digital strategy based on a current state evaluation and a future state vision will ensure you move in the right direction and realize both short- and long-term business value. Thoroughly evaluate your technology and infrastructure by focusing on key aspects of data management. This includes assessing your data management tools and systems, examining data capture methods and sources, analyzing data architecture and frameworks, evaluating data storage and retrieval capabilities, and scrutinizing data sharing infrastructure and integrated systems. The maturity assessment can be performed separately, focusing on specific dimensions: Architecture & Technology, Scientific Processes & Compliance, Governance & Delivery Model, Fair Data, as well as People and Organizational Culture—all based on your preferred focus areas.
**Why Should Food & Beverage Companies Go Through a Digital Transformation?**
The prospect of using data to optimize, predict, and even make intelligent decisions is tantalizing—a flavor-rich promise that beckons companies to embark on the digital transformation journey. By tailoring digital strategies to meet specific business needs, organizations can unlock the full potential of their operations.
**Core Outcomes of Digital Transformation**
Digital transformation has the potential to revolutionize the Food & Beverage industry, enabling companies to enhance various aspects of their operations. The core outcomes of digital transformation can be grouped into three categories: 1) uncover invisible insights, 2) predict the future, and 3) optimize.
**Uncover Invisible Insights:**
Imagine a food company using machine learning (ML) algorithms to analyze social media data and understand what consumers are saying about their products. With this information, the company can develop new products that better align with consumers’ preferences and meet their needs, thereby increasing customer satisfaction and loyalty.
Data collected during R&D can also be used to uncover hidden insights. For example, a food company can analyze and identify correlations between product attributes and customer feedback.By using ML algorithms, the company can develop models that predict customer preferences and optimize product design to meet those needs. By using artificial intelligence (AI) algorithms, companies can identify patterns to predict and identify the most promising food product prototypes, enabling them to optimize resources and speed up the development process..
**Predict the Future:**
One predictive aspect focuses on product quality. For example, ML can be used to analyze product samples and predict their shelf life. This information helps companies optimize production processes, reduce waste, and improve product quality. Various aspects of product stability can also be predicted based on product composition and processing conditions. By using AI algorithms, companies can identify the factors that affect product stability and optimize production processes to maximize product shelf life.
**Optimize:**
Virtual and augmented reality can be incorporated into R&D processes to conduct tests and refine product prototypes. For instance, a food company may use virtual reality to test new packaging designs or simulate production processes before actual implementation, reducing costs, accelerating development and speeding up time-to-market for product innovations.Data can also be used to optimize processes. For example, by using ML algorithms to analyze data collected from multiple sources, companies can identify bottlenecks and optimize resource allocation to speed up product development and reduce the costs of the R&D process. QC processes can be similarly optimized, allowing companies to detect anomalies in production and proactively enhance quality control to prevent issues from arising.
**Conclusion**
As the Food & Beverage industry continues to evolve, embracing digital transformation is no longer a choice but a necessity for companies aiming to thrive in an increasingly competitive landscape. The journey through digital transformation offers unparalleled opportunities to enhance operational efficiency, foster sustainable practices, and create exceptional customer experiences. By recognizing your current digital state and leveraging tailored strategies, your company can not only navigate the complexities of the modern market but also set new standards for innovation and excellence. Let’s view digital transformation not as a daunting challenge but as a flavorful adventure that promises new growth and success. Remember, in the dynamic world of Food & Beverage, staying static is not an option. Embrace change, savor the journey, and let’s transform the future of food together!
**What Next?**
Where should a company focus its efforts in digital transformation? Well, that depends on the current capabilities and the specific needs of the business. The steps chosen within the strategic roadmap need to offer strategic advantages that align withthe business and competitive landscape. Digitalization has the potential to radically transform every aspect of operations, but it is not a one-off, big-bang project. Implementing digitalization is actually about laying the groundwork for a program of continuous improvement, building your digital maturity both organizationally and from a business value perspective.
No matter your current digital state, Zifo can advise on the next steps and be your partner on your digital transformation journey to ensure that business value is added at every step of the way. Whether you would like to analyze your digital maturity, envision, or develop a roadmap.
Do you want to know where you stand in your digital transformation journey? Let’s talk! Feel free to reach out to us at .
**Source**
1. Food Drink Europe Data & Trends. EU Food & Drink Industry 2020. [Data & Trends of the European Food and Drink Industry 2020 – FoodDrinkEurope : FoodDrinkEurope](https://www.fooddrinkeurope.eu/resource/data-trends-of-the-european-food-and-drink-industry-2020/) .
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
**Categories:** Strategic Scientific Consulting Services
---
### [Optimizing Instrument And Equipment Validation: Lean & Cohort Methodology](https://zifo.com/blogs/optimizing-instrument-and-equipment-validation-lean-cohort-methodology/)
**Published:** September 24, 2024
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [Optimizing Instrument And Equipment Validation: Lean & Cohort Methodology](https://zifo.com/blogs/optimizing-instrument-and-equipment-validation-lean-cohort-methodology/ "Optimizing Instrument And Equipment Validation: Lean & Cohort Methodology")
## Optimizing Instrument And Equipment Validation: Lean & Cohort Methodology
Vivekram Apparsundaram, Associate Head – CQV, North America
Sep 24, 2024
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Optimizing%20Instrument%20And%20Equipment%20Validation%3A%20Lean%20%26%20Cohort%20Methodology%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Foptimizing-instrument-and-equipment-validation-lean-cohort-methodology%2F "Share on Email")
- [](https://x.com/intent/post?text=Optimizing%20Instrument%20And%20Equipment%20Validation%3A%20Lean%20%26%20Cohort%20Methodology&url=https%3A%2F%2Fzifo.com%2Fblogs%2Foptimizing-instrument-and-equipment-validation-lean-cohort-methodology%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Optimizing+Instrument+And+Equipment+Validation%3A+Lean+%26+Cohort+Methodology&url=https%3A%2F%2Fzifo.com%2Fblogs%2Foptimizing-instrument-and-equipment-validation-lean-cohort-methodology%2F "Share on LinkedIn")
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Stories
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
In the highly regulated pharmaceutical and biotech industries, ensuring the accuracy and reliability of analytical instruments and equipment is paramount. Validation of these instruments is a critical task, but it often becomes a time-consuming and resource-intensive process. To address these challenges, adopting a risk-based lean validation approach and blending it with cohort validation can significantly reduce redundancies, enhance efficiency and improve turnaround times for Business users.
**Blending Lean and Cohort Validation Approaches (also commonly known as the family approach)**
The integration of lean principles with cohort validation provides a streamlined and efficient method for validating analytical instruments. This combined approach focuses on eliminating waste, leveraging existing resources, and grouping similar systems to maximize efficiency.
**Here is a high-level 5-step process for this journey:**
- **Equivalence:** Assess the equivalence or similarities of a system to an existing one within the organization’s ecosystem. This step involves assessing and documenting whether a system meets the predefined criteria set and allowed by the underlying validation procedures. It includes evaluating the impact, risk, and reasons for equivalence. By understanding the system’s qualifications, organizations can determine what can be leveraged. Grouping similar systems during this assessment can further streamline the process.
- **Relevance:** Reviewing existing documentation for a family of systems helps in understanding their relevance and adequacy. This step ensures that only pertinent documents are considered for the current validation, reducing the effort needed to recreate deliverables that are already sufficient. By applying relevance checks to grouped systems, organizations can avoid redundant documentation efforts.
- **Leverage**: Leveraging relevant existing documents minimizes the need to create new ones. This step maximizes the use of existing resources and knowledge, thereby saving time and effort. Grouping systems allows for the consolidation of documentation, making it easier to leverage existing work. In addition, consider leveraging testing performed by the system vendor (hardware and software IQ, OQ performed during commissioning of the system in labs), allowing room for designing a focused validation effort.
- **Supplement:** Creating only the required supplemental documentation for the current system qualification by leveraging existing documentation and vendor qualifications ensures that efforts are focused and targeted. This step avoids the unnecessary creation of documents that add no value. By focusing on grouped systems, organizations can ensure that supplemental documentation is comprehensive and applicable to all systems in the cohort.
- **Reducing Redundancy:** By focusing on the necessary qualifications and executions, redundancy is minimized. This approach ensures that the validation process is streamlined and efficient. Grouping similar systems together inherently reduces redundancy by avoiding duplicate efforts.
**Benefits of Combined Lean and Cohort Validation:**
- **Efficiency:** Streamlines validation processes by eliminating unnecessary steps and focusing on value-added activities.
- **Consistency:** Ensures consistent validation across similar systems, reducing variability and enhancing reliability.
- **Resource Optimization:** Maximizes the use of existing documentation and knowledge, saving time and effort.
- **Regulatory Compliance:** Adheres to regulatory standards while minimizing redundant activities, ensuring a high level of compliance.
- **Risk Management:** Focuses on assessing and managing risks, ensuring that critical aspects are addressed effectively.
Rooted in efficiency and Risk Management Principles while ensuring compliance. Encouraged by FDA and EMA.
**Case Study**Achieving efficiency in Upgrade Validation of Total Organic Carbon Analyzers Using the Family Approach**Background**A global top 10 U.S. Pharma laboratory operates with eight Total Organic Carbon (TOC) analyzers in one GMP laboratory, which are essential instruments for ensuring sample quality and compliance with regulatory standards. As the software and firmware versions of these TOCs neared the end of their lifecycle, the vendor proposed an upgrade. Given the substantial investment in time and resources required for validation, we decided to adopt the family approach to streamline the process.**Objective**To efficiently validate the upgraded TOC systems, minimize system downtime, and reduce the overall effort involved in the validation process while maintaining compliance and accuracy.**Methodology**Leaner validation using the Family Approach**Implementing the Family Approach****First-in-Family System:** Since this was the first time this version of the software was introduced to this organization, a full suite of deliverables was created, including a Master Validation Plan (VP), Vendor Upgrade Qualification, Specifications Update, Risk Assessments, Installation Qualification (IQ), Operational Qualification (OQ), Performance Qualification (PQ), Traceability Matrix, Standard Operating Procedures (SOPs), and a Master Summary Report. **A 5-Step Process for Rest-in-Family:** The family approach involves a structured five-step process: Equivalence, Relevance, Leverage, Supplement, and Reducing Redundancy. This methodology ensures efficient validation by focusing on similarities between systems, leveraging existing resources, and minimizing unnecessary efforts.
- **Equivalence:** Now that the first-in-family system is validated and a suite of documents has been created, we established the equivalence of each TOC system to the others within the customer’s ecosystem. We documented whether each system met the predefined criteria set by validation procedures, considering the same make, model, software and firmware versions, intended use, and risk impacts as reasons for equivalence. This enables the grouping of TOC systems based on their similarities, streamlining the validation process.
- **Relevance:** Next, we reviewed existing documentation for the family of TOC systems to determine their relevance and adequacy for the current systems. (Note: If a similar system with a matching newer software version exists within the organization, qualification documentation created for that system shall be leveraged.) We focused on identifying documents that could be reused, thereby reducing the need to recreate deliverables that were already sufficient. This helps avoid redundant documentation efforts.
- **Leverage:** We leveraged existing documents and testing performed for the first-in-family systems by the system vendor, such as hardware and software IQ and OQ conducted during the upgrade of the systems in the lab. This use of existing resources and knowledge minimized the need for new documentation and testing.
- **Supplement:** Only the required supplemental documentation necessary for the consecutive systems was created, leveraging the existing documentation and vendor qualifications. This targeted approach avoided unnecessary documentation and ensured that the validation process was comprehensive and applicable to all systems within the cohort.
- **Reducing Redundancy:** By focusing on essential qualifications and executions, redundancy was minimized. Grouping similar systems together inherently reduced duplicate efforts, making the validation process streamlined and efficient.
**Rest-in-Family Systems:**
- A streamlined set of deliverables was used, focusing on essential elements such as the Vendor Upgrade Qualification, IQ, PQ, and a Summary Report with Traceability Matrix
**Results**The family approach significantly reduced the number of deliverables and overall effort: - **First-in-Family System:** In this case, it required 10 comprehensive deliverables, including detailed risk assessments, full qualification protocols, and complete documentation updates.
- **Rest-in-Family Systems:** Required only 5 essential deliverables per system, focusing on validation plans, vendor qualifications, IQ, PQ, and summary reports.
**Efficiency Gains****Time Savings:** Reduced the downtime per system by approximately **40%**, allowing for uninterrupted laboratory operations. **Resource Optimization:** Decreased the total number of deliverables from 80 (10 deliverables for each of the 8 systems) to 45 (10 for the first and 5 each for the rest), **a reduction of 44%**.
**Inference**The family approach to validating TOC analyzers proved to be a highly efficient and effective strategy. By fully validating the first system and applying a streamlined process for the rest, we minimized unnecessary effort.**Assumptions and Considerations**- Validation procedures allow for the use of the family approach, thereby leveraging documentation.
- IQ was repeated for individual systems due to the location of individual systems within the customer site.
- All systems were upgraded to the same version of software/firmware.
In conclusion, by adopting lean and cohort validation approaches, organizations can significantly enhance the efficiency and effectiveness of analytical instrument and equipment validation. By focusing on equivalence assessment, relevancy, leveraging existing documents, supplementing only necessary documentation, and reducing redundancy, organizations can achieve compliance while optimizing resources. These efficiencies could lead to substantial cost savings, with an estimated 30-35% reduction in validation-related expenses, including labor and resource costs. Zifo’s expertise in these areas can help highly regulated organizations successfully implement these strategies, resulting in streamlined validation processes and improved operational efficiency.
If you would like to discuss this topic further, please contact us at .
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Stories
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
**Categories:** Validation Service and Compliance Support
---
### [Evolving Compliance](https://zifo.com/blogs/evolving-compliance/)
**Published:** March 26, 2024
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [Evolving Compliance](https://zifo.com/blogs/evolving-compliance/ "Evolving Compliance")
## Evolving Compliance
Tript Srivastava
Mar 26, 2024
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Evolving%20Compliance%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Fevolving-compliance%2F "Share on Email")
- [](https://x.com/intent/post?text=Evolving%20Compliance&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fevolving-compliance%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Evolving+Compliance&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fevolving-compliance%2F "Share on LinkedIn")
Image reference: / source
**A Closer Look at the new GAMP 5 Guidelines**
In the dynamic realm of technology, adhering to industry standards and regulations is crucial to ensure compliance. The Good Automated Manufacturing Practice (GAMP) guidelines, a set of standards that ensure compliance in regulated spaces, have undergone a significant update after 14 years. This update, known as GAMP 5, responds to the challenges of advancing technology and provides a framework for innovation while maintaining regulatory adherence. This blog takes a look at some of the highlights and critical implications.
**The Evolution from Computer Systems Validation (CSV) to Computer Systems Assurance (CSA)**
The GAMP guidelines have undergone a substantial transformation during their shift from CSV to the newer approach of CSA. Instead of adhering to one-size-fits-all, document-heavy validation processes, GAMP 5 encourages critical thinking. It emphasises the need for appropriate, efficient, risk-based assurance tailored to the system’s specific risk profile. This approach potentially reduces the documentation burden whilst maintaining the quality and extent of testing.
**Embracing a Non-Linear Approach to Validation**
GAMP 5 advocates for an Agile model whenever possible. This approach is iterative, incremental, and focuses on a risk-based strategy. It is beneficial for systems characterised by high complexity and novelty. By adopting an Agile methodology, companies can ensure compliance while remaining adaptable and responsive to change.
**Addressing Digital Transformation**
The rapid advancement of technology necessitates addressing new technologies and infrastructure. GAMP 5 incorporates advanced technologies like blockchain, cloud computing, and artificial intelligence/machine learning (AI/ML). This ensures that regulated industries can keep pace with the evolving technological landscape and harness the benefits of these innovations.
**From Documents to Tools and Systems**
A notable change in GAMP 5 is the departure from conventional paper-based documentation. Instead, the guidelines recommend maintaining information and records in Document Management Systems. This transition provides several advantages, including robust searchability and enhanced security against unauthorised access to data.
**Possible Impacts on Your Compliance Journey**
The introduction of GAMP 5 has far-reaching implications for organisations in regulated industries. Below are some key questions to consider. Are you :
- Implementing Risk-Based Validation and Critical Thinking? GAMP 5 encourages a lean documentation approach. Assess whether your organisation is embracing these principles to streamline compliance efforts.
- Using Third-Party Cloud Services? If you rely on infrastructure, platform, or software as a service from third-party providers, GAMP 5 can guide you on qualifying and maintaining these services effectively.
- Transitioning from Paper to Digital Systems? Evaluate whether your organisation is still dependent on paper documentation for validation or is making the shift towards more efficient and secure digital systems.
- Adopting Agile Software Development? If your organisation is already following or planning to adopt Agile software development and validation methodologies, GAMP 5 provides valuable insights for ensuring compliance within this framework.
In conclusion, GAMP 5 represents a significant step forward in compliance and validation adapting to the ever-changing technological landscape. It encourages innovation and efficiency while ensuring compliance remains a top priority. By aligning with these updated guidelines, organisations can navigate the complex world of regulatory compliance more effectively and position themselves for success in the digital age.
If you have questions or need guidance on your compliance journey, please get in touch with us at
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
**Categories:** Validation Service and Compliance Support
---
### [Optimizing Cloud Spending In Science-Driven Organizations: The Role Of FinOps](https://zifo.com/blogs/optimizing-cloud-spending-in-science-driven-organizations-the-role-of-finops/)
**Published:** September 18, 2024
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [Optimizing Cloud Spending In Science-Driven Organizations: The Role Of FinOps](https://zifo.com/blogs/optimizing-cloud-spending-in-science-driven-organizations-the-role-of-finops/ "Optimizing Cloud Spending In Science-Driven Organizations: The Role Of FinOps")
## Optimizing Cloud Spending In Science-Driven Organizations: The Role Of FinOps
Debrup Mazumdar, Senior Consultant
Sep 18, 2024
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Optimizing%20Cloud%20Spending%20In%20Science-Driven%20Organizations%3A%20The%20Role%20Of%20FinOps%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Foptimizing-cloud-spending-in-science-driven-organizations-the-role-of-finops%2F "Share on Email")
- [](https://x.com/intent/post?text=Optimizing%20Cloud%20Spending%20In%20Science-Driven%20Organizations%3A%20The%20Role%20Of%20FinOps&url=https%3A%2F%2Fzifo.com%2Fblogs%2Foptimizing-cloud-spending-in-science-driven-organizations-the-role-of-finops%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Optimizing+Cloud+Spending+In+Science-Driven+Organizations%3A+The+Role+Of+FinOps&url=https%3A%2F%2Fzifo.com%2Fblogs%2Foptimizing-cloud-spending-in-science-driven-organizations-the-role-of-finops%2F "Share on LinkedIn")
Image reference: / source
As industries driven by scientific R&D navigate an era of rapid digital transformation, managing cloud spending has become a critical concern. With the increasing reliance on cloud services for everything from data management and lab integration to automation and AI/ML & analytics, it’s more important than ever for companies to ensure that their cloud investments deliver maximum value. This is where “FinOps” (Financial Operations), a practice designed to optimize cloud spending, comes into play.
**What is FinOps?**
FinOps, a blend of “Finance” and “Development Operations” (DevOps), is an evolving discipline that unites engineering, finance, and business teams to make data-driven decisions about cloud spending. As cloud adoption grows, FinOps practices help organizations manage costs, improve financial accountability, and maximize the value derived from their cloud investments.
In the context of R&D, where innovation is driven by data and science, and where cloud services are heavily utilized across the entire spectrum of work, such as computational biology, data storage, and regulatory compliance, the importance of a well-structured FinOps practice cannot be overstated.
**The Growing Importance of FinOps in Pharma and Biotech**
As cloud usage expands, so do the challenges associated with managing cloud costs. According to Gartner, by 2024, more than 45 percent of IT spending will have shifted from traditional solutions to the cloud. For R&D-driven companies, this trend underscores the need for a strategic approach to cloud financial management.
**FinOps addresses these challenges by providing a framework that enables organizations to:**
- **Optimize Cloud Spending:** FinOps practices help companies identify cost-saving opportunities, such as rightsizing cloud resources, eliminating unused assets, and optimizing pricing models. In industries like Pharma & Biotech, Chemicals, Food and Beverage, and FMCG (Fast Moving Consumer Goods), where R&D and product innovation costs are high, every dollar saved can be reinvested into innovation or generate product margin.
- **Enhance Collaboration:** FinOps fosters collaboration across departments, ensuring that finance teams understand the technical needs of engineering teams, and vice versa. This alignment is crucial in the biotech and pharma sectors, where cross-functional collaboration is often the key to bringing new therapies to market.
- **Ensure Compliance and Security:** Regulatory compliance is a top priority in the life sciences sector. FinOps practices can help ensure that cloud spending aligns with regulatory requirements, providing transparency and accountability in how resources are allocated and managed.
- **Drive Business Value:** Ultimately, FinOps is about maximizing the business value of cloud investments. By leveraging the FinOps framework, pharma and biotech companies can ensure that their cloud strategies are aligned with their broader business goals, driving innovation and improving patient outcomes.
**Implementing FinOps in Pharma and Biotech**
Implementing FinOps in any organization involves more than just adopting new tools – it’s about creating a cultural shift that prioritizes financial accountability in cloud spending. This can be achieved through:
- **Training and Education:** Ensuring that teams across the organization understand the principles of FinOps and how they can contribute to cloud cost management.
- **Building a FinOps Team:** Establishing a dedicated team that includes members from finance, IT, and operations to oversee cloud spending and optimize resources.
- **Leveraging the FinOps Framework:** Utilizing the FinOps Framework, a set of guidelines and best practices, to structure the company’s approach to cloud financial management.
**The Future of FinOps**
As the sciences industry continues to evolve, the role of FinOps will only become more critical. With the growing complexity of cloud environments and the increasing pressure to deliver innovative solutions faster and more cost-effectively, a robust FinOps practice will be essential for companies looking to stay competitive.
By adopting FinOps, companies can manage their cloud spending more effectively and drive more value from their cloud investments, ultimately accelerating innovation and improving their products.
If you have any questions about FinOps or any related topic, or if you would like to know more, please contact us at
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
**Categories:** Scientific Cloud Computing Services
---
### [Key Considerations For Implementing Environmental Monitoring In LIMS](https://zifo.com/blogs/key-considerations-for-implementing-environmental-monitoring-in-lims/)
**Published:** April 1, 2025
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [Key Considerations For Implementing Environmental Monitoring In LIMS](https://zifo.com/blogs/key-considerations-for-implementing-environmental-monitoring-in-lims/ "Key Considerations For Implementing Environmental Monitoring In LIMS")
## Key Considerations For Implementing Environmental Monitoring In LIMS
Hannah Laidly, Scientific Informatics Application Consultant
Apr 01, 2025
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Key%20Considerations%20For%20Implementing%20Environmental%20Monitoring%20In%20LIMS%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Fkey-considerations-for-implementing-environmental-monitoring-in-lims%2F "Share on Email")
- [](https://x.com/intent/post?text=Key%20Considerations%20For%20Implementing%20Environmental%20Monitoring%20In%20LIMS&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fkey-considerations-for-implementing-environmental-monitoring-in-lims%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Key+Considerations+For+Implementing+Environmental+Monitoring+In+LIMS&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fkey-considerations-for-implementing-environmental-monitoring-in-lims%2F "Share on LinkedIn")
Image reference: / source
When implementing a Laboratory Information Management Systems (LIMS), integrating Environmental Monitoring (EM) is essential for organizations looking to ensure product quality, operational efficiency, and regulatory compliance. However, this implementation comes with its own set of challenges and considerations. Below, we explore the critical factors to consider when adding environmental monitoring capabilities to your LIMS.
**Regulatory Compliance**
Different industries and regions have specific FDA and EMA regulatory standards regarding environmental monitoring. Ensuring that your LIMS can adapt to these regulations will help maintain compliance and avoid potential penalties. A LIMS can help with regulatory compliance by providing extensive audit trails and setting custom alert limits on critical parameters. These features can help determine problem areas and prevent issues in order to stay in compliance.
**System Scalability and Flexibility**
EM needs will evolve over time as expansion of facilities, introduction of new products or processes or even updates to regulations occur. The LIMS should be scalable to be able to accommodate additional data points, sampling locations, or workflows without requiring any custom development.
**Automated Sample Creation**
The volume of sampling locations needed in environmental monitoring can be substantial, including many different sample types such as surface, air, water, gas, and personnel monitoring. Establish how your implementation will visualize these locations in the system by including sampling maps. Before entering data in the system, you need to define how the sampling plans need to be grouped. Specific limits and tests for each sample type and location can be defined as well. Automated sample creation can ensure that your LIMS samples will be created through scheduled tasks by sampling location and increase efficiency of sample collection.
**Integration with Instruments and Other Systems**
A successful LIMS implementation requires integration with new and existing instruments to reduce manual data entry errors. Evaluate how environmental data will be collected and fed into the LIMS. This might include simple and complex instruments. For example, particle counters used for air monitoring can be integrated with LIMS so that results appear directly on data entry and ELN pages for a given sample, which can then be automatically checked against specifications. Ensure that your LIMS can handle diverse data types and formats effectively.
Environmental monitoring in pharmaceutical labs relies on various air and water systems to ensure compliance with stringent regulatory standards and maintain the integrity of products. Air monitoring systems typically include particulate and microbial air sampling units, often using HEPA filters, to detect airborne contaminants in cleanrooms and controlled environments. These systems may also incorporate temperature, humidity, and differential pressure sensors to monitor air quality and ensure proper ventilation. Water systems, on the other hand, focus on the quality of purified water, which is critical in pharmaceutical manufacturing. Systems like Reverse Osmosis (RO), Distilled Water Systems, and WFI (Water for Injection) systems are used to produce high-purity water, with regular monitoring for parameters such as conductivity, endotoxins, and microbial content. The LIMS needs to be able to track all data from these systems to ensure regulatory compliance.
Integrating with other systems should also be considered to enhance operational efficiency and data consistency. The LIMS can be integrated to an ERP system in order to align EM data with inventory and production schedules or a QMS for linking EM data to batch records and CAPA processes.
**Real-time Monitoring and Alerts**
Implementing real-time monitoring capabilities allows organizations to respond promptly to environmental changes or compliance breaches. A LIMS implementation can include alert limits that can flag excursions at the sampling location. Consider setting up automated alerts within the LIMS for critical parameters that require immediate attention, enhancing your ability to manage compliance risks proactively across the organization.
**Customizable Reporting Tools**
Environmental monitoring often requires several reporting formats for regulatory submissions or internal audits. Ensure your LIMS includes customizable reporting tools, especially trend analysis tools, that allow users to generate reports tailored to their needs, thereby simplifying compliance and analysis processes. LIMS reporting tools can also include dashboards that help visualize KPIs and work assignments for end users.
**Continuous Improvement of the System**
EM is an on-going process, and your LIMS should support continuous improvement. Implement internal procedures for regular audits to evaluate the effectiveness of the EM workflows and collect feedback from users to identify areas for improvement.
**Conclusion**
Integrating environmental monitoring into your LIMS can significantly enhance your organization’s operational efficiency and compliance capabilities. By considering the factors outlined above, you can ensure a successful implementation that supports your environmental monitoring requirements and streamlines existing processes.
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
**Categories:** Manufacturing and Quality Informatics Services, Product Development and Design Services
---
### [How To Choose The ELN](https://zifo.com/blogs/how-to-choose-the-eln/)
**Published:** May 27, 2024
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [How To Choose The ELN](https://zifo.com/blogs/how-to-choose-the-eln/ "How To Choose The ELN")
## How To Choose The ELN
Tript Srivastava & Lakshmi Nallaperumal
May 27, 2024
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20How%20To%20Choose%20The%20ELN%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Fhow-to-choose-the-eln%2F "Share on Email")
- [](https://x.com/intent/post?text=How%20To%20Choose%20The%20ELN&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fhow-to-choose-the-eln%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=How+To+Choose+The+ELN&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fhow-to-choose-the-eln%2F "Share on LinkedIn")
Image reference: / source
**Introduction**
In the dynamic landscape of modern laboratories, where data management and collaboration are paramount, Electronic Laboratory Notebooks (ELN) have become a game-changer. Adoption of the right ELN for specific requirements is crucial for optimizing workflows, ensuring data accuracy, and fostering seamless collaboration among researchers. This guide provides an insight into the key factors to consider when selecting the best ELN for your laboratory.
**Identify Laboratory Workflow:**
The first step in choosing the right ELN is to understand your laboratory’s workflow. Identify the specific tasks, processes, and data types involved in daily operations. This understanding will help you select an ELN that aligns seamlessly with your laboratory’s unique requirements.
For example, if genetics research is the primary focus of your laboratory, you’ll need an ELN that supports DNA sequencing data management and analysis. By understanding your workflow, you can ensure the ELN meets your specific needs.
**Prioritize a User-Friendly Interface:**
A user-friendly interface is essential for the widespread adoption and efficient use of the ELN. Look for platforms offering intuitive navigation, customizable features, and a layout supporting easy data entry and retrieval. The user experience plays a pivotal role in the successful implementation of an ELN.
A user-friendly ELN with drag-and-drop functionalities for data entry and a visually appealing dashboard can significantly enhance the user experience, leading to higher engagement and productivity.
**Ensure Data Security and Compliance:**
As laboratories deal with sensitive and regulated data, data security and compliance are critical considerations. Choose an ELN that adheres to industry standards and regulations. Robust features like access controls, audit trails, and encryption should be sought to safeguard data and maintain compliance with relevant guidelines.
An ELN with end-to-end encryption, role-based access controls, and regular security audits will ensure that sensitive data remains secure, complying with industry standards.
**Seek Seamless Integration Capabilities:**
An effective ELN should integrate seamlessly with other laboratory instruments, software, and data sources. Ensure compatibility with existing systems for a smooth transition and efficient data exchange. Integration capabilities enhance automation, reduce manual errors, and improve overall efficiency.
For example, an ELN that integrates with analytical instruments, such as mass spectrometers or chromatographs, can facilitate direct data transfer, reducing manual data entry errors and streamlining the analysis process.
**Opt for Scalability and Flexibility:**
As laboratory needs may evolve over time, it is essential to choose an ELN that is scalable and adaptable. Choose a flexible system that can be customized to accommodate changes in workflows, regulatory requirements, and technological advancements. Scalability ensures that the ELN can grow with the laboratory’s expanding data and user base.
An ELN that can easily accommodate an increase in data volume or user base without significant system overhauls will ensure it remains effective as the laboratory grows.
**Enhance Collaboration Features:**
ELNs are powerful tools for fostering collaboration among researchers. Look for features such as real-time collaboration, document sharing, and commenting capabilities. An ELN that promotes seamless communication and knowledge exchange will boost productivity and innovation.
For example, an ELN with real-time collaboration features, such as shared notebooks and discussion threads, enables researchers from different locations to work together seamlessly, enhancing overall team efficiency.
**Conclusion:**
Choosing the best Electronic Laboratory Notebook is a strategic decision that directly impacts the efficiency and success of laboratory operations. By carefully evaluating your laboratory’s workflow, considering user experience, ensuring data security and compliance, and examining integration and collaboration features, you can make an informed choice that aligns with your specific requirements. Investing time in selecting the right ELN now will yield long-term benefits of increased productivity, data accuracy, and collaboration within your laboratory.
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
**Categories:** RnD Informatics Services
---
### [Rethinking Digital Tools](https://zifo.com/blogs/rethinking-digital-tools/)
**Published:** May 27, 2024
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [Rethinking Digital Tools](https://zifo.com/blogs/rethinking-digital-tools/ "Rethinking Digital Tools")
## Rethinking Digital Tools
Dinesh Agaram, Anisa Heck and Rene Kaufmann
May 27, 2024
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Rethinking%20Digital%20Tools%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Frethinking-digital-tools%2F "Share on Email")
- [](https://x.com/intent/post?text=Rethinking%20Digital%20Tools&url=https%3A%2F%2Fzifo.com%2Fblogs%2Frethinking-digital-tools%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Rethinking+Digital+Tools&url=https%3A%2F%2Fzifo.com%2Fblogs%2Frethinking-digital-tools%2F "Share on LinkedIn")
Image reference: / source
**Introduction:**
In the ever-evolving landscape of research and development (R&D), the implementation of digital tools such as Laboratory Information Management Systems (LIMS) and electronic lab notebooks (ELN) has been a constant. These systems are pivotal in managing the complex data and processes of scientific research. However, despite significant advancements in the offerings from various vendors, a persistent challenge remains: rapidly adapting these tools to meet the diverse and specific needs of scientists.
**The Unchanging Challenge:**
The need for adaptable digital tools in R&D has never been more pronounced than in today’s rapidly advancing scientific landscape. As research methodologies evolve and data complexity increases, traditional approaches to digital tool implementation are proving inadequate. For years, R&D units have grappled with the limitations of LIMS and ELN systems. These platforms, while powerful, often come with a one-size-fits-all approach that scarcely accommodates the nuanced requirements of different scientific disciplines.
The rigidity of such systems can lead to inefficiencies, with scientists spending undue time adapting their workflows to fit the tool rather than the tool fitting the workflow. These inefficiencies are exacerbated in larger scientific organizations, where the diversity of the science typically widens the gap between tool capabilities and user needs.
For example, a molecular biology lab requires specialized workflow integrations for gene editing protocols, but the existing informatics system is designed for more general laboratory processes and lacks the specific functionality needed for CRISPR data management and analysis. This forces scientists to use additional, separate software solutions, complicating data integration, increasing the risk of errors and complicating user experience without adding value to the organization.
**The Advent of No-Code and Low-Code Platforms:**
With the advent of low-code/no-code solutions, the evolution of digital tools for R&D has entered a new era (see Figure 1). This trend could redefine how digital tools are utilized in scientific research. These platforms enable the creation of custom applications with minimal coding, opening up software development to a broader audience. Successful platforms **such as Microsoft PowerApps, Airtable** and **Bubble or Outsystems** have been utilized across various industries to streamline operations, enhance productivity, and foster innovation, showcasing their potential applicability in scientific research. Additionally, platforms like **Sapio and L7** are specialized low/no-code data and workflow platforms for the science domain.
Figure 1: **Timeline of the Evolution of Digital Tools for R&D
**
**Potential Challenges:**
Leveraging these solutions does come with potential pitfalls that should be considered. While these no-code/low-code platforms are designed to be user-friendly, it’s important to remember that scientists are not software engineers. They often lack the expertise to foresee issues that typically arise in software development, such as:
- Adherence to data standards – to ensure data continuity and governance.
- Code performance – using computer memory effectively and avoiding memory leaks.
- Efficient integration into existing systems without overloading networks /systems.
- Code support and commenting – so that applications can be managed by others.
Additionally, the lack of regular maintenance can result in broken and outdated applications leading to user frustration. In conclusion, careful consideration must be given to implementation, training and ongoing management to avoid the common pitfalls. There is a balance between empowering scientists to create their own solutions and ensuring the ongoing cost, integrity and efficiency of the tools built on low-code/no-code platforms.
**The Vision for a Scientist Citizen Developer:**
Imagine a world where scientists are not just the end-users of digital tools but are the architects of their digital environment. This vision involves fostering a new breed of what could be called Scientist Citizen Developers —scientific professionals who are adept not only in their domain of research but also in leveraging no-code and low-code platforms like **Zapier, Webflow, Back4App, Bubble, L7 or Sapio** to build and customize their digital tools. Such empowerment would enable flexibility and efficiency previously unseen in large R&D units.
For example, in pharmaceutical manufacturing, a quality assurance team could use Bubble to create a bespoke dashboard to monitor the environmental conditions of clean rooms in real-time. This dashboard could integrate data from IoT sensors that track temperature, humidity, and particulate counts, directly linking to their LIMS for seamless record-keeping and compliance reporting. This type of custom tool would not only ensure adherence to strict regulatory standards but also empower the team to preemptively address conditions that could compromise product quality, enhancing operational efficiency and product safety.
Or consider a case study from Qiagen. They faced challenges because experimental information was recorded in great detail but on paper worksheets and the bioinformatics systems required manual triggering, which delayed reporting. With the help of the L7 platform, Qiagen built an integrated and automated solution for this end-to-end process to automate the entire laboratory workflow from sample to insight.
**Why Now?**
The convergence of several factors makes now the opportune time for companies to embrace this shift. First, the technological maturity of no-code and low-code platforms has reached a point where the creation of sophisticated, reliable applications is not just feasible but also streamlined. Second, the increasing digitization of R&D processes has created a fertile ground for innovation in how digital tools are developed and used. Finally, the persistent challenges of LIMS and ELN implementations—in terms of adaptability and user-friendliness—underscore the need for a new approach. Recent advancements in no-code platforms have made it easier than ever for scientists to design and deploy custom solutions tailored to their research needs.
**Looking Forward**
For companies willing to pioneer this transition, the benefits extend beyond solving the historical challenges of LIMS and ELN implementations. Empowering scientists to create their tools can lead to innovations in research methodologies, more collaborative and integrated workflows, and, ultimately, a faster path from discovery to development.
However, realizing this potential will require a cultural shift within organizations, one that values flexibility, fosters technical literacy, and supports the continuous learning of its scientific workforce. By fostering an environment where scientists are encouraged to explore and develop their digital tools, organizations can unlock new avenues for research advancement and innovation.
As we stand on the brink of this exciting evolution in R&D digital tooling, are companies ready to rethink their approach? By investing in developing Scientist Citizen Developers and embracing the capabilities of no-code and low-code platforms, we could align the power of digital tools with the specific, nuanced needs of scientific research. This is not an overnight journey; it takes enablement and upskilling of the scientists, and these tools need to deliver on their promises of easy maintenance, adherence to regulatory demands and data security. But, if done right, the future of R&D is not just digital; it can be customizable, flexible, and in the hands of the scientists themselves.
For questions or clarifications:
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
**Categories:** RnD Informatics Services
---
### [Implementing LIMS In Manufacturing QC](https://zifo.com/blogs/implementing-lims-in-manufacturing-qc/)
**Published:** March 26, 2024
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [Implementing LIMS In Manufacturing QC](https://zifo.com/blogs/implementing-lims-in-manufacturing-qc/ "Implementing LIMS In Manufacturing QC")
## Implementing LIMS In Manufacturing QC
Tript Srivastava and Insha Ishrat
Mar 26, 2024
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Implementing%20LIMS%20In%20Manufacturing%20QC%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Fimplementing-lims-in-manufacturing-qc%2F "Share on Email")
- [](https://x.com/intent/post?text=Implementing%20LIMS%20In%20Manufacturing%20QC&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fimplementing-lims-in-manufacturing-qc%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Implementing+LIMS+In+Manufacturing+QC&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fimplementing-lims-in-manufacturing-qc%2F "Share on LinkedIn")
Image reference: / source
**Implementing LIMS in Manufacturing QC**
A robust Laboratory Information Management System (LIMS) is crucial for streamlining manufacturing quality control (QC) processes and subsequent product batch release. A tailored LIMS enables efficient sample tracking, analytical testing, data organization, and reporting, ensuring process optimization, regulatory compliance and data integrity. Below is Zifo’s step-by-step guide for successfully implementing a LIMS focusing on Manufacturing QC laboratories.
**Step 1: Identify Lab-Specific Requirements, Workflows and Processes**
Conduct a thorough assessment of your lab’s unique requirements, processes, data orchestration workflows. Consider factors such as sample management, instrument integration, inventory management, regulatory compliance, and specific industry standards. Alongside the lab processes, consider how the system fits into the overall business process of product batch release. This evaluation will help you define the precise capabilities, processes and data orchestration workflow support needed to meet your lab’s needs. It is also essential to consider the future and how things could be optimized further as you change to the new system.
**Step 2: Select an Industry-Compliant LIMS Vendor**
Research and choose a LIMS vendor with a proven track record of specializing in manufacturing QC. Look for vendors experienced in regulatory compliance, such as current Good Manufacturing Practices (cGMP) and 21 CFR Part 11. Evaluate their system’s capabilities, scalability, support services, and user-friendly interfaces to find the best fit for your lab and ergonomics. The vendor must have a detailed roadmap and vision for their products. Ensure your vendor has a good strategy to deliver/integrate data and process analytics, Artificial Intelligence & Machine Learning (AI/ML) and data reporting as part of their vision and roadmap.
**Step 3: Customize and Configure the LIMS System**
Collaborate with the selected vendor(s) to configure the LIMS to match your lab’s specific workflows and processes – be wary of customization as it can be costly and impacts future upgrade paths and total cost of ownership (TCO). Tailor and configure the system to include relevant modules for sample tracking, results management, stability studies, and quality assurance checks. Ensure the LIMS system seamlessly integrates with existing instruments and laboratory equipment for efficient data capture. Consider the instruments’ importance and plan to add them over time based on the value of the data and amount of times the instrument is used per day.
**Step 4: Ensure Seamless Data Migration and Integration**
Plan and execute the migration of existing data from legacy systems or paper records into the LIMS, ensuring data integrity throughout the process. Additionally, integrate the LIMS with other systems, such as the Enterprise Resource Planning (ERP) systems, to ensure data integrity and streamline data flow to support batch release. Collaborate with the vendor and/or a LIMS service provider to achieve these integrations, using industry-standard protocols and standard APIs for data exchange. Work closely with your IT and laboratory teams to thoroughly validate and test the data migration and integration processes, minimizing disruptions and errors. Finally, set up monitoring and maintenance procedures to ensure the smooth and continuous data flow between systems.
**Step 5: Train Personnel for Effective LIMS Utilization**
Provide comprehensive training to lab personnel on effectively using the LIMS. Cover essential areas such as sample registration, test execution, data entry, and generating reports. Emphasize the benefits of the LIMS system, such as improved efficiency, data traceability, and compliance with industry regulations. Offer ongoing support and additional training sessions as needed.
**Step 6: Validate the LIMS System for Regulatory Compliance**
Collaborate with the LIMS vendor, Service provider and Quality Assurance (QA) team to validate the system for regulatory compliance. Perform thorough testing and documentation to meet the stringent requirements of cGMP and other relevant regulations. Ensure the LIMS provides accurate and auditable results, adhering to data integrity and security guidelines. Ensure the QA team is involved in the project from the start and consider risk-based validation approaches to go faster.
**Step 7: Go-Live**
Plan a smooth transition from existing processes to the LIMS system, ensuring minimal disruption. Provide comprehensive technical support from initial to end phases throughout this transition and beyond. Monitor the system closely during the initial stages (hypercare) and seek continuous feedback from lab personnel.
**Step 8: Continuous Improvement**
Implement necessary refinements and improvements to optimize the system’s performance, data management, and user experience. Continuous improvement is about enhancing the LIMS technical aspects and leveraging the data captured to facilitate data-driven decision-making. This approach can help identify areas for improvement in both business and laboratory processes, ensuring that the LIMS system evolves to meet your ever-changing needs. Additionally, consider incorporating data management principles and FAIR data (Findable, Accessible, Interoperable, and Reusable) to make your laboratory’s data more valuable and accessible for analysis and support for decision-making.
**Conclusion**
Implementing a well-configured and tailored LIMS in manufacturing QC labs is critical to improving efficiency and ensuring data integrity & compliance. By following this step-by-step guide, labs can successfully generate value from LIMS. Our map ensures that:
- The entire batch release processes are considered and potentially optimized.
- Specific sample tracking and analytical testing results capture requirements are met.
- Lab processes are streamlined, simplified and optimized where possible.
- Accurate reporting and regulatory compliance are ensured.
- Process, data analytics and data interrogation are delivered as part of the environment.
If you want to know more about Zifo’s experience supporting LIMS selections and rollouts in this domain, please email us at
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
**Categories:** Manufacturing and Quality Informatics Services
---
### [Experiences & learnings with implementing](https://zifo.com/blogs/experiences-learnings-with-implementing/)
**Published:** January 12, 2026
**Author:** Zifo_user
**Categories:** Chromatography Video Resource
---
### [Strategic Compute Planning For The Posit Platform](https://zifo.com/blogs/strategic-compute-planning-for-the-posit-platform/)
**Published:** February 4, 2026
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [Strategic Compute Planning For The Posit Platform](https://zifo.com/blogs/strategic-compute-planning-for-the-posit-platform/ "Strategic Compute Planning For The Posit Platform")
## Strategic Compute Planning For The Posit Platform
Jeya Priya Senthilkumaran, Project Lead – Cloud Ops
Feb 04, 2026
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Strategic%20Compute%20Planning%20For%20The%20Posit%20Platform%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Fstrategic-compute-planning-for-the-posit-platform%2F "Share on Email")
- [](https://x.com/intent/post?text=Strategic%20Compute%20Planning%20For%20The%20Posit%20Platform&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fstrategic-compute-planning-for-the-posit-platform%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Strategic+Compute+Planning+For+The+Posit+Platform&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fstrategic-compute-planning-for-the-posit-platform%2F "Share on LinkedIn")
Image reference: / source
In today’s pharmaceutical landscape, data science is more than a capability – it’s a core driver of innovation, regulatory agility, and patient‑centric decision‑making. Posit applications have become foundational in this transformation, enabling teams to develop, collaborate, and share insights using R and Python in secure, reproducible environments.
As the Drug Discovery domain continues to generate massive volumes of data for research and analysis, the need for scalable external compute integration grows in parallel. Whether simulating thousands of clinical trial scenarios, analyzing terabytes of omics data, or deploying real‑time machine‑learning models, infrastructure demands are evolving rapidly.
**Here’s the simple truth:**
Your platform architecture strategy will either accelerate or constrain scientific progress.
**Why Strategic Architectures Matter**
Infrastructure decisions are sometimes made in isolation from scientific context. But in pharma—where every second matters, regulations are critical, and insights influence patient outcomes – architecture choices must be driven by actual use cases.
**Choosing the wrong compute model can lead to:**
– Wasted resources
– Slower time‑to‑insight
– Poor reproducibility
– Frustrated teams
**Choosing the right model unlocks:**
– Scalable, secure analytics
– Faster decision‑making
– Seamless collaboration
– Regulatory confidence
**When to Choose HPC: Power for Precision Science**
High‑Performance Computing (HPC) is the optimal choice when R workflows are:
1. **Computationally intensive and long‑running**
- Ideal for simulations, nonlinear mixed‑effects models, and Bayesian inference
2. **Tightly coupled and memory‑bound**
- Best‑suited for workloads requiring shared memory or MPI‑based parallelism.
3. **Batch‑oriented and scheduled**
- Appropriate for bulk processing workloads that run overnight.
4. **Regulated and validated**
- HPC environments often provide controlled, auditable infrastructure.
**When to Choose Kubernetes: Flexibility and Scale**
**Kubernetes is the right fit when R workflows are:**
1. **Modular, containerized, and reproducible**
- Built with targets, drake, or renv, and packaged in Docker containers for portability and consistency.
2. **Horizontally scalable**
- When you need to run the same analysis across hundreds or thousands of independent data slices-common in genomics, RWE, and commercial analytics.
3. **Multi-language and multi-tool**
- Kubernetes supports hybrid workflows that combine R with Python, Bash, SQL, and more—ideal for translational science and ML pipelines.
4. **Interactive or API-driven**
- Perfect for deploying Shiny apps, Plumber APIs, or Quarto dashboards that need to scale dynamically and integrate with other systems.
**Posit Components:**
Posit offers a dedicated tool for development which supports integration with multiple IDE (R, JupyterNotebook, JupyterLab, VS-Code and Positron) that can be launched in localhost or to external integrated environment like Kubernetes or High-Performance Computing Clusters.
**Job Launcher:**
Posit has a dedicated job launcher feature that allows the developers to launch their sessions in an external environment (HPC/K8s) and additional IDE sessions like Python and R IDEs. This acts as the integration between the Slurm and PWB in case of HPC Integration and as integration between Kubernetes scaler and PWB.
**Solution Architecture:**
The architecture of the platform should be formulated based on the business use case and IT infrastructure good practices, there are multiple possibilities. Opting for the best-suited one is critical when delivering robust and cost-effective platform for the Use case we are trying to solve.
The Posit Workbench and Posit Connect can be integrated with scalable environments. As of the time of writing this article, the Posit Connect only supports integration with Kubernetes for hosting the Contents published environment.
**Posit Workbench:**
The Posit workbench with Job Launcher enabled can be integrated with Kubernetes/HPC/Batch environment. There are cases and scenarios where the Workbench would require integration with HPC and Kubernetes cluster enabling the developers to opt for the environment that is more optimal for their workflow. Generally, more stabilized workflows and repetitive tasks by the developers are orchestrated to the Kubernetes platform which will have predefined container images with specific R/Python Versions with required installations. For heavy workload with Parallel processing and long running jobs the HPC integration powered different types of instances for different workloads can be very effective for end results.
**Posit Connect:**
Posit Connect has a plugin to integrate with Kubernetes environment, which allows the contents to be spun up as pod in the Kubernetes node when a viewer/end user consumes them. This integration allows heavy loaded contents to be executed in the individual pods thus scaling of pods for multiple users.
The conceptual diagram below gives an overview on how Posit Workbench with Job Launcher can create session in Local Host/Kubernetes/HPC Environment.
(Source: Zifo Analysis)
**Conclusion**
In pharma data science, infrastructure is strategy. Choosing the right platform-whether HPC for precision workloads or Kubernetes for scalable, interactive analytics—can dramatically accelerate insights and impact. With Posit’s flexible architecture, teams can build reproducible, secure, and high-performing workflows that align with scientific goals and regulatory needs. The right architecture doesn’t just support innovation-it drives it.
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
---
### [Single Cell Omics](https://zifo.com/blogs/single-cell-omics/)
**Published:** June 13, 2024
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [Single Cell Omics](https://zifo.com/blogs/single-cell-omics/ "Single Cell Omics")
## Single Cell Omics
Radesh Nattamai Malli Pooranachandhiran
Jun 13, 2024
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Single%20Cell%20Omics%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Fsingle-cell-omics%2F "Share on Email")
- [](https://x.com/intent/post?text=Single%20Cell%20Omics&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fsingle-cell-omics%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Single+Cell+Omics&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fsingle-cell-omics%2F "Share on LinkedIn")
Image reference: / source
**Single-Cell Omics Unveils the Hidden Symphony of Life**
Imagine peering into the heart of a cell, witnessing the intricate dance of its molecular machinery. This is the power of single-cell omics analysis, a revolutionary approach that’s transforming our understanding of biology and disease. Traditionally, biological analyses have been performed on bulk populations of cells, masking the unique molecular signatures of each cell. Single-cell omics breaks through this limitation, revealing the hidden symphony of gene expression and function occurring within a single cell. At Zifo, we offer cutting-edge tools and expertise to guide you on this exciting exploration.
**A Cellular Revolution: Unveiling Hidden Heterogeneity**
For decades, biologists studied cells as homogenous populations. However, single-cell analysis shatters this illusion. It allows us to examine individual cells, revealing a symphony of diverse gene expression patterns within seemingly uniform tissues. This newfound understanding has profound implications:
- **Unveiling Hidden Cell Types:** We can now discover rare or previously unknown cell populations crucial for development, regeneration, and disease progression.
- **Mapping Cellular Landscapes:** We can now discover rare or previously unknown cell populations crucial for development, regeneration, and disease progression.By analyzing gene expression patterns across a tissue section, spatial omics paints a detailed picture of how cells interact and organize within their microenvironment.
**Challenges and Opportunities: Harnessing the Power of Omics Data**
This revolution comes with its own set of challenges. Single-cell experiments generate massive amounts of complex data. Analyzing this data effectively requires robust bioinformatics tools and expertise. Here at Zifo, we understand these complexities and offer:
- **Advanced Bioinformatics Pipelines:** Our state-of-the-art pipelines seamlessly process and analyze your data, extracting meaningful insights.
- **Expert Guidance:** Our team of bioinformatics specialists and consultants collaborates with you every step of the way, interpreting the data and translating it into actionable knowledge.
**The Power of Single-Cell Multiomics Integration: A More Complete Picture**
The human body is an intricate web of interconnected systems. By integrating data from multiple omics platforms (e.g., RNA sequencing, protein analysis, metabolomics), Zifo helps you paint a more complete picture of cellular function. This multi-modal approach allows us to:
- **Connect Genotype to Phenotype:** Understand how genetic variations influence cellular behavior and disease processes.
- **Identify Novel Therapeutic Targets:** Discover new pathways and molecules critical for disease development, paving the way for targeted therapies.
**Analyzing the Symphony: A Step-by-Step Guide**
Single-cell omics analysis involves several key steps:
- **Sample Preparation:** The quality of your data hinges on careful sample preparation. Zifo offers optimized protocols for a variety of cell and tissue types.
- **Data Acquisition:** Using advanced technologies like next-generation sequencing and imaging platforms, we capture the molecular signatures of individual cells or spatial locations within a tissue.
- **Data Preprocessing:** Our bioinformatics experts clean and filter the raw data, ensuring its accuracy and consistency.
- **Data Analysis:** Advanced computational methods are used to identify cell populations, analyze gene expression patterns, and visualize the relationships between heterogeneous cells within tissues.
- **Integration and Interpretation:** Zifo’s team helps you integrate data from multiple sources and translate the findings into a biological context, uncovering hidden insights into cellular function and disease mechanisms.
**Unlocking the Potential of Your Research with Zifo**
At Zifo, we are passionate about empowering researchers to unlock the secrets of single-cell omics analysis. Our comprehensive suite of services includes:
- **Expert Consultation:** Discuss your research goals and tailor our analysis solutions to meet your specific needs.
- **Cutting-Edge Technology:** Access to the latest single-cell omics platforms ensures the highest quality data acquisition.
- **In-Depth Bioinformatics Analysis:** Our team of bioinformatics specialists will guide you through every step of data analysis and interpretation.
- **Data Visualization and Reporting:** We create clear and compelling visualizations to showcase your findings and facilitate communication with collaborators or stakeholders.
**A More Detailed Look into the Various Aspects of Single-Cell Omics Processes**
- **Preprocessing:**
- **Quality Control:** This is the first and crucial step. Raw data from sequencing machines might contain errors or artifacts. Techniques like filtering out low-quality cells, correcting for technical biases, and normalizing the data for sequencing depth ensure data integrity.
- **Normalization:** Normalizing the data accounts for differences in sequencing depth across cells. This ensures that variations in gene expression reflect biological differences rather than technical artifacts.
- **Dimensionality Reduction:**
- **High-Dimensional Data:** Single-cell data typically measures thousands of genes per cell, making it high-dimensional and difficult to visualize or analyze directly. Techniques like Principal Component Analysis (PCA) or t-distributed Stochastic Neighbor Embedding (t-SNE) are used to reduce the dimensionality and identify the most informative features for further analysis.
- **Cell Clustering:**
- **Grouping Similar Cells:** Clustering algorithms group cells with similar gene expression patterns together. This helps identify distinct cell populations within the data. Common clustering algorithms include k-means clustering and hierarchical clustering.
- **Markers and Annotation:** Once cell clusters are identified, researchers can use known marker genes to assign identities to these clusters (e.g., specific cell types). Databases and prior biological knowledge are crucial for this step.
- **Differential Gene Expression (DGE):**
- **Identifying Differences:** This step aims to identify genes that are differentially expressed between different cell clusters. This can reveal genes specific to certain cell types or genes involved in cellular processes. Statistical tests are used to identify these differentially expressed genes.
- **Visualization:**
- **Visual Exploration:** Throughout the analysis, various visualization techniques are used to explore the data and communicate findings. Heatmaps, scatter plots, and t-SNE plots are some popular tools to visualize cell clusters, gene expression patterns, and relationships within the data.
**Additional Considerations:**
- **Data Integration:** If data from multiple modalities (e.g., RNA sequencing and protein abundance data) is available, it can be integrated to gain a more comprehensive understanding of the cells.
- **Trajectory Analysis:** This advanced approach allows researchers to reconstruct the developmental or differentiation paths of cells within a population.
- **Machine Learning:** Machine learning algorithms are increasingly being used for tasks like cell type identification, prediction of cell states, and uncovering complex relationships within the data.
**Tools and Resources:**
Several software tools and resources are available for single-cell analysis, including:
- **Seurat:** A popular R package specifically designed for single-cell RNA-seq analysis.
( )
- **Cell Ranger:** A software suite for analyzing single-cell and spatial omics data from 10x Genomics.
()
- **Bioconductor:** An open-source software project for bioinformatics that includes packages for single-cell analysis. ()
- Kallisto – ()
- UMAP – ([Dimensionality reduction for visualizing single-cell data using UMAP | Nature Biotechnology](https://zifo.com/blogs/single-cell-omics/Dimensionality%20reduction%20for%20visualizing%20single-cell%20data%20using%20UMAP%20%7C%20Nature%20Biotechnology))
- UMI-tools – ()
- Scanpy, in python ()
In addition to the above tools, there are several other open-source tools, scripts and packages which are coming online and published at a rapid pace transforming single-cell omics analysis.
**Embrace the Future of Omics Research**
Single-cell omics analysis is revolutionizing our understanding of complex biological processes. At Zifo, we are your partner in this exciting journey. With our expertise and cutting-edge technology, you can unlock the hidden symphony of life within your research and advance the frontiers of scientific discovery.
Ready to embark on this exciting journey? Contact Zifo today at and let’s discuss how we can help you harness the power of single-cell and spatial omics analysis!
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
---
### [Language Of Science And Technology](https://zifo.com/blogs/the-language-of-science-and-technology/)
**Published:** March 31, 2022
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [Language Of Science And Technology](https://zifo.com/blogs/the-language-of-science-and-technology/ "Language Of Science And Technology")
## Language Of Science And Technology
Arindam Basu & Aishwarya Balajee & Sujeegar Jeevanandam
Mar 31, 2022
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Language%20Of%20Science%20And%20Technology%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Fthe-language-of-science-and-technology%2F "Share on Email")
- [](https://x.com/intent/post?text=Language%20Of%20Science%20And%20Technology&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fthe-language-of-science-and-technology%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Language+Of+Science+And+Technology&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fthe-language-of-science-and-technology%2F "Share on LinkedIn")
Image reference: / source
**SCENE SETTING**
The journey towards digitalization or transformation of the laboratory landscape is an exciting one, but also a complex, demanding and lengthy endeavour. One of the key pillars of any successful enterprise-wide initiatives such as digitalization is the ability to exchange information – ideas, sentiments, plans, requirements, etc. – freely and precisely among one another with confidence that context and meaning will not be lost.
An R&D transformation project involves many specialized roles that can be broadly classified into 2 camps: Science-focused roles such as R&D Leads, Lab Scientists, Regulatory and Compliance Experts and Scientific Business consultants; and Technology-driven roles such as Project Managers, Digital Architects, Data Engineers, Database Architects and Programmers.
Most of the project team members need to know and speak either the language of science or technology. However, a few roles such as Consultants, Architects need to speak and understand both parlances and act as the bridge between the 2 camps and ensure information is not lost during the translation of scientific needs into technical constructs and vice versa.
Often, the communication challenges in bringing the scientific and technology landscapes together are significant enough to impact the team from realizing the project goals. Here we highlight some of the common pitfalls project teams should consider and manage properly in their communication strategy.
**WHAT TO DO AND NOT TO DO**
**Avoid the use of ambiguous terms:**
Many words and abbreviations mean different ideas in different domains and also are understood differently by the audience based on context. It is important that team members are aware of the potential risk of misunderstanding and mitigate it. For example, API means Application Programming Interface in the IT domain but means Active Pharmaceutical Ingredient in the scientific domain.
Similarly, storage is used to refer to Data Servers and Cloud Storage by technology team members, but to a lab scientist storage means cold refrigerators or walk-in freezers and ambient stores. A third example is a term IP. It could mean “Intellectual Property” or “Intraperitoneal” in the scientific domain and “IP address” in IT domain.
**Use precise scientific terms:**
Scientific informatics consultants need to have a solid understanding of scientific processes and workflows as well as the capabilities and features of the informatics systems that are used. An important part of that knowledge is proficiency in using precise scientific terms while interacting with scientists.
Proper scientific vernacular enables a productive and engaging conversation that helps the scientist understand and respond quickly; for example, when working with Medicinal Chemists, it is appropriate to refer to drug candidates as compounds while with Biologists, drug candidates should be referred to as Antibodies or Proteins.
**Make sure you have a conversation:**
Scientists should not be expected to translate scientific needs into technical requirements. All attempts should be made to optimize the use of Scientists’ time. Engaging in a conversation, where there is a true exchange of valuable information both ways, helps understand the underlying needs of the Scientist. Open-ended questions like “Could you please explain your process?” often take the conversation in multiple directions and fail to keep it focused.
Instead, direct questions like “How do you receive your samples?” or “How do you prepare samples for analysis?” encourage scientists to describe the lab process from their perspective in detail allowing everyone to understand both the context and the specifics.
**KEY TAKEAWAYS**
In summary, approaching informatics systems and data from a scientist’s perspective, engaging in periodic dialogues with scientists on their operations, and seeking feedback on communication gaps and challenges help build a strong relationship with the scientific team and bring them closer to the target of the digitalization journey.
To find out more about how Zifo can help with your Digitalisation, please email us at
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
---
### [What To Expect From A Gxp Saas Vendor?](https://zifo.com/blogs/what-to-expect-from-a-gxp-saas-vendor/)
**Published:** May 15, 2023
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [What To Expect From A Gxp Saas Vendor?](https://zifo.com/blogs/what-to-expect-from-a-gxp-saas-vendor/ "What To Expect From A Gxp Saas Vendor?")
## What To Expect From A Gxp Saas Vendor?
Vivekram Apparsundaram
May 15, 2023
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20What%20To%20Expect%20From%20A%20Gxp%20Saas%20Vendor%3F%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Fwhat-to-expect-from-a-gxp-saas-vendor%2F "Share on Email")
- [](https://x.com/intent/post?text=What%20To%20Expect%20From%20A%20Gxp%20Saas%20Vendor%3F&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fwhat-to-expect-from-a-gxp-saas-vendor%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=What+To+Expect+From+A+Gxp+Saas+Vendor%3F&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fwhat-to-expect-from-a-gxp-saas-vendor%2F "Share on LinkedIn")
Image reference: / source
With cloud-based solutions dominating global workspaces, we now have a myriad of SaaS vendors taking interest in the Scientific R&D IT space. The promise of accessibility, scalability and simplicity over something as common as a stable internet connection has been a great driving force in the shift towards the cloud.
Among the many pieces of the jigsaw puzzle that SaaS Application validation is, responsibility is one chunk. Is it the user’s responsibility to validate the solution? Or should the vendor take up that task?
In reality, the answer is almost never a binary and falls in the middle ground.
**SaaS vendor’s responsibilities**
**Extent of qualification**
The vendor should perform an Installation Qualification (IQ) and an Operational Qualification (OQ) and these documents must be shared with the user. Based on the coverage of testing and a suitable package, the user would be able to understand the extent of qualification already performed.
**Audit-ready**
The procedures followed, along with the evidences must be made available for an audit. Specifically, the software development life cycle, change control process for upgrades, and cases where there might be automated deployment of configurations in the cloud should be presented for a customer audit.
**Customizations**
SaaS products are like ice-cream cones. Each user might want custom-built add-ons and integrations to suit their taste or, in all probability, their purpose. These could be API extensions, or any suitable solution offered by the vendor. Do you think these should be qualified by the vendor or the user?
Absolutely Not!
**Provision of multiple instances for end user**
To support end user’s validation and exclusive cloud environment needs for any customizations or configurational changes, the vendor must provide separate development, validation and production instances.
**Performance Testing**
The vendor would see how the application performs on the cloud in terms of how quickly it can be accessed, used and queried. A combination of timed and automated tests is usually done for this, to verify the performance of the application.
**Security!**
Among the many apprehensions of an end user, cloud security is one of the biggest. A solution that comes with a security feature will be preferred over one that does not. Providing visibility in terms of stats, metrics and insights into the services used would be of great help for an end user. For instance, AWS Security Hub is a collection of CloudTrail (a compliance-governing service), CloudWatch (a performance monitoring tool), Firewall Manager, etc. This way, Security Hub monitors and manages the overall cloud security aspects.
Based on a couple of recent consulting exercises, our cloud qualification and validation team assessed the above key aspects and interestingly, in several discussions, the end users were happy ticking away these parameters, until it came to one more KEY aspect.
While evaluating to purchase a suitable cloud-based solution, is it enough if a vendor checks all the above boxes? Can a simple checklist decide whether you are going to go all in?
*Absolutely Not!*
**End user’s responsibilities**
Validation! Despite a qualification exercise performed by the vendor, the product must be verified for its intended use. From drafting User Requirements, Validation Plan to closing out a Validation Summary Report, with documented qualification for the end user configurations and a re-assuring traceability matrix, the end user needs to validate the cloud-based solution.
The healthcare space has been a vast field with regulations laying down impermeable boundaries. With remarkable innovations changing global businesses, responsible use of systems may also require adopting an innovative strategy, without compromising on regulatory standards.
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
---
### [Bots Automate Clinical Data Management](https://zifo.com/blogs/bots-automate-clinical-data-management/)
**Published:** May 17, 2023
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [Bots Automate Clinical Data Management](https://zifo.com/blogs/bots-automate-clinical-data-management/ "Bots Automate Clinical Data Management")
## Bots Automate Clinical Data Management
Srija Sridhar, Senior Data Manager
May 17, 2023
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Bots%20Automate%20Clinical%20Data%20Management%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Fbots-automate-clinical-data-management%2F "Share on Email")
- [](https://x.com/intent/post?text=Bots%20Automate%20Clinical%20Data%20Management&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fbots-automate-clinical-data-management%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Bots+Automate+Clinical+Data+Management&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fbots-automate-clinical-data-management%2F "Share on LinkedIn")
Image reference: / source
Clinical Trials (CT) remain to be one of the most expensive and critical stage in life science value chain and data collected from CT is critical.
Clinical data management has grown steadily in the past decade from paper-based system to electronic system. This change has created an opportunity to set up Standards that facilitates consistency across.
With all the developed standards, now the industry is moving toward increasing efficiency in the process.
\#Automation has a great opportunity both in terms of cost and efficiency which is fueled by Standards. Automation can be utilized at all the stages of data management like data review, #safety reporting, reconciliation and study closure activities.
Stay tuned for our exclusive series to catch up with automation of Clinical Data management!
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
---
### [Differentiating The Integration Puzzle - How To Master Your ISS/ISE Submissions To FDA](https://zifo.com/blogs/differentiating-the-integration-puzzle-how-to-master-your-iss-ise-submissions-to-fda/)
**Published:** May 17, 2023
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [Differentiating The Integration Puzzle – How To Master Your ISS/ISE Submissions To FDA](https://zifo.com/blogs/differentiating-the-integration-puzzle-how-to-master-your-iss-ise-submissions-to-fda/ "Differentiating The Integration Puzzle – How To Master Your ISS/ISE Submissions To FDA")
## Differentiating The Integration Puzzle – How To Master Your ISS/ISE Submissions To FDA
Amara Bharathy, Abhinav Balakumar and Divya Palaniswamy, Senior Biostatistics Programmers
May 17, 2023
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Differentiating%20The%20Integration%20Puzzle%20%26%238211%3B%20How%20To%20Master%20Your%20ISS%2FISE%20Submissions%20To%20FDA%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Fdifferentiating-the-integration-puzzle-how-to-master-your-iss-ise-submissions-to-fda%2F "Share on Email")
- [](https://x.com/intent/post?text=Differentiating%20The%20Integration%20Puzzle%20–%20How%20To%20Master%20Your%20ISS%2FISE%20Submissions%20To%20FDA&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fdifferentiating-the-integration-puzzle-how-to-master-your-iss-ise-submissions-to-fda%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Differentiating+The+Integration+Puzzle+%E2%80%93+How+To+Master+Your+ISS%2FISE+Submissions+To+FDA&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fdifferentiating-the-integration-puzzle-how-to-master-your-iss-ise-submissions-to-fda%2F "Share on LinkedIn")
Image reference: / source
FDA requirements state that an Integrated Summary of Safety (ISS) and Integrated Summary of Effectiveness (ISE) should be included in the Common Technical Document (CTD) for a regulatory submission.The word ‘summaries’, in this context, can be misleading as they are not summaries of clinical study reports of the individual studies. They are “but rather detailed integrated analyses of all relevant data from the clinical study reports that belong in Module 5”. Integrated summaries go far beyond being a regulatory requirement. They provide a valuable outlook towards the entire study.
**Every study with the potential to include an integrated summary must give importance to it for these reasons:**
- Integrated summaries reiterate and validate the analytical conclusions derived in the individual studies.
- They provide a chance to discover hidden trends and insights that could only be identified with a larger data pool.
- Mistakes made in the individual study are highlighted when the data are pooled and analysed.
If you have any familiarity with the ISS process, you will be aware of the complexity and convoluted nature of its mechanisms. Our in-house team for Integration studies, named the Integration Summary Squadron (ISS, no pun intended), came out of a mammoth 10-month run of integrating a multitude of studies. We asked them to share some of their toughest challenges and how they conquered it. We’ve summarized some of the most important ones here:
- **Planning the execution**
A significant amount of time needs to be spent in planning for the Integration in the early stages of clinical development. Planning the individual studies with Integration in mind will help identify critical endpoints of the component studies, helping build a comprehensive design for them. Focusing on the development of SDTM datasets will help create a hassle-free process for analysis datasets, and thereby for the tables, listings and graphs derived from them. Another crucial part is the need to upgrade the version of various studies to ensure their compliance to the current CDISC standard versions. Documents such as protocols, Statistical Analysis Plans (SAPs), annotated CRFs, coding dictionaries, define-xml need to be made available at the outset to avoid unnecessary delay.
- **Maintaining Consistency across studies**
The most tedious part of an Integration process is reconciling the individual studies to be consistent before moving on to the integration portion. Often, studies are created with a lack of foresight on the potential implications they would have on the integration process. Standards may change drastically over the years, where entire domains could be removed, and new ones added. Also, in some cases, there are chances that different domains might have the same data. For example, our squadron faced an instance where MRI related information is collected in Study 001 in FA domain but in a custom domain called MR in Study 002.
**The Squadron also highlighted some aspects that programmers tend to overlook:**
- Missing to re-populate the sequence numbers for Supplemental domains from the main domain
- Ignoring variable level consistencies across similar studies. For example, in study 001 the result for a test is Y/N, while in study 002 the result is Yes/No.
- Not Planning to combine the safety data in advance, leading to inconsistent coding of both AEs (MedDRA) and concomitant medications (usually WHO Drug dictionary).
- **Efficient Programming**
It is easy to assume that while creating a submission ready ISS/ISE, all you need to do is stack the datasets of the component studies and apply the Statistical tests on the result, and voilà, your submission is ready.
**But the reality is far from that. When you set all your datasets together, you will notice issues like**
- Multiple lengths getting assigned to the same variable
- The datatype of the same variable being different in different studies
- Same data points mapped with two different variables.
These programming intricacies may look trivial, but if predicted well in advance, can help save a ton of time. It increases the overall efficiency of the programming process allowing you to concentrate more on analyzing the data than transfiguring it. Additionally, the squadron recommends creating efficient individual programs since any integration process involves millions of data points, and saving a few minutes per program can translate into hours of saved run time. Review of programs as a Quality control procedure can be implemented for keeping the programs contemporaneous and help programmers stick to the bigger picture.
- **Extension Studies**
One of the biggest challenges faced while integrating Extension studies (often open-label), involves implementing them into existing studies. Open-label extension studies are conducted right after a randomized trial and are used to assess long-term tolerability of the new drug. Reconciling the extension studies in the integration process is a monumental task that requires intuitive planning. Crucial decisions, like how the Demographics domain will represent subjects present in both studies, must be planned prior to the study. This should align with the analysis requirements of the integration.
- **Analysis Considerations**
The focal point of any integration study is the analysis of its endpoints. Identifying data points that need to be analysed, and their source, plays a vital role. Combining the data points and analysing them is not straightforward and depends on the basis for data collection
**The squadron quotes a few examples that they came across:**
- Studies usually do not have a homogeneous study population as the inclusion and exclusion criteria may differ. In such cases, the efficacy measures may be inconsistent and may mean that including certain studies in the ISS/ISE could be inappropriate. Therefore, the rationale for including or excluding certain studies should be justified and documented prior to analysis.
Therefore, the rationale for including or excluding certain studies should be justified and documented prior to analysis.
- Dose ranges will be different in different studies based on study design. Subject pooling strategy can be done in these situations, for dividing the population into groups that reflect the endpoints.
For example, Study A may dose patients for 3 weeks, compared to Study B, that doses patients for 6 weeks. A combined summary of the number of patients who reported an AE may not be appropriate, as one group of patients could be ‘at risk’ and followed up for a greater period. The statistician can help identify the appropriate methodology for addressing such issues. In this example, a solution may be to present AEs using a denominator that adjusts for the time at risk. Our Squadron can keep talking about their ISS/ISE conquests, but we’ve decided to give them a well-deserved break! Do you have any challenges that you’ve faced or a novel solution to the challenges mentioned above? Comment here and we’ll get our squadron to get in touch with you!
Have any thoughts or questions on this? Please email us at
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
---
### [Breaking Down The Blocks: Explaining Blockchain In The Clinical Environment](https://zifo.com/blogs/breaking-down-the-blocks-explaining-blockchain-in-clinical-environment/)
**Published:** May 17, 2023
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [Breaking Down The Blocks: Explaining Blockchain In The Clinical Environment](https://zifo.com/blogs/breaking-down-the-blocks-explaining-blockchain-in-clinical-environment/ "Breaking Down The Blocks: Explaining Blockchain In The Clinical Environment")
## Breaking Down The Blocks: Explaining Blockchain In The Clinical Environment
Amara Bharathy, Senior Biostatistics Programmer
May 17, 2023
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Breaking%20Down%20The%20Blocks%3A%20Explaining%20Blockchain%20In%20The%20Clinical%20Environment%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Fbreaking-down-the-blocks-explaining-blockchain-in-clinical-environment%2F "Share on Email")
- [](https://x.com/intent/post?text=Breaking%20Down%20The%20Blocks%3A%20Explaining%20Blockchain%20In%20The%20Clinical%20Environment&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fbreaking-down-the-blocks-explaining-blockchain-in-clinical-environment%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Breaking+Down+The+Blocks%3A+Explaining+Blockchain+In+The+Clinical+Environment&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fbreaking-down-the-blocks-explaining-blockchain-in-clinical-environment%2F "Share on LinkedIn")
Image reference: / source
If you have searched for emerging trends in technology, you couldn’t have missed Blockchain. While some of you might have known this technology as the one that drives bitcoins, I request you to take a step back, as it does a lot more than just that. In this article I have tried to throw some light on Blockchain and how it might bring about a renaissance in clinical trials.
**What is a Blockchain?**
Going by Wiki “A blockchain, originally block chain, is a growing list of records, called blocks, which are linked using cryptography. Each block contains a cryptographic hash of the previous block, a timestamp, and transaction data (generally represented as a Merkle tree root hash).” Yes, it sounds a bit vague. Let me explain in simple terms.
Let’s say that we start with some datapoint “A”, which is stored in, what is called in blockchain terminology, a block. Whatever change is done on this block “A” creates another block “B” in the chain. The block “B” holds the change that is done in datapoint “A”. Both these blocks are connected by cryptographic messages or hashes. What makes these simple blocks powerful is the way they are protected (encrypted). Each new block that gets added, distributes its hash to the network, so that the whole chain gets synchronized.
Every block within blockchain has three parts:
- “I know.” (The data of the block)
- “I know that you know.” (Hash synchronization along the linear chain)M
- “I know that you know that I know.” (The hash of the previous block)
**Audits**
Right from setting up a clinical trial, data management till decision making, there are a lot of phases that need auditing. Trust is the foundation for the establishment of clinical services for patients. The required trust is bi-directional (i.e., patient to clinical research professional and vice versa). For example, trust between a clinical research professional and a patient involves the belief that the patient is sharing their experiences and conditions truthfully and honestly. Similarly, trust between patient and clinical research professional involves consent-driven sharing of patient’s personal health information for research purposes.
With the ability of systems to use cryptographic keys (hash) to authenticate a user, the risk related to sensitive patient health data leaks reduces drastically. Moreover, use of predefined governance rules would enable an adequate level of privacy. Furthermore, authorized users can define and manage the governance rules of a blockchain solution around predefined access and control permissions to assure the appropriate levels of privacy versus transparency and ensure that only entitled parties (like CROs, the central lab, statisticians, etc.) can see the necessary data. This is during the study setup stage. When the study goes live, data monitor checks for the data integrity in the clinical site; while in data management phase, there is a need to track which data point from the EDC goes where in SDTM/Analysis datasets.
The cryptographic keys or the hash forms the audit center of this blockchain. Whenever there is an erroneous entry to the chain, this audit center performs 2 simple checks – looks for the previous hash information in the chain, and if it is present, passes this information to the entitled users/admins of the blockchain, wherein they must authenticate the new block to the chain. This attribute can be used in clinical data management aspect. Every data point can now be considered a block, and no block in this chain will ever go unaudited! Imagine the scenario now. The data from EDC are made into blocks and verified as and when they are added, saving a lot of time getting wasted in performing checks. All that we need to do is to add the algorithm of data checks along with the hash authentication step.
**Data Integrity**
Blockchain allows for reaching a substantial level of historicity and inviolability of data for the whole document flow in a clinical trial. Blockchain ensures that events are tracked in their correct chronological order, which largely prevents any back and forth communication after data collection.
Within blockchain each transaction is cryptographically validated, thus asserting integrity. Further, each transaction with Blockchain is timestamped. This information is transparent, and user can own their copy of the proof of the time-stamped data.
Another unique feature it has is the decentralization of data. No one owns the data store; it is controlled by users and is not ruled by any trusted third party or central regulatory instance. Trust is coded within the algorithm and maintained by the community of users. Blockchain architecture allows for storing proofs of the existence of data. As the proof of data is the data of proof, we believe that this is a paradigm shift in clinical research methodology.
The above image differentiates the traditional approach of having a central repository that stores the information versus the decentralized blockchain approach.
Blockchain technology is a major opportunity for clinical research: it can help in structuring more transparent checkable methodology; when a set of core metadata is defined it can help check clinical trial integrity, transparently and partly algorithmically.
Ultimately, Blockchain can lead to the structuring of community-driven internet of health data, gathering researchers and patient communities, social networks and Internet of Things on a global dimension, with features of individual granularity, decentralization and security to ensure easier and transparent analysis.
Have any thoughts or questions on this? Please email us at
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
---
### [Webinar - Data Integrity Remediation](https://zifo.com/blogs/data-integrity-remediation/)
**Published:** May 17, 2023
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [Webinar – Data Integrity Remediation](https://zifo.com/blogs/data-integrity-remediation/ "Webinar – Data Integrity Remediation")
## Webinar – Data Integrity Remediation
info@zifo.com
May 17, 2023
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Webinar%20%26%238211%3B%20Data%20Integrity%20Remediation%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Fdata-integrity-remediation%2F "Share on Email")
- [](https://x.com/intent/post?text=Webinar%20–%20Data%20Integrity%20Remediation&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fdata-integrity-remediation%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Webinar+%E2%80%93+Data+Integrity+Remediation&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fdata-integrity-remediation%2F "Share on LinkedIn")
Image reference: / source
When we talk about Data Integrity, are we focusing enough on the R&D space?
Zifo conducted a webinar to discuss how one can address Data Integrity gaps in R&D labs in a cost-effective manner. We had members of the Quality and Compliance functions of leading pharmaceutical companies in our audience.
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
---
### [Answered: Most Burning Questions On Clinical Trials Due To COVID-19](https://zifo.com/blogs/answered-most-burning-questions-on-clinical-trials-due-to-covid-19-2/)
**Published:** May 17, 2023
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [Answered: Most Burning Questions On Clinical Trials Due To COVID-19](https://zifo.com/blogs/answered-most-burning-questions-on-clinical-trials-due-to-covid-19-2/ "Answered: Most Burning Questions On Clinical Trials Due To COVID-19")
## Answered: Most Burning Questions On Clinical Trials Due To COVID-19
Divya Suryanarayanan
May 17, 2023
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Answered%3A%20Most%20Burning%20Questions%20On%20Clinical%20Trials%20Due%20To%20COVID-19%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Fanswered-most-burning-questions-on-clinical-trials-due-to-covid-19-2%2F "Share on Email")
- [](https://x.com/intent/post?text=Answered%3A%20Most%20Burning%20Questions%20On%20Clinical%20Trials%20Due%20To%20COVID-19&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fanswered-most-burning-questions-on-clinical-trials-due-to-covid-19-2%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Answered%3A+Most+Burning+Questions+On+Clinical+Trials+Due+To+COVID-19&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fanswered-most-burning-questions-on-clinical-trials-due-to-covid-19-2%2F "Share on LinkedIn")
Image reference: / source
COVID-19 pandemic has left sponsors with many questions and decisions to take regarding the continuity or adaptation of the ongoing clinical trials.
Sponsor: Yes, I do have a lot of questions.
Zifo: Have you gotten around to reading the “FDA Guidance on Conduct of Clinical Trials of Medical Products during COVID-19 Public Health Emergency” yet?
Sponsor: No, I haven’t yet. I wish I could skim through the guideline quickly.
Zifo: Ask away any questions you may have, and I will try to help you.
**Clinical Trial Protocol Amendments / Deviations**
**Sponsor (Q):** I need to make amendments in the protocol specified procedures to avoid potential exposure of subjects to COVID-19 infection. Patient safety will be compromised if we wait for the amendment to be approved by IRB/IEC. What shall I do?
**Zifo (A):** Protocol amendments having significant impact on safety of subjects can be implemented prior to IRB/IEC approval! But do ensure that the approval can and should be obtained post-facto.
**Sponsor (Q):** In order to ensure that the subjects enrolled in the trial are not infected by COVID-19 while the study is ongoing, it is mandatory to perform Screening Assessments related to COVID-19 during enrolment. I don’t think I can wait till the protocol amendment is done.
**Zifo (A):** No, it is not necessary that you need to wait. COVID-19 related Screening Assessments can be performed in the trial without amending the protocol.
**Sponsor(Q):** After lot of deliberations we decided to proceed with the first follow-up through a telephonic visit. This has worked out well with Adverse Events but not much luck with Vital Signs and ECG. Should we capture this deviation at study-level or subject-level?
**Zifo (A):** Any deviation from the planned course of study due to COVID-19 needs to be recorded at subject-level, summarized and submitted to FDA. Moreover, capturing the deviation at study-level is not advisable, since it can only be listed and not summarized at subject-level.
**Informed Consent Form**
**Sponsor (Q):** The ICF process requires an oral communication with the subject and a signed consent for study participation. In this case we would have to call the subjects to the clinical site, discuss with them and get the ICF signed. How to proceed the ICF signature process with the subject during this quarantine?
**Zifo (A):** Avoid requesting subjects/participants to visit sites, instead you can use other sources to send the ICF document to the client and get their signature. If needed, Video conferencing of ICF explanation involving the subject, investigator and a third-party witness to authenticate the ICF signature is recommended.
**Sponsor (Q):** We started a Phase III trial on neuropathic pain, and we are in recruitment phase. Due to the ongoing COVID-19 pandemic, it is not possible to get the ICF signed from the new subjects. How can we proceed with this?
**Zifo (A):** Yeah, ICF is highly critical for subjects to participate in any clinical trial. If the Informed consent form (ICF) cannot be sent to the site, the photo of the attested and signed ICF can be used as a valid ICF document. It is not mandated to comply the conventional methods for obtaining ICF. There are ‘n’ number of validated platforms where we can get the electronic consent signed from subjects. We can use these systems to get the e-consents signed from the subjects directly from their home.
**Technology in Clinical Trials**
**Sponsor (Q):** We have ongoing trials in which several subjects are in treatment phase. Sites are closed, and it is not always possible for the subjects to come to clinic for IMP refills. How do we ensure the treatment compliance during this pandemic?
**Zifo (A):** Home delivery of IMP from sites using online logistics systems can be used. Note that, IMP from sites can be shipped only if it does not require specific storage and handling conditions.
**Sponsor / Monitoring CRO (Q):** Few of our studies are approaching Database Lock next week. However, there are travel restrictions due to COVID-19 lockdown, and source documents are unable to be transported. Also, monitoring team could not commute to site to perform Source Data Verification. This could delay our submission timelines. How can we perform SDV in this scenario?
**Zifo (A):** The delay due to SDV completely makes sense. But you can request the sites to support remote monitoring – including remote clinical review and SDV by transferring the source documents electronically with general safety practices. Hope this helps to meet the timelines.
**Sponsor (Q):** With the current COVID-19 situation, it is unfeasible for subjects to come to the site for visits within the protocol specified window. Is there an alternative to conduct these visits seamlessly?
**Zifo (A):** Virtual Video Visits using HIPPA-certified online meeting rooms can be used. And, there are few features worth exploring. For instance, you can link the visit dates with the online meeting rooms which will serve as reminders.
Have any thoughts or questions on this? Please email us at
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
---
### [The Changing Face Of Batch Release In Manufacturing](https://zifo.com/blogs/the-changing-face-of-batch-release/)
**Published:** July 21, 2023
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [The Changing Face Of Batch Release In Manufacturing](https://zifo.com/blogs/the-changing-face-of-batch-release/ "The Changing Face Of Batch Release In Manufacturing")
## The Changing Face Of Batch Release In Manufacturing
Jul 21, 2023
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20The%20Changing%20Face%20Of%20Batch%20Release%20In%20Manufacturing%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Fthe-changing-face-of-batch-release%2F "Share on Email")
- [](https://x.com/intent/post?text=The%20Changing%20Face%20Of%20Batch%20Release%20In%20Manufacturing&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fthe-changing-face-of-batch-release%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=The+Changing+Face+Of+Batch+Release+In+Manufacturing&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fthe-changing-face-of-batch-release%2F "Share on LinkedIn")
Image reference: / source
**Introduction – The Importance of Process and Data Orchestration**
Manufacturing in the Pharmaceutical, Food, Fast Moving Consumer Goods (FMCG) and Chemical industries is undergoing a radical transformation, driven largely by the accelerated adoption of digital technologies. Amongst these changes, electronic batch release (EBR) and process & data orchestration have emerged as indispensable approaches, improving efficiency, compliance, and traceability.
**Electronic Batch Release: A Paradigm Shift**
Batch release, a vital step in manufacturing, is traditionally conducted manually, often leading to inefficiencies (slow down of the process), errors (missing data/wrong data), and regulatory complications (process gaps/data integrity). It may shock people, but many organisations still use paper or spreadsheets to manage their batch release processes and tracking. The introduction of electronic batch release has marked a significant shift in this landscape. EBR solutions facilitate a more streamlined, automated, data-driven process, eliminating manual errors and enhancing process efficiency.
Furthermore, EBR improves data integrity, a crucial factor in maintaining compliance with regulatory authorities like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). By digitising batch records, the EBR process can become digitalised, ensuring complete transparency and traceability in the batch release process, simplifying audit procedures and ensuring regulatory compliance.
**The Role of Process and Data Orchestration**
One significant contributor to the growing effectiveness of EBR systems is the integration of process and data orchestration capabilities. Process orchestration acts as a conductor, synchronising various tasks, streamlining workflow steps, and managing exceptions, thus promoting efficient and seamless operations.
Process orchestration in EBR provides a comprehensive, real-time view of batch release processes, enabling companies to control and optimise their operations better. It ensures that the right task is assigned to the right person at the right time, thereby minimising errors, reducing cycle time, and increasing productivity. Data orchestration ensures the right data is moved from one operational system to another in sequence according to the release process, ensuring chain of custody and data integrity.
Moving data through the process from the initial “batch release request” in ERP (Enterprise Resource Planning) to LES (Laboratory Execution System) to LIMS (Laboratory Information Management System) to a given INSTRUMENT then INSTRUMENT back to LIMS back to ERP for checking that the data/results meet the product specification and business rules is an area where process and data orchestration tools like BPO (Business Process Orchestration) and the associated BPMN (Business Process Model Notation) approaches can dramatically impact operational efficiency, insight and integrity.
Figure 1. Example of a Camunda (BPMN and BPO platform) process heat map view showing areas of focus.
BPMN tools allow organisations to keep their current infrastructure and systems, which are validated and integral to their process, and leverage them more effectively: removing manual / semi-manual movement of data through the process and gaining valuable insight into where every function, lab test, and result is in real-time. This means manufacturer plants can see where a batch is at any time – allowing them to plan and predict more effectively.
Moreover, process orchestration tooling allows for a high level of flexibility. It provides a framework that can easily adapt to regulatory requirements, changes in product specifications, manufacturing processes and company policy changes, supporting continuous improvement and scalability whilst maintaining compliance and integrity.
**The Impact of EBR and Process Orchestration on Quality Control**
In the pharmaceutical industry, quality control is paramount. By leveraging EBR and process orchestration, manufacturers can enhance their quality control measures. With real-time visibility into operations and automated workflows, companies can quickly detect and resolve quality issues, reducing the risk of non-compliance and dreaded product recalls.
Additionally, these technologies offer robust analytical capabilities. Manufacturers can identify trends, predict potential problems, and make data-driven decisions to improve product quality and efficiency by aggregating and analysing data from various stages of the batch release process.
One area these technologies are super critical is in the Cell and Gene Therapy space. Here, the process of manufacture is:
- Super time critical – the regulated production process is required to be executed and completed in days and weeks, rather than months or years
- Very complex – as the manufacturing process typically leverages biological systems adapted based on the specific type of therapy for a particular patient
- Dependent on process precision and accuracy – any “gaps” in product quality or precision can result in catastrophic implications for the patient
- Potentially localised in hospitals – as the time taken to send biological samples to a “site” is not feasible
- Temperature dependent sample logistics – as some manufacturing has to be done elsewhere and biological samples must be temperature controlled at -80oC
With these requirements – the common paper and spreadsheet data tracking and manual process control are not appropriate or even tenable as the data and sample chain of custody requirements are too stringent.
**The Road Ahead**
As we navigate towards an increasingly digitised future, the role of technologies like EBR and process orchestration (BPMN) in manufacturing will continue to evolve. They will drive operational efficiency (batch throughput) and enable companies to maintain the highest safety and quality standards.
Artificial Intelligence (AI) and Machine Learning (ML) are expected to be increasingly prominent in this space. Leveraging AI and ML, future EBR systems could predict and prevent manufacturing errors, optimise batch release processes, and provide actionable insights for strategic decision-making.
Despite these promising developments, a successful digital transformation in manufacturing requires a thoughtful, holistic approach. It involves investing in advanced technologies and building a culture that embraces change, prioritises data literacy, and values continuous learning and improvement.
**Conclusion**
In conclusion, EBR and process orchestration are changing the face of manufacturing, offering a way to improve efficiency, compliance, and quality control. By adopting these technologies, companies can stay ahead of the curve, ensuring they are prepared to meet the demands of an ever-changing regulatory landscape and the ever-increasing expectations of humankind.
If you would like to know more about what Zifo is doing in this area please drop us an email at .
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
---
### [Data Centrality – A Key consideration In Data Strategy](https://zifo.com/blogs/data-strategy/)
**Published:** October 9, 2023
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [Data Centrality – A Key consideration In Data Strategy](https://zifo.com/blogs/data-strategy/ "Data Centrality – A Key consideration In Data Strategy")
## Data Centrality – A Key consideration In Data Strategy
Dinesh Agaram, David Jackson, Anisa Heck
Oct 09, 2023
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Data%20Centrality%20%E2%80%93%20A%20Key%20consideration%20In%20Data%20Strategy%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Fdata-strategy%2F "Share on Email")
- [](https://x.com/intent/post?text=Data%20Centrality%20–%20A%20Key%20consideration%20In%20Data%20Strategy&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fdata-strategy%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Data+Centrality+%E2%80%93+A+Key+consideration+In+Data+Strategy&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fdata-strategy%2F "Share on LinkedIn")
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Stories
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
**Introduction**
**Let’s talk about “Data Centrality”.** At Zifo, we have coined this term to capture the notion that not all data holds equal significance and value in the grand scheme of scientific business processes and strategies. Much like the central pieces in a puzzle, certain data types and domains serve as the backbone of operations and business intelligence in your organisation, driving decisions that govern your business’s growth and performance. The concept of “data centrality” urges businesses to identify, categorise, and prioritise data types and associated datasets to streamline operations and formulate **[more informed strategies](https://www.stitchdata.com/resources/data-strategy/#:~:text=A%20data%20strategy%20should%20include,management%2C%20and%20analytics%20will%20vary.)** (around data modelling, architecture, governance and so on). Essential you are scoring your data types based on their importance within a given process or workflow
**When it comes to both strategic and operational decision-making**, an analysis of data centrality could help guide you in navigating complex data landscapes and related investment decisions. In a world that’s increasingly data-driven, the ability to discern the varying impacts of different data types can be a game-changer. By focusing on data centrality, businesses can craft strategies that are not only data-driven but also data smart (as against merely data busy), optimizing resources and efforts towards the data that matters the most
**A (very straightforward) example** is within the realm of pharmaceutical clinical trials. Here, a vast array of data types converge, ranging from clinical trial results to various omics datasets, patient feedback, regulation-relevant information, and more. When implemented, a data centrality model helps in recognizing that some data types that link to clinical trials are of higher value to the strategy than others, as they encompass critical insights into **[drug efficacy and safety](https://www.msdmanuals.com/en-gb/professional/clinical-pharmacology/concepts-in-pharmacotherapy/drug-efficacy-and-safety)**requirements mandated by regulation. Consequently, this data demands a higher level of scrutiny, management and analysis
**The challenge for leaders** is to cultivate an organisational environment that not only acknowledges the value of data but is adept at distinguishing the centrality of various data domains. Leaders must steer teams towards adopting methodologies that assign value scores to different data sets, facilitating a more structured and impactful approach to **[data-driven decision-making](https://www.driveresearch.com/market-research-company-blog/what-is-data-driven-decision-making-and-why-its-so-important/#:~:text=Data%2Ddriven%20decision%2Dmaking%20is%20defined%20as%20using%20facts%2C,benefit%20a%20business%20or%20organization.)**.This also involves fostering a culture of continuous learning, where teams are equipped with the necessary skills to navigate and leverage the insights drawn from the “central” data domains.
**Some types of investments that relate to the centrality of data types and datasets include** technological infrastructure enhancements that facilitate smooth integration and analysis, creation of central master data repositories (to note: master data types, by nature, will have a higher centrality score than others), training and development programs to up skill employees in data management and analysis, and consulting partnerships to devise and implement data centrality strategies effectively. These investments must be aligned with the business’s broader goals and strategies, ensuring a cohesive approach to leveraging data centrality for organisational success.
**We recommend the following best practices** for embedding the concept of data centrality into your science and business strategies:
- **Develop a data centrality matrix:** A tool that visually represents the value and impact of different data types, assisting in informed decision-making.**e.g., here is a summary version of the data centrality matrix illustrated with the example of pharmaceutical R&D. (A more sophisticated, weighted matrix will be available to our customers).**
Data typeCentrality scoreImpact on business processesStrategic importanceIntegration densityImpact on systemsUse frequencyClinical trial data10Direct impact on drug development processes, safety evaluationsCentral to development of effective and safe drugsHighHighHighPatient feedback7Influences adjustments to drug formulation and deliveryImportant for tailoring, repurposing to meet user needsMediumMediumMediumRegulations/ Policies8Critical for compliance and market approvalNecessary for legal compliance and market accessMediumMediumMediumMarket research data6Guides product strategyKey for understanding therapeutic needs and consumer preferencesMediumLowMediumMolecular and genetic data9Facilitates in-depth research into drug mechanisms and potential therapiesPivotal in discovery and personalisation of therapiesHighHighHighResearch supply chain data5Influences production distribution, inventory managementRegular ingredients availability for ResearchLowMediumHighIP records6Affects patent filings and protection of research outputsVital for protecting research investments and fostering innovationMediumMediumLow
**In the above example, the pecking order of data type importance is roughly this:** clinical trial data holds the top position, due to its direct influence on drug development, safety evaluations and in turn, marketability of products. Therefore, critical decisions around resource allocation, research analytics, and technology optimisations should be applied to this data type first because of its higher data centrality compared to other data types like market research or patient feedback. **[Recognising and acting upon this hierarchy](https://www.sciencedaily.com/releases/2022/10/221024131044.htm)** can potentially streamline the development process and enhance the success rate of new pharmaceutical products.
- **Continuous monitoring and adaptation:** Establish mechanisms to constantly review and adjust the data centrality metrics based on evolving innovation and business landscapes.
- **Promote a data-centric culture:** Encourage a workplace culture where data is regarded as a critical business asset, and employees are trained to work with data-centrality concepts.
- **Invest in technology and expertise:** Equip your organisation with the necessary tools and expertise to analyse and leverage data effectively and in a prioritised manner.
**We at Zifo are committed to solving** the intricacies involved in data management and strategy formulation in scientific domains. Through our approach of data centrality, we endeavor to assist science-led businesses not only in navigating the data deluge but also transforming data into a strategic asset (valuable, rare, inimitable and non-repudiable). By focusing on the most central data elements that drive business success – essentially a “more bang for the buck” approach, applying typical organisational trade-offs – Zifo can help to transform the way organisations perceive and utilise data, supporting a future of informed, agile, and successful decision-making.
**Conclusion**
**Please reach out to us to explore how data centrality can support your science and business strategies.**
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Stories
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
**Categories:** Strategic Scientific Consulting Services
---
### [Choosing A New Lims](https://zifo.com/blogs/choosing-a-new-lims/)
**Published:** January 23, 2024
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [Choosing A New Lims](https://zifo.com/blogs/choosing-a-new-lims/ "Choosing A New Lims")
## Choosing A New Lims
Hemal Rajani
Jan 23, 2024
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Choosing%20A%20New%20Lims%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Fchoosing-a-new-lims%2F "Share on Email")
- [](https://x.com/intent/post?text=Choosing%20A%20New%20Lims&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fchoosing-a-new-lims%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Choosing+A+New+Lims&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fchoosing-a-new-lims%2F "Share on LinkedIn")
Image reference: / source
**THE SNOWY SCENE**
Recently, my team and I were on our way to a client’s office for a Business Analysis meeting with their QA (Quality Assurance) team to evaluate and pick the right LIMS (Laboratory Information Management System) solution for their needs. The heavy snow in Chicago slowed us down, giving me some unplanned extra time with the team to discuss on how we would go about the LIMS evaluation and help the client make their purchase decision.
**EAR PHONES AND LIMS**
Just as I was putting my headphones away to get into the discussion, I was suddenly reminded of a different purchase decision I had made just a few weeks ago at an electronics store – where I had bought this pair of headphones.
Since when did we start having so many options for headphones?! Over-ear, in-ear, wireless, noise-cancelling – there is something for every requirement! Work out a lot? Wireless, obviously. Frequent flyer? It must be noise-cancelling. Always on the move? Make sure they’re small enough to fit in your pocket.
This got me thinking that when something as simple as a pair of headphones could have so many specs driving the purchase decision, what are the facets that influence the choice of a laboratory informatics solution? We brainstormed throughout the transit and analysed different solutions in the market.
The discussion brought up an interesting perspective on the factors to consider while choosing the right LIMS solution – while it must solve the pains for the business and be user-friendly, it is also crucial to make an effective vendor assessment, just as how one would evaluate the brand of the headphones, always making sure you’re buying it from a credible seller.
So – we came up with a few key points that sometimes get forgotten/overlooked while choosing a LIMS solution. It is important to vet the processes used by the Product Vendor along with their QMS (Quality Management System) structure and their SDLC (Software Development Life Cycle) processes and practices for understanding in depth their robustness and compliance with GxP (if applicable). Furthermore – we thought about the pros and cons for each of the typical LIMS types. Here are some of the business criteria that should be considered and evaluated while selecting a LIMS solution and our take on each of them:
**GENERIC LIMS.**
**What are they?** Generic LIMS systems are almost universally sample-oriented and laboratory-centric. The challenge of deploying a generic LIMS is that – not many laboratories are sample oriented and most of the industries (such as the Food and Beverages, Chemical or Pharmaceutical) are highly regulated with specificities that are not addressed by generic solutions.
**What’s our take?** In many cases, the magnitude of customization required on top of the generic LIMS can result in a system with huge maintenance, validation and upgrade costs, and there is little difference in expense between a customized generic system and a completely custom-built one. Moreover, taking the decision of how much customisation is required prior to choosing a LIMS alone can cost huge time and money.
**COTS (Commercial Off-The-Shelf Solutions).**
**What are they?** Domain-specific LIMS solutions fit specific needs better than the other options (for example BA LIMS, NGS LIMS etc.). The challenge here is the project’s anticipated growth and expectations should be analysed and managed. URS is the key here, even a high-level one is helpful to determine the right one.
**What’s our take?** While these may have a higher initial purchase price than a generic system, the costs of deployment, training, validation, maintenance and upgrades can be drastically lowered, making the overall cost a fraction of that of buying a customized solution. Also, the purchase should be mindful of any process changes in future which can give excellent progress and efficiencies.
**CUSTOM SOLUTIONS.**
**What are they?** When there are no commercial products available to meet a specific need or when organisations face no pressure to limit the scope or budget of large-scale projects, they choose to build custom solutions in-house or contract software development firms to have custom systems built for them. The challenge here is a need for a technically strong software team having the skill set necessary for maintaining the very specific custom software due to possibly very less training and documentation.
**What’s our take?** This could meet the needs of a pharmaceutical company better than commercial offerings. However, the cost of implementing custom-made LIMS could be very high. Fortunately, many LIMS companies have started creating domain-specific modules such as Oil and Gas, Healthcare, Pharma, Biobanking, Clinical, etc.
**KEY TAKEAWAYS**
Of all these solutions, a COTS (Commercial Off-The-Shelf Solution) would seem to tackle specific needs better than the Generic LIMS and is a more cost-effective alternative to a completely custom-built LIMS solution. However, even a domain-specific COTS solution might not satisfy 100% of the requirements of a laboratory. And while the system validation effort may be reduced, some effort would still be necessary to provide reassurance that the system, as configured, is functioning as expected.
The right LIMS solution should always be chosen by keeping the end-users in mind. It’s also important to understand the current and future technologies that vendor has and whether the current ones are futuristic, serving well for future business needs. With all the requirements and key workflows of the laboratory kept front and centre, there will be an increase in efficiency and an optimally functioning environment which will then deliver the ROI (Return on Investment).
To find out more about how Zifo can help with your LIMS and Digitalisation, please email us at
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
---
### [CBioPortal](https://zifo.com/blogs/cbioportal/)
**Published:** May 10, 2024
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [CBioPortal](https://zifo.com/blogs/cbioportal/ "CBioPortal")
## CBioPortal
Radesh Nattamai Malli Pooranachandhiran
May 10, 2024
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20CBioPortal%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Fcbioportal%2F "Share on Email")
- [](https://x.com/intent/post?text=CBioPortal&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fcbioportal%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=CBioPortal&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fcbioportal%2F "Share on LinkedIn")
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Stories
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
**Introduction**
cBioPortal is an open-source platform that visualises, analyses and serves large-scale cancer genomics data sets. Ingesting data from cBioPortal into a custom database involves several steps and challenges that must be addressed to ensure data integrity and usability.
**Data sources**
The frequency of data updates depends on the availability of new datasets and curation efforts. The Cancer Genome Atlas (TCGA) data within cBioPortal is continuously updated to reflect the latest findings. It includes genomic alterations, copy number variations, mutations, and clinical attributes. TCGA data in cBioPortal is comparable to TCGA data in the Genomic Data Commons (GDC), and some legacy data, such as TCGA Firehose data, are also available.
As of the latest update, cBioPortal has added 5,120 samples from 13 studies, highlighting the platform’s extensive and growing database.
Table 1: **cBioPortal latest Datasets update 2023**
Latest update Dec 29, 2023NameStudy NameSamplesEndometrial Cancer (MSK, Cancer Discovery 2023)1,882Esophagogastric Cancer (MSK, J Natl Cancer Inst 2023)902Diffuse Glioma (GLASS Consortium, 2022)693Bladder Cancer (MSK, Clin Cancer Res 2023)526Non-Small Cell Lung Cancer Brain Metastasis (MSK, Nat Commun 2023)322MSK Make-an-IMPACT Rare Cancers (MSK, Clin Cancer Res 2023)184Cervical Cancer (MSK, Clin Cancer Res 2023)177Mature T and NK Neoplasms (MSK, Blood Adv 2023)132Hepatocellular Carcinoma (MSK, JCO Precis Oncol 2023)90Sarcoma (MSK, J Pathol 2023)82Esophagogastric Cancer (MSK, Clin Cancer Res 2023)64Rhabdomyosarcomas (MSK, NPJ Precis Oncol 2023)42Pediatric Rhabdomyosarcomas (MSK, JCO Precis Oncol 2023)24
**cBioPortal Computational requirements**
PlatformInstance type(v)CPUsRAM (GB)Storage (GB)awsr5.xlarge43250on-premise–43250
**Installation and Data download**
Local installation of cBioPortal can be done using Docker, which will then deploy and start all 4 containers listed below:
- **Mysql** database, which holds all the portal’s data.
- **cBioPortal** Java web app, which serves as the REACT frontend & REST API.
- **Sessions Service** Java web app, which stores session information.
- **Mongo** database that persists the data for the sessions service.
**Challenges**
- Maintaining updates and modifications requires running these containers in a different cloud or on-premise computational ecosystem.
- Sometimes, the Mongo database does not connect from a local instance and times out, which requires recalibration and fine-tuning of computational resources.
**Below is the latest overview of the datasets available in cBioPortal for public review.**
Most of the CBioPortal data is available only in TSV format, which might create a challenge in the downstream or tertiary analysis if a different format such as VCF or MAF, is required.
Table 1: **cBioPortal Datasets Overview**
Datasets available403Mutations182,880CAN138,689RNA-Seq31,179Structural Variants33,336Tumor mRNA (microarray)8,506Tumor miRNA2,882Methylation (HM27)4,564RPPA18,792Protein Mass Spectrometry1,687Complete27,737Treatment Count8,612
**cBioPortal Architecture – key components**
- **Backend** – SQL database
- **Validator** – checking format before importing data into the database
- **Frontend** – built with React, Mobx & Bootstrap
- **Session Service** – Rest API & Mongo Database
- **API from external sources\***
- Multiple API clients in R & Python are available; the most recommended are the Bioconductor package (cBioPortalData) & cBioPortalR.
- **OncoKB** – Precision oncology knowledgebase – effects & treatments of specific cancer gene alterations.
- **CIVIC** – Clinical Interpretation of Variants in Cancer
- **GenomeNexus** – High-throughput annotation of variants in cancer
- **G2S – Genome to Structure** – maps variants to 3D structure
- **CancerHotSpots** – Linking statistically significant mutations in cancer is determined using a binomial statistical model and is not experimentally validated or curated by a literature review.
**Challenges in Data Ingestion from cBioPortal**
- **Data Complexity:** cBioPortal’s data encompasses various types, including genomic, clinical, and molecular data. The complexity requires careful handling to maintain the relationships and integrity during Ingestion and migration.
- **Data Volume:** The large volume of data in cBioPortal can be challenging to manage, requiring scaled-up storage and processing capabilities.
- **Data Consistency:** Maintaining data consistency during transfer is crucial to prevent analysis errors.
- **Data Compatibility:** Custom & external databases may have different data structures, necessitating transformation or mapping of cBioPortal data to fit these structures.
- **Identifier Mapping:** Accurate mapping of identifiers like Entrez Gene IDs and HUGO Gene Symbols is essential for referential integrity.
- **API Limitations:** The cBioPortal API may have request limitations, affecting data transfer efficiency. Listed above\* are a few external data sources requiring separate access protocols.
- **Data Privacy:** Ensuring the privacy of patient data is paramount, which may require additional security measures.
**Gene-Specific Identifiers in cBioPortal**
cBioPortal uses standardised identifiers to ensure consistency and accuracy in data representation and querying:
- **Entrez Gene IDs** Numeric identifiers assigned by the NCBI to genes, widely used for genomic data analysis.
- **HUGO Gene Symbols:** Standardised symbols provided by the HGNC serve as a common language for the genetics community.
These identifiers are essential for accurately querying and analysing genomic data within cBioPortal and when transferring data to other databases.
**Additional Challenges**
After careful analysis and review of the cBioPortal data structures, system architecture, analytics capabilities and overall entity relationships, below are some additional challenges and bottlenecks users will face when trying to ingest/migrate custom data into or out of cBioPortal.
- Some missing metadata & study data which might not be integrated into the MultiAssayExperiment object in the cBioPortal.
- Need to clear Cache when the download is interrupted and no proper way to check the integrity of the download.
- Use the “removeCache ” function. Note that this function only works for data downloaded through the “cBioDataPack” function.
- Prior Z-Score Data normalisation & transformation of the input file is necessary before uploading it to the portal.
Two recommended methods available
- **ConvertExpressionZscores.pl** (diploid samples as base population)
- **NormalizeExpressionLevels\_allsampleref.py** (all samples as base population).
- Multiple API errors for the external data sources listed in the Github issues page.
- Data download issues were recently reported for the seed database.
- No clear instructions on downloading mutations/altered samples of whole genes in one clinical study as the current version can only download the data of mutations/altered samples in serval genes.
- Annotation of mutation data and transcripts needs to follow specific guidelines alternating between MKSCC & UNIPROT database for different sets of data.
- It is very important to annotate the mutation data in the same way else the gene + protein changes would be different when comparing 2 studies.
- **Validation of altered samples** in a study for all the genes is a challenging and a time-consuming process.
- ABCA7 gene has 10 altered samples in the main query page, whereas in the DNA\_mutation.txt file it has listed only 7 altered samples.
- Structural Variants (SV) data is **experimental** and needs validation and can also be linked to external sources such as dbVar (https://www.ncbi.nlm.nih.gov/dbvar/content/human\_hub/) which requires customised API’s and connections to various data sources.
- **Pathway analysis** and download feature is not available and graph data analysis for overlapping, similar and p-value correlated pathways are not available.
- **Cytoscape plugin** and the **CyNDEX-2 app** is required to view pathways features like network analysis.
Ingesting data from cBioPortal to a custom database (either in the cloud or on-premise) is a complex process that requires careful planning and execution. A deep understanding of the portal’s data sources, correlation of data entities, portal architecture, computational expertise, addressing the portal’s challenges and developing solutions are crucial for successful data transfer and utilisation.
Some approaches for resolving missing metadata in cBioPortal are to inspect Data files and descriptions and check for any discrepancies in sample or patient IDs across different studies. In addition to these recommendations, the FAIRification of data generated from cBioPortal would also help researchers effectively analyse cancer Omics data. Aspects of Machine Learning (ML) applications in cBioPortal analytics will significantly impact areas such as Cancer subtype classification, Data integration and visualisation.
If you’re interested in open-source bioinformatics data repository design, custom enhancement, data migration/Ingestion, research and development, contact us by email , and we can discuss further.
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Stories
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
---
### [Unveiling Drug Targets With The Power Of Bioinformatics Orchestration](https://zifo.com/blogs/unveiling-drug-targets-with-the-power-of-bioinformatics-orchestration/)
**Published:** August 8, 2024
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [Unveiling Drug Targets With The Power Of Bioinformatics Orchestration](https://zifo.com/blogs/unveiling-drug-targets-with-the-power-of-bioinformatics-orchestration/ "Unveiling Drug Targets With The Power Of Bioinformatics Orchestration")
## Unveiling Drug Targets With The Power Of Bioinformatics Orchestration
Radesh Nattamai Malli Pooranachandhiran
Aug 08, 2024
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Unveiling%20Drug%20Targets%20With%20The%20Power%20Of%20Bioinformatics%20Orchestration%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Funveiling-drug-targets-with-the-power-of-bioinformatics-orchestration%2F "Share on Email")
- [](https://x.com/intent/post?text=Unveiling%20Drug%20Targets%20With%20The%20Power%20Of%20Bioinformatics%20Orchestration&url=https%3A%2F%2Fzifo.com%2Fblogs%2Funveiling-drug-targets-with-the-power-of-bioinformatics-orchestration%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Unveiling+Drug+Targets+With+The+Power+Of+Bioinformatics+Orchestration&url=https%3A%2F%2Fzifo.com%2Fblogs%2Funveiling-drug-targets-with-the-power-of-bioinformatics-orchestration%2F "Share on LinkedIn")
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Stories
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
The relentless pursuit of new therapeutic targets fuels the engine of drug discovery. Enter Open Targets, a robust platform that harmonizes the vast array of bioinformatics data sources to systematically identify and prioritize promising targets for a wide range of diseases. This article delves into the intricate workings of Open Targets, exploring how it integrates a multitude of bioinformatic data sources and translates them into a powerful scoring system for target-disease associations.
**A Complex Tapestry of Bioinformatics Data Sources**
Open Targets draws upon a rich tapestry of publicly available bioinformatics data, each thread offering a unique perspective on the biological landscape of disease. Here’s a glimpse into some key sources that contribute to the platform:
- **Genetic Whispers:** Genome-wide association studies (GWAS) reveal genetic variations linked to disease susceptibility. Open Targets listens to these whispers, identifying genes harboring these variations—potential targets for therapeutic intervention.
- **Somatic Mutations:** Mutations within diseased tissues can expose genes critical for disease. The platform integrates data on somatic mutations from cancer sequencing projects, providing valuable insights.
- **The Drug-Target Tango:** Existing drugs and their established targets offer a wealth of knowledge. Open Targets incorporates information on approved drugs and their targets to help identify potential targets for similar diseases, facilitating a targeted drug discovery approach.
- **Differential Expression’s Crescendo:** Gene expression profiling across healthy and diseased tissues can reveal genes with altered activity. Open Targets integrates transcriptomics data to identify genes whose expression levels rise or fall in disease states, potentially offering new therapeutic insights.
- **Animal Models:** Understanding the biological pathways and networks associated with diseases can illuminate potential targets. The platform integrates data on pathways and interactions between genes and proteins, revealing insights into the intricacies of disease.
- **Pathway Harmony:** Understanding the biological pathways and networks associated with diseases can illuminate potential targets. The platform integrates data on pathways and interactions between genes and proteins, revealing insights into the intricacies of disease.
**Figure 1. Heterogenous data sources form the backbone of the evidence required for target disease associations.**
**Release 24.06 of Open Targets has the following statistics:**
- 63,226 targets
- 28,198 diseases and phenotypes
- 18,041 drugs and compounds
- 17,703,456 evidence strings
- 8,079,215 target-disease associationsThis release integrates 17,703,456 evidence strings to build 8,079,215 target-disease associations between **28,198** diseases and **63,226** **targets** from the following **23 public resources**. Additionally, the platform now allows users to **explore data on 18,041 drugs**.
Table 1: **List of evidence sources for the Open Targets platform.**
**Open Targets Evidence Summary**
Data SourceCategoryNumber of EntriesReferenceEuropean Variation Archive (EVA)Genetic3,260,235\[2\]Open Targets GeneticsGenetic781,213\[3\]Gene2PhenotypeGenetic3,631\[1\]Genomics England PanelAppGenetic34,407ClinGenGenetic2,642OrphanetGenetic6,673Gene BurdenGenetic36,372CRISPRBrainGenetic21,726UniProt LiteratureGenetic4,505\[4\]European Variation Archive (EVA)Somatic16,962\[2\]intOGenSomatic4,359Cancer Gene CensusSomatic82,754UniprotSomatic28,354\[4\]ChEMBLDrug Target660,575\[1\]Expression AtlasGene Expression230,182ReactomePathway10,181SLAPenrichPathway72,441PROGENyPathway378SysBioSystems Biology389Cancer Genome InterpreterSomatic1,300Pacini et al. (2024)CRISPR-Cas9 (Cancer Cell Lines)517\[5\]IMPCMouse Model1,138,754Europe PMCLiterature Co-occurrence11,304,906
**Note:**
- Numbers are based on the information provided and may not represent the exact number of entries in each data source.
- References are provided where available. 1: denotes reference not provided in snippet, 2: \[2\] refers to European Variation Archive (EVA), 3: \[3\] refers to Open Targets Genetics, 4: \[4\] refers to UniProt Literature, 5: \[5\] refers to Pacini et al. (2024).
**Bioinformatics Workflows: The Unsung Conductor**
Managing and analyzing the plethora of data utilized by Open Targets necessitates robust bioinformatics workflows and pipelines. These automated, multi-step processes ensure efficient and reproducible data processing. Here’s a simplified breakdown of a typical workflow conducting Open Targets’ bioinformatics orchestra:
- **Data Acquisition:** Scripts and data tools need to be nimble, automatically retrieving data from various public repositories.
- **Data Preprocessing:** Downloaded data often requires cleaning and standardization to ensure compatibility with downstream analyses. Workflows perform tasks like filtering irrelevant data points or converting data formats.
- **Data Integration:** Data from diverse sources needs to be integrated into a cohesive knowledge base. Workflows use mapping strategies to link entities (genes, diseases, drugs) across different datasets.
- **Data Analysis:** Depending on the data type, workflows execute specific bioinformatics tools, such as RNA-seq data analysis or GWAS data analysis, employing statistical rigor to identify significant associations.
- **Target-Disease Association Scoring:** Workflows aggregate the results from individual analyses and calculate the final score for each target-disease association, creating the final all-important insights.
**Computational Resources**
Unfortunately, Open Targets isn’t designed to be easily installed and run as a local platform. It’s a complex system leveraging significant computational resources. Having said that, the Open Targets team has released a tool on GitHub called “Standalone local deployment for Open Targets Platform”, which uses the GNU make command to install a local version of the Open Targets platform. Below is the architecture diagram for the local installation:
**Figure2. Overview of the stand-alone installation of the Open Targets platform.Source:**
**There are some challenges when trying to run a local instance of Open Targets:**
- **Large-scale data storage:** Open Targets integrates a vast amount of data from diverse sources. This data would require significant storage (potentially terabytes) depending on the specific data selected, which is not typically possible on a desktop PC.
- **Computational power:** The platform utilizes bioinformatics workflows involving various tools and analyses. These workflows can be computationally intensive, requiring powerful processors and potentially graphics processing units (GPUs) for specific tasks.
- **Software Dependencies:** Open Targets likely relies on a complex software stack with various bioinformatics tools and libraries. Setting up these dependencies on a local machine can be challenging and time-consuming.
- **Scalability and Maintenance:** Open Targets is constantly evolving and integrating new data sources. Maintaining a local instance would necessitate manual updates and potentially significant reconfiguration efforts.
Beyond the extensive trove of public datasets, Open Targets also delves into the world of biomedical literature. A bioinformatics pipeline powered by BioBERT, a natural language processing (NLP) model specifically trained on biomedical text, is employed. BioBERT identifies mentions of genes, diseases and drugs within abstracts and full-text articles by using a method called NER(Named entity recognition) . NER is a form of natural language processing (NLP) that involves extracting and identifying essential information from text. By using more nuanced models like LinkBERT , ClinicalBERT and quite possible LLMs it maybe possible to enhance the pipeline’s ability to extract knowledge from these datasets. \[see slides 8, 15,16 and 17 for reference if required\]. This extracted information is then normalized using identifiers and synonyms to link it to entities within the platform’s knowledge base. Using more nuanced models like LinkBERT, ClinicalBERT employing NER (Named Entity Recognition) and possibly LLMs (Large Language Models) can enhance the pipeline’s ability to extract knowledge from these datasets.
**Architecture and Overview of the Open Targets Platform**
**Typically, an Open Targets architecture leverages a combination of:**
- Distributed data storage systems.
- Workflow managers for data processing pipelines.
- Bioinformatics tools for specific data analysis.
- Natural language processing for literature mining.
- A user-friendly web interface for data access and exploration.
**Major components include:**
- Data storage modules and components.
- Annotation modules.
- Evidence generation and target association.
- Web application and front-end.
**Figure 3. Overview of a typical architecture of the Open Targets platform.Source:**
**There are a number of critical challenges associated with the utilization of the Open Targets platform:**
- **Data Interpretation and Integration:**
- Open Targets integrates a vast amount of data from diverse sources. This presents challenges in data interpretation. Users need a strong understanding of bioinformatics and the specific data types involved to properly evaluate the evidence supporting each target-disease association. Additionally, integrating data from various sources with potential inconsistencies or biases requires careful consideration.
- **Data Quality and Completeness:**
- Open Targets relies on publicly available data sources, which may have inherent limitations in quality and completeness.Users need to be critical of the data and consider factors like potential biases, missing data points, or methodological limitations of the original studies.
- **Focus on Known Genes:**
- Open Targets prioritizes established genes with existing annotations. This can lead to overlooking novel or less-studied genes with potential as drug targets. Researchers needing to explore entirely new avenues may need to complement Open Targets with other resources.
- **Target Druggability:**
- While Open Targets identifies potential target-disease associations, it doesn’t explicitly assess druggability. This is a crucial factor in drug discovery, as not all potential targets are readily amenable to therapeutic intervention. Additional resources or computational tools focusing on druggability prediction may be needed.
- **Visualization:**
- Platform Complexity: Open Targets offers a wealth of information, but the platform itself can be complex to navigate, particularly for users unfamiliar with bioinformatics concepts. A steep learning curve can be a barrier to entry, especially for researchers lacking a strong background in this area.
**There are also a number of additional considerations:**
- **Computational Demands:**
- While users aren’t required to run the platform itself, downloading and analyzing large datasets from Open Targets may require significant computational resources on their local machines.
- **Data Updates:**
- Open Targets is constantly evolving, integrating new data sources and refining scoring methods. Users need to stay updated on these changes to ensure they are utilizing the most current information.
In addition to the above lists, one of the key considerations is the scoring algorithm deployed by the platform. A brief overview of the target-disease association scoring is given below.
**Building and Scoring Target-Disease Associations**
The power of Open Targets lies in its ability to integrate diverse bioinformatics data sources and generate a comprehensive score for each target-disease association. This score reflects the cumulative evidence supporting a particular gene product (protein) as a potential target for a given disease. Here’s a simplified breakdown of the scoring process:
- Each data source contributes a specific weight to the overall score, reflecting its perceived importance in target validation.
- For instance, genetic associations from GWAS might hold a higher weight than findings from animal models.
- Within each data source, individual data points (e.g., a specific mutation or a differentially expressed gene) also contribute a score based on factors like statistical significance or fold-change in expression.
- The platform aggregates these individual scores from each data source, resulting in a final, cumulative score for the target-disease association.
**Strategies for Mitigating Challenges:**
- **Critical Evaluation of Data:** Each data source contributes a specific weight to the overall score, reflecting its perceived importance in target validation.
- **Complementary Resources:** For instance, genetic associations from GWAS might hold a higher weight than findings from animal models.
- **Collaboration:** Within each data source, individual data points (e.g., a specific mutation or a differentially expressed gene) also contribute a score based on factors like statistical significance or fold-change in expression.
- **Staying Updated:** The platform aggregates these individual scores from each data source, resulting in a final, cumulative score for the target-disease association.
**Summary**
The Open Targets platform is a comprehensive, open-source research tool that integrates publicly available datasets to support the systematic identification and prioritization of potential therapeutic drug targets. It scores target-disease associations by combining data from various sources, including genetics, pathways and chemical compounds. Researchers can use this platform to explore and analyze drug targets, aiding drug discovery and development efforts.
The Open Targets platform exemplifies the power of bioinformatics in drug discovery. By integrating and analyzing a vast array of bioinformatics data, Open Targets empowers researchers to prioritize promising drug targets with a strong biological rationale. This not only accelerates the drug discovery process but also increases the likelihood of identifying effective therapies for a multitude of diseases.
As bioinformatics methodologies continue to evolve, we can expect the Open Targets platform to become even more sophisticated, offering researchers an ever-more powerful tool in the fight against disease. In summary, Open Targets is a valuable resource for advancing precision medicine and improving patient outcomes.
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Stories
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
---
### [Journey From DevOps To Platform Engineering: Evolving Towards A Future-Proof Infrastructure](https://zifo.com/blogs/journey-from-devops-to-platform-engineering-evolving-towards-a-future-proof-infrastructure/)
**Published:** September 18, 2024
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [Journey From DevOps To Platform Engineering: Evolving Towards A Future-Proof Infrastructure](https://zifo.com/blogs/journey-from-devops-to-platform-engineering-evolving-towards-a-future-proof-infrastructure/ "Journey From DevOps To Platform Engineering: Evolving Towards A Future-Proof Infrastructure")
## Journey From DevOps To Platform Engineering: Evolving Towards A Future-Proof Infrastructure
Debrup Mazumdar, Senior Consultant
Sep 18, 2024
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Journey%20From%20DevOps%20To%20Platform%20Engineering%3A%20Evolving%20Towards%20A%20Future-Proof%20Infrastructure%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Fjourney-from-devops-to-platform-engineering-evolving-towards-a-future-proof-infrastructure%2F "Share on Email")
- [](https://x.com/intent/post?text=Journey%20From%20DevOps%20To%20Platform%20Engineering%3A%20Evolving%20Towards%20A%20Future-Proof%20Infrastructure&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fjourney-from-devops-to-platform-engineering-evolving-towards-a-future-proof-infrastructure%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Journey+From+DevOps+To+Platform+Engineering%3A+Evolving+Towards+A+Future-Proof+Infrastructure&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fjourney-from-devops-to-platform-engineering-evolving-towards-a-future-proof-infrastructure%2F "Share on LinkedIn")
Image reference: / source
In the past few years, we’ve witnessed a shift in the industry where job titles have transitioned from DevOps engineer to platform engineer. While some view this as a mere rebranding exercise, the reality is that these roles focus on different aspects of software development and operations. DevOps is traditionally centered around operational efficiency, while platform engineering emphasizes optimizing the developer experience.
Whether in DevOps or platform engineering, a true transformation requires a holistic approach that integrates technology, people, and processes across the development lifecycle. It’s not just about optimizing one aspect but considering all stakeholders involved, from engineers to operations to security teams.
**Starting the Platform Engineering Journey**
When the transition began, the DevOps team found itself stuck in what could be called a “fake SRE topology,” where operations teams were labeled as Site Reliability Engineers (SREs) without significant changes to their processes. This led to a situation where developers would hand off feature-complete software to SREs, creating gaps in software observability and limiting the ability of SREs to engage meaningfully with developers to resolve issues.
This scenario, though common, can be a challenging starting point. It was clear that addressing the needs of a single stakeholder, such as software engineers, wasn’t enough. In a large organization, platform engineering must consider the input and requirements of all stakeholders, especially in industries with stringent regulatory requirements.
**Redefining DevOps Principles**
To redefine the role of the DevOps team, a set of principles was established, grounded in automated deployments, lean management, continuous improvement, measurable outcomes, knowledge sharing, integrated security, and governance best practices. These principles laid the foundation for the DevOps team to begin a process of introspection, reflecting on their current challenges and clarifying their goals.
**Owning the Backlog: A Crucial Step**
One of the key insights was the importance of owning the backlog. Without this ownership, the team struggled to understand and communicate the value they were bringing to the organization. This lack of clarity contributed to burnout, a common issue in DevOps roles.
To counter this, the team transitioned towards platform engineering, with the aim of building a self-service platform. By owning at least half of the backlog, the team could set its own goals, drive automation, enhance security, and embed DevOps concepts into their processes.
**Building a Future-Proof Cloud-Native Platform**
The journey towards platform engineering included learning from industry best practices and adopting cloud-native architectures. The goal was to build a scalable, self-service internal developer platform that would enable teams to deploy, monitor, and maintain their production environments independently. This shift was essential for scaling with the organization’s growth.
A significant milestone was the overhaul of the Continuous Integration/Continuous Deployment (CI/CD) pipeline, migrating to a cloud-native stack that improved developer productivity and reduced incidents. This transformation demonstrated the technical capabilities of the new platform engineering team and established a new framework for decision-making within the organization.
**Measuring Impact and Driving Continuous Improvement**
To measure the impact of these changes, the team adopted industry-standard metrics like DORA (DevOps Research and Assessment), which track deployment frequency, lead time for changes, change failure rate, and recovery time. These metrics provided a clear view of the platform’s performance and guided continuous improvement efforts across the organization.
As the organization grew, the platform engineering team expanded its focus to include additional stakeholders like quality, security, and compliance. By codifying automation and self-service within the organization’s processes, the team democratized observability and empowered engineering teams to take ownership of their delivery speed and quality.
**The Future: OrgOps and the Age of Platforms**
As the organization scaled, the platform engineering approach evolved into what could be termed “OrgOps.” This involved building cross-functional teams around the tech stack and including all stakeholders in the software release process. The result was an integrated, organization-wide effort to enhance performance and agility.
The journey from DevOps to platform engineering is ongoing, with the team now managing multiple platforms to meet diverse stakeholder needs. As the company grows, the platform engineering approach will need to evolve further to keep pace with the organization’s demands. This continuous evolution is the essence of successful platform engineering — building a foundation that meets current needs and is adaptable for the future.
If you have any questions or would like to know more, please get in touch with us at
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
**Categories:** Scientific Cloud Computing Services
---
### [Upgrading Your Legacy Pipelines To Nextflow: Here's How!](https://zifo.com/blogs/upgrading-your-legacy-pipelines-to-nextflow-heres-how/)
**Published:** September 18, 2024
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [Upgrading Your Legacy Pipelines To Nextflow: Here’s How!](https://zifo.com/blogs/upgrading-your-legacy-pipelines-to-nextflow-heres-how/ "Upgrading Your Legacy Pipelines To Nextflow: Here’s How!")
## Upgrading Your Legacy Pipelines To Nextflow: Here’s How!
Lathika Madhan Mohan, Senior Consultant
Sep 18, 2024
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Upgrading%20Your%20Legacy%20Pipelines%20To%20Nextflow%3A%20Here%27s%20How%21%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Fupgrading-your-legacy-pipelines-to-nextflow-heres-how%2F "Share on Email")
- [](https://x.com/intent/post?text=Upgrading%20Your%20Legacy%20Pipelines%20To%20Nextflow%3A%20Here%27s%20How!&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fupgrading-your-legacy-pipelines-to-nextflow-heres-how%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Upgrading+Your+Legacy+Pipelines+To+Nextflow%3A+Here%5C%26%23039%3Bs+How%21&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fupgrading-your-legacy-pipelines-to-nextflow-heres-how%2F "Share on LinkedIn")
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Stories
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
**Knowing why**
Start by clearly defining your objectives for migrating the pipelines to Nextflow, as this will guide you through the entire migration process. This clarity will help determine the approaches and steps needed to achieve your objectives. Whether you migrate solely to Nextflow or integrate it with the Seqera Platform for management, ensure the workflows are not merely converted but also modified to incorporate critical features like scalability and portability, which likely influenced your decision.
**Asking the right questions**
You may want to start by asking questions that help put together a technical to-do list. Here are some examples:
- **Pipeline Inventory:** How many pipelines need to be converted to Nextflow?
- **Optimization:** Are there any parts of the current pipeline that are rarely used or obsolete? Should these parts be removed during the conversion process?
- **Tools Upgrade:** Should the tools and dependencies in the current pipeline be upgraded during the conversion, or should they remain as-is?
- **Capacity Planning:** What is the desired throughput of the Nextflow pipelines in terms of sample processing?
Answering these questions will clarify the scale of the migration and the specific requirements for developing the “new” Nextflow pipelines. Blindly converting the pipelines without addressing these considerations could lead to carrying over outdated practices, technical debt and potentially introducing inefficiencies.
**Getting Started**
Migrating a pipeline to Nextflow involves a structured approach to ensure a seamless transition. Figure 1 shows Zifo’s comprehensive approach to facilitate migrations.
Figure 1: Zifo’s approach to Nextflow pipeline migration
**Step 1. Legacy Pipeline Analysis**
Before beginning development tasks, investing time in understanding the current pipeline is crucial. This upfront effort ensures more accurate planning and reduces the need for revisions later on.
Here are some objectives for this step:
Comprehensive Assessment of the Existing Pipeline**Analyze the Workflow Structure:** Understand the sequence of tasks and how data flows through the pipeline and its tools/modules, giving particular importance to any custom scripts.Create a Detailed Workflow Diagram**Inputs and Outputs:** Identify the inputs (including databases, reference genomes, etc.) required for each step and the expected outputs. **Tools and versions:** Clearly specify each tool used in the workflow, along with the version to ensure compatibility and reproducibility.
**Commands and Parameters:** List the exact commands used in the pipeline, including all parameters.
**Mandatory Parameters:** Highlight which parameters are essential for the pipeline to run correctly.
**Optional Parameters:** Specify optional parameters and their default values, if any.
**Input and Output Folder Structure:** Define a clear structure for input (for samples, reference genomes, etc.) and output directories (e.g., sample-wise or tool-wise).
Computational RequirementsUnderstand the computational requirements of the overall pipeline and individual tools (e.g., input data size, reference data/databases, size of output per sample, file retention, etc.).
**Step 2. Nextflow Pipeline Design & Development**
To ensure smooth development in Nextflow, engaging in preparatory tasks such as creating a workflow diagram and conducting evaluations on the parameters mentioned below will be highly beneficial.
Tools and VersionsClearly specify each tool to be included in the workflow, along with the desired version. The version could be different from the legacy pipeline based on requirements.
In the case of custom scripts, evaluate whether they need to be retained as-is or can be made more efficient using Nextflow operators.SubworkflowsIdentify which of the tools can be logically grouped together in a subworkflow.Using nf-core modules/subworkflowsEvaluate which modules/subworkflows are already available in nf-core and can be reused.Docker/SingularityIdentify the Docker/Singularity containers that can be used. If a container is unavailable for a specific version of a tool, create one and identify the appropriate location to host it.Test DataIdentify the test data required for development, review, and testing. This will include minimal test data for initial stages followed by more realistic datasets for testing the robustness of the pipeline.
**Pipeline Development Prerequisites**
Before moving to the next steps, here are a few final tasks that need to be handled. This approach ensures consistency and helps manage the migration effectively, especially when dealing with a large-scale migration of pipelines.
Set-up**Code Repository:** Set up a version controlled code repository (e.g.,GitHub). **Computational Infrastructure:** Set up a Linux-based computational environment (e.g., on-premises server or AWS EC2 instance). It is useful to have tools like Git, Conda, and Docker permissions set up initially.
Project ManagementAny chosen project management (PM) tool for tracking the progress of the pipeline development can be set up, such as Jira or even a simple Microsoft Excel.Development/Review ProcessA simple process can be defined for developers and reviewers to maintain consistency. This includes establishing naming conventions for Git repository branches, providing comments for commits or pull requests, determining the frequency of commits, and establishing methods to track bugs/enhancements.
Now that you’ve wrapped up the understanding and preparation tasks, it’s time to set timelines and dive into development!
Figure 2: Pipeline Migration Overview
While there isn’t much to elaborate on regarding development itself, given the wealth of open-source training resources available from Seqera for Nextflow pipeline development and deployment on the Seqera Platform, there are several tailored actions you can take to facilitate the process. For instance, creating various accelerators like templates for project management, documentation, and guidelines for best practices in development and review. These not only ensure consistency but also streamline workflows, minimize duplication, and enhance overall efficiency.
**Step 3: Pipeline Review**
Conducting a thorough code review ensures high-quality code by maintaining consistent coding styles, enhancing modularity and reusability, and providing clear error-handling messages that are understandable to end-users.
**Step 4: Testing**
Leverage resources like ‘nf-test’ to write unit tests for Nextflow workflows, implement continuous integration (CI) with GitHub Actions, and test with various parameter combinations to ensure the pipeline functions as expected. Additionally, consider testing with multiple input datasets to evaluate the pipeline’s robustness and gain insights into its computational capabilities, such as the number of samples it can handle and the size of input and output data.
If the Seqera Platform is being used, ensure that the pipeline is deployed and tested on the platform to confirm its compatibility and performance.
After development and multiple review and testing cycles, it’s important to compare your new pipeline with the legacy pipeline to ensure it functions as expected and meets the requirements. This takes us to the next step, Validation.
**Step 5. Validation**
You can define the methods and parameters for validation, such as comparing outputs, computational metrics and more. These criteria should also depend on the goals you set at the start. It’s a smart move to document all your validation results, including the methods and commands used. This is where having a predefined documentation template can make things much smoother, ensuring consistency and ease of use. This step is especially important in clinical settings, where accuracy and consistency are key.
Validation poses various challenges—while some steps may proceed smoothly, others may present hurdles. For instance, comparing the two pipelines exactly is often hindered by intentional modifications in the new pipeline, such as upgrading tool versions, removing sections/tools, or changing how intermediate files are managed during migration.
Despite these challenges, we can navigate them by conducting thorough reviews for accuracy and documenting them. This ensures that any differences are understood and accounted for, leading to a robust validation of the new pipeline’s functionality.
The final step in preparing new pipelines is the all-important documentation phase.
**Step 6. Documentation**
In addition to the validation document mentioned earlier, supplementary documentation needs to provide clear instructions on installing and running the pipeline, along with detailed descriptions of each parameter. This will serve as a comprehensive user manual for the pipeline. If the Seqera Platform is used, it is also helpful to include a quick guide on how to launch the pipeline and configure the necessary options before execution.
Rather than rewriting existing open-source documentation, it’s more efficient to provide links to these resources where relevant. Effective documentation should be designed from the user’s perspective, especially for those who may not have prior experience with Nextflow.
**Step 7. Ready to Release!**
Once validation is successfully completed and all issues are resolved, the pipeline is ready for release. At this stage, it is essential to provide necessary training or documentation to users, monitor the pipeline’s real-time performance, and gather feedback for continuous improvement.
With the right framework in place—from gaining a deep understanding of your current pipeline to meticulous validation and achieving seamless deployment—you’re fully equipped to streamline your processes and confidently embrace the migration journey.
Here’s to successfully converting your legacy pipelines to Nextflow!
If you have any questions or would like support with your pipeline migration or ongoing support, please contact us at
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Stories
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
---
### [Integration Of Internet Of Things (IoT) In Laboratories: Revolutionizing Lab Operations](https://zifo.com/blogs/integration-of-internet-of-things-iot-in-laboratories-revolutionizing-lab-operations/)
**Published:** September 24, 2024
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [Integration Of Internet Of Things (IoT) In Laboratories: Revolutionizing Lab Operations](https://zifo.com/blogs/integration-of-internet-of-things-iot-in-laboratories-revolutionizing-lab-operations/ "Integration Of Internet Of Things (IoT) In Laboratories: Revolutionizing Lab Operations")
## Integration Of Internet Of Things (IoT) In Laboratories: Revolutionizing Lab Operations
Tript Srivastava, Engagement Lead and Lakshmi Nallaperumal, Senior Scientific Application Analyst
Sep 24, 2024
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Integration%20Of%20Internet%20Of%20Things%20%28IoT%29%20In%20Laboratories%3A%20Revolutionizing%20Lab%20Operations%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Fintegration-of-internet-of-things-iot-in-laboratories-revolutionizing-lab-operations%2F "Share on Email")
- [](https://x.com/intent/post?text=Integration%20Of%20Internet%20Of%20Things%20(IoT)%20In%20Laboratories%3A%20Revolutionizing%20Lab%20Operations&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fintegration-of-internet-of-things-iot-in-laboratories-revolutionizing-lab-operations%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Integration+Of+Internet+Of+Things+%28IoT%29+In+Laboratories%3A+Revolutionizing+Lab+Operations&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fintegration-of-internet-of-things-iot-in-laboratories-revolutionizing-lab-operations%2F "Share on LinkedIn")
Image reference: / source
The use of Internet of Things (IoT) technology in laboratories is transforming the way lab operations are carried out. By connecting lab equipment and instruments to a network, IoT facilitates real-time data collection, monitoring, and analysis, leading to enhanced efficiency, accuracy, and productivity. This blog explores the numerous benefits of IoT-enabled lab equipment, real-world applications, and success stories, illustrating how IoT is transforming the modern laboratory landscape.
**What is IoT?**
The Internet of Things (IoT) is a system of connected devices that exchange data with one another over the internet. These devices, embedded with sensors and software, can collect and transmit data, allowing for real-time monitoring, control, and analysis. In a laboratory setting, IoT can connect various lab instruments, equipment, and systems, creating a smart lab environment.
**Benefits of IoT-Enabled Lab Equipment**
**Real-Time Monitoring and Data Collection:**
IoT devices can continuously track lab equipment and environmental factors, delivering real-time data on variables like temperature, humidity, pH levels, and equipment performance. This ensures that experiments and processes are conducted under optimal conditions and allows for the immediate detection of any deviations or anomalies.
**Enhanced Accuracy and Precision:**
Automating data collection and monitoring minimizes the chance of human error, resulting in more precise and dependable outcomes. IoT devices can perform precise measurements and record data with high fidelity, improving the overall quality of lab outputs.
**Improved Efficiency and Productivity:**
By automating routine activities such as data logging, equipment calibration, and maintenance scheduling, IoT allows lab staff to concentrate on more complex and critical tasks. This boosts overall lab productivity and efficiency.
**Predictive Maintenance and Reduced Downtime:**
IoT sensors continuously monitor the condition and efficiency of lab equipment, allowing for the detection of potential failures or maintenance requirements before they arise. This proactive approach minimizes downtime and ensures that lab operations run smoothly without unexpected interruptions.
**Enhanced Data Management and Analysis:**
IoT systems can integrate with Laboratory Information Management Systems (LIMS) and other data management platforms, facilitating seamless data transfer and consolidation. This enables comprehensive data analysis, trend identification, and informed decision-making.
**Regulatory Compliance and Documentation:**
IoT can help labs comply with stringent regulatory requirements by providing automated, accurate, and time-stamped records of all lab activities. This ensures transparency and traceability, which are essential for audits and quality assurance.
**Real-World Applications and Success Stories**
**Smart Environmental Monitoring:**
Environmental monitoring is essential in laboratories where conditions like temperature and humidity can affect the outcomes of experiments. IoT-enabled sensors can continuously track these parameters, sending alerts to lab personnel if conditions deviate from predefined thresholds. For instance, in pharmaceutical labs, maintaining precise environmental conditions is vital for the stability of compounds. IoT ensures these conditions are met, safeguarding the integrity of experimental results.
**Automated Sample Management:**
In research labs handling large volumes of samples, IoT can streamline sample management processes. Smart freezers and storage units equipped with IoT sensors can track sample locations, monitor storage conditions, and manage inventory levels. This minimizes the risk of sample degradation or loss while enhancing traceability. For example, a biotech company might use IoT-enabled storage to ensure that biological samples are kept at optimal temperatures, enhancing the reliability of experimental outcomes.
**Lab Equipment Optimization:**
IoT can optimize both the usage and upkeep of lab instruments such as centrifuges, spectrometers, and microscopes. Sensors can monitor equipment performance, usage patterns, and maintenance needs, allowing labs to schedule maintenance proactively and avoid costly breakdowns. A university research lab, for instance, might use IoT to ensure that shared equipment is functioning efficiently and is readily available when needed.
**Enhanced Safety Protocols:**
Safety is a paramount concern in laboratories, particularly those dealing with hazardous materials. IoT enhances safety by monitoring lab conditions and ensuring adherence to safety regulations. For example, gas sensors can detect harmful leaks and automatically activate alarms and ventilation systems, preventing accidents in chemical labs and ensuring a secure environment for researchers.
**Case Study: IoT in a Clinical Laboratory**
A clinical laboratory specializing in diagnostic testing implemented an IoT system to enhance its operations. IoT-enabled devices were used to monitor the temperature and humidity of storage areas for reagents and samples, ensuring they were kept within strict parameters. The system provided real-time alerts to lab technicians if conditions deviated, allowing for immediate corrective action.
Furthermore, IoT sensors were installed on diagnostic equipment to track performance and anticipate maintenance needs. This proactive approach reduced equipment downtime and ensured that the lab could maintain high throughput and accuracy in its testing processes. As a result, the lab saw a significant improvement in operational efficiency and reliability, leading to faster turnaround times for test results and increased satisfaction among healthcare providers and patients.
**Future Prospects of IoT in Laboratories**
Although IoT integration in labs is still in its early phase, future advancements hold great promise. Emerging technologies like 5G, artificial intelligence (AI), and edge computing will further boost IoT’s potential, making lab operations more advanced and efficient.
- **5G Connectivity:** The deployment of 5G networks will allow faster and more reliable data transmission, enabling smoother connectivity for a larger number of IoT devices in labs. This will enable real-time, high-bandwidth applications such as remote monitoring and control of lab equipment.
- **Artificial Intelligence:** AI can process the massive data streams from IoT devices, uncovering patterns and insights that might go unnoticed by human analysts, leading to breakthroughs in research and optimization of lab workflows.
- **Edge Computing:** By processing data closer to where it’s generated, edge computing decreases delays and bandwidth use, allowing for faster and more efficient real-time data analysis and decision-making in labs.
**Conclusion**
The integration of IoT technology in laboratories is transforming the way lab operations are conducted, offering numerous benefits, such as real-time monitoring, enhanced accuracy, improved efficiency, predictive maintenance, and better data management. Real-world applications and success stories demonstrate the significant impact of IoT in various lab settings, from environmental monitoring to sample management and equipment optimization. As IoT technology continues to advance, the future promises even greater innovations and improvements in laboratory operations, making IoT an essential component of the modern lab landscape.
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
---
### [How ACMG Guidelines And gnomAD Are Aligning To Simplify Variant Interpretation](https://zifo.com/blogs/how-acmg-guidelines-and-gnomad-are-aligning-to-simplify-variant-interpretation/)
**Published:** September 30, 2024
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [How ACMG Guidelines And gnomAD Are Aligning To Simplify Variant Interpretation](https://zifo.com/blogs/how-acmg-guidelines-and-gnomad-are-aligning-to-simplify-variant-interpretation/ "How ACMG Guidelines And gnomAD Are Aligning To Simplify Variant Interpretation")
## How ACMG Guidelines And gnomAD Are Aligning To Simplify Variant Interpretation
Jeanette Mccarthy, Principal Consultant – Variant Interpretation
Sep 30, 2024
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20How%20ACMG%20Guidelines%20And%20gnomAD%20Are%20Aligning%20To%20Simplify%20Variant%20Interpretation%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Fhow-acmg-guidelines-and-gnomad-are-aligning-to-simplify-variant-interpretation%2F "Share on Email")
- [](https://x.com/intent/post?text=How%20ACMG%20Guidelines%20And%20gnomAD%20Are%20Aligning%20To%20Simplify%20Variant%20Interpretation&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fhow-acmg-guidelines-and-gnomad-are-aligning-to-simplify-variant-interpretation%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=How+ACMG+Guidelines+And+gnomAD+Are+Aligning+To+Simplify+Variant+Interpretation&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fhow-acmg-guidelines-and-gnomad-are-aligning-to-simplify-variant-interpretation%2F "Share on LinkedIn")
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Stories
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
**Evolution of the ACMG/AMP variant interpretation guidelines**
Establishing the pathogenicity of variants identified in genes is at the heart of clinical genetic testing. In 2015, the American College of Medical Genetics and Genomics (ACMG) and the Association for Molecular Pathology (AMP) released a set of variant interpretation guidelines that quickly became the industry standard. Over the years, groups like ClinGen have refined these guidelines and are working with a consortium on new standards for interpretation (v4), expected to be published this year or next. Concurrently, databases and other resources used in the application of these guidelines to make inferences about variants have grown and matured.
One of the simplest, yet most powerful indicators that a variant may be benign is the frequency with which it appears in the general, ostensibly healthy population. As many Mendelian disease genes that are targets of genetic testing have high penetrance, the expectation is that pathogenic variants in these genes should be at a low prevalence in the healthy population. Conversely, having a high allele frequency is used as strong evidence toward benign variant classification.
The ACMG 2015 guidelines included three allele frequency criteria. Over the years, more nuance was added to each of these criteria, as outlined in the table below.
CriterionStrengthDefinition / RevisionsBA1Stand alone benign>5% in ExAC, 1K Genomes or EVS databases
Gene-specific cutoffs, Use of subpopulation frequenciesBS1Strong benignFrequency higher than expected for the disorder
Use of subpopulation frequenciesPM2Moderate pathogenicAbsent or at an extremely low frequency in controls
Downgraded strength to supporting
It is expected that a new version of the ACMG variant interpretation guidelines (v4) will be released in 2024/2025. A [preview of those guidelines](https://www.youtube.com/watch?v=4NqVGcPy050) describes a further evolution of the allele frequency criteria. Central to this is the establishment of a disease allele frequency (DAF) that users define for each gene.
One common method to derive DAFs is from population allele frequencies of documented pathogenic variants. The idea is that, with so many genomes sequenced, the most common pathogenic variant in a population will have already been observed and that subsequent pathogenic variants will have a lower frequency.
During variant interpretation, the allele frequency of the variant is assessed against the gene’s DAF to see if any sub-population has a frequency above the DAF threshold. If so, it would support a benign classification. Falling below this threshold will no longer be used as evidence in support of pathogenicity (i.e., PM2 no longer holds weight).
Importantly, the new guidelines also make it easier to reach a classification of Likely Benign. Instead of requiring two pieces of evidence, a single piece of evidence, such as surpassing the DAF, can result in a classification of Likely Benign. This highlights the importance of getting the DAF threshold right.
**gnomAD database**
A decade ago, there were a few relatively small databases of sequence variants in healthy individuals: ExAC, 1K Genomes, EVS. Over time, the Broad Institute’s ExAC database grew and in 2017, they released gnomAD, the largest publicly available database of exomes and genomes from healthy individuals, along with a useful browser. gnomAD V2.1, released a few months later, remains the largest such dataset of variants aligned to the GRCh37 reference genome. gnomAD has since released additional versions of its dataset (V3 and V4) that contain a larger number of individuals from more diverse populations and aligned to the GRCh38 reference genome. gnomAD V4, released in 2023, contains over 800,000 genomes/exomes representing several continental sub-populations and additional diverse ancestry groups.
gnomAD presents global allele frequencies for each variant across the entire gnomAD database. In addition, to facilitate the identification of continental sub-populations with the highest allele frequency, gnomAD displays a new metric for each variant called the Grpmax FAF (this replaces PopMax). It is defined as the maximum credible genetic ancestry group allele frequency, calculated as the lower 95% confidence interval of that population’s allele frequency in gnomAD. If the Grpmax FAF for a variant is above the gene-specific DAF, then it supports the variant being benign. The strength of that support depends on how far above the gene-specific FAF the variant Grpmax FAF falls.
**Impact of migrating to gnomAD V4 for labs**
As labs consider migrating over to gnomAD V4, one pertinent question is whether thresholds set for DAFs and/or BA1/BS2/PM2 need to be revisited. Using DAF thresholds derived from gnomAD V2 and then using gnomAD V4 during variant interpretation could lead to unexpected results.
Fortunately, a review of a handful of CDC Tier 1 genes (table below) found that the Grpmax frequencies are typically less than an order of magnitude different between gnomAD V2 and V4, suggesting there may be little impact. Nonetheless, labs may want to review their BA1/BS2/PM2 thresholds prior to migrating to gnomAD V4 to ensure accurate results.
**Highest pathogenic variant allele frequency in gnomAD for select genes (used to calculate DAF and BA1/BS2/PM2 thresholds)**
The availability of the new Grpmax FAF in gnomAD will make the tasks of both establishing allele frequency thresholds for a given gene and determining whether a given variant surpasses these thresholds much easier.
If you have any questions or if you would like to know more, please contact us at .
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Stories
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
**Categories:** Clinical Genomics
---
### [Value Assurance When Upgrading Your LIMS](https://zifo.com/blogs/value-assurance-when-upgrading-your-lims/)
**Published:** December 6, 2024
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [Value Assurance When Upgrading Your LIMS](https://zifo.com/blogs/value-assurance-when-upgrading-your-lims/ "Value Assurance When Upgrading Your LIMS")
## Value Assurance When Upgrading Your LIMS
Tript Srivastava, Engagement Lead | Insha Ishrat, Associate Business Analyst
Dec 06, 2024
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Value%20Assurance%20When%20Upgrading%20Your%20LIMS%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Fvalue-assurance-when-upgrading-your-lims%2F "Share on Email")
- [](https://x.com/intent/post?text=Value%20Assurance%20When%20Upgrading%20Your%20LIMS&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fvalue-assurance-when-upgrading-your-lims%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Value+Assurance+When+Upgrading+Your+LIMS&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fvalue-assurance-when-upgrading-your-lims%2F "Share on LinkedIn")
Image reference: / source
In the dynamic realm of laboratory management, staying current with technological advancements is key to ensuring efficiency, compliance and optimal performance. Upgrading your Laboratory Information Management System (LIMS) from one version to another (preferably the latest released and stable version) is a strategic move that requires careful planning and execution.
This article describes Zifo’s industry best practices for planning the upgrade of an existing LIMS effectively.
**Step 1: Preliminary Assessment**
**1.1 Assessing the Potential Value of Upgrading LIMS:**
The first step to upgrading a LIMS is to understand the reasons behind the upgrade. Upgrading a LIMS offers significant benefits, including enhanced data management and accuracy, improved compliance and reporting capabilities, increased efficiency and productivity through automation, scalability and flexibility to adapt to changing needs, and advanced security features to protect sensitive data. These improvements collectively ensure a more streamlined, compliant, and secure laboratory environment.
**1.2 Assessing the Potential Costs of Upgrading LIMS:**
When estimating the costs of upgrading a LIMS, organizations should consider several key parameters. These include the initial software and licensing costs, implementation and integration expenses, and training and support costs. Regular maintenance and future upgrade expenses, as well as potential downtime and transition costs, are also important. By evaluating these parameters, an organization can develop a comprehensive estimation of potential value versus potential costs for the LIMS upgrade.
**1.3 Review Release Notes:**
Before initiating the upgrade process, it’s crucial to examine the release notes provided by the LIMS vendor for the new version thoroughly. This phase helps in understanding the updates, improvements, bug fixes, and new features in the latest version. Often, upgrades may involve skipping several versions and jumping directly to a newer one, rather than following a sequential version-to-version path. Having a clear understanding of these updates allows you to anticipate how they might impact your laboratory operations and workflows.
**1.4 System Compatibility Check:**
After reviewing the release notes, the next step is to verify the compatibility of the new LIMS version with your existing infrastructure. This includes assessing compatibility with hardware, operating systems, databases, web application hosting solutions, and any integrated instruments or systems. Additionally, consider the impact on local desktop clients, which are commonly used in many LIMS applications instead of web versions. Ensuring compatibility upfront helps prevent issues or system failures during or after the upgrade process, minimizing downtime and disruptions to laboratory operations.
**1.5 Review Customizations:**
Many laboratories customize their LIMS to suit their specific needs and workflows. It’s crucial to evaluate any customizations in the current LIMS version and check their compatibility with the new version before upgrading. This involves identifying custom code, scripts, or configurations and determining whether they need to be modified or updated for the latest version of LIMS. Additionally, consider whether existing customizations should remain as-is or be replaced with new, out-of-the-box (OOB) features offered by the upgraded version. If opting for the latter, ensure that information from old customizations can be integrated seamlessly or migrated to maintain continuity and functionality.
**1.6 Configuration Planning:**
Collaboration between system administrators, end-users and stakeholders is crucial for planning the configuration of the new LIMS version. This step involves identifying user requirements, workflow preferences and any changes needed to adapt the latest version to the laboratory’s specific needs. Planning configuration changes ahead of time ensures a seamless transition and minimizes operational disruptions.
**Step 2: Backup Existing Data**
**2.1 Backup Existing Data:**
Data is the lifeblood of any laboratory, and ensuring its integrity and safety is paramount during an upgrade. Prior to upgrading, creating a thorough backup of all LIMS data, configurations and user settings is vital. This backup serves as a safety net in case of data loss or corruption during the upgrade process, allowing you to restore your system to its pre-upgrade state if needed.
**Step 3: Configuration and Customization**
**3.1 Restore Customizations:**
After backing up the data, the next step is to restore any necessary customizations based on the previous version. This involves implementing custom code, scripts, or configurations identified during the preliminary assessment. Verify that these customizations are compatible with the new version and function correctly.
**3.2 Implement Configuration Changes:**
Based on configuration planning, apply the identified configuration changes to the new LIMS version. This step involves configuring the system to match user requirements and workflow preferences, ensuring the latest version meets the laboratory’s specific needs.
**Step 4: Test Environment Setup**
**4.1 Create a Test Environment:**
Setting up a controlled test environment is essential for simulating the LIMS upgrade process and identifying potential issues before implementing the upgrade in a production environment. The test environment should closely mimic your production environment, including hardware, software, and configurations, to allow for thorough testing without affecting live operations.
**4.2 Data Migration Testing:**
In the test environment, it’s crucial to conduct comprehensive testing of data migration processes, where applicable, to ensure a smooth transition of existing data to the new version of LIMS. This involves migrating sample data from the existing system to the latest version and verifying that all data is transferred accurately and completely. Testing data migration in a controlled setting helps identify and resolve issues before the upgrade, reducing the risk of data loss or corruption.
**Step 5: Upgrade Execution**
**5.1 Schedule Downtime:**
Planning for downtime is essential to minimize disruptions during the upgrade process. Schedule the upgrade when laboratory operations are least affected, such as during off-hours, site closures or weekends. Communicating the downtime schedule to all stakeholders and end-users helps manage expectations and minimizes inconvenience caused by the upgrade.
**5.2 Execute the Upgrade:**
Upgrade scripts typically include instructions for updating the database schema, modifying application code, and implementing any other changes required for the new version. Carefully following the upgrade scripts ensures that the process is executed correctly and efficiently, reducing the risk of errors or complications. Additionally, it is critical to identify a rollback or exit strategy in case of unexpected errors or failures that cannot be resolved immediately. This strategy provides a contingency plan to revert the system to its pre-upgrade state, minimizing disruptions to laboratory operations.
**Step 6: Testing and Validation**
**6.1 Functional Testing:**
After completing the upgrade, conduct comprehensive functional testing to ensure all LIMS features and functionalities work as expected. This involves testing various modules, workflows, and user interactions to identify any issues introduced during the upgrade process. Functional testing ensures the upgraded LIMS meets the requirements and expectations of end-users and stakeholders.
**6.2 User Acceptance Testing (UAT):**
Engaging end-users in user acceptance testing (UAT) ensures the upgraded LIMS meets their needs and expectations. End-users should be allowed to test the system in a real-world environment and provide feedback on usability, performance, and functionality. Incorporating user feedback during UAT helps identify areas for improvement and ensures the upgraded LIMS meets the needs of its primary users.
**6.3 Computer System Validation (CSV):**
Performing Computer System Validation (CSV) is essential to ensure the upgraded LIMS complies with regulatory requirements and standards. A phased approach is recommended, starting with full validation in the test environment, followed by minimal UAT or Performance Qualification (PQ) and smoke testing in the production environment.
Since many tests cannot be performed in the live production environment, completing validation in the test environment helps identify issues while ensuring production stability. This strategy allows for thorough testing while minimizing disruptions to laboratory operations.
If the system is already validated, it is also crucial to evaluate existing validation documentation, including functional specifications, design specifications, system architecture, risk assessments, Installation Qualification (IQ), Operational Qualification (OQ), change management processes, and backup/recovery procedures. Review and update these artifacts to ensure comprehensive validation and compliance.
**Step 7: Communicating Changes and Training for the Upgraded LIMS**
**7.1 Communicate Changes:**
Before rolling out the upgraded LIMS, it’s essential to communicate any changes or new features introduced in the latest version to all stakeholders and end-users. This helps manage expectations and prepares users for necessary adjustments to their workflows or processes.
**7.2 Training Sessions:**
Conducting training sessions before the Go-Live for end-users is essential to ensure a smooth transition to the upgraded LIMS. Training should cover new features, workflow changes, and any other updates relevant to end-users’ roles and responsibilities. Providing comprehensive training helps users adapt to the changes more quickly and reduces the risk of errors or confusion during the transition.
**Step 8: Rollout and Post-Implementation Support**
**8.1 Gradual Rollout:**
A gradual rollout can be beneficial during initial system implementation, allowing end-users to adjust over time. However, this approach may not always be feasible for upgrades, especially those with complex integrations. Many customers prefer a full system upgrade over a phased approach to avoid potential integration issues. Although a phased rollout may not always be practical for upgrades, consulting Subject Matter Experts (SMEs) is crucial to determine the best approach based on the system’s complexity and operational requirements.
**8.2 Post-Implementation (Hypercare) Support:**
Establishing a support system for post-implementation issues ensures a smooth transition to the upgraded LIMS. This may include providing a helpdesk or support hotline for users to report problems or ask questions and assigning dedicated support staff to address technical or operational challenges. Prompt and effective post-implementation support minimizes downtime and helps ensure users resolve issues quickly.
**Step 9: Documentation and Communication**
**9.1 Documentation:**
Documenting the entire upgrade process is crucial for future reference and troubleshooting. This includes configurations, customizations, upgrade procedures, and user manuals. Comprehensive documentation ensures that relevant information is readily available for ongoing maintenance and troubleshooting of the upgraded LIMS.
**9.2 Post-Upgrade Communication:**
Effectively communicating the successful upgrade to stakeholders and end-users is essential for fostering transparency and accountability. This includes notifying them of the upgrade’s completion, providing guidance on accessing new features, and addressing common queries or concerns. Clear and timely communication ensures all stakeholders reamin informed and engaged throughout the upgrade process.
**Step 10: Continuous Monitoring and Optimization**
**10.1 Implement Necessary Refinements and Improvements:**
Continuous improvement involves enhancing the technical aspects of the LIMS and leveraging captured data for data-driven decision-making to optimize system performance, data management, and user experience. This approach identifies opportunities for improvement in both business and laboratory processes, ensuring the LIMS evolves to meet changing needs. Additionally, incorporating data management principles and FAIR data (Findable, Accessible, Interoperable, and Reusable) increases the value and accessibility of laboratory data, supporting more effective analysis and decision-making.
**Conclusion:**
Upgrading your LIMS from one version to another is a strategic investment in the efficiency and longevity of your laboratory operations. By following the foundational steps outlined in this guide, laboratories can navigate the intricacies of the upgrade process, ensuring a seamless transition and reaping the benefits of the enhanced features and functionalities offered by the latest LIMS version.
If you have any questions or would like to discuss LIMS upgrades further, please get in touch at .
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
---
### [High-Performance Computing For AI](https://zifo.com/blogs/high-performance-computing-for-ai/)
**Published:** December 23, 2024
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [High-Performance Computing For AI](https://zifo.com/blogs/high-performance-computing-for-ai/ "High-Performance Computing For AI")
## High-Performance Computing For AI
Debrup Mazumdar, Senior Consultant
Dec 23, 2024
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20High-Performance%20Computing%20For%20AI%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Fhigh-performance-computing-for-ai%2F "Share on Email")
- [](https://x.com/intent/post?text=High-Performance%20Computing%20For%20AI&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fhigh-performance-computing-for-ai%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=High-Performance+Computing+For+AI&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fhigh-performance-computing-for-ai%2F "Share on LinkedIn")
Image reference: / source
**High-Performance Computing for AI: Revolutionizing Public Cloud and Healthcare**
In recent years, artificial intelligence (AI) has evolved from a futuristic concept into an integral part of various industries, driving innovation and enhancing efficiencies. Central to AI’s success is high-performance computing (HPC), which provides the computational power necessary to train complex models and process vast amounts of data. In this blog, we’ll explore how HPC powers AI, its use in public clouds like AWS, and its transformative impact on industries such as healthcare.
**The Need for High-Performance Computing in AI**
AI, particularly deep learning, relies on processing massive datasets and training complex neural networks. This process is computationally intensive, requiring substantial processing power, memory, and storage. HPC addresses these demands by combining multiple processors and nodes into clusters that work in parallel, drastically reducing the time required to perform large-scale computations.
**For AI tasks, HPC enables:**
- **Faster Model Training:** Accelerating the training process for machine learning models, allowing researchers and developers to iterate quickly and improve model accuracy.
- **Real-Time Data Processing:** Handling real-time data streams for applications like autonomous vehicles, real-time fraud detection, and predictive maintenance.
- **Complex Simulations:** Running intricate simulations for industries such as pharmaceuticals, where AI models can simulate molecular interactions to discover new drugs.
HPC and AI in Public Cloud: The Role of AWS
Public cloud platforms like Amazon Web Services (AWS) have democratized access to HPC for AI by offering scalable, on-demand infrastructure that organizations can leverage without the need to invest in expensive on-premises hardware.
**AWS provides a suite of services tailored for AI workloads:**
- **Amazon EC2 Instances:** AWS offers specialized EC2 instances equipped with powerful GPUs (such as NVIDIA V100 and A100) that are optimized for deep learning and HPC tasks. These instances can be scaled up or down based on application needs.
- **AWS Lambda and SageMaker:** For developers and data scientists, AWS offers tools such as Lambda for serverless computing and SageMaker for building, training, and deploying machine learning models at scale.
- **Elastic Kubernetes Service (EKS):** For organizations adopting containerized AI workloads, EKS simplifies the deployment of Kubernetes clusters that manage AI models, ensuring efficient resource allocation and scalability.
- **AWS Batch:** For batch processing of large-scale data, AWS Batch provides fully managed services capable of running thousands of jobs simultaneously, making it ideal for AI training jobs that require substantial compute resources.
By using AWS, businesses can avoid the high capital expenditure associated with on-premises HPC infrastructure while gaining the flexibility to scale resources up or down based on demand.
**The Impact of High-Performance Computing on Public Cloud and Healthcare**
The convergence of HPC, AI, and the public cloud is particularly transformative in healthcare, where data-driven insights can save lives and improve patient outcomes.
1. **Accelerating Drug Discovery:** HPC enables AI models to analyze vast datasets of chemical compounds, predict their interactions, and identify potential new drugs more quickly than traditional methods, expediting the drug discovery process and bringing new treatments to market faster.
2. **Personalized Medicine:** AI powered by HPC can analyze genetic data to provide personalized treatment plans tailored to an individual’s genetic makeup. Public cloud platforms provide the computational resources needed to process and analyze this data at scale.
3. **Medical Imaging:** HPC in the cloud allows AI models to process and interpret medical images quickly, aiding in the early detection of diseases like cancer. Cloud platforms enable healthcare providers to deploy these AI models globally, ensuring consistent and accurate diagnoses regardless of location.
4. **Telemedicine and Remote Monitoring:** With the rise of telemedicine, AI-driven remote monitoring systems can analyze real-time patient data to predict potential health issues before they become critical. HPC in the cloud ensures that these systems can scale to handle data from millions of patients simultaneously.
5. **Operational Efficiency:** Beyond direct patient care, AI and HPC improve healthcare operations by optimizing scheduling, supply chain management, and resource allocation, ultimately reducing costs and improving service delivery.
**Conclusion:**
High-performance computing is the backbone of AI, providing the raw computational power needed to process vast amounts of data and train complex models. With the advent of public cloud platforms like AWS, organizations can now access this power on-demand, enabling rapid innovation and scaling in industries like healthcare.
As AI continues to evolve, the synergy between HPC, public cloud, and AI will unlock new possibilities, driving transformative changes in how we diagnose, treat, and manage health worldwide.
If you have any questions or would like to discuss High-Performance Computing for AI further, please get in touch at .
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
---
### [AI In The Pharmaceutical And Biotech Industries – Private or Public Cloud?](https://zifo.com/blogs/ai-in-the-pharmaceutical-and-biotech-industries-private-or-public-cloud/)
**Published:** December 23, 2024
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [AI In The Pharmaceutical And Biotech Industries – Private or Public Cloud?](https://zifo.com/blogs/ai-in-the-pharmaceutical-and-biotech-industries-private-or-public-cloud/ "AI In The Pharmaceutical And Biotech Industries – Private or Public Cloud?")
## AI In The Pharmaceutical And Biotech Industries – Private or Public Cloud?
Debrup Mazumdar, Senior Consultant
Dec 23, 2024
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20AI%20In%20The%20Pharmaceutical%20And%20Biotech%20Industries%20%E2%80%93%20Private%20or%20Public%20Cloud%3F%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Fai-in-the-pharmaceutical-and-biotech-industries-private-or-public-cloud%2F "Share on Email")
- [](https://x.com/intent/post?text=AI%20In%20The%20Pharmaceutical%20And%20Biotech%20Industries%20–%20Private%20or%20Public%20Cloud%3F&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fai-in-the-pharmaceutical-and-biotech-industries-private-or-public-cloud%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=AI+In+The+Pharmaceutical+And+Biotech+Industries+%E2%80%93+Private+or+Public+Cloud%3F&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fai-in-the-pharmaceutical-and-biotech-industries-private-or-public-cloud%2F "Share on LinkedIn")
Image reference: / source
In the pharmaceutical and biotech industries, the adoption of artificial intelligence (AI) is transforming how companies approach drug development, precision medicine, and other critical areas. However, one of the most crucial decisions when implementing AI solutions is choosing the right cloud environment—public, private, or a combination of both. This choice significantly impacts everything from scalability and cost to security and compliance, especially in the context of pre-clinical stages and beyond.
**Public Cloud:** **Scalability and Flexibility**
Public cloud platforms, such as Amazon Web Services (AWS) and Microsoft Azure, offer unparalleled scalability, making them a top choice for AI projects that involve large datasets and require extensive computational power. These platforms are ideal for biotech firms that experience fluctuating workloads, enabling them to scale resources up or down as needed. The pay-as-you-go model of public cloud services is particularly advantageous for companies looking to manage costs efficiently while maintaining the flexibility to deploy AI-driven initiatives rapidly.
For biotech and pharmaceutical companies, this flexibility is crucial. AI models used in drug discovery or patient data analysis often require bursts of high computational power, which public clouds can provide without the need for upfront investment in physical infrastructure. Moreover, the ability to integrate seamlessly with other advanced services, such as machine learning frameworks and big data analytics tools, further enhances the appeal of public cloud environments.
**Private Cloud:** Security and Compliance
While the public cloud offers flexibility, the private cloud stands out for its enhanced security and compliance capabilities. In the pharmaceutical industry, where handling sensitive patient data and adhering to strict regulatory standards is non-negotiable, a private cloud environment offers the control and protection needed to ensure compliance. Although the initial investment in private cloud infrastructure is higher, it can lead to long-term savings and a more controlled environment for consistent, large-scale AI operations.
Private cloud environments allow organizations to maintain full control over their data, which is critical for protecting intellectual property and ensuring that AI models and datasets remain secure. This is particularly important in an industry where the stakes are high, and data breaches or regulatory non-compliance can result in significant financial and reputational damage.
**Local Hosting:** Maximum Control, High Resource Demands
An alternative to public and private clouds is local hosting, where AI models like ChatGPT are run on-premises. This option provides the highest level of control over data and operations, making it a viable choice for pharmaceutical and biotech companies that handle extremely sensitive information. Local hosting can enhance data privacy and ensure that AI operations are fully aligned with internal security protocols.
However, the trade-offs are significant. Running AI models on-premises requires substantial computational resources, including high-end hardware, specialized software, and ongoing maintenance. This approach is generally feasible only for organizations with the technical expertise and financial resources to support it, limiting its adoption to larger companies or those with specific needs that cannot be met by cloud solutions.
**Finding the Right Balance**
For biotech and pharma companies, the decision between public cloud, private cloud, and local hosting should be guided by a careful assessment of their specific needs. Public cloud environments excel in flexibility and are ideal for projects with variable workloads. Private clouds offer a more secure and stable environment, suitable for handling sensitive data and ensuring compliance with industry regulations. Local hosting, while resource-intensive, provides the highest level of control, making it an option for organizations with the necessary infrastructure and expertise.
Ultimately, striking the right balance between these options is key to driving innovation in drug development and precision medicine. By aligning AI deployments with both operational requirements and regulatory demands, companies can pave the way for groundbreaking advancements while maintaining the highest standards of data security and compliance.
**Conclusion**
As AI continues to shape the future of the pharmaceutical and biotech industries, how is your organization leveraging these technologies?
Are you hosting AI models like ChatGPT on a private cloud for enhanced security, or are you taking advantage of the scalability offered by the public cloud? Or perhaps you’re investing in local hosting to achieve maximum control over your data? The decisions you make today will define your organization’s ability to innovate and succeed in this rapidly evolving landscape.
If you have any questions or would like to discuss AI model hosting further, please get in touch at
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
---
### [Revolutionizing Site Reliability Engineering (SRE) With Large Language Models (LLMs)](https://zifo.com/blogs/revolutionizing-site-reliability-engineering-sre-with-large-language-models-llms/)
**Published:** December 23, 2024
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [Revolutionizing Site Reliability Engineering (SRE) With Large Language Models (LLMs)](https://zifo.com/blogs/revolutionizing-site-reliability-engineering-sre-with-large-language-models-llms/ "Revolutionizing Site Reliability Engineering (SRE) With Large Language Models (LLMs)")
## Revolutionizing Site Reliability Engineering (SRE) With Large Language Models (LLMs)
Debrup Mazumdar, Senior Consultant
Dec 23, 2024
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Revolutionizing%20Site%20Reliability%20Engineering%20%28SRE%29%20With%20Large%20Language%20Models%20%28LLMs%29%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Frevolutionizing-site-reliability-engineering-sre-with-large-language-models-llms%2F "Share on Email")
- [](https://x.com/intent/post?text=Revolutionizing%20Site%20Reliability%20Engineering%20(SRE)%20With%20Large%20Language%20Models%20(LLMs)&url=https%3A%2F%2Fzifo.com%2Fblogs%2Frevolutionizing-site-reliability-engineering-sre-with-large-language-models-llms%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Revolutionizing+Site+Reliability+Engineering+%28SRE%29+With+Large+Language+Models+%28LLMs%29&url=https%3A%2F%2Fzifo.com%2Fblogs%2Frevolutionizing-site-reliability-engineering-sre-with-large-language-models-llms%2F "Share on LinkedIn")
Image reference: / source
Site Reliability Engineering (SRE) is a cornerstone of modern software operations, ensuring reliability, performance, and scalability in increasingly complex systems. However, traditional SRE practices often require intensive manual effort, which can introduce inefficiencies and errors. The advent of Large Language Models (LLMs) offers transformative potential for automating and optimizing SRE processes, pushing the discipline into a new era of innovation and efficiency.
**What Are LLMs and How Do They Assist SRE?**
LLMs are advanced AI models trained on extensive datasets, capable of understanding and generating human-like text, including programming languages. By leveraging neural network architectures, these models can identify patterns in data and provide actionable insights. This versatility makes them highly effective in automating SRE workflows, addressing tasks ranging from code optimization to system monitoring.
**Key Applications of LLMs in SRE**
1. **Automating Critical Tasks:** 1.1. Code Reviews: LLMs can analyze code changes, flag potential issues, and suggest improvements, thereby reducing the need for manual intervention.
1\. 2.Documentation: Automating the creation and updating of technical documents ensures consistency and saves time.1. 3.Troubleshooting and Debugging: LLMs can process logs, detect error patterns, and recommend solutions to common issues.
2. **Optimizing Performance:** 2.1. Experimentation and Microservices: LLMs enable faster hypothesis testing and streamline microservice architectures by suggesting dependency changes or version upgrades.
2.2. Performance Bottlenecks: By analyzing system metrics, LLMs identify areas for optimization and generate code snippets to address inefficiencies.
3. **Enhancing Observability and Deployment:** 3.1. Observability: LLMs aid in crafting monitoring queries, setting alerts, and spotting anomalies in real time.
3.2. Deployment: Automating deployment runbooks and configuration scripts accelerates release cycles and minimizes human error.
**Steps to Incorporate LLMs into SRE Practices**
Integrating LLMs into SRE requires careful planning and execution. Here’s a roadmap:
1. Educate SRE Teams: Equip teams with the knowledge to utilize LLM capabilities effectively.
2. Identify Use Cases: Focus on tasks where LLMs can offer maximum impact, such as repetitive operations or large-scale analysis.
3. Evaluate Solutions: Choose between third-party tools and in-house development based on your organization’s needs and scalability goals.
4. Ensure Privacy and Ethics: Establish protocols to address biases, security, and ethical concerns in AI deployment.
5. Integrate via APIs: Standardized API integrations can seamlessly connect LLMs to existing systems.
6. Monitor and Iterate: Continuously assess the performance of LLM-driven workflows to refine their effectiveness.
**Benefits and Future Implications**
Integrating LLMs into SRE workflows can significantly reduce toil, improve operational efficiency, and accelerate digital transformation. By enabling predictive analytics and fostering collaborative optimization, these models pave the way for smarter, more resilient systems. However, addressing challenges such as training biases and ethical usage is essential for sustainable implementation.
As organizations embrace LLMs, they unlock new possibilities for innovation and competitiveness. With advancements in AI reshaping the landscape, SRE practices powered by LLMs are set to redefine software reliability and operational excellence for years to come.
If you have any questions or would like to discuss LLMs further, please get in touch at
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
---
### [The Evolution Of TechOps](https://zifo.com/blogs/the-evolution-of-techops/)
**Published:** December 23, 2024
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [The Evolution Of TechOps](https://zifo.com/blogs/the-evolution-of-techops/ "The Evolution Of TechOps")
## The Evolution Of TechOps
Debrup Mazumdar, Senior Consultant
Dec 23, 2024
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20The%20Evolution%20Of%20TechOps%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Fthe-evolution-of-techops%2F "Share on Email")
- [](https://x.com/intent/post?text=The%20Evolution%20Of%20TechOps&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fthe-evolution-of-techops%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=The+Evolution+Of+TechOps&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fthe-evolution-of-techops%2F "Share on LinkedIn")
Image reference: / source
In the fast-paced world of pharmaceuticals, staying ahead isn’t just about innovation in drug development—it’s about leveraging technology to streamline operations and enhance efficiency.
One of our clients, a global leader in the pharma industry, recognized the need to evolve its TechOps capabilities to meet increasing demands for integration, automation, and seamless collaboration.
This is where Zifo partnered with the client to provide the expertise needed for this transformation.
**Zifo Continues to Be the Preferred Partner for Our Clients in Driving TechOps Transformation**
Our client faced significant challenges in finding Tech Leads and Tech Analysts with deep expertise in full-stack development, DevOps, integration, cloud, private cloud infrastructure hosting, and enterprise architecture. The company’s complex technological landscape and growing demand for operational efficiency required more than just incremental improvements—it demanded a full-scale transformation.
Zifo’s TechOps team, equipped with these key capabilities, stepped in as Tech Leads and Tech Analysts to drive critical changes across multiple projects.
**Designing and Integrating Downstream Applications**
One of the primary objectives was the seamless integration of the client’s complex network of downstream applications. Zifo implemented DevOps pipelines that automated deployment processes, significantly reducing manual intervention and enabling faster, more reliable updates.
With the introduction of automated testing, we minimized errors, accelerated feedback loops, and ensured consistent quality throughout the development lifecycle.
**Collaborating with Key Stakeholders**
This transformation was not solely technological—it was about fostering collaboration. Zifo’s TechOps team worked closely with ITSOs, platform architects, and other key stakeholders to align the tech transformation with the client’s broader business and compliance objectives.
Through regular touchpoints and transparent communication, the team adapted quickly to evolving requirements, ensuring that each project was delivered seamlessly.
**Optimizing Cloud Costs with FinOps Practices**
As the client’s technology infrastructure expanded, optimizing cloud costs became a priority. By applying FinOps practices, Zifo monitored resource usage in real time and made necessary adjustments to optimize spending without compromising performance.
Our client’s leadership team was impressed with the significant cost savings and operational efficiencies delivered through our approach.
**Embedding Security with DevSecOps**
Given the sensitive nature of the pharmaceutical industry, security was another critical focus. By adopting DevSecOps principles, we embedded security practices into every phase of the development pipeline.
This proactive approach ensured that the client’s data and systems remained secure while adhering to stringent regulatory requirements.
**The Transformative Impact of TechOps on Our Client**
The impact of this TechOps transformation was profound. Our client’s TechOps team evolved from simply maintaining systems to becoming a strategic enabler of innovation, resilience, and efficiency.
Our team’s efforts ensured that the client’s technology infrastructure wasn’t just functional—it was scalable, secure, and optimized for the future.
**A Cornerstone of Our Client’s Success**
In the fast-evolving world of technology and pharmaceuticals, the client’s TechOps journey demonstrates the importance of leadership, collaboration, and embracing change.
Zifo’s partnership with our client helped establish TechOps as a cornerstone of the company’s ongoing success, driving operational excellence and positioning our client for continued growth and innovation.
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
---
### [Foundational Models In Single-Cell Omics](https://zifo.com/blogs/foundational-models-in-single-cell-omics/)
**Published:** January 24, 2025
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [Foundational Models In Single-Cell Omics](https://zifo.com/blogs/foundational-models-in-single-cell-omics/ "Foundational Models In Single-Cell Omics")
## Foundational Models In Single-Cell Omics
Agniruudrra R. Sinha, Bioinformatics Analyst | Mohamed Kassam, Head of Bioinformatics
Jan 24, 2025
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Foundational%20Models%20In%20Single-Cell%20Omics%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Ffoundational-models-in-single-cell-omics%2F "Share on Email")
- [](https://x.com/intent/post?text=Foundational%20Models%20In%20Single-Cell%20Omics&url=https%3A%2F%2Fzifo.com%2Fblogs%2Ffoundational-models-in-single-cell-omics%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Foundational+Models+In+Single-Cell+Omics&url=https%3A%2F%2Fzifo.com%2Fblogs%2Ffoundational-models-in-single-cell-omics%2F "Share on LinkedIn")
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Stories
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
**A New Era of Biological Understanding**
The field of single-cell omics has been revolutionized by the advent of foundational models, ushering in a new era of biological understanding and analysis. These powerful machine learning tools are transforming how we interpret and utilize the vast amounts of data generated by single-cell technologies, offering unprecedented insights into cellular biology and gene expression patterns.
**What Are Foundational Models in Single-Cell Omics?**
Foundational models in single-cell omics are large-scale machine learning models, typically based on transformer architectures, that are pretrained on massive datasets of single-cell and spatial transcriptomics data \[1\]. These models aim to learn a unified cell representation that captures complex relationships between genes and cells across various tissues and conditions.
Figure 1: Foundational models in omics analysis: A snapshot of their diverse applications and basic steps.
A deep dive into foundational models reveals their technical marvels. Transformer architectures, originally designed for natural language processing, have been adapted for single-cell data analysis. In these models, each cell is treated as a “sentence,” with its genes representing “words.” The models use special tokens to denote cell identity and position, with gene expression values often encoded as rank values. This approach allows the model to capture the complex interplay of gene expression patterns within a cell. The self-attention mechanism in transformers enables the model to consider the relationships between all genes simultaneously, making it particularly well-suited for capturing the intricate dependencies in biological systems.
Transformer architectures in single-cell omics models have been further refined to handle the unique challenges of biological data. The self-attention mechanism has been adapted to capture gene-gene interactions, treating genes as tokens and computing attention scores between them. This allows the model to identify influential genes for predicting others’ expression, effectively modeling gene interaction networks. Some models, like scMoFormer, employ multiple transformers to handle different data modalities, with a cross-modality aggregation component bridging these transformers. To address computational challenges, linearized transformers have been implemented to reduce complexity when dealing with large numbers of cells.
Additionally, these models often incorporate domain-specific knowledge about genes and proteins, enhancing their biological relevance. The tokenization of gene expression data, where each cell is represented as a sequence of gene tokens ordered by relative expression levels, helps preserve gene-gene relationships while mitigating technical batch effects. This sophisticated approach enables foundational models in single-cell omics to capture complex patterns across various cell types and conditions, leading to improved performance in tasks such as cell type annotation, gene regulatory network inference, and prediction of cellular responses to perturbations.
**Key characteristics of these models include:**
1. Large-scale pretraining: Models like scFoundation and Nicheformer are trained on tens of millions of cells from diverse tissues and organisms \[2\].
2. Multimodal integration: Some models, such as scGPT and Nicheformer, combine data from both dissociated single-cell and spatial transcriptomics or proteomics technologies \[3\].
3. Flexible architecture: Most models utilize transformer-based architectures, allowing them to capture complex contextual relationships among genes \[3\].
4. Transfer learning capabilities: These models can be fine-tuned or used for zero-shot learning on various downstream tasks \[3\].
**Use Cases**
Use caseDescriptionModelsCell Type AnnotationModels can accurately classify cells into different types based on their gene expression profilesscGPT, Geneformer, scaLRMulti Batch IntegrationFoundational models excel at integrating data from multiple experimental batches, reducing technical variabilityCOSMOS, scGPT, GeneformerPerturbation Response PredictionThese models can predict how cells will respond to various perturbations, such as drug treatments or genetic modificationsscGPT, GeneformerGene Network InferenceBy capturing complex relationships between genes, these models can help to infer gene regulatory networksscGPT, GeneformerSpatial AnalysisPredict spatial context and composition, enabling the transfer of rich spatial information to scRNA-seq datasetsNicheformer, COSMOS
**Challenges**
1. Computational resources: These models can be very resource-intensive, often requiring multiple GPUs to train and run \[5\].
2. Interpretability and explainable AI: Foundational models, while state-of-the-art, might fall victim to the “black box” phenomenon. Developing explainable AI methods is crucial for deeper biological insights.
3. Data quality and bias: As with all machine learning models, the quality of output depends on the quality of input data. These models require heavy preprocessing and their robustness depends on the diversity of the training data.
4. Training data diversity: The quality and diversity of the training data are crucial for developing robust and unbiased models.
**Emerging Trends**
1. Graph-based models: Integrating graph-based approaches with foundational models shows promise for capturing cellular heterogeneity and molecular patterns more effectively. Previous deep learning and graph-based approaches like DeepMAPS have shown great success in identifying gene networks \[7\]. Incorporating foundational models can enhance these approaches to provide more comprehensive representations of cellular interactions and gene regulatory networks.
2. Extensive feature selection: Models like scaLR drastically reduce computational resources by selecting only the most important features for analysis \[6\].
3. Multimodal integration: Future models are likely to incorporate even more diverse data types, including proteomics and epigenomics data \[3\].
4. Spatial Awareness: Models like Nicheformer are paving the way for spatially aware representations of cellular variation at scale \[4\].
**Conclusion**
Foundational models mark a pivotal advancement in single-cell omics analysis. These sophisticated tools, built on extensive datasets and cutting-edge machine learning, offer unparalleled insights into cellular biology. As this field progresses, we anticipate the emergence of increasingly powerful and adaptable models. These innovations will significantly enhance our comprehension of intricate biological systems and catalyze breakthroughs in biomedical research and drug development.
Please reach out to the Zifo Bioinformatics team, info@zifo.com, to set up a discussion about your research and application requirements. We are more than happy to arrange a call to explore your scientific needs in more detail.
**References:**
1.
2. Hao, M., Gong, J., Zeng, X., Liu, C., Guo, Y., Cheng, X., Wang, T., Ma, J., Zhang, X., Song, L. Large-scale foundation model on single-cell transcriptomics. Nat Methods. 2024 Aug;21(8):1481-1491. doi: 10.1038/s41592-024-02305-7. Epub 2024 Jun 6. PMID: 38844628.
3. Cui, H., Wang, C., Maan, H. et al. scGPT: toward building a foundation model for single-cell multi-omics using generative AI. Nat Methods 21, 1470–1480 (2024).
4. Schaar, A. C., Tejada-Lapuerta, A., Palla, G., Gutgesell, R., Halle, L., Minaeva, M., Vornholz, L., Dony, L., Drummer, F., Bahrami, M., & Theis, F. J. (2024). Nicheformer: a foundation model for single-cell and spatial omics. bioRxiv.
5. Ma, Q., Jiang, Y., Cheng, H. et al. Harnessing the deep learning power of foundation models in single-cell omics. Nat Rev Mol Cell Biol 25, 593–594 (2024).
6. Jogani, S., Pol, A.S., Prajapati, M., Samal, A., Bhatia, K., Parmar, J., Patel, U., Shah, F., Vyas, N., Gupta, S. (2024). scaLR: A low-resource deep neural network-based platform for single cell analysis and biomarker discovery. bioRxiv: [https://doi.org/10.1101/2024.09.19.613226.](https://doi.org/10.1038/s41580-024-00756-6)
7. Ma, A., Wang, X., Li, J. et al. Single-cell biological network inference using a heterogeneous graph transformer. Nat Commun 14, 964 (2023).
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Stories
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
**Categories:** Bioinformatics
---
### [ACMG V4 Draft Preview: Transformative Changes In Variant Classification](https://zifo.com/blogs/acmg-v4-draft-preview-transformative-changes-in-variant-classification/)
**Published:** April 4, 2025
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [ACMG V4 Draft Preview: Transformative Changes In Variant Classification](https://zifo.com/blogs/acmg-v4-draft-preview-transformative-changes-in-variant-classification/ "ACMG V4 Draft Preview: Transformative Changes In Variant Classification")
## ACMG V4 Draft Preview: Transformative Changes In Variant Classification
Apr 04, 2025
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20ACMG%20V4%20Draft%20Preview%3A%20Transformative%20Changes%20In%20Variant%20Classification%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Facmg-v4-draft-preview-transformative-changes-in-variant-classification%2F "Share on Email")
- [](https://x.com/intent/post?text=ACMG%20V4%20Draft%20Preview%3A%20Transformative%20Changes%20In%20Variant%20Classification&url=https%3A%2F%2Fzifo.com%2Fblogs%2Facmg-v4-draft-preview-transformative-changes-in-variant-classification%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=ACMG+V4+Draft+Preview%3A+Transformative+Changes+In+Variant+Classification&url=https%3A%2F%2Fzifo.com%2Fblogs%2Facmg-v4-draft-preview-transformative-changes-in-variant-classification%2F "Share on LinkedIn")
Image reference: / source
The field of clinical genomics continues to evolve, and with it, the guidelines for variant classification must adapt to ensure accuracy, consistency, and clarity. The Zifo Clinical Genomics team recently attended ClinGen’s workshop, Overview of DRAFT ACMG/AMP v4 Sequence Variant Guidelines, as well as the ACMG 2025 Clinical Genomics Meeting. These sessions provided valuable insights into the upcoming ACMG v4 guidelines. In this blog, we highlight key observations and updates compared to the previous version.
**Key Insights**
One of the most notable advancements is the complete overhaul of evidence codes assigned to each attribute. These codes have been redesigned to more intuitively reflect the core concept of each attribute, making the classification framework more concept-driven, user-friendly and precise in guiding variant classification.
While the foundational concepts remain largely intact, the current revision has streamlined the evidence structure by consolidating overlapping codes. For example, the previously separate codes PS2 and PM6, both relating to de novo probands, have now been merged into a single unified code—OBS\_DNV. This change not only simplifies the application of the guidelines but also reduces the risk of double counting evidence, thereby enhancing the accuracy of variant classification. Furthermore, unlike earlier versions where evidence codes carried fixed strengths, the new framework assigns flexible point ranges based on context, allowing for a more nuanced and dynamic evaluation.
The structure of evidence codes has also undergone a substantial evolution. The v3 evidence codes were grouped into eight separate evidence concepts, often resulting in related codes being scattered across categories without restrictions on combined usage. To address this, v4 introduces a “Hierarchical Structure of Evidence,” providing a clear framework that prevents redundancy and double counting. This hierarchy is organized into four levels: Evidence Category > Evidence Concept > Evidence Code > Code Components, each with its own sub-branching as required. A point cap system is applied across all these levels (currently under development,) to ensure that overlapping evidence does not inflate scoring. Rather than assigning fixed strengths to codes, the framework now uses continuous Bayesian point-based scoring, determined through detailed code-specific tables and flowcharts.
While the definition at the “code component” level is still under development, the high-level updates are likely to spark curiosity and surprise upon first encounter. With respect to allele frequency, v4 introduces a significant advancement by recommending customized cutoffs tailored to each gene, recognizing that gene characteristics and prevalence can vary widely. Furthermore, v4 recommends checking splicing effects for all amino acid changes and integrating functional data with predictive data. It also advances the framework by incorporating seven extensive flow diagrams, each systematically outlining end-to-end guidance detailing each step for evaluating predictive data.
Another major refinement is the heightened focus on gene-disease association as a primary criterion for reporting pathogenic variants. To classify a variant as Likely Pathogenic (LP), a minimum of moderate gene-disease association is now required. Conversely, variants associated with disputed or refuted relationships are excluded from reporting, regardless of their classification. This clear distinction improves the reliability of variant classification, ensuring that patients receive more accurate and definitive diagnoses.
One of the pivotal and most exciting advancements is the introduction of Variant of Uncertain Significance (VUS) subclassification, aimed at enhancing clarity in clinical reporting. Although detailed recommendations on this are still pending, these subcategories are designed to indicate whether a variant leans more toward benignity or pathogenicity. This added granularity supports more informed clinical decision-making and makes reporting more comprehensive. The Bayesian scale ranges from ≤ -4 to ≥10, with scores between 0 and 5 representing Uncertain Significance, further divided into Low, Mid, and High categories.
The final insight concerns the rules for combining criteria. Under v3, classification as LP required at least two attributes at an appropriate strength, regardless of the strength of individual attributes. This approach ensured a reliable assessment of pathogenicity and effectively prevented over-weighing. In contrast, the new Bayesian point-based scale, while enabling more effective combinations of evidence codes, also allows a variant to reach the LP classification with just one evidence code. This applies to benign lines of evidence as well.
**Conclusion**
In summary, the latest ACMG classification guidelines represent a significant advancement toward a more structured, precise, and flexible framework for variant classification. These updates are expected to greatly enhance the clarity and reliability of genetic testing, ultimately improving patient care and clinical decision-making.
However, this refined system also introduces certain challenges. It is likely to reduce the number of variants classified as VUS and increase the number of Likely Benign classifications—a shift that can be viewed as both beneficial and potentially limiting. It also places heavy reliance on predictive and functional data, with comparatively less emphasis on human observational data. Furthermore, the presence of multiple detailed flow diagrams may feel challenging for some users.
That said, the clearly defined standards offer the advantage of bringing uniformity across classifiers, reducing subjectivity, bias and variability in classification. The guidelines are currently in the pilot phase and are subject to further refinements before their official release, anticipated by mid-2026. Recognizing the critical factors discussed, the working group has sensibly recommended a year-long transition period for variant classifiers to adapt to these new changes.
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
**Categories:** Clinical Genomics
---
### [Beyond The Hype: Biopharma's Tech Transfer Process Needs A Fundamental Reset](https://zifo.com/blogs/beyond-the-hype-biopharmas-tech-transfer-process-needs-a-fundamental-reset/)
**Published:** June 17, 2025
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [Beyond The Hype: Biopharma’s Tech Transfer Process Needs A Fundamental Reset](https://zifo.com/blogs/beyond-the-hype-biopharmas-tech-transfer-process-needs-a-fundamental-reset/ "Beyond The Hype: Biopharma’s Tech Transfer Process Needs A Fundamental Reset")
## Beyond The Hype: Biopharma’s Tech Transfer Process Needs A Fundamental Reset
Sakthi Prasad T, Content Director
Jun 17, 2025
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Beyond%20The%20Hype%3A%20Biopharma%27s%20Tech%20Transfer%20Process%20Needs%20A%20Fundamental%20Reset%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Fbeyond-the-hype-biopharmas-tech-transfer-process-needs-a-fundamental-reset%2F "Share on Email")
- [](https://x.com/intent/post?text=Beyond%20The%20Hype%3A%20Biopharma%27s%20Tech%20Transfer%20Process%20Needs%20A%20Fundamental%20Reset&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fbeyond-the-hype-biopharmas-tech-transfer-process-needs-a-fundamental-reset%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Beyond+The+Hype%3A+Biopharma%5C%26%23039%3Bs+Tech+Transfer+Process+Needs+A+Fundamental+Reset&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fbeyond-the-hype-biopharmas-tech-transfer-process-needs-a-fundamental-reset%2F "Share on LinkedIn")
Image reference: / source
In a Hype Cycle report released by Gartner, Tech Transfer has been placed in the “Trough of Disillusionment.” This signifies that the promised benefits from solution providers are not being delivered, leading to disappointment among customers. The suggested path out of this disillusionment is to bring in external help by collaborating with IT service providers to get the process back on track.
To gain a deep understanding of the current state of tech transfer — an important segment of the biopharma value chain — we spoke to **Adam Paton, Zifo Technology’s** tech transfer and life sciences informatics expert, to learn what can be done to help companies struggling with the tech transfer process.
***1. What is tech transfer in simple terms — explain it with couple of practical examples.***
Tech transfer is the vital process of transitioning a successfully developed item, such as a new product or compound, from one area of an organization to another. Its primary application is often seen when moving a product to the manufacturing floor for commercial-scale production.
This process, as the name suggests, involves the systematic provision of technology and information between different points in a chain. A practical example is the journey of an analytical method: from its initial development (often called method development) to its validation, documentation, approval, and finally, its transfer into a production facility. The goal is to ensure that what has been carefully created and verified can be reliably scaled up for industrial use.
In simpler terms, consider the passing down of a beloved family cake recipe. When a grandmother shares her recipe with her grandchild, she’s not just giving them a list of ingredients. She’s transferring comprehensive knowledge: the tools, the specific steps, and even what the finished cake should look like. This complete sharing of information is, at its heart, tech transfer in action.
***2. Considering the vast amounts of data generated during R&D, how does early planning for data transfer and integration (e.g., data format standardization, metadata management etc) minimize costly delays and errors during later tech transfer stages?***
Tech transfer, at its core, is about knowledge transfer, which is fundamentally data. If we consider the journey from a scientific hypothesis to a new medicine, it’s a path paved with significant time, effort, skill, and investment, all geared towards generating vast amounts of data at every step.
Adding to this complexity is the rise of new modalities like biologics, gene therapies, and cell therapies. These aren’t simple chemical molecules; a single cell contains millions, even billions, of data points compared to the relatively few elements in a traditional medicine like aspirin. This means the sheer volume of data is exploding across research, development, and manufacturing.
Furthermore, advancements in lab equipment and automation are accelerating data production even more. Consequently, data isn’t just crucial; it’s becoming a major bottleneck. If data remains siloed and isn’t considered from end-to-end, trying to piece it together retrospectively becomes incredibly difficult and unsustainable. This approach, while perhaps viable decades ago, is no longer feasible today.
Therefore, we must prioritize strategies that foster incremental optimizations and improvements towards data portability from the very beginning. Even seemingly simple measures, like establishing consistent terminology across research, development, and manufacturing, can have a profound and positive impact on this process.
***3. From what I understand, this sounds like insurance. Everyone understands the importance of insurance, and no one would dispute the value of a good insurance contract. However, sometimes people still fail to secure one, right? So, why do companies miss out on these crucial, seemingly obvious steps, and subsequently find themselves unprepared?***
That’s an excellent question, and it points to what I see as an endemic problem in how life sciences sector has embraced the digital age. The prevailing mindset, often epitomized by Electronic Data Capture (EDC), has historically focused on capturing information after an event has already occurred.
The issue with this approach is that it’s reactive: you’re addressing a problem after it’s been created. While data is indeed being captured, its value is diminished because it’s not being done “in-flight.” This leads to a massive, often retrospective, effort at the end of a process. The attitude has largely been, “if it’s not broken, don’t fix it” — this method has worked for decades, so why change?
However, a closer analysis of current operations reveals this approach is hugely inefficient. I believe much of this stems from historical practices and a lack of awareness. Fortunately, the emergence of newer technologies and the current disruption within the industry are now bringing this critical issue to the forefront, demanding that we address it.
***4. Okay, so if I understand correctly, you’re saying the very process of data capture thus far happens after the data is created. Is that right?***
Yes, exactly. This is an area we’re constantly optimizing within the broader concept of tech transfer, particularly through the lens of manufacturability. While it might be a somewhat contentious term, “manufacturability” serves as an excellent catch-all for what tech transfer aims to achieve in a modern context.
It’s highly beneficial to consider manufacturing concepts as early as possible — ideally, right at the sharp end of discovery. Doing so can significantly accelerate time to market. Within drug discovery, specifically in the pharmaceutical industry, a high percentage of drug candidates, often in the high 60s, fail at Phase 2 of clinical trials. This is after years of investment, millions of dollars, and immense time.
Crucially, some of these failures aren’t due to side effects or fundamental chemical/biological non-viability. Instead, they fail because they simply cannot be produced in a commercial setting. Imagine at the very beginning, during target selection and validation, you identify a promising candidate that effectively cures an illness or shows high efficacy. But then you realize it’s incredibly toxic to handle, prohibitively expensive, or requires freezing to -50°C. Immediately, questions arise: Is this truly viable for a manufacturing plant?
By tagging these “manufacturability properties” as early as you’re running experiments, you introduce critical checkpoints. Someone in a tech transfer cross-check, even in the early stages, could identify a candidate as ‘unmanufacturable’ and suggest cutting losses then and there. Instead of spending years and millions to reach Phase 2 only to arrive at the same conclusion, you can stop after, say, an initial $1 million investment. I’m oversimplifying, of course, but anything that introduces this level of high-quality, attributed information and knowledge upfront can only help.
Currently, these critical decisions often happen too late, right at the very end of the process, by which point significant resources have already been expended. Integrating this proactive assessment into how people work from the outset represents a massive and necessary step change for the industry.
***5. What are the fundamental reasons for things to go wrong in a tech transfer process — can you explain this with a practical situation that you have witnessed over the years?***
Sure, for example, a common issue is the ‘walls’ that get put up between different parts of a biopharmaceutical company’s process development. Traditionally, we have about four or five areas: cell line development, upstream processing, downstream processing, formulations, and fill and finish (which is the release of the product). I have heard many, many times, and still hear frequently, even just between upstream and downstream, comments like: ‘Oh no, that’s upstream,’ ‘No, that’s downstream,’ or ‘That has nothing to do with me; I’m not interested in that.’
They should be highly interested in and invested in what’s happening in other areas. These are two adjacent functions; they directly pass material samples from one to the next. These are colleagues who see and work with each other, yet in their minds, they are completely different operating units. In some cases, they actively do not care what happens in the other area.
If we consider extending this all the way from the sharp end of discovery to the manufacturing floor at the very end, which is a separate entity, you constantly run the risk — and it happens all the time — of people having no consideration or concept for what happens downstream or upstream of them. Therefore, anything that can be done to foster a greater appreciation for other functions, or to establish a consistent naming convention across the organization, or to harmonize and understand processes that move from one stage to the next (including potentially having tooling that facilitates this), represents a huge area for potential improvements to optimize tech transfer. This all leads back to something we were discussing earlier: the importance of doing it in-process rather than retrospectively.
***6.That’s well explained. It’s almost like having a manufacturing expert embedded from the very beginning to assess the viability, isn’t it?***
Yeah, and you know what? Think about those ‘back to the floor’ shows on TV, where the boss goes and sees how their teams really work. Something like that could bring massive benefits, not just for tech transfer to manufacturing, but everywhere. When someone from one part of the business gets to work in another, it’s like they’re doing a crucial reality check. They can say, ‘This all looks good, but we missed something here. The information I’m getting doesn’t cover it. I’m bringing it up now because it could save us a lot later.’
***7. Do companies have a dedicated position for tech transfer? Based on your interactions with different stakeholders and companies, how is it typically structured? Is there someone specifically assigned to these tasks, or does it end up being an ‘orphaned’ project no one really wants to touch? Basically, where does this fit in the org chart?***
We can evolve this to a “process, data, organization, and technology” (PDOT) framework. I’ll make the distinction between “people” and “organization” shortly. If we start with the process, understanding it is crucial for success. You cannot move something from one person or group to another without a clear understanding of what’s being done. You need a well-defined, documented, and transferable script, steps, and process flow. Without this, it’s like starting all over again. If you tell someone what’s been done and what they need to do, but don’t provide clear instructions and confidence in the process, their natural human instinct is to say, “I’ll do it myself.” This, however, leads to a loss of valuable information surrounding the process. Therefore, we must prioritize the process. If it’s done exceptionally well, with all the necessary information and artifacts, it will be more readily accepted.
However, the process is just one piece. Moving on to the organization, which was more central to your question, it’s not just about the individuals but how the entire organization operates. We must consider the people, geography, company culture, organizational setup, and strategy. All of these contribute to a more effective knowledge-sharing strategy; you must consider them together. Is it currently one person handling this? Sometimes. Is it sometimes not? Yes. Should it become part of the organizational thinking? Absolutely. If you have alignment on as many aspects of the organization as possible, the rate and degree of change can be massively accelerated. This represents a significant shift in how people need to think.
An important aspect is integrating business value into the thinking around processes and organization. If you’re moving towards an operating model that allows the business to operate more effectively, more profitably, more agile, or whatever your objective may be, people will then see that everyone is working towards a common goal. While it might sound slightly cliché, ultimately, if this can be achieved to generate products and therapies faster, and deliver them to patients earlier and more effectively, then everyone in this space is essentially achieving their fundamental goal.
***8. Can you give me a ballpark figure as to what percentage of organizations as per your estimate have implemented PDOT framework?***
Having it completely sorted? I would confidently say 0%. However, when we talk about organizations making inroads and doing great things in some or a number of these areas, it’s difficult to put an exact number on it, but it’s probably lower than you’d think. Considering all aspects, you’re likely only looking at 20% to 30% of organizations truly adopting this type of thinking.
This is, in fact, a symptom of the life sciences industry itself. We discussed the PDOT framework, and it’s the ‘T’ – technology — where people tend to gravitate. Technology offers a solution; it’s the ‘solutionizing’ aspect. If you’re a scientist, your brain is almost hardwired to try and find solutions — that’s what we do, solve problems.
So, it’s very easy to jump to technology, thinking, ‘Oh, this piece of technology solves a problem; it gives me what I’m looking for.’ But if your processes aren’t correctly defined and optimized, and if your organization isn’t bought into what you’re trying to achieve, technology can be useless. Many organizations are now realizing this: to successfully implement a data strategy linked to technology, you must also have robust processes and well-managed data.
It’s a significant shift, I would say. Now, more organizations are probably focusing on the ‘D’ (data) and ‘T’ (technology), which might be higher percentages. But when you consider the ‘P’ (process) and ‘O’ (organization), those numbers are much lower. So, as a collective, the overall integration across all four elements remains quite low.
***9. So, what kind of role would a CSO (Chief Scientific Officer) play in this? Does Tech Transfer process fall under the CSO’s domain, or the CIO’s (Chief Information Officer’s) domain?***
Yes, it largely depends on the organization’s culture and operating model; it could indeed fall under the purview of either, or both. However, I hold a specific viewpoint: the CSO (Chief Scientific Officer) should be instrumental in any activity within our domain.
Everything we undertake should ultimately aim for a scientific business outcome. While this outcome can certainly be linked to efficiencies, time savings, or cost reductions, a far more transformative impact would be, for example, developing a cell therapy believed to cure spina bifida. We might be close, but if the therapy is currently unviable due to prohibitive cost, preventing patient access, then cost becomes a major blocker.
In such a scenario, we must re-evaluate the science used to generate that therapy. What can we do scientifically to make it a viable treatment for patients? This necessitates looking at the science, the scientific model, and even the cell model itself in a completely different light, integrating it with data, technology, and our organizational framework. This crucial drive must come from the CSO.
***10. For all-encompassing projects like Tech Transfer, which spans from early discovery to manufacturing, do you think a separate, dedicated team is needed from the outset? This team could be either internal or external. The idea is for them to embed people across the value chain to ensure data and processes are captured effectively. This would allow specialists — like chemists focusing on chemistry or molecular biologists on biology — to concentrate on their core tasks. Meanwhile, someone else would shadow them in the background, capturing data and parameters. This overall view, perhaps at a dashboard level, would confirm things are on track and flag potential pitfalls. I know this sounds futuristic, but is anything like this already happening in the industry? If not, do you think it’s an approach companies should consider?***
You’ve hit on a crucial point: scientists already have demanding day jobs. This is precisely why the life sciences industry isn’t further along in its digital transformation. New activities are constantly being shoehorned into existing core roles, which isn’t sustainable.
The ideal scenario would involve a separate, dedicated team specifically measured on delivering incremental and transformational change for areas like tech transfer. However, this requires significant investment, and whether an organization commits to it depends on its culture, size, and various other factors.
In an ideal world, the impact of such a team would be considered substantial enough to warrant the investment. For me, this isn’t merely a top-down or bottom-up decision; it requires a C-level mandate. A Chief Scientific Officer (CSO) or Chief Information Officer (CIO), for instance, needs to declare: “This is our objective for business outcome — perhaps better science — and to achieve it, we are prepared to mobilize this specific type of structure.” This top-level commitment is essential to drive such a fundamental shift.
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
**Categories:** Bioinformatics, Chromatography Systems Services, Clinical Genomics, Clinical Trials Services, Data Science and Consulting Services, Digital Transformation Consulting, Lab Compute Services, Manufacturing and Quality Informatics Services, Pre-Built Solutions and Blueprints, Product Development and Design Services, RnD Informatics Services, Scientific Application Managed Services, Scientific Cloud Computing Services, Strategic Scientific Consulting Services, Validation Service and Compliance Support
---
### [Evolution In R&D Architecture](https://zifo.com/blogs/evolution-in-rd-architecture/)
**Published:** July 23, 2025
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [Evolution In R&D Architecture](https://zifo.com/blogs/evolution-in-rd-architecture/ "Evolution In R&D Architecture")
## Evolution In R&D Architecture
Debrup Mazumdar, Senior Consultant
Jul 23, 2025
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Evolution%20In%20R%26D%20Architecture%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Fevolution-in-rd-architecture%2F "Share on Email")
- [](https://x.com/intent/post?text=Evolution%20In%20R%26D%20Architecture&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fevolution-in-rd-architecture%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Evolution+In+R%26D+Architecture&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fevolution-in-rd-architecture%2F "Share on LinkedIn")
Image reference: / source
Over the past decade, software architecture in pharma and biotech has evolved from tightly coupled monoliths to modular, distributed systems built on microservices.
While some have dismissed this as a technical trend, the shift reflects a deeper transformation—one that impacts how teams collaborate, innovate and scale within complex, regulated environments.
Architecture is no longer just a technical decision. It is an operational one, a regulatory one, and above all, a strategic one.
Just as the move from DevOps to platform engineering changed how teams think about ownership and delivery, the **journey from monoliths to microservices** redefines how we think about systems, scale and scientific software.
**Recognizing the limits of the monolith**
For many pharma and biotech organizations, the story starts with a monolith: a single application responsible for everything from clinical trial data entry to regulatory submissions.
These systems were often efficient at first—fast to build, easy to host, and tightly aligned with a single use case.
But as organizations grew and added more functions, including real world data integration and AI model deployments, cracks started to show. A single failure could bring the entire platform down. Scaling one feature meant scaling everything. Teams were blocked, waiting on centralized updates. Releases took weeks owing to tight coupling and shared databases.
What began as a unified system slowly turned into a bottleneck for scientific innovation.
**The tipping point: scientific scale and regulatory complexity**
The tipping point came when R&D teams began demanding more autonomy. Bioinformatics groups wanted to deploy machine learning models into production. Clinical teams needed to integrate third-party data vendors. Regulatory affairs needed traceability and version control at every step.
The monolith could not keep up.
Each team had unique needs, but all were bound to the same release cycle. Every request to the central engineering team was met with delays, risk assessments and prioritization debates. Over time, it became clear that this was not just an architecture problem—it was an organizational alignment problem.
**Reimagining architecture as an enabler**
The transition to microservices began with a mindset shift: architecture should **enable** science, not constrain it.
Early on, small, low-risk services were carved out of the monolith: a metadata catalog for compound screening, a separate ingestion pipeline for real-world evidence, and a standalone model-serving endpoint for AI-powered biomarker discovery.
These were not just technical experiments; they were trust-building exercises. Each successful microservice gave a team more control, improved performance and reduced the load on centralized infrastructure.
The architecture was no longer a rigid stack. It was becoming a **platform—**one built on composability, autonomy and accountability.
**Lessons learned in the transition**
**1. You can not rewrite the monolith overnight**
In regulated environments, rewriting core systems is not always feasible. Instead of replacing the monolith, we surrounded it. New services were built on cloud-native stacks and slowly replaced monolithic dependencies. The monolith itself was refactored into smaller, deployable components over time.
**2. Not everything needs to be a microservice**
Some tools, like internal dashboards or ELN integrations, remained monolithic by design. We learned to focus microservice efforts where they added the most value for high-scale, high-change and high-risk areas.
**3. Security and compliance must be first class citizens:**
Microservices added flexibility but also complexity. Every service needed proper authentication, auditability and documentation. A security-by-default approach became a non-negotiable requirement, not an afterthought.
**4. Organizational structure follows architecture:**
As services grew, so did the teams around them. Bioinformatics, clinical ops, regulatory, and data science teams each began owning parts of the platform. The shift was no longer just technical, but it was cultural.
**Microservices and MLOps: unlocking scientific acceleration:**
Nowhere was the architecture shift more impactful than in **R&D.**
In the monolith era, a data scientist might train a model and email the output to engineering for integration.
With microservices and proper MLOps, the workflow changed completely:
- Feature engineering pipelines became reusable services.
- Models were deployed via versioned APIs with A/B testing.
- Training and inference were decoupled and scalable.
- Model metadata was tracked in a centralized registry.
- Scientists could deploy updates without waiting weeks for release windows.
- This did not just make model deployment faster. It made **experimentation reproducible, regulatory audits cleaner,** and **collaboration easier** across multidisciplinary teams.
**Measuring progress and building for the future:**
Just like in platform engineering, we tracked our progress with metrics: service uptime, release frequency, incident response time, model reusability. Every data point told a story of increasing agility, better quality and reduced bottlenecks.
We did not abandon monoliths entirely. They still serve key purposes. But we now treat them as part of a larger architecture, not the whole system.
By adopting microservices where it made sense, we built a more flexible, secure and scalable foundation for scientific innovation.
**What is next: OrgOps for scientific systems**
As more teams adopt microservices, the conversation is evolving again toward something like **OrgOps**. This means architecture, process, and policy are all integrated across the organization. It is no longer just about developers or data scientists. It includes quality, regulatory, compliance, and IT security as active contributors to the system lifecycle.
In this new world, the **architecture** becomes a living organism—a reflection of how the company thinks about experimentation, risk, and growth.
The transition from monolith to microservices is not a one-time migration. It is an ongoing journey. For pharma and biotech organizations, it is a path toward greater agility, transparency and innovation.
Architecture, when done right, becomes more than a framework. It becomes a **force multiplier—**accelerating drug discovery, enabling compliance and empowering the people who make science happen.
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
---
### [Harnessing The Power Of Voice Of Customer (VoC) In Business Consulting: A Strategic Imperative](https://zifo.com/blogs/harnessing-the-power-of-voice-of-customer-voc-in-business-consulting-a-strategic-imperative/)
**Published:** July 25, 2025
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [Harnessing The Power Of Voice Of Customer (VoC) In Business Consulting: A Strategic Imperative](https://zifo.com/blogs/harnessing-the-power-of-voice-of-customer-voc-in-business-consulting-a-strategic-imperative/ "Harnessing The Power Of Voice Of Customer (VoC) In Business Consulting: A Strategic Imperative")
## Harnessing The Power Of Voice Of Customer (VoC) In Business Consulting: A Strategic Imperative
Insha Ishrat, Scientific Informatics Analyst, Sima Bahadori, Senior Consultant
Jul 25, 2025
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Harnessing%20The%20Power%20Of%20Voice%20Of%20Customer%20%28VoC%29%20In%20Business%20Consulting%3A%20A%20Strategic%20Imperative%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Fharnessing-the-power-of-voice-of-customer-voc-in-business-consulting-a-strategic-imperative%2F "Share on Email")
- [](https://x.com/intent/post?text=Harnessing%20The%20Power%20Of%20Voice%20Of%20Customer%20(VoC)%20In%20Business%20Consulting%3A%20A%20Strategic%20Imperative&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fharnessing-the-power-of-voice-of-customer-voc-in-business-consulting-a-strategic-imperative%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Harnessing+The+Power+Of+Voice+Of+Customer+%28VoC%29+In+Business+Consulting%3A+A+Strategic+Imperative&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fharnessing-the-power-of-voice-of-customer-voc-in-business-consulting-a-strategic-imperative%2F "Share on LinkedIn")
Image reference: / source
In today’s rapidly evolving market, businesses can no longer afford to operate on assumptions. Success lies in listening — deeply, strategically and systematically — to the Voice of the Customer (VoC). VoC represents the captured insights, expectations, preferences and aversions of customers. It offers a powerful, data-backed perspective on what matters most to end users and why. In the consulting and business analysis landscape, VoC analysis is not merely a tool but a strategic compass, guiding organizations toward sustainable value creation, customer-centricity and innovation.
**The need for VoC: bridging gaps with insight**
Every product, service, or strategy begins with a fundamental question: What does the customer need? In the world of scientific research, where precision and efficiency are paramount, the tools scientists use, whether it’s a Laboratory Information Management System (LIMS), an Electronic Lab Notebook (ELN), or a custom data analytics platform, must do more than just function. They must fit seamlessly into the workflows of those who rely on them daily. And that’s where the Voice of the Customer (VoC) becomes not just valuable, but essential.
**VoC allows organizations to:**
- Uncover and address inefficiencies in current offerings.
- Identify hidden problems and improve customer experience.
- Drive process improvements and innovation.
- Fine-tune strategies with evidence-backed feedback.
Over the years, we’ve seen firsthand how meaningful engagement with end users: scientists, lab technicians and R&D teams, can transform the trajectory of a software development project.
One example that stands out involved the development of a next-generation ELN platform. Early conversations with lab users revealed that while existing tools captured data effectively, they often disrupted the natural flow of experimentation. Users struggled with clunky interfaces, redundant data entry and poor integration with analytical tools. By listening closely to these frustrations, the need was clear: prioritize intuitive design and interoperability. The result was a solution that felt like an extension of the lab bench rather than a digital hurdle.
**VoC as a strategic asset**
The true power of VoC lies in its ability to transform anecdotal feedback into actionable intelligence. For consultants and analysts, it forms the very foundation of business cases, root cause analysis, and change management strategies. VoC bridges the external market reality with internal decision-making.
It’s also a risk mitigator. Before large investments are made in product development, strategy pivots, or operational revamps, VoC serves as a planning, ideation, conceptualization and validation tool. Does the customer really want this change? Will it solve their pain point—or create a new one?
Imagine you’re a scientist working in a fast-paced research environment. You’re juggling multiple experiments, managing complex datasets and navigating a patchwork of digital tools that don’t always talk to each other. Then comes news of a major upgrade to your internal bioinformatics platform—complete with AI features and a shiny new UI. It sounds promising, but will it actually make your work easier?
This is where the Voice of the Customer becomes more than a buzzword. When organizations take the time to listen—to really understand what scientists and lab users need—they often uncover a different set of priorities. It’s not always about AI or aesthetics. It’s about performance, interoperability and integration with lab instruments. The ability to move seamlessly from data capture to analysis without breaking your workflow.
In many cases, what starts as a vision for cutting-edge innovation evolves into something more grounded—and more impactful—once users are brought into the conversation. Investments shift from surface-level enhancements to backend improvements that actually support the way science happens in the real world.
So, the next time a new tool is announced or a platform is being reimagined, it’s worth asking: Was this built with your voice in the room?
**Let’s explore practical approaches for obtaining Voice of the Customer input**
**Direct and indirect techniques: a two-pronged strategy**
VoC analysis can be broadly categorized into direct and indirect techniques.
**Direct techniques**
**1. Customer interviews**
One-on-one sessions offering deep insight into individual customer needs and sentiments. *In a lab setting, these interviews often uncover workflow bottlenecks or unmet needs that aren’t visible in usage data alone—like how long it takes to log a sample or retrieve historical experiment data.*
**2. Group discussions or focus groups**
Encouraging collective brainstorming, identifying patterns and validating assumptions. *When scientists from different departments come together, these sessions often reveal cross-functional challenges—such as inconsistent data formats or integration gaps between LIMS and ELN systems.*
**3. Surveys and questionnaires**
Useful for quantitative analysis and large-scale feedback collection. *For example, a quick survey across R&D teams can highlight which software features are most valued—or most frustrating—during assay development or data review.*
**Indirect techniques**
**1. Reviewing client feedback**
Existing reviews, complaints, or testimonials provide unfiltered insights. *Feedback from lab users—whether shared during audits, post-implementation reviews, or even informal chats—often points to recurring usability issues or overlooked features.*
**2. Query support notes**
Technical or customer support logs often highlight recurrent issues or confusion points. *Support tickets from scientists struggling with data exports or system timeouts can reveal where documentation is lacking or where the UI needs simplification.*
**3. Analytical methods**
Studying product usage patterns, churn rates, or Net Promoter Score (NPS) trends. *Usage analytics might show that certain modules in a LIMS are rarely used—not because they’re unnecessary, but because they’re too complex or poorly integrated into daily lab routines.*
**4. Competitor benchmarking**
Understanding how customer needs are being met (or missed) by competitors. *Scientists often compare tools informally. Benchmarking helps identify where your platform falls short—or excels—in real-world lab environments, such as faster data processing or better instrument compatibility.*
In practice, every direct technique is followed by indirect validation and vice versa — an approach that brings objectivity and holistic clarity to VoC data.
**Multi-channel listening: the complex yet crucial framework**
Effective VoC analysis doesn’t happen in silos. It’s a multi-channel, multi-stakeholder process that brings together insights from:
- **Sales and marketing:** Understanding expectations from early customer interactions.
- **Technical SMEs and consultants:** Interpreting feasibility and technical alignments.
- **R&D and product development:** Infusing customer feedback into design and innovation cycles.
- **Market strategy teams:** Using VoC to shape pricing, positioning and competitive messaging.
VoC is not just a customer service tool, it is a cross-functional strategic component. When aligned well, it informs long-term growth strategies and fosters market differentiation. It reflects not just innovation, but the collective voice of its users. Built around real workflows, it encourages strong user adoption and delivers immediate impact.
**Implementation: a stepwise approach**
What works well is a structured VoC roadmap:
1. **Define objectives:** What exactly do we want to learn from the customer?
2. **Select techniques:** A mix of direct and indirect methods based on industry and scale.
3. **Data collection:** Across departments, platforms and touchpoints.
4. **Analysis & theming:** Identifying patterns, pain points and opportunities.
5. **Strategic integration:** Feeding insights into design, delivery and strategy teams.
6. **Validation and feedback loops:** Recheck, retune and reaffirm with the customer.
**Listening with purpose**
In the consulting domain, success isn’t just about knowing more — it’s about knowing what truly matters and having deep technical knowledge of the domain. VoC empowers organizations to do exactly that. It transforms ambiguity into clarity, assumptions into facts, and ideas into impact.
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
---
### [Interview: AI By Itself Isn’t Going To Magically Deliver A Drug Today](https://zifo.com/blogs/interview-ai-by-itself-isnt-going-to-magically-deliver-a-drug-today/)
**Published:** August 7, 2025
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [Interview: AI By Itself Isn’t Going To Magically Deliver A Drug Today](https://zifo.com/blogs/interview-ai-by-itself-isnt-going-to-magically-deliver-a-drug-today/ "Interview: AI By Itself Isn’t Going To Magically Deliver A Drug Today")
## Interview: AI By Itself Isn’t Going To Magically Deliver A Drug Today
Sakthi Prasad T, Content Director
Aug 07, 2025
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Interview%3A%20AI%20By%20Itself%20Isn%E2%80%99t%20Going%20To%20Magically%20Deliver%20A%20Drug%20Today%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Finterview-ai-by-itself-isnt-going-to-magically-deliver-a-drug-today%2F "Share on Email")
- [](https://x.com/intent/post?text=Interview%3A%20AI%20By%20Itself%20Isn’t%20Going%20To%20Magically%20Deliver%20A%20Drug%20Today&url=https%3A%2F%2Fzifo.com%2Fblogs%2Finterview-ai-by-itself-isnt-going-to-magically-deliver-a-drug-today%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Interview%3A+AI+By+Itself+Isn%E2%80%99t+Going+To+Magically+Deliver+A+Drug+Today&url=https%3A%2F%2Fzifo.com%2Fblogs%2Finterview-ai-by-itself-isnt-going-to-magically-deliver-a-drug-today%2F "Share on LinkedIn")
Image reference: / source
In a recent survey by Zifo Technologies on [Data Readiness for AI](https://zifo.com/blogs/early-days-for-ai-but-scientific-data-management-gains-momentum/) it was found that only about one-third of scientists and informaticians feel confident in leveraging scientific data for AI initiatives, highlighting foundational data challenges across biopharma, which makes AI adoption that much more difficult in due course, if not addressed soon.
AI gained prominence and popularity after the introduction of OpenAI’s ChatGPT: ordinary consumers got to experience the GenAI technology first hand, creating unprecedented buzz and excitement. At the same time, one should remember that AI/ML has been around for a long time. In fact, the Finance industry is much ahead of all other industries when it comes to gainful deployment of latest technologies. In the U.S. stock market, about 70% of trading volume is initiated through [algorithmic trading,](https://business.fiu.edu/academics/graduate/insights/posts/artificial-intelligence-in-the-stock-market-how-did-it-happen.html#:~:text=Algorithmic%20trading%20has%20increased%20significantly,is%20initiated%20through%20algorithmic%20trading.) which is a forerunner for AI trading. According to Greenwich Coalition [study,](https://www.greenwich.com/market-structure-technology/great-expectations-ai-equity-trading) about a quarter of buy-side equity traders surveyed plan on incorporating internal AI technologies into their trade execution workflow in the coming year.
In this fast-evolving scenario, to gain a deep understanding of the current state of new technology adoption in the Biopharma sector, we spoke to **Sujeegar Jeevanandam, Zifo’s Principal Consultant, Data and AI,** about its real-world impact, moving beyond the glamorous headlines of drug discovery.
***By its very nature, the biopharma industry avoids risk. It must, because of strict regulations, complex manufacturing, and data privacy. You don’t see the kind of rapid tech adoption that Wall Street saw with algorithmic trading, which now uses such technologies to trade trillions.***
***So where does that leave biopharma with AI? Based on your interaction with various industry stakeholders, are they genuinely enthusiastic and making it a priority, or is their cautious nature creating a more lukewarm response? What’s really driving their approach?***
Firstly, I don’t subscribe to the idea that biopharma is “risk averse.” In my view, the industry thrives on risk. The sheer number of clinical trials that launch each year — and the high failure rate they accept — is proof of this. You never start a trial with a guarantee of success; it’s inherently a betting game.
***Yeah, I take your point, maybe I should have qualified it as risk averse when it comes to embracing new technologies.***
Correct. The industry tries to be cautious and control the journey they go through to take a drug to market. That’s true whether it’s with the talent they acquire, the partners they choose, the technologies they adopt, and, most importantly, the processes they follow. The idea is, “I am already taking such a high risk, so I’ll go with a strategy that can mitigate some of those risks.”
So, from a pure technology point of view, the industry can be seen as a laggard compared to other industries, like finance, as you mentioned. But when you think from a larger perspective, if you take a risk in one area, you try to mitigate it in another. Right?
Now let me take up the second part of your question: **the biggest driving factor, I feel, influencing the adoption of AI is FOMO —** everybody feels they will miss out on this wave if they don’t get involved now. Compared to how the industry adopted technologies like electronic lab notebooks (ELN), LIMS, cloud, and other technical advancements, I feel the pharma industry is taking a very driven approach to embrace AI. The ultimate question is going to be: how well will you adopt AI?
***Is it hype? I mean, if I ask you, is AI just hype, or are there genuine use cases for it?***
It’s not hype. It has the potential to significantly reduce the cost of developing and bringing a new drug to market. **However, AI by itself isn’t going to magically deliver a drug today. Everyone wants that — everyone wants to ask a question and have AI say, “Here’s a drug; it’s going to cure.” That’s not what I believe AI is capable of right now.**
But the opportunities for AI to create an impact in a localized manner throughout the drug’s 10-year lifecycle in the industry are tremendous. If you can even create a 5% impact at various stages of the pipeline, it’s going to translate into millions, if not billions, in savings. It will also reduce the cycle time to bring a new drug to market, and it has the potential to significantly reduce challenges and adverse events that can happen once a drug goes to market.
***Many companies already have IT systems in place, and AI essentially sits on top of them. You can use it to harvest data from various instruments and systems to reveal patterns or insights that scientists can study. So, AI’s primary use is to extract these insights from existing data.***
***This brings us to the relationship between basic IT plumbing and AI. Think of it like algebra versus calculus in building a house. Algebra represents the fundamental building blocks — the bricks, cement, and tiles. You can’t build a house without these basic materials. Calculus, on the other hand, is like the design phase: deciding where rooms go, how to arrange furniture, and so on.***
***Many people try to jump straight to calculus without mastering algebra first, finding it difficult. That’s because algebra provides the foundational building blocks applied in real-world situations by calculus.***
***Similarly, you can’t do AI without basic IT plumbing. The question is, where do we draw the line? In what situations will basic IT plumbing solve the problem, and when do you need AI? For some situations, just like algebra is enough for certain problems, basic IT plumbing will suffice; you don’t need to move to the “calculus” level of AI.***
I’m going to use a different example, if that’s fine. I will use the analogy of a laptop and the program that we do in a laptop. To me, the LLM is the CPU. Billions of people use laptops. Most of us don’t have to understand how a CPU works. They all, I hope, know that a CPU is critical for a laptop or a machine, but they have no knowledge about how a CPU functions. They still use the laptop very effectively, right?
When we talk about Gen AI in general, the work that all the tech leaders are performing today — OpenAI, Perplexity, and others — they are building a laptop for the industry to use, on top of the LLM, which is the CPU.
So, if I’m a team leader who wants to leverage AI, I don’t need my team to understand the LLMs. I need my team to be capable of working with a laptop, right? So, **what it means is LLM is yet another technology that is available for knowledge workers to perform their business function. So, in a way, yes, IT Systems and Data are the “Algebra” while AI application is the “Calculus”.**
I used to start programming in BASIC and Mainframe, and when a new technology like Python and C# evolved, I embraced it. I learned it. The tools changed, but the fundamental problems didn’t change — I was still solving the same scientific problem for my customers. This means AI will eventually fold into this term that you called IT plumbing.
***Okay, in that case, scientists don’t need to be an expert in AI or LLM, right?***
**I don’t think scientists have to go out of their way to become an expert in AI or LLMs or any technology to be able to use it.** If I know how to use a laptop — if I understand the purpose of the laptop, keyboards, mouse, and so on — I can do my job effectively without having to know the specifics. And that’s what the industry and society are moving towards: making it easy for consumption. If you make AI easy for consumption, more people will consume it. This means a scientist doesn’t have to worry about whether it’s too tech-heavy for them to leverage. I don’t think that’s what customers, or any individual users, should worry about.
***When we talk about AI in biopharma, most people discuss discovery, specifically the drug discovery phase. Of course, that’s the most glamorous part, where you analyze data and find a cure for a disease — that’s the most often cited use case. However, I’m looking for some non-glamorous areas in biopharma where AI can be equally and potently deployed. Can you give two or three specific or general examples?***
**The most non-glamorous example I can think of is simply getting answers to questions.** We document, capture, and record every aspect of research. Sometimes, we have a question and know the answer lies in a specific document or experiment record. Today, you might spend hours trying to find that record. You get tired and decide to just redo the entire experiment to generate a new copy of the data for your reporting. With AI, you could get those answers very quickly or at least be pointed to the exact location where the answer resides. **I cannot overstate how much in savings we’ll realize by being able to find a fact that we know already exists.**
**Beyond that, there are numerous opportunities to optimize operational activities, particularly with the help of Gen AI combined with digital twin capabilities.** Routine activities a scientist or analyst performs in the lab can be automated through AI. A good example is: I’m a scientist running an experiment. I observe something that I need to document. Today, I can’t stop the experiment to do the documentation; I just hope I’ll remember and diligently capture that observation at the end. But with AI, I could ask ChatGPT or Copilot to make a note of that observation through a voice command. The impact of being able to capture these observations, which could become incredibly valuable when developing new models and finding answers, is tremendous.
***Okay, so AI is not just at the large, glamorous end of discovery. It can be surgically deployed across the process, across the value chain, basically wherever there is a pain point in the entire R&D and manufacturing value chain. Are you saying that it could be surgically deployed to solve a particular pain point, and then one can be imaginative and come up with a use case to solve a problem?***
Absolutely. **In fact, viewing the impact of AI only through the glamorous aspects will result in a lot of pain and disappointment.** I do not believe that even if you put together all the knowledge from all the biotech and pharma companies in the world, we would have the information to accurately map human biology. This is why every clinical trial is a risk; it’s a lottery where you hope all the other pieces that you have not thought of would click into place.
And it is going to take quite a while, in my opinion, to be able to fully model human biology, to be able to say that “here’s the question, here’s the answer, and the answer is the cure.” I truly believe that is where the industry should be going. You have to leverage AI to completely model human biology. But we are not going to get that today. I don’t even think we are going to get there in the next five years or so, maybe much longer after that.
***Beyond speeding up the trial (time as a benefit) or reducing its cost (cost as a benefit) — because everyone cites time and cost as the two distinct benefits for using AI — what other benefits could you think of from AI?***
**The third dimension, I’d say, is knowledge. Today, your knowledge space is limited by the talent you have.** This can result in focusing on a specific indication or pathway or sticking to traditional manufacturing processes to make a new drug, which falls under the CMC domain. The power of AI is that when used correctly, your knowledge space can grow manyfold. You could tap into potential areas that you are currently completely blind to.
For example, let’s look at translational sciences, where we generate a huge volume of multi-modal data. Target identification and target validation are two core milestones at the beginning of a drug’s life cycle. Any pharma or biotech company has a specific indication or targets on which they have a huge knowledge base, and they continue to exploit that because of their in depth understanding. Without AI, they might not even attempt to step out of this comfort zone to look at possibilities like the impact an approved drug could have on a totally novel target or an indication they aren’t focusing on. Why would they? They have limited resources and talent. They operate in a space where they believe they have the best chances of developing a new cure or drug. With AI, however, you can explore new targets and new indications with relatively minimal effort and time
This expansion of knowledge, this opportunity to play on a much larger ground, comes at a cost. You need good quality data to be able to expand your knowledge. To me, compared to the cost and time benefits, knowledge benefits demand larger data capital. As we all know, that’s a space where a lot of improvements driven by FAIR are happening and still need to happen.
***How about privacy concerns? Because it came up in the latest Zifo survey as well. We conducted a survey, and in it, privacy was mentioned as the top concern for why someone might not adopt AI, given that these are all third-party tools.***
The concerns around privacy or security of data are no different from those brought upon when the industry was trying to adopt the cloud. **I believe the industry has learned a lot about how we can protect IP and secure data, even if the data is stored or processed by a third party.**
Naturally, everyone has doubts about how various players are securing and isolating one customer’s data from another, but I do not believe that is going to limit the adoption of AI by the pharma biotech industry. They are doing it already; they are using ChatGPT Enterprise version, for example, leveraging the cloud.
Many customers have their own implementation of these models on-premise or in their own private cloud, to be sure. However, we already see customers leveraging models hosted by third-party providers the same way they are leveraging cloud services hosted by AWS and Google Cloud.
***So, what does success look like? I know these are still very early days, but let’s say a pharma company gets on the AI bandwagon — putting aside the fact that I know people will say, “Okay, we will discover that success” — let’s take that glamorous part out of the equation.***
***From a non-glamorous perspective, how can they enumerate success in the sense that they have created value? What kind of KPIs can they show for it — because they’re making investments that would require ROI. As you said, they will have to invest in data, data capture, and all of that is an investment.***
***What would a truly successful integration of AI look like, where the business value is shown, and that does not necessarily mean faster drug discovery? So, if you take that out of the equation, what would success look like?***
As a life sciences consultant, I see AI becoming a norm in the research and development process, the way ELN and LIMS have become the norm. If anyone isn’t using ELN and LIMS, they’re an outlier; they’re seen as a laggard.
When the industry treats AI adoption with the same lens, it means AI has become core to life sciences research . However, there are still miles to go because **interestingly, even today, believe it or not, there are multiple pharma and biotech companies that still run on paper. They have hundreds, if not thousands, of scientists documenting everything on paper, not even using ELN.**
***You mentioned ELN, how about LIMS?***
I would say a lack of a proper LIMS means you’re sending a lot of instructions through emails, while depending on handwritten notes and Excel sheets. This shows how slow the industry has been in the past when it comes to technology adoption.
ELNs first rolled out at the beginning of the millenium. Twenty-five years later, while some people still use paper , I observe significant adoption of AI in the industry and among the customers I have worked with. **So, I do not believe the industry is going to take 25 years to adopt AI. That’s why I do not believe the risk-averse nature of the industry is impacting or hindering the inclusion of AI into research and development.**
***So, you’re saying, from what you have observed, the adoption of AI is faster, or rather robust than adoption of say, ELN or LIMS?***
Yes, that’s correct. **The rate of AI adoption is faster than ELN or LIMS adoption,** in my opinion.
***Everyone understands the importance of AI — nobody’s disputing it. But if you take any large biopharma company, leaving aside the startups, if you take the large ones, that’s where the complexity lies. So, who’s responsible for this AI strategy? Because they’ll be working on different targets, different projects, different teams, different systems, geographies, languages, and whatnot.***
***So, who’s responsible for coming up with an overall AI strategy and then also deciding when, where, and how to use AI? Do you see any such thing happening in the industry currently? Or is it all being done individually by the teams themselves, with no overarching, centrally driven mandate from top management saying, “Okay, use AI here and here”? Or is it more decentralized?***
I’m going to give you a very boring answer: **everyone is responsible for incorporating AI into their operations.**
However, from what I have seen with my customers and across the industry, there is a top-down approach. Organizations are setting up specific functional units to drive and incorporate AI across the enterprise. These units are reporting directly to the Chief Scientific Officer (CSO) or even the CEO to ensure there is an enterprise-wide strategy for AI incorporation.
But that kind of a top-down approach takes a long time to reach the “leaf nodes,” and the impact is also not very tangible. Some of the most innovative pharma and biotechs are also taking a bottom-up approach, enabling individual teams to be able to fast-track value realization through AI and not have to wait for the entire organization to embrace it.
This kind of “pocket approach” has its own challenges. We talk about privacy, security, the cost, and how you define success. But when done the right way, these pocket exercises bring increased momentum to the organization’s drive towards AI.
Ultimately, I think the boring answer is that everyone, from IT to business to scientists to the CEO, they all have to embrace AI, find ways to integrate it into their workflow. It means asking questions, seeking help, or simply starting to adopt it.
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
---
### [Interview: Tackling AI Anxiety And Technology Obsolescence To Drive Better Science](https://zifo.com/blogs/interview-tackling-ai-anxiety-and-technology-obsolescence-to-drive-better-science/)
**Published:** September 10, 2025
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [Interview: Tackling AI Anxiety And Technology Obsolescence To Drive Better Science](https://zifo.com/blogs/interview-tackling-ai-anxiety-and-technology-obsolescence-to-drive-better-science/ "Interview: Tackling AI Anxiety And Technology Obsolescence To Drive Better Science")
## Interview: Tackling AI Anxiety And Technology Obsolescence To Drive Better Science
Sakthi Prasad T, Content Director
Sep 10, 2025
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Interview%3A%20Tackling%20AI%20Anxiety%20And%20Technology%20Obsolescence%20To%20Drive%20Better%20Science%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Finterview-tackling-ai-anxiety-and-technology-obsolescence-to-drive-better-science%2F "Share on Email")
- [](https://x.com/intent/post?text=Interview%3A%20Tackling%20AI%20Anxiety%20And%20Technology%20Obsolescence%20To%20Drive%20Better%20Science&url=https%3A%2F%2Fzifo.com%2Fblogs%2Finterview-tackling-ai-anxiety-and-technology-obsolescence-to-drive-better-science%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Interview%3A+Tackling+AI+Anxiety+And+Technology+Obsolescence+To+Drive+Better+Science&url=https%3A%2F%2Fzifo.com%2Fblogs%2Finterview-tackling-ai-anxiety-and-technology-obsolescence-to-drive-better-science%2F "Share on LinkedIn")
Image reference: / source
While Gen AI has taken the world by storm, as is evident by the consumerization of this technology, scepticism is creeping into the highest level of business regarding the ROI of AI investments. A recent study released by the MIT Media Lab/Project NANDA found that 95% of investments in generative AI have produced zero returns.
For its part, in what could be termed as a “watershed moment” in the life of this fledgeling technology, Gartner has said that Gen AI has entered the “Trough of Disillusionment” era, the third step in its five-stage technology adoption framework, which is an indicator of widespread dissatisfaction with a technology. To bolster its claim, Gartner report states that less than 30% of AI leaders have reported that their CEOs are happy with AI investment return.
Given that this breakthrough technology is driving individual productivity, albeit sporadically, but struggling to deliver cohesive P&L level ROI, scientific leaders find themselves at an interesting intersection. They are compelled to balance the promise of AI with a realistic estimate of investment ROI — a dichotomy that is potentially anxiety-inducing and laced with uncertain business outcomes.
Given this scenario, we spoke with **Margaret Difilippo, Zifo’s Head of Commercial in North America**, who brings nearly 35 years of experience in the Biopharma industry, about the lingering anxiety and uncertainty surrounding shiny new objects like AI — and how best to balance the differing expectations of the scientific and IT/informatics departments, the two most important stakeholders in driving science forward.
***Right up front, there’s a lot happening in the market today. From an economic point of view, and considering the impact of tariffs, there’s a great deal of business uncertainty. At the same time, many significant AI investments are also being made.***
***Given this charged atmosphere, what are you hearing from the market? What are top executives telling you when you meet with them? Are you picking up on any signals that business newspapers aren’t publishing — any insights that would be interesting for our readers?***
I think right now **there’s a lot of anxiety and uncertainty, especially in large pharma when it comes to how best to make use of AI**. Also, alongside AI induced anxiety, we’re also seeing many executives being replaced, specifically at the VP level, with new people coming in. This is causing a lot of turmoil.
When these transitions happen, budgets often get frozen for a bit because the new executives tend to bring in their own people. This creates uncertainty among the levels below them, who are worried about their jobs and the new direction the company will take.
Right now, I feel there’s a lot of uncertainty. However, in the last few weeks, I’ve noticed things are starting to settle down as the new people get into place. It felt like things came to a halt earlier this summer, around May and June, **but now they’re starting to open up again with the new leadership in place at many companies**.
***When it comes to technology choices, I mean, if you take any industry, technology is the backbone. We may work in a bank, a lab, or on an airplane, but technology is what drives almost all workflows.***
***So, regarding the biopharma sector, what is your take, especially given the AI buzz? Who usually holds the power to make technology decisions? Is it the scientific side i.e., the business side, or the IT/Informatics side? Who decides what technology the business should be using?***
I think there are different cultural components across biopharma. **In some companies, the power is with the business; with others, it’s with the IT group; and with some, it’s a mix**.
What I see is that successful organizations are those where IT and science work collaboratively. When you “throw things over the wall” — if IT has an idea that they need to update their technology and they just throw it over the wall — it will be met with huge resistance. I think organizations that have senior-level people at the top providing a clear direction and vision on how technology will enable them to do their science better with greater efficiency — for instance, helping them identify targets faster or stratify patients faster — that’s where you have the most success.
So where is the power held? **IT may have the power to implement something, but if they can’t convince the scientists to make that change, it’s just not going to happen**. It’s a bit surprising to me, in a sense: some scientists still like to use Excel. Their mentality is, “Why should I change? Give me a reason to change. Why change when I’ve been doing this for the last 30 years and it’s been working for me?”
In research specifically, there needs to be a compelling “why” for them to change. It’s up to the IT department, along with the cultural leaders on the science side, to make that case. The younger generation of new scientists are trained in data science and computational biology, so they are comfortable with AI. But for those who have been in the lab and have been successful for 30 years, there needs to be a whole change management and adoption management process. **People will only make a change if they see value in it, and it’s up to the entire organization to demonstrate that value**.
***Okay, that’s interesting. So, what are some of the most common, or perhaps surprising, forms of resistance you’ve been facing lately? This is especially in the context of large digital transformation programs or even with well-established technologies like ELN or LIMS, not just new ones like AI, which is still in its nascent phase. What are some of the surprising forms of resistance?***
I think there’s a lot of fear about what this means for people. Fear of how it will affect their day-to-day job, and whether they might be out of a job.
**I believe if you look downstream on the manufacturing side, that’s where most of the resistance will be — because of all the compliance, GxP, and GMP regulations.** When systems like LIMS are in place, they’re expected to stay for a decade. It’s amazing to me to find that at some of the big pharma companies, their systems are 12 years behind. They don’t upgrade because the time and money required for an upgrade in a compliant, validated system is a huge effort. So, **they tend to kick the can down the road and don’t keep their technology up to date**. It’s working and validated, they feel secure with it, and there’s always the risk: if we update the system, are we going to introduce errors? Will we be able to answer the auditors’ questions? Fear is probably the biggest factor.
In the clinical space, it’s also about how it’s going to impact the integrity of the data, which is a big concern.
I also think that, **at least in the many decades I’ve been in this industry, there have been a lot of hypes**. Back in the day, computational chemistry was a huge hype. Everyone thought it was going to solve everything and create all these new drugs, so people jumped on the bandwagon. Then combinatorial chemistry came along, and everyone thought we’d be able to develop new drugs using silicon graphics systems and wouldn’t need to do as much lab work. **All of these hypes went through a cycle and then fizzled out**.
Based on who I talk to, there’s a belief that the current hype won’t fizzle out completely but will come to a more standardized level where people will see the true value. **So, some people are taking a wait-and-see approach. They don’t want to be part of the hype. Once it settles down and they can see where the value is and where it can be successfully applied, then they will embrace it and get more involved.**
***That makes a lot of sense. Companies do change their platforms, even if they’d prefer to stick with them for a decade. While it might happen at a glacial pace, digital transformations are indeed taking place.***
***When a company decides to replace its LIMS, for example, it’s a huge undertaking. They must overcome all the hurdles you mentioned — regulations, effort, cost, and investment. If they’ve managed to jump through all those hoops, there must be a very compelling reason for them to do so. What typically pushes them over the edge?***
**At some point, older systems just won’t be able to run on current platforms. Eventually, they will break.**
Most companies are now cloud-based, though I still see manufacturing operations that are on-premise. The research side has moved to SaaS; I don’t know any research organizations I deal with that haven’t moved to the cloud. However, I still see resistance to moving to the cloud in manufacturing.
But with executives seeing the need to break down silos — because it’s all about the data — we need to have things more centralized so we can use data across R&D, clinical, and manufacturing and make the best use of that data. These silos need to be broken down. So, people are starting to see, and it’s coming from the top down, that we need to break them down for a competitive advantage, for speed to market, and so on.
***You mentioned data, and since you have spent decades in this industry, I was wondering: since when have people started realizing the importance of it? When I read articles now, I get the sense that all research basically comes down to data. It’s so much so that the term “Biotech” has been flipped; now there are “TechBio” startups where tech geeks come in with quantum and physics ideas to find patterns in data, similar to what happened in Wall Street trading couple of decades ago. Historically, when did this trend start?***
**I think it’s been a journey, but it’s really picked up speed in the last seven years**. That would be my take. Maybe 10 years ago, it was still a theory, but in the last seven years, it has become more actionable. And honestly, in the last three years, it’s grown exponentially. **People are starting to feel nervous, like “am I missing something?” I went to a forum recently where executives from a big-name pharma said, “We feel so far behind because we’re not using agentic AI.“**
There’s so much hype and talk about using AI that executives are saying, “We need to roll this out. We need to make sure every scientist in the organization understands what it can do for them.” So, **in the last two or three years, I think there has been real pressure from the industry, with companies feeling like they are behind the curve**.
***Big Pharma went through the patent cliff. Did that play a role? Are there any specific reasons you can think of? Something must have happened about seven years ago that pushed people to realize how important data is.***
It’s a natural evolution. I **think it’s also been influenced by the cross-pollination of executives from outside of biopharma who are now entering the industry and bringing a different perspective**. They look at what the industry is doing and say, “Wait, you guys are really far behind. We’ve been doing this for the last decade. Why aren’t you?”
The pharmaceutical industry is far behind other sectors like banking or finance in terms of digital transformation. Why is that? I would go back to fear and regulatory issues that have really prevented people from embracing this transformation as quickly as other industries.
***But could it also be because finding a drug target is getting that much more difficult, and perhaps all the low-hanging fruit have already been taken? Is that something you hear from executives?***
I think yes — it’s gotten harder. I also think the new drugs coming out aren’t just based on biology or chemistry alone. They’re a combination of new modalities, such as cell and gene therapy or combination therapy. This means there’s now a greater need to understand how data science can connect these different, siloed modalities.
**There’s much more emphasis on how data can bring these things together, which is a shift from a time when a scientist might have focused solely on creating the next small molecule.**
***You interact with lot of professionals in the industry and exchange a lot of ideas. So, regarding the importance of data, how does the IT or Informatics side see it versus the scientists? Do they perceive it differently? Is there a gap?***
Yes, I believe so. Scientists have typically focused narrowly on their own data and on owning it. In contrast, IT’s perspective is often, “Let’s do an enterprise-wide solution for everybody.” But when you do something for everyone, each person feels like it doesn’t do exactly what they need for their specific workflow.
**I’ve seen instances where IT just threw a platform over the wall, ripping out of scientists’ hands what they were used to and giving them something that just doesn’t work for them.**
What they should have done is brought people together so they could be part of the solution. People don’t like being told what to use. But when they’re involved, they might accept a solution that’s not 100% perfect for them because they understand it’s for the good of the organization — so that data can be used not just by them and their department, but by others as well. They need buy-in.
**Instead of a two- or three-year transformation that people don’t want to be a part of, organizations should look for quick wins to show value**. They need to demonstrate that a new system won’t replace a person’s job. Instead, it will handle mundane tasks so they can focus on more creative, scientific work. You need to sell them on the value it brings and the reason for the change.
***What’s the mix like? Let’s say out of 10 companies you’ve worked with, what’s the ballpark breakdown? In how many did IT hold the power, and in how many did scientists hold the power?***
I’d say it’s about 50/50. The power dynamic can shift, especially when there are changes in upper-level management, as I mentioned earlier. At times, I’ve seen the business — that is, the scientists — have more power than IT, and at other times, I’ve seen IT have more power than the business. So, it really depends on the situation.
***Margaret, where do you see the industry heading in the next two to three years? What is your reading of the situation, given that you are picking up AI-induced anxiety signals from a section of the industry, and how do you see this playing out?***
**AI is not going away. I believe that organizations are now in the process of essentially trying to accelerate the deployment of AI and are doing more on education and enablement.**
They are also understanding where there could be some quick wins and are getting people brought in and on the bandwagon. I think there is a bit of hype around AI, and that will settle down where it will become a part of everybody’s day-to-day routine, and people will embrace it more. I think that’s where we are right now. **It’s here to stay, but we need to make sure that people understand it is not replacing humans**. It’s making people more efficient and advancing science to ultimately improve human lives.
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
---
### [Finding Our Google Maps Moment In Translational Genomics](https://zifo.com/blogs/finding-our-google-maps-moment-in-translational-genomics/)
**Published:** September 23, 2025
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [Finding Our Google Maps Moment In Translational Genomics](https://zifo.com/blogs/finding-our-google-maps-moment-in-translational-genomics/ "Finding Our Google Maps Moment In Translational Genomics")
## Finding Our Google Maps Moment In Translational Genomics
Sandor Szalma, Scientific Advisor
Sep 23, 2025
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Finding%20Our%20Google%20Maps%20Moment%20In%20Translational%20Genomics%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Ffinding-our-google-maps-moment-in-translational-genomics%2F "Share on Email")
- [](https://x.com/intent/post?text=Finding%20Our%20Google%20Maps%20Moment%20In%20Translational%20Genomics&url=https%3A%2F%2Fzifo.com%2Fblogs%2Ffinding-our-google-maps-moment-in-translational-genomics%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Finding+Our+Google+Maps+Moment+In+Translational+Genomics&url=https%3A%2F%2Fzifo.com%2Fblogs%2Ffinding-our-google-maps-moment-in-translational-genomics%2F "Share on LinkedIn")
Image reference: / source
The growth of large, well-defined biobanks like UK Biobank, FinnGen, and the All of Us Research Program has changed what is possible in the field of genetics research.
Researchers now have access to huge genetic and phenotypic datasets that cover entire populations and can show the genetic structure of disease in ways that have never been possible before. The promise is clear: enable discoveries, make drug development better, improve patient stratification, and eventually make precision medicine a part of everyday healthcare.
However, **even though there is a lot of data, the path from biobank to biological insight is still very fragmented. In Translational Genomics, researchers today are in a strange situation — they have more data than ever, but the tools they have to find, combine, and use this data often don’t work well.**
Metaphorically speaking, bridging large-scale genomic data to biological insights is like driving through a dense city **— each path may lead to a different destination, whether it’s a Polygenic Risk Score, a Biomarker, a Drug Target, or a Pharmacogenomic Guide.** The challenge lies in choosing the optimal route and interpreting the signs along the way.
*(Sandor Szalma, Scientific Advisor at Zifo)*
**Our current tools are like paper road maps — helpful, but not very flexible or connected.** This is where the “Google Maps” metaphor makes sense. **Translational genomics needs a system that is dynamic, interactive, and layered,** just like the map app lets us zoom in and out, see traffic and adapt the route, find alternative routes, add stops, and share our journeys. **A system that not only shows where associations are but also guides researchers from population-scale signals to interpretable biological insights.**
**From Atlases to GPS: Why Current Tools Fall Short**
GWAS and related analyses have been the workhorse of human genetics, producing summary statistics that capture associations between genetic variants and traits. You can now query, visualise, and share these results thanks to public resources like the GWAS Catalog and open-source tools like PheWeb, Open Targets, and GWAS Atlas.
Manhattan plots and QQ plots, for example, are now well-known places on the map of discovery. Of course, **the most sophisticated amongst these is Open Targets which integrates genetic associations data** with a vast array of other biological evidence types (e.g., functional genomics, expression data, pathways, animal models, drug data) and a suite of tools such as fine-mapping, colocalization, and locus-to-gene (L2G) prioritization using machine learning to support in silico target triaging. **The software is available for download and local implementation, but it needs dedicated effort, and customizations can interfere with the evolution of the package by the Open Targets Consortium roadmap.**
Hence, these tools aren’t enough. At best, they are static snapshots that are often optimised for one dataset and are not often made with scalability, collaboration, or integrative analysis in mind. **A researcher who wants to go from a GWAS hit to a possible drug target may have to use a lot of different platforms, download datasets, run command-line scripts, and connect the dots between genetic signals, biological pathways, and phenotypes by hand.** The trip takes a long time, and the path is often unclear.
**Biobanks: The New Cities of Genomics**
Think about the biobank landscape itself to get an idea of how big the problem is. **These massive datasets are like huge new cities: they have a lot of information, but it’s easy to get lost in them if you don’t have the right tools.** The UK Biobank has genomic and longitudinal phenotypic data on 500,000 people. FinnGen combines genetic information with health records that go back decades. All of Us wants to sign up more than a million people from different backgrounds in the U.S. They make up an unprecedented map of human health and disease.
Privacy restrictions often make it hard to get to individual-level data, so summary statistics are usually the best way to do large-scale analysis. **Summary statistics are powerful, but they need advanced downstream analysis — fine-mapping, colocalization, variant annotation, and Mendelian Randomization (MR) — to turn associations into biological meaning.** These steps become roadblocks when workflows aren’t integrated.
**What a Google Maps for Genomics Would Look Like**
So, what would it mean to have a Translational Genomics version of Google Maps? A few ideas stand out:
**Zoom In, Zoom Out —** This feature lets you customise your visualisation beyond basic Manhattan/QQ plots. You can compare multiple traits, explore different regions, and add functional annotations on top of each other.
**Interactive and Intuitive —** Tools that let you explore, test hypotheses, and see things in real time, not just in static plots.
**User-friendly upload and management** of any GWAS summary statistics (private or public) including user management.
**Integrated downstream analysis workflows —** The platform integrates with pipelines for algorithms like MR, fine-mapping, and variant annotation , so you don’t need to know a lot about the command line or download data for each step.
**Ready for collaboration —** Shared workspaces where research teams can mark up and talk about their findings in the same way that maps today let people share routes and get live updates.
**Scalable and Extensible —** A platform that can add custom analysis and visualisation tools and interactive performance does not degrade significantly by increasing the size of the variants and phenotypes/studies.
Such a system would not only help researchers navigate today’s complexity but also accelerate the journey from biobank-scale data to meaningful biological discovery — guiding scientists to see not just where the roads are, but which ones are most promising for translational insights and therapeutic discovery.
**The Road Ahead: Why This Is Important Right Now**
It is very important to build this next-generation infrastructure as soon as possible. **Drug discovery pipelines are relying more on human genetics to derisk targets to improve the probability of technical success.**
Robust interpretation of genomic data across populations is essential for patient stratification and risk prediction. **And for precision medicine to work, we need to find a way to connect large-scale research with personalised care.**
The promise of biobanks could be put on hold if navigation tools don’t get better. **Data will keep piling up, but insights will stay hidden behind technical problems, broken workflows, and separate systems.** The opportunity is clear: we can unlock the full potential of biobank-scale research by thinking of new ways to manage, analyse, and visualize genomic data.
**It’s time for Google Maps Moment**
**Translational genomics is at a turning point. We have the data, the computing power, and the ambition.** What we need now is a platform that is integrated, intuitive, and collaborative — one that can take us from biobank-scale data to discovery-ready insights. **A “Google Maps” for genomics** could change the way we understand the complexity of human health in the same way that GPS changed how we get around cities. **The goal is clear: precision medicine for everyone.** It’s time to make the map that will take us there.
*(Sandor Szalma’s career spans over two decades of senior leadership in drug discovery and computational biology at top pharmaceutical companies, also including a long tenure as an Adjunct Professor at Rutgers University. His experience showcases a deep expertise in leveraging machine learning, data science, and human genetics to drive innovation across the scientific value chain.)*
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
---
### [Blueprint For Pharma Success: A Strategic Guide To Informatics Vendor Evaluation](https://zifo.com/blogs/blueprint-for-pharma-success-a-strategic-guide-to-informatics-vendor-evaluation/)
**Published:** October 7, 2025
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [Blueprint For Pharma Success: A Strategic Guide To Informatics Vendor Evaluation](https://zifo.com/blogs/blueprint-for-pharma-success-a-strategic-guide-to-informatics-vendor-evaluation/ "Blueprint For Pharma Success: A Strategic Guide To Informatics Vendor Evaluation")
## Blueprint For Pharma Success: A Strategic Guide To Informatics Vendor Evaluation
Meena Raja, Business Consultant, Consulting
Oct 07, 2025
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Blueprint%20For%20Pharma%20Success%3A%20A%20Strategic%20Guide%20To%20Informatics%20Vendor%20Evaluation%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Fblueprint-for-pharma-success-a-strategic-guide-to-informatics-vendor-evaluation%2F "Share on Email")
- [](https://x.com/intent/post?text=Blueprint%20For%20Pharma%20Success%3A%20A%20Strategic%20Guide%20To%20Informatics%20Vendor%20Evaluation&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fblueprint-for-pharma-success-a-strategic-guide-to-informatics-vendor-evaluation%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Blueprint+For+Pharma+Success%3A+A+Strategic+Guide+To+Informatics+Vendor+Evaluation&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fblueprint-for-pharma-success-a-strategic-guide-to-informatics-vendor-evaluation%2F "Share on LinkedIn")
Image reference: / source
In today’s rapidly evolving pharmaceutical landscape, data is the new drug. From early discovery to global commercialization, informatics systems have become the backbone of innovation, regulatory compliance, and operational excellence.
Yet, with a crowded vendor marketplace and increasing regulatory scrutiny, selecting the right software partner is no longer optional, it’s mission-critical. According to industry benchmarks, 70% of clinical trial delays stem from vendor misalignment, leading to 20–30% budget overruns. Moreover, failure to comply with data protection regulations such as HIPAA or GDPR – often due to vendor-related shortcomings – can result in penalties ranging from $100,000 to several million dollars.
In an environment defined by stringent regulations, a relentless pursuit of quality, and the demand for seamless digital integration, effective vendor evaluation is not just a best practice – it’s the foundation of compliance, innovation, and competitive advantage. Let’s explore the core principles, a comprehensive framework, and practical methodologies to empower your vendor selection process.
**Core Principles of Vendor Evaluation**
**1. Inclusive Decision-Making: Bringing Everyone on Board**
Effective vendor evaluation starts with collaboration. By involving business, IT, and other stakeholders early in the process, organizations ensure that decisions are well-rounded and widely supported. This inclusive approach fosters ownership and eases the transition to new vendor relationships.
**2. Data-Driven Decisions: Let Facts Lead**
Decisions grounded in data are more credible and defensible. A structured methodology provides leadership with evidence-based insights, enabling clear, objective, and confident decision-making.
**3. Vendor-Agnostic Approach: Level Playing Field**
Neutrality is key. A vendor-agnostic framework ensures all vendors are evaluated fairly, based on performance and fit-not on brand familiarity or bias. This encourages competition and innovation, helping organizations choose the best partner for their needs.
**4. Customer-Centric Evaluation: Focus on What Matters**
Every customer is unique. By understanding and prioritizing what matters most-be it scientific capabilities, regulatory compliance, or partnership potential-organizations can align vendor selection with their strategic goals.
**5. Market Insights: Stay Ahead of the Curve**
Incorporating current industry trends and market intelligence into the evaluation process ensures that selected vendors are not only capable today but also future-ready. This foresight supports long-term success and adaptability.
**Vendor Evaluation Framework**
The vendor evaluation framework aids in selecting potential vendors through a structured format. This framework relies on a set of standard criteria to assess the suitability of prospective vendors and the associated risks. There is no single vendor evaluation method that covers every circumstance. The approach may vary depending on the company’s maturity stage and size etc.
**Preparation:**
**Business Drivers**
- Business Value: Benefits a project brings, including financial gains, market share growth, and customer satisfaction.
- Success Criteria: Metrics to determine if goals are met, such as KPIs, milestones, and deliverables.
Complexity: Assessment of project difficulty, influenced by stakeholders, technical challenges, and interdependencies.
- Maturity: Level of development and sophistication of the organization’s processes and capabilities.
Readiness: Organization’s preparedness, including resource availability and team readiness.
**Strategic Direction**
- Product Pipeline: Planned sequence of products or services to be developed and brought to market.
Delivery Model: Approach to delivering products or services, including traditional and modern methods.
- Disruptive Trends: Emerging trends and technologies that could significantly impact the industry and competitive position.
**Opportunities**
- Process: Areas for process improvement to increase efficiency, reduce costs, and enhance quality.
- People: Enhancing skills, collaboration, and work culture to drive innovation and performance.
Platform: Technological infrastructure and tools, including adopting innovative technologies and upgrading systems.
**Prioritization**
- Future State Capabilities: This involves identifying and prioritizing the capabilities that the organization needs to develop to achieve its strategic goals.
- Prioritization ensures that resources are allocated to the most critical areas that will drive the organization’s success.
**Comprehensive Approach**
**Function Evaluation**
When evaluating vendors, it’s crucial to assess their knowledge of the domain, business processes, emerging needs, and industry best practices. Understanding the product functions is another key aspect of function evaluation. This includes knowing what features are included “out of the box,” what can be configured to meet specific needs, and what requires customization. A robust solution should be capable of delivering a streamlined user experience, ensuring that the end-users can efficiently and effectively utilize the product.
**Technical Evaluation**
Technical evaluation involves a thorough understanding of the vendor’s technology stack, infrastructure requirements, and performance benchmarks. Evaluating the user interface, integration APIs, data models, and dashboards is also essential to ensure that the solution is user-friendly and can seamlessly integrate with existing systems.
Additionally, it’s important to assess the hierarchy, security, audit, archiving, data integrity, and FAIR (Findable, Accessible, Interoperable, and Reusable) capabilities of the vendor’s solution.
**Compliance Evaluation**
Compliance evaluation focuses on understanding the vendor’s adherence to regulatory requirements, such as electronic signature and 21 CFR Part 11 compliance. This ensures that the vendor’s solution meets the necessary legal and regulatory standards for electronic records and signatures. Evaluating record retention, electronic records, and data archival/migration policies is also crucial to ensure that the vendor can securely manage and preserve data over time.
Furthermore, it’s important to assess the audit trail and data privacy features of the vendor’s system. A solution compliant with 21 CFR Part 11 requirements should provide a comprehensive audit trail, ensuring that all actions are recorded and traceable. Data privacy measures should also be in place to protect sensitive information and ensure compliance with data protection regulations.
**Supplier Evaluation**
This pertains to the vendor company’s operations, licensing and subscription models, support and professional services, and general inquiries including their site presence. Occasionally, it involves IT-related aspects.
**Conclusion: Building a Resilient Vendor Network**
Effective vendor evaluation in the pharmaceutical industry is essential for ensuring quality, regulatory compliance, and the consistent delivery of safe and effective medicines. A structured approach encompassing regulatory adherence, quality assurance, risk management, and ongoing performance monitoring enables companies to build and keep a reliable vendor network while mitigating risks and optimizing costs.
Looking ahead, artificial intelligence (AI) is set to revolutionize this process by automating documentation, analyzing vast datasets for compliance and performance trends, and uncovering hidden risks across vendor portfolios. By integrating AI into vendor evaluation workflows, pharmaceutical companies can enhance efficiency, improve decision-making, and unlock new possibilities for smarter, more proactive vendor management.
**Reference:**
1\. Budish, Eric, Benjamin N. Roin, and Heidi Williams. 2015. “Do Firms Underinvest in Long-Term Research? Evidence from Cancer Clinical Trials.” American Economic Review,105(7):2044–85 –
2\. Matthey, M.A., Hollis, A. Pull me – push you? The disparate financing mechanisms of drug research in global health. Global Health 20, 14 (2024):
3\. [Day of Delay White Paper Final](https://csdd.tufts.edu/sites/default/files/2025-02/Aug2024%20Day%20of%20Delay%20White%20Paper%20Final.pdf?1750688827)
4\. Smith, Z.P., DiMasi, J.A. & Getz, K.A. New Estimates on the Cost of a Delay Day in Drug Development. Ther Innov Regul Sci 58, 855–862 (2024). [https://doi.org/10.1007/s43441-024-00667-w](https://link.springer.com/article/10.1007/s43441-024-00667-w)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
---
### [Bridging Chemistry And Informatics: The Role Of Click Chemistry In Managing Complex Bioconjugates](https://zifo.com/blogs/bridging-chemistry-and-informatics-the-role-of-click-chemistry-in-managing-complex-bioconjugates/)
**Published:** January 13, 2026
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Blogs](https://zifo.com/blogs/ "Blogs")> [Bridging Chemistry And Informatics: The Role Of Click Chemistry In Managing Complex Bioconjugates](https://zifo.com/blogs/bridging-chemistry-and-informatics-the-role-of-click-chemistry-in-managing-complex-bioconjugates/ "Bridging Chemistry And Informatics: The Role Of Click Chemistry In Managing Complex Bioconjugates")
## Bridging Chemistry And Informatics: The Role Of Click Chemistry In Managing Complex Bioconjugates
Rahul Anil Babu, Scientific Application Consultant
Jan 13, 2026
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Bridging%20Chemistry%20And%20Informatics%3A%20The%20Role%20Of%20Click%20Chemistry%20In%20Managing%20Complex%20Bioconjugates%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fblogs%2Fbridging-chemistry-and-informatics-the-role-of-click-chemistry-in-managing-complex-bioconjugates%2F "Share on Email")
- [](https://x.com/intent/post?text=Bridging%20Chemistry%20And%20Informatics%3A%20The%20Role%20Of%20Click%20Chemistry%20In%20Managing%20Complex%20Bioconjugates&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fbridging-chemistry-and-informatics-the-role-of-click-chemistry-in-managing-complex-bioconjugates%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Bridging+Chemistry+And+Informatics%3A+The+Role+Of+Click+Chemistry+In+Managing+Complex+Bioconjugates&url=https%3A%2F%2Fzifo.com%2Fblogs%2Fbridging-chemistry-and-informatics-the-role-of-click-chemistry-in-managing-complex-bioconjugates%2F "Share on LinkedIn")
Image reference: / source
The biopharma landscape is rapidly evolving beyond traditional small molecules and biologics toward **conjugated therapeutics**, an innovative drug classes that combine multiple modalities for enhanced precision and efficacy. These include antibody-drug conjugates (ADCs), antibody-oligonucleotide conjugates (AOCs), and peptide-drug conjugates (PDCs), each designed to deliver targeted therapies with improved therapeutic index and reduced off-target effects.
As these conjugates gain prominence, they introduce **two critical challenges**:
1. **Chemical complexity** –requiring site-specific, stable linkages under physiological conditions.
2. **Digital complexity** — demanding accurate representation and traceability in informatics systems for regulatory compliance and IP protection.
**Why AOCs and Conjugates Matter? The Relevance and Evolution of Conjugated Therapeutics**
Conjugated drug classes represent a strategic response to some of the toughest challenges in modern medicine:
- **Targeting hard-to-reach tissues** such as the central nervous system (CNS) and muscle, where traditional biologics often fail.
- **Improving therapeutic index** by delivering cytotoxic payloads directly to diseased cells, minimizing systemic toxicity.
- **Addressing genetic and rare diseases** through oligonucleotide-based approaches that modulate gene expression.
**Antibody-Oligonucleotide Conjugates (AOCs)** exemplify this evolution. By combining the targeting precision of antibodies with the gene-modulating power of oligonucleotides, AOCs open new frontiers in treating neuromuscular disorders and other conditions previously considered intractable.
It is worth noting that ADCs stand alone as a broadly validated therapeutic class, whereas PDCs have faced significant regulatory setbacks that limit their success to niche applications, and AOCs are currently at the emerging proof-of-concept stage without any approved products. However, rapid advancements in linker chemistry and site-specific conjugation are now solving these stability and delivery challenges, positioning the next generation of PDCs and AOCs to eventually join ADCs as pillars of modern precision medicine.
**Market Outlook and Digital Readiness**
Industry momentum underscores this shift. Forecasts from IQVIA and Evaluate Pharma predict sustained growth in novel modalities — including ADCs and AOCs — through 2030. Strategic moves like **Novartis’ acquisition of Avidity Biosciences for $12 billion** highlight the confidence in these platforms and their potential to redefine therapeutic paradigms.
**As conjugates become central to drug pipelines, digital readiness is no longer optional**. Accurate registration of complex structures, linkage chemistries, and experimental parameters is critical for regulatory filings, IP protection, and data-driven decision-making. **This convergence of chemistry and informatics is where Click Chemistry offers a decisive advantage.**
**Click Chemistry Gains Prominence**
Known for its modular, high-yield, and biocompatible reactions, Click Chemistry enables precise conjugation while simplifying digital registration workflows. For scientists, informatics teams, and regulatory professionals, understanding this intersection is essential to accelerate R&D and maintain compliance in a market poised for exponential growth.
**Digital Representation Challenges in Conjugate Informatics**
Electronic Lab Notebooks (ELNs) and Laboratory Information Management Systems (LIMS) were originally designed to handle either biologics or small molecules, but not the complexities of handling conjugates of the two. Keeping track of conjugates, like AOCs, in these systems requires drawing the combined molecule’s structure, accurately defining and maintaining the chemical link between its parts, while maintaining referential integrity to the individual components, which often stretches the capabilities of existing registration software or often requires complex customization. Below are some of the challenges:
- **Preserving Source Component Links:** Biologics and small molecules are handled separately, making hybrid conjugates difficult to maintain without losing key structural details.
- **Incomplete Linkage Representation:** Linking chemistry critical to conjugate function is poorly captured in systems lacking cross-domain structure support, hindering accurate viewing of the combined structure after cross-linking.
- **Searchability:** Key experimental parameters (linker ratios, conjugation sites, modifications) are often unstructured due to customized needs to handle linker chemistry. This could potentially lead to data searchability issues which is particularly important in conjugates as their development involves numerous cycles of varying experimental parameters as well as studying linkages across other conjugates before arriving at the optimal linkage chemistry.
- **Regulatory and Traceability Challenges:** During regulatory filings or patent submissions, reviewers expect clear traceability of experimental parameters such as conjugation ratios, linker composition, and modification sites. If the system can’t retrieve this information systematically, teams must manually reconstruct it which could be a time-consuming and error-prone process.
**Click Chemistry – Fast, Secure, Precise**
Click chemistry refers to a class of highly efficient, selective, and modular chemical reactions that “click” molecules together under mild conditions. A relatable analogy could be of a seatbelt. In order to fasten a seatbelt, you would need to use gentle force (favorable condition/catalyst) to push the seatbelt latch plate (one entity) into the buckle (second entity). Once you hear the “click” sounds, the seatbelt is now secure fastened.
The most commonly known click reaction is the azide–alkyne cycloaddition. These reactions are designed to reliably connect molecular building blocks without generating complex byproducts hence leading to higher yields and lesser need for purification.
**Below are some key terminologies in understanding concept of Click Chemistry**
- **Click Core (or Click Core Residue):** The reactive part of a molecule that forms a covalent bond during a click reaction — such as an alkyne or azide on a peptide, oligonucleotide, or small molecule. It defines the “reaction site” where the two entities will join together.
- **Leaving Group (in registration systems):** Functional groups that are removed during the conjugation process. Tagging leaving groups in registration systems ensures that the final product’s structure and molecular weight are calculated accurately.
**Why Click Chemistry?**
Click chemistry has emerged as a robust and selective approach for constructing complex bioconjugates with molecular precision. Its mild, high-yield reactions enable consistent and site-specific conjugations that help streamline discovery workflows and analytical characterization. Below are some reasons why the approach is important specifically for conjugations.
- **Site-Specific Conjugation**
- Traditional chemistries often produce heterogeneous products (random attachment).
- Click reactions allow predictable attachment at defined sites on proteins or oligonucleotides, improving product consistency.
- **Mild, Biocompatible Condition**
- Many proteins or oligonucleotides are sensitive to harsh reagents. Click reactions proceed under aqueous, room-temperature conditions, preserving biomolecule integrity.
- **High Yield and Minimal Byproduct**
- Conventional conjugation may require extensive purification due to side reactions. Click Chemistry products are more homogeneous, making analytical measurements (MS, HPLC, etc.) easier.
- Click chemistry produces clean, high-yield reactions, simplifying downstream purification.
**Looking Ahead**
As the bioconjugate market expands, biopharma companies must select the right digital tools to register and maintain these complex entities accurately. Proper management is essential not only for protecting intellectual property but also for ensuring regulatory compliance and generating reliable reports for FDA approvals. Incorporating the right tools can also empower scientists working with bioconjugates to track critical parameters, identify trends, and make data-driven decisions, ultimately accelerating research and development.
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
## Recent Blogs
### [Agentic AI Survey: Early Days as Industry Focuses on ROI and Lab Orchestration](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
[  ](https://zifo.com/blogs/agentic-ai-survey-early-days-as-industry-focuses-on-roi-and-lab-orchestration/)
### [CMC: Biopharma’s Strait of Hormuz](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
[  ](https://zifo.com/blogs/cmc-biopharmas-strait-of-hormuz/)
### [Conquering Biopharma’s ‘Mount Everest’: Why People Matter Most in Digital Transformation](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
[  ](https://zifo.com/blogs/accelerating-digital-transformation-with-strategic-change-management-in-pharma/)
---
## Services
### [Bioinformatics](https://zifo.com/services/bioinformatics/)
**Published:** February 17, 2025
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Services](https://zifo.com/services/ "Services")> Bioinformatics
# Bioinformatics
## Transform the Data Deluge into Scientific Discoveries
Partner with Zifo to leverage scientific data for driving decision-making and
innovation.
[ Know More ](#)
- [Analysis and Insight Generation](#)
- [Scientific Workflows and Omics Pipeline Engineering](#)
- [Software and Application Development](#)
- [Data Solutions](#)
## Leveraging the Scientific Expertise in Bioinformatics
Leverage our team’s expertise in extracting insights from diverse data (biological, omics, chemical, clinical, real-world, etc.) Zifo SMEs and consultants will collaborate closely with you to develop tailored solutions, from answering scientific questions to providing dedicated teams for capability building and long-term support. Our engagement models are designed to align with your initiatives and achieve organizational goals.
Application Portfolio
50+
Deployment Efficiency
20
Pipelines
Client Success
95%
Satisfaction
Long-term Partnerships
5+
Multi-year
Collaboration
## Bioinformatics Services
Genomics, proteomics, metabolomics, epigenetics, and microbiomics are all playing critical roles in supporting scientific research and development. Zifo has experience across this entire domain, from data management and orchestration to pipelining, secondary analysis, visualization, and analytics, encompassing many sequencing and cell-based technologies.
Analysis and Insight Generation
Transform your data into actionable insights. Collaborate with Zifo scientists to address key research questions and achieve strategic goals.
[ Learn more >> ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjMzNzYiLCJ0b2dnbGUiOmZhbHNlfQ%3D%3D)
Scientific Workflows and Omics Pipeline Engineering
Build efficient and cost-effective Omics pipelines. Leverage Zifo expertise to optimize your workflows and seamlessly integrate new applications.
[ Learn more >> ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjMzNzkiLCJ0b2dnbGUiOmZhbHNlfQ%3D%3D)
Software and Application Development
Empower your scientists with intuitive tools. Focus on analysis and decision-making, not coding. We build tailored solutions for your data challenges.
[ Learn more >> ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjMzODIiLCJ0b2dnbGUiOmZhbHNlfQ%3D%3D)
Data Solutions
Gain valuable insights from your data. Zifo bridges the gap between scientific expertise and technical proficiency. Our solutions ensure your data is findable, accessible, interoperable, and reusable.
[ Learn more >> ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjMzODYiLCJ0b2dnbGUiOmZhbHNlfQ%3D%3D)
FAQ
## Curious how Zifo’s bioinformatics services turn scientific data into discoveries?
See how Zifo helps leverage scientific data for better decision-making and innovation.
Talk to an Expert
What bioinformatics services does Zifo provide?
Zifo Bioinformatics Services help life sciences organizations analyze and interpret complex biological data generated from modern research technologies. Zifo supports areas such as genomics, proteomics, metabolomics, epigenetics, and microbiome analysis, enabling scientists to transform large biological datasets into meaningful insights for research and development.
How does Zifo help researchers generate insights from biological data?
Zifo works closely with research teams to convert diverse scientific datasets into actionable insights. By combining scientific expertise with advanced data engineering, Zifo helps researchers answer key questions related to target identification, biomarker discovery, drug mechanisms, and pathway analysis.
What types of omics workflows and pipelines can Zifo develop?
Zifo designs and develops custom omics pipelines and bioinformatics workflows tailored to the needs of research organizations. These workflows can support large-scale sequencing data processing, automated data analysis, and integration with enterprise systems to improve efficiency and scalability in research environments.
How does Zifo support scientific data management and FAIR data principles?
Zifo builds scientific data architectures that ensure research data is structured according to FAIR principles — findable, accessible, interoperable, and reusable. This approach helps organizations standardize diverse scientific datasets and make them ready for advanced analytics, machine learning, and collaborative research.
How does Zifo integrate bioinformatics platforms with laboratory systems?
Zifo integrates bioinformatics platforms with laboratory instruments and informatics systems such as LIMS and ELN. By connecting laboratory instruments, data management systems, and analytics platforms, Zifo helps create integrated laboratory environments that streamline data collection, analysis, and reporting.
How does Zifo support data visualization and scientific analytics?
Zifo provides advanced analytics, dashboards, and visualization solutions that help research teams explore complex datasets. These tools allow scientists to interpret results faster, identify patterns in biological data, and make informed decisions during research and drug discovery processes.
Why do life sciences organizations choose Zifo for bioinformatics services?
Organizations choose Zifo because of its deep expertise in scientific informatics, data engineering, and life sciences research. By combining domain knowledge with advanced technologies such as AI, high-performance computing, and workflow automation, Zifo helps organizations accelerate scientific discovery and innovation.
Get in touch
First Name
Last Name
Email
Phone Number
Company
Designation
Enquiry Type
Enquiry Type Request for Zifo Services Product Partnership Job/Internship/Placement Enquiry Other
Message
Acceptance I consent to being contacted by an official Zifo representative
Submit
Featured Resources
[  ](https://zifo.com/blogs/delivering-value-with-spatial-transcriptomics/)
[ Blog ](https://zifo.com/blogs/delivering-value-with-spatial-transcriptomics/)
## [Delivering Value With Spatial Transcriptomics](https://zifo.com/blogs/delivering-value-with-spatial-transcriptomics/)
[  ](https://zifo.com/blogs/foundational-models-in-single-cell-omics/)
[ Blog ](https://zifo.com/blogs/foundational-models-in-single-cell-omics/)
## [Foundational Models In Single-Cell Omics](https://zifo.com/blogs/foundational-models-in-single-cell-omics/)
[  ](https://zifo.com/blogs/loxford-nanopore-technology-ont-for-whole-genome-sequencing-wgs-snp-typing-of-pathogenic-bacterial-strains/)
[ Blog ](https://zifo.com/blogs/loxford-nanopore-technology-ont-for-whole-genome-sequencing-wgs-snp-typing-of-pathogenic-bacterial-strains/)
## [Oxford Nanopore Technology (ONT) For Whole Genome Sequencing (WGS) SNP Typing Of Pathogenic Bacterial Strains](https://zifo.com/blogs/loxford-nanopore-technology-ont-for-whole-genome-sequencing-wgs-snp-typing-of-pathogenic-bacterial-strains/)
[  ](https://zifo.com/blogs/early-days-for-ai-but-scientific-data-management-gains-momentum/)
[ Blog ](https://zifo.com/blogs/early-days-for-ai-but-scientific-data-management-gains-momentum/)
## [Early Days For AI But Scientific Data Management Gains Momentum](https://zifo.com/blogs/early-days-for-ai-but-scientific-data-management-gains-momentum/)
[  ](https://zifo.com/blogs/beyond-the-hype-biopharmas-tech-transfer-process-needs-a-fundamental-reset/)
[ Blog ](https://zifo.com/blogs/beyond-the-hype-biopharmas-tech-transfer-process-needs-a-fundamental-reset/)
## [Beyond The Hype: Biopharma’s Tech Transfer Process Needs A Fundamental Reset](https://zifo.com/blogs/beyond-the-hype-biopharmas-tech-transfer-process-needs-a-fundamental-reset/)
[  ](https://zifo.com/blogs/a-strategic-guide-to-consolidation-in-scientific-informatics/)
[ Blog ](https://zifo.com/blogs/a-strategic-guide-to-consolidation-in-scientific-informatics/)
## [A Strategic Guide To Consolidation In Scientific Informatics](https://zifo.com/blogs/a-strategic-guide-to-consolidation-in-scientific-informatics/)
---
### [Manufacturing CMC Services](https://zifo.com/services/cmc-chemistry-manufacturing-controls/)
**Published:** July 31, 2026
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Services](https://zifo.com/services/ "Services")> Manufacturing CMC Services
# Manufacturing CMC Services
## ## Accelerate Cycle Times by 40% with Connected CMC Data
By transforming fragmented process data into a connected, AI-ready foundation, Zifo’s experts eliminate CMC-related bottlenecks to safely and efficiently scale your manufacturing operations.
[ Know More ](#)
- [End-to-End Consulting](#)
- [Data aggregation for eCTD](#)
- [CMC Data Aggregation & AI-Ready Harmonization](#)
- [Predictive Process Monitoring & Digital Twins](#)
- [Gen AI for Documentation](#)
- [Tech Transfer](#)
- [Regulatory Compliance and Submission](#)
- [Process Automation & Workflow Orchestration](#)
- [Quality and Compliance Consulting](#)
## Driving Manufacturing Success Through Expert Guidance
Chemistry, Manufacturing, and Controls (CMC) is critical to therapy development, requiring the flawless collation of complex manufacturing, stability, and analytical data for global regulatory approval (FDA, EMA). Aggregating this fragmented data is a time-consuming challenge. Zifo combines scientific domain knowledge to reconfigure process, AI know-how, regulatory expertise, and technology partnerships to simplify data integration, ensure compliance, and remove impediments on large scale manufacturing.
20 of the Top 25 Global Biopharma Partners
World-leading biopharma companies trust Zifo to digitize, integrate, and streamline their complex CMC and manufacturing operations.
Improved Performance
Accelerating the transition from R&D to commercial manufacturing by utilizing centralized digital recipes, PLM strategies, and structured knowledge graphs.
Up to 50% Reduction in Execution Timelines
Achieved by eliminating manual data transcription across ERP, LIMS, and CDS, and implementing intelligent, automated Review-by-Exception (RbE) workflows.
>99% Elimination of Documentation Errors
Thousands of hours saved annually per site by deploying automated data validation and GenAI workflows to rapidly synthesize raw manufacturing data into compliant CMC regulatory filings.
## Enabling Rapid Response and Informed Decision-Making
As science is increasingly dependent on computing power, it is imperative for science-focused organizations to ensure smooth application integration and maintenance. Also, it is important to reduce instances of system downtime while providing quick support to business users.
End-to-End Consulting
End-to-end CMC consulting to guide your product from development to commercialization.We support formulation, analytical strategy, regulatory documentation, GMP readiness, and manufacturing scale-up. Our practical, risk-based approach helps simplify complex CMC decisions.
[ Learn more >> ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjcwMzUxIiwidG9nZ2xlIjpmYWxzZX0%3D)
Data aggregation for eCTD and AI
AI-enabled data aggregation for faster, cleaner eCTD submissions. We organize, structure, and validate regulatory data across documents, modules, and sources. Improve submission readiness, reduce manual effort, and enhance consistency.
[ Learn more >> ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjcwMzYwIiwidG9nZ2xlIjpmYWxzZX0%3D)
CMC Data Aggregation & AI-Ready Harmonization
Aggregating manufacturing and analytical data across siloed systems (ERP, LIMS, CDS, QMS) is challenging. Zifo builds robust, scalable data architectures that centralize your CMC data. We ensure your data is FAIR (Findable, Accessible, Interoperable, Reusable), providing an audit-ready source of truth for submissions and building the foundational data layer required for advanced AI and machine learning initiatives.
[ Learn more >> ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjcwMzY5IiwidG9nZ2xlIjpmYWxzZX0%3D)
Predictive Process Monitoring & Digital Twins
Move from reactive quality control to proactive manufacturing. By applying AI to your Critical Process Parameters (CPPs) and historical batch data, we help you build predictive models and digital twins. This empowers your teams to forecast yield, anticipate equipment maintenance, and continuously optimize manufacturing processes in real-time.
[ Learn more >> ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjcwMzk4IiwidG9nZ2xlIjpmYWxzZX0%3D)
Gen AI for CMC Documentation
Drafting complex CMC sections for regulatory filings requires massive manual effort. Zifo leverages Gen AI and natural language processing (NLP) to rapidly synthesize manufacturing data, automate the drafting of standard compliance reports, and streamline regulatory documentation with high accuracy, freeing your scientists to focus on analysis.
[ Learn more >> ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjcwNDA5IiwidG9nZ2xlIjpmYWxzZX0%3D)
Tech Transfer
Zifo offers handover of analytical testing processes, manufacturing process parameters, product specification data transfer, data integrity support, validation and compliance, and manufacturing plant design services. Successful tech transfer hinges on effective knowledge management amidst the rising tide of data.
[ Learn more >> ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjcwNDIzIiwidG9nZ2xlIjpmYWxzZX0%3D)
Regulatory Compliance
From pre-clinical to commercial manufacturing, adhering to GxP and international guidelines is critical. We support the creation of rigorous digital frameworks for your CMC data, ensuring data integrity, traceability, and seamless preparation for electronic regulatory submissions.
[ Learn more >> ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjcwNDM2IiwidG9nZ2xlIjpmYWxzZX0%3D)
Process Automation & Workflow Orchestration
Huge efficiency gains are possible by orchestrating workflows across your manufacturing environment. Zifo leverages both open-source and proprietary software, along with intelligent automation, to remove bottlenecks from the manufacturing lifecycle, driving resilient and cost-effective processes.
[ Learn more >> ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjcwNDQzIiwidG9nZ2xlIjpmYWxzZX0%3D)
Manufacturing Batch Release Automation
We improve efficiency and scalability by optimizing, automating, validating, and controlling processes through BPMN, technology, and change management. Our solutions automate business rules and support data-driven decisions. Zifo integrates your ERP, LIMS, and CDS systems, automating business rules, and deploying AI-driven anomaly detection to deliver faster, highly scalable, and exceptionally accurate batch releases.
[ Learn more >> ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjcwNDU1IiwidG9nZ2xlIjpmYWxzZX0%3D)
FAQ
Talk to an Expert
Get in touch
First Name
Last Name
Email
Phone Number
Company
Designation
Enquiry Type
Enquiry Type Request for Zifo Services Product Partnership Job/Internship/Placement Enquiry Other
Message
Acceptance I consent to being contacted by an official Zifo representative
Submit
Featured Resources
[  ](https://zifo.com/blogs/evolving-compliance/)
[ Blog ](https://zifo.com/blogs/evolving-compliance/)
## [Evolving Compliance](https://zifo.com/blogs/evolving-compliance/)
[  ](https://zifo.com/blogs/optimizing-instrument-and-equipment-validation-lean-cohort-methodology/)
[ Blog ](https://zifo.com/blogs/optimizing-instrument-and-equipment-validation-lean-cohort-methodology/)
## [Optimizing Instrument And Equipment Validation: Lean & Cohort Methodology](https://zifo.com/blogs/optimizing-instrument-and-equipment-validation-lean-cohort-methodology/)
[  ](https://zifo.com/blogs/early-days-for-ai-but-scientific-data-management-gains-momentum/)
[ Blog ](https://zifo.com/blogs/early-days-for-ai-but-scientific-data-management-gains-momentum/)
## [Early Days For AI But Scientific Data Management Gains Momentum](https://zifo.com/blogs/early-days-for-ai-but-scientific-data-management-gains-momentum/)
---
### [Digital Transformation Consulting Services](https://zifo.com/services/digital-transformation-consulting-services/)
**Published:** May 7, 2025
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Services](https://zifo.com/services/ "Services")> Digital Transformation Consulting Services
# Digital Transformation Consulting
## Digital Transformation to Power AI-Enabled Science
Empowering digital transformation with scientific data that’s structured,
contextualized, and AI-ready.
[ Know More ](#)
- [Digital Transformation Strategy](#)
- [Change Management](#)
- [FAIR Data & Scientific Data Architecture](#)
- [Ontology Development and Management](#)
- [Data Stewardship](#)
- [Data Governance](#)
## Transforming Scientific Data into Business Insight
Zifo’s Centre of Excellence in Digital Transformation can guide you through your digital journey, from strategy development to implementation and ongoing support, helping you unlock the full potential of your scientific data and drive innovation.
Increased Data Findability and Access
- Eliminated several hours per week of Scientists’ time in searching for past experimental data.
Accelerated R&D
- Reduce R&D cycle time by 25% through ML-driven predictions and optimizations.
Enhanced Decision-Making Accuracy
- Improve decision accuracy by 20% through advanced analytics and predictive modelling.
Novel Scientific Discoveries
- Helped clients identify new drug targets and therapeutic approaches through data-driven insights.
## Enabling Data-Driven Excellence Across R&D and Manufacturing
Scientific innovation is driven by data. Our Digital Transformation Services provide comprehensive solutions to strategize data integration, automation, and governance across the entire R&D and manufacturing lifecycle, ensuring that data is FAIR (Findable, Accessible, Interoperable, Reusable), high quality, and ready for advanced analytics.
## We specialize in our Scientific focus across:
- Omics and Molecular Data
- Chemistry and Analytical Data
- Preclinical and Bioassay Data
- CMC and Process Data
- Clinical and Real-World Data
- Manufacturing and Quality Data
Digital Transformation Strategy
Many companies find themselves with a plethora of siloed, aging, inefficient or cost-accumulating platforms that not only delay scientific progress, but also impede implementation of newly developed industry standards, such as AI technologies. Zifo helps you modernize your informatics infrastructure, consolidating data sources and streamlining workflows to accelerate scientific discovery and unlock the full potential of AI.
[ Learn more >> ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjMwODMiLCJ0b2dnbGUiOmZhbHNlfQ%3D%3D)
Change Management
Our experts are adept at stakeholder and end-user engagement, requirements and vision capture, change readiness assessment, decision making and consensus building, communication planning and program success monitoring.
[ Learn more >> ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjM0NzQiLCJ0b2dnbGUiOmZhbHNlfQ%3D%3D)
FAIR Data & Scientific Data Architecture
Scientific data architecture is now a critical enabler for maximizing the value of data across the R&D lifecycle. At Zifo, we support the development of domain-specific, FAIR-compliant, and science-focused data architectures that are technology-agnostic and built for scale. With our Foundational Data Model for R&D and a strong commitment to FAIR principles, we help organizations create the data infrastructure needed to accelerate insight, innovation, and impact. We build Data models, Ontologies, Knowledge Graphs that are heavily focussed on the Science.
[ Learn more >> ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjM0NzciLCJ0b2dnbGUiOmZhbHNlfQ%3D%3D)
Ontology Development and Management
Unlock the full potential of your data with our Ontology Development and Management services. We design, build, and maintain custom ontologies that organize complex information into clear, actionable structures. Zifo has domain SMEs that work closely with Scientists to establish concepts, relationships, and standards that drive consistency, interoperability, and smarter insights.
[ Learn more >> ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjM0ODAiLCJ0b2dnbGUiOmZhbHNlfQ%3D%3D)
Data Stewardship
Don’t let bad data undermine your decisions. Zifo provides comprehensive Data Stewardship services, continuously assisting Scientists from the point of data capture, so you can proactively maintain data quality and reliability for better insights.
[ Learn more >> ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjM0ODMiLCJ0b2dnbGUiOmZhbHNlfQ%3D%3D)
Data Governance
It’s important to ensure scientific data is backed by robust Data Governance. Science, data, and technology teams must establish clear policies, processes, and responsibilities to manage data effectively, ensuring compliance and maximizing its value across the organization.
[ Learn more >> ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjM0ODciLCJ0b2dnbGUiOmZhbHNlfQ%3D%3D)
FAQ
## Curious how Zifo’s digital transformation consulting powers AI-enabled science?
Learn how Zifo supports digital transformation with structured, contextualized, AI-ready scientific data.
Talk to an Expert
What digital transformation consulting services does Zifo provide?
Zifo Digital Transformation Consulting Services help life sciences organizations modernize their scientific data infrastructure and workflows. Zifo supports the entire transformation journey—from strategy development and technology selection to implementation and ongoing support—helping companies unlock the value of their scientific data and drive innovation.
How does Zifo help life sciences companies accelerate research through digital transformation?
Zifo enables research teams to integrate and analyze scientific data across R&D and manufacturing environments. By implementing data integration, automation, and advanced analytics, Zifo helps organizations improve data accessibility, accelerate research cycles, and enable faster scientific discoveries.
What types of scientific data can Zifo integrate during digital transformation projects?
Zifo supports integration of diverse scientific datasets, including omics and molecular data, chemistry and analytical data, preclinical and bioassay data, clinical and real-world data, manufacturing data, and quality data. This integration enables end-to-end visibility across the product lifecycle and improves decision-making across research and operations.
How does Zifo ensure scientific data follows FAIR data principles?
Zifo designs scientific data architectures that follow FAIR principles, ensuring that data is findable, accessible, interoperable, and reusable. By standardizing and integrating data across systems, Zifo enables organizations to make their data ready for advanced analytics and machine learning applications.
How does Zifo support cloud transformation for scientific organizations?
Zifo helps organizations transition to scalable cloud environments by modernizing legacy infrastructure and implementing secure cloud architectures. Our services include scientific cloud computing, platform modernization, and integration of enterprise applications to support high-performance research environments.
How does Zifo manage change and system upgrades during digital transformation?
Zifo implements structured change management processes that include impact assessments, risk analysis, and controlled deployment workflows. This approach minimizes disruption during system upgrades or platform implementations and ensures smooth adoption across scientific teams.
Why do life sciences organizations choose Zifo for digital transformation consulting?
Organizations choose Zifo because of its deep expertise in science, technology, and data integration within life sciences environments. Zifo’s consulting approach focuses on aligning technology, workflows, and people to help companies modernize R&D systems, improve data governance, and accelerate innovation.
Get in touch
First Name
Last Name
Email
Phone Number
Company
Designation
Enquiry Type
Enquiry Type Request for Zifo Services Product Partnership Job/Internship/Placement Enquiry Other
Message
Acceptance I consent to being contacted by an official Zifo representative
Submit
Featured Resources
[  ](https://zifo.com/blogs/why-science-is-protesting-for-data-democracy-and-we-must-listen/)
[ Blog ](https://zifo.com/blogs/why-science-is-protesting-for-data-democracy-and-we-must-listen/)
## [Why Science Is Protesting For Data Democracy And We Must Listen](https://zifo.com/blogs/why-science-is-protesting-for-data-democracy-and-we-must-listen/)
[  ](https://zifo.com/blogs/beyond-the-hype-biopharmas-tech-transfer-process-needs-a-fundamental-reset/)
[ Blog ](https://zifo.com/blogs/beyond-the-hype-biopharmas-tech-transfer-process-needs-a-fundamental-reset/)
## [Beyond The Hype: Biopharma’s Tech Transfer Process Needs A Fundamental Reset](https://zifo.com/blogs/beyond-the-hype-biopharmas-tech-transfer-process-needs-a-fundamental-reset/)
[  ](https://zifo.com/blogs/a-strategic-guide-to-consolidation-in-scientific-informatics/)
[ Blog ](https://zifo.com/blogs/a-strategic-guide-to-consolidation-in-scientific-informatics/)
## [A Strategic Guide To Consolidation In Scientific Informatics](https://zifo.com/blogs/a-strategic-guide-to-consolidation-in-scientific-informatics/)
---
### [Scientific Application Managed Services](https://zifo.com/services/scientific-application-managed-services/)
**Published:** May 16, 2025
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Services](https://zifo.com/services/ "Services")> Scientific Application Managed Services
# Scientific Application Managed Services
## Empower Scientists with Enterprise Scientific Managed Services
We simplify the management of your scientific applications, freeing your team to concentrate on driving efficiency and innovation across your entire scientific value chain.
[ Know More ](#)
- [Scientific Technology and IT Help Desk](#)
- [Live Chat Support Services](#)
- [Instrument Integration](#)
- [Cloud Managed Services](#)
- [Change Management](#)
- [Problem Management](#)
- [Service Level Management ](#)
- [Monitoring/Uptime Management](#)
- [Configuration and System Administration](#)
## Simplify App Upkeep, Focus on Science
We have built a Centre of Excellence in Scientific Managed Services. Our team of experts can help you with continuous application support and maintenance, freeing up valuable time of your resources.
Reduced IT Costs
- Cut IT costs by 30% by partnering with a scientific managed service provider
Improved Performance
- Increase application performance by 20% on average by optimizing IT infrastructure
Accelerated Migration
- Leverage Gen AI and intelligent automation for faster go-live
Customer Retention
- Over 95% of customers retained
## Enabling Rapid Response and Informed Decision-Making
As science is increasingly dependent on computing power, it is imperative for science-focused organizations to ensure smooth application integration and maintenance. Also, it is important to reduce instances of system downtime while providing quick support to business users.
Scientific Technology and IT Help Desk
Zifo leverages best practices such as ITIL and “follow the sun” support structures, extensive technology partner network, level 1, 2 & 3 support, early adopter user training, roll out hyper care, BAU support and knowledge base creation.
[ Learn more >> ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjMxMjYiLCJ0b2dnbGUiOmZhbHNlfQ%3D%3D)
Live Chat Support Services
Zifo helps customers with Go Live planning and execution, end-user and super user training, user support, drop-in clinics, hyper care, knowledge base creation, Level 1, 2 & 3 support for any scale rollouts, small, large, global, multisite etc.
[ Learn more >> ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjMxMzAiLCJ0b2dnbGUiOmZhbHNlfQ%3D%3D)
Laboratory Instrument, Sensor Data and System Integration
Partner with Zifo for integration solutions across ERP, Registration, Inventory, ELN, LIMS, laboratory instruments and robotics, project planning & lab audit tools, integration layer technology, instrument data standards (ADF, AniML, SiLA etc.), and tech blueprints.
[ Learn more >> ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjMxMzMiLCJ0b2dnbGUiOmZhbHNlfQ%3D%3D)
Cloud Managed Services
With Zifo’s “always on” end-user support, proven scale, quality processes, and extensive knowledge of scientific applications, organizations experience a measurable impact on end-user efficiency, satisfaction, and application downtime.
[ Learn more >> ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjMxMzYiLCJ0b2dnbGUiOmZhbHNlfQ%3D%3D)
Change Management
Zifo can proactively control and manage all IT changes. Minimize disruptions and ensure smooth transitions. Implement robust processes for seamless updates. Maintain stability and prevent unexpected incidents.
[ Learn more >> ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjMxMzkiLCJ0b2dnbGUiOmZhbHNlfQ%3D%3D)
Problem Management
We help you to dive deep to identify the root cause of recurring issues. Implement permanent fixes to prevent future incidents. Reduce downtime and improve overall system reliability. Proactive problem resolution for a stable environment.
[ Learn more >> ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjMxNDIiLCJ0b2dnbGUiOmZhbHNlfQ%3D%3D)
Service Level Management
By working with your teams, our experts define and agree upon clear IT service performance targets. Monitor and measure service delivery against these targets. Ensure IT services consistently meet business needs. Drive continuous improvement in service quality and satisfaction.
[ Learn more >> ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjMxNDUiLCJ0b2dnbGUiOmZhbHNlfQ%3D%3D)
System and Integration Monitoring/ Uptime Management
Our team continuously monitor critical systems and integrations. We proactively identify and resolve potential issues. Maximize system uptime and ensure consistent availability. Keep your operations running smoothly without interruption.
[ Learn more >> ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjMxNDkiLCJ0b2dnbGUiOmZhbHNlfQ%3D%3D)
Configuration Management and System Administration
Maintain a comprehensive inventory of all IT assets by partnering with Zifo. Effectively manage system configurations and settings. Ensure consistency and compliance across your IT infrastructure. Streamline administration for optimal system performance.
[ Learn more >> ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjMxNTIiLCJ0b2dnbGUiOmZhbHNlfQ%3D%3D)
FAQ
## Curious how Zifo’s scientific application managed services empower scientists?
Learn how Zifo simplifies scientific application management so teams can focus on efficiency and innovation.
Talk to an Expert
What are Zifo Scientific Application Managed Services?
Zifo Scientific Application Managed Services provide continuous support, maintenance, and optimization for scientific software applications used in research and laboratory environments. These services help organizations maintain reliable systems, improve application performance, and allow scientists to focus on research rather than managing complex IT infrastructure.
How does Zifo support scientific applications in life sciences organizations?
Zifo provides multi-level technical support for scientific applications, including service desk operations, troubleshooting, application monitoring, and system optimization. Our team follows industry best practices such as ITIL frameworks and global support models to ensure rapid response and efficient resolution of technical issues affecting research systems.
How does Zifo ensure high availability of scientific applications?
Zifo offers continuous monitoring of critical scientific systems, integrations, and applications to detect potential issues before they impact operations. This proactive monitoring approach helps minimize downtime and ensures that researchers have uninterrupted access to the tools and data they need.
How does Zifo manage service levels and system performance?
Zifo works with organizations to define clear service level agreements (SLAs) aligned with business goals. Our monitoring and reporting capabilities track system performance against these targets and help maintain transparency, accountability, and consistent service delivery.
How does Zifo address recurring issues in scientific applications?
Zifo applies proactive problem management practices to identify the root causes of recurring issues in scientific applications. Through detailed analysis and permanent fixes, our team improves overall system reliability and reduces disruptions for laboratory users.
Can Zifo integrate laboratory instruments and informatics systems?
Yes. Zifo supports integration between laboratory instruments and informatics platforms such as LIMS and ELN systems. These integrations enable automated data flow between instruments and software platforms, helping laboratories streamline workflows and improve data accessibility.
How do Zifo managed services support compliance in regulated environments?
Zifo managed services help organizations maintain compliance with regulatory and quality standards by supporting validated systems, secure access controls, and proper data governance. Our services help ensure laboratory systems meet regulatory requirements while maintaining reliable and secure scientific data environments.
Get in touch
First Name
Last Name
Email
Phone Number
Company
Designation
Enquiry Type
Enquiry Type Request for Zifo Services Product Partnership Job/Internship/Placement Enquiry Other
Message
Acceptance I consent to being contacted by an official Zifo representative
Submit
Featured Resources
[  ](https://zifo.com/blogs/evolving-compliance/)
[ Blog ](https://zifo.com/blogs/evolving-compliance/)
## [Evolving Compliance](https://zifo.com/blogs/evolving-compliance/)
[  ](https://zifo.com/blogs/optimizing-instrument-and-equipment-validation-lean-cohort-methodology/)
[ Blog ](https://zifo.com/blogs/optimizing-instrument-and-equipment-validation-lean-cohort-methodology/)
## [Optimizing Instrument And Equipment Validation: Lean & Cohort Methodology](https://zifo.com/blogs/optimizing-instrument-and-equipment-validation-lean-cohort-methodology/)
[  ](https://zifo.com/blogs/early-days-for-ai-but-scientific-data-management-gains-momentum/)
[ Blog ](https://zifo.com/blogs/early-days-for-ai-but-scientific-data-management-gains-momentum/)
## [Early Days For AI But Scientific Data Management Gains Momentum](https://zifo.com/blogs/early-days-for-ai-but-scientific-data-management-gains-momentum/)
---
### [Chromatographic Data Systems Services](https://zifo.com/services/chromatography-systems-services/)
**Published:** March 18, 2025
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Services](https://zifo.com/services/ "Services")> Chromatographic Data Systems Services
# Chromatographic Data Systems Services
## Streamline Your CDS for Maximum Productivity
Partner with Zifo for tailored solutions and expert support across your entire
CDS lifecycle, ensuring efficient and compliant data management.
[ Know More ](#zifo_contact_us_form)
- [Training and Workshops](#sectionOne)
- [Implementation (Rhizomer)](#sectionTwo)
- [ Validation](#sectionThree)
- [Support and Helpdesk](#sectionFour)
- [ Data Integrity](#sectionFive)
- [ Optimizations and Extensions](#sectionSix)
## 20+ Years of CDS Expertise: Delivering Results
Zifo’s CDS team combines deep expertise in laboratory data systems with a thorough understanding of analytical lab processes. This allows us to provide exceptionally tailored support. We also offer comprehensive basic and advanced training to equip all users with the precise knowledge they need.
Qualified Expertise
- Zifo’s team of experts, with over 80% holding scientific degrees, understands your laboratory’s needs and speaks your language.
Partnership Experience
- Our global presence and partnerships with industry leaders like Waters, Thermo Fisher Scientific, and Agilent ensure comprehensive solutions for all aspects of your lab operations.
Practical Knowledge
- With thousands of hours or project experience, Zifo’s team stability ensures consistent collaboration, and our global project experience helps you efficiently achieve your goals while meeting the highest standards.
## CDS Services
Whether it is training or implementation; validation or support services; or whether you want to ensure data integrity, Zifo is your ideal partner for Chromatographic Data Systems Services.
Training and Workshops
Zifo offers comprehensive training for the leading Chromatographic Data Systems(CDS) Waters Empower 3.
[ Learn more >> ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjI4ODAiLCJ0b2dnbGUiOmZhbHNlfQ%3D%3D)
Implementation (Rhizomer)
Designing and implementing a new CDS in the laboratory is a challenging task. With over 20 years of experience, Zifo is the perfect partner for such a project. Whether you want to set up a small local system or a worldwide network, we know the hurdles and best solutions — experience makes all the difference.
[ Learn more >> ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjI4ODMiLCJ0b2dnbGUiOmZhbHNlfQ%3D%3D)
Validation
In today’s world, the accuracy and reliability of laboratory data systems is critical. Zifo offers comprehensive validation services to ensure that your CDS meets the highest standards.
[ Learn more >> ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjI4ODYiLCJ0b2dnbGUiOmZhbHNlfQ%3D%3D)
Support and Helpdesk
Zifo provides comprehensive support for the entire application lifecycle, addressing the needs of all user levels. Our extensive experience in daily laboratory operations, particularly within GxP environments, sets us apart. Zifo possesses deep expertise with Waters Empower, distinguishing us from purely IT-focused providers or consultants.
[ Learn more >> ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjI4ODkiLCJ0b2dnbGUiOmZhbHNlfQ%3D%3D)
Data Integrity
For 20 years, Zifo has partnered with top pharmaceutical companies on global Empower systems, gaining extensive experience in optimizing their use. This expertise has driven the development of our products and services, designed to enhance regulatory compliance. Benefit from a cohesive system for increased audit security.
[ Learn more >> ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjI4OTMiLCJ0b2dnbGUiOmZhbHNlfQ%3D%3D)
Optimizations and Extensions
Are inefficient, error prone Empower processes slowing down your lab? Cumbersome workflows and manual steps can hinder productivity. We can show you how to save up to 70% of your time using Empower, so you can face your next audit with confidence.
[ Learn more >> ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjI4OTYiLCJ0b2dnbGUiOmZhbHNlfQ%3D%3D)
FAQ
## Curious how Zifo’s Chromatographic Data Systems Services streamline your CDS?
Learn how Zifo supports your CDS lifecycle with tailored solutions for efficient, compliant data management.
[ Talk to an Expert ](https://zifo.com/services/chromatography-systems-services/#contacts-form)
What Chromatographic Data Systems Services does Zifo provide?
Zifo provides comprehensive chromatography systems services that help laboratories implement, optimize, and manage chromatography data environments. These services include Chromatography Data System (CDS) configuration, workflow optimization, system validation, and integration with laboratory informatics platforms to ensure reliable chromatographic data processing in regulated environments.
What is a Chromatography Data System (CDS) and how does Zifo support it?
A Chromatography Data System (CDS) is software used to acquire, process, and manage chromatographic data generated from instruments such as HPLC and GC systems. Zifo supports CDS platforms by providing implementation, configuration, validation, upgrades, and ongoing technical support to help laboratories efficiently manage analytical data.
How does Zifo support Waters Empower Chromatography Data System?
Zifo offers specialized expertise in supporting Waters Empower CDS environments. Our services include system configuration, reporting customization, workflow automation, and validation support to ensure laboratories can maximize the performance and reliability of their chromatography data systems.
How do Zifo Chromatographic Data Systems Services improve laboratory productivity?
Zifo helps laboratories streamline chromatographic workflows by automating data acquisition, optimizing instrument connectivity, and improving data processing and reporting. These improvements reduce manual data handling and allow scientists to focus more on analytical research and quality testing.
How does Zifo ensure regulatory compliance for Chromatographic Data Systems Services?
Zifo ensures chromatography systems meet regulatory standards by implementing validated configurations, maintaining secure audit trails, and following compliance frameworks required for regulated laboratories. This approach helps organizations maintain reliable data integrity and remain audit-ready.
Can Zifo integrate Chromatographic Data Systems Services with other laboratory platforms?
Yes, Zifo can integrate chromatography systems with other laboratory informatics platforms such as laboratory information management systems and electronic laboratory notebooks. This integration enables seamless data transfer, centralized data management, and improved collaboration across laboratory teams.
Why do life sciences organizations choose Zifo for Chromatographic Data Systems Services?
Life sciences organizations choose Zifo because of their strong expertise in laboratory informatics, chromatography systems, and regulated laboratory environments. Zifo helps organizations modernize chromatography workflows, improve system performance, and maintain high standards of data reliability and compliance.
[ Explore Zifo’s CDS Solution ](/chromatography-data-systems-and-solutions/solutions/)
Get in touch
First Name
Last Name
Email
Phone Number
Company
Designation
Enquiry Type
Enquiry Type Request for Zifo Services Product Partnership Job/Internship/Placement Enquiry Other
Message
Acceptance I consent to being contacted by an official Zifo representative
Submit
Featured Resources
## Experiences & learnings with implementing
---
### [RnD Informatics Services](https://zifo.com/services/rnd-informatics-services/)
**Published:** March 11, 2025
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Services](https://zifo.com/services/ "Services")> RnD Informatics Services
# R&D Informatics
## Unlock Life Sciences Potential with Intelligent Informatics
Zifo can help transform your research and shape the future with data-driven solutions.
[ Know More ](#)
- [Business Process Mapping](#)
- [Scientific Platform Installation and Upgrades](#)
- [Scientific Workflow Design and Development](#)
- [ Data Management and Migration](#)
- [Integrated Laboratory](#)
- [Post Implementation Operations and Governance](#)
- [Change Management and User Adoption Strategy](#)
## Leverage our expertise in R&D Informatics
Leverage our expertise in R&D Informatics to optimize your research processes, accelerate drug discovery, and drive innovation.
Accelerated Drug Development Process
- Expedite drug discovery and development timelines by 20%
Research Data Interoperability
- Enhance scientist productivity by 33% through seamless data exchange across systems and improved data interpretation
Predictive Maintenance
- Reduce downtime and maximize efficiency of lab equipment and systems by 50%
Expense Optimization
- Achieve optimal outcomes with minimal costs
## R&D Informatics and Consulting Services
Whether you call it research, discovery or product innovation, the science, processes and informatics demands are high. Zifo’s deep scientific domain experience in chemistry, biology, formulations, and analytical coupled with over 90 scientific informatics product partnerships means we are well placed to support your teams.
Business Process Mapping
Partnering with Zifo empowers R&D labs striving for improved efficiency. Our consultants can help map out lab processes and identify delays, overheads, legacy practices, and manual steps that can be easily automated. This helps devise a strategic roadmap that will allow your lab to operate with improved efficiency, reduced costs and processes
[ Learn more >> ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjI0MzciLCJ0b2dnbGUiOmZhbHNlfQ%3D%3D)
Scientific Platform Installation and Upgrades
Partnering with Zifo can empower R&D labs to leverage a multitude of specialized software and hardware for scientific research. These platforms often support research activities by providing tools for data capture, simulations, analysis, and collaboration.
[ Learn more >> ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjI0NDMiLCJ0b2dnbGUiOmZhbHNlfQ%3D%3D)
Scientific Workflow Design and Development
Zifo can help research organizations implement and optimize Scientific Informatics systems (ELNs, LIMS, etc.) which are increasingly used in research environments to replace paper-based lab notebooks, providing a digital solution that enhances collaboration, data integrity, and compliance with regulatory standards.
[ Learn more >> ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjI0NDkiLCJ0b2dnbGUiOmZhbHNlfQ%3D%3D)
Data Management and Migration
Partnering with Zifo is crucial for organizations navigating the constant innovation in R&D, where vast amounts of data are generated and must ultimately be harnessed and utilized. During strategic transformations or Mergers & Acquisitions, it’s especially important to ensure data is properly managed.
[ Learn more >> ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjI0NTIiLCJ0b2dnbGUiOmZhbHNlfQ%3D%3D)
Integrated Laboratory
By working with Zifo, our integration consultants can help transform your lab by enabling seamless communication between devices, systems, and databases, facilitating real-time data sharing, automating processes, and minimizing the risk of manual errors.
[ Learn more >> ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjI0NTUiLCJ0b2dnbGUiOmZhbHNlfQ%3D%3D)
Post Implementation Operations and Governance
Zifo helps R&D labs maximize their significant investments in technology designed to accelerate drug research and development. Beyond the initial identification, installation, and configuration of these technologies, a robust support framework is essential to ensure successful adoption, effective usage, and regulatory compliance.
[ Learn more >> ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjI0NTgiLCJ0b2dnbGUiOmZhbHNlfQ%3D%3D)
Change Management and User Adoption
Zifo helps R&D organizations successfully adopt new systems, processes, and workflows through effective Change Management. Our consultants specialize in strategically planning and executing change management initiatives that empower scientists to embrace and leverage new technologies.
[ Learn more >> ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjI0NjEiLCJ0b2dnbGUiOmZhbHNlfQ%3D%3D)
FAQ
## Curious how Zifo’s RnD Informatics Services unlock life sciences potential?
See how Zifo helps transform research with data-driven solutions.
Talk to an Expert
What R&D Informatics Services does Zifo provide?
Zifo R&D Informatics Services help life sciences organizations implement and optimize digital platforms used in research and development. Zifo supports activities such as informatics consulting, system selection, platform implementation, data integration, and workflow automation to improve how scientific data is captured, managed, and analyzed across R&D environments.
How does Zifo help organizations implement laboratory informatics platforms?
Zifo assists organizations with the implementation and rollout of laboratory informatics platforms such as electronic lab notebooks (ELN) and laboratory information management systems (LIMS). Our services include requirement gathering, system configuration, workflow design, user training, and integration with laboratory instruments and enterprise systems.
How does Zifo support data integration in R&D environments?
Zifo integrates data from laboratory instruments, research databases, and enterprise platforms to create unified research data environments. These integrations enable automated data collection, improved traceability, and more efficient analysis across research and development workflows.
How does Zifo help organizations select the right informatics platforms?
Zifo uses a vendor-agnostic evaluation methodology to help organizations choose the most suitable informatics platforms for their R&D operations. This evaluation considers functional capabilities, technical requirements, compliance considerations, and supplier performance to ensure the chosen platform aligns with business and scientific needs.
How does Zifo ensure regulatory compliance in R&D informatics systems?
Zifo supports compliance by implementing validated systems and following regulatory standards such as 21 CFR Part 11 and EU Annex 11. Our services include validation, documentation, audit readiness support, and governance frameworks to maintain reliable and compliant research systems.
How does Zifo support scientific workflow automation?
Zifo designs and configures scientific workflows that automate data capture, experiment tracking, and review processes. These workflows help laboratories reduce manual data entry, standardize experimental protocols, and ensure that data is reviewed and validated by the appropriate personnel.
Why do life sciences organizations choose Zifo for R&D informatics services?
Organizations choose Zifo because of its deep expertise in scientific informatics, data integration, and research technologies. With experience supporting pharmaceutical, biotech, and research organizations worldwide, Zifo helps teams modernize R&D environments, improve data quality, and accelerate scientific innovation.
Get in touch
First Name
Last Name
Email
Phone Number
Company
Designation
Enquiry Type
Enquiry Type Request for Zifo Services Product Partnership Job/Internship/Placement Enquiry Other
Message
Acceptance I consent to being contacted by an official Zifo representative
Submit
Featured Resources
[  ](https://zifo.com/blogs/how-to-choose-the-eln/)
[ Blog ](https://zifo.com/blogs/how-to-choose-the-eln/)
## [How To Choose The ELN](https://zifo.com/blogs/how-to-choose-the-eln/)
[  ](https://zifo.com/blogs/rethinking-digital-tools/)
[ Blog ](https://zifo.com/blogs/rethinking-digital-tools/)
## [Rethinking Digital Tools](https://zifo.com/blogs/rethinking-digital-tools/)
[  ](https://zifo.com/blogs/early-days-for-ai-but-scientific-data-management-gains-momentum/)
[ Blog ](https://zifo.com/blogs/early-days-for-ai-but-scientific-data-management-gains-momentum/)
## [Early Days For AI But Scientific Data Management Gains Momentum](https://zifo.com/blogs/early-days-for-ai-but-scientific-data-management-gains-momentum/)
---
### [Scientific Cloud Computing Services](https://zifo.com/services/scientific-cloud-computing-services/)
**Published:** March 17, 2025
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Services](https://zifo.com/services/ "Services")> Scientific Cloud Computing Services
# Scientific Cloud Computing
## Revolutionize R&D with AI, Cloud, and Automation
Zifo’s cloud solutions enable seamless data sharing, advanced analytics,
and AI-driven insights, accelerating drug discovery and development.
[ Know More ](#zifo_contact_us_form)
- [Modeling and Simulation Tools](#sectionOne)
- [Scientific Workflow Automation](#sectionTwo)
- [High Performance Computing](#sectionThree)
- [Data and AI Compute Platforms](#sectionFour)
- [Posit Services](#sectionFive)
- [Compliance Cloud](#sectionSix)
- [Scientific Cloud and Enterprise Architecture Consulting](#sectionSeven)
## Leverage Zifo’s Scientific Cloud Computing
We have established a Centre of Excellence in Scientific Cloud Computing. Our team of experts can set-up, configure, and optimize your cloud infrastructure, ensuring seamless data sharing, advanced analytics, and accelerated R&D processes.
Reduced IT Costs
- Cut IT infrastructure costs by 30% on average using cloud solutions, with potential savings of up to 50% by migrating to public cloud.
Accelerated Time-to-Market
- Reduce time-to-market for new products and services by 25% through efficient cloud-based workflows.
Enhanced Data Security
- Achieve 99.99% data durability and security with our robust cloud security measures.
Improved Performance
- Increase application performance by 20% on average by optimizing cloud infrastructure.
## Scientific Data Integration and Harmonization
Beyond infrastructure setup, Zifo excels in building robust data ecosystems within the scientific cloud. Our specialized team focuses on seamlessly integrating disparate scientific datasets from various instruments, experiments, and research domains.
Modeling and Simulation Tools
Zifo’s Modeling and Simulation IT services empower Pharma and Biotech to accelerate drug development and optimize clinical trials. We collaborate with scientists to deploy and maintain advanced tools for molecular modeling, pharmacometrics, and more.
[ Learn more >> ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjI5NDgiLCJ0b2dnbGUiOmZhbHNlfQ%3D%3D)
Scientific Workflow Automation
Zifo’s Scientific Workflow Automation services leverage cutting-edge cloud technologies like Kubernetes, serverless computing, and AI-driven orchestration to automate data analysis and workflows. This accelerates innovation, enhances collaboration, and ensures secure, reproducible research.
[ Learn more >> ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjI5NTEiLCJ0b2dnbGUiOmZhbHNlfQ%3D%3D)
High Performance Computing
HPC accelerates drug discovery in pharma through simulations like molecular dynamics. Cloud HPC solutions enable resource scaling for cost-efficiency and faster innovation. Use HPC for data analysis, genomic research, and clinical trial modeling, reducing time-to-market.
[ Learn more >> ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjI5NTUiLCJ0b2dnbGUiOmZhbHNlfQ%3D%3D)
Data and AI Compute Platforms
Cloud-native data and AI transform how organizations use data with serverless AI/ML and Edge AI. Generative AI revolutionizes drug discovery, while quantum computing addresses complex issues. We tackle security and automation in labs, driving innovation in cloud-native solutions.
[ Learn more >> ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjI5NTgiLCJ0b2dnbGUiOmZhbHNlfQ%3D%3D)
Posit Services
Posit Services (formerly RStudio) empowers pharma and biotech with streamlined data science for drug discovery and research. Posit Workbench enables collaborative R and Python projects, ensuring reproducibility in genomics and modeling. With Posit Connect, securely deploy and share data-driven insights, accelerating innovation in life sciences.
[ Learn more >> ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjI5NjEiLCJ0b2dnbGUiOmZhbHNlfQ%3D%3D)
Compliance Cloud
Our Qualified Hosting Services on AWS and Azure deliver validated, GxP-ready cloud environments. Automated deployment, continuous compliance, and robust security ensure scalable, audit-ready solutions for regulated industries. Accelerate your cloud adoption with secure and reproducible infrastructure.
[ Learn more >> ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjI5NjQiLCJ0b2dnbGUiOmZhbHNlfQ%3D%3D)
Scientific Cloud and Enterprise Architecture
Zifo offers cloud modernization, migration, security, and cost optimization for pharma and life sciences. Our DevSecOps and FinOps expertise ensures secure, scalable cloud environments, boosting scientific innovation on AWS, Azure, and GCP.
[ Learn more >> ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjI5NjciLCJ0b2dnbGUiOmZhbHNlfQ%3D%3D)
FAQ
## Curious how Zifo’s scientific cloud computing services accelerate R&D?
See how Zifo’s cloud solutions enable data sharing, advanced analytics, and AI-driven insights for drug discovery and development.
[ Talk to an Expert ](https://zifo.com/services/scientific-cloud-computing-services/#contacts-form)
What scientific cloud computing services does Zifo provide?
Zifo Scientific Cloud Computing Services help life sciences organizations build scalable cloud environments for scientific research and data analysis. Zifo supports cloud architecture design, infrastructure setup, workflow automation, and high-performance computing to enable faster data processing and collaboration across research teams.
How does Zifo help organizations migrate scientific workloads to the cloud?
Zifo helps organizations transition from traditional IT infrastructure to modern cloud platforms by designing cloud-native architectures and migrating applications and data securely. Our team configures and optimizes cloud environments to support scientific computing, advanced analytics, and collaborative research workflows.
How does Zifo use high-performance computing in scientific cloud environments?
Zifo deploys cloud-based high-performance computing clusters that support complex simulations, genomic analysis, and large-scale data processing. These environments allow researchers to scale computing resources as needed, enabling faster experimentation and analysis in drug discovery and other research domains.
How does Zifo support scientific workflow automation in the cloud?
Zifo implements automated scientific workflows using modern cloud technologies such as containerization, serverless computing, and orchestration tools. These workflows automate data processing and analysis pipelines, allowing research teams to run complex experiments more efficiently and reproducibly.
How does Zifo enable data and AI platforms in scientific cloud environments?
Zifo helps organizations build cloud-native data and AI platforms that support advanced analytics, machine learning, and large-scale data integration. These platforms allow research teams to analyze scientific data, develop predictive models, and generate insights that support innovation in life sciences.
How does Zifo ensure security and compliance in scientific cloud infrastructure?
Zifo designs GxP cloud environments with strong security controls, including identity management, encryption, and compliance monitoring. These environments can be configured to meet regulatory standards required in life sciences industries, ensuring secure and compliant handling of scientific data.
Why do life sciences organizations choose Zifo for scientific cloud computing services?
Organizations choose Zifo because of its expertise in scientific computing, cloud architecture, and life sciences informatics. Zifo helps research teams modernize infrastructure, integrate scientific datasets, and build scalable platforms that accelerate research and innovation.
Get in touch
First Name
Last Name
Email
Phone Number
Company
Designation
Enquiry Type
Enquiry Type Request for Zifo Services Product Partnership Job/Internship/Placement Enquiry Other
Message
Acceptance I consent to being contacted by an official Zifo representative
Submit
Featured Resources
[  ](https://zifo.com/blogs/optimizing-cloud-spending-in-science-driven-organizations-the-role-of-finops/)
[ Blog ](https://zifo.com/blogs/optimizing-cloud-spending-in-science-driven-organizations-the-role-of-finops/)
## [Optimizing Cloud Spending In Science-Driven Organizations: The Role Of FinOps](https://zifo.com/blogs/optimizing-cloud-spending-in-science-driven-organizations-the-role-of-finops/)
[  ](https://zifo.com/blogs/journey-from-devops-to-platform-engineering-evolving-towards-a-future-proof-infrastructure/)
[ Blog ](https://zifo.com/blogs/journey-from-devops-to-platform-engineering-evolving-towards-a-future-proof-infrastructure/)
## [Journey From DevOps To Platform Engineering: Evolving Towards A Future-Proof Infrastructure](https://zifo.com/blogs/journey-from-devops-to-platform-engineering-evolving-towards-a-future-proof-infrastructure/)
[  ](https://zifo.com/blogs/unlocking-the-power-of-posit-in-pharma-use-cases-and-architecture-best-practices/)
[ Blog ](https://zifo.com/blogs/unlocking-the-power-of-posit-in-pharma-use-cases-and-architecture-best-practices/)
## [Unlocking The Power Of Posit In Pharma : Use Cases And Architecture Best Practices](https://zifo.com/blogs/unlocking-the-power-of-posit-in-pharma-use-cases-and-architecture-best-practices/)
---
### [Strategic Scientific Consulting Services](https://zifo.com/services/strategic-scientific-consulting-services/)
**Published:** March 20, 2025
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Services](https://zifo.com/services/ "Services")> Strategic Scientific Consulting Services
# Strategic Scientific Consulting
## Streamline Informatics, Maximize Impact Through Data and AI
Zifo consultants craft tailored digital strategies and deliver vendor-agnostic
informatics solutions — enabled by AI — supporting your scientific journey.
[ Know More ](#)
- [Strategic Roadmap and Market Research](#)
- [Digital Transformation Strategy](#)
- [Platform Evaluation Decisions](#)
- [Platforms Implementation, Change Management and User Adoption](#)
- [Business Systems Analysis](#)
- [Scientific Expertise Domains](#)
## Driving Business Success Through Expert Guidance
Zifo consultants have a sought-after combination of science and informatics experience. We help our clients develop digital business strategies and road maps to meet their current and future needs. Our customers value our vendor-agnostic approach and decades of experience we draw upon to give a wide range of informatics strategies and solutions that fit our client’s unique scientific and digital needs at every stage of their journey.
Accelerated Drug Development Process
- Clients comprise 4 **out of 5** Top Global Pharma companies
Research Data Interoperability
- **25+** Current clients spanning from large to small pharma, non-pharma research and biotech companies
Predictive Maintenance
- **100%** of our consultants hold a Bachelor of Science (BS) degree in Life Sciences, and **30%** also hold a Master of Science (MS) or PhD
Expense Optimization
- Covering complete RnD landscape: Discovery, Development, Pre-clinical and Clinical stages
## Strategic Consulting to Unlock New Opportunities
Leveraging a comprehensive suite of capabilities, Zifo consultants ensure the delivery of high-quality business analysis, change management, and digital transformation solutions to support your organization in achieving its strategic objectives.
Strategic Roadmap and Market Research
In an ever-evolving Informatics landscape, it is imperative to understand the market state, trends, and industry standards — keeping your company at the forefront of scientific evolution. Zifo partners with you to analyze market trends and implement strategic informatics solutions, driving your scientific evolution.
[ Learn more >> ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjMwODAiLCJ0b2dnbGUiOmZhbHNlfQ%3D%3D)
Digital Transformation Strategy
Many companies find themselves with a plethora of siloed, aging, inefficient or cost-accumulating platforms that not only delay scientific progress, but also impede implementation of newly developed industry standards, such as AI technologies. Zifo helps you modernize your informatics infrastructure, consolidating data sources and streamlining workflows to accelerate scientific discovery and unlock the full potential of AI.
[ Learn more >> ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjMwODMiLCJ0b2dnbGUiOmZhbHNlfQ%3D%3D)
Platform Evaluation Decisions
A modern informatics platform is often a prerequisite to a digital infrastructure and will have long-lasting impact on business operations. Zifo provides strategic planning and optimization services to ensure your informatics platform aligns with your business goals and maximizes its long-term impact.
[ Learn more >> ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjMwODgiLCJ0b2dnbGUiOmZhbHNlfQ%3D%3D)
Platform Implementation, Change Management, and User Adoption
Technological evolution is key to scientific progress. Optimizing workflows and data management will change data capture. A major hurdle in new technology is change management and user adoption, which can be painful. Zifo minimizes disruption and ensures successful user adoption.
[ Learn more >> ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjMwOTEiLCJ0b2dnbGUiOmZhbHNlfQ%3D%3D)
Business Systems Analysis
Zifo provides an end-to-end expertise across all domains of business systems analysis and strategic consulting, addressing everything from organization-wide projects such as Digital Transformation strategies and Global harmonization across siloed workflows to Data governance and Change management.
[ Learn more >> ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjMwOTQiLCJ0b2dnbGUiOmZhbHNlfQ%3D%3D)
Scientific Domain Expertise
Zifo’s scientific expertise covers the entire life science spectrum, from early Discovery and Pre-clinical Development to complex Clinical Trials and Manufacturing.
[ Learn more >> ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjMwOTciLCJ0b2dnbGUiOmZhbHNlfQ%3D%3D)
Data Consulting
Data has become the most valuable asset in the AI era – yet most organizations remain *data-busy* rather than truly data-driven. Our Data Strategy service enables companies to understand their current state, define a target state and turn data into a measurable business advantage. It helps to align the needed data capabilities with business goals, prioritize investments and high‑value use cases. Including a clear, executable roadmap – ready for AI and scalable growth.
[ Learn more >> ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjY4MzU3IiwidG9nZ2xlIjpmYWxzZX0%3D)
FAQ
## Curious how Zifo’s strategic scientific consulting services maximize impact through data and AI?
Learn how Zifo crafts tailored digital strategies and vendor-agnostic informatics solutions to support your scientific journey.
Talk to an Expert
What strategic scientific consulting services does Zifo provide?
Zifo Strategic Scientific Consulting Services help life sciences organizations develop effective digital and scientific strategies for across the entire scientific value chain. Zifo consultants combine expertise in science, informatics, and AI to guide companies in designing strategic roadmaps, improving data management, and modernizing research platforms across the R&D lifecycle.
How does Zifo help organizations build a strategic roadmap for scientific informatics?
Zifo works with organizations to analyze current research systems, evaluate industry trends, and design strategic roadmaps for informatics and digital transformation. These roadmaps help companies adopt modern technologies, improve data integration, and align scientific platforms with long-term research and business goals.
How does Zifo support digital transformation strategies in life sciences?
Zifo helps organizations modernize their scientific infrastructure by consolidating siloed systems, improving data workflows, and enabling advanced technologies such as artificial intelligence and advanced analytics. This approach allows companies to accelerate scientific discovery and improve operational efficiency across research environments.
How does Zifo help organizations evaluate and select informatics platforms?
Zifo provides vendor-agnostic consulting to help organizations assess and select the most suitable scientific platforms. Our evaluation process considers technical capabilities, business requirements, and long-term scalability to ensure that chosen systems support both current needs and future innovation.
How does Zifo support change management during technology adoption?
Zifo supports change management by engaging stakeholders, designing adoption strategies, and providing training and communication plans. This approach helps ensure that new scientific platforms and workflows are successfully adopted by research teams with minimal disruption.
What expertise does Zifo offer across the life sciences R&D lifecycle?
Zifo provides consulting expertise across the full life sciences spectrum, including discovery research, preclinical development, clinical research, and manufacturing. Their consultants help organizations align scientific processes, data systems, and technology platforms across all stages of the product lifecycle.
Why do life sciences organizations choose Zifo for strategic scientific consulting?
Life sciences organizations choose Zifo because of its deep combination of scientific knowledge and informatics expertise. With experience supporting global pharmaceutical and biotech companies, Zifo helps organizations design scalable strategies, modernize research systems, and achieve long-term digital transformation in scientific environments
Get in touch
First Name
Last Name
Email
Phone Number
Company
Designation
Enquiry Type
Enquiry Type Request for Zifo Services Product Partnership Job/Internship/Placement Enquiry Other
Message
Acceptance I consent to being contacted by an official Zifo representative
Submit
Featured Resources
[  ](https://zifo.com/blogs/data-strategy/)
[ Blog ](https://zifo.com/blogs/data-strategy/)
## [Data Centrality – A Key consideration In Data Strategy](https://zifo.com/blogs/data-strategy/)
[  ](https://zifo.com/blogs/unlocking-the-transformative-flavor-of-digital-in-the-food-beverage-industry/)
[ Blog ](https://zifo.com/blogs/unlocking-the-transformative-flavor-of-digital-in-the-food-beverage-industry/)
## [Unlocking The Transformative Flavor Of DIGITAL In The Food & Beverage Industry](https://zifo.com/blogs/unlocking-the-transformative-flavor-of-digital-in-the-food-beverage-industry/)
[  ](https://zifo.com/blogs/early-days-for-ai-but-scientific-data-management-gains-momentum/)
[ Blog ](https://zifo.com/blogs/early-days-for-ai-but-scientific-data-management-gains-momentum/)
## [Early Days For AI But Scientific Data Management Gains Momentum](https://zifo.com/blogs/early-days-for-ai-but-scientific-data-management-gains-momentum/)
---
### [Data Science and Consulting Services](https://zifo.com/services/data-science-and-consulting-services/)
**Published:** April 3, 2025
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Services](https://zifo.com/services/ "Services")> Data Science and Consulting Services
# Data Science and Consulting
## Driving Scientific Innovation Through AI and ML-Powered
Insight Generation
Zifo accelerates scientific innovation through expert-guided AI and ML, uniquely powered by our deep scientific domain expertise.
[ Know More ](#)
- [Data Readiness for AI/ML](#)
- [Accelerating Discovery with AI](#)
- [MLOps: Reliable, Scalable, Explainable ML](#)
- [Real World Data Integration and Insights](#)
- [Data Modeling Consulting](#)
- [Data Extraction and Wrangling](#)
- [Ontology Development and Management](#)
## Unlock the Power of Your Data with our Expertise
We have built a Centre of Excellence in Data Science. Our team of experts can help you unlock the power of your data with advanced analytics and AI.
Accelerated Time to Market
- Reduced time to market for new products/treatments by 6 months
Improved Decision Making
- Reduced decision-making time by 25% and increased decision accuracy by 10%
Top Clients
- 25+ clients spanning from large to small pharma, non-pharma research and biotech companies
Full-Spectrum Coverage
- Covering complete Scientific research landscape: Discovery, Development, Pre-clinical and Clinical, Manufacturing and QC
## Deploy Data Science to Accelerate Science
Ensure your scientific data leads to meaningful business outcomes. Zifo’s Data Science team can accelerate your scientific goals through effective partnerships.
Data Readiness for AI/ML
Zifo specializes in transforming structured and unstructured data into powerful commercial assets. Our approach ensures your data is immediately fit for modeling, reducing time-to-value and enhancing model accuracy.
[ Learn more >> ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjE4NDMiLCJ0b2dnbGUiOmZhbHNlfQ%3D%3D)
Generative AI in Drug Discovery and Protein Engineering
Leveraging Zifo’s domain-specific scientific expertise and cutting-edge generative AI methodologies, we accelerate discovery pipelines with precision and scalability. Our multidisciplinary team integrates advanced machine learning frameworks, deep neural networks, and algorithmic strategies to decode and synthesize complex biological datasets.
[ Learn more >> ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjE5MTUiLCJ0b2dnbGUiOmZhbHNlfQ%3D%3D)
MLOps: Reliable, Scalable, Explainable ML
Zifo ensures reliability and transparency in your ML pipelines with advanced MLOps solutions. We automate workflows, delivering faster deployments and robust monitoring. Combining expertise and compliance, Zifo transforms biopharma and healthcare research, empowering teams to build trust in AI.
[ Learn more >> ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjE5NTIiLCJ0b2dnbGUiOmZhbHNlfQ%3D%3D)
Data Modelling Consulting
Zifo excels at integrating, managing, and analyzing multi-modal Real-World Data (RWD) gathered beyond traditional clinical trials. Through sophisticated analytics and seamless integration, we unlock deeper insights, inform strategic decision-making, and enable you to address real-world complexities effectively.
[ Learn more >> ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjE5NzkiLCJ0b2dnbGUiOmZhbHNlfQ%3D%3D)
Data Extraction and Wrangling
Our data science experts are adept at extracting data from various sources, transform it into alternative formats such as RDF and specialized structures like ADF, and load it into data lakes and warehouses to facilitate data reuse and FAIRification.
[ Learn more >> ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjIwMTMiLCJ0b2dnbGUiOmZhbHNlfQ%3D%3D)
Ontology Development and Management
We can help you with ontology definition and governance in commercial and open-source platforms alongside deep domain and technical knowledge to support your FAIR and semantic data journey.
[ Learn more >> ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjIwMjAiLCJ0b2dnbGUiOmZhbHNlfQ%3D%3D)
FAQ
## Curious how Zifo’s data science and consulting services drive scientific innovation?
Learn how Zifo accelerates scientific innovation through expert-guided AI and ML backed by deep scientific domain expertise.
Talk to an Expert
What data science and consulting services does Zifo provide?
Zifo Data Science and Consulting Services help life sciences organizations unlock the value of their scientific data using advanced analytics, artificial intelligence, and data engineering. Zifo works with pharmaceutical and biotech companies to transform complex research datasets into actionable insights that improve decision-making and accelerate innovation.
How does Zifo prepare scientific data for AI and machine learning?
Zifo helps organizations make their data ready for artificial intelligence and machine learning by performing data quality checks, normalization, feature engineering, and data enrichment. This process ensures datasets are structured, reliable, and suitable for advanced modeling, enabling faster and more accurate analytical outcomes.
How does Zifo use generative AI in drug discovery and scientific research?
Zifo applies generative AI and machine learning techniques to analyze complex biological datasets and accelerate research workflows. By combining domain expertise with advanced neural networks and algorithmic models, Zifo helps organizations explore new drug candidates, analyze protein structures, and support scientific discovery at scale.
What is MLOps and how does Zifo support machine learning operations?
Zifo provides MLOps solutions that help organizations build reliable and scalable machine learning pipelines. These services automate model deployment, monitor performance, and ensure transparency in AI models, enabling research teams to use machine learning systems with confidence and consistency.
How does Zifo help organizations manage and integrate scientific data?
Zifo supports data extraction, transformation, and integration from multiple sources such as laboratory systems, databases, and research platforms. Our experts structure and load data into centralized data lakes and warehouses, enabling easier access, reuse, and advanced analytics across scientific workflows.
How does Zifo support ontology development and semantic data management?
Zifo helps organizations design and manage ontologies to standardize scientific terminology and improve data interoperability. By applying semantic data models and governance frameworks, Zifo ensures scientific datasets remain consistent, searchable, and compatible across multiple platforms and research systems.
How does Zifo help life sciences organizations build a data-driven research environment?
Zifo supports the development of scientific data architectures that integrate research data across discovery, development, clinical research, and manufacturing. By implementing data governance frameworks and analytics platforms, Zifo helps organizations improve collaboration, generate insights faster, and make better data-driven decisions.
Get in touch
First Name
Last Name
Email
Phone Number
Company
Designation
Enquiry Type
Enquiry Type Request for Zifo Services Product Partnership Job/Internship/Placement Enquiry Other
Message
Acceptance I consent to being contacted by an official Zifo representative
Submit
Featured Resources
[  ](https://zifo.com/blogs/natural-language-processing-for-reliability-in-business/)
[ Blog ](https://zifo.com/blogs/natural-language-processing-for-reliability-in-business/)
## [Natural Language Processing For Reliability In Business](https://zifo.com/blogs/natural-language-processing-for-reliability-in-business/)
[  ](https://zifo.com/blogs/why-science-is-protesting-for-data-democracy-and-we-must-listen/)
[ Blog ](https://zifo.com/blogs/why-science-is-protesting-for-data-democracy-and-we-must-listen/)
## [Why Science Is Protesting For Data Democracy And We Must Listen](https://zifo.com/blogs/why-science-is-protesting-for-data-democracy-and-we-must-listen/)
[  ](https://zifo.com/blogs/unlocking-the-power-of-posit-in-pharma-use-cases-and-architecture-best-practices/)
[ Blog ](https://zifo.com/blogs/unlocking-the-power-of-posit-in-pharma-use-cases-and-architecture-best-practices/)
## [Unlocking The Power Of Posit In Pharma : Use Cases And Architecture Best Practices](https://zifo.com/blogs/unlocking-the-power-of-posit-in-pharma-use-cases-and-architecture-best-practices/)
---
### [Clinical Genomics](https://zifo.com/services/clinical-genomics/)
**Published:** September 27, 2024
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Services](https://zifo.com/services/ "Services")> Clinical Genomics
# Clinical Genomics
## Accelerating Clinical Genetic Interpretations
Zifo helps clinical labs deliver high-quality genetic tests using next-
generation sequencing, from test design to physician reports.
[ Know More ](#)
- [Center of Excellence](#)
- [Variant Interpretation Services](#)
- [Zifo’s Role in NGS Test Workflow](#)
- [Zifo Gene Knowledge Base (GeneKB)](#)
## Leveraging Expertise in Clinical Genomics
We have built a Center of Excellence in clinical genome interpretation. Our services cover analysis of gene panels to whole genome/exome.
#### Our Specialists
- Large and growing team
- Variant scientists and bioinformaticians
- ClinGen VCEP contributors
Training & Proficiency
- Rigorous training program
- Proficiency testing
- Continuous learning/development
Technical Expertise
- SNV/CNV/MTDNA
interpretation
- Rare disease methodology
- Proficient in different software platforms
Process
- SOP development/adherence
- Adherence to guidelines from ACMG/ClinGen/ACGS
- Documentation for CLIA/CAP
## Variant Interpretation Services
Our Variant Interpretation Services deliver expert analysis of genetic data. We provide actionable insights to support clinical decision-making.
Start-Up
Jumpstart delivery of tests faster with Zifo’s experienced variant scientists.
Ramp Up
Let Zifo train your interpretation team and develop SOPs and processes for streamlined analysis.
Production
Retain Zifo analysts as part of your team on a contract basis to support ongoing variant interpretations.
Fluctuating Volume
Utilize Zifo interpretation services to provide burst capacity anytime demand surpasses capacity.
## Zifo Takes Over Where the Wet Lab Leaves Off
Expert genome interpretation (platform agnostic) from VCF through clinical reporting
## Wet lab
Sequencing
From sample prep to FastQ file, this step is carried out in the ‘wet lab’ where sequence data are generated.
## Variant Calling
From FastQ to VCF file, this step starts the ‘dry lab’ component where variants are identified from the sequence data.
## Wet lab
Sequencing
From sample prep to FastQ file, this step is carried out in the ‘wet lab’ where sequence data are generated.
## Variant Calling
From FastQ to VCF file, this step starts the ‘dry lab’ component where variants are identified from the sequence data.
## Zifo's Role in NGS workflow
## Variant
Annotation
Variants are annotated with numerous data sources, allowing inference about their role in disease.
## Variant
Interpretation
From VCF to clinical report. Expert evaluation of variants in context of the patient to identify pathogenic variants for reporting.
## Report Sign-out
Review of physician-ready report by qualified lab personnel prior to release.
## Zifo GeneKB
Expertly-curated gene-level information to support selection of panel genes, variant interpretation and reporting.
### Accuracy
Incorporate latest gene-specific guidelines.
### Consistency
One source of baseline data for whole team.
### Efficiency
Curate info upfront instead of during interpretation.
### Automation
Can feed into automated variant interpretation tools.
FAQ
## Curious how Zifo’s clinical genomics services accelerate clinical genetic interpretations?
See how Zifo helps clinical labs deliver high-quality genetic tests using next-generation sequencing, from test design to physician reports.
Talk to an Expert
What clinical genomics services does Zifo provide?
Zifo’s Clinical Genomics Services support laboratories and life sciences organizations with expert genome analysis and variant interpretation. Zifo’s specialists analyze genetic data ranging from targeted gene panels to whole exome and whole genome sequencing, helping clinical teams identify disease-associated variants and deliver clinically meaningful reports.
How does Zifo support variant interpretation in clinical genomics?
Zifo provides expert variant interpretation services that evaluate genetic variants within the context of patient data and scientific evidence. Our specialists annotate and interpret variants to determine their clinical significance, helping laboratories identify pathogenic mutations that may contribute to disease.
What role does Zifo play in the next-generation sequencing workflow?
Zifo supports the downstream “dry lab” stages of next-generation sequencing workflows. After sequencing generates raw data, Zifo experts handle steps such as variant calling, annotation, interpretation, and preparation of clinical reports, transforming sequencing results into actionable clinical insights.
How does Zifo ensure accuracy and consistency in genomic analysis?
Zifo follows established clinical genomics guidelines and best practices when analyzing genetic variants. Our processes adhere to recommendations from organizations such as ACMG, ClinGen, and ACGS, and they maintain standardized operating procedures and documentation required for clinical laboratory compliance.
What expertise does Zifo offer in genomic variant analysis?
Zifo’s clinical genomics specialists include variant scientists and bioinformaticians experienced in analyzing single nucleotide variants (SNVs), copy number variants (CNVs), and mitochondrial DNA variants. Our expertise also includes methodologies for identifying variants related to rare genetic diseases.
How does Zifo support laboratories scaling their clinical genomics operations?
Zifo offers flexible engagement models that help laboratories scale their genomics interpretation capacity. Organizations can use Zifo services to launch new genomic tests, train internal teams, or provide additional analysis capacity when sequencing demand increases.
Why do genomics laboratories choose Zifo for clinical genomics services?
Genomics laboratories choose Zifo because of its specialized expertise in variant interpretation, genomic data analysis, and clinical reporting. By combining bioinformatics knowledge with clinical guidelines and standardized workflows, Zifo helps laboratories deliver accurate and reliable genomic insights for patient care.
Get in touch
First Name
Last Name
Email
Phone Number
Company
Designation
Enquiry Type
Enquiry Type Request for Zifo Services Product Partnership Job/Internship/Placement Enquiry Other
Message
Acceptance I consent to being contacted by an official Zifo representative
Submit
Featured Resources
[  ](https://zifo.com/blogs/a-comparison-of-acmg-amp-and-acgs-guidelines-for-variant-interpretation/)
[ Blog ](https://zifo.com/blogs/a-comparison-of-acmg-amp-and-acgs-guidelines-for-variant-interpretation/)
## [A Comparison Of ACMG/AMP And ACGS Guidelines For Variant Interpretation](https://zifo.com/blogs/a-comparison-of-acmg-amp-and-acgs-guidelines-for-variant-interpretation/)
[  ](https://zifo.com/blogs/how-acmg-guidelines-and-gnomad-are-aligning-to-simplify-variant-interpretation/)
[ Blog ](https://zifo.com/blogs/how-acmg-guidelines-and-gnomad-are-aligning-to-simplify-variant-interpretation/)
## [How ACMG Guidelines And gnomAD Are Aligning To Simplify Variant Interpretation](https://zifo.com/blogs/how-acmg-guidelines-and-gnomad-are-aligning-to-simplify-variant-interpretation/)
[  ](https://zifo.com/blogs/acmg-v4-draft-preview-transformative-changes-in-variant-classification/)
[ Blog ](https://zifo.com/blogs/acmg-v4-draft-preview-transformative-changes-in-variant-classification/)
## [ACMG V4 Draft Preview: Transformative Changes In Variant Classification](https://zifo.com/blogs/acmg-v4-draft-preview-transformative-changes-in-variant-classification/)
[  ](https://zifo.com/blogs/early-days-for-ai-but-scientific-data-management-gains-momentum/)
[ Blog ](https://zifo.com/blogs/early-days-for-ai-but-scientific-data-management-gains-momentum/)
## [Early Days For AI But Scientific Data Management Gains Momentum](https://zifo.com/blogs/early-days-for-ai-but-scientific-data-management-gains-momentum/)
[  ](https://zifo.com/blogs/beyond-the-hype-biopharmas-tech-transfer-process-needs-a-fundamental-reset/)
[ Blog ](https://zifo.com/blogs/beyond-the-hype-biopharmas-tech-transfer-process-needs-a-fundamental-reset/)
## [Beyond The Hype: Biopharma’s Tech Transfer Process Needs A Fundamental Reset](https://zifo.com/blogs/beyond-the-hype-biopharmas-tech-transfer-process-needs-a-fundamental-reset/)
[  ](https://zifo.com/blogs/a-strategic-guide-to-consolidation-in-scientific-informatics/)
[ Blog ](https://zifo.com/blogs/a-strategic-guide-to-consolidation-in-scientific-informatics/)
## [A Strategic Guide To Consolidation In Scientific Informatics](https://zifo.com/blogs/a-strategic-guide-to-consolidation-in-scientific-informatics/)
---
### [Validation Services and Compliance Support](https://zifo.com/services/validation-services-and-compliance-support/)
**Published:** March 17, 2025
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Services](https://zifo.com/services/ "Services")> Validation Services and Compliance Support
# Regulatory Compliance, Validation & Systems Maintenance
## Achieve Regulatory Compliance with Expert Validation and AI
Zifo ensures compliance with regulatory guidelines (e.g., 21 CFR Part 11, GAMP 5) and delivers high-quality, reliable, and secure systems for critical biopharma
operations enabled by AI.
[ Know More ](#)
- [AI Software Assurance (AISA)](#)
- [IT Quality and Compliance Consultation](#)
- [Digital Validation and Assurance (CSV/CSA)](#)
- [Commissioning, Qualification and Validation](#)
- [Medical Device Validation](#)
- [Testing and Automation](#)
## Expert Validation and Consulting at Your Fingertips
We have built a Centre of Excellence in Compliance and Validation. Our team of experts can help you achieve compliance in the most optimized way.
Accelerated Time to Market
- Reduce validation cycle time by 30% to expedite product launches by leveraging CSA and critical thinking concepts
Enhanced Product Quality
- With 40% of professionals seeking AI/ML efficiency, partner with Zifo to navigate the regulatory landscape and unlock innovation.
Reduced Defects
- Lower defect density by 50% to enhance product reliability and safety
Assured Regulatory Compliance
- Maintain 100% adherence to regulatory standards to mitigate risks and avoid penalties
Superior Customer Satisfaction
- Customer satisfaction rating of 4.5 out of 5, fostering long-term partnerships
## Validation Services and Compliance Support
Validation and compliance is a critical aspect within GxP relevant industries and qualification of computer systems (CSV / CSA), laboratory analytical instruments, equipment, process and Medical Devices with the corresponding compliance approaches, systems and ISO processes play a valuable role in ensuring quality compliance. Whether CLOUD or On-premise, informatics platforms require validation to meet various regulatory requirements and standards. Zifo validation team has experience ranging from Validation strategy definition and project planning to Validation execution (IQ/OQ/PQ) and validation process consultation support (e.g. SOPs / Policies).
AI Software Assurance
Leverage Zifo’s expertise to seamlessly integrate AI/ML solutions into your regulated pharmaceutical environment, ensuring compliance and unlocking new levels of efficiency, quality, and innovation.
[ Learn more >> ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjMwMTAiLCJ0b2dnbGUiOmZhbHNlfQ%3D%3D)
IT Quality and Compliance Consultation
Zifo partners with you to design, implement, and maintain robust quality systems tailored to your specific needs, ensuring compliance and driving continuous improvement.
[ Learn more >> ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjMwMTMiLCJ0b2dnbGUiOmZhbHNlfQ%3D%3D)
Digital Validation and Assurance (CSV/CSA)
Whether you are implementing new systems, upgrading existing platforms, or ensuring data integrity, we deliver tailored solutions designed to meet your operational and regulatory needs.
[ Learn more >> ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjMwMTYiLCJ0b2dnbGUiOmZhbHNlfQ%3D%3D)
Commissioning, Qualification and Validation (CQV)
Zifo specializes in Commissioning, Qualification, and Validation (CQV) tailored to the GLP, GCLP, and GMP environments. Our services are designed to minimize business user involvement, allowing focus on scientific operations while ensuring seamless vendor coordination, compliant validation, and efficient instrument and equipment deployment.
[ Learn more >> ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjMwMTkiLCJ0b2dnbGUiOmZhbHNlfQ%3D%3D)
Medical Device Validation
Zifo experts can work on SaMD / AIMD / MLMD validation strategy, IQ, OQ, and PQ development and qualification, software validation execution, and regulatory reporting across SaMD regulations.
[ Learn more >> ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjMwMjIiLCJ0b2dnbGUiOmZhbHNlfQ%3D%3D)
Testing and QA Services
We help you ensure the reliability, performance, and security of your applications through comprehensive Testing and Quality Assurance (QA) services. Our expertise covers a wide range of testing types, ensuring your applications meet the highest standards in both regulated and non-regulated environments.
[ Learn more >> ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjMwMjUiLCJ0b2dnbGUiOmZhbHNlfQ%3D%3D)
FAQ
## Curious how Zifo’s validation services and compliance support help achieve regulatory compliance?
See how Zifo supports compliance with guidelines such as 21 CFR Part 11 and GAMP 5 for AI-enabled biopharma operations.
Talk to an Expert
What validation services does Zifo provide for life sciences organizations?
Zifo’s validation services support pharmaceutical, biotechnology, and life sciences organizations in ensuring their laboratory systems, software platforms, and processes meet stringent regulatory requirements. Zifo provides expertise in computer system validation (CSV), equipment qualification, GxP compliance, and regulatory documentation—helping ensure systems operate reliably while maintaining data integrity in regulated environments.
How does Zifo support computer system validation (CSV)?
Zifo computer system validation (CSV) services ensure that laboratory software and digital platforms function according to regulatory guidelines. Zifo provides risk assessments, validation planning, test script development, validation execution, and compliance documentation aligned with industry standards like GAMP 5 and FDA 21 CFR Part 11.
How does Zifo ensure regulatory compliance for laboratory systems?
Zifo helps organizations maintain regulatory compliance in life sciences by implementing validated systems and standardized processes. Our validation and compliance support services align with global regulations such as GxP, FDA 21 CFR Part 11, GLP, GMP, and GDPR, ensuring laboratories remain audit-ready and compliant with industry standards.
What is CQV and how does Zifo support Commissioning, Qualification, and Validation?
Zifo CQV services support the full lifecycle of system implementation in regulated laboratories. Zifo experts perform Installation Qualification (IQ), Operational Qualification (OQ), and Performance Qualification (PQ) to ensure laboratory equipment and digital systems are properly installed, configured, and validated before use.
How does Zifo help maintain data integrity in regulated laboratory environments?
Zifo ensures data integrity in laboratory systems by implementing validated workflows, secure audit trails, controlled user access, and standardized documentation processes. These practices help organizations maintain accurate, reliable, and traceable scientific data while meeting regulatory compliance requirements.
How does Zifo manage change control and validation updates?
Zifo provides structured change management and validation lifecycle support to ensure that system updates, upgrades, and configuration changes remain compliant. Our services include impact assessments, change control documentation, re-validation activities, and compliance monitoring to minimize operational risks.
Why do life sciences companies choose Zifo for validation and compliance services?
Life sciences organizations choose Zifo validation and compliance services because of their expertise in laboratory informatics, regulatory frameworks, and digital transformation. Zifo helps organizations maintain compliant systems, streamline validation processes, and reduce regulatory risks while supporting innovation in scientific research.
Get in touch
First Name
Last Name
Email
Phone Number
Company
Designation
Enquiry Type
Enquiry Type Request for Zifo Services Product Partnership Job/Internship/Placement Enquiry Other
Message
Acceptance I consent to being contacted by an official Zifo representative
Submit
Featured Resources
[  ](https://zifo.com/blogs/evolving-compliance/)
[ Blog ](https://zifo.com/blogs/evolving-compliance/)
## [Evolving Compliance](https://zifo.com/blogs/evolving-compliance/)
[  ](https://zifo.com/blogs/optimizing-instrument-and-equipment-validation-lean-cohort-methodology/)
[ Blog ](https://zifo.com/blogs/optimizing-instrument-and-equipment-validation-lean-cohort-methodology/)
## [Optimizing Instrument And Equipment Validation: Lean & Cohort Methodology](https://zifo.com/blogs/optimizing-instrument-and-equipment-validation-lean-cohort-methodology/)
[  ](https://zifo.com/blogs/early-days-for-ai-but-scientific-data-management-gains-momentum/)
[ Blog ](https://zifo.com/blogs/early-days-for-ai-but-scientific-data-management-gains-momentum/)
## [Early Days For AI But Scientific Data Management Gains Momentum](https://zifo.com/blogs/early-days-for-ai-but-scientific-data-management-gains-momentum/)
---
### [Lab Compute Services](https://zifo.com/services/lab-compute-services/)
**Published:** November 3, 2025
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Services](https://zifo.com/services/ "Services")> Lab Compute Services
# Lab Compute Services
## Harmonized Lab IT Fuels Higher Scientist Satisfaction
By supporting lab systems directly where your data is generated, Zifo’s Lab Compute engineers ensure operational continuity, minimizing IT-related disruptions and enabling your scientists to focus fully on their research.
[ Know More ](#)
- [Improved Scientific Productivity](#)
- [End-to-End Ownership and Quality Management](#)
- [Lifecycle Management of Lab Systems](#)
- [Increased Security and Data Integrity](#)
- [Visibility and Insight into Lab IT](#)
- [Scalable Global Support Model](#)
- [Strategic Enablement of Digital Lab Transformation](#)
## Compliant and Efficient Lab IT Operations
Zifo’s Lab Compute service unifies lab IT under one global framework ; harmonizing best practices, ensuring GxP compliance, and strengthening data integrity across every site. With proactive monitoring and automation, we eliminate downtime, boost efficiency, and give scientists more time for science. Discover how a unified support model can make your lab more compliant, reliable, and future-ready.
Higher-than-industry average CSAT Scores
- 4.8 out of 5
Scientific Domain Knowledge
- familiarity with 200+ scientific applications
Scalable Global Delivery
- Staff across 20+ countries, enabling consistent lab support globally
Partnership Ecosystem
- 80+ technology and instrument partners; collaboration extends reach and technical depth.
## Leverage Zifo’s Lab Compute Services
Zifo has developed a scalable, flexible, and comprehensive IT support framework that can cover the full life cycle of your Scientific applications from build to decommission, from Server to the Lab Bench. Our all-in-one approach combines advanced technologies, like AI for automated support, with the human expertise needed for complex issues. Our goal is to ensure your scientific technology infrastructure is not just functional, but a driver of growth, scalability, and innovation.
Improved Scientific Productivity and Satisfaction
Free scientists from IT distractions with proactive support, significantly reducing downtime and boosting satisfaction levels to over 90%.
[ Learn more >> ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6Ijg0NTUiLCJ0b2dnbGUiOmZhbHNlfQ%3D%3D)
End-to-End Ownership and Quality Management
Gain a single, accountable team for all infrastructure, instruments, and GxP applications, ensuring compliance, traceability, and harmonized global processes to cut TCO.
[ Learn more >> ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6Ijg0NTgiLCJ0b2dnbGUiOmZhbHNlfQ%3D%3D)
Lifecycle Management of Lab Systems
Maintain systems in a continuously compliant, validated, and secure state, preventing massive periodic upgrade costs with proactive firmware and security patching.
[ Learn more >> ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6Ijg0NjEiLCJ0b2dnbGUiOmZhbHNlfQ%3D%3D)
Increased Security and Data Integrity
Mitigate, on an average, $4 million data breach risks with regular patching and specialized cybersecurity, ensuring your research labs consistently pass demanding Pen-tests.
[ Learn more >> ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6Ijg0NjQiLCJ0b2dnbGUiOmZhbHNlfQ%3D%3D)
Visibility and Insight into Lab IT
Achieve near 100% accurate asset inventory with comprehensive monitoring, providing data-driven insights that power better decisions and automation initiatives.
[ Learn more >> ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6Ijg0NjciLCJ0b2dnbGUiOmZhbHNlfQ%3D%3D)
Scalable Global Support Model
We help you to dive deep to identify the root cause of recurring issues. Implement permanent fixes to prevent future incidents. Reduce downtime and improve overall system reliability. Proactive problem resolution for a stable environment.
[ Learn more >> ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6Ijg0NzAiLCJ0b2dnbGUiOmZhbHNlfQ%3D%3D)
Strategic Enablement of Digital Lab Transformation
Establish a proactive, innovation-enabling foundation for automation and data flow, shifting Lab Compute support from reactive to a trusted scientific partnership.
[ Learn more >> ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6Ijg0NzMiLCJ0b2dnbGUiOmZhbHNlfQ%3D%3D)
FAQ
## Curious how Zifo’s lab compute services improve scientist satisfaction?
See how Zifo supports lab systems where data is generated to maintain continuity and reduce IT disruptions.
Talk to an Expert
What are Zifo Lab Compute Services?
Zifo Lab Compute Services provide specialized IT support for laboratory environments, ensuring that instrument-connected computers, scientific software, and laboratory systems operate efficiently. These services help research teams maintain reliable computing infrastructure, improve system performance, and support the daily technology needs of scientists working in regulated laboratory settings.
How do Zifo Lab Compute Services support scientific laboratories?
Zifo supports scientific laboratories by managing the computing systems that run laboratory instruments and informatics platforms. Our team handles system maintenance, troubleshooting, application support, and compliance management so scientists can focus on research instead of technical issues. These services are designed to maintain stability, reliability, and uptime across laboratory IT environments.
What types of systems are managed under Zifo Lab Compute Services?
Zifo manages a wide range of laboratory technologies, including instrument-connected computers, scientific applications, laboratory informatics platforms, and research data systems. Our engineers also support integrations between instruments and software platforms to enable efficient data flow across laboratory environments.
How do Zifo Lab Compute Services improve laboratory productivity?
By providing proactive system monitoring, technical support, and performance optimization, Zifo helps laboratories minimize downtime and technical disruptions. Reliable lab computing infrastructure allows scientists to access instruments, software, and data systems without delays, enabling faster research workflows and improved productivity.
How does Zifo ensure compliance in laboratory computing environments?
Zifo ensures laboratory computing systems comply with regulatory and corporate standards through validation processes, secure system configurations, and compliance monitoring. These practices help laboratories maintain proper documentation, audit readiness, and data integrity within regulated research environments.
How do Zifo Lab Compute Services support digital laboratory transformation?
Zifo helps laboratories modernize their computing infrastructure by integrating instruments, applications, and data platforms. This integration enables automation, improved data accessibility, and advanced analytics that support digital transformation initiatives in life sciences research.
Why do organizations choose Zifo for lab computing support?
Organizations choose Zifo because of its deep expertise in scientific IT environments and laboratory informatics. Zifo provides scalable support for global research organizations, helping thousands of scientists manage laboratory applications, computing systems, and instrument integrations across multiple sites.
Get in touch
First Name
Last Name
Email
Phone Number
Company
Designation
Enquiry Type
Enquiry Type Request for Zifo Services Product Partnership Job/Internship/Placement Enquiry Other
Message
Acceptance I consent to being contacted by an official Zifo representative
Submit
Featured Resources
[  ](https://zifo.com/blogs/a-comparison-of-acmg-amp-and-acgs-guidelines-for-variant-interpretation/)
[ Blog ](https://zifo.com/blogs/a-comparison-of-acmg-amp-and-acgs-guidelines-for-variant-interpretation/)
## [A Comparison Of ACMG/AMP And ACGS Guidelines For Variant Interpretation](https://zifo.com/blogs/a-comparison-of-acmg-amp-and-acgs-guidelines-for-variant-interpretation/)
[  ](https://zifo.com/blogs/how-acmg-guidelines-and-gnomad-are-aligning-to-simplify-variant-interpretation/)
[ Blog ](https://zifo.com/blogs/how-acmg-guidelines-and-gnomad-are-aligning-to-simplify-variant-interpretation/)
## [How ACMG Guidelines And gnomAD Are Aligning To Simplify Variant Interpretation](https://zifo.com/blogs/how-acmg-guidelines-and-gnomad-are-aligning-to-simplify-variant-interpretation/)
[  ](https://zifo.com/blogs/delivering-value-with-spatial-transcriptomics/)
[ Blog ](https://zifo.com/blogs/delivering-value-with-spatial-transcriptomics/)
## [Delivering Value With Spatial Transcriptomics](https://zifo.com/blogs/delivering-value-with-spatial-transcriptomics/)
---
### [Clinical Trials Services](https://zifo.com/services/clinical-trials-services/)
**Published:** March 12, 2025
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Services](https://zifo.com/services/ "Services")> Clinical Trials Services
# Clinical Trials
## Reduce Clinical Trial Costs and Timelines with AI and Automation
Make informed decisions and optimize your clinical trial strategy with the help of Artificial Intelligence
(AI), saving both time and cost while ensuring regulatory compliance.
[ Know More ](#)
- [Artificial Intelligence](#)
- [Automation](#)
- [Comprehensive Clinical Trial Solutions](#)
## Streamline Your Clinical Trials with Comprehensive Support
We have established a Centre of Excellence in Clinical Trial Operations. Our team of experts can optimize your clinical trials with advanced analytics and data-driven insights, ensuring a smooth regulatory submission process.
Time to First Patient In (TFPI)
- Reduce TFPI by 20% on average compared to industry standards
Patient Recruitment Rate
- Increase patient recruitment rate by 15% through optimized strategies
Data Quality and Completeness
- Achieve 100% data quality and completeness rates, reducing data cleaning efforts
Regulatory Submission Timelines
- Accelerate regulatory submission timelines by 25% on average
## Get Ahead with Zifo’s Clinical Trial Service
With AI-driven capabilities embedded in our comprehensive clinical trial solutions, Zifo helps you at every stage of the clinical trial to stay ahead of the competition.
Artificial Intelligence (AI)
From AI-driven medical writing (including safety assessments) to expert coding and submission package creation, Zifo offers comprehensive solutions for compliant and timely clinical trials.
[ Learn more >> ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjMyMTYiLCJ0b2dnbGUiOmZhbHNlfQ%3D%3D)
Automation
Zifo offers risk-based CDMS and real-time safety reporting solutions, complemented by advanced clinical programming and stat-VIEW for insightful data analysis. We ensure data quality in clinical trials by expertly managing multiple data sources, including decentralized trials through our polycentric network.
[ Learn more >> ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjMyMTkiLCJ0b2dnbGUiOmZhbHNlfQ%3D%3D)
Comprehensive Clinical Trial Solutions
Zifo offers comprehensive solutions for clinical research, including cost-effective IWRS/RTSM models, expert regulatory submission support, and advanced statistical analysis. Our tailored FP and FTE solutions and data cloaking services provide end-to-end support for your therapeutic development needs.
[ Learn more >> ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjMyMjIiLCJ0b2dnbGUiOmZhbHNlfQ%3D%3D)
FAQ
## Curious how Zifo’s clinical trials services reduce trial costs and timelines?
See how Zifo helps optimize clinical trial strategy with AI while saving time and cost and ensuring regulatory compliance.
Talk to an Expert
What clinical trial services does Zifo provide?
Zifo Clinical Trial Services provide end-to-end support for clinical research, helping pharmaceutical and biotech organizations manage the full clinical trial lifecycle. Zifo offers services such as clinical data management, statistical programming, regulatory submission support, and advanced analytics to help organizations run efficient and compliant clinical trials.
How does Zifo improve clinical trial efficiency?
Zifo improves clinical trial efficiency by using advanced analytics, automation, and optimized workflows. Our approach helps organizations reduce the time to first patient in (TFPI) and improve patient recruitment rates while maintaining high levels of data quality and completeness throughout the study.
How does Zifo use artificial intelligence in clinical trials?
Zifo integrates artificial intelligence into clinical trial processes to improve speed and accuracy. AI tools support tasks such as medical writing, safety assessments, medical coding, and regulatory submission preparation, helping teams produce compliant documentation more efficiently.
How does Zifo manage clinical trial data and reporting?
Zifo manages clinical trial data using risk-based clinical data management systems and statistical programming tools. Our services include creating standardized datasets, generating tables and reports, and performing quality checks to ensure accurate analysis and regulatory-ready documentation.
What types of clinical studies does Zifo support?
Zifo supports a wide range of clinical studies across therapeutic areas such as oncology, neurology, cardiology, immunology, and vaccine development. Our expertise also includes clinical trials for medical devices and specialized treatments, providing tailored solutions for diverse research programs.
How does Zifo support regulatory submissions for clinical trials?
Zifo assists organizations in preparing regulatory submission packages for global authorities by generating standardized datasets, annotated case report forms, and regulatory documentation. Our team ensures that clinical data is properly structured and aligned with regulatory guidelines to support successful submissions.
Why do life sciences companies choose Zifo for clinical trial services?
Life sciences companies choose Zifo because of its expertise in scientific informatics, clinical data management, and regulatory compliance. By combining advanced technologies with domain expertise, Zifo helps organizations run efficient clinical trials, improve data quality, and accelerate the development of new therapies.
Get in touch
First Name
Last Name
Email
Phone Number
Company
Designation
Enquiry Type
Enquiry Type Request for Zifo Services Product Partnership Job/Internship/Placement Enquiry Other
Message
Acceptance I consent to being contacted by an official Zifo representative
Submit
Featured Resources
[  ](https://zifo.com/blogs/cdisc-clinical-trials/)
[ Blog ](https://zifo.com/blogs/cdisc-clinical-trials/)
## [Cdisc Clinical Trails](https://zifo.com/blogs/cdisc-clinical-trials/)
[  ](https://zifo.com/blogs/decentralized-clinical-trial/)
[ Blog ](https://zifo.com/blogs/decentralized-clinical-trial/)
## [Decentralized Clinical Trials](https://zifo.com/blogs/decentralized-clinical-trial/)
[  ](https://zifo.com/blogs/early-days-for-ai-but-scientific-data-management-gains-momentum/)
[ Blog ](https://zifo.com/blogs/early-days-for-ai-but-scientific-data-management-gains-momentum/)
## [Early Days For AI But Scientific Data Management Gains Momentum](https://zifo.com/blogs/early-days-for-ai-but-scientific-data-management-gains-momentum/)
[  ](https://zifo.com/blogs/beyond-the-hype-biopharmas-tech-transfer-process-needs-a-fundamental-reset/)
[ Blog ](https://zifo.com/blogs/beyond-the-hype-biopharmas-tech-transfer-process-needs-a-fundamental-reset/)
## [Beyond The Hype: Biopharma’s Tech Transfer Process Needs A Fundamental Reset](https://zifo.com/blogs/beyond-the-hype-biopharmas-tech-transfer-process-needs-a-fundamental-reset/)
[  ](https://zifo.com/blogs/a-strategic-guide-to-consolidation-in-scientific-informatics/)
[ Blog ](https://zifo.com/blogs/a-strategic-guide-to-consolidation-in-scientific-informatics/)
## [A Strategic Guide To Consolidation In Scientific Informatics](https://zifo.com/blogs/a-strategic-guide-to-consolidation-in-scientific-informatics/)
---
### [Genotyping & Sequencing Services](https://zifo.com/services/genotyping-sequencing-services/)
**Published:** January 19, 2022
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Services](https://zifo.com/services/ "Services")> Genotyping & Sequencing Services
Genotyping Sequence Analysis Services
Identifying genomic variation across individuals through Genotyping is used to detect changes in the DNA sequence associated with a trait or disease. Genomic variation comes in a variety of levels, ranging from small nucleotide changes to large scale rearrangements – each of these requires a different assay and analysis method. Our [bioinformatics service](/services/) offers accurate and reproducible data processing for both exome targeted and whole-genome genotyping by sequencing or microarray and can be leveraged to carry out downstream analyses such as variant calling and genome-wide association studies.
[ Know more ](#)
Our Capabilities
Our expertise spans the whole spectrum of scientific process applications, and we’re able
to draw on a huge marketplace of partnerships with science technology providers, so
whatever is needed to fix your current set-up. we’ll determine the best way forward.
Our People
Our people are our business and we invest and support their development and curiosity. We actively promote science in our daily work and over 90% of people in Zifo have a scientific background – meaning we speak & understand the language of science
Glocal
We have a GLOCAL (global & local) presence – meaning we engage with you in your language and time zone but leverage a global delivery support model to remain cost-effective, scalable and very reactive
Focus
We focus on science and scientific process applications and informatics. This means we can provide expertise and domain knowledge without compromising quality, technical and service delivery excellence
Partnerships
Our huge marketplace of partnerships with science technology and informatics platform providers means you can rely on Zifo to be agnostic and advise on strategy, plan & deliver projects, and validate and maintain your scientific informatics environments
Get in touch
First Name
Last Name
Email
Phone Number
Company
Designation
Enquiry Type
Enquiry Type Request for Zifo Services Product Partnership Job/Internship/Placement Enquiry Other
Message
Acceptance I consent to being contacted by an official Zifo representative
Submit
---
### [Manufacturing and Quality Informatics Services](https://zifo.com/services/manufacturing-and-mes-services/)
**Published:** May 5, 2025
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Services](https://zifo.com/services/ "Services")> Manufacturing and Quality Informatics Services
# Manufacturing and Quality Informatics Services
## Human-led Smart Manufacturing Through AI and Automation
Ensure product quality, optimize operations, ensure efficient master data management and accelerate time-to-market.
[ Know More ](#zifo_contact_us_form)
- [Consulting](#sectionOne)
- [Implementation](#sectionTwo)
- [Master Data Management](#sectionThree)
- [AI-Enabled Service Accelerator (QCKen)](#sectionFour)
- [Instrument Integration](#sectionFive)
- [Data Analytics, Dashboards](#sectionSix)
- [Managed Services](#sectionSeven)
- [Data Migration](#sectionEight)
- [Compliance](#sectionNine)
- [Manufacturing Batch Release](#sectionTen)
- [Tech Transfer](#sectionEleven)
## Harness our Manufacturing and Quality Informatics Expertise
We have built a Centre of Excellence in Manufacturing and Quality Informatics. Our team of experts can help you with next gen quality control, master data management, LIMS Implementations and process execution with AI and Automation.
100% Compliance
Our consulting services ensure complete adherence to FDA, ISO, GLP, GMP, HIPAA, and GAMP 5 standards
Seamless Integration with 250+ instruments
Including HPLC, GC-MS, spectrophotometers, PCR machines, and analytical balances
40% Faster Implementation
Rapidly digitizing and automating your batch execution and quality control
Accelerated Migration
Leveraging Gen AI and intelligent automation for faster go-live
Customer Retention
95% of customers retained
## Smart Manufacturing and Quality Informatics Services
As products progress from R&D to Manufacturing, the demands on informatics and business processes change. Zifo can support your labs and operations with our services and product capabilities developed to meet the rigorous demands of software configuration, managed services, compliance and validation.
Consulting
Zifo helps customers identify process gaps, define improvement opportunities, and design future-state solutions. Our consultants follow industry standards like BPMN, ensuring end-to-end requirements traceability and clear functional and non-functional specifications.
[ Learn more >> ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjI3NzIiLCJ0b2dnbGUiOmZhbHNlfQ%3D%3D)
Implementation
Zifo collaborates with lab users, IT, and business stakeholders to manage change effectively and drive adoption. By delivering a Minimum Viable Product (MVP), Zifo enables early wins and builds confidence.
[ Learn more >> ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjI3NzgiLCJ0b2dnbGUiOmZhbHNlfQ%3D%3D)
Master Data Management
Zifo delivers master data management services by combining Gen AI-assisted automation with deep expertise in science, technology, and GxP. Leveraging AI-assisted data extraction, Zifo accelerates the digitization of master data from documents, spreadsheets, and legacy systems — reducing setup time and manual effort by at least 40%.
[ Learn more >> ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjI3ODEiLCJ0b2dnbGUiOmZhbHNlfQ%3D%3D)
AI-Enabled Service Accelerator (qcKen)
Zifo’s Gen AI-powered, automation-led MDM framework along with qcKen service accelerator, accelerates the transition from scattered or paper-based records to a centralized digital repository. Prior implementations have shown up to 40% effort reduction and faster go-lives, thanks to our modular, scalable approach.
[ Learn more >> ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjI3ODUiLCJ0b2dnbGUiOmZhbHNlfQ%3D%3D)
Instrument Integration
Zifo brings deep expertise in integrating leading LIMS platforms — including LabWare, STARLIMS, LabVantage, and Thermo Fisher SampleManager — with 250+ laboratory instruments. Integration solutions are tailored to support direct, middleware-based, and file-based architectures, enabling seamless data flow in modern lab environments. Also, we ensure compliance with global regulatory standards such as FDA, ISO 17025, GLP, GMP, HIPAA, and 21 CFR Part 11.
[ Learn more >> ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjI3ODgiLCJ0b2dnbGUiOmZhbHNlfQ%3D%3D)
Data Analytics, Dashboards and Visualizations and Reporting services
Zifo brings deep expertise in LIMS and business intelligence tools to deliver customized dashboards and reporting solutions that align with regulatory requirements such as FDA 21 CFR Part 11, ISO 17025, GLP, and GMP. Zifo develops tailored visualizations based on industry context, lab type, and workflow needs — enabling real-time insights and operational visibility.
[ Learn more >> ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjI3OTIiLCJ0b2dnbGUiOmZhbHNlfQ%3D%3D)
Managed Services
Zifo provides expert-managed services to ensure LIMS environments operate securely, efficiently, and in full compliance with evolving regulatory standards. With deep expertise across LabWare, STARLIMS, LabVantage, SampleManager, and other leading platforms, Zifo offers end-to-end system management — from routine maintenance and upgrades to performance optimization, troubleshooting, and regulatory support.
[ Learn more >> ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjI3OTUiLCJ0b2dnbGUiOmZhbHNlfQ%3D%3D)
Data Migration
Speed and quality are at the core of Zifo’s data migration services, ensuring laboratories can transition to modern LIMS platforms with minimal disruption and maximum confidence. Zifo combines deep expertise across LabWare, STARLIMS, LabVantage, SampleManager, ELNs, and custom LIMS with intelligent automation and Gen AI-driven tools to accelerate migration timelines while maintaining the highest standards of data integrity, security, and compliance.
[ Learn more >> ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjI3OTgiLCJ0b2dnbGUiOmZhbHNlfQ%3D%3D)
Compliance
Zifo provides comprehensive validation services to ensure that LIMS platforms meet GxP requirements and evolving global regulatory standards, including FDA 21 CFR Part 11, EU Annex 11, and ISO 17025. With proven experience across LabWare, STARLIMS, LabVantage, SampleManager, and custom LIMS, Zifo focuses on validating critical system functions to optimize compliance while minimizing unnecessary overhead.
[ Learn more >> ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjI4MDEiLCJ0b2dnbGUiOmZhbHNlfQ%3D%3D)
Manufacturing Batch Release
We improve efficiency and scalability by optimizing, automating, validating, and controlling processes through BPMN, technology, and change management. Our solutions automate business rules and support data-driven decisions.
[ Learn more >> ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjI4MDQiLCJ0b2dnbGUiOmZhbHNlfQ%3D%3D)
Tech Transfer
Zifo offers handover of analytical testing processes, manufacturing process parameters, product specification data transfer, data integrity support, validation and compliance, and manufacturing plant design services. Successful tech transfer hinges on effective knowledge management amidst the rising tide of data.
[ Learn more >> ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjI4MDciLCJ0b2dnbGUiOmZhbHNlfQ%3D%3D)
FAQ
## Curious how Zifo’s manufacturing and quality informatics services enable smart manufacturing?
See how Zifo helps ensure product quality, optimize operations, improve master data management, and accelerate time-to-market.
[ Talk to an Expert ](https://zifo.com/services/manufacturing-and-mes-services/#contacts-form)
What manufacturing and MES services does Zifo provide?
Zifo Manufacturing and MES Services help life sciences organizations digitize and optimize manufacturing operations through advanced informatics, automation, and data integration. Zifo supports consulting, system implementation, master data management, and process automation to improve manufacturing efficiency and quality control in regulated environments.
How does Zifo support digital transformation in manufacturing operations?
Zifo helps organizations modernize manufacturing processes by integrating laboratory systems, enterprise platforms, and manufacturing execution systems. Their approach focuses on improving data flow, automating workflows, and enabling real-time operational visibility to support smarter decision-making across production and quality management.
How does Zifo help manage manufacturing master data?
Zifo provides master data management solutions that help organizations centralize and standardize manufacturing and laboratory data. Using automation and AI-assisted tools, Zifo helps extract and structure data from documents, spreadsheets, and legacy systems, significantly reducing manual effort and improving data consistency.
How does Zifo support instrument and system integration in manufacturing environments?
Zifo integrates manufacturing and laboratory systems with enterprise platforms and laboratory instruments to enable seamless data exchange. Their solutions support connections with hundreds of laboratory instruments and multiple informatics platforms, allowing automated data capture and improved operational efficiency.
How does Zifo improve manufacturing batch release processes?
Zifo helps organizations streamline manufacturing batch release processes by automating data collection, validation, and review workflows. By reducing manual data transcription and applying automated business rules, Zifo improves process scalability, quality assurance, and decision-making during product release.
How does Zifo ensure regulatory compliance in manufacturing systems?
Zifo ensures manufacturing systems meet global regulatory standards by implementing validated workflows and compliant system configurations. Their services support compliance with standards such as FDA regulations, ISO guidelines, and GxP requirements, helping organizations maintain audit readiness and data integrity.
Why do life sciences companies choose Zifo for manufacturing and MES services?
Life sciences companies choose Zifo because of its expertise in scientific informatics, manufacturing processes, and regulatory compliance. Zifo helps organizations modernize production environments, improve quality control, and create scalable digital manufacturing systems that support innovation and operational efficiency.
Get in touch
First Name
Last Name
Email
Phone Number
Company
Designation
Enquiry Type
Enquiry Type Request for Zifo Services Product Partnership Job/Internship/Placement Enquiry Other
Message
Acceptance I consent to being contacted by an official Zifo representative
Submit
Featured Resources
[  ](https://zifo.com/blogs/implementing-lims-in-manufacturing-qc/)
[ Blog ](https://zifo.com/blogs/implementing-lims-in-manufacturing-qc/)
## [Implementing LIMS In Manufacturing QC](https://zifo.com/blogs/implementing-lims-in-manufacturing-qc/)
[  ](https://zifo.com/blogs/key-considerations-for-implementing-environmental-monitoring-in-lims/)
[ Blog ](https://zifo.com/blogs/key-considerations-for-implementing-environmental-monitoring-in-lims/)
## [Key Considerations For Implementing Environmental Monitoring In LIMS](https://zifo.com/blogs/key-considerations-for-implementing-environmental-monitoring-in-lims/)
[  ](https://zifo.com/blogs/beyond-the-hype-biopharmas-tech-transfer-process-needs-a-fundamental-reset/)
[ Blog ](https://zifo.com/blogs/beyond-the-hype-biopharmas-tech-transfer-process-needs-a-fundamental-reset/)
## [Beyond The Hype: Biopharma’s Tech Transfer Process Needs A Fundamental Reset](https://zifo.com/blogs/beyond-the-hype-biopharmas-tech-transfer-process-needs-a-fundamental-reset/)
---
### [Product Development and Design](https://zifo.com/services/product-development-and-design/)
**Published:** April 7, 2025
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Services](https://zifo.com/services/ "Services")> Product Development and Design
# Product Development and Design
## Optimized Product Informatics: From Concept to Commercialization
By delivering optimized informatics, Zifo experts make the challenges of product development easier to navigate, from research to market.
[ Know More ](#)
- [Technology Transfer Support](#)
- [ Stability Studies](#sectionTwo)
- [Quality and Compliance Consulting](#sectionThree)
- [Business Process Automation](#sectionFour)
- [Manufacturing Batch Release](#sectionFive)
- [CMC Services in Manufacturing](#sectionSix)
- [Analytical Testing and Lab Services](#sectionSeven)
## Leverage Zifo’s Product Innovation Capabilities
We have established a Centre of Excellence in Product Lifecycle Management and Informatics Consulting. Our team of experts can optimize your product lifecycle, from formulation development to market withdrawal, by leveraging cutting-edge technologies and industry best practices.
Reduced time-to-market
- Accelerate product launch by 20%
Improved Product Quality
- Increase product quality by 15% with robust quality management and control systems
Enhanced Regulatory Compliance
- Achieve 100% regulatory compliance with our expert guidance and automated processes
Operational Efficiency
- Reduce operational costs by 10%
## Leverage Informatics to Supercharge Product Design and Development
Deep knowledge of how new products and medicines are developed, the processes, science and technologies used, really helps Zifo to understand, support and contribute to your informatics projects in any scientific domain.
Technology Transfer Support Services
Zifo offers handover of analytical testing processes, manufacturing process parameters, product specification data transfer, data integrity support, validation and compliance, and manufacturing plant design services.
[ Learn more >> ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjI2NDkiLCJ0b2dnbGUiOmZhbHNlfQ%3D%3D)
Stability Studies
We can help with study design (DoE) and planning, sample tracking and pull date scheduling, environmental monitoring, sample testing and analytical test results capture, study results aggregation, validation, statistical analysis.
[ Learn more >> ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjI2NTIiLCJ0b2dnbGUiOmZhbHNlfQ%3D%3D)
Quality and Compliance Consulting
Partner with Zifo for new quality system design, delivery, and maintenance, auditing against regional regulatory guidelines (21 CFR Part 11, GLP, GMP, GCP, GAMP 5), quality system audits, recommendations, and best practice adoption.
[ Learn more >> ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjI2NTUiLCJ0b2dnbGUiOmZhbHNlfQ%3D%3D)
Business Process Automation Service
Zifo offers automated assay and screening, batch release, workflow orchestration, BPMN, low-code-no-code process automation (RPA) and robotics platforms.
[ Learn more >> ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjI2NTkiLCJ0b2dnbGUiOmZhbHNlfQ%3D%3D)
Manufacturing Batch Release
We improve efficiency and scalability by optimizing, automating, validating, and controlling processes through BPMN, technology, and change management. Our solutions automate business rules and support data-driven decisions.
[ Learn more >> ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjI2NjIiLCJ0b2dnbGUiOmZhbHNlfQ%3D%3D)
CMC Services in Manufacturing
Zifo aggregates and ensures the regulatory integrity of information for specifications, manufacturing process control parameters, stability parameters, and analytical test variance data
[ Learn more >> ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjI2NjUiLCJ0b2dnbGUiOmZhbHNlfQ%3D%3D)
Analytical Testing and Lab Services
Zifo provides solutions for assay development and validation, instrument data acquisition and integration, regulatory and QC data reporting, lab inventory and metrology, workflow automation and validation.
[ Learn more >> ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjI2NjgiLCJ0b2dnbGUiOmZhbHNlfQ%3D%3D)
FAQ
## Curious how Zifo’s product development and design services optimize product informatics?
See how Zifo delivers optimized informatics to make product development easier to navigate, from research to market.
Talk to an Expert
What product development and design services does Zifo provide?
Zifo Product Development and Design Services help life sciences organizations optimize the entire product lifecycle—from formulation development to commercialization and market withdrawal. Zifo combines scientific expertise, digital technologies, and industry best practices to improve product quality, reduce time-to-market, and streamline development processes.
How does Zifo support product lifecycle management in life sciences?
Zifo provides consulting and informatics solutions that support product lifecycle management across research, development, manufacturing, and quality operations. By
integrating scientific data, digital platforms, and workflow automation, Zifo helps organizations manage product information efficiently throughout every stage of the lifecycle.
How does Zifo assist with technology transfer from R&D to manufacturing?
Zifo offers technology transfer support services that ensure the smooth handover of knowledge and data from research teams to manufacturing operations. This includes transferring analytical testing processes, product specifications, manufacturing parameters, and ensuring data integrity during the transition to production.
How does Zifo support stability studies during product development?
Zifo helps organizations plan and manage stability studies that evaluate the shelf life and environmental performance of products. Their services include study design, sample tracking, environmental monitoring, analytical testing, and statistical analysis to ensure reliable results and regulatory readiness.
How does Zifo improve manufacturing batch release processes?
Zifo works with life sciences companies to streamline manufacturing batch release by reducing manual data entry and improving system integration between enterprise and laboratory platforms. By automating workflows and applying business rules, Zifo helps organizations improve efficiency and quality assurance in manufacturing operations.
How does Zifo support scientific data architecture during product development?
Zifo designs scientific data architectures that connect data across the product lifecycle, including chemistry, analytical, preclinical, clinical, and manufacturing data. This integrated approach ensures better data governance, traceability, and analytics-ready datasets that support informed decision-making across R&D and operations.
Why do life sciences companies choose Zifo for product development and design services?
Organizations choose Zifo because of its expertise in scientific informatics, digital transformation, and life sciences research. By combining technology, data strategy, and domain knowledge, Zifo helps companies accelerate product innovation, improve operational efficiency, and ensure regulatory compliance throughout product development.
Get in touch
First Name
Last Name
Email
Phone Number
Company
Designation
Enquiry Type
Enquiry Type Request for Zifo Services Product Partnership Job/Internship/Placement Enquiry Other
Message
Acceptance I consent to being contacted by an official Zifo representative
Submit
Featured Resources
[  ](https://zifo.com/blogs/lab-informatics-projects-handling-dynamic-requirements-with-grace/)
[ Blog ](https://zifo.com/blogs/lab-informatics-projects-handling-dynamic-requirements-with-grace/)
## [Lab Informatics Projects: Handling Dynamic Requirements With Grace](https://zifo.com/blogs/lab-informatics-projects-handling-dynamic-requirements-with-grace/)
[  ](https://zifo.com/blogs/key-considerations-for-implementing-environmental-monitoring-in-lims/)
[ Blog ](https://zifo.com/blogs/key-considerations-for-implementing-environmental-monitoring-in-lims/)
## [Key Considerations For Implementing Environmental Monitoring In LIMS](https://zifo.com/blogs/key-considerations-for-implementing-environmental-monitoring-in-lims/)
[  ](https://zifo.com/blogs/beyond-the-hype-biopharmas-tech-transfer-process-needs-a-fundamental-reset/)
[ Blog ](https://zifo.com/blogs/beyond-the-hype-biopharmas-tech-transfer-process-needs-a-fundamental-reset/)
## [Beyond The Hype: Biopharma’s Tech Transfer Process Needs A Fundamental Reset](https://zifo.com/blogs/beyond-the-hype-biopharmas-tech-transfer-process-needs-a-fundamental-reset/)
---
### [Cell & Molecular Biology](https://zifo.com/services/cell-mol-biol/)
**Published:** January 19, 2022
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Services](https://zifo.com/services/ "Services")> Cell & Molecular Biology
Cell & Molecular Biology
Cell and Molecular biology have become critical for many organisations, whether in pharmaceuticals, Biotechs or in Food&Bev and [Fast-Moving Consumer Goods](/industries/fmcg-informatics-and-consulting-services/), Agrotech and Speciality Chemicals. Manipulation of biology at the ‘Omic level and its downstream effects uses many different techniques and scientific applications to support cloning, plasmid design, cell transfection and protein/product production. Cell and Molecular biology technology like CRISPR is now delivering gene editing and cell-based therapies and have their own specific science and application demands. [Zifo](/)‘s experience covers the entire spectrum of open source and commercial applications, databases, workflows, registration and process development tools that are used widely in this domain.
[ Know more ](#)
Our Capabilities
Our expertise spans the whole spectrum of scientific process applications, and we’re able
to draw on a huge marketplace of partnerships with science technology providers, so
whatever is needed to fix your current set-up. we’ll determine the best way forward.
Our People
Our people are our business and we invest and support their development and curiosity. We actively promote science in our daily work and over 90% of people in Zifo have a scientific background – meaning we speak & understand the language of science
Glocal
We have a GLOCAL (global & local) presence – meaning we engage with you in your language and time zone but leverage a global delivery support model to remain cost-effective, scalable and very reactive
Focus
We focus on science and scientific process applications and informatics. This means we can provide expertise and domain knowledge without compromising quality, technical and service delivery excellence
Partnerships
Our huge marketplace of partnerships with science technology and informatics platform providers means you can rely on Zifo to be agnostic and advise on strategy, plan & deliver projects, and validate and maintain your scientific informatics environments
Get in touch
First Name
Last Name
Email
Phone Number
Company
Designation
Enquiry Type
Enquiry Type Request for Zifo Services Product Partnership Job/Internship/Placement Enquiry Other
Message
Acceptance I consent to being contacted by an official Zifo representative
Submit
---
### [Clinical Pharmacology & DMPK Services](https://zifo.com/services/clinical-pharmacology-dmpk-services/)
**Published:** January 19, 2022
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Services](https://zifo.com/services/ "Services")> Clinical Pharmacology & DMPK Services
Clinical Pharmacology & DMPK Services
There are many types of [pharmacology](https://www.zifo.com/services/in-vivo-and-in-vitro-pharmacology-inforamtics-services/) assay types and science involved in treatment development, coupled with ADME and DMPK they deliver insights into how products interact with the body. Whilst some areas have developed computational modelling approaches to help filter out molecules with unwanted ADME and PK profiles early on – there is still a need for testing. [Zifo](https://www.zifo.com/)‘s experience extends from early Pharmacology, through to kinetic assay and tissue-based assays, through the ADME cascade approaches including automation and decisions support, onto DMPK with study design, resource management, data acquisition, Bioanalysis, analytical method development and validation and finally onto validation, PK modelling and regulatory submissions.
[ Know more ](#)
Our Capabilities
Our expertise spans the whole spectrum of scientific process applications, and we’re able
to draw on a huge marketplace of partnerships with science technology providers, so
whatever is needed to fix your current set-up. we’ll determine the best way forward.
Our People
Our people are our business and we invest and support their development and curiosity. We actively promote science in our daily work and over 90% of people in Zifo have a scientific background – meaning we speak & understand the language of science
Glocal
We have a GLOCAL (global & local) presence – meaning we engage with you in your language and time zone but leverage a global delivery support model to remain cost-effective, scalable and very reactive
Focus
We focus on science and scientific process applications and informatics. This means we can provide expertise and domain knowledge without compromising quality, technical and service delivery excellence
Partnerships
Our huge marketplace of partnerships with science technology and informatics platform providers means you can rely on Zifo to be agnostic and advise on strategy, plan & deliver projects, and validate and maintain your scientific informatics environments
Get in touch
First Name
Last Name
Email
Phone Number
Company
Designation
Enquiry Type
Enquiry Type Request for Zifo Services Product Partnership Job/Internship/Placement Enquiry Other
Message
Acceptance I consent to being contacted by an official Zifo representative
Submit
---
### [In Vitro & In Vivo Scientific IT Services & Informatics Consulting](https://zifo.com/services/in-vivo-and-in-vitro-pharmacology-inforamtics-services/)
**Published:** January 19, 2022
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Services](https://zifo.com/services/ "Services")> In Vitro & In Vivo Scientific IT Services & Informatics Consulting
In Vitro & In Vivo Scientific IT Services & Informatics Consulting
[In vitro pharmacology and In Vivo testing](/services/in-vivo-and-in-vitro-pharmacology-inforamtics-services/) requires many different scientific, process and informatics tools to be successful. The use of robotics and automation in early phases, coupled with end-point and kinetics pharmacology, alongside test campaign cascading, Bioanalysis and PK/PD analytics make this an interesting business area. [Zifo](/) has extensive experience in Early Pharmacology, ADME, Assay Automation, PK/PD, Assay Development & Validation, Bioanalysis, Animal Management etc. and linked regulatory and validation aspects of GLP and IND/NDA/BLA creation.
[ Know more ](#)
Our Capabilities
Our expertise spans the whole spectrum of scientific process applications, and we’re able
to draw on a huge marketplace of partnerships with science technology providers, so
whatever is needed to fix your current set-up. we’ll determine the best way forward.
Our People
Our people are our business and we invest and support their development and curiosity. We actively promote science in our daily work and over 90% of people in Zifo have a scientific background – meaning we speak & understand the language of science
Glocal
We have a GLOCAL (global & local) presence – meaning we engage with you in your language and time zone but leverage a global delivery support model to remain cost-effective, scalable and very reactive
Focus
We focus on science and scientific process applications and informatics. This means we can provide expertise and domain knowledge without compromising quality, technical and service delivery excellence
Partnerships
Our huge marketplace of partnerships with science technology and informatics platform providers means you can rely on Zifo to be agnostic and advise on strategy, plan & deliver projects, and validate and maintain your scientific informatics environments
Get in touch
First Name
Last Name
Email
Phone Number
Company
Designation
Enquiry Type
Enquiry Type Request for Zifo Services Product Partnership Job/Internship/Placement Enquiry Other
Message
Acceptance I consent to being contacted by an official Zifo representative
Submit
---
### [Analytical Testing & Lab Services](https://zifo.com/services/analytical-testing-lab-services/)
**Published:** January 19, 2022
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Services](https://zifo.com/services/ "Services")> Analytical Testing & Lab Services
Analytical Testing Lab Informatics Services
[Analytical test development](/services/analytical-testing/) and execution is ubiquitous in science-based organisations where information is needed to make decisions. The many facets of testing from assay development and validation, through instrument data acquisition and integration, regulatory and QC data reporting as COAs, test specifications, to lab inventory and metrology monitoring all require specialist informatics and hardware such as LIMS, LIS, CDS, Metrology, Inventory, Robotics etc. [Zifo](/) has deep experience and expertise in delivering informatics solutions in the analytical testing ecosystem across many different market verticals and lab operations.
[ Know more ](#)
Our Capabilities
Our expertise spans the whole spectrum of scientific process applications, and we’re able
to draw on a huge marketplace of partnerships with science technology providers, so
whatever is needed to fix your current set-up. we’ll determine the best way forward.
Our People
Our people are our business and we invest and support their development and curiosity. We actively promote science in our daily work and over 90% of people in Zifo have a scientific background – meaning we speak & understand the language of science
Glocal
We have a GLOCAL (global & local) presence – meaning we engage with you in your language and time zone but leverage a global delivery support model to remain cost-effective, scalable and very reactive
Focus
We focus on science and scientific process applications and informatics. This means we can provide expertise and domain knowledge without compromising quality, technical and service delivery excellence
Partnerships
Our huge marketplace of partnerships with science technology and informatics platform providers means you can rely on Zifo to be agnostic and advise on strategy, plan & deliver projects, and validate and maintain your scientific informatics environments
Get in touch
First Name
Last Name
Email
Phone Number
Company
Designation
Enquiry Type
Enquiry Type Request for Zifo Services Product Partnership Job/Internship/Placement Enquiry Other
Message
Acceptance I consent to being contacted by an official Zifo representative
Submit
---
### [Data Integrity & Compliance Experts](https://zifo.com/services/data-integrity-compliance-companies/)
**Published:** January 19, 2022
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Services](https://zifo.com/services/ "Services")> Data Integrity & Compliance Experts
Data Integrity & Compliance Services
[Data](/services/data-sciences-ai-ml-modelling-services/) is the ultimate building block. Zifo deploys and constantly maintains numerous data review tools and processes suggested by GLP, GCDMP and GMP to deliver the best possible quality of data that meets the current and emerging trends. In clinical trials where sensitive patient data is handled, CDM must be executed with utmost care to ensure that all the mandates of 21CFR Part 11, GCP, HIPAA, EU ANNEX 11 and GDPR are covered to ensure data integrity. [Zifo](/) also executes Data Integrity remediation for Manufacturing and QC laboratories to align with [Data Integrity](/services/data-integrity-compliance-companies/) guidance issued by regulatory agencies.
[ Know more ](#)
Our Capabilities
Our expertise spans the whole spectrum of scientific process applications, and we’re able
to draw on a huge marketplace of partnerships with science technology providers, so
whatever is needed to fix your current set-up. we’ll determine the best way forward.
Our People
Our people are our business and we invest and support their development and curiosity. We actively promote science in our daily work and over 90% of people in Zifo have a scientific background – meaning we speak & understand the language of science
Glocal
We have a GLOCAL (global & local) presence – meaning we engage with you in your language and time zone but leverage a global delivery support model to remain cost-effective, scalable and very reactive
Focus
We focus on science and scientific process applications and informatics. This means we can provide expertise and domain knowledge without compromising quality, technical and service delivery excellence
Partnerships
Our huge marketplace of partnerships with science technology and informatics platform providers means you can rely on Zifo to be agnostic and advise on strategy, plan & deliver projects, and validate and maintain your scientific informatics environments
Get in touch
First Name
Last Name
Email
Phone Number
Company
Designation
Enquiry Type
Enquiry Type Request for Zifo Services Product Partnership Job/Internship/Placement Enquiry Other
Message
Acceptance I consent to being contacted by an official Zifo representative
Submit
---
### [Clinical Trial Data & Management Services](https://zifo.com/services/clinical-data-management-services/)
**Published:** January 19, 2022
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Services](https://zifo.com/services/ "Services")> Clinical Trial Data & Management Services
Clinical Trial Data & Management Services
Ensuring studies are predictable and controlled is critical and we leverage proven libraries (CDASH / SDTM / ADaM / TLG standards), Therapeutic Area-Specific Assets, SDTM and Define-XML Tools, [Data Management](/partner-category/clinical-data-management/) Dashboards (Remote & Statistical Monitoring), Online Data Management Binder etc.. [Zifo](/) is well-positioned to support your EDC/CRF setup based on the phase of the study, type of study, therapeutic area, features, [helpdesk support](/services/technology-help-desk-and-user-support-services/) and licensing cost.
[ Know more ](#)
Our Capabilities
Our expertise spans the whole spectrum of scientific process applications, and we’re able
to draw on a huge marketplace of partnerships with science technology providers, so
whatever is needed to fix your current set-up. we’ll determine the best way forward.
Our People
Our people are our business and we invest and support their development and curiosity. We actively promote science in our daily work and over 90% of people in Zifo have a scientific background – meaning we speak & understand the language of science
Glocal
We have a GLOCAL (global & local) presence – meaning we engage with you in your language and time zone but leverage a global delivery support model to remain cost-effective, scalable and very reactive
Focus
We focus on science and scientific process applications and informatics. This means we can provide expertise and domain knowledge without compromising quality, technical and service delivery excellence
Partnerships
Our huge marketplace of partnerships with science technology and informatics platform providers means you can rely on Zifo to be agnostic and advise on strategy, plan & deliver projects, and validate and maintain your scientific informatics environments
Get in touch
First Name
Last Name
Email
Phone Number
Company
Designation
Enquiry Type
Enquiry Type Request for Zifo Services Product Partnership Job/Internship/Placement Enquiry Other
Message
Acceptance I consent to being contacted by an official Zifo representative
Submit
---
### [Biometric Services](https://zifo.com/services/biometric-screening-service-company/)
**Published:** January 19, 2022
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Services](https://zifo.com/services/ "Services")> Biometric Services
Biometric Services
Statistical inputs are required across all study types from observational studies, bioavailability and bioequivalence (BA / BE), to Phase I-III [Clinical Trials](/services/clinical-trials-services/) and Post-marketing Studies. From clinical protocol and CRF design, sample size determination, through creating statistical analysis plans, generating tables, listings and graphs, to interpreting and reporting of trial results – all require biostatistics support. [Zifo’s](/) biostatistics services support analysis across the entire trial process in many platforms such as SaS, JMP, R, Phoenix etc.
[ Know more ](#)
Our Capabilities
Our expertise spans the whole spectrum of scientific process applications, and we’re able
to draw on a huge marketplace of partnerships with science technology providers, so
whatever is needed to fix your current set-up. we’ll determine the best way forward.
Our People
Our people are our business and we invest and support their development and curiosity. We actively promote science in our daily work and over 90% of people in Zifo have a scientific background – meaning we speak & understand the language of science
Glocal
We have a GLOCAL (global & local) presence – meaning we engage with you in your language and time zone but leverage a global delivery support model to remain cost-effective, scalable and very reactive
Focus
We focus on science and scientific process applications and informatics. This means we can provide expertise and domain knowledge without compromising quality, technical and service delivery excellence
Partnerships
Our huge marketplace of partnerships with science technology and informatics platform providers means you can rely on Zifo to be agnostic and advise on strategy, plan & deliver projects, and validate and maintain your scientific informatics environments
Get in touch
First Name
Last Name
Email
Phone Number
Company
Designation
Enquiry Type
Enquiry Type Request for Zifo Services Product Partnership Job/Internship/Placement Enquiry Other
Message
Acceptance I consent to being contacted by an official Zifo representative
Submit
---
### [Clinical Trial Data Management (CDMS) Services](https://zifo.com/services/clinical-data-management-services-cdms/)
**Published:** January 19, 2022
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Services](https://zifo.com/services/ "Services")> Clinical Trial Data Management (CDMS) Services
Clinical Trial Data Management (CDMS) Services
Ensuring patient safety during clinical trials involves expert regulatory, domain and [informatics](/) knowledge. managing a trials data processes and systems is a critical part of any trial. Moving through [data management](/services/clinical-data-management-services/) planning, central monitoring, data acquisition, on-going data review and query management, lab data setup and management, through SAE reconciliation, medical coding of terms and events, to final database Lock – Zifo integrates domain, [clinical informatics](/services/clinical-trials-services/) platform and regulatory expertise, to ensure clean study data at an optimised cost without increasing study risks.
[ Know more ](#)
Our Capabilities
Our expertise spans the whole spectrum of scientific process applications, and we’re able
to draw on a huge marketplace of partnerships with science technology providers, so
whatever is needed to fix your current set-up. we’ll determine the best way forward.
Our People
Our people are our business and we invest and support their development and curiosity. We actively promote science in our daily work and over 90% of people in Zifo have a scientific background – meaning we speak & understand the language of science
Glocal
We have a GLOCAL (global & local) presence – meaning we engage with you in your language and time zone but leverage a global delivery support model to remain cost-effective, scalable and very reactive
Focus
We focus on science and scientific process applications and informatics. This means we can provide expertise and domain knowledge without compromising quality, technical and service delivery excellence
Partnerships
Our huge marketplace of partnerships with science technology and informatics platform providers means you can rely on Zifo to be agnostic and advise on strategy, plan & deliver projects, and validate and maintain your scientific informatics environments
Get in touch
First Name
Last Name
Email
Phone Number
Company
Designation
Enquiry Type
Enquiry Type Request for Zifo Services Product Partnership Job/Internship/Placement Enquiry Other
Message
Acceptance I consent to being contacted by an official Zifo representative
Submit
---
### [Clinical Trial Protocol Designing & Writing Services](https://zifo.com/services/clinical-trial-protocol-design-and-writing-services/)
**Published:** January 19, 2022
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Services](https://zifo.com/services/ "Services")> Clinical Trial Protocol Designing & Writing Services
Clinical Trial Protocol Designing & Writing Services
Clinical study protocol design is a foundation of [clinical trials](/services/clinical-data-management-services/) where the complexity is striking a balance between ensuring that the conclusions drawn will be robust as well as meeting all statutory requirements for data quality, integrity and subject safety. Protocols must have clearly defined objectives/endpoints, schedule of events, scientifically sound sample size considerations, statistical analyses and meet all regulatory requirements whilst also being operationally feasible. [Zifo](/)’s expert and experienced team of protocol writers, biostatisticians and medical writers work with sponsors & clinical researchers to deliver designs across clinical trials (Phase I-IV), Epidemiology / Observational studies, registry studies as well as Real World Evidence (RWE) studies.
[ Know more ](#)
Our Capabilities
Our expertise spans the whole spectrum of scientific process applications, and we’re able
to draw on a huge marketplace of partnerships with science technology providers, so
whatever is needed to fix your current set-up. we’ll determine the best way forward.
Our People
Our people are our business and we invest and support their development and curiosity. We actively promote science in our daily work and over 90% of people in Zifo have a scientific background – meaning we speak & understand the language of science
Glocal
We have a GLOCAL (global & local) presence – meaning we engage with you in your language and time zone but leverage a global delivery support model to remain cost-effective, scalable and very reactive
Focus
We focus on science and scientific process applications and informatics. This means we can provide expertise and domain knowledge without compromising quality, technical and service delivery excellence
Partnerships
Our huge marketplace of partnerships with science technology and informatics platform providers means you can rely on Zifo to be agnostic and advise on strategy, plan & deliver projects, and validate and maintain your scientific informatics environments
Get in touch
First Name
Last Name
Email
Phone Number
Company
Designation
Enquiry Type
Enquiry Type Request for Zifo Services Product Partnership Job/Internship/Placement Enquiry Other
Message
Acceptance I consent to being contacted by an official Zifo representative
Submit
---
### [eCRF for Clinical Research and Trials](https://zifo.com/services/ecrf-clinical-trials/)
**Published:** January 19, 2022
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Services](https://zifo.com/services/ "Services")> eCRF for Clinical Research and Trials
Clinical Trials eCRF services
Thousands of [clinical trials](/services/clinical-data-management-services/) occur across the globe every year, each with its own set of needs and specific [data management](/services/clinical-data-management-services/) requirements. From edit checks development, RTSM, data mapping, and migration, though ePRO, SAE, pregnancy and other reports, onto exports and therapeutic area-specific data standards – meaning the right choice of EDC is critical. Along with excelling in all CRF and EDC areas, Zifo’s eCRF setup adheres to global standards of data collection, documentation, and quality.
[ Know more ](#)
Our Capabilities
Our expertise spans the whole spectrum of scientific process applications, and we’re able
to draw on a huge marketplace of partnerships with science technology providers, so
whatever is needed to fix your current set-up. we’ll determine the best way forward.
Our People
Our people are our business and we invest and support their development and curiosity. We actively promote science in our daily work and over 90% of people in Zifo have a scientific background – meaning we speak & understand the language of science
Glocal
We have a GLOCAL (global & local) presence – meaning we engage with you in your language and time zone but leverage a global delivery support model to remain cost-effective, scalable and very reactive
Focus
We focus on science and scientific process applications and informatics. This means we can provide expertise and domain knowledge without compromising quality, technical and service delivery excellence
Partnerships
Our huge marketplace of partnerships with science technology and informatics platform providers means you can rely on Zifo to be agnostic and advise on strategy, plan & deliver projects, and validate and maintain your scientific informatics environments
Get in touch
First Name
Last Name
Email
Phone Number
Company
Designation
Enquiry Type
Enquiry Type Request for Zifo Services Product Partnership Job/Internship/Placement Enquiry Other
Message
Acceptance I consent to being contacted by an official Zifo representative
Submit
---
### [Adverse Event Reporting for Clinical Trials](https://zifo.com/services/adverse-event-reporting-clinical-trials/)
**Published:** January 19, 2022
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Services](https://zifo.com/services/ "Services")> Adverse Event Reporting for Clinical Trials
Clinical Trial Adverse Event Reporting Services
Though objectives, outcomes, efficacy, and endpoints play a key role in [clinical trials](https://www.zifo.com/services/clinical-data-management-services/), the Safety of subjects has always been the top priority. Every adverse event and SAE reported must be promptly reviewed and the respective stakeholders notified. As per regulatory requirements and using pre-defined formats like MedWatch, CIOMS, and sponsor validated specific formats, [Zifo](https://www.zifo.com/) has been supporting and accelerating adverse event reporting directly from EDC systems through cloud and on-prem automation solutions for many years.
[ Know more ](#)
Our Capabilities
Our expertise spans the whole spectrum of scientific process applications, and we’re able
to draw on a huge marketplace of partnerships with science technology providers, so
whatever is needed to fix your current set-up. we’ll determine the best way forward.
Our People
Our people are our business and we invest and support their development and curiosity. We actively promote science in our daily work and over 90% of people in Zifo have a scientific background – meaning we speak & understand the language of science
Glocal
We have a GLOCAL (global & local) presence – meaning we engage with you in your language and time zone but leverage a global delivery support model to remain cost-effective, scalable and very reactive
Focus
We focus on science and scientific process applications and informatics. This means we can provide expertise and domain knowledge without compromising quality, technical and service delivery excellence
Partnerships
Our huge marketplace of partnerships with science technology and informatics platform providers means you can rely on Zifo to be agnostic and advise on strategy, plan & deliver projects, and validate and maintain your scientific informatics environments
Get in touch
First Name
Last Name
Email
Phone Number
Company
Designation
Enquiry Type
Enquiry Type Request for Zifo Services Product Partnership Job/Internship/Placement Enquiry Other
Message
Acceptance I consent to being contacted by an official Zifo representative
Submit
---
### [Clinical Trial Operations Management Services](https://zifo.com/services/clinical-trial-data-curation-and-submissions-services/)
**Published:** January 19, 2022
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Services](https://zifo.com/services/ "Services")> Clinical Trial Operations Management Services
Clinical Trial Operations Management Services
SEND data standards for NDA, ANDA, and BLA submissions are part of the clinical data sharing regulation. With a specialized in-house team of dedicated data standards experts, [Zifo](/) offers a spectrum of services that target the SEND and [CDISC](/blogs/cdisc-clinical-trials/) initiatives to standardize clinical and animal data.
[ Know more ](#)
Our Capabilities
Our expertise spans the whole spectrum of scientific process applications, and we’re able
to draw on a huge marketplace of partnerships with science technology providers, so
whatever is needed to fix your current set-up. we’ll determine the best way forward.
Our People
Our people are our business and we invest and support their development and curiosity. We actively promote science in our daily work and over 90% of people in Zifo have a scientific background – meaning we speak & understand the language of science
Glocal
We have a GLOCAL (global & local) presence – meaning we engage with you in your language and time zone but leverage a global delivery support model to remain cost-effective, scalable and very reactive
Focus
We focus on science and scientific process applications and informatics. This means we can provide expertise and domain knowledge without compromising quality, technical and service delivery excellence
Partnerships
Our huge marketplace of partnerships with science technology and informatics platform providers means you can rely on Zifo to be agnostic and advise on strategy, plan & deliver projects, and validate and maintain your scientific informatics environments
Get in touch
First Name
Last Name
Email
Phone Number
Company
Designation
Enquiry Type
Enquiry Type Request for Zifo Services Product Partnership Job/Internship/Placement Enquiry Other
Message
Acceptance I consent to being contacted by an official Zifo representative
Submit
---
### [Research & Development Translational Sciences](https://zifo.com/services/research-translational-life-science-services/)
**Published:** January 19, 2022
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Services](https://zifo.com/services/ "Services")> Research & Development Translational Sciences
Research & Development Translational Sciences
Whether you call it Translational Research or Translational Medicine or Translational Science, the domain has been described and defined in many ways. Essentially [Zifo](/) sees it as the translation of biomedical discovery from the early research laboratory, through development and manufacturing to clinical trials and clinical practice. The multidirectional and multidisciplinary integration of research, development, manufacturing, clinical & patient-oriented research, and population-based research, with the long-term aim of improving the health of the public, requires deep knowledge across many scientific and process domains.
[ Know more ](#)
Our Capabilities
Our expertise spans the whole spectrum of scientific process applications, and we’re able
to draw on a huge marketplace of partnerships with science technology providers, so
whatever is needed to fix your current set-up. we’ll determine the best way forward.
Our People
Our people are our business and we invest and support their development and curiosity. We actively promote science in our daily work and over 90% of people in Zifo have a scientific background – meaning we speak & understand the language of science
Glocal
We have a GLOCAL (global & local) presence – meaning we engage with you in your language and time zone but leverage a global delivery support model to remain cost-effective, scalable and very reactive
Focus
We focus on science and scientific process applications and informatics. This means we can provide expertise and domain knowledge without compromising quality, technical and service delivery excellence
Partnerships
Our huge marketplace of partnerships with science technology and informatics platform providers means you can rely on Zifo to be agnostic and advise on strategy, plan & deliver projects, and validate and maintain your scientific informatics environments
Get in touch
First Name
Last Name
Email
Phone Number
Company
Designation
Enquiry Type
Enquiry Type Request for Zifo Services Product Partnership Job/Internship/Placement Enquiry Other
Message
Acceptance I consent to being contacted by an official Zifo representative
Submit
---
### [Epigenomics | Epigenetics Company](https://zifo.com/services/epigenomics-epigenetics-company/)
**Published:** January 19, 2022
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Services](https://zifo.com/services/ "Services")> Epigenomics | Epigenetics Company
Epigenomics & Epigenetics Services
The study of the complete set of epigenetic modifications on the genetic material of a cell, known as the epigenome is now part of modern science. These modifications inform the spatial-temporal expression of genes and are often implicated in oncology and neurological disease. In order to develop therapies, scientists must determine the genome-wide landscape of modifications such as DNA methylation, DNA-protein interactions, chromatin accessibility, histone modifications etc. [Zifo](/)‘s expert lead bioinformatics service provides accurate and reproducible data processing for a broad range of epigenomics applications, followed by custom downstream analyses and visualizations so you can stay focussed on the science.
[ Know more ](#)
Our Capabilities
Our expertise spans the whole spectrum of scientific process applications, and we’re able
to draw on a huge marketplace of partnerships with science technology providers, so
whatever is needed to fix your current set-up. we’ll determine the best way forward.
Our People
Our people are our business and we invest and support their development and curiosity. We actively promote science in our daily work and over 90% of people in Zifo have a scientific background – meaning we speak & understand the language of science
Glocal
We have a GLOCAL (global & local) presence – meaning we engage with you in your language and time zone but leverage a global delivery support model to remain cost-effective, scalable and very reactive
Focus
We focus on science and scientific process applications and informatics. This means we can provide expertise and domain knowledge without compromising quality, technical and service delivery excellence
Partnerships
Our huge marketplace of partnerships with science technology and informatics platform providers means you can rely on Zifo to be agnostic and advise on strategy, plan & deliver projects, and validate and maintain your scientific informatics environments
Our Capabilities
Our expertise spans the whole spectrum of scientific process applications, and we’re able
to draw on a huge marketplace of partnerships with science technology providers, so
whatever is needed to fix your current set-up. we’ll determine the best way forward.
Our People
Our people are our business and we invest and support their development and curiosity. We actively promote science in our daily work and over 90% of people in Zifo have a scientific background – meaning we speak & understand the language of science
Glocal
We have a GLOCAL (global & local) presence – meaning we engage with you in your language and time zone but leverage a global delivery support model to remain cost-effective, scalable and very reactive
Focus
We focus on science and scientific process applications and informatics. This means we can provide expertise and domain knowledge without compromising quality, technical and service delivery excellence
Partnerships
Our huge marketplace of partnerships with science technology and informatics platform providers means you can rely on Zifo to be agnostic and advise on strategy, plan & deliver projects, and validate and maintain your scientific informatics environments
Get in touch
First Name
Last Name
Email
Phone Number
Company
Designation
Enquiry Type
Enquiry Type Request for Zifo Services Product Partnership Job/Internship/Placement Enquiry Other
Message
Acceptance I consent to being contacted by an official Zifo representative
Submit
---
### [Gene Editing & Next-Gen Sequencing Analysis Services](https://zifo.com/services/next-generation-sequence-analysis-services/)
**Published:** January 19, 2022
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Services](https://zifo.com/services/ "Services")> Gene Editing & Next-Gen Sequencing Analysis Services
Gene Editing & Next-Gen Sequencing Analysis Services
Using [Next Generation Sequencing (NGS)](/services/next-generation-sequence-analysis-services/) to assess the functional significance of a gene edit is a key step in any successful genome editing workflow – particularly since the rise of the revolutionary CRISPR-Cas9 technology. [Zifo’s](/) bioinformatics services can provide analysis support for any downstream requirements following genome editing experiments. We can provide support screening cell populations to assess the functional impact of a mutation on the transcriptome (e.g. RNA-seq, scRNA-seq), or epigenome (e.g. ChIP-seq, Methylation sequencing) using NGS or array-based platforms. Alongside this, NGS-based analysis support to confirm genome edits at a targeted or genome-wide level ( e.g. WGS) and support to optimize sgRNA design to help accelerate any genome editing experiment.
[ Know more ](#)
Our Capabilities
Our expertise spans the whole spectrum of scientific process applications, and we’re able
to draw on a huge marketplace of partnerships with science technology providers, so
whatever is needed to fix your current set-up. we’ll determine the best way forward.
Our People
Our people are our business and we invest and support their development and curiosity. We actively promote science in our daily work and over 90% of people in Zifo have a scientific background – meaning we speak & understand the language of science
Glocal
We have a GLOCAL (global & local) presence – meaning we engage with you in your language and time zone but leverage a global delivery support model to remain cost-effective, scalable and very reactive
Focus
We focus on science and scientific process applications and informatics. This means we can provide expertise and domain knowledge without compromising quality, technical and service delivery excellence
Partnerships
Our huge marketplace of partnerships with science technology and informatics platform providers means you can rely on Zifo to be agnostic and advise on strategy, plan & deliver projects, and validate and maintain your scientific informatics environments
Get in touch
First Name
Last Name
Email
Phone Number
Company
Designation
Enquiry Type
Enquiry Type Request for Zifo Services Product Partnership Job/Internship/Placement Enquiry Other
Message
Acceptance I consent to being contacted by an official Zifo representative
Submit
---
### [Microbiome Sequencing Analysis Services](https://zifo.com/services/microbiome-sequencing-data-analysis-service/)
**Published:** January 19, 2022
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Services](https://zifo.com/services/ "Services")> Microbiome Sequencing Analysis Services
Microbiome Sequencing Analysis Services
We use next-generation sequencing techniques (16S V3-V4 and ITS) to derive a full profile of the bacterial and fungal community. Through general analysis pipelines and specific pipelines, we deliver a full spectrum of analysis support including 16s/ITS Metagenomics & Meta-transcriptomics. [Zifo’s expertise](/) spans pre-processing of raw high-throughput sequencing data, dereplication of sequences and chimeric reads removal, through to OTU picking and Quality filtering along with taxonomical classification. [Our services](/services/) can be bespoke or use standardised analysis pipelines to ensure you get the most from your experiment design and data sets.
[ Know more ](#)
Our Capabilities
Our expertise spans the whole spectrum of scientific process applications, and we’re able
to draw on a huge marketplace of partnerships with science technology providers, so
whatever is needed to fix your current set-up. we’ll determine the best way forward.
Our People
Our people are our business and we invest and support their development and curiosity. We actively promote science in our daily work and over 90% of people in Zifo have a scientific background – meaning we speak & understand the language of science
Glocal
We have a GLOCAL (global & local) presence – meaning we engage with you in your language and time zone but leverage a global delivery support model to remain cost-effective, scalable and very reactive
Focus
We focus on science and scientific process applications and informatics. This means we can provide expertise and domain knowledge without compromising quality, technical and service delivery excellence
Partnerships
Our huge marketplace of partnerships with science technology and informatics platform providers means you can rely on Zifo to be agnostic and advise on strategy, plan & deliver projects, and validate and maintain your scientific informatics environments
Get in touch
First Name
Last Name
Email
Phone Number
Company
Designation
Enquiry Type
Enquiry Type Request for Zifo Services Product Partnership Job/Internship/Placement Enquiry Other
Message
Acceptance I consent to being contacted by an official Zifo representative
Submit
---
### [Data Extraction & Wrangling Services](https://zifo.com/services/data-extraction-and-wrangling-services/)
**Published:** January 19, 2022
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Services](https://zifo.com/services/ "Services")> Data Extraction & Wrangling Services
Data Extraction & Wrangling Services
Getting the most from data requires extraction, [transformation](/services/digital-transformation-consulting-services/) and piping to and from platforms both on-prem and in the cloud – data wrangling. During this ETL data is transformed to alternate formats and structures to support downstream consumption like loading to data lakes, data warehouses. There are many nuances to this process and no two projects are ever identical due to the variability of data source and end state data structures. [Zifo](/) has experience with many “[data wrangling](/services/data-extraction-and-wrangling-services/)” approaches, extraction automation and scaling, ETL tools, data formats and enrichment techniques that all support the data re-use and FAIR data journey.
[ Know more ](#)
Our Capabilities
Our expertise spans the whole spectrum of scientific process applications, and we’re able
to draw on a huge marketplace of partnerships with science technology providers, so
whatever is needed to fix your current set-up. we’ll determine the best way forward.
Our People
Our people are our business and we invest and support their development and curiosity. We actively promote science in our daily work and over 90% of people in Zifo have a scientific background – meaning we speak & understand the language of science
Glocal
We have a GLOCAL (global & local) presence – meaning we engage with you in your language and time zone but leverage a global delivery support model to remain cost-effective, scalable and very reactive
Focus
We focus on science and scientific process applications and informatics. This means we can provide expertise and domain knowledge without compromising quality, technical and service delivery excellence
Partnerships
Our huge marketplace of partnerships with science technology and informatics platform providers means you can rely on Zifo to be agnostic and advise on strategy, plan & deliver projects, and validate and maintain your scientific informatics environments
Get in touch
First Name
Last Name
Email
Phone Number
Company
Designation
Enquiry Type
Enquiry Type Request for Zifo Services Product Partnership Job/Internship/Placement Enquiry Other
Message
Acceptance I consent to being contacted by an official Zifo representative
Submit
---
### [Graph Data Management and Analysis Support Services](https://zifo.com/services/graph-data-science-services/)
**Published:** January 19, 2022
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Services](https://zifo.com/services/ "Services")> Graph Data Management and Analysis Support Services
Graph Data Management and Analysis Support Services
Very few systems generate graph data formats such as RDF and so nearly all data needs transforming to support graph data technologies and storage. Coupled with this “structure” change the [ontology and relationships](/services/biomedical-ontology-development-and-governance/) of the data elements also need to be coded and stored. [Zifo](/) has experience with generating, transforming existing data, and handling graph data storage technology like GRAKN, NEPTUNE, NEO4J etc. Our experience with the associated ontology definition and management enables us to ensure data is truly interoperable and reusable.
[ Know more ](#)
Our Capabilities
Our expertise spans the whole spectrum of scientific process applications, and we’re able
to draw on a huge marketplace of partnerships with science technology providers, so
whatever is needed to fix your current set-up. we’ll determine the best way forward.
Our People
Our people are our business and we invest and support their development and curiosity. We actively promote science in our daily work and over 90% of people in Zifo have a scientific background – meaning we speak & understand the language of science
Glocal
We have a GLOCAL (global & local) presence – meaning we engage with you in your language and time zone but leverage a global delivery support model to remain cost-effective, scalable and very reactive
Focus
We focus on science and scientific process applications and informatics. This means we can provide expertise and domain knowledge without compromising quality, technical and service delivery excellence
Partnerships
Our huge marketplace of partnerships with science technology and informatics platform providers means you can rely on Zifo to be agnostic and advise on strategy, plan & deliver projects, and validate and maintain your scientific informatics environments
Get in touch
First Name
Last Name
Email
Phone Number
Company
Designation
Enquiry Type
Enquiry Type Request for Zifo Services Product Partnership Job/Internship/Placement Enquiry Other
Message
Acceptance I consent to being contacted by an official Zifo representative
Submit
---
### [Ontology Development & Management Services](https://zifo.com/services/biomedical-ontology-development-and-governance/)
**Published:** January 19, 2022
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Services](https://zifo.com/services/ "Services")> Ontology Development & Management Services
Ontology Development & Management Services
Ontologies are a foundation of FAIRification, data exploration and reuse in AI and ML. They are an extension of [Master Data Management](/services/mdm-data-enrichment-services/) (MDM) taking taxonomies and vocabularies and adding a layer of context and real-world relationships to the data. Defining ontologies is not simple and requires a combination of deep scientific domain knowledge and data management understanding. Coupled with the definition is their ongoing management and governance to ensure the scientific and business needs are met. [Zifo](/) has experience in ontology development and various commercial and open-source ontology definition and management platforms alongside deep domain and technical knowledge to support your FAIR and semantic data journey.
[ Know more ](#)
Our Capabilities
Our expertise spans the whole spectrum of scientific process applications, and we’re able
to draw on a huge marketplace of partnerships with science technology providers, so
whatever is needed to fix your current set-up. we’ll determine the best way forward.
Our People
Our people are our business and we invest and support their development and curiosity. We actively promote science in our daily work and over 90% of people in Zifo have a scientific background – meaning we speak & understand the language of science
Glocal
We have a GLOCAL (global & local) presence – meaning we engage with you in your language and time zone but leverage a global delivery support model to remain cost-effective, scalable and very reactive
Focus
We focus on science and scientific process applications and informatics. This means we can provide expertise and domain knowledge without compromising quality, technical and service delivery excellence
Partnerships
Our huge marketplace of partnerships with science technology and informatics platform providers means you can rely on Zifo to be agnostic and advise on strategy, plan & deliver projects, and validate and maintain your scientific informatics environments
Get in touch
First Name
Last Name
Email
Phone Number
Company
Designation
Enquiry Type
Enquiry Type Request for Zifo Services Product Partnership Job/Internship/Placement Enquiry Other
Message
Acceptance I consent to being contacted by an official Zifo representative
Submit
---
### [Big Data Wrangling & AI/ML Services](https://zifo.com/services/model-development-cloud-data-management/)
**Published:** January 19, 2022
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Services](https://zifo.com/services/ "Services")> Big Data Wrangling & AI/ML Services
Big Data Wrangling & AI/ML Services
The reuse of data is becoming more commonplace and the ways the data is reused using Machine Learning (ML) and Artificial Intelligence (AI) models is also growing. Getting the data to the right place and structure is one aspect ([Data Wrangling](/services/data-extraction-and-wrangling-services/)), the other is the development of the models and their management and governance to ensure traceability and scientific rigour. Many “models” are required to support decisions or workflows and so they are integrated into other platforms such as ELNs, LIMS, Analytics platforms to streamline their usage. [Zifo](/) has experience in all aspects of model development, integration and management to support scientific decisions and analysis.
[ Know more ](#)
Our Capabilities
Our expertise spans the whole spectrum of scientific process applications, and we’re able
to draw on a huge marketplace of partnerships with science technology providers, so
whatever is needed to fix your current set-up. we’ll determine the best way forward.
Our People
Our people are our business and we invest and support their development and curiosity. We actively promote science in our daily work and over 90% of people in Zifo have a scientific background – meaning we speak & understand the language of science
Glocal
We have a GLOCAL (global & local) presence – meaning we engage with you in your language and time zone but leverage a global delivery support model to remain cost-effective, scalable and very reactive
Focus
We focus on science and scientific process applications and informatics. This means we can provide expertise and domain knowledge without compromising quality, technical and service delivery excellence
Partnerships
Our huge marketplace of partnerships with science technology and informatics platform providers means you can rely on Zifo to be agnostic and advise on strategy, plan & deliver projects, and validate and maintain your scientific informatics environments
Get in touch
First Name
Last Name
Email
Phone Number
Company
Designation
Enquiry Type
Enquiry Type Request for Zifo Services Product Partnership Job/Internship/Placement Enquiry Other
Message
Acceptance I consent to being contacted by an official Zifo representative
Submit
---
### [MDM & Data Enrichment Services](https://zifo.com/services/mdm-data-enrichment-services/)
**Published:** January 19, 2022
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Services](https://zifo.com/services/ "Services")> MDM & Data Enrichment Services
MDM & Data Enrichment Services
Sometimes viewed as part of Data Sciences, [Master Data Management](/services/model-development-cloud-data-management/) (MDM), Semantics and Data Enrichment can help maximise data value and support FAIRification of data assets. There are many technologies and approaches that can be used to support these data manipulations. With a deep knowledge of science and numerous commercial and open-source technology partners in MDM, Semantics and Data Enrichment, Zifo is well placed to support your digital transformation.
[ Know more ](#)
Our Capabilities
Our expertise spans the whole spectrum of scientific process applications, and we’re able
to draw on a huge marketplace of partnerships with science technology providers, so
whatever is needed to fix your current set-up. we’ll determine the best way forward.
Our People
Our people are our business and we invest and support their development and curiosity. We actively promote science in our daily work and over 90% of people in Zifo have a scientific background – meaning we speak & understand the language of science
Glocal
We have a GLOCAL (global & local) presence – meaning we engage with you in your language and time zone but leverage a global delivery support model to remain cost-effective, scalable and very reactive
Focus
We focus on science and scientific process applications and informatics. This means we can provide expertise and domain knowledge without compromising quality, technical and service delivery excellence
Partnerships
Our huge marketplace of partnerships with science technology and informatics platform providers means you can rely on Zifo to be agnostic and advise on strategy, plan & deliver projects, and validate and maintain your scientific informatics environments
Get in touch
First Name
Last Name
Email
Phone Number
Company
Designation
Enquiry Type
Enquiry Type Request for Zifo Services Product Partnership Job/Internship/Placement Enquiry Other
Message
Acceptance I consent to being contacted by an official Zifo representative
Submit
---
### [Data Modelling Consulting Services](https://zifo.com/services/data-sciences-ai-ml-modelling-services/)
**Published:** January 19, 2022
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Services](https://zifo.com/services/ "Services")> Data Modelling Consulting Services
Data Modelling Consulting Services
[Data Science](/blogs/ai-ml-dl-why-does-it-matter-data-science/) and all its manifestations such as data modelling, wrangling, transformation, management, enrichment are critical in today’s world of data-driven science. Without very good “data modelling & plumbing,” it is very hard to leverage the subsequent aspects of Machine Learning (ML) and artificial intelligence (AI) because these need good quality data to work well. [Zifo](/)‘s focus on science and informatics makes us uniquely positioned to help in this area as we deliver services across all aspects of data modelling, wrangling and management, graph data storage, data visualisation, semantic enrichment, ML & Analytics, and AI development & deployment experience to give support where needed.
[ Know more ](#)
Our Capabilities
Our expertise spans the whole spectrum of scientific process applications, and we’re able
to draw on a huge marketplace of partnerships with science technology providers, so
whatever is needed to fix your current set-up. we’ll determine the best way forward.
Our People
Our people are our business and we invest and support their development and curiosity. We actively promote science in our daily work and over 90% of people in Zifo have a scientific background – meaning we speak & understand the language of science
Glocal
We have a GLOCAL (global & local) presence – meaning we engage with you in your language and time zone but leverage a global delivery support model to remain cost-effective, scalable and very reactive
Focus
We focus on science and scientific process applications and informatics. This means we can provide expertise and domain knowledge without compromising quality, technical and service delivery excellence
Partnerships
Our huge marketplace of partnerships with science technology and informatics platform providers means you can rely on Zifo to be agnostic and advise on strategy, plan & deliver projects, and validate and maintain your scientific informatics environments
Get in touch
First Name
Last Name
Email
Phone Number
Company
Designation
Enquiry Type
Enquiry Type Request for Zifo Services Product Partnership Job/Internship/Placement Enquiry Other
Message
Acceptance I consent to being contacted by an official Zifo representative
Submit
---
### [Cloud Management Services](https://zifo.com/services/cloud-architecture-services/)
**Published:** January 19, 2022
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Services](https://zifo.com/services/ "Services")> Cloud Management Services
Cloud Management Services
Cloud has the potential to really enable businesses and deliver cost benefits. [Zifo](/) have deep domain knowledge across the many areas of cloud, from architecting and delivery on the major (and minor) providers like [AWS, AZURE, GOOGLE](/services/cloud/), to integrations across clouds and on prem systems, with [DevOPs and TechOps](/services/devops-techops-consulting-services/) and managed services being a foundation to successful projects.
[ Know more ](#)
Our Capabilities
Our expertise spans the whole spectrum of scientific process applications, and we’re able
to draw on a huge marketplace of partnerships with science technology providers, so
whatever is needed to fix your current set-up. we’ll determine the best way forward.
Our People
Our people are our business and we invest and support their development and curiosity. We actively promote science in our daily work and over 90% of people in Zifo have a scientific background – meaning we speak & understand the language of science
Glocal
We have a GLOCAL (global & local) presence – meaning we engage with you in your language and time zone but leverage a global delivery support model to remain cost-effective, scalable and very reactive
Focus
We focus on science and scientific process applications and informatics. This means we can provide expertise and domain knowledge without compromising quality, technical and service delivery excellence
Partnerships
Our huge marketplace of partnerships with science technology and informatics platform providers means you can rely on Zifo to be agnostic and advise on strategy, plan & deliver projects, and validate and maintain your scientific informatics environments
Get in touch
First Name
Last Name
Email
Phone Number
Company
Designation
Enquiry Type
Enquiry Type Request for Zifo Services Product Partnership Job/Internship/Placement Enquiry Other
Message
Acceptance I consent to being contacted by an official Zifo representative
Submit
---
### [Internet of Things (IoT) Consulting & Managed Services](https://zifo.com/services/managed-iot-internet-of-things-services/)
**Published:** January 19, 2022
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Services](https://zifo.com/services/ "Services")> Internet of Things (IoT) Consulting & Managed Services
Internet of Things (IoT) Consulting & Managed Services
Connecting remote robotics, automation, sensors, instruments and applications to deliver a truly digital experience for scientists and to support digital twin and process optimisation is a complex task. Many topics such as security, authentication, bandwidth, latency, data formats, and automation all play into the architecture design, build and production management. Ongoing management of distributed architectures is also a big factor when designing and managing lab integration frameworks. [Zifo](/) has expertise and experience in scientific lab IoT and Edge open-source and commercial technologies, with proven solution architecture blueprints and [managed services](/services/cloud-managed-services/) models ready to help accelerate your journey.
[ Know more ](#)
Our Capabilities
Our expertise spans the whole spectrum of scientific process applications, and we’re able
to draw on a huge marketplace of partnerships with science technology providers, so
whatever is needed to fix your current set-up. we’ll determine the best way forward.
Our People
Our people are our business and we invest and support their development and curiosity. We actively promote science in our daily work and over 90% of people in Zifo have a scientific background – meaning we speak & understand the language of science
Glocal
We have a GLOCAL (global & local) presence – meaning we engage with you in your language and time zone but leverage a global delivery support model to remain cost-effective, scalable and very reactive
Focus
We focus on science and scientific process applications and informatics. This means we can provide expertise and domain knowledge without compromising quality, technical and service delivery excellence
Partnerships
Our huge marketplace of partnerships with science technology and informatics platform providers means you can rely on Zifo to be agnostic and advise on strategy, plan & deliver projects, and validate and maintain your scientific informatics environments
Get in touch
First Name
Last Name
Email
Phone Number
Company
Designation
Enquiry Type
Enquiry Type Request for Zifo Services Product Partnership Job/Internship/Placement Enquiry Other
Message
Acceptance I consent to being contacted by an official Zifo representative
Submit
---
### [End-2-End On Premise to Cloud Migration Services](https://zifo.com/services/cloud-migration-strategy-consulting/)
**Published:** January 19, 2022
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Services](https://zifo.com/services/ "Services")> End-2-End On Premise to Cloud Migration Services
End-2-End On Premise to Cloud Migration Services
Moving an [on-premise](/services/cloud-migration-strategy-consulting/) infrastructure to a [cloud infrastructure](/category/managed-cloud-migration-services/) is not a simple “flick of a switch”. We know it requires planning, iterative migration, new skills development around [TechOps and DevOps](/services/devops-techops-consulting-services/), and finally dedicated managed services to be successful. It is also very common that not all your platforms will move to the cloud, so Zifo’s rigorous understanding and delivery of CLOUD-ON-PREMISE integrations and management will be crucial.
[ Know more ](#zifo_contact_us_form)
Our Capabilities
Our expertise spans the whole spectrum of scientific process applications, and we’re able
to draw on a huge marketplace of partnerships with science technology providers, so
whatever is needed to fix your current set-up. we’ll determine the best way forward.
Our People
Our people are our business and we invest and support their development and curiosity. We actively promote science in our daily work and over 90% of people in Zifo have a scientific background – meaning we speak & understand the language of science
Glocal
We have a GLOCAL (global & local) presence – meaning we engage with you in your language and time zone but leverage a global delivery support model to remain cost-effective, scalable and very reactive
Focus
We focus on science and scientific process applications and informatics. This means we can provide expertise and domain knowledge without compromising quality, technical and service delivery excellence
Partnerships
Our huge marketplace of partnerships with science technology and informatics platform providers means you can rely on Zifo to be agnostic and advise on strategy, plan & deliver projects, and validate and maintain your scientific informatics environments
Get in touch
First Name
Last Name
Email
Phone Number
Company
Designation
Enquiry Type
Enquiry Type Request for Zifo Services Product Partnership Job/Internship/Placement Enquiry Other
Message
Acceptance I consent to being contacted by an official Zifo representative
Submit
---
### [Devops & Techops Consulting Services](https://zifo.com/services/devops-techops-consulting-services/)
**Published:** January 19, 2022
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Services](https://zifo.com/services/ "Services")> Devops & Techops Consulting Services
Devops & Techops Consulting Services
DevOps is a critical part of effective systems deployment, upgrade and maintenance. Whether [on-prem](/services/cloud-migration-strategy-consulting/) or in public/private cloud, ensuring smooth and robust application maintenance using “code” to deploy is now commonplace. [Zifo](/) has experience across the board in DevOps and can help define a strategy, implement and support an enterprise-grade DevOps capability for your scientific informatics environment.
[ Know more ](#)
Our Capabilities
Our expertise spans the whole spectrum of scientific process applications, and we’re able
to draw on a huge marketplace of partnerships with science technology providers, so
whatever is needed to fix your current set-up. we’ll determine the best way forward.
Our People
Our people are our business and we invest and support their development and curiosity. We actively promote science in our daily work and over 90% of people in Zifo have a scientific background – meaning we speak & understand the language of science
Glocal
We have a GLOCAL (global & local) presence – meaning we engage with you in your language and time zone but leverage a global delivery support model to remain cost-effective, scalable and very reactive
Focus
We focus on science and scientific process applications and informatics. This means we can provide expertise and domain knowledge without compromising quality, technical and service delivery excellence
Partnerships
Our huge marketplace of partnerships with science technology and informatics platform providers means you can rely on Zifo to be agnostic and advise on strategy, plan & deliver projects, and validate and maintain your scientific informatics environments
Get in touch
First Name
Last Name
Email
Phone Number
Company
Designation
Enquiry Type
Enquiry Type Request for Zifo Services Product Partnership Job/Internship/Placement Enquiry Other
Message
Acceptance I consent to being contacted by an official Zifo representative
Submit
---
### [Cloud to Cloud Integrations](https://zifo.com/services/cloud-to-cloud-integration-services/)
**Published:** January 19, 2022
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Services](https://zifo.com/services/ "Services")> Cloud to Cloud Integrations
Cloud Integration & Consulting
Services
[Cloud to Cloud](/services/cloud-architecture-services/) and Cloud to On-Prem system integrations, security, performance and ongoing support are foundational to [modern informatics](/services/) architectures.
[ Know more ](#)
Our Capabilities
Our expertise spans the whole spectrum of scientific process applications, and we’re able
to draw on a huge marketplace of partnerships with science technology providers, so
whatever is needed to fix your current set-up. we’ll determine the best way forward.
Our People
Our people are our business and we invest and support their development and curiosity. We actively promote science in our daily work and over 90% of people in Zifo have a scientific background – meaning we speak & understand the language of science
Glocal
We have a GLOCAL (global & local) presence – meaning we engage with you in your language and time zone but leverage a global delivery support model to remain cost-effective, scalable and very reactive
Focus
We focus on science and scientific process applications and informatics. This means we can provide expertise and domain knowledge without compromising quality, technical and service delivery excellence
Partnerships
Our huge marketplace of partnerships with science technology and informatics platform providers means you can rely on Zifo to be agnostic and advise on strategy, plan & deliver projects, and validate and maintain your scientific informatics environments
Get in touch
First Name
Last Name
Email
Phone Number
Company
Designation
Enquiry Type
Enquiry Type Request for Zifo Services Product Partnership Job/Internship/Placement Enquiry Other
Message
Acceptance I consent to being contacted by an official Zifo representative
Submit
---
### [Cloud Managed Services](https://zifo.com/services/cloud-managed-services/)
**Published:** January 19, 2022
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Services](https://zifo.com/services/ "Services")> Cloud Managed Services
Cloud Managed Services
Ensuring [enterprise applications](/services/cloud-managed-services/) and systems are “always on” and end-users are supported with their issues and help requests is a critical endeavour of IT departments. [Zifo](/) has proven scale, quality, processes and application knowledge that can reduce the burden of your scientific application management. Our processes and use of industry-standard approaches such as ITIL can have a measurable impact on end-user efficiency, satisfaction and reduced application downtime.
[ Know more ](#)
Our Capabilities
Our expertise spans the whole spectrum of scientific process applications, and we’re able
to draw on a huge marketplace of partnerships with science technology providers, so
whatever is needed to fix your current set-up. we’ll determine the best way forward.
Our People
Our people are our business and we invest and support their development and curiosity. We actively promote science in our daily work and over 90% of people in Zifo have a scientific background – meaning we speak & understand the language of science
Glocal
We have a GLOCAL (global & local) presence – meaning we engage with you in your language and time zone but leverage a global delivery support model to remain cost-effective, scalable and very reactive
Focus
We focus on science and scientific process applications and informatics. This means we can provide expertise and domain knowledge without compromising quality, technical and service delivery excellence
Partnerships
Our huge marketplace of partnerships with science technology and informatics platform providers means you can rely on Zifo to be agnostic and advise on strategy, plan & deliver projects, and validate and maintain your scientific informatics environments
Get in touch
First Name
Last Name
Email
Phone Number
Company
Designation
Enquiry Type
Enquiry Type Request for Zifo Services Product Partnership Job/Internship/Placement Enquiry Other
Message
Acceptance I consent to being contacted by an official Zifo representative
Submit
---
### [Computer System Validation & Consulting Services](https://zifo.com/services/computer-system-validation-consulting-services/)
**Published:** February 21, 2022
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Services](https://zifo.com/services/ "Services")> Computer System Validation & Consulting Services
Computer System Validation & Consulting Services
[Validation and qualification](/services/lab-instrument-validation/) of both [on-prem](/services/cloud-migration-strategy-consulting/) and cloud computer systems is a crucial part of any validated and compliant environment to ensure quality and compliance. Regulatory constraints are wide-reaching and deep knowledge and up to date awareness of all CSV strategy, IQ, OQ, PQ, risk-based validation, execution and reporting requirements are needed to ensure compliant operations. [Zifo](/) has extensive experience in this domain and experience with many different relevant frameworks such as risk-based validation methodologies, computer software assurance, GAMP5 based approaches.
[ Know more ](#)
Our Capabilities
Our expertise spans the whole spectrum of scientific process applications, and we’re able
to draw on a huge marketplace of partnerships with science technology providers, so
whatever is needed to fix your current set-up. we’ll determine the best way forward.
Our People
Our people are our business and we invest and support their development and curiosity. We actively promote science in our daily work and over 90% of people in Zifo have a scientific background – meaning we speak & understand the language of science
Glocal
We have a GLOCAL (global & local) presence – meaning we engage with you in your language and time zone but leverage a global delivery support model to remain cost-effective, scalable and very reactive
Focus
We focus on science and scientific process applications and informatics. This means we can provide expertise and domain knowledge without compromising quality, technical and service delivery excellence
Partnerships
Our huge marketplace of partnerships with science technology and informatics platform providers means you can rely on Zifo to be agnostic and advise on strategy, plan & deliver projects, and validate and maintain your scientific informatics environments
Get in touch
First Name
Last Name
Email
Phone Number
Company
Designation
Enquiry Type
Enquiry Type Request for Zifo Services Product Partnership Job/Internship/Placement Enquiry Other
Message
Acceptance I consent to being contacted by an official Zifo representative
Submit
---
### [Lab Instrument Validation](https://zifo.com/services/lab-instrument-validation/)
**Published:** February 22, 2022
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Services](https://zifo.com/services/ "Services")> Lab Instrument Validation
Lab Instrument Validation
[Validation](/services/validation-services-and-compliance-support/) and qualification of lab instruments and equipment is a crucial part of GLP/GCLP/GMP industries. Regulatory constraints are wide-reaching and deep knowledge and up to date awareness of all Validation / Qualification strategies, [Vendor Qualification & Support](/services/vendor-selection-and-rfps/), IQ, OQ, PQ, risk-based validation, periodic review of systems, execution and reporting requirements are needed to ensure compliant operations. [Zifo](/) has extensive experience in this domain and experience with many different relevant frameworks such as risk-based validation methodologies, computer software assurance, and GAMP5 based approaches.
[ Know more ](#)
Our Capabilities
Our expertise spans the whole spectrum of scientific process applications, and we’re able
to draw on a huge marketplace of partnerships with science technology providers, so
whatever is needed to fix your current set-up. we’ll determine the best way forward.
Our People
Our people are our business and we invest and support their development and curiosity. We actively promote science in our daily work and over 90% of people in Zifo have a scientific background – meaning we speak & understand the language of science
Glocal
We have a GLOCAL (global & local) presence – meaning we engage with you in your language and time zone but leverage a global delivery support model to remain cost-effective, scalable and very reactive
Focus
We focus on science and scientific process applications and informatics. This means we can provide expertise and domain knowledge without compromising quality, technical and service delivery excellence
Partnerships
Our huge marketplace of partnerships with science technology and informatics platform providers means you can rely on Zifo to be agnostic and advise on strategy, plan & deliver projects, and validate and maintain your scientific informatics environments
Get in touch
First Name
Last Name
Email
Phone Number
Company
Designation
Enquiry Type
Enquiry Type Request for Zifo Services Product Partnership Job/Internship/Placement Enquiry Other
Message
Acceptance I consent to being contacted by an official Zifo representative
Submit
---
### [Software as Medical Device (SaMD)](https://zifo.com/services/samd-software-as-medical-device-companies/)
**Published:** February 22, 2022
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Services](https://zifo.com/services/ "Services")> Software as Medical Device (SaMD)
Software as Medical Device (SaMD) Services
Validation of Medical Devices involving Mobile Applications, Software-based, [AI/ML-based devices](/category/data-sciences-semantics-ai-ml-consulting-services/) is critical to gaining regulatory approval and marketing. Regulatory constraints are wide-reaching and deep knowledge and up to date awareness of Quality System Regulations (QSR), CSA/CSV process, and cybersecurity regulations are needed to ensure compliant medical devices. [Zifo](/) has extensive experience in this domain and experience with SaMD development and validation approaches.
[ Know more ](#)
Our Capabilities
Our expertise spans the whole spectrum of scientific process applications, and we’re able
to draw on a huge marketplace of partnerships with science technology providers, so
whatever is needed to fix your current set-up. we’ll determine the best way forward.
Our People
Our people are our business and we invest and support their development and curiosity. We actively promote science in our daily work and over 90% of people in Zifo have a scientific background – meaning we speak & understand the language of science
Glocal
We have a GLOCAL (global & local) presence – meaning we engage with you in your language and time zone but leverage a global delivery support model to remain cost-effective, scalable and very reactive
Focus
We focus on science and scientific process applications and informatics. This means we can provide expertise and domain knowledge without compromising quality, technical and service delivery excellence
Partnerships
Our huge marketplace of partnerships with science technology and informatics platform providers means you can rely on Zifo to be agnostic and advise on strategy, plan & deliver projects, and validate and maintain your scientific informatics environments
Get in touch
First Name
Last Name
Email
Phone Number
Company
Designation
Enquiry Type
Enquiry Type Request for Zifo Services Product Partnership Job/Internship/Placement Enquiry Other
Message
Acceptance I consent to being contacted by an official Zifo representative
Submit
---
### [Project Management Services](https://zifo.com/services/project-management-service-company/)
**Published:** March 9, 2022
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Services](https://zifo.com/services/ "Services")> Project Management Services
Project Management Services
Programs and projects are the foundation on which new technology & processes are delivered and so their management and delivery are of critical importance. Many methods and approaches are used currently ranging from AGILE to WATERFALL and all the different connotations in between. [Zifo](/)‘s experience spans all aspects of project management and delivery, starting at project scoping and resource planning, through kick-off and project delivery, onto reporting, finalisation and closing. Whether with individual projects or as a program of work, we adopt customers’ project ethos and structures or we work within our own [project delivery](/services/project-management-service-company/) models that are proven and scalable.
[ Know more ](#)
Our Capabilities
Our expertise spans the whole spectrum of scientific process applications, and we’re able
to draw on a huge marketplace of partnerships with science technology providers, so
whatever is needed to fix your current set-up. we’ll determine the best way forward.
Our People
Our people are our business and we invest and support their development and curiosity. We actively promote science in our daily work and over 90% of people in Zifo have a scientific background – meaning we speak & understand the language of science
Glocal
We have a GLOCAL (global & local) presence – meaning we engage with you in your language and time zone but leverage a global delivery support model to remain cost-effective, scalable and very reactive
Focus
We focus on science and scientific process applications and informatics. This means we can provide expertise and domain knowledge without compromising quality, technical and service delivery excellence
Partnerships
Our huge marketplace of partnerships with science technology and informatics platform providers means you can rely on Zifo to be agnostic and advise on strategy, plan & deliver projects, and validate and maintain your scientific informatics environments
Get in touch
First Name
Last Name
Email
Phone Number
Company
Designation
Enquiry Type
Enquiry Type Request for Zifo Services Product Partnership Job/Internship/Placement Enquiry Other
Message
Acceptance I consent to being contacted by an official Zifo representative
Submit
---
### [Vendor Selection and RFPs](https://zifo.com/services/vendor-selection-and-rfps/)
**Published:** March 9, 2022
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Services](https://zifo.com/services/ "Services")> Vendor Selection and RFPs
VENDOR SELECTIONS & RFPs
Running vendor selections and RFPs is part of many [enterprise processes](/services/cloud-managed-services/) and is often a prerequisite for new technology acquisition and can be a time-consuming process. [Zifo](/) can help with all aspects using your internal processes or our own to ensure fairness and transparency of decisions. We support the entire process from RFI and early vendor assessments, requirements translation to use cases for demonstrations, through demonstration scoring tools and methods, to RFP creation, budgeting and financial assessments, along with project decision support tools to help make those critical decisions. We have experience in running global RFPs across many sites and thousands of users to small, single-site, group selection processes and can adapt our approach as required.
[ Know more ](#)
Our Capabilities
Our expertise spans the whole spectrum of scientific process applications, and we’re able
to draw on a huge marketplace of partnerships with science technology providers, so
whatever is needed to fix your current set-up. we’ll determine the best way forward.
Our People
Our people are our business and we invest and support their development and curiosity. We actively promote science in our daily work and over 90% of people in Zifo have a scientific background – meaning we speak & understand the language of science
Glocal
We have a GLOCAL (global & local) presence – meaning we engage with you in your language and time zone but leverage a global delivery support model to remain cost-effective, scalable and very reactive
Focus
We focus on science and scientific process applications and informatics. This means we can provide expertise and domain knowledge without compromising quality, technical and service delivery excellence
Partnerships
Our huge marketplace of partnerships with science technology and informatics platform providers means you can rely on Zifo to be agnostic and advise on strategy, plan & deliver projects, and validate and maintain your scientific informatics environments
Get in touch
First Name
Last Name
Email
Phone Number
Company
Designation
Enquiry Type
Enquiry Type Request for Zifo Services Product Partnership Job/Internship/Placement Enquiry Other
Message
Acceptance I consent to being contacted by an official Zifo representative
Submit
---
### [Change Management Consulting & Services](https://zifo.com/services/change-management-consultant-and-services/)
**Published:** March 9, 2022
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Services](https://zifo.com/services/ "Services")> Change Management Consulting & Services
Organisational Change Management Services
Ensuring that organisations can adopt new technology and processes requires careful management and engagement. [Zifo](/) has expertise and experience in delivering enterprise change management programs and is well versed in the processes and techniques that can be used to ensure good adoption of change. Our change management approach looks at the engagement of stakeholders and end-users, through requirements and vision capture, decision making and consensus building, to communication planning and program success monitoring. We have been there and worked in projects that have been very successful and some projects that have failed and actively bring that experience to the table in our engagements.
[ Know more ](#)
Our Capabilities
Our expertise spans the whole spectrum of scientific process applications, and we’re able
to draw on a huge marketplace of partnerships with science technology providers, so
whatever is needed to fix your current set-up. we’ll determine the best way forward.
Our People
Our people are our business and we invest and support their development and curiosity. We actively promote science in our daily work and over 90% of people in Zifo have a scientific background – meaning we speak & understand the language of science
Glocal
We have a GLOCAL (global & local) presence – meaning we engage with you in your language and time zone but leverage a global delivery support model to remain cost-effective, scalable and very reactive
Focus
We focus on science and scientific process applications and informatics. This means we can provide expertise and domain knowledge without compromising quality, technical and service delivery excellence
Partnerships
Our huge marketplace of partnerships with science technology and informatics platform providers means you can rely on Zifo to be agnostic and advise on strategy, plan & deliver projects, and validate and maintain your scientific informatics environments
Get in touch
First Name
Last Name
Email
Phone Number
Company
Designation
Enquiry Type
Enquiry Type Request for Zifo Services Product Partnership Job/Internship/Placement Enquiry Other
Message
Acceptance I consent to being contacted by an official Zifo representative
Submit
---
### [Scientific Technology & IT Help Desk](https://zifo.com/services/technology-help-desk-and-user-support-services/)
**Published:** March 9, 2022
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Services](https://zifo.com/services/ "Services")> Scientific Technology & IT Help Desk
Scientific Technology & IT Help Desk Services
Getting the most from technology requires ensuring that the end-users of systems are fully supported in their day-2-day use of the applications and hardware. [Zifo](/) provides full end-user support desk provision and combines expert science with extensive scientific software and systems understanding with the process and scaling to ensure end-user satisfaction. Our [support services](/services/) cover early user training as part of [project delivery](/services/project-management/), then onto hyper care during early roll-out, then onto BAU support and knowledge base creation to feedback into ongoing training to reduce help desk tickets and upskill users. Leveraging industry best practices such as ITIL and “follow the sun” support structures and combining those with our science and technology partnership collaborations to ensure end-users get the support they need.
[ Know more ](#)
Our Capabilities
Our expertise spans the whole spectrum of scientific process applications, and we’re able
to draw on a huge marketplace of partnerships with science technology providers, so
whatever is needed to fix your current set-up. we’ll determine the best way forward.
Our People
Our people are our business and we invest and support their development and curiosity. We actively promote science in our daily work and over 90% of people in Zifo have a scientific background – meaning we speak & understand the language of science
Glocal
We have a GLOCAL (global & local) presence – meaning we engage with you in your language and time zone but leverage a global delivery support model to remain cost-effective, scalable and very reactive
Focus
We focus on science and scientific process applications and informatics. This means we can provide expertise and domain knowledge without compromising quality, technical and service delivery excellence
Partnerships
Our huge marketplace of partnerships with science technology and informatics platform providers means you can rely on Zifo to be agnostic and advise on strategy, plan & deliver projects, and validate and maintain your scientific informatics environments
Get in touch
First Name
Last Name
Email
Phone Number
Company
Designation
Enquiry Type
Enquiry Type Request for Zifo Services Product Partnership Job/Internship/Placement Enquiry Other
Message
Acceptance I consent to being contacted by an official Zifo representative
Submit
---
### [Live Chat Support Services](https://zifo.com/services/go-live-chat-support-services/)
**Published:** March 9, 2022
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Services](https://zifo.com/services/ "Services")> Live Chat Support Services
Live Chat and System Support Services
Ensuring a smooth and successful rollout of new software and hardware is a critical step of [informatics](/services/) projects and requires focus, flexibility and experience. As projects near Go Live, the emphasis changes from planning and technical configuration to training, user support and hyper care of early adopters. Once into Go-Live, the emphasis becomes learning, scale and building a knowledge base of help and support of the ongoing use of the systems. [Zifo](/) has experience in very large, global, multisite lab rollouts and smaller, focused, single lab group rollouts – but we bring the same focus on quality, user satisfaction and responsiveness to all projects.
[ Know more ](#)
Our Capabilities
Our expertise spans the whole spectrum of scientific process applications, and we’re able
to draw on a huge marketplace of partnerships with science technology providers, so
whatever is needed to fix your current set-up. we’ll determine the best way forward.
Our People
Our people are our business and we invest and support their development and curiosity. We actively promote science in our daily work and over 90% of people in Zifo have a scientific background – meaning we speak & understand the language of science
Glocal
We have a GLOCAL (global & local) presence – meaning we engage with you in your language and time zone but leverage a global delivery support model to remain cost-effective, scalable and very reactive
Focus
We focus on science and scientific process applications and informatics. This means we can provide expertise and domain knowledge without compromising quality, technical and service delivery excellence
Partnerships
Our huge marketplace of partnerships with science technology and informatics platform providers means you can rely on Zifo to be agnostic and advise on strategy, plan & deliver projects, and validate and maintain your scientific informatics environments
Get in touch
First Name
Last Name
Email
Phone Number
Company
Designation
Enquiry Type
Enquiry Type Request for Zifo Services Product Partnership Job/Internship/Placement Enquiry Other
Message
Acceptance I consent to being contacted by an official Zifo representative
Submit
---
### [Custom Software Development Services](https://zifo.com/services/custom-software-development-service-company/)
**Published:** March 9, 2022
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Services](https://zifo.com/services/ "Services")> Custom Software Development Services
Custom Software Development Services
Sometimes there is not a commercial of the shelf solution (COTS) to the problem you have. [Zifo](/)‘s expertise spans the full lifecycle of software applications from architecture and design, through build and test to maintenance and upgrade management. Whether your need is web or [cloud-based applications](/services/cloud-to-cloud-integration-services/) or integrations or visualisations our technical team has the scientific enterprise software skills in many modern languages from JAVA, Python, C++, to JavaScript, REACT, and modern development environments (IDEs). To ensure success and user acceptance we include our scientific expertise in our [custom development projects](/services/custom-software-development-service-company/) to ensure that the science is properly understood and enabled.
[ Know more ](#)
Our Capabilities
Our expertise spans the whole spectrum of scientific process applications, and we’re able
to draw on a huge marketplace of partnerships with science technology providers, so
whatever is needed to fix your current set-up. we’ll determine the best way forward.
Our People
Our people are our business and we invest and support their development and curiosity. We actively promote science in our daily work and over 90% of people in Zifo have a scientific background – meaning we speak & understand the language of science
Glocal
We have a GLOCAL (global & local) presence – meaning we engage with you in your language and time zone but leverage a global delivery support model to remain cost-effective, scalable and very reactive
Focus
We focus on science and scientific process applications and informatics. This means we can provide expertise and domain knowledge without compromising quality, technical and service delivery excellence
Partnerships
Our huge marketplace of partnerships with science technology and informatics platform providers means you can rely on Zifo to be agnostic and advise on strategy, plan & deliver projects, and validate and maintain your scientific informatics environments
Get in touch
First Name
Last Name
Email
Phone Number
Company
Designation
Enquiry Type
Enquiry Type Request for Zifo Services Product Partnership Job/Internship/Placement Enquiry Other
Message
Acceptance I consent to being contacted by an official Zifo representative
Submit
---
### [Business Analysis & Consulting Services](https://zifo.com/services/business-analysis-consulting-services/)
**Published:** March 30, 2022
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Services](https://zifo.com/services/ "Services")> Business Analysis & Consulting Services
Scientific Business Analysis & Consulting Services
Understanding and documenting what the current state of business, application and data processes are and defining the TO-BE state is a cornerstone of any [informatics project](/services/) – without it, the project is at risk of not delivering. [Zifo](/) has extensive expertise in AS-IS process mapping, TO-BE state definition, application landscape & data landscape mapping, instrument and lab audits, requirements capture, FRS (functional requirements specification) creation and FAIR assessments. This expertise coupled with deep scientific domain understanding and a broad partner ecosystem knowledge allows us to help scope, define, deliver your scientific informatics projects and support your digital transformation initiatives.
[ Know more ](#)
Our Capabilities
Our expertise spans the whole spectrum of scientific process applications, and we’re able
to draw on a huge marketplace of partnerships with science technology providers, so
whatever is needed to fix your current set-up. we’ll determine the best way forward.
Our People
Our people are our business and we invest and support their development and curiosity. We actively promote science in our daily work and over 90% of people in Zifo have a scientific background – meaning we speak & understand the language of science
Glocal
We have a GLOCAL (global & local) presence – meaning we engage with you in your language and time zone but leverage a global delivery support model to remain cost-effective, scalable and very reactive
Focus
We focus on science and scientific process applications and informatics. This means we can provide expertise and domain knowledge without compromising quality, technical and service delivery excellence
Partnerships
Our huge marketplace of partnerships with science technology and informatics platform providers means you can rely on Zifo to be agnostic and advise on strategy, plan & deliver projects, and validate and maintain your scientific informatics environments
Get in touch
First Name
Last Name
Email
Phone Number
Company
Designation
Enquiry Type
Enquiry Type Request for Zifo Services Product Partnership Job/Internship/Placement Enquiry Other
Message
Acceptance I consent to being contacted by an official Zifo representative
Submit
---
### [Laboratory Instrument and Sensor Data & System Integration](https://zifo.com/services/data-systems-and-instrument-integration/)
**Published:** March 9, 2022
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Services](https://zifo.com/services/ "Services")> Laboratory Instrument and Sensor Data & System Integration
Laboratory Instrument and Sensor Data & System Integration and management Services
[Scientific informatics](https://www.zifo.com/) systems typically need to be integrated into the lab and other systems to deliver the most value to the users and to streamline reference data from ERP, registration and inventory for example. Labs very often also require systems, like ELN and LIMS, integration with laboratory instruments – from simple balances and pH meters to HPLC and NMR instruments and their associated software. [Zifo](https://www.zifo.com/)‘s experience is both broad and deep and we have project planning & lab audit tools alongside extensive integration layer technology experience, instrument data standards (ADF, AniML, SiLA etc.) and tech blueprints to help accelerate your integration projects.
[ Know more ](#)
Our Capabilities
Our expertise spans the whole spectrum of scientific process applications, and we’re able
to draw on a huge marketplace of partnerships with science technology providers, so
whatever is needed to fix your current set-up. we’ll determine the best way forward.
Our People
Our people are our business and we invest and support their development and curiosity. We actively promote science in our daily work and over 90% of people in Zifo have a scientific background – meaning we speak & understand the language of science
Glocal
We have a GLOCAL (global & local) presence – meaning we engage with you in your language and time zone but leverage a global delivery support model to remain cost-effective, scalable and very reactive
Focus
We focus on science and scientific process applications and informatics. This means we can provide expertise and domain knowledge without compromising quality, technical and service delivery excellence
Partnerships
Our huge marketplace of partnerships with science technology and informatics platform providers means you can rely on Zifo to be agnostic and advise on strategy, plan & deliver projects, and validate and maintain your scientific informatics environments
Get in touch
First Name
Last Name
Email
Phone Number
Company
Designation
Enquiry Type
Enquiry Type Request for Zifo Services Product Partnership Job/Internship/Placement Enquiry Other
Message
Acceptance I consent to being contacted by an official Zifo representative
Submit
---
### [Lab Data Automation (LDAS)](https://zifo.com/services/lab-data-automation-solution-ldas/)
**Published:** April 8, 2024
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Services](https://zifo.com/services/ "Services")> Lab Data Automation (LDAS)
Automate Your Lab’s Data Backbone
Supercharged by AI
# Simplify Management. Acquire, Orchestrate, and Standardize with LDAS.
SIMPLIFY LAB DATA MANAGEMENT
## Acquire, Orchestrate & Standardize
Explore Solutions to Lab Data Challenges
#### Research Solutions
CRDMO Assay Standardization Flow Cytometry Workflows CDS- ELN/LIMS Integration NGS Pipeline Management CDS- ELN/LIMS Integration Small Molecule Optimization PCR Assay Development Bioprocess Development Cell Culture Workflows CRDMO Data Harmonization Compliance & Data Integrity Connected Lab Strengths CDS- ELN/LIMS Integration Small Molecule Compliance CRDMO Data Standardization
Research
Development
Manufacturing QA/QC
Expand All
## Research
### CRDMO Assay Data Standardization for Research Labs
From Fragmented Data to Informed Decisions: Enabling AI-Ready Research Workflows
CROs deliver experimental data in fragmented, proprietary formats lacking standardized structure and metadata. This complicates data handoffs, extends review, and delays decisions. Researchers often limit data collection to only key results which risks missing anomalies and necessary metadata that could change experimental direction. Traceability gaps slow discovery, reproducibility, and readiness for downstream analysis.
#### How LDAS Benefits your Lab
 **Universal data handling**LDAS converts proprietary data formats from instruments, ELNs, and LIMS into standardized, AI-ready datasets using prebuilt parser library.
 **Metadata Enrichment**Each dataset is enriched with metadata from file attributes, sample tracking systems, or templates—ensuring completeness, traceability, and compliance readiness.
 **Accelerates AI Adoption**LDAS transforms raw data into structured, contextualized datasets, enabling faster insights through pattern recognition, assay optimizations and predictive analysis.
### Optimizing Flow Cytometry Workflows for Scalable, Insight-Driven Research
Enable high-throughput, metadata-rich, and AI-ready cytometry data pipelines across research
Flow cytometry experiments generate large, complex result files across diverse systems. Flow cytometers produce proprietary formats with variable metadata, complicating downstream analysis and documentation. Manual transfers to tools, analytical software and ELNs cause context loss, inconsistent gating, and poor reproducibility.
#### How LDAS Benefits your Lab
 **Context-Rich Metadata Capture**Captures antibody panels, gating strategies, operator info, and sample context as metadata to ensure traceable, reproducible datasets.
 **Cross-Platform Data Harmonization**Integrates outputs from leading cytometry platforms into standardized, vendor-neutral FAIR formats for consistent analysis.
 **Automated QC & Exception-Based Review**Streamline cytometer health checks and gating workflows with automated QC pipelines, by flagging only anomalies for manual review.
 **AI-Ready Data for Accelerated Insights**Structure large cytometry datasets into searchable data lakes, enabling machine learning models to drive faster, more reliable research conclusions.
### CDS- ELN/LIMS Integration
Accelerating Biopharma Research with CDS–ELN/LIMS Connectivity
In biopharma research, manual data transfers from CDS Systems to ELNs or LIMS often lack essential metadata. This disconnect introduces errors and delays scientific insights, undermining reproducibility. In environments where rapid iteration and scientific decision-making are critical, fragmented data pipelines slow hypothesis testing, hinder data interpretation, and limit advanced analytics — impeding accelerated research progress.
#### How LDAS Benefits your Lab
 **Automated Experiment Setup**Connects CDS systems to ELN/LIMS, automating real-time data capture and metadata linking to ensure accuracy and full traceability.
 **Contextual Data Mapping**Each dataset is enriched with metadata like method versions, injection parameters, and operator details, extracted automatically from file attributes.
 **Accelerated Decision-Making**Real-time monitoring and data transfer ensure immediate availability of analytical results, reducing validation time and speeding interpretation.
 **FAIR-Compliant Data Transformation**LDAS converts fragmented CDS outputs into structured, machine-readable formats enriched with metadata—enabling AI/ML analysis.
### Integrating molecular biology laboratories – NGS pipeline management
From Fragmented Sequencing to AI-Ready Discovery
Modern molecular biology labs generate massive, diverse NGS datasets. However, fragmented data from pipelines, missing metadata, and manual checks compromise traceability, reproducibility, and scientific insight. Poor integration across sequencers, bioinformatics tools, and storage systems leads to delays, errors, and data loss—slowing discovery.
#### How LDAS Benefits your Lab
 **Automated Bioinformatics Workflows**LDAS automates sequencing pipelines, triggers alert, prevents manual errors, and ensures accurate, reproducible results
 **Robust Data Storage**Scalable, version-controlled archival ensures secure backup, efficient retrieval, and long-term storage of large sequencing datasets.
 **Real-Time Monitoring & Alerts**LDAS integrates NGS pipelines with analysis tools and ELN/LIMS systems, enabling real-time monitoring, anomaly detection, and faster, more reliable results.
 **AI-Ready Data Standardization**Results are transformed into structured, metadata-rich formats—FAIR-compliant and optimized for AI/ML-driven insights.
### CDS- ELN/LIMS Integration
CDS Integration: Scalable Infrastructure for Development Labs
In development labs, Chromatography Data Systems (CDS) supports method scouting, formulation optimization, and stability studies. However, without seamless integration with ELNs or LIMS, manual data handling fragments records, delays timelines, complicates tech transfer, and risks rework—impacting regulatory filings, IP protection, and traceability.
#### How LDAS Benefits your Lab
 **AI-Ready Data Architecture**Enables standardized and contextualized capture of CDS data into ELNs/LIMS, ensuring harmonized, structured data that support advanced analytics and AI-readiness.
 **Real-Time Chromatographic Data Flow**Enables fast, iterative method development by capturing CDS data in real time, allowing scientists to assess results and adjust methods without delays or data loss.
 **Accelerated Tech Transfer Across Sites**Centralized chromatographic data improves collaboration, reduces rework, and streamlines tech transfer across development sites
 **Traceable Outputs for IP and Compliance**Ensures AI-ready, traceable chromatography data with e-signatures, login tracking, and ALCOA+ compliance for regulatory and IP needs.
### Enabling Robust Method Optimization Through AI-Ready Workflows in Small Molecule R&D
Ensure reproducibility, traceability, and scientific value across multi-modal analytical platforms
Small molecule development involves high-volume, iterative experimentation across diverse analytical techniques—each generating proprietary data formats. Method optimization demands rapid cross-run comparisons, but fragmented systems and manual workflows compromise reproducibility and traceability. The absence of systems that enforce compliance and support advanced analytics hinders quick and accurate decision-making.
#### How LDAS Benefits your Lab
 **Reproducibility & Method Traceability**Maintains consistent experimental lineage with metadata-rich records and version control across methods and conditions.
 **Multi-Technique Integration & Collaboration**Standardizes data from LC/MS, GC/MS, NMR, and spectroscopy into FAIR formats for seamless data sharing across R&D teams.
 **ALCOA+ Compliance & Audit Trails**Capture time-stamped, version-controlled data with electronic signatures to meet regulatory expectations and ensure traceability.
 **AI-Ready Data Foundation**Creates structured, searchable data lakes that support ML models for trend detection, method optimization, and molecule progression.
### Optimizing PCR Assay Development with Intelligent Lab Data Automation
Accelerating Assay Optimization with End-to-End PCR Data Integration
High-throughput PCR workflows generate complex datasets across plates, wells, and assay conditions. After result capture, downstream analysis often relies on disconnected tools like Excel macros or standalone Python scripts. Manual entry, disconnected systems, and missing metadata slow optimization, reduce reproducibility, and increase compliance risk -- limiting scalability and AI-readiness.
#### How LDAS Benefits your Lab
 **End-to-End PCR Data Automation**Automates the entire PCR assay lifecycle — from request and result capture to integration with analytical/processing software and ELN/LIMS — eliminating manual errors and enabling high-throughput, scalable data processing.
 **Reproducibility & Assay Design Protection**Enriches datasets with structured metadata, that ensures traceability, reproducibility, integrity, and consistent assay comparisons across proprietary experimental designs.
 **Regulatory and Filing Readiness**LDAS enforces ALCOA+ and 21 CFR Part 11 standards with audit trails and e-signatures, ensuring inspection-ready datasets and IP protection.
 **AI-Ready Data for Predictive Optimization**Transforms raw PCR data into standardized, metadata-rich formats, enabling AI-driven insights for trend detection and predictive assay refinement.
### Streamlining Bioprocess Development: Automating and unifying laboratory processes
Accelerating Bioprocess Optimization: Integrated Data for Smarter Decisions
Bioprocess development labs face increasing complexity when scaling experiments across bioreactors, inline, at line and offline instruments. Orchestrating time series real time data with sample info from at-line tools like cell analysers is tedious and error-prone. Lack of visibility to holistic high dimensional data hinders traceability, reproducibility, and decision-making.
#### How LDAS Benefits your Lab
 **Vendor-Neutral Integration**Automates data capture from bioreactors and at-line instruments using connectors and file watchers, eliminating manual handling and streamlining lab workflows.
 **Ontology-Based Data Structuring**Standardizes raw data using ontologies like Allotrope and AnIML, enriching it with metadata for contextual insights.
 **Data Traceability Across Systems**Auto-aligns sample and run data with enriched metadata and link them to experiments and assays in ELN/LIMS.
 **AI-Ready Bioprocess Insights**Structures bioprocess data into AI-ready formats, flags anomalies, and enables faster, exception-based decisions for scale-up optimization.
### Intelligent Automation for Scalable and Predictive Cell Culture Workflows
Accelerating Process Optimization with Real-Time Bioreactor Data Integration
Cell culture labs generate high-frequency real-time data from bioreactors and inline, at-line, offline instruments. Fragmentation and manual reconciliation disrupt traceability. Without proactive monitoring, scalable and AI-ready infrastructure, reproducibility, predictive modelling, and method transfer suffer.
#### How LDAS Benefits your Lab
 **Automated Time Series Bioreactor Data Capture**Connects directly to bioreactors and associated inline, at-line, and offline instruments, capturing real-time data and mapping it to sample IDs and assay results
 **Cross-Run Comparability and Process Optimization**Standardized metadata enables comparisons across bioreactors and runs, supporting robust reproducibility and process refinement.
 **Regulatory and IP Filing Readiness**Ensures ALCOA+ and 21 CFR Part 11 compliance, enabling audit-ready, traceable data for regulatory and IP filings.
 **AI-Ready Data for Predictive Cell Culture Modelling**Transforms raw bioreactor data into structured, metadata-rich formats for AI/ML-driven insights—accelerating decisions and future-proofing scale-up.
### CRDMO Data Harmonization for Accelerated Biopharma Development
Unify Fragmented CRDMO Data to Optimize Scale-Up and Method Reproducibility
In development labs complexity grows with data volume and CDMO handoffs. Incompatible formats from proprietary files to flat reports- create silos, delaying method optimization, complicating data transfer, and increasing compliance risk, operational burden, and decision-making challenges.
#### How LDAS Benefits your Lab
 **Cross-Partner Harmonization**LDAS integrates CDMO data from instruments, ELNs, and LIMS into a standardized, vendor-neutral format using pre-built parser library, eliminating silos and manual rework.
 **Metadata-Enriched Context**Datasets retain lineage with metadata, aligning FAIR and ALCOA+ standards for traceability and scientific defensibility.
 **Reliable Data Capture with Built-In Integrity Controls**LDAS enforces 21 CFR Part 11 and ALCOA+ with secure, error-free data capture and immutable audit trails, reducing compliance risks.
 **AI-Powered Optimization**Structured, AI-ready data enables predictive analysis and method optimization.
### Strengthening Compliance and Data Integrity in QA/QC
Bridging the Compliance Gap: Achieve ALCOA+ Compliance through Unified Data Infrastructure
QA/QC labs face compliance risks due to fragmented data across instruments, LIMS, and ELNs. Disconnected systems disrupt data lineage and audit trails, increasing manual effort and errors. Legacy infrastructure slows analysis, delaying decisions and inspection readiness.
#### How LDAS Benefits your Lab
 **Real-Time Compliance Automation**LDAS captures instrument data in real time via protocols like serial and OPC, enriches it with metadata, and ensures contemporaneous, complete, and compliant records—ready for AI-driven insights.
 **Exception-Based Quality Control**Automated anomaly detection enables review-by-exception workflows, reducing manual errors and allowing QA/QC teams to focus on critical deviations.
 **End-to-End Data Traceability**LDAS logs user actions, timestamps, and system events, ensuring transparent, inspection-ready traceability aligned with ALCOA+ and 21 CFR Part 11.
 **Unified Infrastructure for Inspection Readiness**Establishes a centralized data backbone, enabling real-time visibility, anomaly detection, and proactive compliance management.
### Turning Compliance Challenges into Connected Lab Strengths
Compliance Focused Integration and Data management for QC labs
Biopharma QC labs face strict regulatory scrutiny, where even minor data lapses can trigger FDA warnings and delays. Legacy and modern instruments often rely on manual data transfers, leading to transcription errors, fragmented workflows, and incomplete audit trails. Disconnected systems further increase compliance risks. Labs need secure connectivity, SOP-compliant workflows, and Pharma 4.0 readiness.
#### How LDAS Benefits your Lab
 **Compliance Driven Data Integrity**Captures instrument raw data with e-signatures and audit trails, ensuring ALCOA+ and 21 CFR Part 11 compliance.
 **Operational Assurance through Automation**Eliminates manual errors and broken traceability for complete, compliant records.
 **Building Robust Lab Connectivity**Bridges legacy and modern instruments via RS232, OPC, and proprietary protocols, enabling SOP-aligned, AI-ready workflows.
 **Secured and Efficient Lab Operations**Enables SOP-aligned, AI-ready workflows with full traceability and secure data retention.
### CDS- ELN/LIMS Integration
CDS Integration: From Raw Data to Regulatory-Ready Insights
In manufacturing QA/QC labs, lack of CDS–ELN/LIMS integration leads to manual transcription, increasing errors, delaying batch release, and raising regulatory risks. Disconnected systems create data silos, limit real-time access to quality insights, and weaken audit readiness—slowing QA review and compromising compliance.
#### How LDAS Benefits your Lab
 **Enhanced Lab Productivity**LDAS breaks down data silos, enabling real-time access to chromatographic data, reducing manual effort, and supporting faster, compliant batch release.
 **AI-compatible Standardized Data formats**Secure, automated data transfer from CDS to ELN/LIMS ensures AI-compatible formats, eliminating transcription errors and speeding decision-making.
 **Exception-Driven QA Review**LDAS detects anomalies and out-of-spec values in real time, enabling QA teams to focus on critical exceptions.
 **Inspection-Ready Outputs**Time-stamped records, version-controlled chromatograms, and e-signatures ensure ALCOA+ compliance and enable AI-driven audit readiness.
### Strengthening Compliance and Data Integrity in Small Molecule Research
Standardize and Integrate Diverse Instrument Data in Small Molecule Development
Small molecule QA/QC labs face significant challenges in managing analytical outputs from mass spectrometry, NMR, and chromatography. These instruments generate diverse, proprietary data formats. Manual transcription not only introduces errors but also breaks data lineage, making it hard to trace results back to source instruments. This fragmentation prevents AI/ML analytics and compromises regulatory compliance—especially for batch release, impurity profiling, and audit readiness.
#### How LDAS Benefits your Lab
 **Unified Data Capture**LDAS ingests raw data from varied instruments via serial, OPC, and proprietary protocols, converting it into standardized, metadata-rich data sets.
 **Compliance-Ready Records**Time-stamped, version-controlled entries with e-signatures ensure ALCOA+ and 21 CFR Part 11 compliance across workflows.
 **Accelerated Decision-Making**Automated anomaly detection enables review-by-exception workflows, reducing manual errors and allowing QA/QC teams to focus on critical deviations.
 **Inspection-Ready Infrastructure**Establishes a centralized data backbone, enabling real-time visibility into assay results and trends.
### CRDMO Data Standardization for Quality and Compliance
Quality Meets Compliance: Proactive Batch Decisions Powered by Harmonized Data
In biopharma manufacturing, QC, stability, and batch data from CMOs often arrive in fragmented formats—flat files, images, or proprietary systems. These silos delay reviews, obscure Out-of-Specification (OOS) results and increase compliance risks. Without standardized, accessible data, AI-enabled quality control and predictive insights remain out of reach.
#### How LDAS Benefits your Lab
 **Standardized Data Capture for Scalable Compliance**LDAS ingests batch, QC, and stability data in any format, converting it into structured, vendor-neutral datasets enriched with traceable metadata for regulatory submissions.
 **Compliance Driven Data Integrity**Electronic signatures and audit trails, ensure ALCOA+ and 21 CFR Part 11 compliance for inspection-ready records.
 **Automated Anomaly Detection and Alerts**LDAS flags anomalies and OOS values in real time, enabling faster, exception-based quality decisions.
 **AI-Enabled Insights for Proactive Quality Control**Contextualized datasets empower AI to detect trends, predict deviations, and support real-time batch release strategies.
Building Blocks for Your Digital Lab Strategy
Data Integrity
Implement ALCOA+ principles to ensure consistent and complete data.
Data Orchestration
Effortlessly capture and manage multistage experiments for faster, smarter results.
Enterprise Integration
Combine the lab data stream into your enterprise architecture with our open and modular framework.
Data Centralization
Get data off your instruments and centralize them in the cloud.
Meta Data Enrichment
Contextualize your instrument data with metadata from various repositories
Data Standardization
Transform instrument raw content to your standard for FAIR data and mining.
[View Instrument Parsers >>](https://zifo.com/services/instrument-and-system-agents-parsers/)
## ON-DEMAND WEBINAR | FROM INSTRUMENTS TO INSIGHTS LAB DATA AUTOMATION @ ZIFO
[ Register to Watch the Recording ](#)
Register to View
First Name
Last Name
Work Email
Company
Job Title
Submit
Our Capabilities
Our team of experts includes domain experts, service professionals, project managers, software developers, and cloud data architects to ensure the success of your lab data automation project. While our list of out-of-the-box instrument connectors is ever-growing, our team has the capacity and skills to build those needed for your specific project.
Our People
Project support during implementation
Glocal
Training of administrators and lab staff on how to use the LabX-Empower-Integration
Focus
Support for creating the Master Sample Set Methods
Partnerships
Ongoing support for LabX-Empower-Integration
Get in touch
First Name
Last Name
Email
Phone Number
Company
Designation
Enquiry Type
Enquiry Type Request for Zifo Services Product Partnership Job/Internship/Placement Enquiry Other
Message
Acceptance I consent to being contacted by an official Zifo representative
Submit
---
### [Gene Expression & Sequencing Services](https://zifo.com/services/gene-expression-sequencing-services/)
**Published:** January 19, 2022
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Services](https://zifo.com/services/ "Services")> Gene Expression & Sequencing Services
Gene Expression & Sequencing Services
Advances in the throughput of transcriptomic assays have allowed researchers to analyse many thousands of genes simultaneously instead of focusing on only a few key genes (e.g. qPCR). Furthermore, recent developments in the field are allowing us to see details at an increasingly high resolution, at a single cell level, with spatial information, and often with additional multiomics data in need of integration. Zifo’s bioinformatics services can provide analysis support for any Next Generation Sequencing (NGS) or array based gene expression analysis. We have extensive experience analysing bulk and single-cell RNA-seq spanning multiple protocols and can provide support integrating accompanying epigenetic data, as well as analysing cutting edge spatial transcriptomics.
[ Know more ](#)
Our Capabilities
Our expertise spans the whole spectrum of scientific process applications, and we’re able
to draw on a huge marketplace of partnerships with science technology providers, so
whatever is needed to fix your current set-up. we’ll determine the best way forward.
Our People
Our people are our business and we invest and support their development and curiosity. We actively promote science in our daily work and over 90% of people in Zifo have a scientific background – meaning we speak & understand the language of science
Glocal
We have a GLOCAL (global & local) presence – meaning we engage with you in your language and time zone but leverage a global delivery support model to remain cost-effective, scalable and very reactive
Focus
We focus on science and scientific process applications and informatics. This means we can provide expertise and domain knowledge without compromising quality, technical and service delivery excellence
Partnerships
Our huge marketplace of partnerships with science technology and informatics platform providers means you can rely on Zifo to be agnostic and advise on strategy, plan & deliver projects, and validate and maintain your scientific informatics environments
Get in touch
First Name
Last Name
Email
Phone Number
Company
Designation
Enquiry Type
Enquiry Type Request for Zifo Services Product Partnership Job/Internship/Placement Enquiry Other
Message
Acceptance I consent to being contacted by an official Zifo representative
Submit
---
### [Instrument and System Agents & Parsers](https://zifo.com/services/instrument-and-system-agents-parser/)
**Published:** April 8, 2024
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Services](https://zifo.com/services/ "Services")> Instrument and System Agents & Parsers
Fast Integration of All Your Lab
Instruments
Accelerate your scientific data connectivity with our pre-built library of
connectors and parsers.
[ Talk to an Expert ](/contact-us-today/)
Search Library
It is challenging to provide coverage for all lab instruments in any lab data automation solution. Interfacing an instrument to other scientific data platforms requires a connector (for data acquisition) and a parser (for data standardization) to work effectively. **Zifo has a dedicated team that builds and maintains an extensive library of pre-built connectors.**
## Filters
Reset All
## Instrument Type
Instrument Filter ThermoGravimetric analyser
Sorption Analyser
Calorimeter
Ring Shear Tester
Chromatograph
Spectrometer
Titrator
Bioreactor
Binding Affinity Analyzer
Compaction Simulator
Cell Analyzer
Cytometers
X-ray Diffraction
Application Connector
Liquid Particle Counter
Electrophoresis
Plate Reader
PCR
Fluorometer
Total Organic Carbon Analyzer
Bioprocess Analyser
pH Meter
Polarimeter
Rheometer
Melting Point Apparatus
Particle Size Analyzer
Liquid Handler
Conductivity Meter
Dissolution Tester
Analytical Balance
Protein Stability Analyzer
Hardness Tester
Tablet Tester
## Vendor
Vendor Filter TA instruments
Dr. Dietmar Schulze
Agilent Technologies
Bruker
Metrohm
Malvern Panalytical
Sartorius
Thermo Fisher Scientific
Cytiva
Huxley Bertram
Repligen
Revvity
BD Biosciences
Rigaku Corporation
Molecular Devices
Labvantage
Bio-Rad
Beckman
Meso Scale Discovery
Cellular Technology Limited
MabTech
Perkin Elmer
Luminex Corporation
Qiagen
Ulvac PHI
Spectro Analytical
ChemoMetec
Shimadzu
Mettler Toledo
Sapio
Dotmatics
IDBS EWB
OSISoft
Labware
Benchling
Waters
Physical Electronics
Applied Biosystems
Analab Scientific
Rudolph
AMETEK Brookfield
IONTOF
Lab India
Hamilton
Veego Instruments Corporation
Nova Biomedical
Sotax
Roche
Tecan
Pion
Micromeritics
Unchained labs
Sympatec
Sentronic
Horiba
Surface Measurement Systems (SMS)
Biotek
Kraemer Elektronik GmbH
Showing 12 of 100+ instruments
Kraemer Elektronik GmbH
Lab Line P5
Instrument
Tablet Tester
Type
Tablet Tester
Agilent Technologies
xCELLigence
Instrument
Real-Time Cell Analysis
Type
Cell Analyzer
Perkin Elmer
EnVision
Instrument
Multimode Plate Reader
Type
Plate Reader
Thermo Fisher Scientific
NANODROP 8000C
Instrument
UV-VIS Spectrophotometer
Type
Spectrometer
Biotek
Synergy H1
Instrument
Multimode Plate Reader
Type
Plate Reader
Thermo Fisher Scientific
NANODROP 2000C
Instrument
UV-Vis Spectrophotometer
Type
Spectrometer
Shimadzu
Nexera series
Instrument
UHPLC
Type
Chromatograph
Waters
Acquity UPLC I-Class
Instrument
UPLC
Type
Chromatograph
Waters
Acquity UPLC H-Class
Instrument
UPLC
Type
Chromatograph
Surface Measurement Systems (SMS)
DVS Resolution
Instrument
Dynamic Vapor Sorption Analyzer
Type
Sorption Analyser
Horiba
LA-960A2
Instrument
Laser Diffraction Particle Size Analyser
Type
Particle Size Analyzer
Revvity
Cellometer K2
Instrument
Automated Cell Counter
Type
Cell Analyzer
'; if (currentPage > 1) { prevArrow.onclick = function(e) { e.preventDefault(); processed = false; scrollToListing(); const prevItem = items[currentPage - 2]; if (prevItem) prevItem.click(); }; } container.insertBefore(prevArrow, container.firstChild); // Add NEXT arrow const nextArrow = document.createElement('div'); nextArrow.className = 'jet-filters-pagination__item pagination-arrow pagination-next'; nextArrow.style.cssText = 'display: inline-block !important; visibility: visible !important; cursor: ' + (currentPage < totalPages ? 'pointer' : 'not-allowed') + '; opacity: ' + (currentPage < totalPages ? '1' : '0.4') + ';'; nextArrow.innerHTML = '
'; if (currentPage < totalPages) { nextArrow.onclick = function(e) { e.preventDefault(); processed = false; scrollToListing(); const nextItem = items[currentPage]; if (nextItem) nextItem.click(); }; } container.appendChild(nextArrow); container.setAttribute('data-processed', 'true'); processed = true; isProcessing = false; }, 50); } if (document.readyState === 'loading') { document.addEventListener('DOMContentLoaded', function() { setTimeout(updatePagination, 300); }); } else { setTimeout(updatePagination, 300); } // Scroll + update on page number click document.addEventListener('click', function(e) { if (e.target.closest('.jet-filters-pagination__item:not(.pagination-arrow)')) { processed = false; scrollToListing(); document.querySelectorAll('.jet-filters-pagination__item:not(.pagination-arrow)').forEach(item => { item.style.display = 'none'; item.style.visibility = 'hidden'; }); setTimeout(updatePagination, 300); } }); let observerTimeout; const observer = new MutationObserver(function(mutations) { const hasNewPagination = mutations.some(function(mutation) { return Array.from(mutation.addedNodes).some(function(node) { return node.nodeType === 1 && ( node.classList.contains('jet-filters-pagination') || node.querySelector('.jet-filters-pagination') ); }); }); if (hasNewPagination) { clearTimeout(observerTimeout); processed = false; observerTimeout = setTimeout(updatePagination, 300); } }); setTimeout(function() { const wrapper = document.querySelector('.jet-smart-filters-pagination'); if (wrapper) { observer.observe(wrapper, { childList: true, subtree: false }); } }, 500); if (typeof jQuery !== 'undefined') { jQuery(document).on('jet-filter-content-rendered jet-filter-custom-content-render', function() { processed = false; setTimeout(updatePagination, 300); }); } })();
---
## News
### [CMC Bottleneck is Choking Biopharma's Drug Pipeline, says Zifo](https://zifo.com/news/cmc-bottleneck-is-choking-biopharmas-drug-pipeline-says-zifo/)
**Published:** September 11, 2026
**Author:** Zifo_user
**Content:**
## CMC Bottleneck is Choking Biopharma’s Drug Pipeline, says Zifo
Sep 02, 2026
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20CMC%20Bottleneck%20is%20Choking%20Biopharma%27s%20Drug%20Pipeline%2C%20says%20Zifo%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fnews%2Fcmc-bottleneck-is-choking-biopharmas-drug-pipeline-says-zifo%2F "Share on Email")
- [](https://x.com/intent/post?text=CMC%20Bottleneck%20is%20Choking%20Biopharma%27s%20Drug%20Pipeline%2C%20says%20Zifo&url=https%3A%2F%2Fzifo.com%2Fnews%2Fcmc-bottleneck-is-choking-biopharmas-drug-pipeline-says-zifo%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=CMC+Bottleneck+is+Choking+Biopharma%5C%26%23039%3Bs+Drug+Pipeline%2C+says+Zifo&url=https%3A%2F%2Fzifo.com%2Fnews%2Fcmc-bottleneck-is-choking-biopharmas-drug-pipeline-says-zifo%2F "Share on LinkedIn")
*New position paper argues that fragmented data, broken scientific handoffs, and outdated tech transfer models are turning Chemistry, Manufacturing, Controls (CMC) into a billion-dollar bottleneck.*
CAMBRIDGE, Mass. and CAMBRIDGE, England, Sept. 2, 2026 /PRNewswire/ — The biopharma industry has invested heavily in accelerating discovery. AI, machine learning (ML), high-throughput experimentation and advanced modelling are helping scientists identify promising therapeutic candidates faster than ever.
But there is a problem.
Before any therapy can reach patients, it must pass through Chemistry, Manufacturing and Controls, or CMC. And that pathway is struggling to keep pace.
In its new position paper, **“The Billion-Dollar Bottleneck: Why CMC is Strangling the Biopharma Pipeline,”** Zifo argues that CMC has become one of the industry’s most consequential operational constraints. The paper examines how scientific complexity, fragmented data, manual documentation, and poorly connected tech transfer processes are delaying commercialization and consuming valuable scientific capacity.
The stakes are significant. CMC deficiencies have contributed to 74% of FDA Complete Response Letters (CRLs), while every day of delayed prescription sales may represent about $800,000 in lost value, according to the paper. For therapies approaching fixed patent-expiry dates, those delays cannot always be recovered later. They can permanently reduce an asset’s commercial life.
Yet the impact reaches well beyond revenue.
“CMC delay is often discussed as an operational or regulatory problem. It is both, but that framing is incomplete,” said **Raj Prakash Govindarajan, Chief Executive Officer and Co-Founder at Zifo**. “When process and manufacturing knowledge cannot move at the speed of the science, patients wait longer, facilities remain underutilized and highly trained scientists spend their time reconstructing information that should already be connected.”
**A Modern Scientific Pipeline Running On Fractured Infrastructure**
The challenge has intensified as biopharma pipelines have shifted from comparatively predictable small-molecule processes toward biologics, cell and gene therapies, nucleic-acid therapeutics and other advanced modalities.
These therapies introduce hundreds, sometimes thousands, of potentially influential process, material, equipment and environmental variables. Small changes in mixing, oxygen transfer, pH, temperature, shear or raw materials can affect the behaviour and quality of the final product.
The science has changed. Much of the operating model has not.
Critical information still moves between process development, analytical teams, quality functions, manufacturing sites, and external partners through spreadsheets, PDFs, paper batch records, slide decks and email. Context is lost at every handoff. Scientists then spend hours finding data, reconciling sample identifiers and manually rebuilding experimental histories.
The paper describes this as the **“Data Janitor” epidemic**, with current operational analyses indicating that PhD-level scientists may spend between 30% and 40% of their working time on data cleanup and reconciliation rather than scientific problem-solving.
**Digitizing Paper Is Not Transformation**
The viewpoint also challenges a familiar response to CMC friction: purchasing another platform.
Replicating an inefficient paper process on a screen does not remove the underlying problem. It can make the process more rigid. In dynamic scientific environments, systems built around fixed templates and isolated workflows can restrict experimentation and encourage scientists to return to spreadsheets or paper simply to get the work done.
Instead, **Zifo proposes a scientist-centered CMC** operating model built around six connected moves:
1. **Liberate evidence** trapped in batch records, certificates of analysis, PDFs and legacy reports.
2. **Connect the most valuable data choke points** across instruments and scientific systems.
3. **Rewire Design-Make-Test-Analyse (DMTA) workflows** so context travels with every sample and result.
4. **Create an orchestration layer** that adapts to scientists without replacing validated systems of record.
5. **Apply governed Scientific Language Models** grounded in proprietary CMC evidence.
6. **Treat tech transfer as a continuous knowledge flow**, not a late-stage baton pass.
The ambition is substantial: reduce overall CMC cycle times by as much as 40%, with phase acceleration of up to 60%. Achieving that goal will require more than incremental optimization. It will demand a joint operating model across CMC, IT, Quality and data teams, supported by targeted lighthouse projects that demonstrate value quickly and scale under appropriate governance.
“CMC does not need another digital filing cabinet,” said **Paul Denny-Gouldson, Chief Scientific Officer at Zifo and a co-author of the position paper**. “It needs an operating environment in which scientific evidence and knowledge remain connected, decisions can be made faster and remain traceable, and tech transfer readiness begins on day one. The bottleneck is not inevitable. But removing it requires the industry to stop incrementally improving individual fragments and redesign the entire process flow and how the science is done.”
****Download the position paper**** The full viewpoint examines the causes and costs of the CMC bottleneck and presents a practical blueprint for building a connected, AI-enabled and scientist-centred CMC ecosystem.**[ https://zifo.com/cmc-million-dollar-bottleneck-biopharma/](https://zifo.com/cmc-million-dollar-bottleneck-biopharma/)**
**About Zifo**
Zifo is the leading global enabler of AI and data driven enterprise informatics for science driven organizations. With extensive solutions and services expertise spanning research, development, manufacturing, and clinical domains, we serve a diverse range of industries, including Pharma, Biotech, Chemicals, Food and Beverage, Oil & Gas, and FMCG. Trusted by over 190 science-focused organizations worldwide, Zifo is the partner of choice for advancing digital scientific innovation. [**https://zifo.com/**](https://zifo.com/)
## Recent News
### [Zifo Co-Launches REAL 2026 to Spotlight the Next Generation of Connected, AI-Enabled Lab Environments](https://zifo.com/news/zifo-co-launches-real-2026-to-spotlight-the-next-generation-of-connected-ai-enabled-lab-environments/)
[  ](https://zifo.com/news/zifo-co-launches-real-2026-to-spotlight-the-next-generation-of-connected-ai-enabled-lab-environments/)
### [CMC Bottleneck is Choking Biopharma’s Drug Pipeline, says Zifo](https://zifo.com/news/cmc-bottleneck-is-choking-biopharmas-drug-pipeline-says-zifo/)
[  ](https://zifo.com/news/cmc-bottleneck-is-choking-biopharmas-drug-pipeline-says-zifo/)
### [Zifo Accelerates LIMS Master Data Validation with New AI-Enabled Services Accelerator](https://zifo.com/news/zifo-accelerates-lims-master-data-validation-with-new-ai-enabled-services-accelerator/)
[  ](https://zifo.com/news/zifo-accelerates-lims-master-data-validation-with-new-ai-enabled-services-accelerator/)
---
### [Zifo Co-Launches REAL 2026 to Spotlight the Next Generation of Connected, AI-Enabled Lab Environments](https://zifo.com/news/zifo-co-launches-real-2026-to-spotlight-the-next-generation-of-connected-ai-enabled-lab-environments/)
**Published:** September 11, 2026
**Author:** Zifo_user
**Content:**
## Zifo Co-Launches REAL 2026 to Spotlight the Next Generation of Connected, AI-Enabled Lab Environments
Sep 10, 2026
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Zifo%20Co-Launches%20REAL%202026%20to%20Spotlight%20the%20Next%20Generation%20of%20Connected%2C%20AI-Enabled%20Lab%20Environments%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fnews%2Fzifo-co-launches-real-2026-to-spotlight-the-next-generation-of-connected-ai-enabled-lab-environments%2F "Share on Email")
- [](https://x.com/intent/post?text=Zifo%20Co-Launches%20REAL%202026%20to%20Spotlight%20the%20Next%20Generation%20of%20Connected%2C%20AI-Enabled%20Lab%20Environments&url=https%3A%2F%2Fzifo.com%2Fnews%2Fzifo-co-launches-real-2026-to-spotlight-the-next-generation-of-connected-ai-enabled-lab-environments%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Zifo+Co-Launches+REAL+2026+to+Spotlight+the+Next+Generation+of+Connected%2C+AI-Enabled+Lab+Environments&url=https%3A%2F%2Fzifo.com%2Fnews%2Fzifo-co-launches-real-2026-to-spotlight-the-next-generation-of-connected-ai-enabled-lab-environments%2F "Share on LinkedIn")
*REAL 2026 is designed as a curated, invite-only event for senior leaders across pharma, biotech, automation, data, and AI*
CAMBRIDGE, Mass. and CAMBRIDGE, England, Sept. 10, 2026 /PRNewswire/ — As physical AI and agentic platforms rapidly reshape biopharma R&D and accelerate the convergence of robotics, scientific data, analytics, and AI, Zifo today announced the launch of **REAL 2026: Readiness & Enablement for Automated Labs**, an industry summit dedicated to advancing the next generation of connected, AI-enabled lab environments.
*(Margaret Difilippo, Zifo’s Head of Commercial in North America.)*
Taking place on **September 15, 2026, at Boston’s Seaport District**,
REAL 2026 will bring together leaders from pharma, biotech, automation,
data, and AI to explore what it will take to realize the industry’s vision
of a fully integrated ‘lab-in-the-loop’ environment.
By fostering candid discussions between the organizations developing these
technologies and those deploying them in real-world research settings, the
summit aims to accelerate collective learning around the data,
infrastructure, operating models, and collaboration needed to make
automated laboratories a practical reality.
**Margaret DiFilippo, Zifo’s Head of Commercial in North America**,
stated: “The future of lab innovation will depend on more than automation
alone. Real progress requires bringing together scientists, automation
experts, data leaders, and AI practitioners to address the technical,
operational, and organizational challenges of creating truly connected
laboratories.”
**Industry Perspectives from Across the Automated Lab Ecosystem**
REAL 2026 will feature leaders who are actively building, operating, and scaling automated laboratory environments. The program is designed to combine strategic perspectives with practical implementation experiences, creating an opportunity for attendees to learn from organizations working across the automation stack.
Featured speakers include leaders from companies such as **Novo Nordisk, Merck, Pacific Northwest National Laboratory (PNNL), Lila Sciences, TetraScience, Benchling, Dotmatics, HighRes, and Automata**, representing diverse perspectives across the evolving automated laboratory ecosystem.
The agenda includes:
- **The Autonomous Wet Lab of the Future**
- Jason Kelly.
- **Unlocking Next Gen Translational Bioanalytics for Vaccine Studies for
Preclinical and Clinical Studies**
- **Xinnian Li**, Principal Scientist Leading Autonomous Robotic Orchestration, Merck and **Carol Rohl**, Associate Vice President, Global Research IT and Informatics at Merck
- **Building the Digital Ecosystem for the Lab of the Future — From Data Chaos
to AI-Ready Infrastructure**
- **Nevin Gerek**, Director, Digital Labs, Research Digital
Products, Novo Nordisk
- **A National Lab Perspective: A Real Implementation Story**
- **Todd Edwards**, Chief Technology Integration Officer,
Environmental Molecular Sciences, PNNL
- **Market View: What We Are Seeing Across the Industry**
- Zifo (Organization-led session) A 25-minute view from the front lines of
the market, plus live Q&A on where the puck is headed next.
- **Hardware Innovator Lightning Talks (Rapid-fire talks on what’s possible
today and what’s on the roadmap from the teams building the physical layer of automated labs)**
- **Tom Rawlins**, VP, Marketing, HighRes
- **Bohui Li**, Ph.D., Product Manager, Lab Automation
Solutions, XtalPi
- **Chirag Patel**, Head of Sales, Automata
- **Software & Data Infrastructure Lightning Talks (Rapid-fire talks from the
other half of the stack — the platforms turning lab data into usable intelligence)**
- **Michael Hopkins**, Product Management, Lab Automation,
Benchling
- **Darren Pittman**, Principal Lab Orchestration Architect,
Dotmatics
- **Matt Studney**, Chief Customer Officer, TetraScience
- **Scaling the Scientific Method: Frontier AI & Autonomous Labs on the Path
to Superintelligence**
- **Ryan Leung**, Vice President, Head of Life
Sciences, LILA
- **Closing Panel: What Will It Actually Take to Make It REAL?**
- Moderated by **Stacie Calad-Thomson**, PhD, Global
Business Development Lead, Pharma Labs and Manufacturing at NVIDIA
**Advancing Readiness and Enablement for Automated Labs**
As labs generate growing volumes of scientific data and organizations pursue new levels of automation, the need for integrated, interoperable, and scalable research environments continues to increase. REAL 2026 aims to help the industry navigate that transition by fostering collaboration among organizations developing automation technologies and those deploying them within scientific environments.
For Zifo this event reflects a continued commitment to helping science-driven organizations connect laboratory processes, scientific data, informatics platforms, and AI capabilities to optimize discovery and improve decision-making. By bringing together experts from across the ecosystem, REAL 2026 seeks to advance the readiness and enablement needed to move automated laboratories from aspiration to reality.
REAL 2026 is designed as a curated event for senior leaders across pharma, biotech, automation, data, and AI. To encourage the candid discussions that are central to the summit’s mission, most sessions will not be recorded; however, a written recap will be shared with attendees. Participation is by invitation, and interested attendees can request an invitation through the event registration page. ; [https://zifo.com/event/real-2026-readiness-enablement-for-automated-labs/](https://zifo.com//event/real-2026-readiness-enablement-for-automated-labs/)
**About REAL 2026**
REAL 2026 (Readiness & Enablement for Automated Labs) is a one-day summit taking place on **September 15, 2026**, in Boston’s Seaport District. The event brings together leaders across biopharma, biotechnology, laboratory automation, data infrastructure, and AI to accelerate learning and collaboration around the future of automated laboratories. ;
**About Zifo**
Zifo is the leading global enabler of AI and data driven enterprise informatics for science driven organizations. With extensive solutions and services expertise spanning research, development, manufacturing, and clinical domains, we serve a diverse range of industries, including Pharma, Biotech, Chemicals, Food and Beverage, Oil & Gas, and FMCG. Trusted by over 190 science-focused organizations worldwide, Zifo is the partner of choice for advancing digital scientific innovation. [https://zifo.com/](https://.zifo.com/)
## Recent News
### [Zifo Co-Launches REAL 2026 to Spotlight the Next Generation of Connected, AI-Enabled Lab Environments](https://zifo.com/news/zifo-co-launches-real-2026-to-spotlight-the-next-generation-of-connected-ai-enabled-lab-environments/)
[  ](https://zifo.com/news/zifo-co-launches-real-2026-to-spotlight-the-next-generation-of-connected-ai-enabled-lab-environments/)
### [CMC Bottleneck is Choking Biopharma’s Drug Pipeline, says Zifo](https://zifo.com/news/cmc-bottleneck-is-choking-biopharmas-drug-pipeline-says-zifo/)
[  ](https://zifo.com/news/cmc-bottleneck-is-choking-biopharmas-drug-pipeline-says-zifo/)
### [Zifo Accelerates LIMS Master Data Validation with New AI-Enabled Services Accelerator](https://zifo.com/news/zifo-accelerates-lims-master-data-validation-with-new-ai-enabled-services-accelerator/)
[  ](https://zifo.com/news/zifo-accelerates-lims-master-data-validation-with-new-ai-enabled-services-accelerator/)
---
### [Zifo Now Partners with 20 of the Top 25 Global Biopharma Companies to Unblock the CMC Process Data Pipeline](https://zifo.com/news/zifo-now-partners-with-20-of-the-top-25-global-biopharma-companies-to-unblock-the-cmc-process-data-pipeline/)
**Published:** May 11, 2026
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [News](https://zifo.com/news/ "News")> Zifo Now Partners with 20 of the Top 25 Global Biopharma Companies to Unblock the CMC Process Data Pipeline
## Zifo Now Partners with 20 of the Top 25 Global Biopharma Companies to Unblock the CMC Process Data Pipeline
May 11, 2026
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Zifo%20Now%20Partners%20with%2020%20of%20the%20Top%2025%20Global%20Biopharma%20Companies%20to%20Unblock%20the%20CMC%20Process%20Data%20Pipeline%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fnews%2Fzifo-now-partners-with-20-of-the-top-25-global-biopharma-companies-to-unblock-the-cmc-process-data-pipeline%2F "Share on Email")
- [](https://x.com/intent/post?text=Zifo%20Now%20Partners%20with%2020%20of%20the%20Top%2025%20Global%20Biopharma%20Companies%20to%20Unblock%20the%20CMC%20Process%20Data%20Pipeline&url=https%3A%2F%2Fzifo.com%2Fnews%2Fzifo-now-partners-with-20-of-the-top-25-global-biopharma-companies-to-unblock-the-cmc-process-data-pipeline%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Zifo+Now+Partners+with+20+of+the+Top+25+Global+Biopharma+Companies+to+Unblock+the+CMC+Process+Data+Pipeline&url=https%3A%2F%2Fzifo.com%2Fnews%2Fzifo-now-partners-with-20-of-the-top-25-global-biopharma-companies-to-unblock-the-cmc-process-data-pipeline%2F "Share on LinkedIn")
CAMBRIDGE, Mass. and CAMBRIDGE, England, May 11, 2026 /PRNewswire/ — Zifo announced today that 20 of the world’s top 25 biopharma companies have adopted its Chemistry, Manufacturing, and Controls (CMC) services, as the company pursues its mission to meet customer demands for a 50% reduction in execution timelines and solve one of the industry’s most persistent bottlenecks: moving new therapies from development into regulated manufacturing and patient trials.
Pharma and Biotech industries are very efficient at early-stage research. However, transitioning those discoveries into clinical trials remains a severe bottleneck as the CMC process is currently very time-consuming and complex with estimates anywhere between 18-36 months.
Every new therapy must undergo the CMC phase. To achieve this, companies must conduct extensive analytical testing and experimentation, then synthesize a vast amount of complex data — ranging from manufacturing process controls and stability parameters to a deep understanding of analytical test variance.
Hence, navigating the CMC landscape requires a unique blend of deep science, data management, and organizational empathy; Zifo’s mastery of Science, Technology, Data, AI, Change Management, and automation stands as a testament to its leadership in the field.
“Think of the CMC process like a really narrow funnel,” said **Paul Denny-Gouldson, Chief Scientific Officer, at Zifo**. “You have all this wide-open scientific discovery and development, and then the process slows and becomes very sequential. Executing all the process steps, testing and process evaluations and then pulling all that data from disconnected lab systems into regulatory documentation is painfully slow and currently a very manual process. Our work with our customers is revolutionising the way CMC is thought of, executed and managed”.
And this is where Zifo’s Practical AI Blueprints come into play during the CMC stage. Instead of relying on unpredictable, ‘black box’ AI models, Zifo uses targeted AI to do the heavy lifting of data structuring. The models automatically pull and map unstructured CMC data from different source documents, turning it into standardized, audit-ready formats. It takes the administrative burden off the scientists, drastically cuts down on manual transcription errors, and ensures the data is ready for FDA and EMA submissions.
It’s an approach that solves very different problems for scientific and technology leaders.
For Scientists, the benefit is trust. Because over 90% of Zifo’s experts have a scientific background, research teams know their data will maintain strict regulatory compliance during the transfer. They can get back to focusing on the pipeline instead of fighting with paperwork.
For IT teams, it’s about reducing technical debt whilst enabling better science without compromising quality. Zifo’s strategy looks to leverage current systems where possible, limiting the need for a massive, ground-up overhaul. Plus, with a global and local delivery model, Zifo provides the 24/7 support needed to take this CMC transformation from idea to production in previously unimaginable speed — meaning faster time to value and outcomes for the business.
“At the end of the day, our clients are making life-saving drugs. They can’t afford to get stuck in a historical lab execution, data, and informatics traffic jam during the critical CMC stage,” added Paul. “We just want to make sure scientists can work so much faster than today and where data flows safely and securely from the lab to the regulatory submissions and internal tech transfer teams to meet those 50% reduction in CMC timelines”.
For more information on Zifo’s CMC Services, visit [https://zifo.com/services/cmc-services-manufacturing/](/services/cmc-services-manufacturing/)
**About Zifo:**
Zifo is the leading global enabler of AI and data driven enterprise informatics for science driven organizations. With extensive solutions and services expertise spanning research, development, manufacturing, and clinical domains, we serve a diverse range of industries, including Pharma, Biotech, Chemicals, Food and Beverage, Oil & Gas, and FMCG. Trusted by over 190 science-focused organizations worldwide, Zifo is the partner of choice for advancing digital scientific innovation. ; [https://zifo.com/services/cmc-services-manufacturing/](/services/cmc-services-manufacturing/); [https://zifo.com/practical-ai-blueprints/](/practical-ai-blueprints/)
## Recent News
### [Zifo Co-Launches REAL 2026 to Spotlight the Next Generation of Connected, AI-Enabled Lab Environments](https://zifo.com/news/zifo-co-launches-real-2026-to-spotlight-the-next-generation-of-connected-ai-enabled-lab-environments/)
[  ](https://zifo.com/news/zifo-co-launches-real-2026-to-spotlight-the-next-generation-of-connected-ai-enabled-lab-environments/)
### [CMC Bottleneck is Choking Biopharma’s Drug Pipeline, says Zifo](https://zifo.com/news/cmc-bottleneck-is-choking-biopharmas-drug-pipeline-says-zifo/)
[  ](https://zifo.com/news/cmc-bottleneck-is-choking-biopharmas-drug-pipeline-says-zifo/)
### [Zifo Accelerates LIMS Master Data Validation with New AI-Enabled Services Accelerator](https://zifo.com/news/zifo-accelerates-lims-master-data-validation-with-new-ai-enabled-services-accelerator/)
[  ](https://zifo.com/news/zifo-accelerates-lims-master-data-validation-with-new-ai-enabled-services-accelerator/)
---
### [Zifo Accelerates LIMS Master Data Validation with New AI-Enabled Services Accelerator](https://zifo.com/news/zifo-accelerates-lims-master-data-validation-with-new-ai-enabled-services-accelerator/)
**Published:** August 27, 2026
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [News](https://zifo.com/news/ "News")> Zifo Accelerates LIMS Master Data Validation with New AI-Enabled Services Accelerator
## Zifo Accelerates LIMS Master Data Validation with New AI-Enabled Services Accelerator
Aug 26, 2026
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Zifo%20Accelerates%20LIMS%20Master%20Data%20Validation%20with%20New%20AI-Enabled%20Services%20Accelerator%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fnews%2Fzifo-accelerates-lims-master-data-validation-with-new-ai-enabled-services-accelerator%2F "Share on Email")
- [](https://x.com/intent/post?text=Zifo%20Accelerates%20LIMS%20Master%20Data%20Validation%20with%20New%20AI-Enabled%20Services%20Accelerator&url=https%3A%2F%2Fzifo.com%2Fnews%2Fzifo-accelerates-lims-master-data-validation-with-new-ai-enabled-services-accelerator%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Zifo+Accelerates+LIMS+Master+Data+Validation+with+New+AI-Enabled+Services+Accelerator&url=https%3A%2F%2Fzifo.com%2Fnews%2Fzifo-accelerates-lims-master-data-validation-with-new-ai-enabled-services-accelerator%2F "Share on LinkedIn")
*The new solution reduces master data review cycles from weeks to hours through automated cross-referencing, calculation verification, and real-time compliance checking.*
CAMBRIDGE, Mass. and CAMBRIDGE, England, Aug. 26, 2026 /PRNewswire/ — Zifo, a leading global enabler of AI and data-driven enterprise informatics for science-driven organizations, today announced the launch of its new AI-enabled services accelerator designed to transform Laboratory Information Management System (LIMS) master data validation.
In traditional LIMS deployments, validating calculations and complex Data File Definitions (DFDs) across multiple documents is a highly manual, labor-intensive process that can take potentially take weeks. Ensuring parameter names are correct and checking formula accuracy against pharmacopoeia standards requires deep LIMS expertise, and iterative dual-review cycles frequently create project bottlenecks. Furthermore, semantic inconsistencies and calculation syntax errors are often discovered late in testing, leading to costly rework.
****Customer Challenges and How Zifo’s Services Accelerator Helps****
**Customer** **Challenge****Solution****Manual Cross-Referencing:** Validating calculations across multiple documents takes days.**Automated Extraction:** AI automatically extracts and validates formulas from DFD files, cross-referencing against method specifications in minutes.**Pharmacopoeia Verification:** Checking formula correctness against standards is highly time-consuming.**Regulatory Alignment:** The LLM compares calculations to USP/Ph. Eur. standards and flags discrepancies with specific citations.**Parameter References:** Ensuring correct parameter naming requires deep LIMS expertise.**Automated Checks:** Validates that parameter names and Parameter List IDs used in calculations exactly match defined parameters.**Syntax Errors:** Calculation syntax errors are often discovered late in testing.**Real-Time Validation:** Identifies notation and embedded Groovy code errors during creation to prevent execution failures.**Semantic Inconsistencies:** Logic mismatches between DFDs and method specs are hard to detect.**Contextual Analysis:** Verifies that calculation logic aligns with method specification narratives(e.g., dilution factor consistency).**Review Bottlenecks:** Iterative dual review cycles (Zifo + Customer) create project delays.**Streaming Results:** Delivers real-time validation results to enable parallel reviews, reducing round-trip iterations by 60%.
LIMS implementations and master data creation are frequently constrained by the immense volume and complexity of data validation. Zifo’s new AI-enabled services accelerator addresses this challenge by transforming a manual, weeks-long review cycle into a streamlined, real-time process that takes just hours. This will drastically accelerate go-live timelines for clients while ensuring strict regulatory compliance, audit readiness, and calculation accuracy.
****Key capabilities of the newly launched services accelerator include:****
- **Multi-Document Cross-Referencing:** Performs semantic cross-referencing across DFD calculations, method specification narratives, and pharmacopoeia formulas to detect contextual inconsistencies (such as dilution factor logic) that simple logic checks often miss.
- **Real-Time Streaming Validation:** Utilizes Server-Sent Events (SSE) to stream partial validation results instantly, allowing review teams to begin their analysis immediately rather than waiting for batch processing. This reduces round-trip iterations by up to 60%.
- **Citation-Backed Findings:** Every validation finding includes specific citations from source documents (e.g., “Method Spec Section 7.3.2”), ensuring quality and compliance teams can quickly and confidently verify the AI’s reasoning.
- **Pharmacopoeia Formula Matching:** Automatically compares calculations against standard USP/Ph. Eur. formulas when not explicitly defined in the method specs, immediately flagging any deviations with regulatory implications.
- **Automated Syntax and Parameter Verification:** Identifies embedded Groovy code errors and notation mistakes during creation to prevent execution failures, while validating that parameter names and Parameter List IDs exactly match defined parameters.
- **Custom Prompt Management:** Allows flexible, session-level configurations to accommodate different validation rules for various project types—from strict drug substance compliance to flexible in-house methods—without requiring code changes.
Operating specifically within the Quality Control & Laboratory Informatics segment, the services accelerator delivers measurable impact across the LIMS value chain.
Powered by a robust technical architecture that includes an AI agent and custom document extractors, the services accelerator seamlessly handles diverse PDF method specifications and structured data formats, laying the foundation for future enhancements like automated test data generation and collaborative dual-review workflows.
****Bridging Science and Technology Across the Value Chain****
This AI-powered master data validation services accelerator is just one piece of a much larger puzzle. For science-driven organizations, persistent bottlenecks can easily drag down progress. Zifo solves this. Drawing on deep expertise as a global enabler of data-driven enterprise informatics, we bring domain-aware intelligence directly to the scientific value chain. By combining automated verification, real-time compliance alignment, and intelligent orchestration, we ensure that actionable, high-quality data is seamlessly integrated — and actively maintained — across the entire scientific value chain.
**About Zifo**
Zifo is the leading global enabler of AI and data-driven enterprise informatics for science-driven organizations. With extensive solutions and services expertise spanning research, development, manufacturing, and clinical domains, we serve a diverse range of industries, including Pharma, Biotech, Chemicals, Food and Beverage, Oil & Gas, and FMCG. Trusted by over 190 science-focused organizations worldwide, Zifo is the partner of choice for advancing digital scientific innovation.
For more information, please visit:
## Recent News
### [Zifo Co-Launches REAL 2026 to Spotlight the Next Generation of Connected, AI-Enabled Lab Environments](https://zifo.com/news/zifo-co-launches-real-2026-to-spotlight-the-next-generation-of-connected-ai-enabled-lab-environments/)
[  ](https://zifo.com/news/zifo-co-launches-real-2026-to-spotlight-the-next-generation-of-connected-ai-enabled-lab-environments/)
### [CMC Bottleneck is Choking Biopharma’s Drug Pipeline, says Zifo](https://zifo.com/news/cmc-bottleneck-is-choking-biopharmas-drug-pipeline-says-zifo/)
[  ](https://zifo.com/news/cmc-bottleneck-is-choking-biopharmas-drug-pipeline-says-zifo/)
### [Zifo Accelerates LIMS Master Data Validation with New AI-Enabled Services Accelerator](https://zifo.com/news/zifo-accelerates-lims-master-data-validation-with-new-ai-enabled-services-accelerator/)
[  ](https://zifo.com/news/zifo-accelerates-lims-master-data-validation-with-new-ai-enabled-services-accelerator/)
---
### [Zifo Open Quiz 2026 Draws Over 1,200 Quizzers on Independence Day](https://zifo.com/news/zifo-open-quiz-2026-draws-over-1200-quizzers-on-independence-day/)
**Published:** August 25, 2026
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [News](https://zifo.com/news/ "News")> Zifo Open Quiz 2026 Draws Over 1,200 Quizzers on Independence Day
## Zifo Open Quiz 2026 Draws Over 1,200 Quizzers on Independence Day
Aug 20, 2026
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Zifo%20Open%20Quiz%202026%20Draws%20Over%201%2C200%20Quizzers%20on%20Independence%20Day%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fnews%2Fzifo-open-quiz-2026-draws-over-1200-quizzers-on-independence-day%2F "Share on Email")
- [](https://x.com/intent/post?text=Zifo%20Open%20Quiz%202026%20Draws%20Over%201%2C200%20Quizzers%20on%20Independence%20Day&url=https%3A%2F%2Fzifo.com%2Fnews%2Fzifo-open-quiz-2026-draws-over-1200-quizzers-on-independence-day%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Zifo+Open+Quiz+2026+Draws+Over+1%2C200+Quizzers+on+Independence+Day&url=https%3A%2F%2Fzifo.com%2Fnews%2Fzifo-open-quiz-2026-draws-over-1200-quizzers-on-independence-day%2F "Share on LinkedIn")
*( Zifo Open Quiz 2026 Champion: Team ‘Zi Fosis’ — Represented by Rajiv, Jayakanthan, Swaminathan )*
CHENNAI, India, Aug. 20, 2026 /PRNewswire/ — Zifo, a leading global enabler of AI and data-driven enterprise informatics for science-driven organizations, successfully hosted the 35th annual Zifo Open Quiz (ZOQ) on Indian Independence Day. The event continues its legacy as a beloved Chennai tradition, drawing an enthusiastic crowd to celebrate curiosity, trivia, and community.
This year’s edition was a spectacular showcase of intellect, with 400 teams taking their seats and bringing together 1,200 passionate quizzers. The journey to the main stage was preceded by a massive school-level preliminary phase. Conducted over a month, this dedicated school round saw enthusiastic participation from 600+ school teams and 1,800+ students, highlighting a growing interest in quizzing among the youth.
Anand Narayanan, Chief Marketing Officer at Zifo, said, “The overwhelming response to the 2026 edition is a testament to the thriving culture of curiosity in our community. We are incredibly proud to continue this Independence Day tradition and watch new generations embrace the thrill of discovery.”
The grand event was conducted in collaboration with renowned quizmaster Dr. Navin Jayakumar and the Quiz Federation of India (QFI).
“The joy lies in discovering something new and saying, ‘I didn’t know that. That’s fascinating,” noted Quizmaster Dr. Navin on the enduring appeal of the event.
The competition showcased a mix of seasoned veterans, families, and new challengers, all battling across diverse topics ranging from history and current affairs to science and pop culture.
****Zifo Open Quiz 2026 Winners**:**
- **Champion:** ‘Zi Fosis’ — Represented by Rajiv, Jayakanthan, Swaminathan.
- **First Runner-Up:** ‘Assad: Syria’s Quizzing Minds’ — Represented by Aadisht, Aswath, Sania
- **Second Runner-Up:** ‘WIMWI’ — Represented by Srinath Bashyam, Vinoo Sanjay, Preetham Upadhya
- **School Winner:** ‘Pharos 3.0’ (Bhavan’s Rajaji Vidyasharam, Kilpauk) — Represented by Dev Naveen, Aarush A Dhanujnat, Sachin Sathyasivan
- **School Runner-Up:** ‘T. Nagar Thayirsadams’ (PSBB, Nungambakkam) — Represented by Keshav Krishna, Rushil Chandrasekar, Bhargav Thyagarajan
- **College Winner:** ‘Diddlers on the Roof’ (IIT Madras) — Represented by Advik Kabra, Arvind Vidhyashankar, and Sreeram Madhanan.
- **College Runner-Up:** ‘Poora India Quizzega’ (IIT Madras) — Represented by Anirvin, Sneha, and Magizhan.
- **Best Team Name Winner:** ‘Lakshiammal Mapla Naroda’ — Represented by Pranav, Mithilesh, and Adi Amartya Shankar.
- **Best Family Team:** ‘Generational Fumble’ — Represented by Suresh, Nandhini, and Abishek.
- **Best Corporate Team:**‘Straights of Hormuz’ (TVS Capital Funds) — Represented by Suchet Gopal, Samiha Gopal, Surabhi Gopal
Zifo remains committed to nurturing intellectual curiosity and believes the Zifo Open Quiz is a significant step toward achieving this goal. We extend our heartfelt congratulations to all the winners, participants, and the dedicated volunteers who made this event a resounding success.
Watch the recording of Preliminary Round here:
Watch the recording of Semifinal and Final Round here: [https://www.youtube.com/watch?v=e\_aj4uCZeQc](https://www.youtube.com/watch?v=e_aj4uCZeQc)
**About Zifo**
Zifo is the leading global enabler of AI and data-driven enterprise informatics for science-driven organizations. With extensive solutions and services expertise spanning research, development, manufacturing, and clinical domains, we serve various industries, including pharma, biotech, chemicals, food and beverage, oil and gas, and FMCG. Trusted by over 190 science-focused organizations worldwide, Zifo is the partner of choice for advancing digital scientific innovation.
## Recent News
### [Zifo Co-Launches REAL 2026 to Spotlight the Next Generation of Connected, AI-Enabled Lab Environments](https://zifo.com/news/zifo-co-launches-real-2026-to-spotlight-the-next-generation-of-connected-ai-enabled-lab-environments/)
[  ](https://zifo.com/news/zifo-co-launches-real-2026-to-spotlight-the-next-generation-of-connected-ai-enabled-lab-environments/)
### [CMC Bottleneck is Choking Biopharma’s Drug Pipeline, says Zifo](https://zifo.com/news/cmc-bottleneck-is-choking-biopharmas-drug-pipeline-says-zifo/)
[  ](https://zifo.com/news/cmc-bottleneck-is-choking-biopharmas-drug-pipeline-says-zifo/)
### [Zifo Accelerates LIMS Master Data Validation with New AI-Enabled Services Accelerator](https://zifo.com/news/zifo-accelerates-lims-master-data-validation-with-new-ai-enabled-services-accelerator/)
[  ](https://zifo.com/news/zifo-accelerates-lims-master-data-validation-with-new-ai-enabled-services-accelerator/)
---
### [Zifo Redefines "Data Products" to Accelerate Value Creation in Science-Driven Industries](https://zifo.com/news/zifo-redefines-data-products-to-accelerate-value-creation-in-science-driven-industries/)
**Published:** April 27, 2026
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [News](https://zifo.com/news/ "News")> Zifo Redefines “Data Products” to Accelerate Value Creation in Science-Driven Industries
## Zifo Redefines “Data Products” to Accelerate Value Creation in Science-Driven Industries
Apr 27, 2026
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Zifo%20Redefines%20%27Data%20Products%27%20to%20Accelerate%20Value%20Creation%20in%20Science-Driven%20Industries%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fnews%2Fzifo-redefines-data-products-to-accelerate-value-creation-in-science-driven-industries%2F "Share on Email")
- [](https://x.com/intent/post?text=Zifo%20Redefines%20%27Data%20Products%27%20to%20Accelerate%20Value%20Creation%20in%20Science-Driven%20Industries&url=https%3A%2F%2Fzifo.com%2Fnews%2Fzifo-redefines-data-products-to-accelerate-value-creation-in-science-driven-industries%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Zifo+Redefines+%5C%26%23039%3BData+Products%5C%26%23039%3B+to+Accelerate+Value+Creation+in+Science-Driven+Industries&url=https%3A%2F%2Fzifo.com%2Fnews%2Fzifo-redefines-data-products-to-accelerate-value-creation-in-science-driven-industries%2F "Share on LinkedIn")
CAMBRIDGE, Mass. and CAMBRIDGE, England, April 27, 2026 /PRNewswire/ — Zifo, a leading global enabler of AI and data driven enterprise informatics for science driven organizations, has released a white paper titled “Redefining Data Products: Context, Clarity, and the Rise of Data-as-a-Product”. **Authored by scientific informatics experts Bruno Fievet, Melchor Sanchez Martinez, and David Jackson**, the paper addresses widespread industry ambiguity by introducing a critical two-tiered classification for scientific data assets.
**Solving the Data Ambiguity Gap**
While the term “data product” is common in digital transformation circles, its meaning often shifts depending on the organization’s core business. Zifo’s research identifies that for science-driven organizations — such as those in Pharma and Biotech — failing to distinguish between different types of data products leads to wasted time and misallocated investment.
To provide a shared understanding, the white paper proposes two distinct categories:
- **Lite Data Products**: Curated, standardized datasets packaged for reuse or resale. These serve as dependable, reusable foundations similar to “scientific components” like compounds or reagents.
- **Full Data Products**: Managed digital solutions — such as dashboards, machine-learning models, or digital twins — that convert data into specific business or scientific value.
**The “Data-as-a-Product” Mindset**
The paper argues that the true shift is not just in what is built, but in how it is managed. Zifo introduces **Data-as-a-Product** as a philosophy that applies product management disciplines to data work. This model ensures every data initiative is governed by five key principles: **purpose and audience, ownership, lifecycle management, quality, and user-centric value creation**.
**Transformative Value Beyond ROI**
Traditional metrics often fail to capture the strategic impact of these initiatives. **Adam Paton**, Head of Strategic Accounts at **Zifo**, notes that for transformative objectives, value must be articulated as “enabling capabilities that were previously impossible,” requiring a narrative-driven approach to value.
The release of this white paper marks a pivotal shift in the industry conversation, moving beyond technical architecture to a focus on tangible business value. By adopting the “Data-as-a-Product” mindset, Biopharma and other science-focussed organizations can move away from passive data assets toward managed, living sources of sustained growth.
“This framework allows leaders to prioritize investments correctly by providing a shared understanding of what they are actually building,” says **David Jackson**, Head of the Scientific Data Foundation Business Unit at **Zifo**. Whether through the foundational reliability of Lite Data Products or the high-impact insights of Full Data Products, Zifo’s approach ensures that every data initiative is managed with intentionality, accountability, and purpose.
To Download the whitepaper, please click here:[https://zifo.com/white-papers/redefining-data-products/](/white-papers/redefining-data-products/)
**About Zifo:**
Zifo is the leading global enabler of AI and data driven enterprise informatics for science driven organizations. With extensive solutions and services expertise spanning research, development, manufacturing, and clinical domains, we serve a diverse range of industries, including Pharma, Biotech, Chemicals, Food and Beverage, Oil & Gas, and FMCG. Trusted by over 190 science-focused organizations worldwide, Zifo is the partner of choice for advancing digital scientific innovation
## Recent News
### [Zifo Co-Launches REAL 2026 to Spotlight the Next Generation of Connected, AI-Enabled Lab Environments](https://zifo.com/news/zifo-co-launches-real-2026-to-spotlight-the-next-generation-of-connected-ai-enabled-lab-environments/)
[  ](https://zifo.com/news/zifo-co-launches-real-2026-to-spotlight-the-next-generation-of-connected-ai-enabled-lab-environments/)
### [CMC Bottleneck is Choking Biopharma’s Drug Pipeline, says Zifo](https://zifo.com/news/cmc-bottleneck-is-choking-biopharmas-drug-pipeline-says-zifo/)
[  ](https://zifo.com/news/cmc-bottleneck-is-choking-biopharmas-drug-pipeline-says-zifo/)
### [Zifo Accelerates LIMS Master Data Validation with New AI-Enabled Services Accelerator](https://zifo.com/news/zifo-accelerates-lims-master-data-validation-with-new-ai-enabled-services-accelerator/)
[  ](https://zifo.com/news/zifo-accelerates-lims-master-data-validation-with-new-ai-enabled-services-accelerator/)
---
### [Conquering Biopharma’s ‘Mount Everest’: The Human Element of Digital Transformation](https://zifo.com/news/change-management-strategies-elevating-digital-transformation-in-pharma/)
**Published:** July 22, 2026
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [News](https://zifo.com/news/ "News")> Conquering Biopharma’s ‘Mount Everest’: The Human Element of Digital Transformation
## Conquering Biopharma’s ‘Mount Everest’: The Human Element of Digital Transformation
Jul 22, 2026
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Conquering%20Biopharma%E2%80%99s%20%E2%80%98Mount%20Everest%E2%80%99%3A%20The%20Human%20Element%20of%20Digital%20Transformation%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fnews%2Fchange-management-strategies-elevating-digital-transformation-in-pharma%2F "Share on Email")
- [](https://x.com/intent/post?text=Conquering%20Biopharma’s%20‘Mount%20Everest’%3A%20The%20Human%20Element%20of%20Digital%20Transformation&url=https%3A%2F%2Fzifo.com%2Fnews%2Fchange-management-strategies-elevating-digital-transformation-in-pharma%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Conquering+Biopharma%E2%80%99s+%E2%80%98Mount+Everest%E2%80%99%3A+The+Human+Element+of+Digital+Transformation&url=https%3A%2F%2Fzifo.com%2Fnews%2Fchange-management-strategies-elevating-digital-transformation-in-pharma%2F "Share on LinkedIn")
CAMBRIDGE, Mass. and CAMBRIDGE, England, July 21, 2026 /PRNewswire/ — As the Biopharma industry adopt advanced technologies at breakneck speeds, organizations are running into a surprising roadblock. It isn’t the technology. It’s human behavior. In a recent Zifo virtual panel discussion, ‘*Change Management Strategies Elevating Digital Transformation in Pharma*,’ Zifo experts decoded exactly why technological investments often fall flat, and how robust change management is the true secret to real-world success.
Host ****Shivani Vohra, Zifo’s Consultant Analyst****, opened the session with a comparison, likening Biopharma digital transformation to climbing Mount Everest. “The goal is clear… but the success of that mission does not depend only on the climb itself,” Shivani noted. “It depends entirely on the preparation that has happened at the base,” she added.
**Core Themes and Key Takeaways from the discussion:**
****1. Macro Vision vs. Micro Execution****
Successful digital transformation requires a balanced approach. While leadership must set a clear, long-term strategic ‘North Star’ (the macro vision), the ability to realize this vision falls short unless leaders actively address the granular, day-to-day workflow frictions (the micro execution) that scientists face at the bench.
****Zifo’s Change Practitioner, Harsha Nirmal Kumar****, emphasized how true transformation requires balancing the boardroom’s ‘why’ with the bench scientist’s daily ‘how.’
****2. Reframing Resistance as a Health Check****
Rather than viewing user pushback as behavioral sabotage, the speakers reframe it as a vital health check. As the discussion highlighted, ‘Resistance is not troublemaking; rather, it is a signal that a piece of the adoption puzzle is missing.’ Understanding what is driving the resistance is an important first step in figuring out how to best support the scientists through the transition.
****Zifo’s Shari Bickford****, a specialist in change leadership, shared a case study of a lab team fiercely resisting a new digital rollout. By digging deeper via a focus group, the project team discovered the resistance stemmed from a poorly managed past software transition that left the scientists stuck with unresolved workarounds for years. The team was then able to proactively establish supports for the team to make this transition smoother for them.
****3. Governance vs. Operationalization****
Governance frameworks (policies, compliance charters, and audit readiness) act as essential enterprise guardrails. However, these blueprints would remain hollow without the human element for operationalization: building user habits, setting up governance council, and using adaptive tools (like Jira and Confluence) to make adoption seamless.
Harsha outlined this as an intersection of people and policies, noting that terms like COMPLIANCE shouldn’t frighten users; He also emphasized, “Policies should be guardrails that guide people. They should not impede your progress.”
****4. The Transformation Toolkit****
To successfully pull high-stakes digital initiatives out of ‘pilot purgatory’ and scale them globally, organizations need agile, tactical frameworks. Shari highlighted models like vision and value workshops (what the transition is fundamentally intended to accomplish and how does the organization define concrete metrics of success beyond technical deployment), dynamic stakeholder mapping (knowing how to reach all segments of the audience through balancing user buy-in against enterprise influence), and the CDV (Communicate, Demonstrate, Validate) framework to support leaders in knowing how to best drive change.
**Tech Alone Cannot Drive Transformation**
Ultimately, the virtual panel discussion hammered home one vital truth. Technology alone cannot drive transformation. True success requires a structured, empathetic, and people-first approach that brings the entire community along for the journey. Bringing along the community during the transition will lead to better adoption, in turn driving overall success.
To watch the full discussion, please visit:
**About Zifo**
Zifo is the leading global enabler of AI and data driven enterprise informatics for science driven organizations. With extensive solutions and services expertise spanning research, development, manufacturing, and clinical domains, we serve a diverse range of industries, including Pharma, Biotech, Chemicals, Food and Beverage, Oil & Gas, and FMCG. Trusted by over 190 science-focused organizations worldwide, Zifo is the partner of choice for advancing digital scientific innovation. and
## Recent News
### [Zifo Co-Launches REAL 2026 to Spotlight the Next Generation of Connected, AI-Enabled Lab Environments](https://zifo.com/news/zifo-co-launches-real-2026-to-spotlight-the-next-generation-of-connected-ai-enabled-lab-environments/)
[  ](https://zifo.com/news/zifo-co-launches-real-2026-to-spotlight-the-next-generation-of-connected-ai-enabled-lab-environments/)
### [CMC Bottleneck is Choking Biopharma’s Drug Pipeline, says Zifo](https://zifo.com/news/cmc-bottleneck-is-choking-biopharmas-drug-pipeline-says-zifo/)
[  ](https://zifo.com/news/cmc-bottleneck-is-choking-biopharmas-drug-pipeline-says-zifo/)
### [Zifo Accelerates LIMS Master Data Validation with New AI-Enabled Services Accelerator](https://zifo.com/news/zifo-accelerates-lims-master-data-validation-with-new-ai-enabled-services-accelerator/)
[  ](https://zifo.com/news/zifo-accelerates-lims-master-data-validation-with-new-ai-enabled-services-accelerator/)
---
### [Zifo's AI Blueprints for Clinical Research Honored in CDISC Challenge](https://zifo.com/news/zifos-ai-blueprints-for-clinical-research-honored-in-cdisc-challenge/)
**Published:** September 25, 2025
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [News](https://zifo.com/news/ "News")> Zifo’s AI Blueprints for Clinical Research Honored in CDISC Challenge
## Zifo’s AI Blueprints for Clinical Research Honored in CDISC Challenge
Sep 25, 2025
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Zifo%27s%20AI%20Blueprints%20for%20Clinical%20Research%20Honored%20in%20CDISC%20Challenge%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fnews%2Fzifos-ai-blueprints-for-clinical-research-honored-in-cdisc-challenge%2F "Share on Email")
- [](https://x.com/intent/post?text=Zifo%27s%20AI%20Blueprints%20for%20Clinical%20Research%20Honored%20in%20CDISC%20Challenge&url=https%3A%2F%2Fzifo.com%2Fnews%2Fzifos-ai-blueprints-for-clinical-research-honored-in-cdisc-challenge%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Zifo%5C%26%23039%3Bs+AI+Blueprints+for+Clinical+Research+Honored+in+CDISC+Challenge&url=https%3A%2F%2Fzifo.com%2Fnews%2Fzifos-ai-blueprints-for-clinical-research-honored-in-cdisc-challenge%2F "Share on LinkedIn")
**Cambridge, MA, USA, Cambridge England, and Chennai India, Sept 25, 2025** — Zifo, a leading global enabler of AI and data-driven enterprise informatics for science-driven organizations, has been named runner-up in the prestigious CDISC 2025 AI Innovation Challenge for its approach in two key clinical research areas: creating a unified data model for study design and developing a comprehensive system for tracking the lineage of clinical data.
The recognition by Clinical Data Interchange Standards Consortium (CDISC) **highlights Zifo’s commitment to leverage its Scientific expertise and AI to contribute to better outcomes and ROI across the entire biopharma value chain** — from R&D to clinical to manufacturing.
The AI Innovation Challenge, hosted by CDISC — the global body that creates standards to make clinical research data easier to collect, share, and understand — **recognizes innovative solutions that leverage AI and CDISC standards to address key pain points in the clinical research landscape.**
**Zifo’s AI blueprints streamline the complex process of clinical study design and ensure end-to-end data integrity and transparency**, which are essential for accelerating drug development and securing regulatory approval.
“We are honored to be recognized by CDISC for our contributions to the AI Innovation Challenge,” said Deepak Ananthan, Head of Clinical Services and AI Scaling at Zifo. “This **achievement is a testament to our team’s scientific expertise combined with AI know-how that addresses the real-world challenges faced by the clinical research community**. We are proud to be at the forefront of leveraging AI and CDISC standards to streamline processes and accelerate the development of life-saving therapies.”
**CDISC Judges Commend Zifo’s Innovative Solutions**
In Use Case 1 **(USDM)**, Zifo was lauded for its well-designed, USDM-driven application that seamlessly integrates CDISC standards and Biomedical Concepts. Judges commended the solution’s intuitive workflows and advanced features, including validation and traceability, noting its strong potential to drive significant value and impact in the industry.
For Use Case 3 **(Semantic Traceability)**, Zifo’s solution was praised as a comprehensive and AI-driven approach to traceability. The innovative platform unifies a diverse range of elements — from protocols and CRFs to SDTM, ADaM, TLFs, Biomedical Concepts, and USDM — into an interactive lineage explorer. The judges highlighted the solution’s ambitious scope and innovative use of standards, positioning it as a breakthrough for advancing digital transformation in clinical research.
“In addition to being recognized as a runner-up, we want to especially thank your team for submitting solutions across **all three use cases**. Your dedication and breadth of effort truly stood out and demonstrated remarkable commitment to the Challenge. Your team did an amazing job, and it is commendable that you were selected as the runner-up in both use cases 1 and 3,” a CDISC spokesperson informed Zifo via email announcing the award.
Zifo has been invited to present its AI solution — Use Case 1 and Use Case 3 — at the CDISC U.S. Interchange in Nashville on Monday, October 13, providing the company an opportunity to showcase its work to the broader community.
*(In this video, explore how the platform connects every CDISC standard layer — from TLFs → ADaM → SDTM → CRF → Protocol — enriched with Biomedical Concepts (BCs) and metadata intelligence. The result: complete transparency, compliance, and confidence in your clinical data lineage).*
*(In this video, explore how Zifo’s AI-based solution transforms clinical study protocols into structured, compliant USDM outputs with full traceability and automation. From intuitive dashboards to deep study insights, see how every step is streamlined for accuracy, compliance, and speed).*
**About Zifo**
Zifo is the leading global enabler of AI and data-driven enterprise informatics for science-driven organizations. With extensive solutions and services expertise spanning research, development, manufacturing, and clinical domains, we serve various industries, including pharma, biotech, chemicals, food and beverage, oil and gas, and FMCG. Trusted by over 190 science-focused organizations worldwide, Zifo is the partner of choice for advancing digital scientific innovation. For more information, visit
**About CDISC**
CDISC is a 501(c)(3) global non-profit charitable organization that streamlines research and enables connections to healthcare through the development of clinical research data standards. CDISC has developed a suite of standards to support clinical research from protocol through analysis and reporting. CDISC standards make it possible for data to speak the same language, empowering simple data collection and private sharing that makes the most of the valuable information offered by patients participating in research studies around the globe.
## Recent News
### [Zifo Co-Launches REAL 2026 to Spotlight the Next Generation of Connected, AI-Enabled Lab Environments](https://zifo.com/news/zifo-co-launches-real-2026-to-spotlight-the-next-generation-of-connected-ai-enabled-lab-environments/)
[  ](https://zifo.com/news/zifo-co-launches-real-2026-to-spotlight-the-next-generation-of-connected-ai-enabled-lab-environments/)
### [CMC Bottleneck is Choking Biopharma’s Drug Pipeline, says Zifo](https://zifo.com/news/cmc-bottleneck-is-choking-biopharmas-drug-pipeline-says-zifo/)
[  ](https://zifo.com/news/cmc-bottleneck-is-choking-biopharmas-drug-pipeline-says-zifo/)
### [Zifo Accelerates LIMS Master Data Validation with New AI-Enabled Services Accelerator](https://zifo.com/news/zifo-accelerates-lims-master-data-validation-with-new-ai-enabled-services-accelerator/)
[  ](https://zifo.com/news/zifo-accelerates-lims-master-data-validation-with-new-ai-enabled-services-accelerator/)
---
### [Zifo to Present Biobank Data Breakthrough at the Festival of Genomics Boston](https://zifo.com/news/zifo-to-present-biobank-data-breakthrough-at-the-festival-of-genomics-boston/)
**Published:** June 4, 2026
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [News](https://zifo.com/news/ "News")> Zifo to Present Biobank Data Breakthrough at the Festival of Genomics Boston
## Zifo to Present Biobank Data Breakthrough at the Festival of Genomics Boston
Jun 03, 2026
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Zifo%20to%20Present%20Biobank%20Data%20Breakthrough%20at%20the%20Festival%20of%20Genomics%20Boston%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fnews%2Fzifo-to-present-biobank-data-breakthrough-at-the-festival-of-genomics-boston%2F "Share on Email")
- [](https://x.com/intent/post?text=Zifo%20to%20Present%20Biobank%20Data%20Breakthrough%20at%20the%20Festival%20of%20Genomics%20Boston&url=https%3A%2F%2Fzifo.com%2Fnews%2Fzifo-to-present-biobank-data-breakthrough-at-the-festival-of-genomics-boston%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Zifo+to+Present+Biobank+Data+Breakthrough+at+the+Festival+of+Genomics+Boston&url=https%3A%2F%2Fzifo.com%2Fnews%2Fzifo-to-present-biobank-data-breakthrough-at-the-festival-of-genomics-boston%2F "Share on LinkedIn")
*Zifo Presentation****:*** *Unveiling an enterprise platform that harmonizes 100 billion+ genetic association results across 30,000+ analyses.*
BOSTON, Mass., June 3, 2026 /PRNewswire/ — As biopharma companies grapple with a massive influx of fragmented multiomics data, Zifo is stepping onto the stage at the Festival of Genomics & Biodata in Boston to demonstrate how advanced scientific data engineering can unlock the pathway toward precision medicine.
Serving as an official Agenda Partner, Zifo arrives in Boston prepared to tackle the industry’s most pressing data bottlenecks, headlined by a presentation that reveals **how to transform hundreds of billions of raw genetic association results into immediate, actionable evidence.**
The core challenge facing translational genomics today isn’t a lack of data, but the fragmentation of it. Summary statistics from global biobanks are often siloed, agonizingly slow to query, and locked behind technical barriers that prevent non-computational scientists from leveraging them. Throughout the event, Zifo’s experts will be on the ground to show organizations how to bridge this gap by applying FAIR data principles and robust data architectures that democratize access to critical scientific insights.
Early this year, Zifo, the leading global enabler of AI and data-driven enterprise informatics for science driven organizations and Maze Therapeutics Inc announced that they have partnered to solve the critical challenge of managing, storing, and scaling massive, disparate biobank data to help in their quest for precision medicine via AI-powered scientific workflows.
**Unveiling a 10x Leap in Genomics Architecture**
The centerpiece of Zifo’s agenda partnership is a highly anticipated presentation on the Biopharma Data Management Stage, scheduled for **Wednesday, June 3, 2026, from 16:40 to 17:10 EDT.**
The session, titled *“Turning Biobank-Scale Genetic Associations into Actionable Evidence for Drug Discovery,”* will be delivered by **Sandor Szalma, Scientific Advisor and a Data Veteran in the Omics space at Zifo**. Sandor will pull back the curtain on an enterprise-grade platform that successfully harmonizes and serves over 100 billion genetic association results across more than 30,000 analyses.
The presentation will detail how this cutting-edge system achieves unprecedented performance:
- **Hours to Seconds:** How a scalable lakehouse architecture built on Apache Iceberg compresses complex genomic data query times from hours down to mere seconds.
- **Unprecedented Scale:** Expanding supported scale by over 10x relative to comparable systems.
- **AI-Ready Provenance:** The integration of strict auditability, role-based access, and FAIR-aligned data pathways designed to feed directly into downstream AI/ML models.
**Connect with Zifo at Stand 44**
“Advanced therapeutics require a data foundation that moves at the speed of scientific curiosity,” said Zifo’s **Sandor Szalma.** “We look forward to connecting with pioneers in Boston to discuss how combining deep scientific domain knowledge with modern data lakehouse architecture can remove the friction from R&D and accelerate the translation of genetic insights into clinical breakthroughs.”
For more information regarding the presentation or to view the full event schedule, visit the official event page:
**About Zifo**
Zifo is the leading global enabler of AI and data-driven enterprise informatics for science-driven organizations. With extensive solutions and services expertise spanning research, development, manufacturing, and clinical domains, Zifo serves a diverse range of industries—including Pharma, Biotech, Chemicals, Food and Beverage, Oil & Gas, and FMCG. Trusted by over 190 organizations worldwide, Zifo is the partner of choice for advancing digital scientific innovation. [https://zifo.com/; ](https://zifo.com/)
## Recent News
### [Zifo Co-Launches REAL 2026 to Spotlight the Next Generation of Connected, AI-Enabled Lab Environments](https://zifo.com/news/zifo-co-launches-real-2026-to-spotlight-the-next-generation-of-connected-ai-enabled-lab-environments/)
[  ](https://zifo.com/news/zifo-co-launches-real-2026-to-spotlight-the-next-generation-of-connected-ai-enabled-lab-environments/)
### [CMC Bottleneck is Choking Biopharma’s Drug Pipeline, says Zifo](https://zifo.com/news/cmc-bottleneck-is-choking-biopharmas-drug-pipeline-says-zifo/)
[  ](https://zifo.com/news/cmc-bottleneck-is-choking-biopharmas-drug-pipeline-says-zifo/)
### [Zifo Accelerates LIMS Master Data Validation with New AI-Enabled Services Accelerator](https://zifo.com/news/zifo-accelerates-lims-master-data-validation-with-new-ai-enabled-services-accelerator/)
[  ](https://zifo.com/news/zifo-accelerates-lims-master-data-validation-with-new-ai-enabled-services-accelerator/)
---
### [Zifo Highlights New Everest Group Report Showcasing Critical Need For Science-First IT Delivery](https://zifo.com/news/zifo-highlights-new-everest-group-report-showcasing-critical-need-for-science-first-it-delivery/)
**Published:** March 19, 2026
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [News](https://zifo.com/news/ "News")> Zifo Highlights New Everest Group Report Showcasing Critical Need For Science-First IT Delivery
## Zifo Highlights New Everest Group Report Showcasing Critical Need For Science-First IT Delivery
Mar 19, 2026
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Zifo%20Highlights%20New%20Everest%20Group%20Report%20Showcasing%20Critical%20Need%20For%20Science-First%20IT%20Delivery%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fnews%2Fzifo-highlights-new-everest-group-report-showcasing-critical-need-for-science-first-it-delivery%2F "Share on Email")
- [](https://x.com/intent/post?text=Zifo%20Highlights%20New%20Everest%20Group%20Report%20Showcasing%20Critical%20Need%20For%20Science-First%20IT%20Delivery&url=https%3A%2F%2Fzifo.com%2Fnews%2Fzifo-highlights-new-everest-group-report-showcasing-critical-need-for-science-first-it-delivery%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Zifo+Highlights+New+Everest+Group+Report+Showcasing+Critical+Need+For+Science-First+IT+Delivery&url=https%3A%2F%2Fzifo.com%2Fnews%2Fzifo-highlights-new-everest-group-report-showcasing-critical-need-for-science-first-it-delivery%2F "Share on LinkedIn")
**CAMBRIDGE, Mass. and CAMBRIDGE, England, March 19, 2026 –** Zifo, the global leader in AI and data-driven informatics for science-driven organizations, highlights the release of a new Everest Group research report: “Embedding Scientific Expertise at the Core of Life Sciences IT Service Delivery”. The report’s central finding is straightforward: digital transformation in the Biopharma and other science-focused industries only works if scientific accuracy is baked into the AI and tech process from day one.
For years now, biopharma and other science-driven industries have faced a subtle disconnect: scientific breakthroughs are happening faster than ever, but the informatics supporting them haven’t kept pace. The way organizations build, deploy, and manage scientific informatics systems lags scientific breakthroughs, with legacy data handling and processes remaining mostly unchanged.
The current AI boom makes this problem more obvious. Generic technology platforms promise speed and efficiency, but they usually stumble when faced with the highly complex workflows that scientists rely on. Simply put, Zifo believes that if an organization’s process, data and technology doesn’t understand the basic language of biology, chemistry, or physics, it won’t deliver useful results.
Everest Group’s research backs this up. The report shows that even the most advanced AI models and data architectures will fail if they aren’t deeply tied to scientific reality. It’s no longer enough for IT partners to just know tech — they have to understand the science, too. Integrating scientific expertise into process, data, and organizational changes is what actually drives business value.
Treating Science IT like generic corporate IT creates massive enterprise risks. When systems are built on standard business logic rather than specific scientific context, companies run into several major roadblocks:
- **Compliance exposure:** Blackbox nature of AI models can lead to compliance breaches and long-term reputational consequences with regulators.
- **Outcome risks:** Inconsistent decisions in clinical trials and unpredictable manufacturing quality.
- **Loss of trust:** Scientists, clinicians, and regulators losing faith in the digital platforms.
- **Reputational damage:** The fallout from publishing flawed or unsubstantiated results.
- **Wasted investments:** Low user adoption rates and expensive AI pilots that fail to scale.
- **Scaling failures:** Lack of scientific domain depth in AI pilots can lead to organizations facing an accumulation of stalled PoCs and poor ROI.
While you don’t necessarily need deep scientific context for every single back-office IT operation, it becomes critical in areas with high complexity and strict regulations. According to the report, companies saw the most value from embedding scientific expertise in drug discovery and research (77%), clinical development (73%), and manufacturing operations (37%). Because of this clear ROI, nearly 8 in 10 pharma leaders say scientific expertise will be a major deciding factor with 4 in 10 already viewing it as a key future differentiator.
To help companies make this transition, the report outlines a practical, four-step blueprint for scaling a science-first digital strategy:
1. **Assess:** Look at your current operations to see how deeply science is currently integrated and figure out your starting point.
2. **Embed:** Set up the right data and governance foundations to support science-driven IT execution.
3. **Scale:** Build hybrid delivery teams that seamlessly combine strong tech skills with actual scientific backgrounds.
4. **Institutionalize:** Make this science-first approach the standard way of operating across the entire company.
**To read the Everest Group report, please click here:** [https://zifo.com/scientific-it-service-delivery-everest-whitepaper/]()
**About Zifo**
Zifo is the leading global enabler of AI and data driven enterprise informatics for science driven organizations. With extensive solutions and services expertise spanning research, development, manufacturing, and clinical domains, we serve a diverse range of industries, including Pharma, Biotech, Chemicals, Food and Beverage, Oil & Gas, and FMCG. Trusted by over 190 science-focused organizations worldwide, Zifo is the partner of choice for advancing digital scientific innovation. ;
## Recent News
### [Zifo Co-Launches REAL 2026 to Spotlight the Next Generation of Connected, AI-Enabled Lab Environments](https://zifo.com/news/zifo-co-launches-real-2026-to-spotlight-the-next-generation-of-connected-ai-enabled-lab-environments/)
[  ](https://zifo.com/news/zifo-co-launches-real-2026-to-spotlight-the-next-generation-of-connected-ai-enabled-lab-environments/)
### [CMC Bottleneck is Choking Biopharma’s Drug Pipeline, says Zifo](https://zifo.com/news/cmc-bottleneck-is-choking-biopharmas-drug-pipeline-says-zifo/)
[  ](https://zifo.com/news/cmc-bottleneck-is-choking-biopharmas-drug-pipeline-says-zifo/)
### [Zifo Accelerates LIMS Master Data Validation with New AI-Enabled Services Accelerator](https://zifo.com/news/zifo-accelerates-lims-master-data-validation-with-new-ai-enabled-services-accelerator/)
[  ](https://zifo.com/news/zifo-accelerates-lims-master-data-validation-with-new-ai-enabled-services-accelerator/)
---
### [Biopharma Companies Encounter AI's Weak Spot: Scientific Context, Says Zifo](https://zifo.com/news/biopharma-companies-encounter-ais-weak-spot-scientific-context-says-zifo/)
**Published:** April 21, 2026
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [News](https://zifo.com/news/ "News")> Biopharma Companies Encounter AI’s Weak Spot: Scientific Context, Says Zifo
## Biopharma Companies Encounter AI’s Weak Spot: Scientific Context, Says Zifo
Apr 21, 2026
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Biopharma%20Companies%20Encounter%20AI%27s%20Weak%20Spot%3A%20Scientific%20Context%2C%20Says%20Zifo%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fnews%2Fbiopharma-companies-encounter-ais-weak-spot-scientific-context-says-zifo%2F "Share on Email")
- [](https://x.com/intent/post?text=Biopharma%20Companies%20Encounter%20AI%27s%20Weak%20Spot%3A%20Scientific%20Context%2C%20Says%20Zifo&url=https%3A%2F%2Fzifo.com%2Fnews%2Fbiopharma-companies-encounter-ais-weak-spot-scientific-context-says-zifo%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Biopharma+Companies+Encounter+AI%5C%26%23039%3Bs+Weak+Spot%3A+Scientific+Context%2C+Says+Zifo&url=https%3A%2F%2Fzifo.com%2Fnews%2Fbiopharma-companies-encounter-ais-weak-spot-scientific-context-says-zifo%2F "Share on LinkedIn")
CAMBRIDGE, Mass. and CAMBRIDGE, England, April 21, 2026 /PRNewswire/ — As AI accelerates across biopharma and other science-driven industries, organizations are encountering a critical bottleneck: advanced technologies fall short without proper scientific context. In a newly published insight piece titled ‘[Biopharma Companies Discover AI’s Weak Spot: Scientific Context](/blogs/biopharma-companies-discover-ais-weak-spot-scientific-context/),’ **Zifo Data Stewardship Practice Lead, Marilyne Labasque, PhD**, reveals why even the most sophisticated machine learning and agentic systems cannot deliver value when relying on fragmented, poorly described data.
Biopharma organizations and other science-driven industries are at a pivotal moment. Investments in AI are accelerating across discovery, development, and manufacturing, and expectations are rising just as quickly. However, the data that should power these ambitions is often fragmented, inconsistently managed, and missing the context needed for meaningful and responsible use. AI, whether powered by agentic systems or machine learning models, does not fall short because of the technology itself. It falls short when the basics are missing. Without the minimum stewardship and contextualization that automation and reproducibility depend on, AI cannot deliver. The hard truth remains, no matter how advanced the technology becomes, it will not create value if knowledge and data are not shared.
In an AI‑native landscape, not all information can or should be fully structured. What matters is that it is discoverable, well described, and handled in ways that preserve scientific context and ethical use. The cost of falling short shows up every day as rework, repeated experiments, stalled data initiatives and digital programs, alongside increasing scrutiny around traceability, integrity, and reproducibility.
In this context, stewardship gains renewed significance. As AI increases the scale, speed, and reach of data use, the cost of ambiguity, inconsistency, and lost context rises sharply. Decisions that were once recoverable through expert memory or manual review become opaque when automated systems operate on poorly described data. Stewardship provides the discipline needed to preserve scientific intent as data moves across experiments, systems, and analytical uses. By embedding clarity, traceability, and accountability into everyday data practices, stewardship enables organizations to scale analytics and AI with confidence rather than compounding risk.
**Why Stewardship Matters Now**
Scientific data today forms an intricate ecosystem: multimodal assay outputs, instrument files, electronic lab notebook (ELN) records, laboratory information management system (LIMS) entries, in vivo study data, and chemistry, manufacturing and controls (CMC) packages. Each domain evolves at its own pace. Without stewardship, coherence depends on what individuals remember, where an experiment ran, how an instrument was configured, which field captured the real scientific meaning. Even large platform investments struggle when local conventions and inconsistent practices shape how data is captured, interpreted, and shared.
Expectations across the industry now go far beyond correctness. Teams need auditable lineage, validated processing, robust description, reproducible results, and analytics they can explain with confidence. Stewardship turns these expectations into daily practice. It clarifies meaning, harmonizes descriptions, curates context, strengthens traceability, and makes reuse the rule rather than the exception. Applied systematically, stewardship shortens the time scientists spend searching for information or reconstructing decisions, slows data decay, prevents drift between silos, and lays the foundation for AI that can be trusted.
**Stewardship as an Operational Capability**
Much of the literature describes what stewardship should be. Fewer address what stewardship looks like in practice, within the constraints of real scientific environments. Effective stewardship requires working across roles – scientists, data owners, architects, and engineers – so that decisions reflect how experiments are designed, how instruments are used, and how results are consumed. The outcome is practical change that improves how data is captured, described, and reused, without adding friction to scientific work.
Stewardship efforts are most effective when informed by scientific depth and operational consistency. Across data domains such as biospecimen, assay, omics, biologics, CMC, and clinical data, stewardship decisions must reflect real experimental practice rather than theoretical assumptions. Leaders also need a clear view of where they stand and what to address first. Structured diagnostic approaches and capability assessments can provide visibility into current stewardship maturity and help prioritize the most impactful improvements.
Stewardship operating models vary by organization and context. Some functions are embedded within scientific teams, others operate as shared responsibility models, and some are centralized. Regardless of structure, successful efforts follow a consistent pattern: diagnosis of current practices, deliberate design of standards and workflows, development of enabling processes, and sustained delivery and improvement. When approached this way, stewardship holds up in real laboratories and scientific programs.
**The Layered Model for AI‑Ready Scientific Data**
Becoming AI‑ready requires more than cleaner data. It requires a layered foundation that connects scientific defensibility with machine‑actionable design and responsible use. At the base is trusted data: information that is accurate, attributable, traceable, and handled with the discipline expected in scientific settings. This ensures every data point has a clear origin and every transformation can be explained.
Above that are FAIR‑driven enhancements: semantic alignment, richer description, standardized terminologies, interoperable formats, and normalization practices. These ensure data is understandable to people and usable by automation and machine‑learning pipelines. Without this layer, even high‑quality data remains largely invisible to AI.
Finally, the human layer ensures accountability over time. Data stewards and data owners monitor drift, guide lifecycle management, and safeguard ethical use as new assays, instruments, and workflows emerge.
When these layers work together, organizations create datasets that are not only usable but also suitable for analytics and AI that must be explainable and defensible.
**FAIR, Data Quality, and Stewardship: A Unified Perspective**
A persistent misconception is that FAIR and data quality measure the same thing. They do not. FAIR – standing for Findable, Accessible, Interoperable, and Reusable – describes how well data and its description support discovery and reuse, especially by machines (1). Data quality focuses on characteristics such as accuracy, completeness, consistency, and timeliness. A dataset may excel at quality yet fail FAIR if its description is sparse or identifiers are not machine‑actionable. The reverse can also be true.
Both dimensions are essential for AI readiness, and stewardship is the discipline that brings them together. With trained evaluators, structured scoring rubrics, and aligned maturity models, FAIR and quality assessments can reinforce one another rather than duplicate effort. This integration makes FAIR durable, preventing the drift that occurs when assessments are infrequent, inconsistent, or detached from daily practice.
**Real‑World Impact: A Practical Example**
A large pharmaceutical organization sought to resolve longstanding issues in its CMC equipment reference and master data. Thousands of equipment records had accumulated across sites, each with different naming conventions and inconsistent descriptions. Scientists struggled to select the appropriate record, integrations frequently broke, and teams could not rely on a single, authoritative view of the equipment used in critical CMC processes.
Working across CMC, IT, and digital teams, legacy records were standardized and harmonized, and a dynamic data collection template was introduced to ensure new entries were captured consistently at creation. This effort reconciled thousands of records, established clear naming and de‑duplication rules, and introduced preventive checks so issues were identified at source rather than downstream.
Within months, the organization gained a unified equipment data model across multiple CMC data environments, with improved FAIR characteristics and reliable interoperability. Scientists and engineers could find and reuse equipment information in hours rather than days, integration issues decreased, and longstanding traceability gaps were closed. The result was not only cleaner and more reliable data, but a sustainable way of working that supported future analytics and model‑driven CMC initiatives.
**Assessing Stewardship Capability**
Structured stewardship assessments offer a way to understand how scientific data is managed in practice. Adapted from existing stewardship maturity approaches and aligned with FAIR and established quality principles, these assessments evaluate both individual datasets and the conditions surrounding their management (2).
Key components – preservability, accessibility, usability, preventive quality practices, lifecycle monitoring, transparency, integrity, and sustainability – create an evidence‑based view of current capability and the most impactful next steps (2, 3). Clear maturity levels provide a progression path, and alignment with FAIR maturity indicators ensures that improvements support both human understanding and machine‑actionable reuse (4).
**Evidence That Matters to Executives**
Stewardship must demonstrate tangible impact. Indicators such as reduced time‑to‑find, increased reuse, faster remediation turnaround, shorter analytics cycles, and stronger audit outcomes translate stewardship from concept to performance. These measures connect stewardship to outcomes executives care about: productivity, risk reduction, and return on scientific and digital investments.
Organizations that begin in one domain, demonstrate value, and then expand to adjacent areas often experience faster returns and more durable improvement, as teams build confidence and adopt new ways of working. Over time, the foundation strengthens and AI initiatives progress beyond isolated pilots.
**The Leadership Mandate**
AI‑ready data cannot be bolted onto the end of a project. It must be designed, curated, managed, and monitored from the outset. Leaders who expect AI to play a strategic role must treat stewardship as a core enabler: establish repeatable assessment practices, ensure stewards and related roles receive formal training, embed stewardship into the broader scientific data foundation, and make value visible through shared metrics.
Stewardship is not optional for organizations that aim for scientific excellence. It is the operational backbone that turns data into a durable, strategic asset, supporting innovation, compliance confidence, and AI at scale.
**References**
- Wilkinson MD et al., The FAIR Guiding Principles for scientific data management and stewardship. Sci Data. 2016 Mar 15;3:160018. doi: 10.1038/sdata.2016.18. Erratum in: Sci Data. 2019 Mar 19;6(1):6. DOI: 10.1038/s41597-019-0009-6
- Peng G et al., Crosswalks among stewardship maturity assessment approaches promoting trustworthy FAIR data and repositories. Sci Data. 2022 Sep 21;9(1):576. DOI: 10.1038/s41597-022-01683-x
- Peng G et al., Practical Application of a Data Stewardship Maturity Matrix for the NOAA OneStop Project, 2019, Data Science Journal, DOI: 10.5334/dsj-2019-041
- [FAIR Maturity Matrix | An organisational maturity model of FAIR implementation](https://pistoiaalliance.github.io/FAIRMaturityMatrix/)
**About Zifo:**
Zifo is the leading global enabler of AI and data driven enterprise informatics for science driven organizations. With extensive solutions and services expertise spanning research, development, manufacturing, and clinical domains, we serve a diverse range of industries, including Pharma, Biotech, Chemicals, Food and Beverage, Oil & Gas, and FMCG. Trusted by over 190 science-focused organizations worldwide, Zifo is the partner of choice for advancing digital scientific innovation.
; [https://zifo.com/practical-ai-blueprints/](/practical-ai-blueprints/)
## Recent News
### [Zifo Co-Launches REAL 2026 to Spotlight the Next Generation of Connected, AI-Enabled Lab Environments](https://zifo.com/news/zifo-co-launches-real-2026-to-spotlight-the-next-generation-of-connected-ai-enabled-lab-environments/)
[  ](https://zifo.com/news/zifo-co-launches-real-2026-to-spotlight-the-next-generation-of-connected-ai-enabled-lab-environments/)
### [CMC Bottleneck is Choking Biopharma’s Drug Pipeline, says Zifo](https://zifo.com/news/cmc-bottleneck-is-choking-biopharmas-drug-pipeline-says-zifo/)
[  ](https://zifo.com/news/cmc-bottleneck-is-choking-biopharmas-drug-pipeline-says-zifo/)
### [Zifo Accelerates LIMS Master Data Validation with New AI-Enabled Services Accelerator](https://zifo.com/news/zifo-accelerates-lims-master-data-validation-with-new-ai-enabled-services-accelerator/)
[  ](https://zifo.com/news/zifo-accelerates-lims-master-data-validation-with-new-ai-enabled-services-accelerator/)
---
### [Zifo Accelerates Scientific Batch Release Cycles with AI-Powered Certificate of Analysis Solution](https://zifo.com/news/zifo-accelerates-scientific-batch-release-cycles-with-ai-powered-certificate-of-analysis-solution/)
**Published:** April 28, 2026
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [News](https://zifo.com/news/ "News")> Zifo Accelerates Scientific Batch Release Cycles with AI-Powered Certificate of Analysis Solution
## Zifo Accelerates Scientific Batch Release Cycles with AI-Powered Certificate of Analysis Solution
Apr 28, 2026
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Zifo%20Accelerates%20Scientific%20Batch%20Release%20Cycles%20with%20AI-Powered%20Certificate%20of%20Analysis%20Solution%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fnews%2Fzifo-accelerates-scientific-batch-release-cycles-with-ai-powered-certificate-of-analysis-solution%2F "Share on Email")
- [](https://x.com/intent/post?text=Zifo%20Accelerates%20Scientific%20Batch%20Release%20Cycles%20with%20AI-Powered%20Certificate%20of%20Analysis%20Solution&url=https%3A%2F%2Fzifo.com%2Fnews%2Fzifo-accelerates-scientific-batch-release-cycles-with-ai-powered-certificate-of-analysis-solution%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Zifo+Accelerates+Scientific+Batch+Release+Cycles+with+AI-Powered+Certificate+of+Analysis+Solution&url=https%3A%2F%2Fzifo.com%2Fnews%2Fzifo-accelerates-scientific-batch-release-cycles-with-ai-powered-certificate-of-analysis-solution%2F "Share on LinkedIn")
*Advanced hybrid AI approach combines OCR and Large Language Models to transform manual document processing into real-time digital insights.*
CAMBRIDGE, Mass. and CAMBRIDGE, England, April 28, 2026 /PRNewswire/ — Zifo, a premier global provider of AI and data-driven informatics for science-focused organizations, today announced the launch of its AI-powered Certificate of Analysis (CoA) Automation solution. This service accelerator is designed to eliminate the bottlenecks associated with manual data extraction, allowing quality and manufacturing teams to rapidly move from raw data to critical decisions.
**Overcoming the Bottlenecks of Manual CoA Processing**
Traditional Certificate of Analysis processing has long been a slow and error-prone hurdle for science-driven industries. As document volumes grow, manual transcription becomes difficult to scale, leading to high-risk tasks that can delay product releases. Zifo’s automated solution addresses these challenges by leveraging Optical Character Recognition (OCR) and Large Language Models (LLMs) to extract data quickly and accurately. This shift not only reduces operational costs but also provides real-time insights that empower teams to dedicate their expertise to higher-value scientific work.
**Addressing the High-Friction Reality of Batch Release**
Batch release is a complex, multi-stage process involving production logs, environmental monitoring, and final testing. However, the documentation phase is where momentum often stalls. Zifo focuses on the CoA because it represents a high-friction touchpoint where digital data often reverts to ‘analog’ (PDFs/Paper) before going back into a digital system (LIMS). This transcription lag creates a significant administrative hurdle that can delay the release of critical products.
While AI can mean all or nothing, Zifo’s approach targets these specific gaps in the Manufacturing and CMC segments, ensuring that critical data doesn’t get stuck in transcription limbo. The goal is to keep the entire release cycle moving. This CoA solution is just one example of how Zifo uses its [‘Practical AI’](/practical-ai-blueprints/) framework to maintain digital continuity from the lab to the final product release.
**A Solution Designed for Complex Scientific Data**
The AI-powered CoA Solution directly addresses the primary pain points found in manufacturing and quality control environments:
- **Automated Data Extraction**: Significantly reduces human error and manual effort by using OCR to pull data directly from documents.
- **Standardization of Diverse Formats**: Employs LLMs to intelligently interpret and map various manufacturer formats into a single, unified data model.
- **Multilingual Capabilities**: Facilitates global operations by understanding and translating multiple languages for consistent mapping into Laboratory Information Management Systems (LIMS).
- **Faster Product Release**: Streamlines review processes and LIMS integration to accelerate batch disposition and product release cycles.
- **Seamless System Integration**: Features ready-to-use LIMS connectors with two-way synchronization to ensure data is updated the moment it becomes available.
**Unique Features include:**
- **Hybrid AI Extraction**: Combines structural parsing and LLM reasoning to achieve high accuracy across diverse layouts.
- **Language-Agnostic Processing**: Handles CoAs in any language without the need for manual translation or custom templates.
- **Visual Review Interface**: Provides a structured, spreadsheet-like view for human-in-the-loop validation, including automated specification-limit highlighting.
- **Enterprise-Scale Adaptability**: Natively supports multiple manufacturers and formats out of the box without per-vendor configurations.
**Strategic Value Across the Scientific Chain**
The solution is positioned to benefit the Manufacturing and Chemistry, Manufacturing, and Controls (CMC) segments of the value chain. By automating transcription and logging, it facilitates high-throughput operations and early detection of quality deviations. It further supports regulatory compliance with Good Manufacturing Practice (GMP) standards through secure and auditable data handling.
**Practical AI in Action**
This CoA automation represents Zifo’s commitment to delivering Practical AI — solutions that solve tangible, complex problems across the entire scientific value chain. By moving beyond theoretical applications, Zifo provides blueprints like this one to help organizations achieve digital transformation in their research, development, and manufacturing operations.
**About Zifo:**
Zifo is the leading global enabler of AI and data-driven enterprise informatics for science-driven organizations. With expertise spanning research, development, manufacturing, and clinical domains, Zifo serves a diverse range of industries including Pharma, Biotech, Chemicals, Food and Beverage, and more. Trusted by over 190 organizations worldwide, Zifo is the partner of choice for advancing digital scientific innovation. ; [https://zifo.com/practical-ai-blueprints/](/practical-ai-blueprints/)
## Recent News
### [Zifo Co-Launches REAL 2026 to Spotlight the Next Generation of Connected, AI-Enabled Lab Environments](https://zifo.com/news/zifo-co-launches-real-2026-to-spotlight-the-next-generation-of-connected-ai-enabled-lab-environments/)
[  ](https://zifo.com/news/zifo-co-launches-real-2026-to-spotlight-the-next-generation-of-connected-ai-enabled-lab-environments/)
### [CMC Bottleneck is Choking Biopharma’s Drug Pipeline, says Zifo](https://zifo.com/news/cmc-bottleneck-is-choking-biopharmas-drug-pipeline-says-zifo/)
[  ](https://zifo.com/news/cmc-bottleneck-is-choking-biopharmas-drug-pipeline-says-zifo/)
### [Zifo Accelerates LIMS Master Data Validation with New AI-Enabled Services Accelerator](https://zifo.com/news/zifo-accelerates-lims-master-data-validation-with-new-ai-enabled-services-accelerator/)
[  ](https://zifo.com/news/zifo-accelerates-lims-master-data-validation-with-new-ai-enabled-services-accelerator/)
---
### [Zifo Transforms Ontology Engineering with AI-Powered Intelligent Automation](https://zifo.com/news/zifo-transforms-ontology-engineering-with-ai-powered-intelligent-automation/)
**Published:** April 30, 2026
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [News](https://zifo.com/news/ "News")> Zifo Transforms Ontology Engineering with AI-Powered Intelligent Automation
## Zifo Transforms Ontology Engineering with AI-Powered Intelligent Automation
Apr 30, 2026
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Zifo%20Transforms%20Ontology%20Engineering%20with%20AI-Powered%20Intelligent%20Automation%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fnews%2Fzifo-transforms-ontology-engineering-with-ai-powered-intelligent-automation%2F "Share on Email")
- [](https://x.com/intent/post?text=Zifo%20Transforms%20Ontology%20Engineering%20with%20AI-Powered%20Intelligent%20Automation&url=https%3A%2F%2Fzifo.com%2Fnews%2Fzifo-transforms-ontology-engineering-with-ai-powered-intelligent-automation%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Zifo+Transforms+Ontology+Engineering+with+AI-Powered+Intelligent+Automation&url=https%3A%2F%2Fzifo.com%2Fnews%2Fzifo-transforms-ontology-engineering-with-ai-powered-intelligent-automation%2F "Share on LinkedIn")
*Advanced AI solution speeds up ontology creation by 80%, generating structured, interoperable knowledge models for science-driven organizations.*
CAMBRIDGE, Mass. and CAMBRIDGE, England, April 30, 2026 /PRNewswire/ — Zifo, the leading global enabler of AI and data-driven enterprise informatics for science-driven organizations, has developed an Intelligent Automation solution for Ontology Engineering, which is designed to seamlessly generate structured, interoperable knowledge models while accelerating ontology creation by 80%.
**Overcoming the Bottlenecks of Manual Ontology Creation**
Manual ontology creation in the biopharma industry has traditionally been a time-consuming process that requires specialized expertise. Organizations frequently struggle with semantic ambiguity, complex integration challenges, and limited scalability, resulting in workflows that can take weeks to complete. Zifo’s AI-powered automation tackles these challenges head-on by eliminating 80% of the manual work through automated class generation, description creation, and precise IRI mapping.
**Addressing the Complexities of Semantic Knowledge**
Developing comprehensive knowledge models often demands deep domain expertise to define relationships and align terminology. Zifo’s intelligent solution overcomes this by providing an AI-guided workflow featuring an intuitive interface, meaning specialized ontology engineering knowledge is no longer required. By leveraging LLM-powered generation, the solution creates precise definitions with a deep understanding of domain-specific context, while generating standardized synonyms and establishing controlled vocabulary alignment to eliminate inconsistent terminology.
**A Solution Designed for Scalable Scientific Data Modeling**
The AI-powered solution addresses critical format compatibility and integration points in ontology management:
- **Seamless Integration**: Automated mapping connects directly to established ontologies, including NCIT, CHEBI, OBI, and EFO, via BioPortal and OLS APIs.
- **Massive Scalability**: Parallel processing and batch operations empower teams to execute large-scale ontology projects without performance limitations.
- **Automated Hierarchies:** The AI autonomously generates semantic relationships and parent-child hierarchies based on domain context and predefined relation vocabularies.
- **Format Compatibility**: The solution produces direct OWL/RDF exports with proper URIs, ensuring seamless downstream integration.
**Unique Features include:**
- **Multi-Source Integration**: The solution combines BioPortal, OLS, and EMBL-EBI APIs to guarantee comprehensive ontology coverage.
- **Intelligent Ranking System**: The system uses AI-powered relevance scoring and justification for precise ontology mappings.
- **Precise IRI Mapping**: It ensures that each generated class is linked to the correct IRI, directly promoting semantic web compatibility.
- **Human-in-the-Loop Design:** The solution automates repetitive tasks while maintaining vital expert oversight.
- **End-to-End Workflow**: Users are guided through a complete pipeline, from initial domain knowledge input straight to exportable OWL files.
- **Visual Knowledge Graph**: An interactive graph visualization allows for intuitive relationship exploration and validation.
- **Multi-Format Exports**: Provides seamless export options in CSV, OWL, or HTML Ontograph formats for downstream use, collaboration, and visualization.
**Strategic Value Across the Scientific Chain**
This solution breaks down the traditional barriers of data structuring. Built on a robust backend of Python, LangChain, and leading LLM models, alongside a frontend framework using Next.js 15 and Cytoscape.js for graph visualization, the solution is highly adaptable. Furthermore, future optimization enhancements will include provisions for uploading user-defined classes or semi-ready ontologies.
**About Zifo:**
Zifo is the leading global enabler of AI and data-driven enterprise informatics for science-driven organizations. With expertise spanning research, development, manufacturing, and clinical domains, Zifo serves a diverse range of industries including Pharma, Biotech, Chemicals, Food and Beverage, and more. Trusted by over 190 organizations worldwide, Zifo is the partner of choice for advancing digital scientific innovation. For more information, visit ; [https://zifo.com/practical-ai-blueprints/](/practical-ai-blueprints/)
## Recent News
### [Zifo Co-Launches REAL 2026 to Spotlight the Next Generation of Connected, AI-Enabled Lab Environments](https://zifo.com/news/zifo-co-launches-real-2026-to-spotlight-the-next-generation-of-connected-ai-enabled-lab-environments/)
[  ](https://zifo.com/news/zifo-co-launches-real-2026-to-spotlight-the-next-generation-of-connected-ai-enabled-lab-environments/)
### [CMC Bottleneck is Choking Biopharma’s Drug Pipeline, says Zifo](https://zifo.com/news/cmc-bottleneck-is-choking-biopharmas-drug-pipeline-says-zifo/)
[  ](https://zifo.com/news/cmc-bottleneck-is-choking-biopharmas-drug-pipeline-says-zifo/)
### [Zifo Accelerates LIMS Master Data Validation with New AI-Enabled Services Accelerator](https://zifo.com/news/zifo-accelerates-lims-master-data-validation-with-new-ai-enabled-services-accelerator/)
[  ](https://zifo.com/news/zifo-accelerates-lims-master-data-validation-with-new-ai-enabled-services-accelerator/)
---
### [Zifo Streamlines Regulatory Submissions with AI-Powered Document Authoring Solution](https://zifo.com/news/zifo-streamlines-regulatory-submissions-with-ai-powered-document-authoring-solution/)
**Published:** May 8, 2026
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [News](https://zifo.com/news/ "News")> Zifo Streamlines Regulatory Submissions with AI-Powered Document Authoring Solution
## Zifo Streamlines Regulatory Submissions with AI-Powered Document Authoring Solution
May 08, 2026
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Zifo%20Streamlines%20Regulatory%20Submissions%20with%20AI-Powered%20Document%20Authoring%20Solution%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fnews%2Fzifo-streamlines-regulatory-submissions-with-ai-powered-document-authoring-solution%2F "Share on Email")
- [](https://x.com/intent/post?text=Zifo%20Streamlines%20Regulatory%20Submissions%20with%20AI-Powered%20Document%20Authoring%20Solution&url=https%3A%2F%2Fzifo.com%2Fnews%2Fzifo-streamlines-regulatory-submissions-with-ai-powered-document-authoring-solution%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Zifo+Streamlines+Regulatory+Submissions+with+AI-Powered+Document+Authoring+Solution&url=https%3A%2F%2Fzifo.com%2Fnews%2Fzifo-streamlines-regulatory-submissions-with-ai-powered-document-authoring-solution%2F "Share on LinkedIn")
CAMBRIDGE, Mass. and CAMBRIDGE, England, May 8, 2026 /PRNewswire/ — Zifo, a premier global provider of AI and data-driven enterprise informatics for science-driven organizations, has developed an AI-powered document authoring solution that streamlines regulatory submissions by cutting first-draft timelines from days to hours while ensuring complete 21 CFR Part 11 and EU ANNEX 11 compliance.
Infusing AI into the manual and time-consuming process of creating complex regulatory submissions — such as Clinical Study Reports (CSRs), Investigator Brochures, and CMC submissions — streamlines first-draft timelines significantly. Leveraging Large Language Models (LLMs) and AI-assisted templating, this solution automates drafting by extracting and summarizing both structured and unstructured data. The system generates consistent, human-like content while validating it against configurable checks to preserve traceability and writer oversight.
**Addressing Critical Industry Challenges**
Regulatory writing teams often face significant bottlenecks that this solution is designed to resolve:
- **Time Constraints:** AI-assisted co-authoring reduces first-draft timelines from days to hours.
- **Consistency Issues:** A template-driven structure ensures uniform quality and formatting across documents.
- **Data Fragmentation:** The solution supports the ingestion and synthesis of data from multiple sources.
- **Capacity Gaps:** By automating repetitive sections, writers can focus on high-value content during high-volume phases.
- **Compliance Risks:** The solution includes source-linked references and audit trails to ensure traceability.
**Addressing the High-Friction Reality of Regulatory Drafting**
While many AI tools offer broad text generation, Zifo’s solution targets the specific gaps in the regulatory lifecycle by automating the drafting of first-draft content from both structured and unstructured data. The goal is to eliminate ‘transcription limbo’ by providing a template-driven structure that ensures consistency across every submission.
**Bridging Science and Technology Across the Value Chain**
This document authoring solution is just one piece of a much larger puzzle. Zifo leverages its deep scientific knowledge, technical expertise, and AI know-how to solve the pesky, recurring issues that frequently drag down progress across the entire scientific value chain. By combining domain-specific insights with advanced technologies — like multi-agent orchestration and RAG-based LLM processing — Zifo ensures digital and data continuity is maintained from the earliest stages of research, development, and CMC through clinical trials, manufacturing, and quality control.
Zifo’s Practical AI framework isn’t just about generating text; it is about creating an intelligent, interoperable ecosystem where data flows seamlessly across the scientific value chain of industries like Biopharma, Chemicals, and Agro.
**Unique Features of the AI-Powered Solution**
What sets this solution apart is its adaptability and focus on professional transparency:
- **Domain-Agnostic Flexibility:** It can be adapted to suit research, regulatory, CMC, or clinical domains.
- **Explainable AI:** Every generated section includes source references and metadata to support audits.
- **Human-in-the-Loop:** Writers retain full control with options to accept, modify, or regenerate any section.
- **Flexible Deployment:** To ensure data confidentiality, it can be hosted in a customer’s private cloud or on-premises.
**Impact Across the Scientific Value Chain**
The solution provides strategic value at every stage of the lifecycle:
- **Discovery & Preclinical:** Summarizes scientific literature and generates screening reports.
- **Clinical Trials:** Speeds up the creation of protocols, Investigator Brochures, and safety narratives.
- **Regulatory Affairs:** Delivers submission-ready documents aligned with FDA, EMA, and ICH standards.
- **Pharmacovigilance:** Automates safety data integration for Periodic Safety Update Reports (PSURs).
**About Zifo**
Zifo is the leading global enabler of AI and data-driven enterprise informatics for science-driven organizations. With expertise spanning research, development, manufacturing, and clinical domains, Zifo serves a diverse range of industries including Pharma, Biotech, Chemicals, Food and Beverage, and more. Trusted by over 190 organizations worldwide, Zifo is the partner of choice for advancing digital scientific innovation. For more information, visit ;
## Recent News
### [Zifo Co-Launches REAL 2026 to Spotlight the Next Generation of Connected, AI-Enabled Lab Environments](https://zifo.com/news/zifo-co-launches-real-2026-to-spotlight-the-next-generation-of-connected-ai-enabled-lab-environments/)
[  ](https://zifo.com/news/zifo-co-launches-real-2026-to-spotlight-the-next-generation-of-connected-ai-enabled-lab-environments/)
### [CMC Bottleneck is Choking Biopharma’s Drug Pipeline, says Zifo](https://zifo.com/news/cmc-bottleneck-is-choking-biopharmas-drug-pipeline-says-zifo/)
[  ](https://zifo.com/news/cmc-bottleneck-is-choking-biopharmas-drug-pipeline-says-zifo/)
### [Zifo Accelerates LIMS Master Data Validation with New AI-Enabled Services Accelerator](https://zifo.com/news/zifo-accelerates-lims-master-data-validation-with-new-ai-enabled-services-accelerator/)
[  ](https://zifo.com/news/zifo-accelerates-lims-master-data-validation-with-new-ai-enabled-services-accelerator/)
---
### [Zifo Transforms GxP Compliance with AI-Enabled Audit Trail Review Solution](https://zifo.com/news/zifo-transforms-gxp-compliance-with-ai-enabled-audit-trail-review-solution/)
**Published:** May 13, 2026
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [News](https://zifo.com/news/ "News")> Zifo Transforms GxP Compliance with AI-Enabled Audit Trail Review Solution
## Zifo Transforms GxP Compliance with AI-Enabled Audit Trail Review Solution
May 13, 2026
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Zifo%20Transforms%20GxP%20Compliance%20with%20AI-Enabled%20Audit%20Trail%20Review%20Solution%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fnews%2Fzifo-transforms-gxp-compliance-with-ai-enabled-audit-trail-review-solution%2F "Share on Email")
- [](https://x.com/intent/post?text=Zifo%20Transforms%20GxP%20Compliance%20with%20AI-Enabled%20Audit%20Trail%20Review%20Solution&url=https%3A%2F%2Fzifo.com%2Fnews%2Fzifo-transforms-gxp-compliance-with-ai-enabled-audit-trail-review-solution%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Zifo+Transforms+GxP+Compliance+with+AI-Enabled+Audit+Trail+Review+Solution&url=https%3A%2F%2Fzifo.com%2Fnews%2Fzifo-transforms-gxp-compliance-with-ai-enabled-audit-trail-review-solution%2F "Share on LinkedIn")
*AI solution generates checklists and parses audit logs, ensuring data integrity, traceability, and compliance in regulated systems.*
CAMBRIDGE, Mass. and CAMBRIDGE, England, May 13, 2026 /PRNewswire/ — Zifo, the leading global enabler of AI and data driven enterprise informatics for science driven organizations, has announced its AI-enabled Audit Trail Review solution to streamline the audit trail process for regulated systems and ensure robust GxP compliance, as the company strives to push for better science across the value chain.
While this solution immediately transforms a traditionally manual, bottlenecked compliance process into an automated workflow, it represents just one solution within Zifo’s broader [‘Practical AI’](/practical-ai-blueprints/) framework. Because Zifo is fundamentally bilingual — fluently speaking the complex languages of both rigorous science and advanced technology — the company moves beyond isolated, single-point fixes. This Audit Trail Review solution exemplifies how Zifo acts as a comprehensive player, seamlessly integrating informatics to enable better, faster, and more compliant science across the entire organizational value chain.
**Overcoming the Bottlenecks of Manual Audit Reviews**
Functional audit trails track essential user actions like data entry and deletion in regulated systems. This tracking ensures data integrity, traceability, and compliance with strict standards such as 21 CFR Part 11. While regular review of these trails is a strict regulatory and quality assurance requirement, the industry currently relies heavily on manual processes guided by SOPs and checklists.
Zifo’s AI-powered solution tackles this manual, time-consuming challenge by introducing automated, AI-driven analysis. This shift creates consistent, transparent audit trails that effectively mitigate ongoing compliance risks.
**Addressing Siloed Workflows and Scalability Challenges**
Organizations often face siloed data and workflows along with limited scalability across diverse systems. Zifo addresses these challenges through integrated document mapping and workflow tools. The solution can be seamlessly scaled across multiple GxP systems using configurable rules. Uniquely system-agnostic and SOP-flexible, the solution is designed to work for audit logs of diverse applications. It can adapt to any SOP-audit log combination without the need for custom coding.
**A Unique Solution Designed for Quality and Operations**
Designed to fit within the Quality Assurance, Regulatory Compliance, and Operations segments of the value chain, the solution offers several standout functionalities:
- **AI Agents**: The system combines AI agents for audit review, checklist analysis, and violation detection.
- **Seamless Integration**: It offers a seamless integration of backend intelligence with a modern, intuitive frontend.
- **Customization**: The solution is customizable for specific biopharma regulatory needs.
- **Advanced Architecture**: Core components include backend AI modules automating complex compliance tasks, a RESTful API Layer for document mapping and workflow management, and a Next.js-based frontend UI for user interaction and results visualization.
- **Powerful Technologies**: Under the hood, the solution utilizes technologies including leading Cloud platforms, LLMs, the LangChain and LangGraph agent framework, and a Chroma vector database.
**Future-Ready Enhancements**
To ensure continuous optimization, Zifo’s solution supports numerous potential enhancements:
- **Instrument-Based Audit Review Framework:** This framework uses reusable and version-controlled checklist templates specific to different instruments (like HPLC, GC-MS). This ensures consistency and speeds up audit cycles.
- **Robust User Management**: A robust system with role-based access control (RBAC) allows multiple users to work concurrently without compromising data integrity. Furthermore, a parallel processing engine improves throughput, and session isolation prevents data leakage.
- **Real-Time Processing**: Live progress tracking is provided through real-time updates. A centralized dashboard monitors system health, while an auto-scaling mechanism ensures consistent performance under varying workloads.
**About Zifo:**
Zifo is the leading global enabler of AI and data driven enterprise informatics for science driven organizations. With extensive solutions and services expertise spanning research, development, manufacturing, and clinical domains, we serve a diverse range of industries, including Pharma, Biotech, Chemicals, Food and Beverage, Oil & Gas, and FMCG. Trusted by over 190 science-focused organizations worldwide, Zifo is the partner of choice for advancing digital scientific innovation. ; [https://zifo.com/practical-ai-blueprints/](/practical-ai-blueprints/)
## Recent News
### [Zifo Co-Launches REAL 2026 to Spotlight the Next Generation of Connected, AI-Enabled Lab Environments](https://zifo.com/news/zifo-co-launches-real-2026-to-spotlight-the-next-generation-of-connected-ai-enabled-lab-environments/)
[  ](https://zifo.com/news/zifo-co-launches-real-2026-to-spotlight-the-next-generation-of-connected-ai-enabled-lab-environments/)
### [CMC Bottleneck is Choking Biopharma’s Drug Pipeline, says Zifo](https://zifo.com/news/cmc-bottleneck-is-choking-biopharmas-drug-pipeline-says-zifo/)
[  ](https://zifo.com/news/cmc-bottleneck-is-choking-biopharmas-drug-pipeline-says-zifo/)
### [Zifo Accelerates LIMS Master Data Validation with New AI-Enabled Services Accelerator](https://zifo.com/news/zifo-accelerates-lims-master-data-validation-with-new-ai-enabled-services-accelerator/)
[  ](https://zifo.com/news/zifo-accelerates-lims-master-data-validation-with-new-ai-enabled-services-accelerator/)
---
### [Zifo Minimizes Risk and Maximizes Compliance with AI-Powered Data Migration Solution](https://zifo.com/news/zifo-minimizes-risk-and-maximizes-compliance-with-ai-powered-data-migration-solution/)
**Published:** May 14, 2026
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [News](https://zifo.com/news/ "News")> Zifo Minimizes Risk and Maximizes Compliance with AI-Powered Data Migration Solution
## Zifo Minimizes Risk and Maximizes Compliance with AI-Powered Data Migration Solution
May 14, 2026
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Zifo%20Minimizes%20Risk%20and%20Maximizes%20Compliance%20with%20AI-Powered%20Data%20Migration%20Solution%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fnews%2Fzifo-minimizes-risk-and-maximizes-compliance-with-ai-powered-data-migration-solution%2F "Share on Email")
- [](https://x.com/intent/post?text=Zifo%20Minimizes%20Risk%20and%20Maximizes%20Compliance%20with%20AI-Powered%20Data%20Migration%20Solution&url=https%3A%2F%2Fzifo.com%2Fnews%2Fzifo-minimizes-risk-and-maximizes-compliance-with-ai-powered-data-migration-solution%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Zifo+Minimizes+Risk+and+Maximizes+Compliance+with+AI-Powered+Data+Migration+Solution&url=https%3A%2F%2Fzifo.com%2Fnews%2Fzifo-minimizes-risk-and-maximizes-compliance-with-ai-powered-data-migration-solution%2F "Share on LinkedIn")
CAMBRIDGE, Mass. and CAMBRIDGE, England, May 14, 2026 /PRNewswire/ — Zifo, the leading global enabler of AI and data driven enterprise informatics for science driven organizations, has developed an AI-enabled data migration solution that automates complex tasks across the scientific value chain while ensuring validated data transfer, which is critical for compliance and innovation in regulated industries such as biopharma.
Data migration is a critical process of transferring data between scientific informatics systems — from legacy architectures to modern setups, or during upgrades, consolidations, or cloud transitions. Recognizing that this is a strategic enabler of digital transformation requiring precision, planning, and a deep understanding of the scientific data landscape, Zifo’s solution covers the full migration lifecycle, from extraction to post-migration validation.
**Addressing Critical Industry Challenges**
Data Migration teams often face significant bottlenecks that this solution is designed to resolve:
- **Manual Extraction:** Smart source adaptors automate discovery and data retrieval.
- **Error-Prone Mapping:**Schema intelligence enables contextual auto-mapping using historical data, replacing manual field mapping.
- **Rigid Pipelines and Manual Logic:**AI learns and applies transformation rules dynamically, while AI-enhanced ETL builds and adjusts pipelines for ingestion and detects issues in real-time.
- **Downtime and Disruption:**Parallel execution and orchestration minimize downtime during migration.
- **Post-Migration Verification:**Agentic AI automates reconciliation and validation.
**Addressing the High-Friction Reality of System Transitions**
While many tools offer basic data movement, Zifo’s solution targets specific gaps by handling unstructured data formats using AI-powered workflows that extract schemas and metadata while preserving relationships. It standardizes inconsistent legacy formats into custom and canonical data models, ensuring that context-aware mapping maintains business rules and data integrity even when dealing with schema mismatches.
**Bridging Science and Technology Across the Value Chain**
This data migration solution is just one piece of a much larger puzzle. Zifo leverages its deep scientific knowledge, technical expertise, and AI know-how to solve the pesky, recurring issues that frequently drag down progress across the scientific value chain. By combining domain-aware intelligence with advanced technologies such as multi-agent orchestration, dynamic ETL pipelines, and LLM-driven vector stores, Zifo ensures digital and data continuity is maintained from the earliest stages of Research & Discovery, through CMC, and into Clinical trials.
Zifo’s approach is more than just a technical exercise of moving data; it is a strategic enabler of digital transformation. It is about creating an intelligent, interoperable ecosystem where legacy and modern architectures seamlessly connect, ensuring context-rich data flows securely across the scientific value chain of industries like Pharma, Biotech, and Chemicals.
**Unique Features of the AI-Powered Solution**
What sets this solution apart is its adaptability and technical sophistication:
- **Domain-Aware Intelligence:** Understands complex data relationships and experimental hierarchies.
- **Scalability:** Handles large datasets across diverse digital ecosystems.
- **Hybrid Collaboration:** Integrates customer expertise with AI capabilities for tailored execution.
- **Robust Data Validation:**Implements a validation pipeline to verify data consistency across source, staging, and target stages.
**Impact Across the Scientific Value Chain**
The solution fits strategically within multiple segments of the value chain:
- **Research & Discovery:** Migration of experimental data, compound libraries, and assay results with preserved scientific relationships.
- **CMC (Chemistry, Manufacturing & Controls):** Transfer of formulation, stability, and process data with contextual integrity.
- **Clinical:** Migration of clinical datasets, patient records, Trial Master Files (TMF) and trial metadata with version control and historical context.
**About Zifo**
Zifo is the leading global enabler of AI and data driven enterprise informatics for science driven organizations. With extensive solutions and services expertise spanning research, development, manufacturing, and clinical domains, Zifo serves a diverse range of industries, including Pharma, Biotech, Chemicals, Food and Beverage, Oil & Gas, and FMCG. Trusted by over 190 science-focused organizations worldwide, Zifo is the partner of choice for advancing digital scientific innovation.
; [https://zifo.com/practical-ai-blueprints/](/practical-ai-blueprints/)
## Recent News
### [Zifo Co-Launches REAL 2026 to Spotlight the Next Generation of Connected, AI-Enabled Lab Environments](https://zifo.com/news/zifo-co-launches-real-2026-to-spotlight-the-next-generation-of-connected-ai-enabled-lab-environments/)
[  ](https://zifo.com/news/zifo-co-launches-real-2026-to-spotlight-the-next-generation-of-connected-ai-enabled-lab-environments/)
### [CMC Bottleneck is Choking Biopharma’s Drug Pipeline, says Zifo](https://zifo.com/news/cmc-bottleneck-is-choking-biopharmas-drug-pipeline-says-zifo/)
[  ](https://zifo.com/news/cmc-bottleneck-is-choking-biopharmas-drug-pipeline-says-zifo/)
### [Zifo Accelerates LIMS Master Data Validation with New AI-Enabled Services Accelerator](https://zifo.com/news/zifo-accelerates-lims-master-data-validation-with-new-ai-enabled-services-accelerator/)
[  ](https://zifo.com/news/zifo-accelerates-lims-master-data-validation-with-new-ai-enabled-services-accelerator/)
---
### [Advancing Better Science: Zifo Brings Scientific Knowledge and AI Expertise to Bio-IT World](https://zifo.com/news/advancing-better-science-zifo-brings-scientific-knowledge-and-ai-expertise-to-bio-it-world/)
**Published:** May 19, 2026
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [News](https://zifo.com/news/ "News")> Advancing Better Science: Zifo Brings Scientific Knowledge and AI Expertise to Bio-IT World
## Advancing Better Science: Zifo Brings Scientific Knowledge and AI Expertise to Bio-IT World
May 19, 2026
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Advancing%20Better%20Science%3A%20Zifo%20Brings%20Scientific%20Knowledge%20and%20AI%20Expertise%20to%20Bio-IT%20World%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fnews%2Fadvancing-better-science-zifo-brings-scientific-knowledge-and-ai-expertise-to-bio-it-world%2F "Share on Email")
- [](https://x.com/intent/post?text=Advancing%20Better%20Science%3A%20Zifo%20Brings%20Scientific%20Knowledge%20and%20AI%20Expertise%20to%20Bio-IT%20World&url=https%3A%2F%2Fzifo.com%2Fnews%2Fadvancing-better-science-zifo-brings-scientific-knowledge-and-ai-expertise-to-bio-it-world%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Advancing+Better+Science%3A+Zifo+Brings+Scientific+Knowledge+and+AI+Expertise+to+Bio-IT+World&url=https%3A%2F%2Fzifo.com%2Fnews%2Fadvancing-better-science-zifo-brings-scientific-knowledge-and-ai-expertise-to-bio-it-world%2F "Share on LinkedIn")
CAMBRIDGE, Mass., May 19, 2026 /PRNewswire/ — The landscape of precision medicine is evolving rapidly, driven by unprecedented growth in scientific data, but the life sciences industry has an AI problem: the algorithms are ready, but the data is not. To solve this critical bottleneck and drive better science, Zifo is showcasing a suite of operational frameworks designed to bridge the gap between Scientific Context, AI Ambition, and Lab Reality.
These ideas will take centre stage this week as **Zifo steps up as a Gold Sponsor of the Annual Bio-IT World Conference & Expo**, taking place May 19–21 at the Omni Boston Hotel at the Seaport. Now marking its 25th anniversary, Bio-IT World will convene more than 2,900 researchers, clinicians, data scientists, and technology leaders. Their shared objective? Defining the next generation of life sciences innovation and driving the future of precision medicine. Zifo is uniquely positioned to facilitate this transformation.
“AI remains a central focus across the life sciences sector, but the critical differentiator is scientific knowledge along with practical, scalable implementation,” said **Margaret DiFilippo, Vice President of Customer Success at Zifo**. “Advanced algorithms require impeccable data foundations. We are attending Bio-IT World to help science-driven organizations refine their overall scientific data and AI strategy, optimize readiness, and ultimately remove the impediments that hinder the pace of scientific discovery.”
Attendees seeking to maximize the value of their scientific data ecosystems can engage directly with Zifo’s domain experts at **Booth 413**.
**Featured Speaker Sessions**
Beyond the exhibition floor, Zifo will share strategic insights during two featured presentations, addressing critical data bottlenecks in biologics and genomics:
- **Session 1: Your AI Doesn’t Know Your Data Isn’t Ready**
- Overview: A strategic examination of data readiness, the hidden costs of AI implementation, and effective stewardship of Biologics data to ensure actionable results.
- Speaker: Rumana Begum Raffi, Scientific Data Architect, Zifo
- Schedule: Tuesday, May 19, 2026 at 9:55 AM (Track: AI for Biologics)
- **Session 2: A Unified PheWAS Framework: Integrating Multiple Biobanks for Accelerated Genomic Discovery**
- Overview: Advanced methodologies for seamlessly integrating disparate biobanks to accelerate genomic research and fast-track therapeutic breakthroughs.
- Speaker: Sachin Kothandaraman, Scientific Application Lead (Bioinformatics), Zifo
- Schedule: Wednesday, May 20, 2026 at 11:55 AM (Track: Bioinformatics)
**Innovative Poster Presentations**
In addition to the main stage sessions, Zifo experts will present three technical posters detailing advanced frameworks for data processing:
- **A Canonical Framework for Multi-Dimensional Retrosynthetic Scoring.** Presented by Mohamed Kassam, Head of Bioinformatics, this poster outlines a pipeline to automate Route of Synthesis (ROS) selection. By running parallel retrosynthesis engines and applying multidimensional scoring, the framework aims to reduce production costs and speed up time-to-market.
- **From System Exports to Standards: Will Standardisation of External Vendor Data Redefine Clinical Data Management/Analysis?**Presented by Sai Sri Sravya Deevi, this study highlights a vendor data integration framework. It ensures external clinical trial data is delivered in CDISC-compliant formats from the very first transfer, improving integration efficiency and scalability.
- **From Chaos to Clarity: Can AI/ML Truly Decode Unstructured Clinical Data?**Presented by Uma Maheswari Adiseshan, this poster examines the deployment of a hybrid Gen AI approach for automated PHI redaction in unstructured clinical images. The implemented workflow demonstrated 50% faster PHI redaction and prepares images for compliant downstream analysis.
Whether an organization is navigating scientific complexities, scaling infrastructure, advancing omics, or running trials, Zifo offers tailored, domain-specific expertise.
**About Zifo**
Zifo is the leading global enabler of AI and data-driven enterprise informatics for science-driven organizations. With extensive solutions and services expertise spanning research, development, manufacturing, and clinical domains, Zifo serves a diverse range of industries—including Pharma, Biotech, Chemicals, Food and Beverage, Oil & Gas, and FMCG. Trusted by over 190 organizations worldwide, Zifo is the partner of choice for advancing digital scientific innovation.
; [https://zifo.com/practical-ai-blueprints/](/practical-ai-blueprints/)
## Recent News
### [Zifo Co-Launches REAL 2026 to Spotlight the Next Generation of Connected, AI-Enabled Lab Environments](https://zifo.com/news/zifo-co-launches-real-2026-to-spotlight-the-next-generation-of-connected-ai-enabled-lab-environments/)
[  ](https://zifo.com/news/zifo-co-launches-real-2026-to-spotlight-the-next-generation-of-connected-ai-enabled-lab-environments/)
### [CMC Bottleneck is Choking Biopharma’s Drug Pipeline, says Zifo](https://zifo.com/news/cmc-bottleneck-is-choking-biopharmas-drug-pipeline-says-zifo/)
[  ](https://zifo.com/news/cmc-bottleneck-is-choking-biopharmas-drug-pipeline-says-zifo/)
### [Zifo Accelerates LIMS Master Data Validation with New AI-Enabled Services Accelerator](https://zifo.com/news/zifo-accelerates-lims-master-data-validation-with-new-ai-enabled-services-accelerator/)
[  ](https://zifo.com/news/zifo-accelerates-lims-master-data-validation-with-new-ai-enabled-services-accelerator/)
---
### [Zifo Unveils AI-Powered Solution to Generate Traceable, RAG-Driven Toxicology Summaries](https://zifo.com/news/zifo-unveils-ai-powered-solution-to-generate-traceable-rag-driven-toxicology-summaries/)
**Published:** May 20, 2026
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [News](https://zifo.com/news/ "News")> Zifo Unveils AI-Powered Solution to Generate Traceable, RAG-Driven Toxicology Summaries
## Zifo Unveils AI-Powered Solution to Generate Traceable, RAG-Driven Toxicology Summaries
May 20, 2026
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Zifo%20Unveils%20AI-Powered%20Solution%20to%20Generate%20Traceable%2C%20RAG-Driven%20Toxicology%20Summaries%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fnews%2Fzifo-unveils-ai-powered-solution-to-generate-traceable-rag-driven-toxicology-summaries%2F "Share on Email")
- [](https://x.com/intent/post?text=Zifo%20Unveils%20AI-Powered%20Solution%20to%20Generate%20Traceable%2C%20RAG-Driven%20Toxicology%20Summaries&url=https%3A%2F%2Fzifo.com%2Fnews%2Fzifo-unveils-ai-powered-solution-to-generate-traceable-rag-driven-toxicology-summaries%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Zifo+Unveils+AI-Powered+Solution+to+Generate+Traceable%2C+RAG-Driven+Toxicology+Summaries&url=https%3A%2F%2Fzifo.com%2Fnews%2Fzifo-unveils-ai-powered-solution-to-generate-traceable-rag-driven-toxicology-summaries%2F "Share on LinkedIn")
*New flexible RAG assistant automates toxicology evidence gathering from disparate sources, ensuring strict traceability for confident decision-making.*
CAMBRIDGE, Mass. and CAMBRIDGE, England, May 20, 2026 /PRNewswire/ — Zifo, the leading global enabler of AI and data-driven enterprise informatics for science-driven organizations, today unveiled its AI-Powered Toxicology Summary solution, a flexible Retrieval-Augmented Generation (RAG) assistant that eliminates manual research bottlenecks by automating the rapid retrieval and summarization of disparate toxicology evidence.
Historically, toxicology evidence gathering has been a manual and tedious process across numerous sources, leading to data overload and making it difficult to spot and resolve conflicting findings across studies. Furthermore, generic Large Language Models (LLMs) often suffer from ‘knowledge cutoffs,’ a lack of domain grounding, and generate user mistrust due to potential inaccuracies, bias, and a lack of transparency.
Zifo’s new solution addresses these challenges by utilizing a RAG architecture to ground responses in up-to-date, curated literature rather than relying solely on model pretraining. By producing consistent, structured outputs designed for faster review and downstream reporting, the AI solution condenses insights from large collections of publications into decision-ready responses.
Key capabilities and unique features of the AI-powered solution include:
- **Evidence-Grounded Answers with Provenance**: Outputs are paired with citations and links to original sources, significantly improving user trust and auditability.
- **Toxicology-First Experience**: Unlike generic chat interfaces, the platform is specifically focused on toxicology evidence gathering, compound-centric queries, and concerns such as CMR and skin sensitization.
- **Curated and Extensible Knowledge Base**: The system is designed around curated toxicology datasets and can expand to include both additional public and internal sources.
- **Multiple Analysis Modes**: Depending on user needs, the platform supports semantic search, precise passage extraction (extractive QA), and literature-grounded narrative answers (generative QA).
- **Query Intelligence:** The system improves recall by automatically expanding compound queries to include synonyms and identifiers before retrieval.
The solution operates on a robust technical architecture featuring automated data ingestion pipelines, a vector database for semantic indexing (Weaviate), a document store (MongoDB), and domain-suitable embedding models such as SapBERT alongside advanced generative models. The solution is highly configurable and can be deployed in the cloud or on-premise.
**Bridging Science and Technology Across the Value Chain**
This AI-driven toxicology solution is just one piece of a much larger puzzle. Zifo leverages its deep scientific knowledge, technical expertise, and AI know-how to solve the recurring research bottlenecks that frequently drag down progress across the scientific value chain. By combining domain-aware intelligence with advanced technologies such as Retrieval-Augmented Generation (RAG), dynamic data processing pipelines, and semantic vector databases, Zifo ensures that critical safety evidence is maintained and accessible from the earliest stages of Discovery and Preclinical Safety, through Translational Development, and into Regulatory and Medical Writing.
Zifo’s approach is more than just a technical exercise in document summarization; it is a strategic enabler of confident, evidence-backed decision-making. It is about creating an intelligent, auditable ecosystem where disparate public literature and internal study databases seamlessly connect, ensuring context-rich, traceable data flows securely across the scientific value chain of industries like Pharma, Biotech, and Chemicals.
**Looking Ahead**
Moving forward, Zifo plans future enhancements to expand beyond PubMed/PMC data to include internal study reports and databases like ToxCast. Additional planned updates include automated report generation features and seamless integrations with Electronic Lab Notebooks (ELNs), Laboratory Information Management Systems (LIMS), and knowledge graphs.
The AI-powered Toxicology Summary solution works best within the Discovery & Preclinical/Nonclinical Safety, Translational & Early Development, and Regulatory/Medical Writing support segments of the life sciences value chain.
**About Zifo:**
Zifo is the leading global enabler of AI and data-driven enterprise informatics for science-driven organizations. With extensive solutions and services expertise spanning research, development, manufacturing, and clinical domains, Zifo serves a diverse range of industries, including Pharma, Biotech, Chemicals, Food and Beverage, Oil & Gas, and FMCG. Trusted by over 190 science-focused organizations worldwide, Zifo is the partner of choice for advancing digital scientific innovation. For more information, visit ; [https://zifo.com/practical-ai-blueprints/](/practical-ai-blueprints/)
## Recent News
### [Zifo Co-Launches REAL 2026 to Spotlight the Next Generation of Connected, AI-Enabled Lab Environments](https://zifo.com/news/zifo-co-launches-real-2026-to-spotlight-the-next-generation-of-connected-ai-enabled-lab-environments/)
[  ](https://zifo.com/news/zifo-co-launches-real-2026-to-spotlight-the-next-generation-of-connected-ai-enabled-lab-environments/)
### [CMC Bottleneck is Choking Biopharma’s Drug Pipeline, says Zifo](https://zifo.com/news/cmc-bottleneck-is-choking-biopharmas-drug-pipeline-says-zifo/)
[  ](https://zifo.com/news/cmc-bottleneck-is-choking-biopharmas-drug-pipeline-says-zifo/)
### [Zifo Accelerates LIMS Master Data Validation with New AI-Enabled Services Accelerator](https://zifo.com/news/zifo-accelerates-lims-master-data-validation-with-new-ai-enabled-services-accelerator/)
[  ](https://zifo.com/news/zifo-accelerates-lims-master-data-validation-with-new-ai-enabled-services-accelerator/)
---
### [Zifo to Showcase AI-Driven Validation and Compliance Innovations at CSV & CSA University Europe 2026 in Dublin](https://zifo.com/news/zifo-to-showcase-ai-driven-validation-and-compliance-innovations-at-csv-csa-university-europe-2026-in-dublin/)
**Published:** May 21, 2026
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [News](https://zifo.com/news/ "News")> Zifo to Showcase AI-Driven Validation and Compliance Innovations at CSV & CSA University Europe 2026 in Dublin
## Zifo to Showcase AI-Driven Validation and Compliance Innovations at CSV & CSA University Europe 2026 in Dublin
May 21, 2026
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Zifo%20to%20Showcase%20AI-Driven%20Validation%20and%20Compliance%20Innovations%20at%20CSV%20%26%20CSA%20University%20Europe%202026%20in%20Dublin%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fnews%2Fzifo-to-showcase-ai-driven-validation-and-compliance-innovations-at-csv-csa-university-europe-2026-in-dublin%2F "Share on Email")
- [](https://x.com/intent/post?text=Zifo%20to%20Showcase%20AI-Driven%20Validation%20and%20Compliance%20Innovations%20at%20CSV%20%26%20CSA%20University%20Europe%202026%20in%20Dublin&url=https%3A%2F%2Fzifo.com%2Fnews%2Fzifo-to-showcase-ai-driven-validation-and-compliance-innovations-at-csv-csa-university-europe-2026-in-dublin%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Zifo+to+Showcase+AI-Driven+Validation+and+Compliance+Innovations+at+CSV+%26+CSA+University+Europe+2026+in+Dublin&url=https%3A%2F%2Fzifo.com%2Fnews%2Fzifo-to-showcase-ai-driven-validation-and-compliance-innovations-at-csv-csa-university-europe-2026-in-dublin%2F "Share on LinkedIn")
CAMBRIDGE, Mass. and CAMBRIDGE, England, May 21, 2026 /PRNewswire/ — Zifo, a leading global enabler of AI and data driven enterprise informatics for science driven organizations, today announced that it will be speaking and exhibiting at the upcoming Computerised Systems, Software Assurance + AI Validation University (CSV & CSA University Europe 2026), hosted by KENX, at a time when the integration of AI is forcing the biopharma industry to completely rethink legacy validation, driving an urgent need for AI-ready compliance ecosystems.
As a Gold Sponsor, Zifo will join this industry event taking place on June 2–3, 2026, at the Hyatt Centric in Dublin, Ireland.
This conference brings together thought leaders and experts across life sciences, validation, compliance, and digital transformation. Attendees will gather to explore the evolving future of Computer Software Assurance (CSA), Computer System Validation (CSV), data integrity, Artificial Intelligence (AI), and regulatory innovation.
A key highlight of Zifo’s participation will be an expert session led by **Loganathan Kumarasamy, Global Head of Compliance Services at Zifo**.
**Session Details:**
- **Track**: AI for Paperless Validation
- **Title**: AI for Paperless Validation: How Intelligent Automation Transforms Documentation
- **Date & Time**: June 2, 2026 | 13:50 – 14:30
- **Speaker**: Loganathan Kumarasamy (MS, RAC, AIGP), Global Head – Compliance Services, Zifo
During his presentation, Loganathan will detail how organizations can apply AI to generate, review, and manage validation deliverables without compromising data integrity. He will share actionable perspectives on:
- Advancing GxP compliant digital transformation through paperless validation.
- Enabling smarter, risk-based approaches in regulated environments using AI.
- Critical factors to consider for the successful implementation of AI in GxP settings.
In addition to the speaking session, Zifo invites all attendees to visit its dedicated exhibit space. The Zifo team will be available to connect, share insights, and discuss how they are partnering with organizations to accelerate innovation across the life sciences sector. Visitors to the booth can learn more about Zifo’s capabilities in:
- CSA and CSV modernization
- AI-ready quality and compliance strategies
- Digital validation transformation
- Scalable and compliant data ecosystems
- Smarter risk-based approaches for regulated labs and manufacturing
“We are looking forward to great conversations, making new connections, and experiencing an inspiring event alongside the broader life sciences community,” Loganathan said.
To know more about Zifo’s Practical AI program, please visit: [https://zifo.com/practical-ai-blueprints/](/practical-ai-blueprints/)
For more information about the conference or to register for the event, please visit the KENX website at:
**About Zifo:**
Zifo is the leading global enabler of AI and data driven enterprise informatics for science driven organizations. With extensive solutions and services expertise spanning research, development, manufacturing, and clinical domains, we serve a diverse range of industries, including Pharma, Biotech, Chemicals, Food and Beverage, Oil & Gas, and FMCG. Trusted by over 190 science-focused organizations worldwide, Zifo is the partner of choice for advancing digital scientific innovation.
## Recent News
### [Zifo Co-Launches REAL 2026 to Spotlight the Next Generation of Connected, AI-Enabled Lab Environments](https://zifo.com/news/zifo-co-launches-real-2026-to-spotlight-the-next-generation-of-connected-ai-enabled-lab-environments/)
[  ](https://zifo.com/news/zifo-co-launches-real-2026-to-spotlight-the-next-generation-of-connected-ai-enabled-lab-environments/)
### [CMC Bottleneck is Choking Biopharma’s Drug Pipeline, says Zifo](https://zifo.com/news/cmc-bottleneck-is-choking-biopharmas-drug-pipeline-says-zifo/)
[  ](https://zifo.com/news/cmc-bottleneck-is-choking-biopharmas-drug-pipeline-says-zifo/)
### [Zifo Accelerates LIMS Master Data Validation with New AI-Enabled Services Accelerator](https://zifo.com/news/zifo-accelerates-lims-master-data-validation-with-new-ai-enabled-services-accelerator/)
[  ](https://zifo.com/news/zifo-accelerates-lims-master-data-validation-with-new-ai-enabled-services-accelerator/)
---
### [Zifo Unifies Disconnected Lab Systems with AI-Enabled Data Orchestration](https://zifo.com/news/zifo-unifies-disconnected-lab-systems-with-ai-enabled-data-orchestration/)
**Published:** May 29, 2026
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [News](https://zifo.com/news/ "News")> Zifo Unifies Disconnected Lab Systems with AI-Enabled Data Orchestration
## Zifo Unifies Disconnected Lab Systems with AI-Enabled Data Orchestration
May 28, 2026
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Zifo%20Unifies%20Disconnected%20Lab%20Systems%20with%20AI-Enabled%20Data%20Orchestration%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fnews%2Fzifo-unifies-disconnected-lab-systems-with-ai-enabled-data-orchestration%2F "Share on Email")
- [](https://x.com/intent/post?text=Zifo%20Unifies%20Disconnected%20Lab%20Systems%20with%20AI-Enabled%20Data%20Orchestration&url=https%3A%2F%2Fzifo.com%2Fnews%2Fzifo-unifies-disconnected-lab-systems-with-ai-enabled-data-orchestration%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Zifo+Unifies+Disconnected+Lab+Systems+with+AI-Enabled+Data+Orchestration&url=https%3A%2F%2Fzifo.com%2Fnews%2Fzifo-unifies-disconnected-lab-systems-with-ai-enabled-data-orchestration%2F "Share on LinkedIn")
CAMBRIDGE, Mass. and CAMBRIDGE, England, May 28, 2026 /PRNewswire/ — Zifo, the leading global enabler of AI and data-driven enterprise informatics for science-driven organizations, has developed an AI-enabled Data Orchestration accelerator that seamlessly unifies fragmented lab systems by establishing an event-driven orchestration layer, creating a continuous digital thread across analytical applications and instrumentation to pave the way for hands-free, error-free science.
**Overcoming the Bottlenecks of Fragmented Lab Systems**
Labs frequently struggle with fragmented systems that scatter data across Electronic Laboratory Notebooks (ELN), Laboratory Information Management Systems (LIMS), Chromatography Data Systems (CDS), and other separate physical instruments. This fragmentation causes operational delays, data entry errors, weak audit trails, and highly manual, inefficient workflows that pull scientists away from core scientific work. Zifo’s data orchestration services accelerator resolves these challenges by connecting all systems automatically, ensuring that data flows seamlessly from instruments to LIMS and ELN without human intervention.
**Addressing the Complexities of Hands-Busy Scientific Workflows**
Executing precise laboratory protocols often requires researchers to constantly stop physical operations to interact with software or transcribe numbers. Zifo’s intelligent services accelerator addresses this by designing hands-free voice interactions as a primary interface rather than an optional add-on. This voice-enabled guidance allows researchers to weigh samples, prepare solutions, and record real-time observations directly at the bench. By delivering step-by-step voice instructions through AI-guided workflows, the accelerator reduces overall training time and guarantees consistent protocol execution.
**An Event-Driven Architecture Designed for Ultimate Integrity**
The AI-powered services accelerator fundamentally alters how scientific activities are executed, integrated, and validated across the scientific life cycle:
- **Automated Data Propagation:** Direct instrument integration automatically captures barcode scans, weighing balance readings, and analytical results in real time, eliminating manual transcription entirely.
- **Real-Time Orchestration:** AI-guided workflows go beyond basic data movement to deeply understand experimental context, automatically triggering appropriate downstream actions and validating process compliance.
- **Action as Audit:** Driven by the core philosophy that ‘the act of doing a task is the proof of that task being done,’ the accelerator builds a single, immutable audit trail natively through work execution without requiring separate documentation steps.
- **Complete Digital Lineage:** Every captured event carries comprehensive contextual metadata — recording who performed the action, when it occurred, why it changed, and its system origin — enabling instant reconstruction of the entire sample journey via dedicated correlation IDs.
**Unique Architecture Features Include:**
- **Universal Connectivity:** Seamless integration spans the full analytical ecosystem, tracking operations from initial ELN order creation through sample processing and instrument analysis straight to final results and sign-off — all without requiring the replacement of existing infrastructure.
- **Live Event Timelines:** A dedicated event timeline viewer and experiment dashboard provide immediate, transparent visibility into the exact stage of every sample across all connected systems.
- **Advanced Multi-Layered Framework:** The accelerator features modular frontend user navigation interfaces, robust backend orchestration engines, integration adapters (including ELN and CDS bridges), and intelligent AI guidance services.
**Strategic Value and Technical Underpinnings**
Fitting seamlessly into Analytical Sciences, Quality Control, R&D, and Manufacturing domains, this highly adaptable services accelerator is built on a powerful technology stack. It utilizes leading AI models and AWS Nova Sonic (v1), to power its sophisticated voice processing and guidance capabilities. The accelerator’s backend and integration infrastructure are engineered using Python, Next.js, FastAPI, FastMCP, AWS SDK, and LangGraph, running side-by-side with the Empower SDK and Signals APIs.
Looking ahead, Zifo has mapped out advanced optimization capabilities to further extend the accelerator’s impact. Future additions will include extended Augmented Reality (AR) instrument identification via QR code scanning, conversational context retention to maintain dialogue flow during multi-step procedures, deeper CDS procedure automation for electronic signatures, and intelligent session management to accurately separate user events in multi-user laboratory environments.
**Bridging Science and Technology Across the Value Chain**
This data orchestration services accelerator is just one piece of a much larger puzzle. Zifo leverages its extensive expertise as a leading global enabler of AI and data-driven enterprise informatics to solve the pesky, recurring issues that frequently drag down progress across the scientific value chain. By combining domain-aware intelligence with advanced capabilities like an event-driven orchestration layer, real-time workflow engines, and intelligent AI guidance systems, Zifo ensures digital and data continuity is maintained from the earliest stages of R&D, through CMC, Quality Control, and into Manufacturing.
Zifo’s approach is more than just a technical exercise of linking systems; it is a strategic enabler of digital transformation. It is about creating an intelligent, interoperable ecosystem where fragmented lab software and equipment — including ELN, LIMS, CDS, and other standalone instruments — seamlessly connect without requiring the replacement of existing infrastructure. This ensures that context-rich, traceable data flows securely across the scientific value chain.
**About Zifo**
Zifo is the leading global enabler of AI and data driven enterprise informatics for science driven organizations. With extensive solutions and services expertise spanning research, development, manufacturing, and clinical domains, we serve a diverse range of industries, including Pharma, Biotech, Chemicals, Food and Beverage, Oil & Gas, and FMCG. Trusted by over 190 science-focused organizations worldwide, Zifo is the partner of choice for advancing digital scientific innovation. ; [https://zifo.com/practical-ai-blueprints/](/practical-ai-blueprints/)
## Recent News
### [Zifo Co-Launches REAL 2026 to Spotlight the Next Generation of Connected, AI-Enabled Lab Environments](https://zifo.com/news/zifo-co-launches-real-2026-to-spotlight-the-next-generation-of-connected-ai-enabled-lab-environments/)
[  ](https://zifo.com/news/zifo-co-launches-real-2026-to-spotlight-the-next-generation-of-connected-ai-enabled-lab-environments/)
### [CMC Bottleneck is Choking Biopharma’s Drug Pipeline, says Zifo](https://zifo.com/news/cmc-bottleneck-is-choking-biopharmas-drug-pipeline-says-zifo/)
[  ](https://zifo.com/news/cmc-bottleneck-is-choking-biopharmas-drug-pipeline-says-zifo/)
### [Zifo Accelerates LIMS Master Data Validation with New AI-Enabled Services Accelerator](https://zifo.com/news/zifo-accelerates-lims-master-data-validation-with-new-ai-enabled-services-accelerator/)
[  ](https://zifo.com/news/zifo-accelerates-lims-master-data-validation-with-new-ai-enabled-services-accelerator/)
---
### [Zifo Unlocks Hidden Experiment Patterns with New AI-Enabled Services Accelerator](https://zifo.com/news/zifo-unlocks-hidden-experiment-patterns-with-new-ai-enabled-services-accelerator/)
**Published:** June 3, 2026
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [News](https://zifo.com/news/ "News")> Zifo Unlocks Hidden Experiment Patterns with New AI-Enabled Services Accelerator
## Zifo Unlocks Hidden Experiment Patterns with New AI-Enabled Services Accelerator
Jun 02, 2026
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Zifo%20Unlocks%20Hidden%20Experiment%20Patterns%20with%20New%20AI-Enabled%20Services%20Accelerator%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fnews%2Fzifo-unlocks-hidden-experiment-patterns-with-new-ai-enabled-services-accelerator%2F "Share on Email")
- [](https://x.com/intent/post?text=Zifo%20Unlocks%20Hidden%20Experiment%20Patterns%20with%20New%20AI-Enabled%20Services%20Accelerator&url=https%3A%2F%2Fzifo.com%2Fnews%2Fzifo-unlocks-hidden-experiment-patterns-with-new-ai-enabled-services-accelerator%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Zifo+Unlocks+Hidden+Experiment+Patterns+with+New+AI-Enabled+Services+Accelerator&url=https%3A%2F%2Fzifo.com%2Fnews%2Fzifo-unlocks-hidden-experiment-patterns-with-new-ai-enabled-services-accelerator%2F "Share on LinkedIn")
CAMBRIDGE, Mass. and CAMBRIDGE, England, June 2, 2026 /PRNewswire/ — Zifo, a leading global enabler of AI and data-driven enterprise informatics for science-driven organizations, today announced its new AI-powered Experiment Insight services accelerator, which understands complex scientific language to empower scientists to turn buried knowledge into actionable intelligence, extract structured data, and uncover critical patterns across vast datasets.
Scientists routinely conduct thousands of experiments, but poor documentation and insights buried within unstructured text often make it difficult to extract meaningful learnings or answer key scientific questions. This leads to compounding challenges: institutional knowledge is lost when scientists depart, time-consuming manual reviews are required to find past records, and researchers unknowingly repeat failed experiments because historical data isn’t easily discoverable.
Zifo’s latest services accelerator directly addresses these hurdles by turning buried scientific knowledge into clear, actionable intelligence.
A core differentiator is its quality-first approach. While most approaches assume incoming data quality is sufficient, this AI-powered services accelerator assesses conclusion quality first, helping organizations actively improve their documentation standards rather than simply attempting to extract data from poorly written records.
**Key capabilities and benefits include:**
- **Rapid Pattern Discovery:** The AI analyzes thousands of experiments in minutes to surface relevant insights automatically. It can discover hidden statistical patterns across all experiments that humans would rarely, if ever, spot manually.
- **Preserved Institutional Knowledge:** The AI continually extracts and structures knowledge from past experiments, preserving insights permanently in a searchable format so expertise is never lost.
- **Data-Driven Decisions:** Decisions can be backed by statistical evidence from an organization’s entire experimental history rather than recent memory.
- **Multi-Layer Validation:** To ensure maximum accuracy, the AI checks its own work using multiple validation layers, including schema compliance, hallucination detection, and completeness checks, allowing it to function without constant human oversight.
- **Scientific Ontology Integration:** The services accelerator understands scientific concepts using established industry ontologies (such as ChEBI) rather than basic keywords. For example, the AI natively understands that “buffer” and “PBS” are related concepts.
- **Explainable Results:** Every data extraction displays confidence levels and validation results, allowing scientists to always verify the AI’s reasoning and safely trust the output.
The solution is highly adaptable and fits seamlessly into multiple segments of the scientific value chain, including Drug Discovery & Development, Analytical & Quality Control, Process Development & Manufacturing, and Regulatory & Compliance.
**Bridging Science and Technology Across the Value Chain**
This AI-powered Experiment Insight services accelerator is just one piece of a much larger puzzle. Zifo leverages its extensive expertise as a leading global enabler of AI and data-driven enterprise informatics for science-driven organizations to solve the persistent scientific, technological, and data challenges that frequently drag down progress across the value chain. By combining domain-aware intelligence with advanced capabilities like scientific ontology integration, multi-layer validation, and automated pattern discovery, Zifo ensures actionable insights are seamlessly extracted and maintained across Drug Discovery & Development, Analytical & Quality Control, Process Development & Manufacturing, and Regulatory & Compliance.
Zifo’s approach is more than just a technical exercise of extracting unstructured text; it is a strategic enabler of data-driven decision-making. It is about creating an intelligent ecosystem where decades of historical experiments are permanently preserved in a searchable format, effortlessly adapting to how scientists actually write without forcing them into rigid templates. This ensures that context-rich, statistically backed evidence flows securely across the scientific value chain, preventing repeated errors and uncovering hidden trends that would be nearly impossible to spot manually.
**About Zifo**
Zifo is the leading global enabler of AI and data-driven enterprise informatics for science-driven organizations. With extensive domain expertise spanning research, development, manufacturing, and clinical domains, Zifo serves a diverse range of industries, including Pharma, Biotech, Chemicals, Food and Beverage, Oil & Gas, and FMCG. Trusted by over 190 science-focused organizations worldwide, Zifo is the partner of choice for advancing digital scientific innovation.
For more information, visit [https://zifo.com/; ](https://zifo.com/)
## Recent News
### [Zifo Co-Launches REAL 2026 to Spotlight the Next Generation of Connected, AI-Enabled Lab Environments](https://zifo.com/news/zifo-co-launches-real-2026-to-spotlight-the-next-generation-of-connected-ai-enabled-lab-environments/)
[  ](https://zifo.com/news/zifo-co-launches-real-2026-to-spotlight-the-next-generation-of-connected-ai-enabled-lab-environments/)
### [CMC Bottleneck is Choking Biopharma’s Drug Pipeline, says Zifo](https://zifo.com/news/cmc-bottleneck-is-choking-biopharmas-drug-pipeline-says-zifo/)
[  ](https://zifo.com/news/cmc-bottleneck-is-choking-biopharmas-drug-pipeline-says-zifo/)
### [Zifo Accelerates LIMS Master Data Validation with New AI-Enabled Services Accelerator](https://zifo.com/news/zifo-accelerates-lims-master-data-validation-with-new-ai-enabled-services-accelerator/)
[  ](https://zifo.com/news/zifo-accelerates-lims-master-data-validation-with-new-ai-enabled-services-accelerator/)
---
### [Zifo, Pistoia Alliance, and Pharma Majors Launch Global IVP Assay Repository](https://zifo.com/news/zifo-pistoia-alliance-and-pharma-majors-launch-global-ivp-assay-repository/)
**Published:** May 27, 2026
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [News](https://zifo.com/news/ "News")> Zifo, Pistoia Alliance, and Pharma Majors Launch Global IVP Assay Repository
## Zifo, Pistoia Alliance, and Pharma Majors Launch Global IVP Assay Repository
May 26, 2026
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Zifo%2C%20Pistoia%20Alliance%2C%20and%20Pharma%20Majors%20Launch%20Global%20IVP%20Assay%20Repository%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fnews%2Fzifo-pistoia-alliance-and-pharma-majors-launch-global-ivp-assay-repository%2F "Share on Email")
- [](https://x.com/intent/post?text=Zifo%2C%20Pistoia%20Alliance%2C%20and%20Pharma%20Majors%20Launch%20Global%20IVP%20Assay%20Repository&url=https%3A%2F%2Fzifo.com%2Fnews%2Fzifo-pistoia-alliance-and-pharma-majors-launch-global-ivp-assay-repository%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Zifo%2C+Pistoia+Alliance%2C+and+Pharma+Majors+Launch+Global+IVP+Assay+Repository&url=https%3A%2F%2Fzifo.com%2Fnews%2Fzifo-pistoia-alliance-and-pharma-majors-launch-global-ivp-assay-repository%2F "Share on LinkedIn")
- Repository standardizes how biological assays are captured, shared, and reused
- Zifo worked collaboratively with regulatory authorities and Pistoia Alliance members
- Steering committee included representatives from AbbVie, Novartis, Merck and Roche
CAMBRIDGE, Mass. and CAMBRIDGE, England, May 26, 2026 /PRNewswire/ — Zifo, the leading global enabler of AI and data-driven enterprise informatics for science-driven organizations, is proud to announce the successful development and launch of the In Vitro Pharmacology (IVP) Assay Repository, marking an important step toward standardizing how biological assays are captured, shared, and reused across the life sciences industry.
**Bridging the Gap Between Science and Data**
For years, the life sciences industry has struggled with fragmented in vitro pharmacology data, inconsistent assay documentation, and limited interoperability across organisations and platforms. These “data silos” hinder efficient data exchange, cross-study comparison, and reuse of assay data across the drug discovery and development ecosystem. The new IVP Assay Repository addresses this by providing a structured framework where researchers can register and manage in vitro pharmacology assays in a consistent and transparent way.
As the development and implementation partner, Zifo’s contribution went beyond traditional software development. **The company’s Scientific Informatics and Data experts worked collaboratively with regulatory authorities and Pistoia Alliance members — including steering committee representatives from AbbVie, Novartis, Merck and Roche — to develop the underlying platform.** By applying controlled vocabularies and standardized data fields, the repository, which builds on public ontologies like Bioassay Ontology (BAO), ensures that data is of higher quality, reduces duplication, and acts as a shared foundation that benefits the entire biopharma ecosystem.
“We are excited to see the release of version 1.0 of the IVP Assay Repository. This is an important milestone toward a more open and interoperable future for biological data,” said **Aishwarya Balajee, Head of Scientific Data and Digital at Zifo.** “Over the past two years, Zifo has been proud to collaborate with the Pistoia Alliance and its member community to help design and build this standardized biological assay registration platform. By enabling interoperable assay registration within a shared, open framework, the IVP Assay Repository helps the industry consistently describe, discover, and reuse assays across organizations. We look forward to seeing the broader scientific community leverage this platform to strengthen collaboration, improve reproducibility, and accelerate innovation,” she said.
“By enabling a standardized way to register protocols, the Assay Repository facilitates the systematic transmission of in vitro pharmacology data reducing the time spent on manual data cleanup and ensuring that critical safety information is both transparent and easily accessible,” said **Christian Baber, Chief Portfolio Officer at Pistoia Alliance.** “It is an open, centralized bioassay repository linked to standardized result templates that addresses the critical need for industry-wide consistency during data exchanges such as IND submissions. The IVP Assay Repository creates a shared foundation that benefits the entire biopharma ecosystem.”
**Key Impact of the Repository:**
- **Enhanced Data Exchange and Interoperability:** Provides a FAIR-aligned centralized repository for in vitro pharmacology assays, improving assay discoverability, consistency of assay documentation, and interoperability across platforms and organisations.
- **Industry Collaboration:** Facilitates cross-sector collaboration between biopharma companies, CROs, technology providers, and regulatory stakeholders by promoting a common framework for assay registration and information sharing.
- **Informatics Excellence:** Utilizes Zifo’s deep expertise in scientific informatics to provide a guided interface where users can easily search, filter, and contribute new entries covering assay design, targets, and molecular details.
**Open for community feedback**
This first version of the IVP Assay Repository is now available to the community, with the Pistoia Alliance inviting feedback from across the life sciences community.
As governance models and usage frameworks continue to evolve, the platform will be iteratively developed within the Pistoia Alliance In Vitro Pharmacology project to ensure it meets the needs of researchers, data scientists, organizations, and regulators. **To know more about the project, please visit:**
**About Zifo**
Zifo is the leading global enabler of AI and data driven enterprise informatics for science driven organizations. With extensive solutions and services expertise spanning research, development, manufacturing, and clinical domains, we serve a diverse range of industries, including Pharma, Biotech, Chemicals, Food and Beverage, Oil & Gas, and FMCG. Trusted by over 190 science-focused organizations worldwide, Zifo is the partner of choice for advancing digital scientific innovation.
**About the Pistoia Alliance**
The Pistoia Alliance is a global, not-for-profit members’ organization made up of life science companies, technology and service providers, publishers, and academic groups working to lower barriers to innovation in R&D through collaboration.
## Recent News
### [Zifo Co-Launches REAL 2026 to Spotlight the Next Generation of Connected, AI-Enabled Lab Environments](https://zifo.com/news/zifo-co-launches-real-2026-to-spotlight-the-next-generation-of-connected-ai-enabled-lab-environments/)
[  ](https://zifo.com/news/zifo-co-launches-real-2026-to-spotlight-the-next-generation-of-connected-ai-enabled-lab-environments/)
### [CMC Bottleneck is Choking Biopharma’s Drug Pipeline, says Zifo](https://zifo.com/news/cmc-bottleneck-is-choking-biopharmas-drug-pipeline-says-zifo/)
[  ](https://zifo.com/news/cmc-bottleneck-is-choking-biopharmas-drug-pipeline-says-zifo/)
### [Zifo Accelerates LIMS Master Data Validation with New AI-Enabled Services Accelerator](https://zifo.com/news/zifo-accelerates-lims-master-data-validation-with-new-ai-enabled-services-accelerator/)
[  ](https://zifo.com/news/zifo-accelerates-lims-master-data-validation-with-new-ai-enabled-services-accelerator/)
---
### [Zifo's Global Survey Reveals Early Momentum for AI in Biopharma, But Data Readiness Remains Key Hurdle](https://zifo.com/news/zifos-global-survey-reveals-early-momentum-for-ai-in-biopharma-but-data-readiness-remains-key-hurdle/)
**Published:** July 24, 2025
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [News](https://zifo.com/news/ "News")> Zifo’s Global Survey Reveals Early Momentum for AI in Biopharma, But Data Readiness Remains Key Hurdle
## Zifo’s Global Survey Reveals Early Momentum for AI in Biopharma, But Data Readiness Remains Key Hurdle
Jul 24, 2025
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Zifo%27s%20Global%20Survey%20Reveals%20Early%20Momentum%20for%20AI%20in%20Biopharma%2C%20But%20Data%20Readiness%20Remains%20Key%20Hurdle%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fnews%2Fzifos-global-survey-reveals-early-momentum-for-ai-in-biopharma-but-data-readiness-remains-key-hurdle%2F "Share on Email")
- [](https://x.com/intent/post?text=Zifo%27s%20Global%20Survey%20Reveals%20Early%20Momentum%20for%20AI%20in%20Biopharma%2C%20But%20Data%20Readiness%20Remains%20Key%20Hurdle&url=https%3A%2F%2Fzifo.com%2Fnews%2Fzifos-global-survey-reveals-early-momentum-for-ai-in-biopharma-but-data-readiness-remains-key-hurdle%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Zifo%5C%26%23039%3Bs+Global+Survey+Reveals+Early+Momentum+for+AI+in+Biopharma%2C+But+Data+Readiness+Remains+Key+Hurdle&url=https%3A%2F%2Fzifo.com%2Fnews%2Fzifos-global-survey-reveals-early-momentum-for-ai-in-biopharma-but-data-readiness-remains-key-hurdle%2F "Share on LinkedIn")
RALEIGH, N.C., CAMBRIDGE, England and CHENNAI, India, July 24, 2025 /PRNewswire/ — A new survey of scientists and informaticians reveals that while investment in artificial intelligence (AI) and machine learning (ML) is rapidly accelerating across the R&D, manufacturing, and clinical value chain, persistent data silos and integration headaches are stalling progress — raising crucial questions about whether science-focused companies are truly ready to harness the full power of AI.
The **[Data Readiness Survey](/blogs/early-days-for-ai-but-scientific-data-management-gains-momentum/),** conducted by Zifo Technologies, polled scientists and informaticians from over 30 science-driven companies, revealing both enthusiasm for AI’s transformative potential and persistent challenges in data management and integration.
While nearly two-thirds of organizations have begun investing in AI and ML across their value chains, only 32% of respondents express high confidence in their company’s ability to leverage scientific data effectively for AI initiatives.
A striking 70% report that accessing the data needed for AI projects is either difficult or somewhat difficult, underscoring a widespread struggle with data accessibility. Data is not harmonized in terms of storage or metadata, the report noted, highlighting the lack of standardized practices that hampers progress.
Data silos, interoperability, and automation gaps emerge as major obstacles. Nearly half of organizations find it “somewhat difficult” or worse to pipeline and integrate data from lab instruments, with aging infrastructure and a lack of common standards complicating seamless data exchange. Automation of data capture is growing, but 26% still rely primarily on manual processes, and 10% use no automation at all. Adoption of standardized data formats and ontologies is mixed, with 39% agreeing their organization has them, and an equal proportion either unsure or disagreeing.
The report also noted that a critical gap exists in current data management solutions for High-Performance Computing (HPC) environments. Most systems, such as Electronic Lab Notebooks (ELNs), are not designed to handle the petabytes of unstructured data generated during complex analysis. While the initial capture of instrument data and the final storage of analyzed data products are well-automated, the crucial intermediate processing stage on HPC systems remains poorly supported.
As Zifo’s Chief Scientific Officer Paul Denny-Gouldson observes, “Data management is fundamental to ensuring data reuse and data retrieval, because that is the lifeblood of what enables FAIR \[Findable, Accessible, Interoperable, Reusable\] data”.
Despite these hurdles, AI adoption in R&D is advancing, with 39% of organizations reporting moderate adoption and another 26% noting minimal uptake.
The focus for AI applications is strongest in research (32%) and development (27%), with clinical, manufacturing, and precision medicine also showing growing interest. Organizations are prioritizing targeted, incremental AI interventions rather than large-scale, disruptive deployments. “The true value is increasingly seen in integrating AI and machine learning into routine workflows across the entire value chain,” Paul said.
Key challenges identified include data quality issues (27%), data privacy concerns (23%), and integration difficulties with lab instruments (21%). Privacy anxieties have been amplified by the rise of generative AI, prompting many organizations to develop in-house solutions to retain control over proprietary data.
The report also states that because organizations tend to be large and diverse, and each department is focused on producing results with available technologies, it is difficult to gauge each department’s ability to use AI-driven programs to enhance productivity and efficiency.
When asked about the greatest potential benefits of AI, respondents highlighted accelerated discovery, increased efficiency and cost savings, and enhanced scientific insights. “While improved patient outcomes should ideally be the end goal, the survey results suggest that respondents are also strongly focused on other tangible benefits of AI,” Paul notes. These intermediate gains — faster research cycles, optimized processes, and deeper data-driven insights — are seen as stepping stones to better products and, ultimately, improved outcomes for patients and consumers.
Looking ahead, Zifo emphasizes that data standardization and seamless data exchange among different lab instruments are critical for science-driven industries to fully realize the promise of AI. “The current era could be called ‘The Age of Data Management,’ which will eventually lead to ‘The Age of AI,’” the report concludes. Companies that invest in robust data infrastructure, cross-functional collaboration, and targeted AI applications will be best positioned to turn data into discovery — and innovation into impact.
To Read and Download the Data Readiness Survey Report, please click here: [https://zifo.com/blogs/early-days-for-ai-but-scientific-data-management-gains-momentum/](/blogs/early-days-for-ai-but-scientific-data-management-gains-momentum/)
**About Zifo:**
Zifo is the leading global enabler of AI and data driven enterprise informatics for science driven organizations. With extensive solutions and services expertise spanning research, development, manufacturing, and clinical domains, we serve a diverse range of industries, including Pharma, Biotech, Chemicals, Food and Beverage, Oil & Gas, and FMCG. Trusted by over 190 science-focused organizations worldwide, Zifo is the partner of choice for advancing digital scientific innovation. For more information, visit ; [https://zifo.com/practical-ai-blueprints/](/practical-ai-blueprints/)
## Recent News
### [Zifo Co-Launches REAL 2026 to Spotlight the Next Generation of Connected, AI-Enabled Lab Environments](https://zifo.com/news/zifo-co-launches-real-2026-to-spotlight-the-next-generation-of-connected-ai-enabled-lab-environments/)
[  ](https://zifo.com/news/zifo-co-launches-real-2026-to-spotlight-the-next-generation-of-connected-ai-enabled-lab-environments/)
### [CMC Bottleneck is Choking Biopharma’s Drug Pipeline, says Zifo](https://zifo.com/news/cmc-bottleneck-is-choking-biopharmas-drug-pipeline-says-zifo/)
[  ](https://zifo.com/news/cmc-bottleneck-is-choking-biopharmas-drug-pipeline-says-zifo/)
### [Zifo Accelerates LIMS Master Data Validation with New AI-Enabled Services Accelerator](https://zifo.com/news/zifo-accelerates-lims-master-data-validation-with-new-ai-enabled-services-accelerator/)
[  ](https://zifo.com/news/zifo-accelerates-lims-master-data-validation-with-new-ai-enabled-services-accelerator/)
---
### [Zifo on AI in Biopharma: Not a Magic Wand, But a Transformative Tool](https://zifo.com/news/zifo-on-ai-in-biopharma-not-a-magic-wand-but-a-transformative-tool/)
**Published:** August 12, 2025
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [News](https://zifo.com/news/ "News")> Zifo on AI in Biopharma: Not a Magic Wand, But a Transformative Tool
## Zifo on AI in Biopharma: Not a Magic Wand, But a Transformative Tool
Aug 12, 2025
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Zifo%20on%20AI%20in%20Biopharma%3A%20Not%20a%20Magic%20Wand%2C%20But%20a%20Transformative%20Tool%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fnews%2Fzifo-on-ai-in-biopharma-not-a-magic-wand-but-a-transformative-tool%2F "Share on Email")
- [](https://x.com/intent/post?text=Zifo%20on%20AI%20in%20Biopharma%3A%20Not%20a%20Magic%20Wand%2C%20But%20a%20Transformative%20Tool&url=https%3A%2F%2Fzifo.com%2Fnews%2Fzifo-on-ai-in-biopharma-not-a-magic-wand-but-a-transformative-tool%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Zifo+on+AI+in+Biopharma%3A+Not+a+Magic+Wand%2C+But+a+Transformative+Tool&url=https%3A%2F%2Fzifo.com%2Fnews%2Fzifo-on-ai-in-biopharma-not-a-magic-wand-but-a-transformative-tool%2F "Share on LinkedIn")
RALEIGH, N.C., CAMBRIDGE, England and CHENNAI, India, Aug. 12, 2025 /PRNewswire/ — As the race to use artificial intelligence (AI) in drug discovery intensifies, Zifo’s Sujeegar Jeevanandam [cautions](/blogs/interview-ai-by-itself-isnt-going-to-magically-deliver-a-drug-today/) that the real power of AI isn’t in headline-making breakthroughs, but in the practical ways it streamlines research and enables better science.
Zifo’s [latest survey](/blogs/early-days-for-ai-but-scientific-data-management-gains-momentum/) reveals that only one in three scientists feels confident using scientific data for AI, highlighting deep data readiness challenges. Yet, despite biopharma’s reputation for caution in technology adoption, Sujeegar asserts, “I don’t subscribe to the idea that biopharma is risk averse. The industry thrives on risk. You never start a trial with a guarantee of success; it’s inherently a betting game.”
Sujeegar Jeevanandam, who goes by his nickname SJ, is the Principal Consultant for Data and AI at Zifo, with over 15 years of experience in R&D scientific informatics.
AI, Sujeegar explains, is less about sudden, headline-grabbing breakthroughs and more about targeted, cumulative value: “If you can even create a 5% impact at various stages of the pipeline, it’s going to translate into millions, if not billions, in savings.” Beyond speeding up discovery, AI’s often-overlooked power lies in the mundane: “The most non-glamorous example is simply getting answers to questions. With AI, you could get those answers very quickly or at least be pointed to the exact location where the answer resides. I cannot overstate how much in savings we’ll realize by being able to find a fact that we know already exists.”
Addressing concerns about privacy and the role of scientists, Sujeegar believes, “I don’t think scientists have to go out of their way to become an expert in AI or LLMs. If you make AI easy for consumption, more people will consume it.”
With the rate of AI adoption outpacing past revolutions like ELN and LIMS, Sujeegar concludes, “Everyone is responsible for incorporating AI into their operations,” from lab scientists to CEOs, and all must “find ways to integrate it into their workflow.”
To access the full viewpoint, click here: [https://zifo.com/blogs/interview-ai-by-itself-isnt-going-to-magically-deliver-a-drug-today/](/blogs/interview-ai-by-itself-isnt-going-to-magically-deliver-a-drug-today/)
**About Zifo:**
Zifo is the leading global enabler of AI and data driven enterprise informatics for science driven organizations. With extensive solutions and services expertise spanning research, development, manufacturing, and clinical domains, we serve a diverse range of industries, including Pharma, Biotech, Chemicals, Food and Beverage, Oil & Gas, and FMCG. Trusted by over 190 science-focused organizations worldwide, Zifo is the partner of choice for advancing digital scientific innovation.
; [https://zifo.com/practical-ai-blueprints/](/practical-ai-blueprints/)
## Recent News
### [Zifo Co-Launches REAL 2026 to Spotlight the Next Generation of Connected, AI-Enabled Lab Environments](https://zifo.com/news/zifo-co-launches-real-2026-to-spotlight-the-next-generation-of-connected-ai-enabled-lab-environments/)
[  ](https://zifo.com/news/zifo-co-launches-real-2026-to-spotlight-the-next-generation-of-connected-ai-enabled-lab-environments/)
### [CMC Bottleneck is Choking Biopharma’s Drug Pipeline, says Zifo](https://zifo.com/news/cmc-bottleneck-is-choking-biopharmas-drug-pipeline-says-zifo/)
[  ](https://zifo.com/news/cmc-bottleneck-is-choking-biopharmas-drug-pipeline-says-zifo/)
### [Zifo Accelerates LIMS Master Data Validation with New AI-Enabled Services Accelerator](https://zifo.com/news/zifo-accelerates-lims-master-data-validation-with-new-ai-enabled-services-accelerator/)
[  ](https://zifo.com/news/zifo-accelerates-lims-master-data-validation-with-new-ai-enabled-services-accelerator/)
---
### [Zifo Open Quiz: A Cultural Cornerstone on Indian Independence Day with Over 1,500 Competitors](https://zifo.com/news/zifo-open-quiz-a-cultural-cornerstone-on-indian-independence-day-with-over-1500-competitors/)
**Published:** August 19, 2025
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [News](https://zifo.com/news/ "News")> Zifo Open Quiz: A Cultural Cornerstone on Indian Independence Day with Over 1,500 Competitors
## Zifo Open Quiz: A Cultural Cornerstone on Indian Independence Day with Over 1,500 Competitors
Aug 19, 2025
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Zifo%20Open%20Quiz%3A%20A%20Cultural%20Cornerstone%20on%20Indian%20Independence%20Day%20with%20Over%201%2C500%20Competitors%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fnews%2Fzifo-open-quiz-a-cultural-cornerstone-on-indian-independence-day-with-over-1500-competitors%2F "Share on Email")
- [](https://x.com/intent/post?text=Zifo%20Open%20Quiz%3A%20A%20Cultural%20Cornerstone%20on%20Indian%20Independence%20Day%20with%20Over%201%2C500%20Competitors&url=https%3A%2F%2Fzifo.com%2Fnews%2Fzifo-open-quiz-a-cultural-cornerstone-on-indian-independence-day-with-over-1500-competitors%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Zifo+Open+Quiz%3A+A+Cultural+Cornerstone+on+Indian+Independence+Day+with+Over+1%2C500+Competitors&url=https%3A%2F%2Fzifo.com%2Fnews%2Fzifo-open-quiz-a-cultural-cornerstone-on-indian-independence-day-with-over-1500-competitors%2F "Share on LinkedIn")
*Event flagged off by Monsieur Christophe Bramoullé, Deputy Consul General of France in Chennai*
CHENNAI, India, Aug. 19, 2025 /PRNewswire/ — Zifo, a leading global enabler of AI and data driven enterprise informatics for science driven organizations, successfully hosted the 34th annual “Zifo Open Quiz” on Indian Independence Day, drawing a large and enthusiastic crowd to The Music Academy auditorium, solidifying its status as a cornerstone of Chennai’s cultural calendar.
With over **500 teams and 1,500** **eager participants** from across the city, nation, and even the globe, this year’s Zifo Open Quiz was an unforgettable spectacle. Competitors vied for a prize pool exceeding half a million rupees. **Nearly half of the participants were attending the quiz for the very first time, showing that interest is expanding beyond its traditional base**.
For the first time in the quiz’s history, the champion team included a woman, Sania Narulkar, who said: “It was a great quiz, the quizmasters put on a superb show. We as a team bring together complementary strengths”.
The competition also showcased a new generation of quizzing talent, as s**ix of the eight finalists were on stage for the first time ever**, including the champion team.
The gala event was flagged off by Monsieur Christophe Bramoullé, Deputy Consul General of France in Chennai, who said: “Reviving this quiz tradition in Chennai is a fantastic celebration of curiosity and a wonderful bridge for cultural exchange, resonating with the spirit of shared knowledge and joint innovation at the heart of the relationship between France and India”.
The Zifo Open Quiz was conducted in collaboration with renowned quizmaster **Dr. Navin Jayakumar** and the **Quiz Federation of India (QFI). Dr. Navin was assisted by Siddhanth Rao**.
For the second year in a row, the event witnessed enthusiastic participation from numerous schools, with nearly **1,500 school students from over 15 schools** participating in this festival of curiosity. The school round was conducted in individual schools across Chennai in the months of June and July.
“We have seen a clear shift in how people engage with information,” said Dr. Navin Jayakumar, Ophthalmologist and Quizmaster. “Quizzing isn’t just about static facts anymore. Our questions now incorporate trends and viral moments from social media, reflecting the dynamic nature of how this generation consumes knowledge.”
The event’s seamless execution was a testament to the dedication of Zifo’s volunteers, who worked tirelessly on ground logistics, from the registration desk to backstage management, ensuring a smooth and memorable experience for all.
“It’s the World Cup of quizzing. Everyone from across the country came together. The historic Music Academy auditorium was full; it shows the passion for quizzing in Chennai. We came here to live that experience. Kudos to Zifo for organizing this event, everything was smooth,” according to Praveen, Chandrakanth and Rishi from the team “CIDs from Kerala”, who made it to the semi-final.
To accommodate participants traveling from across India and overseas, Zifo established a dedicated bell desk to assist guests with their luggage. This thoughtful addition ensured a smooth and convenient experience for those who traveled to Chennai specifically for the quiz.
**Zifo Open Quiz 2025 Winners**
**Champion:** “Team Niresa” represented by Nirmal Rajagopalan, Reitesh KV Raman, and Sania Narulkar.
**First Runners Up:** Team Congrats All
**Second Runners Up:** Team Wimwi Mandram
**College Round Winners and Runners Up:** IIT Madras
**School Round Winners:** Bhavan’s Rajaji Vidyashram
Zifo remains committed to nurturing intellectual curiosity and believes the Zifo Open Quiz is a significant step toward achieving this goal. We extend our heartfelt congratulations to all the winners and participants.
[Click here to watch the full recording of the quiz show.](https://www.youtube.com/live/4WjBkqzcSjM)
**About Zifo:**
Zifo is the leading global enabler of AI and data-driven enterprise informatics for science-driven organizations. With extensive solutions and services expertise spanning research, development, manufacturing, and clinical domains, we serve various industries, including pharma, biotech, chemicals, food and beverage, oil and gas, and FMCG. Trusted by over 190 science-focused organizations worldwide, Zifo is the partner of choice for advancing digital scientific innovation.
## Recent News
### [Zifo Co-Launches REAL 2026 to Spotlight the Next Generation of Connected, AI-Enabled Lab Environments](https://zifo.com/news/zifo-co-launches-real-2026-to-spotlight-the-next-generation-of-connected-ai-enabled-lab-environments/)
[  ](https://zifo.com/news/zifo-co-launches-real-2026-to-spotlight-the-next-generation-of-connected-ai-enabled-lab-environments/)
### [CMC Bottleneck is Choking Biopharma’s Drug Pipeline, says Zifo](https://zifo.com/news/cmc-bottleneck-is-choking-biopharmas-drug-pipeline-says-zifo/)
[  ](https://zifo.com/news/cmc-bottleneck-is-choking-biopharmas-drug-pipeline-says-zifo/)
### [Zifo Accelerates LIMS Master Data Validation with New AI-Enabled Services Accelerator](https://zifo.com/news/zifo-accelerates-lims-master-data-validation-with-new-ai-enabled-services-accelerator/)
[  ](https://zifo.com/news/zifo-accelerates-lims-master-data-validation-with-new-ai-enabled-services-accelerator/)
---
### [Zifo Executive: Biopharma Grapples with AI Anxiety and Tech Obsolescence](https://zifo.com/news/zifo-executive-biopharma-grapples-with-ai-anxiety-and-tech-obsolescence/)
**Published:** October 2, 2025
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [News](https://zifo.com/news/ "News")> Zifo Executive: Biopharma Grapples with AI Anxiety and Tech Obsolescence
## Zifo Executive: Biopharma Grapples with AI Anxiety and Tech Obsolescence
Oct 02, 2025
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Zifo%20Executive%3A%20Biopharma%20Grapples%20with%20AI%20Anxiety%20and%20Tech%20Obsolescence%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fnews%2Fzifo-executive-biopharma-grapples-with-ai-anxiety-and-tech-obsolescence%2F "Share on Email")
- [](https://x.com/intent/post?text=Zifo%20Executive%3A%20Biopharma%20Grapples%20with%20AI%20Anxiety%20and%20Tech%20Obsolescence&url=https%3A%2F%2Fzifo.com%2Fnews%2Fzifo-executive-biopharma-grapples-with-ai-anxiety-and-tech-obsolescence%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Zifo+Executive%3A+Biopharma+Grapples+with+AI+Anxiety+and+Tech+Obsolescence&url=https%3A%2F%2Fzifo.com%2Fnews%2Fzifo-executive-biopharma-grapples-with-ai-anxiety-and-tech-obsolescence%2F "Share on LinkedIn")
CAMBRIDGE, Mass. and CAMBRIDGE, England and CHENNAI, India, Oct. 2, 2025 /PRNewswire/ — Despite the transformative potential of Artificial Intelligence, a pervasive ‘AI anxiety’ is holding back a significant portion of the biopharma industry, a worry that is directly linked to the need for a clear return on investment, according to Margaret Difilippo, Zifo’s Head of Commercial in North America.
This executive-level concern is proving to be more of a barrier to innovation than technological limitations themselves, creating a critical need to bridge the gap between cutting-edge AI and a cautious scientific community.
According to Margaret, the hesitation to adopt new technologies, from AI to established systems like LIMS and ELN, also stems from a fear of business disruption and high costs. “The single greatest fear is the risk of introducing errors into a regulatory process,” she noted, explaining how this anxiety leads some companies to delay critical tech upgrades for a decade or more.
She points to a divide between generations of scientists. While a new cohort of scientists, fluent in computational biology and data science, are readily embracing these tools, more experienced scientists often resist change unless they are shown a clear value proposition — which is a fair ask. She argues that the entire organization shares the responsibility for rolling out new technology.
She also highlighted the underlying power dynamic between scientific teams and their IT counterparts. Historically, IT has been seen as a support function, but the digital transformation in science-focused industries requires a shift toward a collaborative partnership. According to Margaret, both sides need to take shared ownership of technological success. Scientists must articulate their needs and be open to change, while the informatics department must evolve from simply maintaining infrastructure to actively enabling scientific innovation.
Looking ahead, Margaret is optimistic that the current ‘AI hype’ will settle, allowing companies to focus on a more practical approach. The key to overcoming widespread anxiety, she believes, is moving from a ‘wait-and-see’ mindset to proactive education and enablement. By helping employees understand that AI is a tool for efficiency, not a threat to their jobs, organizations can unlock its transformative potential and drive better science.
To read the viewpoint, please visit: [https://zifo.com/blogs/interview-tackling-ai-anxiety-and-technology-obsolescence-to-drive-better-science/](/blogs/interview-tackling-ai-anxiety-and-technology-obsolescence-to-drive-better-science/)
**About Zifo:**
Zifo is the leading global enabler of AI and data-driven enterprise informatics for science-driven organizations. With extensive solutions and services expertise spanning research, development, manufacturing, and clinical domains, we serve various industries, including pharma, biotech, chemicals, food and beverage, oil and gas, and FMCG. Trusted by over 190 science-focused organizations worldwide, Zifo is the partner of choice for advancing digital scientific innovation.
; [https://zifo.com/practical-ai-blueprints/](/practical-ai-blueprints/)
## Recent News
### [Zifo Co-Launches REAL 2026 to Spotlight the Next Generation of Connected, AI-Enabled Lab Environments](https://zifo.com/news/zifo-co-launches-real-2026-to-spotlight-the-next-generation-of-connected-ai-enabled-lab-environments/)
[  ](https://zifo.com/news/zifo-co-launches-real-2026-to-spotlight-the-next-generation-of-connected-ai-enabled-lab-environments/)
### [CMC Bottleneck is Choking Biopharma’s Drug Pipeline, says Zifo](https://zifo.com/news/cmc-bottleneck-is-choking-biopharmas-drug-pipeline-says-zifo/)
[  ](https://zifo.com/news/cmc-bottleneck-is-choking-biopharmas-drug-pipeline-says-zifo/)
### [Zifo Accelerates LIMS Master Data Validation with New AI-Enabled Services Accelerator](https://zifo.com/news/zifo-accelerates-lims-master-data-validation-with-new-ai-enabled-services-accelerator/)
[  ](https://zifo.com/news/zifo-accelerates-lims-master-data-validation-with-new-ai-enabled-services-accelerator/)
---
### [Zifo's SiEE Boston Summit Charts New Roadmap for 'Practical AI' in Life Sciences, Bridging the Gap Between Business Vision and Lab Reality](https://zifo.com/news/zifos-siee-boston-summit-charts-new-roadmap-for-practical-ai-in-life-sciences-bridging-the-gap-between-business-vision-and-lab-reality/)
**Published:** May 6, 2026
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [News](https://zifo.com/news/ "News")> Zifo’s SiEE Boston Summit Charts New Roadmap for ‘Practical AI’ in Life Sciences, Bridging the Gap Between Business Vision and Lab Reality
## Zifo’s SiEE Boston Summit Charts New Roadmap for ‘Practical AI’ in Life Sciences, Bridging the Gap Between Business Vision and Lab Reality
May 05, 2026
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Zifo%27s%20SiEE%20Boston%20Summit%20Charts%20New%20Roadmap%20for%20%27Practical%20AI%27%20in%20Life%20Sciences%2C%20Bridging%20the%20Gap%20Between%20Business%20Vision%20and%20Lab%20Reality%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fnews%2Fzifos-siee-boston-summit-charts-new-roadmap-for-practical-ai-in-life-sciences-bridging-the-gap-between-business-vision-and-lab-reality%2F "Share on Email")
- [](https://x.com/intent/post?text=Zifo%27s%20SiEE%20Boston%20Summit%20Charts%20New%20Roadmap%20for%20%27Practical%20AI%27%20in%20Life%20Sciences%2C%20Bridging%20the%20Gap%20Between%20Business%20Vision%20and%20Lab%20Reality&url=https%3A%2F%2Fzifo.com%2Fnews%2Fzifos-siee-boston-summit-charts-new-roadmap-for-practical-ai-in-life-sciences-bridging-the-gap-between-business-vision-and-lab-reality%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Zifo%5C%26%23039%3Bs+SiEE+Boston+Summit+Charts+New+Roadmap+for+%5C%26%23039%3BPractical+AI%5C%26%23039%3B+in+Life+Sciences%2C+Bridging+the+Gap+Between+Business+Vision+and+Lab+Reality&url=https%3A%2F%2Fzifo.com%2Fnews%2Fzifos-siee-boston-summit-charts-new-roadmap-for-practical-ai-in-life-sciences-bridging-the-gap-between-business-vision-and-lab-reality%2F "Share on LinkedIn")
BOSTON, May 5, 2026 /PRNewswire/ — Trading the abstract allure of AI hype for a technical implementation roadmap, **Zifo’s 2026 Scientific Informatics Experience Exchange (SiEE) in Boston** concluded with heavyweights from Sanofi, Takeda, AbbVie, Regeneron, Biogen, Eli Lilly, Novo Nordisk, J&J, and Broad Institute establishing that the industry’s digital future now rests on the ‘first mile’ of lab data integrity.
As the industry grapples with the transition from experimental digital pilots to enterprise-wide AI scaling, Zifo’s SiEE Boston summit served as a critical decision-making forum. The primary outcome was a unified consensus: it is time to move beyond the theoretical underpinnings of what is possible and focus on solving the thorny problems that scientists and informaticians face on a day-to-day basis.
“SiEE Boston 2026 proved that the industry is ready to stop asking ‘what’ AI can do and start solving ‘how’ it can be implemented with regulatory rigor,” said **Margaret DiFilippo, Vice President of Customer Success at Zifo.** “The exchange established that the future of science depends on democratizing data access and ensuring that our digital transformation projects are built on a foundation of yesterday’s data quality combined with tomorrow’s automation.”
**Future-Focused Outcomes and Expert Highlights** the summit featured a heavy-hitting agenda of 16 industry practitioners who provided actionable insights into the future of scientific informatics:
- **Defining the New Scientific Method: Leah O’Brien (Sanofi)** challenged the traditional research status quo, outlining how the digital lab revolution is fundamentally accelerating and removing friction from the scientific method for the next generation of researchers.
- **AI Implementation at Scale: Mike Crowe (formerly Colgate)** delivered critical considerations for AI-assisted product development, while **Kelly Desino (AbbVie)** showcased how graph analytics are now being used to drive clinical asset prioritization.
- **The Data-Identity Nexus:** A headline panel featuring **Ragavi Shanmugam (Zifo), Will Weiss (Eli Lilly), Sovanda Kaing (Takeda),** and **David Nirschl (J&J)** debated that AI-ready data is certainly a prerequisite for AI, but the way to get there will be a combination of mining historical high-value data with for-cause regeneration of new data, with all the right controls and metadata.
- **Translational Outcomes: Vinayagam (Vinu) Arunachalam (Takeda)** bridged the gap between computational biology and the clinic, discussing the journey from biomarker insight to clinical decisions under regulatory scrutiny.
**Deep-Dive Breakout Success** The afternoon sessions divided the collective expertise into two specialized tracks to solve technical hurdles in the drug development journey:
- **R&D Track: Cathy Kuang (Formerly Takeda)** spoke on how data, AI, and automation are reshaping life sciences; **Ricardo Schiavo (Regeneron)** detailed the democratization of lab data; and **Chris Perkins (Broad Institute)** shared strategies for operationalizing the ‘first mile’ of lab data flow in complex research environments.
- **QA/CMC Track: Lira Mishra (Biogen)** addressed the rising urgency of laboratory cybersecurity; **Diana Bowley (AbbVie)** mapped the digital transformation of bioprocess labs; **Clark Leininger (Formerly Moderna)** shared lessons on ‘Failing Successfully’ to ensure project delivery; and **Nara Aravamudhan (Zifo)** tackled the specific challenges of AI-assisted LIMS rollouts.
**A High-Commitment Exchange**
The exclusivity of the event was underscored by the high level of engagement from the scientific community. The summit hosted a focused group of nearly 120 attendees. Notably, registered partner organizations showed a remarkable **84% attendance rate,** reflecting the critical importance of the SiEE platform in the current technology landscape.
**Watch the Sessions**
If you missed the debate or want to revisit the technical deep dives, the full event recording is now available. **To watch the recording, click here:**
**What’s Next?**
The energy from Boston is moving across the Atlantic. Zifo will host its next global dialogue (SiEE) in **Basel on June 2, 2026.**
**About Zifo**
Zifo is the leading global enabler of AI and data driven enterprise informatics for science driven organizations. With extensive solutions and services expertise spanning research, development, manufacturing, and clinical domains, we serve a diverse range of industries, including Pharma, Biotech, Chemicals, Food and Beverage, Oil & Gas, and FMCG. Trusted by over 190 science-focused organizations worldwide, Zifo is the partner of choice for advancing digital scientific innovation.
## Recent News
### [Zifo Co-Launches REAL 2026 to Spotlight the Next Generation of Connected, AI-Enabled Lab Environments](https://zifo.com/news/zifo-co-launches-real-2026-to-spotlight-the-next-generation-of-connected-ai-enabled-lab-environments/)
[  ](https://zifo.com/news/zifo-co-launches-real-2026-to-spotlight-the-next-generation-of-connected-ai-enabled-lab-environments/)
### [CMC Bottleneck is Choking Biopharma’s Drug Pipeline, says Zifo](https://zifo.com/news/cmc-bottleneck-is-choking-biopharmas-drug-pipeline-says-zifo/)
[  ](https://zifo.com/news/cmc-bottleneck-is-choking-biopharmas-drug-pipeline-says-zifo/)
### [Zifo Accelerates LIMS Master Data Validation with New AI-Enabled Services Accelerator](https://zifo.com/news/zifo-accelerates-lims-master-data-validation-with-new-ai-enabled-services-accelerator/)
[  ](https://zifo.com/news/zifo-accelerates-lims-master-data-validation-with-new-ai-enabled-services-accelerator/)
---
### [Zifo’s Fast Growth Recognised](https://zifo.com/news/zifo-listed-as-one-of-the-nations-fastest-growing-company/)
**Published:** May 5, 2023
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [News](https://zifo.com/news/ "News")> Zifo’s Fast Growth Recognised
## Zifo’s Fast Growth Recognised
May 05, 2023
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Zifo%E2%80%99s%20Fast%20Growth%20Recognised%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fnews%2Fzifo-listed-as-one-of-the-nations-fastest-growing-company%2F "Share on Email")
- [](https://x.com/intent/post?text=Zifo’s%20Fast%20Growth%20Recognised&url=https%3A%2F%2Fzifo.com%2Fnews%2Fzifo-listed-as-one-of-the-nations-fastest-growing-company%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Zifo%E2%80%99s+Fast+Growth+Recognised&url=https%3A%2F%2Fzifo.com%2Fnews%2Fzifo-listed-as-one-of-the-nations-fastest-growing-company%2F "Share on LinkedIn")
**Zifo Listed as One of the Nation’s Fastest Growing Company**
We are extremely pleased to announce that we have been listed as one of the companies in The Economic Times & Statista’s India’s Growth Champions 2023. Zifo ranks 53 in the top 125 companies that have achieved the highest growth between 2019 and 2022.
Zifo’s presence in the 2023 list marks the third time of us being in the list since 2021. This is yet another recognition and reflection of the tenacity and ownership displayed by each Zifoite!
**India’s Growth Champions 2023 Ranks Nation’s Fastest-growing Companies**
## Recent News
### [Zifo Co-Launches REAL 2026 to Spotlight the Next Generation of Connected, AI-Enabled Lab Environments](https://zifo.com/news/zifo-co-launches-real-2026-to-spotlight-the-next-generation-of-connected-ai-enabled-lab-environments/)
[  ](https://zifo.com/news/zifo-co-launches-real-2026-to-spotlight-the-next-generation-of-connected-ai-enabled-lab-environments/)
### [CMC Bottleneck is Choking Biopharma’s Drug Pipeline, says Zifo](https://zifo.com/news/cmc-bottleneck-is-choking-biopharmas-drug-pipeline-says-zifo/)
[  ](https://zifo.com/news/cmc-bottleneck-is-choking-biopharmas-drug-pipeline-says-zifo/)
### [Zifo Accelerates LIMS Master Data Validation with New AI-Enabled Services Accelerator](https://zifo.com/news/zifo-accelerates-lims-master-data-validation-with-new-ai-enabled-services-accelerator/)
[  ](https://zifo.com/news/zifo-accelerates-lims-master-data-validation-with-new-ai-enabled-services-accelerator/)
---
### [Zifo and Maze Therapeutics Partner to Power Precision Medicine](https://zifo.com/news/zifo-and-maze-therapeutics-partner-to-power-precision-medicine/)
**Published:** February 18, 2026
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [News](https://zifo.com/news/ "News")> Zifo and Maze Therapeutics Partner to Power Precision Medicine
## Zifo and Maze Therapeutics Partner to Power Precision Medicine
Feb 18, 2026
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Zifo%20and%20Maze%20Therapeutics%20Partner%20to%20Power%20Precision%20Medicine%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fnews%2Fzifo-and-maze-therapeutics-partner-to-power-precision-medicine%2F "Share on Email")
- [](https://x.com/intent/post?text=Zifo%20and%20Maze%20Therapeutics%20Partner%20to%20Power%20Precision%20Medicine&url=https%3A%2F%2Fzifo.com%2Fnews%2Fzifo-and-maze-therapeutics-partner-to-power-precision-medicine%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Zifo+and+Maze+Therapeutics+Partner+to+Power+Precision+Medicine&url=https%3A%2F%2Fzifo.com%2Fnews%2Fzifo-and-maze-therapeutics-partner-to-power-precision-medicine%2F "Share on LinkedIn")
SAN FRANCISCO, Feb. 18, 2026 — Zifo, the leading global enabler of AI and data-driven enterprise informatics for science driven organizations and Maze Therapeutics Inc (Nasdaq: MAZE) have partnered to solve the critical challenge of managing, storing, and scaling massive, disparate biobank data to help in their quest for precision medicine via AI-powered scientific workflows.
While massive, well-defined biobanks like UK Biobank and the All of Us Research Program have made huge genetic and phenotypic datasets available, researchers often struggle with static tools that are difficult to implement, scale, and extend for complex scientific workflows.
The current landscape forces a disjointed, manual process where researchers must stitch together different platforms and datasets to connect the dots between genetic signals, biological pathways, and phenotypes.
Zifo’s solution, developed in partnership with Maze Therapeutics addresses the manual effort and data fragmentation with AI-enabled workflows.
“Working with Zifo, we have gained a truly scalable and robust solution for managing our biobank data. The platform’s ability to handle diverse datasets and render results so quickly has been a game-changer for our research, allowing us to accelerate our work in target identification and validation,” a Maze spokesperson said.
“Our translational genomics solution provides a dynamic, integrated system that takes researchers from population-scale signals to biological insights,” said Sandor Szalma, Scientific Advisor and a Data Veteran in the Omics space at Zifo. “We are solving a [fundamental problem for the industry](https://zifo.com/blogs/finding-our-google-maps-moment-in-translational-genomics/) by offering a seamless journey through previously fragmented data. The ability to render summary statistics in under five seconds is a testament to the solution’s robust back-end engineering, which is crucial for accelerating decision-making and empowering scientists to focus on the science rather than the technology.”
The Zifo platform integrates downstream analysis workflows, enabling a seamless process from data ingestion to meaningful discoveries. Its architecture is built to be scalable and future-ready, with a data model and back-end engineering designed to accommodate new biobank data, such as UKBB-Proteomics, AGD/NashBio, and G&H. This lays the groundwork for future AI solutions for protein modeling and genotype phenotype mapping, making the data “AI-ready” and further de-risking drug targets.
**About Zifo
Zifo is the leading global enabler of AI and data-driven enterprise informatics for science driven organizations. With extensive solutions and services expertise spanning research, development, manufacturing, and clinical domains, we serve various industries, including pharma, biotech, chemicals, food and beverage, oil and gas, and FMCG. Trusted by over 190 science-focused organizations worldwide, Zifo is the partner of choice for advancing digital scientific innovation. For more information, visit ; ;
**About Maze Therapeutics**
Maze Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel small molecule precision medicines for patients with kidney and metabolic diseases, including obesity. Guided by its Compass™ platform, Maze pursues genetically validated targets by integrating variant discovery and functionalization to discover and advance small molecule programs with first- or best-in-class potential. Maze’s pipeline is led by MZE829, a dual-mechanism APOL1 inhibitor in Phase 2 development for APOL1-mediated kidney disease (AMKD), and MZE782, a SLC6A19 inhibitor advancing to Phase 2 with the potential to treat both phenylketonuria (PKU) and chronic kidney disease (CKD). Maze is headquartered in South San Francisco. For more information, please visit [mazetx.com](http://mazetx.com), or follow the company on LinkedIn and X.
## Recent News
### [Zifo Co-Launches REAL 2026 to Spotlight the Next Generation of Connected, AI-Enabled Lab Environments](https://zifo.com/news/zifo-co-launches-real-2026-to-spotlight-the-next-generation-of-connected-ai-enabled-lab-environments/)
[  ](https://zifo.com/news/zifo-co-launches-real-2026-to-spotlight-the-next-generation-of-connected-ai-enabled-lab-environments/)
### [CMC Bottleneck is Choking Biopharma’s Drug Pipeline, says Zifo](https://zifo.com/news/cmc-bottleneck-is-choking-biopharmas-drug-pipeline-says-zifo/)
[  ](https://zifo.com/news/cmc-bottleneck-is-choking-biopharmas-drug-pipeline-says-zifo/)
### [Zifo Accelerates LIMS Master Data Validation with New AI-Enabled Services Accelerator](https://zifo.com/news/zifo-accelerates-lims-master-data-validation-with-new-ai-enabled-services-accelerator/)
[  ](https://zifo.com/news/zifo-accelerates-lims-master-data-validation-with-new-ai-enabled-services-accelerator/)
---
### [Zifo at JPM Healthcare Conference 2026: Why Technology Alone Cannot Deliver the AI Promise](https://zifo.com/news/zifo-at-jpm-healthcare-conference-2026-why-technology-alone-cannot-deliver-the-ai-promise/)
**Published:** January 22, 2026
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [News](https://zifo.com/news/ "News")> Zifo at JPM Healthcare Conference 2026: Why Technology Alone Cannot Deliver the AI Promise
## Zifo at JPM Healthcare Conference 2026: Why Technology Alone Cannot Deliver the AI Promise
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Zifo%20at%20JPM%20Healthcare%20Conference%202026%3A%20Why%20Technology%20Alone%20Cannot%20Deliver%20the%20AI%20Promise%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fnews%2Fzifo-at-jpm-healthcare-conference-2026-why-technology-alone-cannot-deliver-the-ai-promise%2F "Share on Email")
- [](https://x.com/intent/post?text=Zifo%20at%20JPM%20Healthcare%20Conference%202026%3A%20Why%20Technology%20Alone%20Cannot%20Deliver%20the%20AI%20Promise&url=https%3A%2F%2Fzifo.com%2Fnews%2Fzifo-at-jpm-healthcare-conference-2026-why-technology-alone-cannot-deliver-the-ai-promise%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Zifo+at+JPM+Healthcare+Conference+2026%3A+Why+Technology+Alone+Cannot+Deliver+the+AI+Promise&url=https%3A%2F%2Fzifo.com%2Fnews%2Fzifo-at-jpm-healthcare-conference-2026-why-technology-alone-cannot-deliver-the-ai-promise%2F "Share on LinkedIn")
SAN FRANCISCO, Jan. 8, 2026 /PRNewswire/ — The life sciences industry is buzzing about AI’s potential to transform drug discovery. But at this year’s J.P. Morgan Healthcare Conference, the real conversation isn’t about finding the perfect algorithm — it’s about fixing the ecosystem that makes AI work.
That’s the message Zifo — a leading global enabler of AI and data-driven enterprise informatics for science-driven organizations — is taking to San Francisco next week.
As biopharma companies face growing pressure to show returns on their massive tech investments, Zifo wants to make one thing clear: buying **Technology** is relatively the easy part. The real challenge lies in the other three pillars of the lab — **Process, Data, and Organization (PDOT)**.
Also known as the ‘Super Bowl of Biotech,’ the J.P. Morgan conference brings together the most influential voices in healthcare to shape the future of investment. This year, the agenda signals a major shift: moving beyond shiny innovation to the hard work of making it operational.
Representing Zifo will be **Narasimhan Aravamudhan**, VP of Scientific Data for AI, and **Kannan Jagamoorthy**, VP and GM for the Americas. Their message? The industry’s move toward ‘Agentic AI’ — systems that can plan and execute tasks on their own across the scientific value chain — will stall unless companies embrace a holistic PDOT strategy.
“Successful AI adoption isn’t just about impressive demos — it’s about disciplined execution. At Zifo, we help leaders strengthen their scientific processes and data foundations, so their technology investments deliver real value. It starts with identifying the right use case and ensuring every step is built for success,” said Narasimhan, a [recognized AI expert](https://zifo.com/news/zifos-narasimhan-aravamudhan-recognized-as-a-top-ai-consultant-and-leader-by-the-consulting-report/) who leads Zifo’s AI strategy known as the ‘[Practical AI](https://zifo.com/practical-ai-blueprints/)‘ program.
The presence of Kannan Jagamoorthy, based locally in the San Francisco Bay Area, highlights the ‘Organization’ component of the framework — specifically the human side of technology adoption.
“Technology doesn’t solve problems; people using technology solve problems,” says Kannan, who heads Zifo in North America. “Our clients are moving from exploration to scaling. The winners in 2026 will be the ones that treat PDOT as a single, unified strategy — not four separate silos.”
During the conference, Zifo’s leadership will share how PDOT makes AI work in practice:
- **Process and Data**: Laying the foundation for agentic systems that need clean, standardized inputs to act autonomously.
- **Organization**: Managing the human side of change so scientists trust and use the new tools.
- **Technology**: Connecting physical lab automation with digital AI strategies to create the ‘Lab of the Future.’
**About Zifo**
Zifo is the leading global enabler of AI and data driven enterprise informatics for science driven organizations. With extensive solutions and services expertise spanning research, development, manufacturing, and clinical domains, we serve a diverse range of industries, including Pharma, Biotech, Chemicals, Food and Beverage, Oil & Gas, and FMCG. Trusted by over 190 science-focused organizations worldwide, Zifo is the partner of choice for advancing digital scientific innovation. ;
## Recent News
### [Zifo Co-Launches REAL 2026 to Spotlight the Next Generation of Connected, AI-Enabled Lab Environments](https://zifo.com/news/zifo-co-launches-real-2026-to-spotlight-the-next-generation-of-connected-ai-enabled-lab-environments/)
[  ](https://zifo.com/news/zifo-co-launches-real-2026-to-spotlight-the-next-generation-of-connected-ai-enabled-lab-environments/)
### [CMC Bottleneck is Choking Biopharma’s Drug Pipeline, says Zifo](https://zifo.com/news/cmc-bottleneck-is-choking-biopharmas-drug-pipeline-says-zifo/)
[  ](https://zifo.com/news/cmc-bottleneck-is-choking-biopharmas-drug-pipeline-says-zifo/)
### [Zifo Accelerates LIMS Master Data Validation with New AI-Enabled Services Accelerator](https://zifo.com/news/zifo-accelerates-lims-master-data-validation-with-new-ai-enabled-services-accelerator/)
[  ](https://zifo.com/news/zifo-accelerates-lims-master-data-validation-with-new-ai-enabled-services-accelerator/)
---
### [Zifo Launches AI Antibody Engineering App on Snowflake Marketplace to Accelerate Biologics and Drug Discovery](https://zifo.com/news/zifo-launches-ai-antibody-engineering-app-on-snowflake-marketplace-to-accelerate-biologics-and-drug-discovery/)
**Published:** August 18, 2025
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [News](https://zifo.com/news/ "News")> Zifo Launches AI Antibody Engineering App on Snowflake Marketplace to Accelerate Biologics and Drug Discovery
## Zifo Launches AI Antibody Engineering App on Snowflake Marketplace to Accelerate Biologics and Drug Discovery
Aug 18, 2025
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Zifo%20Launches%20AI%20Antibody%20Engineering%20App%20on%20Snowflake%20Marketplace%20to%20Accelerate%20Biologics%20and%20Drug%20Discovery%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fnews%2Fzifo-launches-ai-antibody-engineering-app-on-snowflake-marketplace-to-accelerate-biologics-and-drug-discovery%2F "Share on Email")
- [](https://x.com/intent/post?text=Zifo%20Launches%20AI%20Antibody%20Engineering%20App%20on%20Snowflake%20Marketplace%20to%20Accelerate%20Biologics%20and%20Drug%20Discovery&url=https%3A%2F%2Fzifo.com%2Fnews%2Fzifo-launches-ai-antibody-engineering-app-on-snowflake-marketplace-to-accelerate-biologics-and-drug-discovery%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Zifo+Launches+AI+Antibody+Engineering+App+on+Snowflake+Marketplace+to+Accelerate+Biologics+and+Drug+Discovery&url=https%3A%2F%2Fzifo.com%2Fnews%2Fzifo-launches-ai-antibody-engineering-app-on-snowflake-marketplace-to-accelerate-biologics-and-drug-discovery%2F "Share on LinkedIn")
Zifo accelerates antibody engineering and therapeutics development with launch of AI-Powered Protein Models on Snowflake
CAMBRIDGE, Mass., CAMBRIDGE, England and CHENNAI, India, Aug. 14, 2025 /PRNewswire/ — Zifo announced the launch of its [Antibody Engineering application](https://zifo.com/snowflake-antibody-engineering-documentation/), a cloud-native GenAI platform built on the Snowflake Data Cloud and available on the [Snowflake Marketplace](https://app.snowflake.com/marketplace/listing/GZTSZ3BDFQ8/zifo-technologies-inc-zifo-antibody-engineering), which empowers biopharma companies, research institutions, and contract research organizations to design and optimize therapeutic antibodies faster and potentially shortening the timeline for new drug discovery without needing to move data outside of Snowflake.
The development of new antibody-based therapies is traditionally a complex, time-consuming, and expensive process. Zifo’s Antibody Engineering app directly confronts this challenge by integrating state-of-the-art AI into a seamless, end-to-end workflow that promises to improve the hit rate for high-affinity therapeutic antibodies.
“We are entering a new era of drug discovery, one where AI and data converge to solve biology’s most complex puzzles,” said Chris McClure, Head of Solution Services for Zifo in North America. “Zifo Antibody Engineering is more than just a tool; it’s a strategic partner for scientists. By building it as a Snowflake Native App, we’re giving researchers the power to innovate faster, reduce R&D costs, and ultimately bring life-saving therapies to patients sooner. We’ve effectively democratized access to complex AI, removing the need for deep machine learning expertise.”
Leveraging the power and scalability of Snowflake’s platform, including Snowpark Container Services, the application provides a no-code, intuitive interface for scientists and bioinformaticians. Users can fine-tune powerful protein language models like ProtGPT2, RoBERTa, and ESM2 on their proprietary datasets without moving sensitive information outside of their secure Snowflake environment. The platform facilitates the entire discovery pipeline, from generating novel antibody sequences to predicting their 3D structures and analyzing key regions.
“Zifo Antibody Engineering, combined with Snowflake’s infrastructure, offers life sciences a cutting-edge tool for research development,” said Lisa Arbogast, Industry Principal for Healthcare and Life Sciences Ecosystem at Snowflake. “Together, we enable use of data to its fullest potential while helping customers adhere to high standards of security and compliance.”
The value of Zifo’s Antibody Engineering platform extends across the life sciences ecosystem:
- **Biopharma R&D Teams:** Streamline antibody discovery by generating novel sequences and predicting binding affinities faster than traditional methods.
- **CDMOs and CROs:** Offer AI-powered protein engineering as a service to clients developing therapeutic antibodies.
- **Academic and Research Institutions:** Leverage advanced protein modeling tools to push the boundaries of computational biology and structural bioinformatics.
- **Clinical and Preclinical Development:** Validate AI-generated antibodies with experimental data, expediting lead selection.
The architecture is designed for high-performance AI workloads, handling massive datasets and multi-modal inputs with ease, all within Snowflake’s managed environment. After fine-tuning models, users can generate new antibody sequences, visualize their 3D protein structures, download PDB files, and review analysis of complementarity-determining regions (CDRs).
Zifo’s Antibody Engineering App can be downloaded from Snowflake Marketplace [here](https://zifo.com/snowflake-antibody-engineering-documentation/).
To access the Antibody Engineering App Documentation, please click [here](https://zifo.com/snowflake-antibody-engineering-documentation/).
**About Zifo**
Zifo is the leading global enabler of AI and data-driven enterprise informatics for science-driven organizations. With extensive solutions and services expertise spanning research, development, manufacturing, and clinical domains, we serve various industries, including pharma, biotech, chemicals, food and beverage, oil and gas, and FMCG. Trusted by over 190 science-focused organizations worldwide, Zifo is the partner of choice for advancing digital scientific innovation. For more information, visit [zifo.com](https://zifo.com/).
Video:
Logo: [https://mma.prnewswire.com/media/2731415/5460327/Zifo\_Technologies\_Logo.jpg](https://mma.prnewswire.com/media/2731415/5460327/Zifo_Technologies_Logo.jpg)
## Recent News
### [Zifo Co-Launches REAL 2026 to Spotlight the Next Generation of Connected, AI-Enabled Lab Environments](https://zifo.com/news/zifo-co-launches-real-2026-to-spotlight-the-next-generation-of-connected-ai-enabled-lab-environments/)
[  ](https://zifo.com/news/zifo-co-launches-real-2026-to-spotlight-the-next-generation-of-connected-ai-enabled-lab-environments/)
### [CMC Bottleneck is Choking Biopharma’s Drug Pipeline, says Zifo](https://zifo.com/news/cmc-bottleneck-is-choking-biopharmas-drug-pipeline-says-zifo/)
[  ](https://zifo.com/news/cmc-bottleneck-is-choking-biopharmas-drug-pipeline-says-zifo/)
### [Zifo Accelerates LIMS Master Data Validation with New AI-Enabled Services Accelerator](https://zifo.com/news/zifo-accelerates-lims-master-data-validation-with-new-ai-enabled-services-accelerator/)
[  ](https://zifo.com/news/zifo-accelerates-lims-master-data-validation-with-new-ai-enabled-services-accelerator/)
---
### [Zifo's Narasimhan Aravamudhan Recognized as a Top AI Consultant and Leader by The Consulting Report](https://zifo.com/news/zifos-narasimhan-aravamudhan-recognized-as-a-top-ai-consultant-and-leader-by-the-consulting-report/)
**Published:** July 17, 2025
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [News](https://zifo.com/news/ "News")> Zifo’s Narasimhan Aravamudhan Recognized as a Top AI Consultant and Leader by The Consulting Report
## Zifo’s Narasimhan Aravamudhan Recognized as a Top AI Consultant and Leader by The Consulting Report
Jul 17, 2025
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Zifo%27s%20Narasimhan%20Aravamudhan%20Recognized%20as%20a%20Top%20AI%20Consultant%20and%20Leader%20by%20The%20Consulting%20Report%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fnews%2Fzifos-narasimhan-aravamudhan-recognized-as-a-top-ai-consultant-and-leader-by-the-consulting-report%2F "Share on Email")
- [](https://x.com/intent/post?text=Zifo%27s%20Narasimhan%20Aravamudhan%20Recognized%20as%20a%20Top%20AI%20Consultant%20and%20Leader%20by%20The%20Consulting%20Report&url=https%3A%2F%2Fzifo.com%2Fnews%2Fzifos-narasimhan-aravamudhan-recognized-as-a-top-ai-consultant-and-leader-by-the-consulting-report%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Zifo%5C%26%23039%3Bs+Narasimhan+Aravamudhan+Recognized+as+a+Top+AI+Consultant+and+Leader+by+The+Consulting+Report&url=https%3A%2F%2Fzifo.com%2Fnews%2Fzifos-narasimhan-aravamudhan-recognized-as-a-top-ai-consultant-and-leader-by-the-consulting-report%2F "Share on LinkedIn")
Zifo Technologies, a leading global enabler of AI and data-driven enterprise informatics for science-driven organizations, is proud to announce that Narasimhan Aravamudhan has been named one of The Top 25 Artificial Intelligence Consultants and Leaders of 2025 by The Consulting Report.
The Consulting Report’s annual list highlights professionals who are at the forefront of shaping AI implementation within large organizations. These leaders oversee enterprise-wide deployments, structure adoption roadmaps, and guide critical decisions on applying machine learning with precision in high-stakes environments. Narasimhan’s inclusion on this list is a testament to his depth of expertise, the quality of his advisory work, and the tangible outcomes he has delivered through AI-driven transformation.
Narasimhan, fondly known as Nara, serves as VP, Scientific Data for AI at Zifo. His expertise is instrumental in identifying and implementing opportunities suitable for generative AI, agentic AI, and traditional AI deployment. He is a driving force behind enhancing customer experiences and accelerating commercial growth through data, AI, and machine learning. His hands-on approach delivers rapid impact, evidenced by his work in piloting projects, developing AI blueprints, and creating proof of concepts that empower businesses to understand and capitalize on AI opportunities.
“It’s all about delivering what we at Zifo term as ‘Practical AI’ to bring tangible value for businesses,” says Narasimhan Aravamudhan. “At Zifo, we see AI as the key to turning all that complex scientific data into real business wins — whether that’s speeding up growth, making things run smoother, or giving customers a much better experience. We are here to help our clients really get a handle on AI, from generative to agentic to traditional.”
Notably, Nara’s work on the acceleration of Master Data Management for QC LIMS implementations using Gen AI has significantly benefited both customers and vendors in expediting LIMS deployments. Narasimhan holds a bachelor’s degree in electrical and electronics engineering from the University of Madras and has completed the executive education program (AMP) at The Wharton School, University of Pennsylvania. “We are incredibly proud of Nara for this well-deserved recognition,” said Paul Denny-Gouldson, Chief Scientific Officer at Zifo. “His visionary leadership and practical application of AI solutions are central to our mission of helping science-driven organizations leverage data and AI for groundbreaking advancements. This honour reflects his dedication and the impactful work he delivers to our clients globally.”
**About Zifo:**
Zifo is the leading global enabler of AI and data driven enterprise informatics for science driven organizations. With extensive solutions and services expertise spanning research, development, manufacturing, and clinical domains, we serve a diverse range of industries, including Pharma, Biotech, Chemicals, Food and Beverage, Oil & Gas, and FMCG. Trusted by over 190 science-focused organizations worldwide, Zifo is the partner of choice for advancing digital scientific innovation.
Photo: [https://mma.prnewswire.com/media/2731416/Zifo\_VP\_Nara.jpg](https://mma.prnewswire.com/media/2731416/Zifo_VP_Nara.jpg)
Logo: [https://mma.prnewswire.com/media/2731415/Zifo\_Technologies\_Logo.jpg](https://mma.prnewswire.com/media/2731415/Zifo_Technologies_Logo.jpg)
## Recent News
### [Zifo Co-Launches REAL 2026 to Spotlight the Next Generation of Connected, AI-Enabled Lab Environments](https://zifo.com/news/zifo-co-launches-real-2026-to-spotlight-the-next-generation-of-connected-ai-enabled-lab-environments/)
[  ](https://zifo.com/news/zifo-co-launches-real-2026-to-spotlight-the-next-generation-of-connected-ai-enabled-lab-environments/)
### [CMC Bottleneck is Choking Biopharma’s Drug Pipeline, says Zifo](https://zifo.com/news/cmc-bottleneck-is-choking-biopharmas-drug-pipeline-says-zifo/)
[  ](https://zifo.com/news/cmc-bottleneck-is-choking-biopharmas-drug-pipeline-says-zifo/)
### [Zifo Accelerates LIMS Master Data Validation with New AI-Enabled Services Accelerator](https://zifo.com/news/zifo-accelerates-lims-master-data-validation-with-new-ai-enabled-services-accelerator/)
[  ](https://zifo.com/news/zifo-accelerates-lims-master-data-validation-with-new-ai-enabled-services-accelerator/)
---
### [Zifo Joins Veeva’s Product Partner Program](https://zifo.com/news/zifo-joins-veevas-product-partner-program/)
**Published:** December 3, 2024
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [News](https://zifo.com/news/ "News")> Zifo Joins Veeva’s Product Partner Program
## Zifo Joins Veeva’s Product Partner Program
Dec 03, 2024
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Zifo%20Joins%20Veeva%E2%80%99s%20Product%20Partner%20Program%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fnews%2Fzifo-joins-veevas-product-partner-program%2F "Share on Email")
- [](https://x.com/intent/post?text=Zifo%20Joins%20Veeva’s%20Product%20Partner%20Program&url=https%3A%2F%2Fzifo.com%2Fnews%2Fzifo-joins-veevas-product-partner-program%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Zifo+Joins+Veeva%E2%80%99s+Product+Partner+Program&url=https%3A%2F%2Fzifo.com%2Fnews%2Fzifo-joins-veevas-product-partner-program%2F "Share on LinkedIn")
Zifo, a leading global enabler of AI and data-driven enterprise informatics for science-driven organizations, is excited to announce it has become an official Veeva Product Partner, building on our existing relationship as a Veeva Services Partner.
**Areas of Collaboration and Support**
As a Veeva Product Partner, Zifo will work alongside Veeva to deliver cutting-edge quality control solutions to their customers. The initial focus will be on integrating Veeva Vault LIMS (Laboratory Information Management System) with qcKen, an advanced platform for master data integration and management. qcKen can import data directly from any source document to Vault LIMS. The integration will help accelerate test and specification data creation, streamline implementation and site deployments, and achieve faster returns on investment.
**Additionally, Zifo will collaborate with Veeva on:**
- **Implementation Support:** As we continue to progress toward achieving Implementation Partner status, Zifo will play a key role in helping Veeva’s customers implement and optimize Veeva’s suite of products.
- **Training and Managed Services:** Zifo will provide essential training and ongoing support, assisting customers in maximizing the value of their Veeva solutions through our managed services offerings.
“We are excited to partner with Veeva to offer powerful solutions to the life sciences industry. This collaboration will help customers expedite their adoption of Veeva Vault LIMS and streamline their operations,” said Kannan Jagamoorthy, General Manager and Head, Zifo North America.
For **customers**, this partnership combines Zifo’s deep technical expertise with Veeva’s trusted platform, allowing for smoother implementations and more effective system integrations that enhance data management and regulatory compliance processes.
To learn more, visit
## Recent News
### [Zifo Co-Launches REAL 2026 to Spotlight the Next Generation of Connected, AI-Enabled Lab Environments](https://zifo.com/news/zifo-co-launches-real-2026-to-spotlight-the-next-generation-of-connected-ai-enabled-lab-environments/)
[  ](https://zifo.com/news/zifo-co-launches-real-2026-to-spotlight-the-next-generation-of-connected-ai-enabled-lab-environments/)
### [CMC Bottleneck is Choking Biopharma’s Drug Pipeline, says Zifo](https://zifo.com/news/cmc-bottleneck-is-choking-biopharmas-drug-pipeline-says-zifo/)
[  ](https://zifo.com/news/cmc-bottleneck-is-choking-biopharmas-drug-pipeline-says-zifo/)
### [Zifo Accelerates LIMS Master Data Validation with New AI-Enabled Services Accelerator](https://zifo.com/news/zifo-accelerates-lims-master-data-validation-with-new-ai-enabled-services-accelerator/)
[  ](https://zifo.com/news/zifo-accelerates-lims-master-data-validation-with-new-ai-enabled-services-accelerator/)
---
### [Zifo and Sapio Sciences Strike Partnership Deal](https://zifo.com/news/zifo-and-sapio-sciences-strike-partnership-deal/)
**Published:** August 8, 2024
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [News](https://zifo.com/news/ "News")> Zifo and Sapio Sciences Strike Partnership Deal
## Zifo and Sapio Sciences Strike Partnership Deal
Aug 08, 2024
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Zifo%20and%20Sapio%20Sciences%20Strike%20Partnership%20Deal%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fnews%2Fzifo-and-sapio-sciences-strike-partnership-deal%2F "Share on Email")
- [](https://x.com/intent/post?text=Zifo%20and%20Sapio%20Sciences%20Strike%20Partnership%20Deal&url=https%3A%2F%2Fzifo.com%2Fnews%2Fzifo-and-sapio-sciences-strike-partnership-deal%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Zifo+and+Sapio+Sciences+Strike+Partnership+Deal&url=https%3A%2F%2Fzifo.com%2Fnews%2Fzifo-and-sapio-sciences-strike-partnership-deal%2F "Share on LinkedIn")
**Industry leaders to provide world-class lab informatics platform, services and support to life science customers.**
BALTIMORE, MD, July 30, 2024 — [Sapio Sciences](http://coolblue.com), the science-aware™ lab informatics platform, and Zifo, the leading scientific informatics services company today announced a strategic partnership to bring best-in-class laboratory information management solutions to customers across the biotech, clinical diagnostics, and pharmaceutical industries.
Zifo will join the [Sapio Sciences Partner Program](https://www.sapiosciences.com/sspp-partner-program-sapio-sciences/) as a Services Partner, focusing on delivering solutions that combine Zifo’s exceptional IT services and consulting capabilities with Sapio’s lab informatics platform. The partnership combines Zifo’s consulting expertise in AI & ML services with Sapio’s highly configurable lab informatics platform and expertise in system design, deployment, and integration.
Additionally, the partnership will see Sapio certify Zifo engineers to ensure joint customers can access highly skilled engineers and solution consultants when deploying Sapio solutions. This close collaboration will allow laboratories to navigate complex digital transformation journeys, and streamline and accelerate research.
Raj Prakash, Co-Founder and CEO of Zifo commented: “Zifo and Sapio have collaborated closely for several years, working together to ensure seamless integration of the Sapio Platform with our Lab Data Automation Solution (LDAS). By combining our expertise in scientific informatics services, with Sapio’s lab informatics solutions, we can provide our customers with a world-class approach to lab automation and further the adoption of AI in biotech and pharma.”
Andrew Wyatt, Chief Growth Officer, Sapio Sciences added: “The relationship between Zifo and Sapio has already helped advance how labs worldwide can collect, analyze, and use information. This renewed partnership will further deepen how we can collaborate on driving forward our goals of making life easier for the scientist and accelerating scientific discovery.”
Sapio is pleased to announce it is a headline sponsor of Zifo’s annual [Scientific Informatics Experience Exchange](https://zifo.com/event/siee-basel-2026/) event, taking place in Boston in October 2024
**About Sapio Sciences**
Sapio Sciences’ mission is to improve lives by accelerating discovery, and because science is complex, Sapio makes technology simple. Sapio is a global business offering an all-in-one science-aware™ lab informatics platform combining cloud-based [LIMS](https://www.sapiosciences.com/products/lims/), [ELN](https://www.sapiosciences.com/products/electronic-lab-notebook/), and [Jarvis](https://www.sapiosciences.com/products/sdms-scientific-data-cloud/)data solutions.
**About Zifo**
Zifo is an AI/ML and “data for AI” based scientific informatics services company. Zifo’s experience extends across research, development, manufacturing, and clinical domains in the Pharma, Biotech, Chemicals, Food and Beverage, Oil & Gas, and FMCG industries. Zifo is the preferred partner for over 190 scientifically driven organizations around the globe.
For more information, visit Zifo at .
## Recent News
### [Zifo Co-Launches REAL 2026 to Spotlight the Next Generation of Connected, AI-Enabled Lab Environments](https://zifo.com/news/zifo-co-launches-real-2026-to-spotlight-the-next-generation-of-connected-ai-enabled-lab-environments/)
[  ](https://zifo.com/news/zifo-co-launches-real-2026-to-spotlight-the-next-generation-of-connected-ai-enabled-lab-environments/)
### [CMC Bottleneck is Choking Biopharma’s Drug Pipeline, says Zifo](https://zifo.com/news/cmc-bottleneck-is-choking-biopharmas-drug-pipeline-says-zifo/)
[  ](https://zifo.com/news/cmc-bottleneck-is-choking-biopharmas-drug-pipeline-says-zifo/)
### [Zifo Accelerates LIMS Master Data Validation with New AI-Enabled Services Accelerator](https://zifo.com/news/zifo-accelerates-lims-master-data-validation-with-new-ai-enabled-services-accelerator/)
[  ](https://zifo.com/news/zifo-accelerates-lims-master-data-validation-with-new-ai-enabled-services-accelerator/)
---
### [Zifo's Partnership with Blue Mountain](https://zifo.com/news/zifos-partnership-blue-mountain/)
**Published:** July 1, 2024
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [News](https://zifo.com/news/ "News")> Zifo’s Partnership with Blue Mountain
## Zifo’s Partnership with Blue Mountain
Jul 01, 2024
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Zifo%27s%20Partnership%20with%20Blue%20Mountain%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fnews%2Fzifos-partnership-blue-mountain%2F "Share on Email")
- [](https://x.com/intent/post?text=Zifo%27s%20Partnership%20with%20Blue%20Mountain&url=https%3A%2F%2Fzifo.com%2Fnews%2Fzifos-partnership-blue-mountain%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Zifo%5C%26%23039%3Bs+Partnership+with+Blue+Mountain&url=https%3A%2F%2Fzifo.com%2Fnews%2Fzifos-partnership-blue-mountain%2F "Share on LinkedIn")
Trusted and reputable industry leaders to offer best-in-class GXP software, services, and consulting to drive optimal asset performance in life sciences
**\[Philadelphia, PA and Chennai, India, June 27, 2024\]** – Blue Mountain, whose Regulatory Asset Management (RAM) platform is the standard for life sciences manufacturers, and Zifo, the leading scientific informatics services company, are thrilled to announce a strategic partnership designed to deliver cutting-edge technology and unparalleled services to the life sciences sector. This partnership aims to provide comprehensive solutions that will enhance operational efficiency and innovation for pharmaceutical manufacturers, Contract Development and Manufacturing Organizations (CDMOs), MedTech companies, medical device manufacturers, and Laboratory Developed Test (LDT) manufacturers.
Blue Mountain is renowned for its best-of-breed EAM technology built exclusively for life sciences, which empowers organizations to optimize their assets, reduce downtime, and improve overall productivity. By connecting this with Zifo’s world-class IT services and consulting expertise, the partnership will deliver a robust, end-to-end solution tailored specifically for the life sciences industry with reach to all corners of the globe.
**CEO of Blue Mountain, David Rode, commented:**
“We are excited to join forces with Zifo to bring transformative solutions to the life sciences industry. Our EAM technology, combined with Zifo’s exceptional IT services and consulting capabilities, will provide our customers with the tools they need to maximize their assets and drive significant efficiencies in their operations. This partnership is a testament to our commitment to innovation and excellence in serving the life sciences sector, and to expanding our reach across the globe.”
**Co-Founder and CEO of Zifo, Raj Prakash, added:**
“Our partnership with Blue Mountain represents a significant milestone in our mission to deliver innovative and impactful IT solutions. By leveraging Blue Mountain’s leading EAM technology, we are poised to offer an integrated approach that addresses the unique challenges faced by life sciences companies. Together, we will help our clients achieve greater operational agility and compliance, ultimately leading to improved patient outcomes.”
The partnership expands Zifo’s partnership program to include a GXP Asset Management category that will enable life sciences organizations to benefit from a seamless integration of advanced EAM technology and comprehensive IT services. This includes streamlined asset management, enhanced regulatory compliance, calibration, validation, predictive maintenance, and data-driven decision-making capabilities. Pharmaceutical manufacturers, CDMOs, MedTech firms, medical device companies, and LDT manufacturers will all gain from the partnership’s innovative solutions, driving efficiency, reducing costs, and accelerating time-to-market for their products.
**About Blue Mountain**
Leading the Life Sciences in asset management for 35 years, Blue Mountain has a unique position in the life sciences industry backed by a proven legacy. Founded in 1989, Blue Mountain offers a complete, integrated solution, helping hundreds of Pharmaceutical, Biotech, Cell and Gene Therapy, Medical Device, and Contract Manufacturing companies. From set-up to installation and from training to validation, our company helps life sciences manufacturing master GMP asset management by implementing our best-in-class software – enabling them to leverage the cloud, drive paperless processes, and ensure regulatory compliance. Blue Mountain is backed by Accel-KKR and based in the greater Philadelphia, PA region. For more information, please visit www.coolblue.com.
**About Zifo**
Zifo is an AI/ML and ‘data for AI’ based Scientific informatics services company. Our experience extends across research, development, manufacturing, and clinical domains in the Pharma, Biotech, Chemicals, Food and Beverage, Oil & Gas and FMCG industries. Zifo is the preferred partner for over 190 scientifically driven organizations around the globe.
## Recent News
### [Zifo Co-Launches REAL 2026 to Spotlight the Next Generation of Connected, AI-Enabled Lab Environments](https://zifo.com/news/zifo-co-launches-real-2026-to-spotlight-the-next-generation-of-connected-ai-enabled-lab-environments/)
[  ](https://zifo.com/news/zifo-co-launches-real-2026-to-spotlight-the-next-generation-of-connected-ai-enabled-lab-environments/)
### [CMC Bottleneck is Choking Biopharma’s Drug Pipeline, says Zifo](https://zifo.com/news/cmc-bottleneck-is-choking-biopharmas-drug-pipeline-says-zifo/)
[  ](https://zifo.com/news/cmc-bottleneck-is-choking-biopharmas-drug-pipeline-says-zifo/)
### [Zifo Accelerates LIMS Master Data Validation with New AI-Enabled Services Accelerator](https://zifo.com/news/zifo-accelerates-lims-master-data-validation-with-new-ai-enabled-services-accelerator/)
[  ](https://zifo.com/news/zifo-accelerates-lims-master-data-validation-with-new-ai-enabled-services-accelerator/)
---
### [Zifo Expands Informatics Services to Help Solve Difficult Scientific and Data Problems with AI-driven Service Accelerators](https://zifo.com/news/zifo-expands-informatics-services-to-help-solve-difficult-scientific-and-data-problems-with-ai-driven-service-accelerators/)
**Published:** October 27, 2025
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [News](https://zifo.com/news/ "News")> Zifo Expands Informatics Services to Help Solve Difficult Scientific and Data Problems with AI-driven Service Accelerators
## Zifo Expands Informatics Services to Help Solve Difficult Scientific and Data Problems with AI-driven Service Accelerators
Oct 27, 2025
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Zifo%20Expands%20Informatics%20Services%20to%20Help%20Solve%20Difficult%20Scientific%20and%20Data%20Problems%20with%20AI-driven%20Service%20Accelerators%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fnews%2Fzifo-expands-informatics-services-to-help-solve-difficult-scientific-and-data-problems-with-ai-driven-service-accelerators%2F "Share on Email")
- [](https://x.com/intent/post?text=Zifo%20Expands%20Informatics%20Services%20to%20Help%20Solve%20Difficult%20Scientific%20and%20Data%20Problems%20with%20AI-driven%20Service%20Accelerators&url=https%3A%2F%2Fzifo.com%2Fnews%2Fzifo-expands-informatics-services-to-help-solve-difficult-scientific-and-data-problems-with-ai-driven-service-accelerators%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Zifo+Expands+Informatics+Services+to+Help+Solve+Difficult+Scientific+and+Data+Problems+with+AI-driven+Service+Accelerators&url=https%3A%2F%2Fzifo.com%2Fnews%2Fzifo-expands-informatics-services-to-help-solve-difficult-scientific-and-data-problems-with-ai-driven-service-accelerators%2F "Share on LinkedIn")
CAMBRIDGE, Mass. and CAMBRIDGE, England and CHENNAI, India, Oct. 23, 2025 /PRNewswire/ — Zifo, a leading global enabler of AI and data-driven enterprise informatics for science-driven organizations, announced it is expanding its informatics services offering by **incorporating AI and data-driven service accelerators to help scientists and informaticians enhance scientific workflows and make data AI-ready across the scientific value chain**.
**Organizations often struggle to manage, analyze, and utilize the vast amounts of complex data generated by scientific research**. This **explosive growth in data is an opportunity** to provide science-focused industries such as Biopharma, Material sciences and so on, **with specialized**, **AI-powered tools and expertise to overcome data-related challenges**, enabling effective decision-making across the scientific value chain. For example, **improving data quality and consistency enables deeper scientific insights**, which in turn help drive better science. Similarly, maintaining comprehensive data points of all experiments **prevents different teams from repeating the same errors or same steps at later stages of research**, improving efficiency and reproducibility across the scientific process.
Zifo’s AI-enabled informatics capabilities span a range of scientific domains. For instance, Zifo’s AI capabilities can assist in compound screening and assay optimization, while natural language processing (NLP) tools can extract insights from unstructured experimental reports. Predictive analytics also help scientists forecast outcomes, design better experiments, and improve decision-making in areas such as bioinformatics, clinical data management, materials research, and so on.
**Paul Denny-Gouldson, Zifo’s Chief Scientific Officer**, said, “By combining our deep understanding of science with cutting-edge AI platforms, we are helping our customers transform data chaos into data intelligence. Our goal is to make AI practical in biopharma, materials science, and other research-driven industries, enabling smarter, better science.”
Zifo now offers a comprehensive range of service accelerators, from **mapping business processes and setting up scientific platforms** to moving and managing data in more advanced ways.
Zifo’s **expertise extends across a wide range of platforms**, including Electronic Lab Notebooks (ELN), Laboratory Information Management Systems (LIMS), Chromatography Data Systems (CDS), Electronic Data Capture (EDC), and Omics Data Management and Analysis Platforms that support genomics, proteomics, metabolomics, and other multi-omics research.
The company also **specializes in designing and developing scientific workflows and applications**.
Zifo’s method focuses on making scientific systems work together and be more efficient so that scientists can get more out of their data. The services play a key role in critical areas such as:
- **Strategic Consulting:** Giving expert advice on how to plan and carry out a data strategy.
- **Workflow Design:** Making scientific processes run more smoothly and automatically to boost productivity.
- **Data Migration:** Help migrate data between different scientific systems seamlessly considering all the nuances.
- **Data Management:** Making sure that data is safe and easy to get to on different systems.
- **Regulatory, Validation, and Compliance:** Ensuring all systems and processes meet regulations such as FDA 21 CFR part 11 and EU Annex 11, quality standards, and validation requirements to maintain scientific integrity and audit readiness.
- **Scientific Platform Sustenance:** Implementing, upgrading, and maintaining specialized scientific software such as ELN, LIMS, CDS, and so on.
The latest initiative highlights Zifo’s commitment to leverage its Scientific Expertise and AI Know-How to contribute to better outcomes and ROI across the entire scientific value chain.
To access Zifo’s Data Readiness Survey Report, please click here:
**About Zifo**
Zifo is the leading global enabler of AI and data-driven enterprise informatics for science-driven organizations. With extensive solutions and services expertise spanning research, development, manufacturing, and clinical domains, we serve various industries, including pharma, biotech, chemicals, food and beverage, oil and gas, and FMCG. Trusted by over 190 science-focused organizations worldwide, Zifo is the partner of choice for advancing digital scientific innovation. For more information, visit
## Recent News
### [Zifo Co-Launches REAL 2026 to Spotlight the Next Generation of Connected, AI-Enabled Lab Environments](https://zifo.com/news/zifo-co-launches-real-2026-to-spotlight-the-next-generation-of-connected-ai-enabled-lab-environments/)
[  ](https://zifo.com/news/zifo-co-launches-real-2026-to-spotlight-the-next-generation-of-connected-ai-enabled-lab-environments/)
### [CMC Bottleneck is Choking Biopharma’s Drug Pipeline, says Zifo](https://zifo.com/news/cmc-bottleneck-is-choking-biopharmas-drug-pipeline-says-zifo/)
[  ](https://zifo.com/news/cmc-bottleneck-is-choking-biopharmas-drug-pipeline-says-zifo/)
### [Zifo Accelerates LIMS Master Data Validation with New AI-Enabled Services Accelerator](https://zifo.com/news/zifo-accelerates-lims-master-data-validation-with-new-ai-enabled-services-accelerator/)
[  ](https://zifo.com/news/zifo-accelerates-lims-master-data-validation-with-new-ai-enabled-services-accelerator/)
---
### [Zifo Democratizes Data Access for Scientists through its AI-Powered Conversational Dashboard](https://zifo.com/news/zifo-democratizes-data-access-for-scientists-through-its-ai-powered-conversational-dashboard/)
**Published:** October 31, 2025
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [News](https://zifo.com/news/ "News")> Zifo Democratizes Data Access for Scientists through its AI-Powered Conversational Dashboard
## Zifo Democratizes Data Access for Scientists through its AI-Powered Conversational Dashboard
Oct 31, 2025
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Zifo%20Democratizes%20Data%20Access%20for%20Scientists%20through%20its%20AI-Powered%20Conversational%20Dashboard%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fnews%2Fzifo-democratizes-data-access-for-scientists-through-its-ai-powered-conversational-dashboard%2F "Share on Email")
- [](https://x.com/intent/post?text=Zifo%20Democratizes%20Data%20Access%20for%20Scientists%20through%20its%20AI-Powered%20Conversational%20Dashboard&url=https%3A%2F%2Fzifo.com%2Fnews%2Fzifo-democratizes-data-access-for-scientists-through-its-ai-powered-conversational-dashboard%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Zifo+Democratizes+Data+Access+for+Scientists+through+its+AI-Powered+Conversational+Dashboard&url=https%3A%2F%2Fzifo.com%2Fnews%2Fzifo-democratizes-data-access-for-scientists-through-its-ai-powered-conversational-dashboard%2F "Share on LinkedIn")
CAMBRIDGE, Mass., CAMBRIDGE, England and CHENNAI, India, Oct. 30, 2025 /PRNewswire/ — Zifo, a leading global enabler of AI and data-driven enterprise informatics for science-driven organizations, today announced the launch of its **AI-powered Conversational Dashboard**, a no-code, natural language interface that is set to redefine how scientists, QA teams, and business stakeholders interact with and derive insights from their data, leading to better scientific outcomes.
**Instant Insights, No Technical Expertise Required**
Zifo’s Conversational Dashboard redefines how scientists, QA teams, and business stakeholders in science-focused industries engage with their data. By reimagining rigid, custom-built dashboards, the solution empowers organizations with **faster, traceable, and powerful decision-making capabilities**. It is especially valuable in dynamic situations where **time-sensitive insights are critical**, or where evolving scientific questions outpace traditional dashboard development.
The new dashboard empowers teams to explore, visualize, and analyze data seamlessly with natural language prompts, completely eliminating the need for technical expertise or reliance on rigid, predefined dashboards.
The AI-powered Conversational Dashboard is available now as part of Zifo’s growing suite of AI-driven service accelerators designed for science-driven enterprises.
**Ending the Frustration of Slow Data Retrieval**
“Let’s be honest, waiting weeks for a custom report while your scientific question is evolving is incredibly frustrating. We built this to end that,” said **Suchitra Ramaswamy, Zifo’s Head of Customer Success in UK and Ireland**. “Our Conversational Dashboard is about giving time back to the scientists. You simply ask a question, and the AI gives you the answer and the visual, right now. It’s about getting **instant, reliable insights** directly into the hands of the people who need to make critical decisions.”
**Customer Challenge and How Zifo’s Solution Solves it**
The Zifo Conversational Dashboard directly solves major pain points across the R&D, CMC, and Manufacturing segments of the value chain:
Customer challengeHow Zifo’s Solution Solves itHigh dependency on data analysts for custom reports and dashboardsScientists and QA teams can self-serve insights using natural language promptsStatic dashboards with rigid filters and limited flexibilityDynamic, ad hoc querying with real-time visualizations and summariesLack of traceability from formulation to batch to test resultsThis tool understands entity relationships and enables end-to-end traceabilityNon-technical users struggle with complex BI toolsNo-code, natural language interface democratizes data access for all stakeholdersDelayed decision-making due to slow data retrieval and analysisInstant answers and visualizations accelerate decision-makingInability to explore data freely or ask follow-up questionsThis tool maintains context and supports exploratory, conversational analysisLack of guided decision support and contextual awarenessHighlights anomalies, and provides insights**What Makes This AI-Powered Solution Unique**
The core differentiator of Zifo’s solution is its **Conversational Data Exploration**. By maintaining context across a line of questioning, the tool enables users to drill down into complex data relationships (like moving from a product batch to specific test results) as easily as having a conversation. This approach replaces complex workflows and rigid report designs with an **intuitive**, **continuous flow** of inquiry and insight.
**About Zifo**
Zifo is the leading global enabler of AI and data-driven enterprise informatics for science-driven organizations. With extensive solutions and services expertise spanning research, development, manufacturing, and clinical domains, we serve various industries, including pharma, biotech, chemicals, food and beverage, oil and gas, and FMCG. Trusted by over 190 science-focused organizations worldwide, Zifo is the partner of choice for advancing digital scientific innovation. For more information, visit ,
## Recent News
### [Zifo Co-Launches REAL 2026 to Spotlight the Next Generation of Connected, AI-Enabled Lab Environments](https://zifo.com/news/zifo-co-launches-real-2026-to-spotlight-the-next-generation-of-connected-ai-enabled-lab-environments/)
[  ](https://zifo.com/news/zifo-co-launches-real-2026-to-spotlight-the-next-generation-of-connected-ai-enabled-lab-environments/)
### [CMC Bottleneck is Choking Biopharma’s Drug Pipeline, says Zifo](https://zifo.com/news/cmc-bottleneck-is-choking-biopharmas-drug-pipeline-says-zifo/)
[  ](https://zifo.com/news/cmc-bottleneck-is-choking-biopharmas-drug-pipeline-says-zifo/)
### [Zifo Accelerates LIMS Master Data Validation with New AI-Enabled Services Accelerator](https://zifo.com/news/zifo-accelerates-lims-master-data-validation-with-new-ai-enabled-services-accelerator/)
[  ](https://zifo.com/news/zifo-accelerates-lims-master-data-validation-with-new-ai-enabled-services-accelerator/)
---
### [Zifo Reports Record Customer Satisfaction Scores for Scientific Application Support and Lab Compute Services](https://zifo.com/news/zifo-reports-record-customer-satisfaction-scores-for-scientific-application-support-and-lab-compute-services/)
**Published:** November 5, 2025
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [News](https://zifo.com/news/ "News")> Zifo Reports Record Customer Satisfaction Scores for Scientific Application Support and Lab Compute Services
## Zifo Reports Record Customer Satisfaction Scores for Scientific Application Support and Lab Compute Services
Nov 05, 2025
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Zifo%20Reports%20Record%20Customer%20Satisfaction%20Scores%20for%20Scientific%20Application%20Support%20and%20Lab%20Compute%20Services%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fnews%2Fzifo-reports-record-customer-satisfaction-scores-for-scientific-application-support-and-lab-compute-services%2F "Share on Email")
- [](https://x.com/intent/post?text=Zifo%20Reports%20Record%20Customer%20Satisfaction%20Scores%20for%20Scientific%20Application%20Support%20and%20Lab%20Compute%20Services&url=https%3A%2F%2Fzifo.com%2Fnews%2Fzifo-reports-record-customer-satisfaction-scores-for-scientific-application-support-and-lab-compute-services%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Zifo+Reports+Record+Customer+Satisfaction+Scores+for+Scientific+Application+Support+and+Lab+Compute+Services&url=https%3A%2F%2Fzifo.com%2Fnews%2Fzifo-reports-record-customer-satisfaction-scores-for-scientific-application-support-and-lab-compute-services%2F "Share on LinkedIn")
- Average CSAT ratings **of 4.7 to 4.9 out of 5**
- Nearly **89% of all ratings were a perfect 5**
- Zifo’s Lab Compute engineers and analysts have resolved more than **10,000 incidents**
**CAMBRIDGE, Mass. and CAMBRIDGE, England and CHENNAI, India, Nov 5, 2025 —** Zifo, a leading global enabler of AI and data-driven enterprise informatics for science-driven organizations, **reported higher-than-industry-average customer satisfaction (CSAT) scores for its support of scientific applications, including the Lab Compute Service (LCS) for the second quarter**, underscoring the company’s reputation for customer focus, reliability, responsiveness, and scientific IT excellence.
While the overall customer satisfaction score in the U.S. has dropped for three consecutive quarters, according to the American Customer Satisfaction Index (ASCI), with the latest score being at the same level as it was in 2012, Zifo’s Lab Compute Service has consistently outperformed this benchmark by achieving average ratings **of 4.7 to 4.9 out of 5**, with nearly **89% of all scores a perfect 5**.
The number of **customer satisfaction (CSAT) responses** for Zifo’s LCS service has **doubled since 2021**, reflecting increased engagement from the scientist community. In the **second quarter of 2025**, LCS surpassed **2,500 customer ratings**, with **fewer than 1% of all scores ever falling below 3** — a testament to sustained service quality amid rapid growth.
To know more: [https: //zifo.com/services/lab-compute-services/](https://zifo.com/services/lab-compute-services/)
Zifo’s CSAT results demonstrate the company’s technical prowess as well as its capacity to convert complex scientific computing requirements into IT outcomes that are in line with business objectives. Such consistency indicates both operational maturity and user trust in a field where stability, compliance, and uptime are crucial, while also significantly reducing the daily frustration that scientists feel when IT systems impede their research.
“Science moves fast, but bad IT slows it down,” said **Neil Whitworth, Global Director, Lab Compute Services at Zifo**. “For too long, scientists have had to fight their tools instead of using them. Our Lab Compute Services flip that story — turning IT from the villain everyone dreads into the quiet partner they actually like working with. And we know that many labs out there are struggling with failure-to-launch across their Digital and Lab Automation initiatives, and they tell us that lack of skills on the ground are the cause. Good Lab Compute establishes the foundation for automation, integration, and digital evolution by placing knowledgeable, dependable people where you need them,” he said.
Zifo’s Lab Compute team provides comprehensive **Scientific System Platform support** — from instruments to informatics — tailored to the needs of global life sciences organizations. Operating across **43 global sites**, Zifo’s LCS team supports more than **25,000 scientists**, manages over **100 unique applications**. And thus far, Zifo’s Lab Compute engineers and analysts have resolved more than **10,000 incidents**, consistently delivering stability, compliance, and speed.
The exceptional CSAT scores were made possible by a **global team of more than 2,500 certified professionals and consulting scientists**, supported by over **100 AI accelerators** developed through Zifo’s Practical AI³ program. This approach enhances operational intelligence — enabling predictive maintenance, risk mitigation, and smarter automation in research environments.
With over **15 years** of proven partnership in the life sciences sector, Zifo’s LCS integrates **local lab IT support, automation and AI expertise**, and managed services spanning cloud, data, and biometrics. The service also encompasses **testing and validation**, **compliance consulting**, and **change and release management**, ensuring systems meet stringent global standards.
To support customers across a range of regulatory and operational needs, Zifo offers three distinct service models in the Lab Compute vertical:
- **GxP App Operations and Support Services** for validated systems, managing compliance, validation, and audit readiness.
- **Application Operations and Support Services** for biomedical research platforms, optimizing performance through automation and self-service tools.
- **Minimal Maintenance Teams (MMT)** that provide “lights-on” stability and readiness for systems in, or approaching, retirement.
Zifo’s commitment to continuous improvement in satisfaction, scalability, and scientific enablement ensures its LCS offering continues to meet the demanding standards of global life science organizations.
**About Zifo**
Zifo is the leading global enabler of AI and data-driven enterprise informatics for science-driven organizations. With extensive solutions and services expertise spanning research, development, manufacturing, and clinical domains, we serve various industries, including pharma, biotech, chemicals, food and beverage, oil and gas, and FMCG. Trusted by over 190 science-focused organizations worldwide, Zifo is the partner of choice for advancing digital scientific innovation. For more information, visit ; ;
## Recent News
### [Zifo Co-Launches REAL 2026 to Spotlight the Next Generation of Connected, AI-Enabled Lab Environments](https://zifo.com/news/zifo-co-launches-real-2026-to-spotlight-the-next-generation-of-connected-ai-enabled-lab-environments/)
[  ](https://zifo.com/news/zifo-co-launches-real-2026-to-spotlight-the-next-generation-of-connected-ai-enabled-lab-environments/)
### [CMC Bottleneck is Choking Biopharma’s Drug Pipeline, says Zifo](https://zifo.com/news/cmc-bottleneck-is-choking-biopharmas-drug-pipeline-says-zifo/)
[  ](https://zifo.com/news/cmc-bottleneck-is-choking-biopharmas-drug-pipeline-says-zifo/)
### [Zifo Accelerates LIMS Master Data Validation with New AI-Enabled Services Accelerator](https://zifo.com/news/zifo-accelerates-lims-master-data-validation-with-new-ai-enabled-services-accelerator/)
[  ](https://zifo.com/news/zifo-accelerates-lims-master-data-validation-with-new-ai-enabled-services-accelerator/)
---
## White Papers
### [CDISC Send Fair Data Guide](https://zifo.com/white-papers/cdisc-send-fair-data-guide/)
**Published:** October 13, 2023
**Author:** Zifo_user
**Content:**
' ); } }); } }); /* ------------------------------------- FORM VALIDATION (INLINE MESSAGES) Updated to work with Elementor form --------------------------------------*/ jQuery(document).ready(function($) { // Prevent default form submission $('.elementor-down-pdf-form form').on('submit', function(e) { e.preventDefault(); validateForm(); }); // Also attach to button click $('.elementor-down-pdf-form .elementor-button').on('click', function(e) { e.preventDefault(); validateForm(); }); }); function validateForm() { // Clear previous errors jQuery(".error-message").remove(); jQuery('.elementor-down-pdf-form input').removeClass('error'); // Get form values - using Elementor field IDs let firstname = jQuery("#form-field-name").val().trim(); let lastname = jQuery("#form-field-field_f313a9e").val().trim(); let email = jQuery("#form-field-email").val().trim(); let company = jQuery("#form-field-field_cf8f855").val().trim(); let jobtitle = jQuery("#form-field-field_c49cb5f").val().trim(); let checkbox = jQuery('.elementor-down-pdf-form input[type="checkbox"]'); let consentChecked = checkbox.is(":checked"); let isValid = true; let emailPattern = /^[^\s@]+@[^\s@]+\.[^\s@]+$/; function showError(inputElement, message) { inputElement.addClass('error'); // Insert error message after the input field inputElement.after('' + message + '
'); } // Validate First Name if (firstname === "") { showError(jQuery("#form-field-name"), "Please fill this field."); isValid = false; } // Validate Last Name if (lastname === "") { showError(jQuery("#form-field-field_f313a9e"), "Please fill this field."); isValid = false; } // Validate Email if (email === "") { showError(jQuery("#form-field-email"), "Please fill this field."); isValid = false; } else if (!emailPattern.test(email)) { showError(jQuery("#form-field-email"), "Enter a valid email address."); isValid = false; } // Validate Company if (company === "") { showError(jQuery("#form-field-field_cf8f855"), "Please fill this field."); isValid = false; } // Validate Job Title if (jobtitle === "") { showError(jQuery("#form-field-field_c49cb5f"), "Please fill this field."); isValid = false; } // Validate Checkbox if (!consentChecked) { checkbox.addClass('error'); checkbox.closest('.elementor-field-subgroup').after( 'Please fill this field
' ); isValid = false; } // If form is valid, trigger download if (isValid) { // Trigger the download let link = document.createElement("a"); link.href = "https://cdn.zifo.com/2025/12/The-case-for-SEND_Analysis-report.pdf"; link.download = "The-case-for-SEND_Analysis-report.pdf"; document.body.appendChild(link); link.click(); document.body.removeChild(link); // Clear form values clearForm(); return true; } return false; } /* ------------------------------------- CLEAR FORM FUNCTION --------------------------------------*/ function clearForm() { // Clear all input values jQuery('.elementor-down-pdf-form input[type="text"]').val(''); jQuery('.elementor-down-pdf-form input[type="email"]').val(''); // Reset checkbox to checked jQuery('.elementor-down-pdf-form input[type="checkbox"]').prop('checked', true); // Remove floating-active class from all fields jQuery('.elementor-down-pdf-form .elementor-field-group').removeClass('floating-active'); // Remove any error classes jQuery('.elementor-down-pdf-form input').removeClass('error'); // Clear any remaining error messages jQuery('.error-message').remove(); } /* ------------------------------------- REAL-TIME VALIDATION Remove error when user starts typing --------------------------------------*/ jQuery(document).ready(function($) { $('.elementor-down-pdf-form input[type="text"], .elementor-down-pdf-form input[type="email"]').on('input', function() { var $input = $(this); var $errorMessage = $input.next('.error-message'); if ($input.val().trim() !== '' && $errorMessage.length) { $input.removeClass('error'); $errorMessage.remove(); // For email field, also validate format if ($input.attr('type') === 'email' && $input.val().trim() !== '') { var emailPattern = /^[^\s@]+@[^\s@]+\.[^\s@]+$/; if (!emailPattern.test($input.val().trim())) { $input.addClass('error'); $input.after('Enter a valid email address.
'); } } } }); });
[Home](https://zifo.com "Home")> [White Papers](https://zifo.com/white-papers/ "White Papers")> CDISC Send Fair Data Guide
## CDISC Send Fair Data Guide
Aishwarya Balajee
Oct 13, 2023
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20CDISC%20Send%20Fair%20Data%20Guide%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fwhite-papers%2Fcdisc-send-fair-data-guide%2F "Share on Email")
- [](https://x.com/intent/post?text=CDISC%20Send%20Fair%20Data%20Guide&url=https%3A%2F%2Fzifo.com%2Fwhite-papers%2Fcdisc-send-fair-data-guide%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=CDISC+Send+Fair+Data+Guide&url=https%3A%2F%2Fzifo.com%2Fwhite-papers%2Fcdisc-send-fair-data-guide%2F "Share on LinkedIn")
Image reference: / source
**Abstract**
Collectively called the Standard for Exchange of Nonclinical Data (SEND). the standards have been in development and recommended since early 2000s by Clinical Data Interchange Standards Consortium (CDISC) and the FDA.
They are now a requirement for preclinical studies started after December 2016 for New Drug Applications (NDA) and 2017 for Investigational New Drug (IND) submissions.
**Who is this analysis report for?**
- Toxicologists, Pathologists, Bioanalysts and others involved in creating data for in-vivo/animal studies
- Those responsible for submission of INDs or NDAs of in-vivo studies
**What you will get out of this report?**
- Learn how CDISC SEND standardization and FAIR go hand-in-hand
- Understand the benefits of FAIRification of data
- Typical challenges to look out for in your standardization journey
*The PDF report is embedded on this page. Please scroll to read or download it. Download option button is available below the PDF embed*
[ Click Here to Download the Report ](#)
## GET YOUR FREE COPY
First Name
Last Name
Email
Company
Job Title
I consent to being contacted by an official Zifo representative
Submit
GET YOUR FREE COPY
First Name
Last Name
Email
Company
Job Title
Acceptance I consent to being contacted by an official Zifo representative
Submit
## Recent Whitepapers
### [Redefining Data Products](https://zifo.com/white-papers/redefining-data-products/)
[  ](https://zifo.com/white-papers/redefining-data-products/)
### [Artificial Intelligence In The Pharmaceutical Industry](https://zifo.com/white-papers/artificial-intelligence-in-the-pharmaceutical-industry/)
[  ](https://zifo.com/white-papers/artificial-intelligence-in-the-pharmaceutical-industry/)
### [ePRO- Subject Centric Approach](https://zifo.com/white-papers/epro-subject-centric-approach/)
[  ](https://zifo.com/white-papers/epro-subject-centric-approach/)
---
### [ePRO- Subject Centric Approach](https://zifo.com/white-papers/epro-subject-centric-approach/)
**Published:** March 28, 2024
**Author:** Zifo_user
**Content:**
' ); } }); } }); /* ------------------------------------- FORM VALIDATION (INLINE MESSAGES) Updated to work with Elementor form --------------------------------------*/ jQuery(document).ready(function($) { // Prevent default form submission $('.elementor-down-pdf-form form').on('submit', function(e) { e.preventDefault(); validateForm(); }); // Also attach to button click $('.elementor-down-pdf-form .elementor-button').on('click', function(e) { e.preventDefault(); validateForm(); }); }); function validateForm() { // Clear previous errors jQuery(".error-message").remove(); jQuery('.elementor-down-pdf-form input').removeClass('error'); // Get form values - using Elementor field IDs let firstname = jQuery("#form-field-name").val().trim(); let lastname = jQuery("#form-field-field_f313a9e").val().trim(); let email = jQuery("#form-field-email").val().trim(); let company = jQuery("#form-field-field_cf8f855").val().trim(); let jobtitle = jQuery("#form-field-field_c49cb5f").val().trim(); let checkbox = jQuery('.elementor-down-pdf-form input[type="checkbox"]'); let consentChecked = checkbox.is(":checked"); let isValid = true; let emailPattern = /^[^\s@]+@[^\s@]+\.[^\s@]+$/; function showError(inputElement, message) { inputElement.addClass('error'); // Insert error message after the input field inputElement.after('' + message + '
'); } // Validate First Name if (firstname === "") { showError(jQuery("#form-field-name"), "Please fill this field."); isValid = false; } // Validate Last Name if (lastname === "") { showError(jQuery("#form-field-field_f313a9e"), "Please fill this field."); isValid = false; } // Validate Email if (email === "") { showError(jQuery("#form-field-email"), "Please fill this field."); isValid = false; } else if (!emailPattern.test(email)) { showError(jQuery("#form-field-email"), "Enter a valid email address."); isValid = false; } // Validate Company if (company === "") { showError(jQuery("#form-field-field_cf8f855"), "Please fill this field."); isValid = false; } // Validate Job Title if (jobtitle === "") { showError(jQuery("#form-field-field_c49cb5f"), "Please fill this field."); isValid = false; } // Validate Checkbox if (!consentChecked) { checkbox.addClass('error'); checkbox.closest('.elementor-field-subgroup').after( 'Please fill this field
' ); isValid = false; } // If form is valid, trigger download if (isValid) { // Trigger the download let link = document.createElement("a"); link.href = "https://cdn.zifo.com/2025/12/ePRO-Subject-Centric-Approach.pdf"; link.download = "ePRO-Subject-Centric-Approach.pdf"; document.body.appendChild(link); link.click(); document.body.removeChild(link); // Clear form values clearForm(); return true; } return false; } /* ------------------------------------- CLEAR FORM FUNCTION --------------------------------------*/ function clearForm() { // Clear all input values jQuery('.elementor-down-pdf-form input[type="text"]').val(''); jQuery('.elementor-down-pdf-form input[type="email"]').val(''); // Reset checkbox to checked jQuery('.elementor-down-pdf-form input[type="checkbox"]').prop('checked', true); // Remove floating-active class from all fields jQuery('.elementor-down-pdf-form .elementor-field-group').removeClass('floating-active'); // Remove any error classes jQuery('.elementor-down-pdf-form input').removeClass('error'); // Clear any remaining error messages jQuery('.error-message').remove(); } /* ------------------------------------- REAL-TIME VALIDATION Remove error when user starts typing --------------------------------------*/ jQuery(document).ready(function($) { $('.elementor-down-pdf-form input[type="text"], .elementor-down-pdf-form input[type="email"]').on('input', function() { var $input = $(this); var $errorMessage = $input.next('.error-message'); if ($input.val().trim() !== '' && $errorMessage.length) { $input.removeClass('error'); $errorMessage.remove(); // For email field, also validate format if ($input.attr('type') === 'email' && $input.val().trim() !== '') { var emailPattern = /^[^\s@]+@[^\s@]+\.[^\s@]+$/; if (!emailPattern.test($input.val().trim())) { $input.addClass('error'); $input.after('Enter a valid email address.
'); } } } }); });
[Home](https://zifo.com "Home")> [White Papers](https://zifo.com/white-papers/ "White Papers")> ePRO- Subject Centric Approach
## ePRO- Subject Centric Approach
Amal Krishna Girish
Mar 28, 2024
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20ePRO-%20Subject%20Centric%20Approach%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fwhite-papers%2Fepro-subject-centric-approach%2F "Share on Email")
- [](https://x.com/intent/post?text=ePRO-%20Subject%20Centric%20Approach&url=https%3A%2F%2Fzifo.com%2Fwhite-papers%2Fepro-subject-centric-approach%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=ePRO-+Subject+Centric+Approach&url=https%3A%2F%2Fzifo.com%2Fwhite-papers%2Fepro-subject-centric-approach%2F "Share on LinkedIn")
Image reference: / source
**Abstract**
This paper delves into the burgeoning trend of Electronic Patient Reported Outcomes (ePRO), which is evolving alongside Electronic Data Capture (EDC) systems. The COVID-19 pandemic accelerated the integration of ePRO systems into clinical trials, a trend that is expected to continue. Through the lens of the author’s insights, we explore the current landscape of ePRO systems, addressing their significant impacts on healthcare and clinical research. Furthermore, we discuss anticipated advancements, underscoring the role of ePRO in enhancing patient-centred care and research methodologies. This exploration highlights the transformative potential of ePRO systems and sets the stage for upcoming developments in this critical area of digital health.
*The PDF report is embedded on this page. Please scroll to read or download it. Download option button is available below the PDF embed*
[ Click Here to Download the Report ](#)
## GET YOUR FREE COPY
First Name
Last Name
Email
Company
Job Title
I consent to being contacted by an official Zifo representative
Submit
GET YOUR FREE COPY
First Name
Last Name
Email
Company
Job Title
Acceptance I consent to being contacted by an official Zifo representative
Submit
## Recent Whitepapers
### [Redefining Data Products](https://zifo.com/white-papers/redefining-data-products/)
[  ](https://zifo.com/white-papers/redefining-data-products/)
### [Artificial Intelligence In The Pharmaceutical Industry](https://zifo.com/white-papers/artificial-intelligence-in-the-pharmaceutical-industry/)
[  ](https://zifo.com/white-papers/artificial-intelligence-in-the-pharmaceutical-industry/)
### [ePRO- Subject Centric Approach](https://zifo.com/white-papers/epro-subject-centric-approach/)
[  ](https://zifo.com/white-papers/epro-subject-centric-approach/)
---
### [Artificial Intelligence In The Pharmaceutical Industry](https://zifo.com/white-papers/artificial-intelligence-in-the-pharmaceutical-industry/)
**Published:** August 28, 2024
**Author:** Zifo_user
**Content:**
' ); } }); } }); /* ------------------------------------- FORM VALIDATION (INLINE MESSAGES) Updated to work with Elementor form --------------------------------------*/ jQuery(document).ready(function($) { // Prevent default form submission $('.elementor-down-pdf-form form').on('submit', function(e) { e.preventDefault(); validateForm(); }); // Also attach to button click $('.elementor-down-pdf-form .elementor-button').on('click', function(e) { e.preventDefault(); validateForm(); }); }); function validateForm() { // Clear previous errors jQuery(".error-message").remove(); jQuery('.elementor-down-pdf-form input').removeClass('error'); // Get form values - using Elementor field IDs let firstname = jQuery("#form-field-name").val().trim(); let lastname = jQuery("#form-field-field_f313a9e").val().trim(); let email = jQuery("#form-field-email").val().trim(); let company = jQuery("#form-field-field_cf8f855").val().trim(); let jobtitle = jQuery("#form-field-field_c49cb5f").val().trim(); let checkbox = jQuery('.elementor-down-pdf-form input[type="checkbox"]'); let consentChecked = checkbox.is(":checked"); let isValid = true; let emailPattern = /^[^\s@]+@[^\s@]+\.[^\s@]+$/; function showError(inputElement, message) { inputElement.addClass('error'); // Insert error message after the input field inputElement.after('' + message + '
'); } // Validate First Name if (firstname === "") { showError(jQuery("#form-field-name"), "Please fill this field."); isValid = false; } // Validate Last Name if (lastname === "") { showError(jQuery("#form-field-field_f313a9e"), "Please fill this field."); isValid = false; } // Validate Email if (email === "") { showError(jQuery("#form-field-email"), "Please fill this field."); isValid = false; } else if (!emailPattern.test(email)) { showError(jQuery("#form-field-email"), "Enter a valid email address."); isValid = false; } // Validate Company if (company === "") { showError(jQuery("#form-field-field_cf8f855"), "Please fill this field."); isValid = false; } // Validate Job Title if (jobtitle === "") { showError(jQuery("#form-field-field_c49cb5f"), "Please fill this field."); isValid = false; } // Validate Checkbox if (!consentChecked) { checkbox.addClass('error'); checkbox.closest('.elementor-field-subgroup').after( 'Please fill this field
' ); isValid = false; } // If form is valid, trigger download if (isValid) { // Trigger the download let link = document.createElement("a"); link.href = "https://cdn.zifo.com/2025/12/AI-Pharma-Drug.pdf"; link.download = "AI-Pharma-Drug.pdf"; document.body.appendChild(link); link.click(); document.body.removeChild(link); // Clear form values clearForm(); return true; } return false; } /* ------------------------------------- CLEAR FORM FUNCTION --------------------------------------*/ function clearForm() { // Clear all input values jQuery('.elementor-down-pdf-form input[type="text"]').val(''); jQuery('.elementor-down-pdf-form input[type="email"]').val(''); // Reset checkbox to checked jQuery('.elementor-down-pdf-form input[type="checkbox"]').prop('checked', true); // Remove floating-active class from all fields jQuery('.elementor-down-pdf-form .elementor-field-group').removeClass('floating-active'); // Remove any error classes jQuery('.elementor-down-pdf-form input').removeClass('error'); // Clear any remaining error messages jQuery('.error-message').remove(); } /* ------------------------------------- REAL-TIME VALIDATION Remove error when user starts typing --------------------------------------*/ jQuery(document).ready(function($) { $('.elementor-down-pdf-form input[type="text"], .elementor-down-pdf-form input[type="email"]').on('input', function() { var $input = $(this); var $errorMessage = $input.next('.error-message'); if ($input.val().trim() !== '' && $errorMessage.length) { $input.removeClass('error'); $errorMessage.remove(); // For email field, also validate format if ($input.attr('type') === 'email' && $input.val().trim() !== '') { var emailPattern = /^[^\s@]+@[^\s@]+\.[^\s@]+$/; if (!emailPattern.test($input.val().trim())) { $input.addClass('error'); $input.after('Enter a valid email address.
'); } } } }); });
[Home](https://zifo.com "Home")> [White Papers](https://zifo.com/white-papers/ "White Papers")> Artificial Intelligence In The Pharmaceutical Industry
## Artificial Intelligence In The Pharmaceutical Industry
David Jackson
Dec 15, 2023
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Artificial%20Intelligence%20In%20The%20Pharmaceutical%20Industry%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fwhite-papers%2Fartificial-intelligence-in-the-pharmaceutical-industry%2F "Share on Email")
- [](https://x.com/intent/post?text=Artificial%20Intelligence%20In%20The%20Pharmaceutical%20Industry&url=https%3A%2F%2Fzifo.com%2Fwhite-papers%2Fartificial-intelligence-in-the-pharmaceutical-industry%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Artificial+Intelligence+In+The+Pharmaceutical+Industry&url=https%3A%2F%2Fzifo.com%2Fwhite-papers%2Fartificial-intelligence-in-the-pharmaceutical-industry%2F "Share on LinkedIn")
Image reference: / source
**Abstract**
The utility of AI within drug discovery and pre-clinical development heralds a new era of innovation in biomedical research. In the complex journey from the lab bench to the patient’s bedside, the preclinical phase stands as a pivotal crossroad where potential drug candidates are identified, validated and rigorously analyzed before potential clinical testing in patients.
*The PDF report is embedded on this page. Please scroll to read or download it. Download option button is available below the PDF embed*
[ Click Here to Download the Report ](#download-survey-report-container)
GET YOUR FREE COPY
First Name
Last Name
Email
Company
Job Title
Acceptance I consent to being contacted by an official Zifo representative
Submit
## Recent Whitepapers
### [Redefining Data Products](https://zifo.com/white-papers/redefining-data-products/)
[  ](https://zifo.com/white-papers/redefining-data-products/)
### [Artificial Intelligence In The Pharmaceutical Industry](https://zifo.com/white-papers/artificial-intelligence-in-the-pharmaceutical-industry/)
[  ](https://zifo.com/white-papers/artificial-intelligence-in-the-pharmaceutical-industry/)
### [ePRO- Subject Centric Approach](https://zifo.com/white-papers/epro-subject-centric-approach/)
[  ](https://zifo.com/white-papers/epro-subject-centric-approach/)
---
### [Redefining Data Products](https://zifo.com/white-papers/redefining-data-products/)
**Published:** March 3, 2026
**Author:** Zifo_user
**Content:**
' ); } }); } }); /* ------------------------------------- FORM VALIDATION (INLINE MESSAGES) Updated to work with Elementor form --------------------------------------*/ jQuery(document).ready(function($) { // Prevent default form submission $('.elementor-down-pdf-form form').on('submit', function(e) { e.preventDefault(); validateForm(); }); // Also attach to button click $('.elementor-down-pdf-form .elementor-button').on('click', function(e) { e.preventDefault(); validateForm(); }); }); function validateForm() { // Clear previous errors jQuery(".error-message").remove(); jQuery('.elementor-down-pdf-form input').removeClass('error'); // Get form values - using Elementor field IDs let firstname = jQuery("#form-field-name").val().trim(); let lastname = jQuery("#form-field-field_f313a9e").val().trim(); let email = jQuery("#form-field-email").val().trim(); let company = jQuery("#form-field-field_cf8f855").val().trim(); let jobtitle = jQuery("#form-field-field_c49cb5f").val().trim(); let checkbox = jQuery('.elementor-down-pdf-form input[type="checkbox"]'); let consentChecked = checkbox.is(":checked"); let isValid = true; let emailPattern = /^[^\s@]+@[^\s@]+\.[^\s@]+$/; function showError(inputElement, message) { inputElement.addClass('error'); // Insert error message after the input field inputElement.after('' + message + '
'); } // Validate First Name if (firstname === "") { showError(jQuery("#form-field-name"), "Please fill this field."); isValid = false; } // Validate Last Name if (lastname === "") { showError(jQuery("#form-field-field_f313a9e"), "Please fill this field."); isValid = false; } // Validate Email if (email === "") { showError(jQuery("#form-field-email"), "Please fill this field."); isValid = false; } else if (!emailPattern.test(email)) { showError(jQuery("#form-field-email"), "Enter a valid email address."); isValid = false; } // Validate Company if (company === "") { showError(jQuery("#form-field-field_cf8f855"), "Please fill this field."); isValid = false; } // Validate Job Title if (jobtitle === "") { showError(jQuery("#form-field-field_c49cb5f"), "Please fill this field."); isValid = false; } // Validate Checkbox if (!consentChecked) { checkbox.addClass('error'); checkbox.closest('.elementor-field-subgroup').after( 'Please fill this field
' ); isValid = false; } // If form is valid, trigger download if (isValid) { // Trigger the download let link = document.createElement("a"); link.href = "https://cdn.zifo.com/2025/12/AI-Pharma-Drug.pdf"; link.download = "AI-Pharma-Drug.pdf"; document.body.appendChild(link); link.click(); document.body.removeChild(link); // Clear form values clearForm(); return true; } return false; } /* ------------------------------------- CLEAR FORM FUNCTION --------------------------------------*/ function clearForm() { // Clear all input values jQuery('.elementor-down-pdf-form input[type="text"]').val(''); jQuery('.elementor-down-pdf-form input[type="email"]').val(''); // Reset checkbox to checked jQuery('.elementor-down-pdf-form input[type="checkbox"]').prop('checked', true); // Remove floating-active class from all fields jQuery('.elementor-down-pdf-form .elementor-field-group').removeClass('floating-active'); // Remove any error classes jQuery('.elementor-down-pdf-form input').removeClass('error'); // Clear any remaining error messages jQuery('.error-message').remove(); } /* ------------------------------------- REAL-TIME VALIDATION Remove error when user starts typing --------------------------------------*/ jQuery(document).ready(function($) { $('.elementor-down-pdf-form input[type="text"], .elementor-down-pdf-form input[type="email"]').on('input', function() { var $input = $(this); var $errorMessage = $input.next('.error-message'); if ($input.val().trim() !== '' && $errorMessage.length) { $input.removeClass('error'); $errorMessage.remove(); // For email field, also validate format if ($input.attr('type') === 'email' && $input.val().trim() !== '') { var emailPattern = /^[^\s@]+@[^\s@]+\.[^\s@]+$/; if (!emailPattern.test($input.val().trim())) { $input.addClass('error'); $input.after('Enter a valid email address.
'); } } } }); });
[Home](https://zifo.com "Home")> [White Papers](https://zifo.com/white-papers/ "White Papers")> Redefining Data Products
## Redefining Data Products
Bruno Fievet, Melchor Sanchez Martinez, David Jackson
Mar 03, 2026
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Redefining%20Data%20Products%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fwhite-papers%2Fredefining-data-products%2F "Share on Email")
- [](https://x.com/intent/post?text=Redefining%20Data%20Products&url=https%3A%2F%2Fzifo.com%2Fwhite-papers%2Fredefining-data-products%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Redefining+Data+Products&url=https%3A%2F%2Fzifo.com%2Fwhite-papers%2Fredefining-data-products%2F "Share on LinkedIn")
Image reference: / source
**Abstract**
The term “data product” is widely used but inconsistently understood across industries. This paper clarifies the ambiguity by distinguishing between two valid interpretations: curated datasets that enable data reuse, referred to as Lite Data Products, and digital solutions that convert data into measurable business value, referred to as Full Data Products. Context determines which definition applies, and organizations seeking to operate in value-driven, outcome-oriented models should prioritize the latter. Building on this distinction, the paper introduces the concept of Data-as-a-Product. This is a mindset and operating model that applies product management principles such as ownership, lifecycle management, and continuous improvement to data itself, transforming it from a passive asset into a managed, living source of sustained value.
*The PDF report is embedded on this page. Please scroll to read or download it. Download option button is available below the PDF embed*
[ Click Here to Download the Report ](#download-survey-report-container)
GET YOUR FREE COPY
First Name
Last Name
Email
Company
Job Title
Acceptance I consent to being contacted by an official Zifo representative
Submit
## Recent Whitepapers
### [Redefining Data Products](https://zifo.com/white-papers/redefining-data-products/)
[  ](https://zifo.com/white-papers/redefining-data-products/)
### [Artificial Intelligence In The Pharmaceutical Industry](https://zifo.com/white-papers/artificial-intelligence-in-the-pharmaceutical-industry/)
[  ](https://zifo.com/white-papers/artificial-intelligence-in-the-pharmaceutical-industry/)
### [ePRO- Subject Centric Approach](https://zifo.com/white-papers/epro-subject-centric-approach/)
[  ](https://zifo.com/white-papers/epro-subject-centric-approach/)
---
### [Streamlining Pharma Formulations](https://zifo.com/white-papers/streamlining-pharma/)
**Published:** April 1, 2022
**Author:** Zifo_user
**Content:**
' ); } }); } }); /* ------------------------------------- FORM VALIDATION (INLINE MESSAGES) Updated to work with Elementor form --------------------------------------*/ jQuery(document).ready(function($) { // Prevent default form submission $('.elementor-down-pdf-form form').on('submit', function(e) { e.preventDefault(); validateForm(); }); // Also attach to button click $('.elementor-down-pdf-form .elementor-button').on('click', function(e) { e.preventDefault(); validateForm(); }); }); function validateForm() { // Clear previous errors jQuery(".error-message").remove(); jQuery('.elementor-down-pdf-form input').removeClass('error'); // Get form values - using Elementor field IDs let firstname = jQuery("#form-field-name").val().trim(); let lastname = jQuery("#form-field-field_f313a9e").val().trim(); let email = jQuery("#form-field-email").val().trim(); let company = jQuery("#form-field-field_cf8f855").val().trim(); let jobtitle = jQuery("#form-field-field_c49cb5f").val().trim(); let checkbox = jQuery('.elementor-down-pdf-form input[type="checkbox"]'); let consentChecked = checkbox.is(":checked"); let isValid = true; let emailPattern = /^[^\s@]+@[^\s@]+\.[^\s@]+$/; function showError(inputElement, message) { inputElement.addClass('error'); // Insert error message after the input field inputElement.after('' + message + '
'); } // Validate First Name if (firstname === "") { showError(jQuery("#form-field-name"), "Please fill this field."); isValid = false; } // Validate Last Name if (lastname === "") { showError(jQuery("#form-field-field_f313a9e"), "Please fill this field."); isValid = false; } // Validate Email if (email === "") { showError(jQuery("#form-field-email"), "Please fill this field."); isValid = false; } else if (!emailPattern.test(email)) { showError(jQuery("#form-field-email"), "Enter a valid email address."); isValid = false; } // Validate Company if (company === "") { showError(jQuery("#form-field-field_cf8f855"), "Please fill this field."); isValid = false; } // Validate Job Title if (jobtitle === "") { showError(jQuery("#form-field-field_c49cb5f"), "Please fill this field."); isValid = false; } // Validate Checkbox if (!consentChecked) { checkbox.addClass('error'); checkbox.closest('.elementor-field-subgroup').after( 'Please fill this field
' ); isValid = false; } // If form is valid, trigger download if (isValid) { // Trigger the download let link = document.createElement("a"); link.href = "https://cdn.zifo.com/2025/12/Streamlining-of-Pharmaceutical-Development.pdf"; link.download = "Streamlining-of-Pharmaceutical-Development.pdf"; document.body.appendChild(link); link.click(); document.body.removeChild(link); // Clear form values clearForm(); return true; } return false; } /* ------------------------------------- CLEAR FORM FUNCTION --------------------------------------*/ function clearForm() { // Clear all input values jQuery('.elementor-down-pdf-form input[type="text"]').val(''); jQuery('.elementor-down-pdf-form input[type="email"]').val(''); // Reset checkbox to checked jQuery('.elementor-down-pdf-form input[type="checkbox"]').prop('checked', true); // Remove floating-active class from all fields jQuery('.elementor-down-pdf-form .elementor-field-group').removeClass('floating-active'); // Remove any error classes jQuery('.elementor-down-pdf-form input').removeClass('error'); // Clear any remaining error messages jQuery('.error-message').remove(); } /* ------------------------------------- REAL-TIME VALIDATION Remove error when user starts typing --------------------------------------*/ jQuery(document).ready(function($) { $('.elementor-down-pdf-form input[type="text"], .elementor-down-pdf-form input[type="email"]').on('input', function() { var $input = $(this); var $errorMessage = $input.next('.error-message'); if ($input.val().trim() !== '' && $errorMessage.length) { $input.removeClass('error'); $errorMessage.remove(); // For email field, also validate format if ($input.attr('type') === 'email' && $input.val().trim() !== '') { var emailPattern = /^[^\s@]+@[^\s@]+\.[^\s@]+$/; if (!emailPattern.test($input.val().trim())) { $input.addClass('error'); $input.after('Enter a valid email address.
'); } } } }); });
[Home](https://zifo.com "Home")> [White Papers](https://zifo.com/white-papers/ "White Papers")> Streamlining Pharma Formulations
## Streamlining Pharma Formulations
#### Streamlining Pharma Product Development Through Digital Coaching
Mehnaz Husain
Apr 01, 2022
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Streamlining%20Pharma%20Formulations%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fwhite-papers%2Fstreamlining-pharma%2F "Share on Email")
- [](https://x.com/intent/post?text=Streamlining%20Pharma%20Formulations&url=https%3A%2F%2Fzifo.com%2Fwhite-papers%2Fstreamlining-pharma%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Streamlining+Pharma+Formulations&url=https%3A%2F%2Fzifo.com%2Fwhite-papers%2Fstreamlining-pharma%2F "Share on LinkedIn")
Image reference: / source
In this white paper, we explore the case study when an existing customer reached out to Zifo to help plan and execute a transition to a web-based ELN for their large, global, formulations group from a legacy on-prem thick client solution.
**TRANSITIONING FROM ON-PREM TO CLOUD ELN**
There are many aspects that can make a cloud migration successful – and many that can derail or put the project at risk. Ensuring stakeholder engagement, process understanding and optimisation, simplification of scientists’ day-2-day lives and measurable positive business impact are just some of them.
**In this white paper we cover:**
- **The situation: an on premise Thick Client ELN move to Web**
- **Building a plan of Action**
- **Stakeholder engagement**
- **Process mapping using SIPOC**
- **Prioritisation and consolidation of workflows**
- **Impacts on the lab workflows**
*The PDF report is embedded on this page. Please scroll to read or download it. Download option button is available below the PDF embed*
[ Click Here to Download the Report ](#)
## GET YOUR FREE COPY
First Name
Last Name
Email
Company
Job Title
I consent to being contacted by an official Zifo representative
Submit
GET YOUR FREE COPY
First Name
Last Name
Email
Company
Job Title
Acceptance I consent to being contacted by an official Zifo representative
Submit
## Recent Whitepapers
### [Redefining Data Products](https://zifo.com/white-papers/redefining-data-products/)
[  ](https://zifo.com/white-papers/redefining-data-products/)
### [Artificial Intelligence In The Pharmaceutical Industry](https://zifo.com/white-papers/artificial-intelligence-in-the-pharmaceutical-industry/)
[  ](https://zifo.com/white-papers/artificial-intelligence-in-the-pharmaceutical-industry/)
### [ePRO- Subject Centric Approach](https://zifo.com/white-papers/epro-subject-centric-approach/)
[  ](https://zifo.com/white-papers/epro-subject-centric-approach/)
---
### [The Role Of Scientific Business Systems Analysts In Driving Science Forward](https://zifo.com/white-papers/the-role-of-scientific-business-systems-analysts-in-driving-science-forward/)
**Published:** September 28, 2022
**Author:** Zifo_user
**Content:**
' ); } }); } }); /* ------------------------------------- FORM VALIDATION (INLINE MESSAGES) Updated to work with Elementor form --------------------------------------*/ jQuery(document).ready(function($) { // Prevent default form submission $('.elementor-down-pdf-form form').on('submit', function(e) { e.preventDefault(); validateForm(); }); // Also attach to button click $('.elementor-down-pdf-form .elementor-button').on('click', function(e) { e.preventDefault(); validateForm(); }); }); function validateForm() { // Clear previous errors jQuery(".error-message").remove(); jQuery('.elementor-down-pdf-form input').removeClass('error'); // Get form values - using Elementor field IDs let firstname = jQuery("#form-field-name").val().trim(); let lastname = jQuery("#form-field-field_f313a9e").val().trim(); let email = jQuery("#form-field-email").val().trim(); let company = jQuery("#form-field-field_cf8f855").val().trim(); let jobtitle = jQuery("#form-field-field_c49cb5f").val().trim(); let checkbox = jQuery('.elementor-down-pdf-form input[type="checkbox"]'); let consentChecked = checkbox.is(":checked"); let isValid = true; let emailPattern = /^[^\s@]+@[^\s@]+\.[^\s@]+$/; function showError(inputElement, message) { inputElement.addClass('error'); // Insert error message after the input field inputElement.after('' + message + '
'); } // Validate First Name if (firstname === "") { showError(jQuery("#form-field-name"), "Please fill this field."); isValid = false; } // Validate Last Name if (lastname === "") { showError(jQuery("#form-field-field_f313a9e"), "Please fill this field."); isValid = false; } // Validate Email if (email === "") { showError(jQuery("#form-field-email"), "Please fill this field."); isValid = false; } else if (!emailPattern.test(email)) { showError(jQuery("#form-field-email"), "Enter a valid email address."); isValid = false; } // Validate Company if (company === "") { showError(jQuery("#form-field-field_cf8f855"), "Please fill this field."); isValid = false; } // Validate Job Title if (jobtitle === "") { showError(jQuery("#form-field-field_c49cb5f"), "Please fill this field."); isValid = false; } // Validate Checkbox if (!consentChecked) { checkbox.addClass('error'); checkbox.closest('.elementor-field-subgroup').after( 'Please fill this field
' ); isValid = false; } // If form is valid, trigger download if (isValid) { // Trigger the download let link = document.createElement("a"); link.href = "https://cdn.zifo.com/2025/12/Scientific-Informatics-BSA-V3.pdf"; link.download = "Scientific-Informatics-BSA-V3.pdf"; document.body.appendChild(link); link.click(); document.body.removeChild(link); // Clear form values clearForm(); return true; } return false; } /* ------------------------------------- CLEAR FORM FUNCTION --------------------------------------*/ function clearForm() { // Clear all input values jQuery('.elementor-down-pdf-form input[type="text"]').val(''); jQuery('.elementor-down-pdf-form input[type="email"]').val(''); // Reset checkbox to checked jQuery('.elementor-down-pdf-form input[type="checkbox"]').prop('checked', true); // Remove floating-active class from all fields jQuery('.elementor-down-pdf-form .elementor-field-group').removeClass('floating-active'); // Remove any error classes jQuery('.elementor-down-pdf-form input').removeClass('error'); // Clear any remaining error messages jQuery('.error-message').remove(); } /* ------------------------------------- REAL-TIME VALIDATION Remove error when user starts typing --------------------------------------*/ jQuery(document).ready(function($) { $('.elementor-down-pdf-form input[type="text"], .elementor-down-pdf-form input[type="email"]').on('input', function() { var $input = $(this); var $errorMessage = $input.next('.error-message'); if ($input.val().trim() !== '' && $errorMessage.length) { $input.removeClass('error'); $errorMessage.remove(); // For email field, also validate format if ($input.attr('type') === 'email' && $input.val().trim() !== '') { var emailPattern = /^[^\s@]+@[^\s@]+\.[^\s@]+$/; if (!emailPattern.test($input.val().trim())) { $input.addClass('error'); $input.after('Enter a valid email address.
'); } } } }); });
[Home](https://zifo.com "Home")> [White Papers](https://zifo.com/white-papers/ "White Papers")> The Role Of Scientific Business Systems Analysts In Driving Science Forward
## The Role Of Scientific Business Systems Analysts In Driving Science Forward
Aishwarya Balajee
Sep 28, 2022
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20The%20Role%20Of%20Scientific%20Business%20Systems%20Analysts%20In%20Driving%20Science%20Forward%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fwhite-papers%2Fthe-role-of-scientific-business-systems-analysts-in-driving-science-forward%2F "Share on Email")
- [](https://x.com/intent/post?text=The%20Role%20Of%20Scientific%20Business%20Systems%20Analysts%20In%20Driving%20Science%20Forward&url=https%3A%2F%2Fzifo.com%2Fwhite-papers%2Fthe-role-of-scientific-business-systems-analysts-in-driving-science-forward%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=The+Role+Of+Scientific+Business+Systems+Analysts+In+Driving+Science+Forward&url=https%3A%2F%2Fzifo.com%2Fwhite-papers%2Fthe-role-of-scientific-business-systems-analysts-in-driving-science-forward%2F "Share on LinkedIn")
Image reference: / source
**Abstract**
Research and development (R&D) Informatics projects are rapidly growing both in number and scope in recent years. While all informatics projects have long relied on business systems analysts (BSAs) for successful project delivery, we have identified that ***“R&D Informatics projects require specialized BSAs with unique skills, having scientific domain knowledge and understanding of scientific informatics tools and technologies to be successful”***. In this paper, we discuss R&D Informatics projects, the role of SI-BSAs and maximizing organizational value through successful SI-BSAs.
**Introduction**
**Research and Development Informatics Projects**
The COVID-19 pandemic has highlighted the intricacy of the life sciences research and development sector. This industry is characterized by large growth and rapid innovation, as demonstrated by the 295% increase in pipeline drugs since 2001(1). While the rate of innovation leads to new discoveries and breakthroughs, it must be matched with equal innovation in the scientific informatics so that scientists have the tools and throughput to sustain their innovation and continue their research.
**Ultimately, the goal of R&D Informatics Projects is typically one, two, or all of the following**
- **to enable scientific business efficiency**
- **to create/deliver tools that allow for more rapid and data-driven decision making**
- **to improve Quality and Compliance.**
**Unique skills of Scientific Informatic Business Systems Analyst (SI-BSA)**
With Science evolving rapidly, new modalities such as ADCs, and mABs, new scientific technologies such as NGS, RNAi are all making data continually more complex. New laboratory techniques and instruments provide opportunities for automation and efficiency. All of this change demands more Informatics solutions and new projects. This presents SI-BSAs involved in these projects with a unique set of challenges and opportunities which means they must possess special skills to be successful. As such, SI-BSAS are often part of a project from conceptualization to strategy implementation. During this entire project phase, SI-BSAS must continue to have productive conversations and requirements gathering sessions with scientists while providing the voice of the customer guidance to the project team. Below, we have identified several major categories of skills that are specifically important as an SI-BSA over a typical BSA.
*The PDF report is embedded on this page. Please scroll to read or download it. Download option button is available below the PDF embed*
[ Click Here to Download the Report ](#)
## GET YOUR FREE COPY
First Name
Last Name
Email
Company
Job Title
I consent to being contacted by an official Zifo representative
Submit
GET YOUR FREE COPY
First Name
Last Name
Email
Company
Job Title
Acceptance I consent to being contacted by an official Zifo representative
Submit
## Recent Whitepapers
### [Redefining Data Products](https://zifo.com/white-papers/redefining-data-products/)
[  ](https://zifo.com/white-papers/redefining-data-products/)
### [Artificial Intelligence In The Pharmaceutical Industry](https://zifo.com/white-papers/artificial-intelligence-in-the-pharmaceutical-industry/)
[  ](https://zifo.com/white-papers/artificial-intelligence-in-the-pharmaceutical-industry/)
### [ePRO- Subject Centric Approach](https://zifo.com/white-papers/epro-subject-centric-approach/)
[  ](https://zifo.com/white-papers/epro-subject-centric-approach/)
---
### [Informatics Vendor Evaluation Approach Update](https://zifo.com/white-papers/informatics-vendor-evaluation-approach-update/)
**Published:** August 2, 2023
**Author:** Zifo_user
**Content:**
' ); } }); } }); /* ------------------------------------- FORM VALIDATION (INLINE MESSAGES) Updated to work with Elementor form --------------------------------------*/ jQuery(document).ready(function($) { // Prevent default form submission $('.elementor-down-pdf-form form').on('submit', function(e) { e.preventDefault(); validateForm(); }); // Also attach to button click $('.elementor-down-pdf-form .elementor-button').on('click', function(e) { e.preventDefault(); validateForm(); }); }); function validateForm() { // Clear previous errors jQuery(".error-message").remove(); jQuery('.elementor-down-pdf-form input').removeClass('error'); // Get form values - using Elementor field IDs let firstname = jQuery("#form-field-name").val().trim(); let lastname = jQuery("#form-field-field_f313a9e").val().trim(); let email = jQuery("#form-field-email").val().trim(); let company = jQuery("#form-field-field_cf8f855").val().trim(); let jobtitle = jQuery("#form-field-field_c49cb5f").val().trim(); let checkbox = jQuery('.elementor-down-pdf-form input[type="checkbox"]'); let consentChecked = checkbox.is(":checked"); let isValid = true; let emailPattern = /^[^\s@]+@[^\s@]+\.[^\s@]+$/; function showError(inputElement, message) { inputElement.addClass('error'); // Insert error message after the input field inputElement.after('' + message + '
'); } // Validate First Name if (firstname === "") { showError(jQuery("#form-field-name"), "Please fill this field."); isValid = false; } // Validate Last Name if (lastname === "") { showError(jQuery("#form-field-field_f313a9e"), "Please fill this field."); isValid = false; } // Validate Email if (email === "") { showError(jQuery("#form-field-email"), "Please fill this field."); isValid = false; } else if (!emailPattern.test(email)) { showError(jQuery("#form-field-email"), "Enter a valid email address."); isValid = false; } // Validate Company if (company === "") { showError(jQuery("#form-field-field_cf8f855"), "Please fill this field."); isValid = false; } // Validate Job Title if (jobtitle === "") { showError(jQuery("#form-field-field_c49cb5f"), "Please fill this field."); isValid = false; } // Validate Checkbox if (!consentChecked) { checkbox.addClass('error'); checkbox.closest('.elementor-field-subgroup').after( 'Please fill this field
' ); isValid = false; } // If form is valid, trigger download if (isValid) { // Trigger the download let link = document.createElement("a"); link.href = "https://cdn.zifo.com/2025/12/Vendor-Selection-Approach-V4.pdf"; link.download = "Vendor-Selection-Approach-V4.pdf"; document.body.appendChild(link); link.click(); document.body.removeChild(link); // Clear form values clearForm(); return true; } return false; } /* ------------------------------------- CLEAR FORM FUNCTION --------------------------------------*/ function clearForm() { // Clear all input values jQuery('.elementor-down-pdf-form input[type="text"]').val(''); jQuery('.elementor-down-pdf-form input[type="email"]').val(''); // Reset checkbox to checked jQuery('.elementor-down-pdf-form input[type="checkbox"]').prop('checked', true); // Remove floating-active class from all fields jQuery('.elementor-down-pdf-form .elementor-field-group').removeClass('floating-active'); // Remove any error classes jQuery('.elementor-down-pdf-form input').removeClass('error'); // Clear any remaining error messages jQuery('.error-message').remove(); } /* ------------------------------------- REAL-TIME VALIDATION Remove error when user starts typing --------------------------------------*/ jQuery(document).ready(function($) { $('.elementor-down-pdf-form input[type="text"], .elementor-down-pdf-form input[type="email"]').on('input', function() { var $input = $(this); var $errorMessage = $input.next('.error-message'); if ($input.val().trim() !== '' && $errorMessage.length) { $input.removeClass('error'); $errorMessage.remove(); // For email field, also validate format if ($input.attr('type') === 'email' && $input.val().trim() !== '') { var emailPattern = /^[^\s@]+@[^\s@]+\.[^\s@]+$/; if (!emailPattern.test($input.val().trim())) { $input.addClass('error'); $input.after('Enter a valid email address.
'); } } } }); });
[Home](https://zifo.com "Home")> [White Papers](https://zifo.com/white-papers/ "White Papers")> Informatics Vendor Evaluation Approach Update
## Informatics Vendor Evaluation Approach Update
Uma Maheswari Adiseshan
Aug 02, 2023
## Share This Post
- [](mailto:?subject=Visit%20this%20site%20https%3A%2F%2Fzifo.com&body=Hi%2C%20this%20may%20be%20interesting%20you%3A%20Informatics%20Vendor%20Evaluation%20Approach%20Update%21%20This%20is%20the%20link%3A%20https%3A%2F%2Fzifo.com%2Fwhite-papers%2Finformatics-vendor-evaluation-approach-update%2F "Share on Email")
- [](https://x.com/intent/post?text=Informatics%20Vendor%20Evaluation%20Approach%20Update&url=https%3A%2F%2Fzifo.com%2Fwhite-papers%2Finformatics-vendor-evaluation-approach-update%2F "Share on Twitter")
- [](https://www.linkedin.com/shareArticle?mini=true&ro=true&trk=EasySocialShareButtons&title=Informatics+Vendor+Evaluation+Approach+Update&url=https%3A%2F%2Fzifo.com%2Fwhite-papers%2Finformatics-vendor-evaluation-approach-update%2F "Share on LinkedIn")
Image reference: / source
**Abstract**
“Research and development (R&D) industries have a rapidly changing informatics landscape with digitalization. The industry is moving towards a data-centric world. So they are adopting and investing heavily in solutions that help them focus on the science with improved user experience, quality, data security, and reduced cost. In this paper, we discuss the challenges faced by industries with technological advances and our recommended approach/framework for vendor selection with the success story.”
**Introduction**
The R&D industry faces several challenges in adopting new technological advances. Often, customers are forced to switch technologies due to advances, and at other times, it is to evolve and make the best use of them. Lab Informatics vendors offer a variety of solutions, but not all will necessarily fit the scientists’ needs.
**Key Challenges faced by Scientific R&D**
- Struggle to use data-driven insights because the availability of specialized data scientists/analysts, and tools with appropriate business domain expertise are limited.
- Labs generate an enormous amount of data so the demand to manage and store lab data is continually rising, which demands a platform and data storage and integration strategy.
- Delivering ‘Lab of the future’ focuses on the changes to immersive work behaviours, automation and harmonization of data is collection is not yet common place.
- Complex and new scientific domains and workflows (like NGS, novel modalities, etc) are constantly cropping up, despite most organizations’ over-dependence on shadow IT and “patchwork” approach to scientific workbenches leading to limited enterprise empowerment in these areas.
- Upgrading and maintaining legacy systems is a constant demand and can be tricky if platforms do not evolve with the science and workflows.
To add to the above key challenges faced by R&D, many of the core informatics platforms are approaching or are well over a decade in age. Often these legacy systems are monolithic that are heavily customized, making them extremely difficult to maintain and upgrade.
We often see one of two “vendor selection” routes taken by our customers.
1. The lab personnel drive vendor selection themselves, given their familiarity with the lab and processes, leaving informatics to pick up the pieces or
2. Informatics systems being selected by IT without business involvement.
The figure below depicts a general lab informatics summary of small to large biopharmaceutical companies.
*The PDF report is embedded on this page. Please scroll to read or download it. Download option button is available below the PDF embed*
[ Click Here to Download the Report ](#)
## GET YOUR FREE COPY
First Name
Last Name
Email
Company
Job Title
I consent to being contacted by an official Zifo representative
Submit
GET YOUR FREE COPY
First Name
Last Name
Email
Company
Job Title
Acceptance I consent to being contacted by an official Zifo representative
Submit
## Recent Whitepapers
### [Redefining Data Products](https://zifo.com/white-papers/redefining-data-products/)
[  ](https://zifo.com/white-papers/redefining-data-products/)
### [Artificial Intelligence In The Pharmaceutical Industry](https://zifo.com/white-papers/artificial-intelligence-in-the-pharmaceutical-industry/)
[  ](https://zifo.com/white-papers/artificial-intelligence-in-the-pharmaceutical-industry/)
### [ePRO- Subject Centric Approach](https://zifo.com/white-papers/epro-subject-centric-approach/)
[  ](https://zifo.com/white-papers/epro-subject-centric-approach/)
---
## Industries
### [Large Pharma and Biotech](https://zifo.com/industries/pharmaceutical-informatics-and-consulting-services/)
**Published:** December 22, 2025
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Industries](https://zifo.com/industries/ "Industries")> Large Pharma and Biotech
Large Pharma and Biotech
Integrated Excellence:
Unifying R&D, Clinical, CMC,
Manufacturing, and Quality
[ Connect With Us ](#)
Speed of
Discovery
Personalised
Treatments
Supply Chain
Resilience
IMPROVED PATIENT OUTCOMES
Leverage AI and Data Standardisation at Every Level of
Your Scientific Informatics Process Workflow
AI-Native Ecosystem
# Value Chain
All Stages
Research
Development
Clinical
Manufacturing
## Full Value Chain View
All Platforms Informatics Data Specialist
Expand All
### Research
TI/TV Analytical & Scientific data management - SDMS
Visualisation & Dashboarding
Lab Robotics & Automation
Multiomics Informatics
Data Informatics
Data Standarizaton and Analytics
Bioinformatics
Simulation and Modelling
No filter data found
HTS & Hit Discovery Sample Management - LIMS
Visualisation & Dashboarding
Lab Robotics & Automation
Multiomics Informatics
Data Informatics
Data Standardizaton & Analytics
Cheminformatics
No filter data found
Lead Development Experiment Capture - ELN
Visualisation & Dashboarding
Lab Robotics & Automation
Data Informatics
Data Standardizaton & Analytics
Cheminformatics
Simulation and Modelling
No filter data found
Pharmacology Experiment Capture - ELN
Visualisation & Dashboarding
Lab Robotics & Automation
Data Informatics
Data Standardizaton & Analytics
Cheminformatics
Simulation and Modelling
No filter data found
ADMET Experiment Capture - ELN
Visualisation & Dashboarding
Lab Robotics & Automation
Data Informatics
Data Standardizaton & Analytics
Cheminformatics
Simulation and Modelling
No filter data found
### Development
Invivo Experiment Capture - ELN
Chromatography Data Management - CDS
Visualisation & Dashboarding
Lab Robotics & Automation
Data Informatics
Data Standarizaton and Analytics
Cheminformatics
Bioinformatics
Simulation and Modelling
No filter data found
Safety / Tox Experiment Capture - ELN
Sample Management - LIMS
Visualisation & Dashboarding
Lab Robotics & Automation
Data Informatics
Data Standarizaton and Analytics
Cheminformatics
Simulation and Modelling
No filter data found
PK / PD Experiment Capture - ELN
Lab Robotics & Automation
Sample Management - LIMS
Visualisation & Dashboarding
Quality Management Systems
Data Informatics
Data Standarizaton and Analytics
Cheminformatics
Simulation and Modelling
No filter data found
Formulations Experiment Capture - ELN
Sample Management - LIMS
Chromatography Data Management - CDS
Lab Robotics & Automation
Visualisation & Dashboarding
Quality Management Systems
Data Informatics
Data Standarizaton and Analytics
Simulation and Modelling
No filter data found
Process development Experiment Capture - ELN
Sample Management - LIMS
Chromatography Data Management - CDS
Lab experiment execution - LES
Analytical & Scientific data management - SDMS
Visualisation & Dashboarding
Lab Robotics & Automation
Process Historians / RT Data systems
Quality Management Systems
Data Informatics
Data Standarizaton and Analytics
Simulation and Modelling
No filter data found
Analytical Development Experiment Capture - ELN
Sample Management - LIMS
Chromatography Data Management - CDS
Lab experiment execution - LES
Analytical & Scientific data management - SDMS
Visualisation & Dashboarding
Lab Robotics & Automation
Process Historians / RT Data systems
Quality Management Systems
Data Informatics
Data Standarizaton and Analytics
Simulation and Modelling
No filter data found
CMC Experiment Capture - ELN
Sample Management - LIMS
Chromatography Data Management - CDS
Analytical & Scientific data management - SDMS
Visualisation & Dashboarding
Lab Robotics & Automation
Process Historians / RT Data systems
Quality Management Systems
Data Informatics
Data Standarizaton and Analytics
Simulation and Modelling
No filter data found
### Clinical
Protocol Design & Approval Visualisation & Dashboarding
Quality Management Systems
Data Informatics
Data Standarizaton and Analytics
Simulation and Modelling
No filter data found
Site Selection & Feasibility Visualisation & Dashboarding
Quality Management Systems
Data Informatics
Data Standarizaton and Analytics
Simulation and Modelling
No filter data found
Patient Recruitment & Screening Visualisation & Dashboarding
Quality Management Systems
Data Informatics
Data Standarizaton and Analytics
Simulation and Modelling
No filter data found
Biometrics Visualisation & Dashboarding
Quality Management Systems
Data Informatics
Data Standarizaton and Analytics
Simulation and Modelling
No filter data found
Regulatory Submissions Visualisation & Dashboarding
Quality Management Systems
Data Informatics
Data Standarizaton and Analytics
Simulation and Modelling
No filter data found
### Manufacturing
Pilot & Scale Up Sample Management - LIMS
Chromatography Data Management - CDS
Lab experiment execution - LES
Analytical & Scientific data management - SDMS
Visualisation & Dashboarding
Lab Robotics & Automation
Process Historians / RT Data systems
Quality Management Systems
Data Informatics
Data Standarizaton and Analytics
Simulation and Modelling
No filter data found
Analytical QC & Batch Release Sample Management - LIMS
Chromatography Data Management - CDS
Lab experiment execution - LES
Analytical & Scientific data management - SDMS
Visualisation & Dashboarding
Lab Robotics & Automation
Process Historians / RT Data systems
Quality Management Systems
Data Informatics
Data Standarizaton and Analytics
No filter data found
## Platforms - Applicable Across the Value Chain
Enterprise Infrastructure (IaaS)
- AWS
- AZURE
- Google
- HPC
- ML/AIOps
- DevOps
- ClinOps
- Nvidia
AI Platforms
- Microsoft Discovery
- Gemini
- OpenAI
- Anthropic
- Bedrock AgentCore
Enterprise Resource Planning (ERP)
- SAP
- Oracle
Manufacturing Execution System (MES)
- Rockwell
- Siemens
- Honeywell
[ Contact Us ](#)
FAQ
## Curious how Zifo helps Large Pharma and Biotech companies achieve scientific and informatics success?
Find answers to common questions about Zifo’s capabilities for large pharma and biotech industries
Talk to an Expert
Is the real ROI of Scientific Informatics just about "saving time," or is it something deeper?
Most people look at a new digital system and ask, “How many hours will this save my scientists?” That’s a fair question, **but for a VP or CxO, the real return is Better Science.** In this industry, the most expensive thing you can do is make a high-stakes “Go” decision on a candidate that’s destined to fail, or worse, kill a promising molecule because the data was too messy to see the truth. Zifo’s approach is about stripping the “noise” out of your scientific data. When your leadership team can trust the data sitting in front of them, informatics stops being an IT cost and starts being a primary tool for protecting your capital and de-risking the entire pipeline.
Can we just skip the "informatics" part and go straight to an AI strategy?
There’s a **massive temptation right now to treat AI as a “magic fix” for a broken data environment.** The hard truth? **AI is only as good as the architecture underneath it.** You simply cannot have a functional AI strategy without a rock-solid informatics foundation. We focus on building what we call an **AI-Native Ecosystem.** This means moving beyond just “using” AI tools to becoming an organization where your data is captured and validated so cleanly at the source that it can actually power better science at every stage of the value chain. Think of informatics as the refinery: without it, you just have raw scientific chaos; with it, you have the high-octane fuel that modern AI needs to actually deliver a breakthrough.
What does an "AI-Native Ecosystem" look like in Zifo’s informatics matrix?
It’s the “connective tissue.” An AI-native ecosystem uses the data captured in the informatics matrix to feed LLMs and SLMs depending on the client’s need. This enables “Agentic AI” to assist scientists and helps VPs and CxO’s visualize the informatics flow across entire value chain.
How does Zifo map informatics tools across the "Full Value Chain"?
We don’t view informatics as a single software install. Our matrix approach maps specific digital tools — like **HTS & Hit Discovery** in Research or **Process Historians** in Manufacturing — against the entire drug lifecycle. This ensures that data generated during early-stage discovery is structured to be usable by the time it reaches Clinical and QA/QC teams.
Where does Zifo sit in the transition from Research to Development?
That transition is often a “data graveyard.” We bridge it by integrating, say, for example, **Multiomics Informatics** and **Cheminformatics** in Research with **Experiment Capture (ELN)** and **Sample Management (LIMS)** in Development. By maintaining a unified digital thread, we prevent the loss of critical institutional knowledge as a candidate moves toward scale-up.
What specific support do you offer for Analytical and Scientific Data Management (SDMS)?
SDMS is the silent hero of the lab. Our matrix highlights its role across the board — from **TI/TV** in early research to **Analytical Development** and **CMC.** We ensure that raw data from various lab instruments is automatically captured, indexed, and made searchable, which is non-negotiable for 21st century scientific reproducibility.
How does Zifo handle the distinct informatics needs of Clinical vs. Manufacturing?
In **Clinical,** Zifo manages the lifecycle from **Protocol Design** and **Site Selection** to **Biometrics** and **Regulatory Submissions.** We leverage **Simulation & Modelling** and **Data Analytics** to de-risk study arms and accelerate patient recruitment. In **Manufacturing,** the focus pivots to **Pilot Scale-Up** and **Analytical QC.** We integrate **Process Historians, RT Data Systems,** and **LES** with **CDS/SDMS** for real-time batch monitoring. We bridge the gap between “exploratory” clinical data and high-volume manufacturing rigor while maintaining absolute **GxP integrity.**
What is the role of "Simulation and Modeling" in your R&D informatics matrix?
Simulation and Modeling are the predictive engines of our matrix. We apply them in **ADMET, PK/PD,** and **Process Development** to “fail fast” and “fail cheap.” By modeling molecular behavior digitally before moving to wet-lab experiments, our clients save millions in R&D spend.
How do "Chromatography Data Systems (CDS)" support CMC and Manufacturing?
In the CMC and Manufacturing columns, CDS is critical for batch release and quality control. We provide specialized services to ensure that systems like Empower or Chromeleon are not only functional but fully integrated with your **Quality Management Systems (QMS),** ensuring every injection is traceable and audit-ready.
How does Zifo support the high-stakes transition from the lab to full-scale Manufacturing and QC?
When you move from the lab to commercial manufacturing, the stakes change completely. It’s no longer just about the science; it’s about “Right First Time” execution at scale. We don’t just look at sensors on a tank — we look at the entire data ecosystem. This means bridging the gap between the production line and the QC lab so that your batch records, quality tests, and real-time process data are all talking to each other.
By creating this “live” visibility, we help you catch deviations the moment they happen, rather than days later in a lab report. The goal isn’t just to avoid a discarded batch; it’s to accelerate the entire Batch Release cycle. When your manufacturing and quality data are unified, compliance becomes a seamless part of the flow, preserving your capital and getting therapies to patients significantly faster.
How do you unify "Quality Management Systems (QMS)" across the lifecycle?
Quality and compliance shouldn’t be “gatekeepers” at the end of the line; they are foundational layers across the entire matrix. From **Pharmacology** to **Clinical Trials** and **Batch Release,** we integrate QMS directly with your **ELNs, LIMS,** and **CDS** to ensure that **GxP compliance** is a byproduct of the digital workflow, not a manual burden. By applying a **risk-based CSV/CSA** **(Computer Software Assurance)** framework and ensuring absolute **Data Integrity (ALCOA+),** we help you move from reactive documentation to proactive, “audit-ready” operations. This approach simplifies **21 CFR Part 11** and **EU Annex 11** adherence while accelerating the path to **Electronic Batch Release (EBR),** making compliance a seamless part of your scientific execution.
Does Zifo just "install" ELN and LIMS, and other informatics, or do you actually make them work for the lab?
Let’s be honest: the industry is full of expensive lab software that scientists absolutely hate using because it was configured by people who have never stepped foot in a wet lab. We don’t just “flip a switch” on a new implementation. We are bilingual and speak the language of science and technology. We bridge the gap between the software’s capabilities and your actual scientific workflows. Whether it’s configuring complex sample tracking or designing intuitive digital notebooks, our goal is high adoption, not just high technical specs. We make sure these systems aren’t just “data repositories”—they become the engine that helps your team move faster.
What happens after the rollout? How does Zifo support the long-term health of these systems?
The biggest mistake companies make is thinking the job is done once the software is “live.” These systems are living organisms, they need updates, troubleshooting, and constant refinement as your science evolves. Our Managed Services take that operational burden off your internal IT and Scientific teams. We provide specialized support that understands both the code and the context of the data. By handling the day-to-day maintenance and system optimization, we ensure your informatics foundation remains stable and compliant, so your scientists can stay focused on the next breakthrough instead of technical tickets.
## Case Files
## Case file 001
## Transforming Biologics CMC Data From Fragmented to Future-Ready
[ Download Now ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjMyMzMzIiwidG9nZ2xlIjpmYWxzZX0%3D)
## Case file 002
## Building trust in data, compliance, and device performance through scientific validation
[ Download Now ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjUyOTQ1IiwidG9nZ2xlIjpmYWxzZX0%3D)
'); } else { $cb.removeClass('error'); } }); /* 2. FLOATING LABELS */ function toggleFloating($input) { const $group = $input.closest('.elementor-field-group'); if ($input.val().trim() || $input.is(':focus')) { $group.addClass('floating-active'); } else { $group.removeClass('floating-active'); } } $(document).on('focus input blur', `${formWrap} input.elementor-field`, function () { toggleFloating($(this)); }); /* 3. SUBMIT VALIDATION */ $(document).on('click', `${formWrap} button[type="submit"]`, function (e) { let isValid = true; const $form = $(this).closest('form'); $form.find('.error-message').remove(); $form.find('.error').removeClass('error'); $form.find('input[required], input[type="email"]').each(function() { const $field = $(this); const val = $field.val().trim(); if (!val) { showError($field, 'Please fill this field.'); isValid = false; } else if ($field.attr('type') === 'email' && !/^[^\s@]+@[^\s@]+\.[^\s@]+$/.test(val)) { showError($field, 'Enter a valid email address.'); isValid = false; } }); const $cb = $form.find('input[type="checkbox"]'); if (!$cb.is(':checked')) { $cb.addClass('error'); $cb.closest('.elementor-field-subgroup').after('Please fill this field.
'); isValid = false; } if (!isValid) { e.preventDefault(); e.stopImmediatePropagation(); const $firstError = $form.find('.error').first(); if($firstError.length) { $('html, body').animate({ scrollTop: $firstError.offset().top - 120 }, 500); } } }); function showError($field, message) { $field.addClass('error'); $field.closest('.elementor-field-group').append(`${message}
`); } /* 4. SUCCESS & DOWNLOAD (With Lock) */ $(document).on('submit_success', function (event) { // Ensure it's the right form AND we aren't already downloading if ($(event.target).closest(formWrap).length > 0 && !isDownloading) { isDownloading = true; // Set the lock console.log('Form Success - Downloading PDF'); const link = document.createElement('a'); link.href = pdfURL; link.download = 'AI-Pharma-Drug.pdf'; link.target = '_blank'; document.body.appendChild(link); link.click(); document.body.removeChild(link); // Reset and release lock after 3 seconds setTimeout(() => { $(`${formWrap} .elementor-field-group`).removeClass('floating-active'); forceCheckbox(); isDownloading = false; // Release the lock }, 3000); } }); // Final Init setTimeout(() => { $(`${formWrap} .elementor-field`).each(function () { toggleFloating($(this)); }); }, 500); });
Get in touch
First Name
Last Name
Email
Phone Number
Company
Designation
Enquiry Type
Enquiry Type Request for Zifo Services Product Partnership Job/Internship/Placement Enquiry Other
Message
Acceptance I consent to being contacted by an official Zifo representative
Submit
---
### [Specialty Chemicals](https://zifo.com/industries/speciality-chemicals-informatics-and-consulting-services/)
**Published:** December 22, 2025
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Industries](https://zifo.com/industries/ "Industries")> Specialty Chemicals
Chemicals
Drive Product Margins via
Resilient, Efficient Processes
[ Connect With Us ](#)
Green
Chemistry
Cost
Optimisation
Supply Chain Efficiency and
Resilience Compliance
Improved Product Margin
Leverage AI and Data Standardisation at Every Level of
Your Scientific Informatics Process Workflow
AI-Native Ecosystem
# Value Chain
All Stages
Research
Development
Manufacturing
## Full Value Chain View
All Platforms Informatics Data Specialist
Expand All
### Research
Active Ingredient Discovery Experiment Capture - ELN
Visualisation & Dashboarding
Lab Robotics & Automation
Data Informatics
Data Standarizaton and Analytics
Cheminformatics
Simulation and Modelling
No filter data found
Synthetic Chemistry Experiment Capture - ELN
Sample Management - LIMS
Chromatography Data Management - CDS
Lab experiment execution - LES
Analytical & Scientific data management - SDMS
Visualisation & Dashboarding
Lab Robotics & Automation
Data Informatics
Data Standarizaton and Analytics
Cheminformatics
Simulation and Modelling
No filter data found
### Development
Formulation Experiment Capture - ELN
Sample Management - LIMS
Chromatography Data Management - CDS
Lab experiment execution - LES
Analytical & Scientific data management - SDMS
Visualisation & Dashboarding
Lab Robotics & Automation
Data Informatics
Data Standarizaton and Analytics
Simulation and Modelling
No filter data found
Product Evaluation Experiment Capture - ELN
Sample Management - LIMS
Chromatography Data Management - CDS
Lab experiment execution - LES
Analytical & Scientific data management - SDMS
Visualisation & Dashboarding
Lab Robotics & Automation
Data Informatics
Data Standarizaton and Analytics
Simulation and Modelling
No filter data found
Process development Experiment Capture - ELN
Sample Management - LIMS
Chromatography Data Management - CDS
Lab experiment execution - LES
Analytical & Scientific data management - SDMS
Visualisation & Dashboarding
Lab Robotics & Automation
Process Historians / RT Data systems
Quality Management Systems
Data Informatics
Data Standarizaton and Analytics
Simulation and Modelling
No filter data found
Analytical Development Experiment Capture - ELN
Sample Management - LIMS
Chromatography Data Management - CDS
Lab experiment execution - LES
Analytical & Scientific data management - SDMS
Visualisation & Dashboarding
Lab Robotics & Automation
Process Historians / RT Data systems
Quality Management Systems
Data Informatics
Data Standarizaton and Analytics
Simulation and Modelling
No filter data found
Stability & Shelf Life Testing Sample Management - LIMS
Chromatography Data Management - CDS
Lab experiment execution - LES
Analytical & Scientific data management - SDMS
Visualisation & Dashboarding
Lab Robotics & Automation
Process Historians / RT Data systems
Quality Management Systems
Data Informatics
Data Standarizaton and Analytics
Simulation and Modelling
No filter data found
### Manufacturing
Pilot & Scale Up Sample Management - LIMS
Chromatography Data Management - CDS
Lab experiment execution - LES
Analytical & Scientific data management - SDMS
Visualisation & Dashboarding
Lab Robotics & Automation
Process Historians / RT Data systems
Quality Management Systems
Data Informatics
Data Standarizaton and Analytics
Simulation and Modelling
No filter data found
Analytical QC & Batch Release Sample Management - LIMS
Chromatography Data Management - CDS
Lab experiment execution - LES
Analytical & Scientific data management - SDMS
Visualisation & Dashboarding
Lab Robotics & Automation
Process Historians / RT Data systems
Quality Management Systems
Data Informatics
Data Standarizaton and Analytics
Simulation and Modelling
No filter data found
## Platforms - Applicable Across the Value Chain
Enterprise Infrastructure (IaaS)
- AWS
- AZURE
- Google
- HPC
- ML/AIOps
- DevOps
- ClinOps
- Nvidia
AI Platforms
- Microsoft Discovery
- Gemini
- OpenAI
- Anthropic
- Bedrock AgentCore
Enterprise Resource Planning (ERP)
- SAP
- Oracle
Manufacturing Execution System (MES)
- Rockwell
- Siemens
- Honeywell
[ Contact Us ](#)
## Case Files
## Case file 001
## Transforming Biologics CMC Data From Fragmented to Future-Ready
[ Download Now ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjMyMzMzIiwidG9nZ2xlIjpmYWxzZX0%3D)
'); } else { $cb.removeClass('error'); } }); /* 2. FLOATING LABELS */ function toggleFloating($input) { const $group = $input.closest('.elementor-field-group'); if ($input.val().trim() || $input.is(':focus')) { $group.addClass('floating-active'); } else { $group.removeClass('floating-active'); } } $(document).on('focus input blur', `${formWrap} input.elementor-field`, function () { toggleFloating($(this)); }); /* 3. SUBMIT VALIDATION */ $(document).on('click', `${formWrap} button[type="submit"]`, function (e) { let isValid = true; const $form = $(this).closest('form'); $form.find('.error-message').remove(); $form.find('.error').removeClass('error'); $form.find('input[required], input[type="email"]').each(function() { const $field = $(this); const val = $field.val().trim(); if (!val) { showError($field, 'Please fill this field.'); isValid = false; } else if ($field.attr('type') === 'email' && !/^[^\s@]+@[^\s@]+\.[^\s@]+$/.test(val)) { showError($field, 'Enter a valid email address.'); isValid = false; } }); const $cb = $form.find('input[type="checkbox"]'); if (!$cb.is(':checked')) { $cb.addClass('error'); $cb.closest('.elementor-field-subgroup').after('Please fill this field.
'); isValid = false; } if (!isValid) { e.preventDefault(); e.stopImmediatePropagation(); const $firstError = $form.find('.error').first(); if($firstError.length) { $('html, body').animate({ scrollTop: $firstError.offset().top - 120 }, 500); } } }); function showError($field, message) { $field.addClass('error'); $field.closest('.elementor-field-group').append(`${message}
`); } /* 4. SUCCESS & DOWNLOAD (With Lock) */ $(document).on('submit_success', function (event) { // Ensure it's the right form AND we aren't already downloading if ($(event.target).closest(formWrap).length > 0 && !isDownloading) { isDownloading = true; // Set the lock console.log('Form Success - Downloading PDF'); const link = document.createElement('a'); link.href = pdfURL; link.download = 'AI-Pharma-Drug.pdf'; link.target = '_blank'; document.body.appendChild(link); link.click(); document.body.removeChild(link); // Reset and release lock after 3 seconds setTimeout(() => { $(`${formWrap} .elementor-field-group`).removeClass('floating-active'); forceCheckbox(); isDownloading = false; // Release the lock }, 3000); } }); // Final Init setTimeout(() => { $(`${formWrap} .elementor-field`).each(function () { toggleFloating($(this)); }); }, 500); });
## Case file 002
## Transforming Biologics CMC Data From Fragmented to Future-Ready
[ Download Now ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjMyMzMzIiwidG9nZ2xlIjpmYWxzZX0%3D)
'); } else { $cb.removeClass('error'); } }); /* 2. FLOATING LABELS */ function toggleFloating($input) { const $group = $input.closest('.elementor-field-group'); if ($input.val().trim() || $input.is(':focus')) { $group.addClass('floating-active'); } else { $group.removeClass('floating-active'); } } $(document).on('focus input blur', `${formWrap} input.elementor-field`, function () { toggleFloating($(this)); }); /* 3. SUBMIT VALIDATION */ $(document).on('click', `${formWrap} button[type="submit"]`, function (e) { let isValid = true; const $form = $(this).closest('form'); $form.find('.error-message').remove(); $form.find('.error').removeClass('error'); $form.find('input[required], input[type="email"]').each(function() { const $field = $(this); const val = $field.val().trim(); if (!val) { showError($field, 'Please fill this field.'); isValid = false; } else if ($field.attr('type') === 'email' && !/^[^\s@]+@[^\s@]+\.[^\s@]+$/.test(val)) { showError($field, 'Enter a valid email address.'); isValid = false; } }); const $cb = $form.find('input[type="checkbox"]'); if (!$cb.is(':checked')) { $cb.addClass('error'); $cb.closest('.elementor-field-subgroup').after('Please fill this field.
'); isValid = false; } if (!isValid) { e.preventDefault(); e.stopImmediatePropagation(); const $firstError = $form.find('.error').first(); if($firstError.length) { $('html, body').animate({ scrollTop: $firstError.offset().top - 120 }, 500); } } }); function showError($field, message) { $field.addClass('error'); $field.closest('.elementor-field-group').append(`${message}
`); } /* 4. SUCCESS & DOWNLOAD (With Lock) */ $(document).on('submit_success', function (event) { // Ensure it's the right form AND we aren't already downloading if ($(event.target).closest(formWrap).length > 0 && !isDownloading) { isDownloading = true; // Set the lock console.log('Form Success - Downloading PDF'); const link = document.createElement('a'); link.href = pdfURL; link.download = 'AI-Pharma-Drug.pdf'; link.target = '_blank'; document.body.appendChild(link); link.click(); document.body.removeChild(link); // Reset and release lock after 3 seconds setTimeout(() => { $(`${formWrap} .elementor-field-group`).removeClass('floating-active'); forceCheckbox(); isDownloading = false; // Release the lock }, 3000); } }); // Final Init setTimeout(() => { $(`${formWrap} .elementor-field`).each(function () { toggleFloating($(this)); }); }, 500); });
## Case file 003
## Transforming Biologics CMC Data From Fragmented to Future-Ready
[ Download Now ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjMyMzMzIiwidG9nZ2xlIjpmYWxzZX0%3D)
'); } else { $cb.removeClass('error'); } }); /* 2. FLOATING LABELS */ function toggleFloating($input) { const $group = $input.closest('.elementor-field-group'); if ($input.val().trim() || $input.is(':focus')) { $group.addClass('floating-active'); } else { $group.removeClass('floating-active'); } } $(document).on('focus input blur', `${formWrap} input.elementor-field`, function () { toggleFloating($(this)); }); /* 3. SUBMIT VALIDATION */ $(document).on('click', `${formWrap} button[type="submit"]`, function (e) { let isValid = true; const $form = $(this).closest('form'); $form.find('.error-message').remove(); $form.find('.error').removeClass('error'); $form.find('input[required], input[type="email"]').each(function() { const $field = $(this); const val = $field.val().trim(); if (!val) { showError($field, 'Please fill this field.'); isValid = false; } else if ($field.attr('type') === 'email' && !/^[^\s@]+@[^\s@]+\.[^\s@]+$/.test(val)) { showError($field, 'Enter a valid email address.'); isValid = false; } }); const $cb = $form.find('input[type="checkbox"]'); if (!$cb.is(':checked')) { $cb.addClass('error'); $cb.closest('.elementor-field-subgroup').after('Please fill this field.
'); isValid = false; } if (!isValid) { e.preventDefault(); e.stopImmediatePropagation(); const $firstError = $form.find('.error').first(); if($firstError.length) { $('html, body').animate({ scrollTop: $firstError.offset().top - 120 }, 500); } } }); function showError($field, message) { $field.addClass('error'); $field.closest('.elementor-field-group').append(`${message}
`); } /* 4. SUCCESS & DOWNLOAD (With Lock) */ $(document).on('submit_success', function (event) { // Ensure it's the right form AND we aren't already downloading if ($(event.target).closest(formWrap).length > 0 && !isDownloading) { isDownloading = true; // Set the lock console.log('Form Success - Downloading PDF'); const link = document.createElement('a'); link.href = pdfURL; link.download = 'AI-Pharma-Drug.pdf'; link.target = '_blank'; document.body.appendChild(link); link.click(); document.body.removeChild(link); // Reset and release lock after 3 seconds setTimeout(() => { $(`${formWrap} .elementor-field-group`).removeClass('floating-active'); forceCheckbox(); isDownloading = false; // Release the lock }, 3000); } }); // Final Init setTimeout(() => { $(`${formWrap} .elementor-field`).each(function () { toggleFloating($(this)); }); }, 500); });
## Case file 004
## Transforming Biologics CMC Data From Fragmented to Future-Ready
[ Download Now ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjMyMzMzIiwidG9nZ2xlIjpmYWxzZX0%3D)
'); } else { $cb.removeClass('error'); } }); /* 2. FLOATING LABELS */ function toggleFloating($input) { const $group = $input.closest('.elementor-field-group'); if ($input.val().trim() || $input.is(':focus')) { $group.addClass('floating-active'); } else { $group.removeClass('floating-active'); } } $(document).on('focus input blur', `${formWrap} input.elementor-field`, function () { toggleFloating($(this)); }); /* 3. SUBMIT VALIDATION */ $(document).on('click', `${formWrap} button[type="submit"]`, function (e) { let isValid = true; const $form = $(this).closest('form'); $form.find('.error-message').remove(); $form.find('.error').removeClass('error'); $form.find('input[required], input[type="email"]').each(function() { const $field = $(this); const val = $field.val().trim(); if (!val) { showError($field, 'Please fill this field.'); isValid = false; } else if ($field.attr('type') === 'email' && !/^[^\s@]+@[^\s@]+\.[^\s@]+$/.test(val)) { showError($field, 'Enter a valid email address.'); isValid = false; } }); const $cb = $form.find('input[type="checkbox"]'); if (!$cb.is(':checked')) { $cb.addClass('error'); $cb.closest('.elementor-field-subgroup').after('Please fill this field.
'); isValid = false; } if (!isValid) { e.preventDefault(); e.stopImmediatePropagation(); const $firstError = $form.find('.error').first(); if($firstError.length) { $('html, body').animate({ scrollTop: $firstError.offset().top - 120 }, 500); } } }); function showError($field, message) { $field.addClass('error'); $field.closest('.elementor-field-group').append(`${message}
`); } /* 4. SUCCESS & DOWNLOAD (With Lock) */ $(document).on('submit_success', function (event) { // Ensure it's the right form AND we aren't already downloading if ($(event.target).closest(formWrap).length > 0 && !isDownloading) { isDownloading = true; // Set the lock console.log('Form Success - Downloading PDF'); const link = document.createElement('a'); link.href = pdfURL; link.download = 'AI-Pharma-Drug.pdf'; link.target = '_blank'; document.body.appendChild(link); link.click(); document.body.removeChild(link); // Reset and release lock after 3 seconds setTimeout(() => { $(`${formWrap} .elementor-field-group`).removeClass('floating-active'); forceCheckbox(); isDownloading = false; // Release the lock }, 3000); } }); // Final Init setTimeout(() => { $(`${formWrap} .elementor-field`).each(function () { toggleFloating($(this)); }); }, 500); });
Get in touch
First Name
Last Name
Email
Phone Number
Company
Designation
Enquiry Type
Enquiry Type Request for Zifo Services Product Partnership Job/Internship/Placement Enquiry Other
Message
Acceptance I consent to being contacted by an official Zifo representative
Submit
---
### [Small and Medium Biotech](https://zifo.com/industries/biotech-informatics-and-consulting-services/)
**Published:** February 12, 2026
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Industries](https://zifo.com/industries/ "Industries")> Small and Medium Biotech
Small and Medium Biotech
Unlock Novel Therapies Through
Better Data Integration and
Practical AI Solutions
[ Connect With Us ](#)
Improved Data
Integration
Standardized Scientific
Workflows
Practical AI
Solution
BETTER SCIENTIFIC OUTCOMES
Leverage AI and Data Standardisation at Every Level of
Your Scientific Informatics Process Workflow
AI-Native Ecosystem
# Value Chain
All Stages
Research
Development
Clinical
Manufacturing
## Full Value Chain View
All Platforms Informatics Data Specialist
Expand All
### Research
TI/TV Analytical & Scientific data management - SDMS
Visualisation & Dashboarding
Lab Robotics & Automation
Multiomics Informatics
Data Informatics
Data Standarizaton and Analytics
Bioinformatics
Simulation and Modelling
No filter data found
HTS & Hit Discovery Sample Management - LIMS
Visualisation & Dashboarding
Lab Robotics & Automation
Multiomics Informatics
Data Informatics
Data Standarizaton and Analytics
Cheminformatics
No filter data found
Lead Development Experiment Capture - ELN
Visualisation & Dashboarding
Lab Robotics & Automation
Data Informatics
Data Standarizaton and Analytics
Cheminformatics
Simulation and Modelling
No filter data found
In Vitro Pharmacology Experiment Capture - ELN
Visualisation & Dashboarding
Lab Robotics & Automation
Data Informatics
Data Standarizaton and Analytics
Cheminformatics
Simulation and Modelling
No filter data found
ADMET Experiment Capture - ELN
Visualisation & Dashboarding
Lab Robotics & Automation
Data Informatics
Data Standarizaton and Analytics
Cheminformatics
Simulation and Modelling
No filter data found
### Development
Invivo Pharmacology Experiment Capture - ELN
Chromatography Data Management - CDS
Visualisation & Dashboarding
Lab Robotics & Automation
Data Informatics
Data Standarizaton and Analytics
Cheminformatics
Bioinformatics
Simulation and Modelling
No filter data found
Safety / Tox Experiment Capture - ELN
Sample Management - LIMS
Visualisation & Dashboarding
Lab Robotics & Automation
Data Informatics
Data Standarizaton and Analytics
Cheminformatics
Simulation and Modelling
No filter data found
PK/PD Experiment Capture - ELN
Sample Management - LIMS
Visualisation & Dashboarding
Lab Robotics & Automation
Quality Management Systems
Data Informatics
Data Standarizaton and Analytics
Cheminformatics
Simulation and Modelling
No filter data found
Formulations Experiment Capture - ELN
Sample Management - LIMS
Chromatography Data Management - CDS
Visualisation & Dashboarding
Lab Robotics & Automation
Quality Management Systems
Data Informatics
Data Standarizaton and Analytics
Simulation and Modelling
No filter data found
Process development Experiment Capture - ELN
Sample Management - LIMS
Chromatography Data Management - CDS
Lab experiment execution - LES
Analytical & Scientific data management - SDMS
Visualisation & Dashboarding
Lab Robotics & Automation
Process Historians / RT Data systems
Quality Management Systems
Data Informatics
Data Standarizaton and Analytics
Simulation and Modelling
No filter data found
Analytical Development Experiment Capture - ELN
Sample Management - LIMS
Chromatography Data Management - CDS
Lab experiment execution - LES
Analytical & Scientific data management - SDMS
Visualisation & Dashboarding
Lab Robotics & Automation
Process Historians / RT Data systems
Quality Management Systems
Data Informatics
Data Standarizaton and Analytics
Simulation and Modelling
No filter data found
CMC Experiment Capture - ELN
Sample Management - LIMS
Chromatography Data Management - CDS
Analytical & Scientific data management - SDMS
Visualisation & Dashboarding
Lab Robotics & Automation
Process Historians / RT Data systems
Quality Management Systems
Data Informatics
Data Standarizaton and Analytics
Simulation and Modelling
No filter data found
### Clinical
Protocol Design & Approval Quality Management Systems
Data Informatics
Data Standarizaton and Analytics
Simulation and Modelling
No filter data found
Site Selection & Feasibility Visualisation & Dashboarding
Quality Management Systems
Data Informatics
Data Standarizaton and Analytics
Simulation and Modelling
No filter data found
Patient Recruitment & Screening Visualisation & Dashboarding
Quality Management Systems
Data Informatics
Data Standarizaton and Analytics
Simulation and Modelling
No filter data found
Biometrics Quality Management Systems
Data Informatics
Data Standarizaton and Analytics
Simulation and Modelling
No filter data found
Regulatory Submissions Quality Management Systems
Data Informatics
Data Standarizaton and Analytics
Simulation and Modelling
No filter data found
### Manufacturing
Pilot & Scale Up Sample Management - LIMS
Chromatography Data Management - CDS
Lab experiment execution - LES
Analytical & Scientific data management - SDMS
Visualisation & Dashboarding
Lab Robotics & Automation
Process Historians / RT Data systems
Quality Management Systems
Data Informatics
Data Standarizaton and Analytics
Simulation and Modelling
No filter data found
Analytical QC & Batch Release Sample Management - LIMS
Chromatography Data Management - CDS
Lab experiment execution - LES
Analytical & Scientific data management - SDMS
Visualisation & Dashboarding
Lab Robotics & Automation
Process Historians / RT Data systems
Quality Management Systems
Data Informatics
Data Standarizaton and Analytics
No filter data found
## Platforms - Applicable Across the Value Chain
Enterprise Infrastructure (IaaS)
- AWS
- AZURE
- Google
- HPC
- ML/AIOps
- DevOps
- ClinOps
- Nvidia
AI Platforms
- Microsoft Discovery
- Gemini
- OpenAI
- Anthropic
- Bedrock AgentCore
Enterprise Resource Planning (ERP)
- SAP
- Oracle
Manufacturing Execution System (MES)
- Rockwell
- Siemens
- Honeywell
[ Contact Us ](#)
## Case Files
## Case file 001
## Transforming Biologics CMC Data From Fragmented to Future-Ready
[ Download Now ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjMyMzMzIiwidG9nZ2xlIjpmYWxzZX0%3D)
'); } else { $cb.removeClass('error'); } }); /* 2. FLOATING LABELS */ function toggleFloating($input) { const $group = $input.closest('.elementor-field-group'); if ($input.val().trim() || $input.is(':focus')) { $group.addClass('floating-active'); } else { $group.removeClass('floating-active'); } } $(document).on('focus input blur', `${formWrap} input.elementor-field`, function () { toggleFloating($(this)); }); /* 3. SUBMIT VALIDATION */ $(document).on('click', `${formWrap} button[type="submit"]`, function (e) { let isValid = true; const $form = $(this).closest('form'); $form.find('.error-message').remove(); $form.find('.error').removeClass('error'); $form.find('input[required], input[type="email"]').each(function() { const $field = $(this); const val = $field.val().trim(); if (!val) { showError($field, 'Please fill this field.'); isValid = false; } else if ($field.attr('type') === 'email' && !/^[^\s@]+@[^\s@]+\.[^\s@]+$/.test(val)) { showError($field, 'Enter a valid email address.'); isValid = false; } }); const $cb = $form.find('input[type="checkbox"]'); if (!$cb.is(':checked')) { $cb.addClass('error'); $cb.closest('.elementor-field-subgroup').after('Please fill this field.
'); isValid = false; } if (!isValid) { e.preventDefault(); e.stopImmediatePropagation(); const $firstError = $form.find('.error').first(); if($firstError.length) { $('html, body').animate({ scrollTop: $firstError.offset().top - 120 }, 500); } } }); function showError($field, message) { $field.addClass('error'); $field.closest('.elementor-field-group').append(`${message}
`); } /* 4. SUCCESS & DOWNLOAD (With Lock) */ $(document).on('submit_success', function (event) { // Ensure it's the right form AND we aren't already downloading if ($(event.target).closest(formWrap).length > 0 && !isDownloading) { isDownloading = true; // Set the lock console.log('Form Success - Downloading PDF'); const link = document.createElement('a'); link.href = pdfURL; link.download = 'AI-Pharma-Drug.pdf'; link.target = '_blank'; document.body.appendChild(link); link.click(); document.body.removeChild(link); // Reset and release lock after 3 seconds setTimeout(() => { $(`${formWrap} .elementor-field-group`).removeClass('floating-active'); forceCheckbox(); isDownloading = false; // Release the lock }, 3000); } }); // Final Init setTimeout(() => { $(`${formWrap} .elementor-field`).each(function () { toggleFloating($(this)); }); }, 500); });
## Case file 002
## Building Trust in Data, Compliance, and Device Performance Through Scientific Validation
[ Download Now ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjMyMzMzIiwidG9nZ2xlIjpmYWxzZX0%3D)
'); } else { $cb.removeClass('error'); } }); /* 2. FLOATING LABELS */ function toggleFloating($input) { const $group = $input.closest('.elementor-field-group'); if ($input.val().trim() || $input.is(':focus')) { $group.addClass('floating-active'); } else { $group.removeClass('floating-active'); } } $(document).on('focus input blur', `${formWrap} input.elementor-field`, function () { toggleFloating($(this)); }); /* 3. SUBMIT VALIDATION */ $(document).on('click', `${formWrap} button[type="submit"]`, function (e) { let isValid = true; const $form = $(this).closest('form'); $form.find('.error-message').remove(); $form.find('.error').removeClass('error'); $form.find('input[required], input[type="email"]').each(function() { const $field = $(this); const val = $field.val().trim(); if (!val) { showError($field, 'Please fill this field.'); isValid = false; } else if ($field.attr('type') === 'email' && !/^[^\s@]+@[^\s@]+\.[^\s@]+$/.test(val)) { showError($field, 'Enter a valid email address.'); isValid = false; } }); const $cb = $form.find('input[type="checkbox"]'); if (!$cb.is(':checked')) { $cb.addClass('error'); $cb.closest('.elementor-field-subgroup').after('Please fill this field.
'); isValid = false; } if (!isValid) { e.preventDefault(); e.stopImmediatePropagation(); const $firstError = $form.find('.error').first(); if($firstError.length) { $('html, body').animate({ scrollTop: $firstError.offset().top - 120 }, 500); } } }); function showError($field, message) { $field.addClass('error'); $field.closest('.elementor-field-group').append(`${message}
`); } /* 4. SUCCESS & DOWNLOAD (With Lock) */ $(document).on('submit_success', function (event) { // Ensure it's the right form AND we aren't already downloading if ($(event.target).closest(formWrap).length > 0 && !isDownloading) { isDownloading = true; // Set the lock console.log('Form Success - Downloading PDF'); const link = document.createElement('a'); link.href = pdfURL; link.download = 'AI-Pharma-Drug.pdf'; link.target = '_blank'; document.body.appendChild(link); link.click(); document.body.removeChild(link); // Reset and release lock after 3 seconds setTimeout(() => { $(`${formWrap} .elementor-field-group`).removeClass('floating-active'); forceCheckbox(); isDownloading = false; // Release the lock }, 3000); } }); // Final Init setTimeout(() => { $(`${formWrap} .elementor-field`).each(function () { toggleFloating($(this)); }); }, 500); });
## Case file 001
## Transforming Biologics CMC Data From Fragmented to Future-Ready
[ Download Now ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjMyMzMzIiwidG9nZ2xlIjpmYWxzZX0%3D)
## Case file 002
## Building Trust in Data, Compliance, and Device Performance Through Scientific Validation
[ Download Now ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjUyOTQ1IiwidG9nZ2xlIjpmYWxzZX0%3D)
'); } else { $cb.removeClass('error'); } }); /* 2. FLOATING LABELS */ function toggleFloating($input) { const $group = $input.closest('.elementor-field-group'); if ($input.val().trim() || $input.is(':focus')) { $group.addClass('floating-active'); } else { $group.removeClass('floating-active'); } } $(document).on('focus input blur', `${formWrap} input.elementor-field`, function () { toggleFloating($(this)); }); /* 3. SUBMIT VALIDATION */ $(document).on('click', `${formWrap} button[type="submit"]`, function (e) { let isValid = true; const $form = $(this).closest('form'); $form.find('.error-message').remove(); $form.find('.error').removeClass('error'); $form.find('input[required], input[type="email"]').each(function() { const $field = $(this); const val = $field.val().trim(); if (!val) { showError($field, 'Please fill this field.'); isValid = false; } else if ($field.attr('type') === 'email' && !/^[^\s@]+@[^\s@]+\.[^\s@]+$/.test(val)) { showError($field, 'Enter a valid email address.'); isValid = false; } }); const $cb = $form.find('input[type="checkbox"]'); if (!$cb.is(':checked')) { $cb.addClass('error'); $cb.closest('.elementor-field-subgroup').after('Please fill this field.
'); isValid = false; } if (!isValid) { e.preventDefault(); e.stopImmediatePropagation(); const $firstError = $form.find('.error').first(); if($firstError.length) { $('html, body').animate({ scrollTop: $firstError.offset().top - 120 }, 500); } } }); function showError($field, message) { $field.addClass('error'); $field.closest('.elementor-field-group').append(`${message}
`); } /* 4. SUCCESS & DOWNLOAD (With Lock) */ $(document).on('submit_success', function (event) { // Ensure it's the right form AND we aren't already downloading if ($(event.target).closest(formWrap).length > 0 && !isDownloading) { isDownloading = true; // Set the lock console.log('Form Success - Downloading PDF'); const link = document.createElement('a'); link.href = pdfURL; link.download = 'AI-Pharma-Drug.pdf'; link.target = '_blank'; document.body.appendChild(link); link.click(); document.body.removeChild(link); // Reset and release lock after 3 seconds setTimeout(() => { $(`${formWrap} .elementor-field-group`).removeClass('floating-active'); forceCheckbox(); isDownloading = false; // Release the lock }, 3000); } }); // Final Init setTimeout(() => { $(`${formWrap} .elementor-field`).each(function () { toggleFloating($(this)); }); }, 500); });
FAQ
## Curious how Zifo helps Small and Medium Biotech companies achieve scientific and informatics success?
Find answers to common questions about Zifo’s capabilities for small and medium biotech industries
Talk to an Expert
Is the real ROI of informatics just about "saving time"?
Honestly? No. Saving a scientist five hours a week is great, **but for a VP or CxO, the real return is Better Science.** In this industry, the most expensive thing you can do is make a “Go” decision on a candidate that’s destined to fail because the data was too noisy to see the truth. Our approach is about stripping that noise out. When you can **actually trust the data on your screen, informatics stops being an IT cost and starts being a tool for protecting your capital.**
Can we just skip the "informatics" part and go straight to an AI strategy?
It’s a tempting shortcut, but it’s a trap. AI is only as good as the architecture underneath it. **You simply cannot have a functional AI strategy without a rock-solid informatics foundation.** We focus on building an **AI-Native Ecosystem.** This means moving beyond just “using” AI tools to becoming an organization where data is captured so cleanly that it can actually power autonomous discovery. Informatics is the refinery; without it, you just have raw scientific chaos.
What does an "AI-Native Ecosystem" look like in Zifo’s informatics matrix?
It’s the “connective tissue.” An AI-native ecosystem uses the data captured in the informatics matrix to feed **LLMs and SLMs** depending on the client’s need. This enables “Agentic AI” to assist scientists and helps VPs and CxO’s visualize the informatics flow across entire value chain.
How do you scale a Biotech without the data turning into a total nightmare?
In the early days, everyone’s just trying to survive the next milestone, so data ends up in a **“digital wild west” of spreadsheets and local drives.** But as you grow, that mess becomes a massive liability. We don’t just throw software at the problem. We build a digital foundation that actually grows with you. The goal is to make sure the data **created by a team of five members** is still searchable and **“audit-ready” when you’re a 50-person Biotech powerhouse.** It’s about building a lab that works as a strategic asset, not just a storage unit.
Why is "clean" data actually a survival strategy for our valuation?
**In Biotech, your data is your price tag.** Whether you are looking at an **IPO,** a partnership, or a buyout, the “cleanliness” of your research is what’s under the microscope. We help you turn data standardization into a competitive edge. By making sure your results are high-fidelity from Day 1, you skip those agonizing, month-long cleanup projects that usually stall due diligence. Clean data means a faster path to a deal. Period.
How do you handle the high-stakes jump from the lab to the clinic?
**The transition from exploratory research to human trials is where many biotechs stumble.** The data requirements move from “fluid” to “rigid” almost overnight. Zifo manages this shift in data “personality” by unifying your research findings with the biometric rigor needed for the clinic. We make sure your protocol design and site selection are driven by data, not guesswork. It’s about de-risking the most expensive stage of your company’s journey.
How do you make compliance feel like less of a "separate" headache?
Compliance shouldn’t be a gatekeeper waiting for you at the end of the line. That’s how projects get killed. We integrate quality management directly into the digital workflow so that staying compliant becomes an automated byproduct of the science itself. By **using risk-based frameworks, we make global GxP standards a seamless part of the day-to-day.** This lets your team stay focused on innovation while we make sure the “regulatory safety net” is always there.
Can a better digital strategy actually help us keep our best scientists?
This is the **hidden ROI of digital transformation.** Top-tier researchers don’t quit because the science is hard; they quit because of “data drudgery”–spending a third of their week on manual entry and fighting systems that don’t talk to each other. By streamlining the digital lab, we remove that friction. A lab that “just works” is a lab where scientists can actually do science. It’s a massive, and overlooked, tool for talent retention.
Is there any real value left in our "failed" legacy experiments?
Most biotechs treat their early experiments as dead history. We see them as a goldmine. We specialize in extracting and standardizing scientific data from retired formats and making it usable for modern AI models. This turns years of sunk R&D costs into the high-octane fuel your current team needs to train the predictive models that will drive your next breakthrough.
What happens to the data when we move into Manufacturing and QC?
When a molecule moves to a pilot plant or a CDMO, the focus pivots to “Right First Time” execution. **We look at the entire ecosystem — bridging the gap between the production line and the quality lab.** By creating live visibility into your manufacturing and QC data, we help you catch deviations the moment they happen. The goal isn’t just to avoid a discarded batch; it’s to accelerate the whole batch release cycle.
Do you just install the software, or do you actually make it work for the lab?
The industry is full of expensive software that scientists hate because it was configured by people who have never stepped foot in a wet lab. We don’t just “flip a switch.” **We bridge the gap between what the software can do and how your scientists actually work.** Whether it’s sample tracking or digital notebooks, our goal is high adoption, not just high technical specs. We make sure these systems are the engine that helps your team move faster, not a hurdle they have to jump over.
Get in touch
First Name
Last Name
Email
Phone Number
Company
Designation
Enquiry Type
Enquiry Type Request for Zifo Services Product Partnership Job/Internship/Placement Enquiry Other
Message
Acceptance I consent to being contacted by an official Zifo representative
Submit
---
### [Agrotech](https://zifo.com/industries/agrotech-informatics-and-consulting-services/)
**Published:** December 22, 2025
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Industries](https://zifo.com/industries/ "Industries")> Agrotech
Agrotech
Ensure Crop Success with
Adaptable, High-Yield Strains
[ Connect With Us ](#)
Adapting to
climate change
Increased Nutritional
value and crop yield
Meeting sustainability goals
Improved Product Margin
Leverage AI and Data Standardisation at Every Level of
Your Scientific Informatics Process Workflow
AI-Native Ecosystem
# Value Chain
All Stages
Research
Development
Manufacturing
## Full Value Chain View
All Platforms Informatics Data Specialist
Expand All
### Research
Target Development Analytical & Scientific data management - SDMS
Visualisation & Dashboarding
Lab Robotics & Automation
Multiomics / Image Informatics
Data Informatics
Data Standarizaton and Analytics
Bioinformatics
Simulation and Modelling
No filter data found
Small Molecule Hit Discovery Experiment Capture - ELN
Sample Management - LIMS
Analytical & Scientific data management - SDMS
Visualisation & Dashboarding
Lab Robotics & Automation
Multiomics / Image Informatics
Data Informatics
Data Standarizaton and Analytics
Cheminformatics
No filter data found
Genomics & Breeding Experiment Capture - ELN
Sample Management - LIMS
Analytical & Scientific data management - SDMS
Visualisation & Dashboarding
Lab Robotics & Automation
Quality Management Systems
Multiomics / Image Informatics
Bioinformatics
No filter data found
### Development
Lead Development Experiment Capture - ELN
Sample Management - LIMS
Analytical & Scientific data management - SDMS
Visualisation & Dashboarding
Lab Robotics & Automation
Multiomics / Image Informatics
Data Informatics
Data Standarizaton and Analytics
Cheminformatics
Simulation and Modelling
No filter data found
Safety Experiment Capture - ELN
Sample Management - LIMS
Visualisation & Dashboarding
Lab Robotics & Automation
Multiomics / Image Informatics
Data Informatics
Data Standarizaton and Analytics
Cheminformatics
Simulation and Modelling
No filter data found
Formulations Experiment Capture - ELN
Sample Management - LIMS
Chromatography Data Management - CDS
Visualisation & Dashboarding
Lab Robotics & Automation
Quality Management Systems
Data Informatics
Data Standarizaton and Analytics
Cheminformatics
Simulation and Modelling
No filter data found
Greenhouse & Breeding Field Management Sample Management - LIMS
Analytical & Scientific data management - SDMS
Visualisation & Dashboarding
Lab Robotics & Automation
Quality Management Systems
Data Informatics
Data Standarizaton and Analytics
Simulation and Modelling
No filter data found
Process development Experiment Capture - ELN
Sample Management - LIMS
Chromatography Data Management - CDS
Lab experiment execution - LES
Analytical & Scientific data management - SDMS
Visualisation & Dashboarding
Lab Robotics & Automation
Process Historians / RT Data systems
Quality Management Systems
Data Informatics
Data Standarizaton and Analytics
Simulation and Modelling
No filter data found
Analytical Development Experiment Capture - ELN
Sample Management - LIMS
Chromatography Data Management - CDS
Lab experiment execution - LES
Analytical & Scientific data management - SDMS
Visualisation & Dashboarding
Lab Robotics & Automation
Process Historians / RT Data systems
Quality Management Systems
Data Informatics
Data Standarizaton and Analytics
Simulation and Modelling
No filter data found
### Manufacturing
Pilot & Scale Up Sample Management - LIMS
Chromatography Data Management - CDS
Lab experiment execution - LES
Analytical & Scientific data management - SDMS
Visualisation & Dashboarding
Lab Robotics & Automation
Process Historians / RT Data systems
Quality Management Systems
Data Informatics
Data Standarizaton and Analytics
Simulation and Modelling
No filter data found
Analytical QC & Batch Release Sample Management - LIMS
Chromatography Data Management - CDS
Lab experiment execution - LES
Analytical & Scientific data management - SDMS
Visualisation & Dashboarding
Lab Robotics & Automation
Process Historians / RT Data systems
Quality Management Systems
Data Informatics
Data Standarizaton and Analytics
No filter data found
## Platforms - Applicable Across the Value Chain
Enterprise Infrastructure (IaaS)
- AWS
- AZURE
- Google
- HPC
- ML/AIOps
- DevOps
- ClinOps
- Nvidia
AI Platforms
- Microsoft Discovery
- Gemini
- OpenAI
- Anthropic
- Bedrock AgentCore
Enterprise Resource Planning (ERP)
- SAP
- Oracle
Manufacturing Execution System (MES)
- Rockwell
- Siemens
- Honeywell
[ Contact Us ](#)
## Case Files
## Case file 001
## Transforming Biologics CMC Data From Fragmented to Future-Ready
[ Download Now ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjMyMzMzIiwidG9nZ2xlIjpmYWxzZX0%3D)
'); } else { $cb.removeClass('error'); } }); /* 2. FLOATING LABELS */ function toggleFloating($input) { const $group = $input.closest('.elementor-field-group'); if ($input.val().trim() || $input.is(':focus')) { $group.addClass('floating-active'); } else { $group.removeClass('floating-active'); } } $(document).on('focus input blur', `${formWrap} input.elementor-field`, function () { toggleFloating($(this)); }); /* 3. SUBMIT VALIDATION */ $(document).on('click', `${formWrap} button[type="submit"]`, function (e) { let isValid = true; const $form = $(this).closest('form'); $form.find('.error-message').remove(); $form.find('.error').removeClass('error'); $form.find('input[required], input[type="email"]').each(function() { const $field = $(this); const val = $field.val().trim(); if (!val) { showError($field, 'Please fill this field.'); isValid = false; } else if ($field.attr('type') === 'email' && !/^[^\s@]+@[^\s@]+\.[^\s@]+$/.test(val)) { showError($field, 'Enter a valid email address.'); isValid = false; } }); const $cb = $form.find('input[type="checkbox"]'); if (!$cb.is(':checked')) { $cb.addClass('error'); $cb.closest('.elementor-field-subgroup').after('Please fill this field.
'); isValid = false; } if (!isValid) { e.preventDefault(); e.stopImmediatePropagation(); const $firstError = $form.find('.error').first(); if($firstError.length) { $('html, body').animate({ scrollTop: $firstError.offset().top - 120 }, 500); } } }); function showError($field, message) { $field.addClass('error'); $field.closest('.elementor-field-group').append(`${message}
`); } /* 4. SUCCESS & DOWNLOAD (With Lock) */ $(document).on('submit_success', function (event) { // Ensure it's the right form AND we aren't already downloading if ($(event.target).closest(formWrap).length > 0 && !isDownloading) { isDownloading = true; // Set the lock console.log('Form Success - Downloading PDF'); const link = document.createElement('a'); link.href = pdfURL; link.download = 'AI-Pharma-Drug.pdf'; link.target = '_blank'; document.body.appendChild(link); link.click(); document.body.removeChild(link); // Reset and release lock after 3 seconds setTimeout(() => { $(`${formWrap} .elementor-field-group`).removeClass('floating-active'); forceCheckbox(); isDownloading = false; // Release the lock }, 3000); } }); // Final Init setTimeout(() => { $(`${formWrap} .elementor-field`).each(function () { toggleFloating($(this)); }); }, 500); });
## Case file 002
## Transforming Biologics CMC Data From Fragmented to Future-Ready
[ Download Now ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjMyMzMzIiwidG9nZ2xlIjpmYWxzZX0%3D)
'); } else { $cb.removeClass('error'); } }); /* 2. FLOATING LABELS */ function toggleFloating($input) { const $group = $input.closest('.elementor-field-group'); if ($input.val().trim() || $input.is(':focus')) { $group.addClass('floating-active'); } else { $group.removeClass('floating-active'); } } $(document).on('focus input blur', `${formWrap} input.elementor-field`, function () { toggleFloating($(this)); }); /* 3. SUBMIT VALIDATION */ $(document).on('click', `${formWrap} button[type="submit"]`, function (e) { let isValid = true; const $form = $(this).closest('form'); $form.find('.error-message').remove(); $form.find('.error').removeClass('error'); $form.find('input[required], input[type="email"]').each(function() { const $field = $(this); const val = $field.val().trim(); if (!val) { showError($field, 'Please fill this field.'); isValid = false; } else if ($field.attr('type') === 'email' && !/^[^\s@]+@[^\s@]+\.[^\s@]+$/.test(val)) { showError($field, 'Enter a valid email address.'); isValid = false; } }); const $cb = $form.find('input[type="checkbox"]'); if (!$cb.is(':checked')) { $cb.addClass('error'); $cb.closest('.elementor-field-subgroup').after('Please fill this field.
'); isValid = false; } if (!isValid) { e.preventDefault(); e.stopImmediatePropagation(); const $firstError = $form.find('.error').first(); if($firstError.length) { $('html, body').animate({ scrollTop: $firstError.offset().top - 120 }, 500); } } }); function showError($field, message) { $field.addClass('error'); $field.closest('.elementor-field-group').append(`${message}
`); } /* 4. SUCCESS & DOWNLOAD (With Lock) */ $(document).on('submit_success', function (event) { // Ensure it's the right form AND we aren't already downloading if ($(event.target).closest(formWrap).length > 0 && !isDownloading) { isDownloading = true; // Set the lock console.log('Form Success - Downloading PDF'); const link = document.createElement('a'); link.href = pdfURL; link.download = 'AI-Pharma-Drug.pdf'; link.target = '_blank'; document.body.appendChild(link); link.click(); document.body.removeChild(link); // Reset and release lock after 3 seconds setTimeout(() => { $(`${formWrap} .elementor-field-group`).removeClass('floating-active'); forceCheckbox(); isDownloading = false; // Release the lock }, 3000); } }); // Final Init setTimeout(() => { $(`${formWrap} .elementor-field`).each(function () { toggleFloating($(this)); }); }, 500); });
## Case file 003
## Transforming Biologics CMC Data From Fragmented to Future-Ready
[ Download Now ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjMyMzMzIiwidG9nZ2xlIjpmYWxzZX0%3D)
'); } else { $cb.removeClass('error'); } }); /* 2. FLOATING LABELS */ function toggleFloating($input) { const $group = $input.closest('.elementor-field-group'); if ($input.val().trim() || $input.is(':focus')) { $group.addClass('floating-active'); } else { $group.removeClass('floating-active'); } } $(document).on('focus input blur', `${formWrap} input.elementor-field`, function () { toggleFloating($(this)); }); /* 3. SUBMIT VALIDATION */ $(document).on('click', `${formWrap} button[type="submit"]`, function (e) { let isValid = true; const $form = $(this).closest('form'); $form.find('.error-message').remove(); $form.find('.error').removeClass('error'); $form.find('input[required], input[type="email"]').each(function() { const $field = $(this); const val = $field.val().trim(); if (!val) { showError($field, 'Please fill this field.'); isValid = false; } else if ($field.attr('type') === 'email' && !/^[^\s@]+@[^\s@]+\.[^\s@]+$/.test(val)) { showError($field, 'Enter a valid email address.'); isValid = false; } }); const $cb = $form.find('input[type="checkbox"]'); if (!$cb.is(':checked')) { $cb.addClass('error'); $cb.closest('.elementor-field-subgroup').after('Please fill this field.
'); isValid = false; } if (!isValid) { e.preventDefault(); e.stopImmediatePropagation(); const $firstError = $form.find('.error').first(); if($firstError.length) { $('html, body').animate({ scrollTop: $firstError.offset().top - 120 }, 500); } } }); function showError($field, message) { $field.addClass('error'); $field.closest('.elementor-field-group').append(`${message}
`); } /* 4. SUCCESS & DOWNLOAD (With Lock) */ $(document).on('submit_success', function (event) { // Ensure it's the right form AND we aren't already downloading if ($(event.target).closest(formWrap).length > 0 && !isDownloading) { isDownloading = true; // Set the lock console.log('Form Success - Downloading PDF'); const link = document.createElement('a'); link.href = pdfURL; link.download = 'AI-Pharma-Drug.pdf'; link.target = '_blank'; document.body.appendChild(link); link.click(); document.body.removeChild(link); // Reset and release lock after 3 seconds setTimeout(() => { $(`${formWrap} .elementor-field-group`).removeClass('floating-active'); forceCheckbox(); isDownloading = false; // Release the lock }, 3000); } }); // Final Init setTimeout(() => { $(`${formWrap} .elementor-field`).each(function () { toggleFloating($(this)); }); }, 500); });
## Case file 004
## Transforming Biologics CMC Data From Fragmented to Future-Ready
[ Download Now ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjMyMzMzIiwidG9nZ2xlIjpmYWxzZX0%3D)
'); } else { $cb.removeClass('error'); } }); /* 2. FLOATING LABELS */ function toggleFloating($input) { const $group = $input.closest('.elementor-field-group'); if ($input.val().trim() || $input.is(':focus')) { $group.addClass('floating-active'); } else { $group.removeClass('floating-active'); } } $(document).on('focus input blur', `${formWrap} input.elementor-field`, function () { toggleFloating($(this)); }); /* 3. SUBMIT VALIDATION */ $(document).on('click', `${formWrap} button[type="submit"]`, function (e) { let isValid = true; const $form = $(this).closest('form'); $form.find('.error-message').remove(); $form.find('.error').removeClass('error'); $form.find('input[required], input[type="email"]').each(function() { const $field = $(this); const val = $field.val().trim(); if (!val) { showError($field, 'Please fill this field.'); isValid = false; } else if ($field.attr('type') === 'email' && !/^[^\s@]+@[^\s@]+\.[^\s@]+$/.test(val)) { showError($field, 'Enter a valid email address.'); isValid = false; } }); const $cb = $form.find('input[type="checkbox"]'); if (!$cb.is(':checked')) { $cb.addClass('error'); $cb.closest('.elementor-field-subgroup').after('Please fill this field.
'); isValid = false; } if (!isValid) { e.preventDefault(); e.stopImmediatePropagation(); const $firstError = $form.find('.error').first(); if($firstError.length) { $('html, body').animate({ scrollTop: $firstError.offset().top - 120 }, 500); } } }); function showError($field, message) { $field.addClass('error'); $field.closest('.elementor-field-group').append(`${message}
`); } /* 4. SUCCESS & DOWNLOAD (With Lock) */ $(document).on('submit_success', function (event) { // Ensure it's the right form AND we aren't already downloading if ($(event.target).closest(formWrap).length > 0 && !isDownloading) { isDownloading = true; // Set the lock console.log('Form Success - Downloading PDF'); const link = document.createElement('a'); link.href = pdfURL; link.download = 'AI-Pharma-Drug.pdf'; link.target = '_blank'; document.body.appendChild(link); link.click(); document.body.removeChild(link); // Reset and release lock after 3 seconds setTimeout(() => { $(`${formWrap} .elementor-field-group`).removeClass('floating-active'); forceCheckbox(); isDownloading = false; // Release the lock }, 3000); } }); // Final Init setTimeout(() => { $(`${formWrap} .elementor-field`).each(function () { toggleFloating($(this)); }); }, 500); });
Get in touch
First Name
Last Name
Email
Phone Number
Company
Designation
Enquiry Type
Enquiry Type Request for Zifo Services Product Partnership Job/Internship/Placement Enquiry Other
Message
Acceptance I consent to being contacted by an official Zifo representative
Submit
---
### [Fast-Moving Consumer Goods](https://zifo.com/industries/fmcg-informatics-and-consulting-services/)
**Published:** December 22, 2025
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Industries](https://zifo.com/industries/ "Industries")> Fast-Moving Consumer Goods
FMCG
Shorten Time-to-Revenue
with Regulated Efficiency
[ Connect With Us ](#)
Environmental
Impact
Regulatory
Compliance
Supply Chain Efficiency
and Resilience
Speed to Market
and Shorter Time to Revenue
Leverage AI and Data Standardisation at Every Level of
Your Scientific Informatics Process Workflow
AI-Native Ecosystem
# Value Chain
All Stages
Research
Development
Manufacturing
## Full Value Chain View
All Platforms Informatics Data Specialist
Expand All
### Research
Concept Development Experiment Capture - ELN
Sample Management - LIMS
Data Informatics
Data Standarizaton and Analytics
No filter data found
Active Ingredient Discovery Experiment Capture - ELN
Sample Management - LIMS
Chromatography Data Management - CDS
Lab experiment execution - LES
Analytical & Scientific data management - SDMS
Visualisation & Dashboarding
Lab Robotics & Automation
Data Informatics
Data Standarizaton and Analytics
Simulation and Modelling
No filter data found
### Development
Formulation Experiment Capture - ELN
Sample Management - LIMS
Chromatography Data Management - CDS
Visualisation & Dashboarding
Lab Robotics & Automation
Data Informatics
Data Standarizaton and Analytics
Simulation and Modelling
No filter data found
Product Evaluation Experiment Capture - ELN
Sample Management - LIMS
Lab experiment execution - LES
Analytical & Scientific data management - SDMS
Visualisation & Dashboarding
Lab Robotics & Automation
Data Informatics
Data Standarizaton and Analytics
Simulation and Modelling
No filter data found
Process development Experiment Capture - ELN
Sample Management - LIMS
Chromatography Data Management - CDS
Lab experiment execution - LES
Analytical & Scientific data management - SDMS
Visualisation & Dashboarding
Lab Robotics & Automation
Process Historians / RT Data systems
Quality Management Systems
Data Informatics
Data Standarizaton and Analytics
Simulation and Modelling
No filter data found
Analytical Development Experiment Capture - ELN
Sample Management - LIMS
Chromatography Data Management - CDS
Lab experiment execution - LES
Analytical & Scientific data management - SDMS
Visualisation & Dashboarding
Lab Robotics & Automation
Process Historians / RT Data systems
Quality Management Systems
Data Informatics
Data Standarizaton and Analytics
Simulation and Modelling
No filter data found
Stability & Shelf Life Testing Sample Management - LIMS
Chromatography Data Management - CDS
Lab experiment execution - LES
Analytical & Scientific data management - SDMS
Visualisation & Dashboarding
Lab Robotics & Automation
Process Historians / RT Data systems
Quality Management Systems
Data Informatics
Data Standarizaton and Analytics
Simulation and Modelling
No filter data found
### Manufacturing
Pilot & Scale Up Sample Management - LIMS
Chromatography Data Management - CDS
Lab experiment execution - LES
Analytical & Scientific data management - SDMS
Visualisation & Dashboarding
Lab Robotics & Automation
Process Historians / RT Data systems
Quality Management Systems
Data Informatics
Data Standarizaton and Analytics
Simulation and Modelling
No filter data found
Analytical QC & Batch Release Sample Management - LIMS
Chromatography Data Management - CDS
Lab experiment execution - LES
Analytical & Scientific data management - SDMS
Visualisation & Dashboarding
Lab Robotics & Automation
Process Historians / RT Data systems
Quality Management Systems
Data Informatics
Data Standarizaton and Analytics
Simulation and Modelling
No filter data found
## Platforms - Applicable Across the Value Chain
Enterprise Infrastructure (IaaS)
- AWS
- AZURE
- Google
- HPC
- ML/AIOps
- DevOps
- ClinOps
- Nvidia
AI Platforms
- Microsoft Discovery
- Gemini
- OpenAI
- Anthropic
- Bedrock AgentCore
Enterprise Resource Planning (ERP)
- SAP
- Oracle
Manufacturing Execution System (MES)
- Rockwell
- Siemens
- Honeywell
[ Contact Us ](#)
## Case Files
## Case file 001
## Transforming Biologics CMC Data From Fragmented to Future-Ready
[ Download Now ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjMyMzMzIiwidG9nZ2xlIjpmYWxzZX0%3D)
'); } else { $cb.removeClass('error'); } }); /* 2. FLOATING LABELS */ function toggleFloating($input) { const $group = $input.closest('.elementor-field-group'); if ($input.val().trim() || $input.is(':focus')) { $group.addClass('floating-active'); } else { $group.removeClass('floating-active'); } } $(document).on('focus input blur', `${formWrap} input.elementor-field`, function () { toggleFloating($(this)); }); /* 3. SUBMIT VALIDATION */ $(document).on('click', `${formWrap} button[type="submit"]`, function (e) { let isValid = true; const $form = $(this).closest('form'); $form.find('.error-message').remove(); $form.find('.error').removeClass('error'); $form.find('input[required], input[type="email"]').each(function() { const $field = $(this); const val = $field.val().trim(); if (!val) { showError($field, 'Please fill this field.'); isValid = false; } else if ($field.attr('type') === 'email' && !/^[^\s@]+@[^\s@]+\.[^\s@]+$/.test(val)) { showError($field, 'Enter a valid email address.'); isValid = false; } }); const $cb = $form.find('input[type="checkbox"]'); if (!$cb.is(':checked')) { $cb.addClass('error'); $cb.closest('.elementor-field-subgroup').after('Please fill this field.
'); isValid = false; } if (!isValid) { e.preventDefault(); e.stopImmediatePropagation(); const $firstError = $form.find('.error').first(); if($firstError.length) { $('html, body').animate({ scrollTop: $firstError.offset().top - 120 }, 500); } } }); function showError($field, message) { $field.addClass('error'); $field.closest('.elementor-field-group').append(`${message}
`); } /* 4. SUCCESS & DOWNLOAD (With Lock) */ $(document).on('submit_success', function (event) { // Ensure it's the right form AND we aren't already downloading if ($(event.target).closest(formWrap).length > 0 && !isDownloading) { isDownloading = true; // Set the lock console.log('Form Success - Downloading PDF'); const link = document.createElement('a'); link.href = pdfURL; link.download = 'AI-Pharma-Drug.pdf'; link.target = '_blank'; document.body.appendChild(link); link.click(); document.body.removeChild(link); // Reset and release lock after 3 seconds setTimeout(() => { $(`${formWrap} .elementor-field-group`).removeClass('floating-active'); forceCheckbox(); isDownloading = false; // Release the lock }, 3000); } }); // Final Init setTimeout(() => { $(`${formWrap} .elementor-field`).each(function () { toggleFloating($(this)); }); }, 500); });
## Case file 002
## Transforming Biologics CMC Data From Fragmented to Future-Ready
[ Download Now ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjMyMzMzIiwidG9nZ2xlIjpmYWxzZX0%3D)
'); } else { $cb.removeClass('error'); } }); /* 2. FLOATING LABELS */ function toggleFloating($input) { const $group = $input.closest('.elementor-field-group'); if ($input.val().trim() || $input.is(':focus')) { $group.addClass('floating-active'); } else { $group.removeClass('floating-active'); } } $(document).on('focus input blur', `${formWrap} input.elementor-field`, function () { toggleFloating($(this)); }); /* 3. SUBMIT VALIDATION */ $(document).on('click', `${formWrap} button[type="submit"]`, function (e) { let isValid = true; const $form = $(this).closest('form'); $form.find('.error-message').remove(); $form.find('.error').removeClass('error'); $form.find('input[required], input[type="email"]').each(function() { const $field = $(this); const val = $field.val().trim(); if (!val) { showError($field, 'Please fill this field.'); isValid = false; } else if ($field.attr('type') === 'email' && !/^[^\s@]+@[^\s@]+\.[^\s@]+$/.test(val)) { showError($field, 'Enter a valid email address.'); isValid = false; } }); const $cb = $form.find('input[type="checkbox"]'); if (!$cb.is(':checked')) { $cb.addClass('error'); $cb.closest('.elementor-field-subgroup').after('Please fill this field.
'); isValid = false; } if (!isValid) { e.preventDefault(); e.stopImmediatePropagation(); const $firstError = $form.find('.error').first(); if($firstError.length) { $('html, body').animate({ scrollTop: $firstError.offset().top - 120 }, 500); } } }); function showError($field, message) { $field.addClass('error'); $field.closest('.elementor-field-group').append(`${message}
`); } /* 4. SUCCESS & DOWNLOAD (With Lock) */ $(document).on('submit_success', function (event) { // Ensure it's the right form AND we aren't already downloading if ($(event.target).closest(formWrap).length > 0 && !isDownloading) { isDownloading = true; // Set the lock console.log('Form Success - Downloading PDF'); const link = document.createElement('a'); link.href = pdfURL; link.download = 'AI-Pharma-Drug.pdf'; link.target = '_blank'; document.body.appendChild(link); link.click(); document.body.removeChild(link); // Reset and release lock after 3 seconds setTimeout(() => { $(`${formWrap} .elementor-field-group`).removeClass('floating-active'); forceCheckbox(); isDownloading = false; // Release the lock }, 3000); } }); // Final Init setTimeout(() => { $(`${formWrap} .elementor-field`).each(function () { toggleFloating($(this)); }); }, 500); });
## Case file 003
## Transforming Biologics CMC Data From Fragmented to Future-Ready
[ Download Now ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjMyMzMzIiwidG9nZ2xlIjpmYWxzZX0%3D)
'); } else { $cb.removeClass('error'); } }); /* 2. FLOATING LABELS */ function toggleFloating($input) { const $group = $input.closest('.elementor-field-group'); if ($input.val().trim() || $input.is(':focus')) { $group.addClass('floating-active'); } else { $group.removeClass('floating-active'); } } $(document).on('focus input blur', `${formWrap} input.elementor-field`, function () { toggleFloating($(this)); }); /* 3. SUBMIT VALIDATION */ $(document).on('click', `${formWrap} button[type="submit"]`, function (e) { let isValid = true; const $form = $(this).closest('form'); $form.find('.error-message').remove(); $form.find('.error').removeClass('error'); $form.find('input[required], input[type="email"]').each(function() { const $field = $(this); const val = $field.val().trim(); if (!val) { showError($field, 'Please fill this field.'); isValid = false; } else if ($field.attr('type') === 'email' && !/^[^\s@]+@[^\s@]+\.[^\s@]+$/.test(val)) { showError($field, 'Enter a valid email address.'); isValid = false; } }); const $cb = $form.find('input[type="checkbox"]'); if (!$cb.is(':checked')) { $cb.addClass('error'); $cb.closest('.elementor-field-subgroup').after('Please fill this field.
'); isValid = false; } if (!isValid) { e.preventDefault(); e.stopImmediatePropagation(); const $firstError = $form.find('.error').first(); if($firstError.length) { $('html, body').animate({ scrollTop: $firstError.offset().top - 120 }, 500); } } }); function showError($field, message) { $field.addClass('error'); $field.closest('.elementor-field-group').append(`${message}
`); } /* 4. SUCCESS & DOWNLOAD (With Lock) */ $(document).on('submit_success', function (event) { // Ensure it's the right form AND we aren't already downloading if ($(event.target).closest(formWrap).length > 0 && !isDownloading) { isDownloading = true; // Set the lock console.log('Form Success - Downloading PDF'); const link = document.createElement('a'); link.href = pdfURL; link.download = 'AI-Pharma-Drug.pdf'; link.target = '_blank'; document.body.appendChild(link); link.click(); document.body.removeChild(link); // Reset and release lock after 3 seconds setTimeout(() => { $(`${formWrap} .elementor-field-group`).removeClass('floating-active'); forceCheckbox(); isDownloading = false; // Release the lock }, 3000); } }); // Final Init setTimeout(() => { $(`${formWrap} .elementor-field`).each(function () { toggleFloating($(this)); }); }, 500); });
## Case file 003
## Transforming Biologics CMC Data From Fragmented to Future-Ready
[ Download Now ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjMyMzMzIiwidG9nZ2xlIjpmYWxzZX0%3D)
'); } else { $cb.removeClass('error'); } }); /* 2. FLOATING LABELS */ function toggleFloating($input) { const $group = $input.closest('.elementor-field-group'); if ($input.val().trim() || $input.is(':focus')) { $group.addClass('floating-active'); } else { $group.removeClass('floating-active'); } } $(document).on('focus input blur', `${formWrap} input.elementor-field`, function () { toggleFloating($(this)); }); /* 3. SUBMIT VALIDATION */ $(document).on('click', `${formWrap} button[type="submit"]`, function (e) { let isValid = true; const $form = $(this).closest('form'); $form.find('.error-message').remove(); $form.find('.error').removeClass('error'); $form.find('input[required], input[type="email"]').each(function() { const $field = $(this); const val = $field.val().trim(); if (!val) { showError($field, 'Please fill this field.'); isValid = false; } else if ($field.attr('type') === 'email' && !/^[^\s@]+@[^\s@]+\.[^\s@]+$/.test(val)) { showError($field, 'Enter a valid email address.'); isValid = false; } }); const $cb = $form.find('input[type="checkbox"]'); if (!$cb.is(':checked')) { $cb.addClass('error'); $cb.closest('.elementor-field-subgroup').after('Please fill this field.
'); isValid = false; } if (!isValid) { e.preventDefault(); e.stopImmediatePropagation(); const $firstError = $form.find('.error').first(); if($firstError.length) { $('html, body').animate({ scrollTop: $firstError.offset().top - 120 }, 500); } } }); function showError($field, message) { $field.addClass('error'); $field.closest('.elementor-field-group').append(`${message}
`); } /* 4. SUCCESS & DOWNLOAD (With Lock) */ $(document).on('submit_success', function (event) { // Ensure it's the right form AND we aren't already downloading if ($(event.target).closest(formWrap).length > 0 && !isDownloading) { isDownloading = true; // Set the lock console.log('Form Success - Downloading PDF'); const link = document.createElement('a'); link.href = pdfURL; link.download = 'AI-Pharma-Drug.pdf'; link.target = '_blank'; document.body.appendChild(link); link.click(); document.body.removeChild(link); // Reset and release lock after 3 seconds setTimeout(() => { $(`${formWrap} .elementor-field-group`).removeClass('floating-active'); forceCheckbox(); isDownloading = false; // Release the lock }, 3000); } }); // Final Init setTimeout(() => { $(`${formWrap} .elementor-field`).each(function () { toggleFloating($(this)); }); }, 500); });
Get in touch
First Name
Last Name
Email
Phone Number
Company
Designation
Enquiry Type
Enquiry Type Request for Zifo Services Product Partnership Job/Internship/Placement Enquiry Other
Message
Acceptance I consent to being contacted by an official Zifo representative
Submit
---
### [Food & Beverage](https://zifo.com/industries/food-and-beverage-informatics-and-consulting-services/)
**Published:** December 22, 2025
**Author:** Zifo_user
**Content:**
[Home](https://zifo.com "Home")> [Industries](https://zifo.com/industries/ "Industries")> Food & Beverage
Food & Beverage
Drive Market Speed via
Verified Safety
[ Connect With Us ](#)
Safety and
Traceability
Nutritional
Quality
Supply Chain Efficiency
and Resilience
Speed to Market
and Shorter Time to Revenue
Leverage AI and Data Standardisation at Every Level of
Your Scientific Informatics Process Workflow
AI-Native Ecosystem
# Value Chain
All Stages
Research
Development
Manufacturing
## Full Value Chain View
All Platforms Informatics Data Specialist
Expand All
### Research
Concept Development Experiment Capture - ELN
Sample Management - LIMS
Data Informatics
Data Standarizaton and Analytics
No filter data found
Active Ingredient Discovery Experiment Capture - ELN
Sample Management - LIMS
Chromatography Data Management - CDS
Lab experiment execution - LES
Analytical & Scientific data management - SDMS
Visualisation & Dashboarding
Lab Robotics & Automation
Data Informatics
Data Standarizaton and Analytics
Simulation and Modelling
No filter data found
### Development
Formulation Experiment Capture - ELN
Sample Management - LIMS
Chromatography Data Management - CDS
Visualisation & Dashboarding
Lab Robotics & Automation
Data Informatics
Data Standarizaton and Analytics
Simulation and Modelling
No filter data found
Product Evaluation Experiment Capture - ELN
Sample Management - LIMS
Lab experiment execution - LES
Analytical & Scientific data management - SDMS
Visualisation & Dashboarding
Lab Robotics & Automation
Data Informatics
Data Standarizaton and Analytics
Simulation and Modelling
No filter data found
Process development Experiment Capture - ELN
Sample Management - LIMS
Chromatography Data Management - CDS
Lab experiment execution - LES
Analytical & Scientific data management - SDMS
Visualisation & Dashboarding
Lab Robotics & Automation
Process Historians / RT Data systems
Quality Management Systems
Data Informatics
Data Standarizaton and Analytics
Simulation and Modelling
No filter data found
Analytical Development Experiment Capture - ELN
Sample Management - LIMS
Chromatography Data Management - CDS
Lab experiment execution - LES
Analytical & Scientific data management - SDMS
Visualisation & Dashboarding
Lab Robotics & Automation
Process Historians / RT Data systems
Quality Management Systems
Data Informatics
Data Standarizaton and Analytics
Simulation and Modelling
No filter data found
Stability & Shelf Life Testing Sample Management - LIMS
Chromatography Data Management - CDS
Lab experiment execution - LES
Analytical & Scientific data management - SDMS
Visualisation & Dashboarding
Lab Robotics & Automation
Process Historians / RT Data systems
Quality Management Systems
Data Informatics
Data Standarizaton and Analytics
Simulation and Modelling
No filter data found
### Manufacturing
Pilot & Scale Up Sample Management - LIMS
Chromatography Data Management - CDS
Lab experiment execution - LES
Analytical & Scientific data management - SDMS
Visualisation & Dashboarding
Lab Robotics & Automation
Process Historians / RT Data systems
Quality Management Systems
Data Informatics
Data Standarizaton and Analytics
Simulation and Modelling
No filter data found
Analytical QC & Batch Release Sample Management - LIMS
Chromatography Data Management - CDS
Lab experiment execution - LES
Analytical & Scientific data management - SDMS
Visualisation & Dashboarding
Lab Robotics & Automation
Process Historians / RT Data systems
Quality Management Systems
Data Informatics
Data Standarizaton and Analytics
Simulation and Modelling
No filter data found
## Platforms - Applicable Across the Value Chain
Enterprise Infrastructure (IaaS)
- AWS
- AZURE
- Google
- HPC
- ML/AIOps
- DevOps
- ClinOps
- Nvidia
AI Platforms
- Microsoft Discovery
- Gemini
- OpenAI
- Anthropic
- Bedrock AgentCore
Enterprise Resource Planning (ERP)
- SAP
- Oracle
Manufacturing Execution System (MES)
- Rockwell
- Siemens
- Honeywell
[ Contact Us ](#)
## Case Files
## Case file 001
## Transforming Biologics CMC Data From Fragmented to Future-Ready
[ Download Now ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjMyMzMzIiwidG9nZ2xlIjpmYWxzZX0%3D)
'); } else { $cb.removeClass('error'); } }); /* 2. FLOATING LABELS */ function toggleFloating($input) { const $group = $input.closest('.elementor-field-group'); if ($input.val().trim() || $input.is(':focus')) { $group.addClass('floating-active'); } else { $group.removeClass('floating-active'); } } $(document).on('focus input blur', `${formWrap} input.elementor-field`, function () { toggleFloating($(this)); }); /* 3. SUBMIT VALIDATION */ $(document).on('click', `${formWrap} button[type="submit"]`, function (e) { let isValid = true; const $form = $(this).closest('form'); $form.find('.error-message').remove(); $form.find('.error').removeClass('error'); $form.find('input[required], input[type="email"]').each(function() { const $field = $(this); const val = $field.val().trim(); if (!val) { showError($field, 'Please fill this field.'); isValid = false; } else if ($field.attr('type') === 'email' && !/^[^\s@]+@[^\s@]+\.[^\s@]+$/.test(val)) { showError($field, 'Enter a valid email address.'); isValid = false; } }); const $cb = $form.find('input[type="checkbox"]'); if (!$cb.is(':checked')) { $cb.addClass('error'); $cb.closest('.elementor-field-subgroup').after('Please fill this field.
'); isValid = false; } if (!isValid) { e.preventDefault(); e.stopImmediatePropagation(); const $firstError = $form.find('.error').first(); if($firstError.length) { $('html, body').animate({ scrollTop: $firstError.offset().top - 120 }, 500); } } }); function showError($field, message) { $field.addClass('error'); $field.closest('.elementor-field-group').append(`${message}
`); } /* 4. SUCCESS & DOWNLOAD (With Lock) */ $(document).on('submit_success', function (event) { // Ensure it's the right form AND we aren't already downloading if ($(event.target).closest(formWrap).length > 0 && !isDownloading) { isDownloading = true; // Set the lock console.log('Form Success - Downloading PDF'); const link = document.createElement('a'); link.href = pdfURL; link.download = 'AI-Pharma-Drug.pdf'; link.target = '_blank'; document.body.appendChild(link); link.click(); document.body.removeChild(link); // Reset and release lock after 3 seconds setTimeout(() => { $(`${formWrap} .elementor-field-group`).removeClass('floating-active'); forceCheckbox(); isDownloading = false; // Release the lock }, 3000); } }); // Final Init setTimeout(() => { $(`${formWrap} .elementor-field`).each(function () { toggleFloating($(this)); }); }, 500); });
## Case file 002
## Transforming Biologics CMC Data From Fragmented to Future-Ready
[ Download Now ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjMyMzMzIiwidG9nZ2xlIjpmYWxzZX0%3D)
'); } else { $cb.removeClass('error'); } }); /* 2. FLOATING LABELS */ function toggleFloating($input) { const $group = $input.closest('.elementor-field-group'); if ($input.val().trim() || $input.is(':focus')) { $group.addClass('floating-active'); } else { $group.removeClass('floating-active'); } } $(document).on('focus input blur', `${formWrap} input.elementor-field`, function () { toggleFloating($(this)); }); /* 3. SUBMIT VALIDATION */ $(document).on('click', `${formWrap} button[type="submit"]`, function (e) { let isValid = true; const $form = $(this).closest('form'); $form.find('.error-message').remove(); $form.find('.error').removeClass('error'); $form.find('input[required], input[type="email"]').each(function() { const $field = $(this); const val = $field.val().trim(); if (!val) { showError($field, 'Please fill this field.'); isValid = false; } else if ($field.attr('type') === 'email' && !/^[^\s@]+@[^\s@]+\.[^\s@]+$/.test(val)) { showError($field, 'Enter a valid email address.'); isValid = false; } }); const $cb = $form.find('input[type="checkbox"]'); if (!$cb.is(':checked')) { $cb.addClass('error'); $cb.closest('.elementor-field-subgroup').after('Please fill this field.
'); isValid = false; } if (!isValid) { e.preventDefault(); e.stopImmediatePropagation(); const $firstError = $form.find('.error').first(); if($firstError.length) { $('html, body').animate({ scrollTop: $firstError.offset().top - 120 }, 500); } } }); function showError($field, message) { $field.addClass('error'); $field.closest('.elementor-field-group').append(`${message}
`); } /* 4. SUCCESS & DOWNLOAD (With Lock) */ $(document).on('submit_success', function (event) { // Ensure it's the right form AND we aren't already downloading if ($(event.target).closest(formWrap).length > 0 && !isDownloading) { isDownloading = true; // Set the lock console.log('Form Success - Downloading PDF'); const link = document.createElement('a'); link.href = pdfURL; link.download = 'AI-Pharma-Drug.pdf'; link.target = '_blank'; document.body.appendChild(link); link.click(); document.body.removeChild(link); // Reset and release lock after 3 seconds setTimeout(() => { $(`${formWrap} .elementor-field-group`).removeClass('floating-active'); forceCheckbox(); isDownloading = false; // Release the lock }, 3000); } }); // Final Init setTimeout(() => { $(`${formWrap} .elementor-field`).each(function () { toggleFloating($(this)); }); }, 500); });
## Case file 003
## Transforming Biologics CMC Data From Fragmented to Future-Ready
[ Download Now ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjMyMzMzIiwidG9nZ2xlIjpmYWxzZX0%3D)
'); } else { $cb.removeClass('error'); } }); /* 2. FLOATING LABELS */ function toggleFloating($input) { const $group = $input.closest('.elementor-field-group'); if ($input.val().trim() || $input.is(':focus')) { $group.addClass('floating-active'); } else { $group.removeClass('floating-active'); } } $(document).on('focus input blur', `${formWrap} input.elementor-field`, function () { toggleFloating($(this)); }); /* 3. SUBMIT VALIDATION */ $(document).on('click', `${formWrap} button[type="submit"]`, function (e) { let isValid = true; const $form = $(this).closest('form'); $form.find('.error-message').remove(); $form.find('.error').removeClass('error'); $form.find('input[required], input[type="email"]').each(function() { const $field = $(this); const val = $field.val().trim(); if (!val) { showError($field, 'Please fill this field.'); isValid = false; } else if ($field.attr('type') === 'email' && !/^[^\s@]+@[^\s@]+\.[^\s@]+$/.test(val)) { showError($field, 'Enter a valid email address.'); isValid = false; } }); const $cb = $form.find('input[type="checkbox"]'); if (!$cb.is(':checked')) { $cb.addClass('error'); $cb.closest('.elementor-field-subgroup').after('Please fill this field.
'); isValid = false; } if (!isValid) { e.preventDefault(); e.stopImmediatePropagation(); const $firstError = $form.find('.error').first(); if($firstError.length) { $('html, body').animate({ scrollTop: $firstError.offset().top - 120 }, 500); } } }); function showError($field, message) { $field.addClass('error'); $field.closest('.elementor-field-group').append(`${message}
`); } /* 4. SUCCESS & DOWNLOAD (With Lock) */ $(document).on('submit_success', function (event) { // Ensure it's the right form AND we aren't already downloading if ($(event.target).closest(formWrap).length > 0 && !isDownloading) { isDownloading = true; // Set the lock console.log('Form Success - Downloading PDF'); const link = document.createElement('a'); link.href = pdfURL; link.download = 'AI-Pharma-Drug.pdf'; link.target = '_blank'; document.body.appendChild(link); link.click(); document.body.removeChild(link); // Reset and release lock after 3 seconds setTimeout(() => { $(`${formWrap} .elementor-field-group`).removeClass('floating-active'); forceCheckbox(); isDownloading = false; // Release the lock }, 3000); } }); // Final Init setTimeout(() => { $(`${formWrap} .elementor-field`).each(function () { toggleFloating($(this)); }); }, 500); });
## Case file 004
## Transforming Biologics CMC Data From Fragmented to Future-Ready
[ Download Now ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjMyMzMzIiwidG9nZ2xlIjpmYWxzZX0%3D)
'); } else { $cb.removeClass('error'); } }); /* 2. FLOATING LABELS */ function toggleFloating($input) { const $group = $input.closest('.elementor-field-group'); if ($input.val().trim() || $input.is(':focus')) { $group.addClass('floating-active'); } else { $group.removeClass('floating-active'); } } $(document).on('focus input blur', `${formWrap} input.elementor-field`, function () { toggleFloating($(this)); }); /* 3. SUBMIT VALIDATION */ $(document).on('click', `${formWrap} button[type="submit"]`, function (e) { let isValid = true; const $form = $(this).closest('form'); $form.find('.error-message').remove(); $form.find('.error').removeClass('error'); $form.find('input[required], input[type="email"]').each(function() { const $field = $(this); const val = $field.val().trim(); if (!val) { showError($field, 'Please fill this field.'); isValid = false; } else if ($field.attr('type') === 'email' && !/^[^\s@]+@[^\s@]+\.[^\s@]+$/.test(val)) { showError($field, 'Enter a valid email address.'); isValid = false; } }); const $cb = $form.find('input[type="checkbox"]'); if (!$cb.is(':checked')) { $cb.addClass('error'); $cb.closest('.elementor-field-subgroup').after('Please fill this field.
'); isValid = false; } if (!isValid) { e.preventDefault(); e.stopImmediatePropagation(); const $firstError = $form.find('.error').first(); if($firstError.length) { $('html, body').animate({ scrollTop: $firstError.offset().top - 120 }, 500); } } }); function showError($field, message) { $field.addClass('error'); $field.closest('.elementor-field-group').append(`${message}
`); } /* 4. SUCCESS & DOWNLOAD (With Lock) */ $(document).on('submit_success', function (event) { // Ensure it's the right form AND we aren't already downloading if ($(event.target).closest(formWrap).length > 0 && !isDownloading) { isDownloading = true; // Set the lock console.log('Form Success - Downloading PDF'); const link = document.createElement('a'); link.href = pdfURL; link.download = 'AI-Pharma-Drug.pdf'; link.target = '_blank'; document.body.appendChild(link); link.click(); document.body.removeChild(link); // Reset and release lock after 3 seconds setTimeout(() => { $(`${formWrap} .elementor-field-group`).removeClass('floating-active'); forceCheckbox(); isDownloading = false; // Release the lock }, 3000); } }); // Final Init setTimeout(() => { $(`${formWrap} .elementor-field`).each(function () { toggleFloating($(this)); }); }, 500); });
Get in touch
First Name
Last Name
Email
Phone Number
Company
Designation
Enquiry Type
Enquiry Type Request for Zifo Services Product Partnership Job/Internship/Placement Enquiry Other
Message
Acceptance I consent to being contacted by an official Zifo representative
Submit
---
## Events
### [Pharma 4.0 in Practice: Building AI-Ready, Connected and Compliant Manufacturing](https://zifo.com/event/manufsummit2026/)
**Published:** September 9, 2026
**Author:** tina
**Excerpt:** Thank you for registering for our "Pharma 4.0 in Practice: Building AI-Ready, Connected and Compliant Manufacturing" event taking place in Durham, NC at the , October 15, 2026 at the North Carolina Biotechnology Center, 15 TW Alexander Dr, Durham, NC 27713.
Please check our website regularly for updates to our agenda https://zifo.com/event/manufsummit2026/
In the meantime, if you have any questions please contact tina@zifo.com
Kind regards
Your Zifo Team!
**Event Categories:** Zifo Event
---
### [From In Silico to Molecule to Medicine: Every AI Journey Starts with Connected Science](https://zifo.com/event/insilicotomol/)
**Published:** September 8, 2026
**Author:** tina
**Excerpt:** Thank you for registering for our "Happy Hour | From In Silico to Molecule to Medicine: Every AI Journey Starts with Connected Science" taking place in San Francisco, October 15, 2026 at the Foundry & Lux, 151 Oyster Point Blvd, South San Francisco, CA 94080.
Please check our website regularly for updates to our agenda https://zifo.com/event/insilicotomol/
In the meantime, if you have any questions please contact tina@zifo.com
Kind regards
Your Zifo Team!
**Event Categories:** Zifo Event
---
### [SiEE Basel 2026](https://zifo.com/event/siee-basel-2026-ondemand/)
**Published:** June 18, 2026
**Author:** Zifo_user
**Event Categories:** On Demand, Zifo Signature Event
---
### [SLAS 2027](https://zifo.com/event/slas-2027/)
**Published:** July 16, 2026
**Author:** tina
**Event Categories:** Industry Event
---
### [Scientific Informatics Experience Exchange (SiEE) | Boston April 13, 2027](https://zifo.com/event/siee-boston-2027/)
**Published:** July 31, 2026
**Author:** Zifo_user
**Excerpt:** Thank you for registering for our "2027 Scientific Informatics Experience Exchange" taking place in Boston on April 13 at the Kimpton Marlowe Hotel, 25 Edwin H Land Blvd, Cambridge, MA 02141.
Please check our website regularly for updates to our agenda https://zifo.com/event/siee-boston-2027/
In the meantime, if you have any questions please contact tina@zifornd.com
Kind regards
Your Zifo Team!
**Event Categories:** Zifo Signature Event
---
### [Scientific Informatics Experience Exchange (SiEE) | Basel June 1, 2027](https://zifo.com/event/siee-basel-2027/)
**Published:** July 31, 2026
**Author:** Zifo_user
**Excerpt:** Thank you for registering for our "2027 Scientific Informatics Experience Exchange" taking place in Basel, June 1 at the Movenpick Hotel Basel, Aeschengraben 25, 4051 Basel, Switzerland
Please check our website regularly for updates to our agenda https://zifo.com/event/siee-basel-2027/
In the meantime, if you have any questions please contact tina@zifo.com
Kind regards
Your Zifo Team!
**Event Categories:** Zifo Signature Event
---
### [REAL 2026: Readiness & Enablement for Automated Labs](https://zifo.com/event/real-2026-readiness-enablement-for-automated-labs/)
**Published:** July 23, 2026
**Author:** Zifo_user
**Event Categories:** Industry Event
---
### [BioTechX EMEA](https://zifo.com/event/biotechx-emea/)
**Published:** March 12, 2026
**Author:** tina
**Event Categories:** Industry Event
---
### [BioTechX USA](https://zifo.com/event/biotechx-usa-3/)
**Published:** February 13, 2026
**Author:** Zifo_user
**Event Categories:** Industry Event
---
### [Biomarkers, CDx & Precision Medicine](https://zifo.com/event/biomarkers-cdx-precision-medicine/)
**Published:** July 15, 2026
**Author:** tina
**Event Categories:** Industry Event
---
### [Paperless Lab Academy | India 2027](https://zifo.com/event/paperless-lab-academy-india-2025/)
**Published:** February 13, 2026
**Author:** Zifo_user
**Event Categories:** Industry Event
---
### [Pharma Omics & AI](https://zifo.com/event/pharma-omics-ai/)
**Published:** July 16, 2026
**Author:** tina
**Event Categories:** Industry Event
---
### [2026 ISPE Annual Meeting & Expo](https://zifo.com/event/2026-ispe-annual-meeting-expo/)
**Published:** July 15, 2026
**Author:** tina
**Event Categories:** Industry Event
---
### [CSV & CSA University](https://zifo.com/event/csv-csa-university/)
**Published:** July 16, 2026
**Author:** tina
**Event Categories:** Industry Event
---
### [AiDDD Summit](https://zifo.com/event/aiddd-summit/)
**Published:** July 16, 2026
**Author:** tina
**Event Categories:** Industry Event
---
### [From AI Promise to Real Impact in R&D](https://zifo.com/event/zifo_revvity_lunch_learn_paris/)
**Published:** May 11, 2026
**Author:** Zifo_user
**Excerpt:** Thank you for registering for our "Zifo - Revvity Signals Lunch & Learn" taking place in Paris on July 7.
Please check our website regularly for updates to our agenda https://zifo.com/event/Zifo_Revvity_Lunch_Learn_Paris/
In the meantime, if you have any questions please contact tina@zifornd.com
Kind regards
Your Zifo Team!
**Event Categories:** Zifo Event
---
### [Passer de la promesse de l’IA à un levier réel en R&D](https://zifo.com/event/passer-de-la-promesse-de-lia-a-un-levier-reel-en-rd/)
**Published:** May 27, 2026
**Author:** Zifo_user
**Excerpt:** Merci de vous être inscrit à notre déjeuner-conférence "Zifo - Revvity Signals" qui aura lieu à Paris le 7 juillet.
Veuillez consulter régulièrement notre site web pour prendre connaissance des mises à jour de notre programme https://zifo.com/event/passer-de-la-promesse-de-lia-a-un-levier-reel-en-rd/
En attendant, si vous avez des questions, veuillez nous contacter tina@zifornd.com
Kind regards
Votre équipe Zifo !
**Event Categories:** Zifo Event
---
### [Lab of the Future EMEA | 2026](https://zifo.com/event/lab-of-the-future-emea-2026/)
**Published:** March 12, 2026
**Author:** tina
**Event Categories:** Industry Event
---
### [Benchtalk EU](https://zifo.com/event/benchtalk-eu/)
**Published:** July 16, 2026
**Author:** tina
**Event Categories:** Industry Event
---
### [Veeva R&D Summit US](https://zifo.com/event/veeva-rd-summit/)
**Published:** July 15, 2026
**Author:** tina
**Event Categories:** Industry Event
---
### [Benchtalk US](https://zifo.com/event/benchtalk-us/)
**Published:** July 15, 2026
**Author:** tina
**Event Categories:** Industry Event
---
### [Bioprocessing Summit](https://zifo.com/event/bioprocessing-summit/)
**Published:** April 22, 2026
**Author:** tina
**Event Categories:** Industry Event
---
### [Harness the Power of AI in GxP East](https://zifo.com/event/harness-the-power-of-ai-in-gxp-east/)
**Published:** July 15, 2026
**Author:** tina
**Event Categories:** Industry Event
---
### [SiEE Boston 2026](https://zifo.com/event/siee-boston-2026-ondemand/)
**Published:** April 22, 2026
**Author:** Zifo_user
**Tags:** Featured Event
**Event Categories:** On Demand, Zifo Signature Event
---
### [SiEE Boston 2023](https://zifo.com/event/siee-2023/)
**Published:** February 11, 2026
**Author:** Zifo_user
**Event Categories:** On Demand, Zifo Signature Event
---
### [SiEE San Francisco 2023](https://zifo.com/event/siee-san-francisco/)
**Published:** February 11, 2026
**Author:** Zifo_user
**Event Categories:** On Demand, Zifo Signature Event
---
### [SiEE Basel 2024](https://zifo.com/event/siee-2024-basel/)
**Published:** February 3, 2026
**Author:** Zifo_user
**Event Categories:** On Demand, Zifo Signature Event
---
### [SiEE Boston 2024](https://zifo.com/event/siee-2024-on-demand-boston-oct-16/)
**Published:** February 9, 2026
**Author:** Zifo_user
**Event Categories:** On Demand, Zifo Signature Event
---
### [Manufacturing Summit 2025](https://zifo.com/event/manufacturing-summit-2025/)
**Published:** February 11, 2026
**Author:** Zifo_user
**Event Categories:** On Demand, Zifo Signature Event
---
### [SiEE Basel 2025](https://zifo.com/event/siee-2025on-demand-basel/)
**Published:** February 11, 2026
**Author:** Zifo_user
**Event Categories:** On Demand, Zifo Signature Event
---
### [Future Labs Live | EMEA](https://zifo.com/event/future-labs-live-emea/)
**Published:** March 12, 2026
**Author:** tina
**Event Categories:** Industry Event
---
### [BioIT World](https://zifo.com/event/bioit-world/)
**Published:** April 22, 2026
**Author:** tina
**Event Categories:** Industry Event
---
### [London Labs Live | EMEA](https://zifo.com/event/london-labs-live-emea/)
**Published:** March 12, 2026
**Author:** tina
**Event Categories:** Industry Event
---
### [SmartLab USA](https://zifo.com/event/smartlab-usa/)
**Published:** February 13, 2026
**Author:** Zifo_user
**Event Categories:** Industry Event
---
### [Practical AI for Science Leaders: Platforms, Data, and Real Outcomes](https://zifo.com/event/zifo-sapio-sciences-lunch-learn-hamburg/)
**Published:** February 24, 2026
**Author:** Zifo_user
**Excerpt:** Thank you for registering for our "Zifo - Sapio Sciences Lunch & Learn, Hamburg" taking place in Hamburg on April 23 at the Hamburg, Germany.
Please check our website regularly for updates to our agenda https://zifo.com/event/zifo-sapio-sciences-lunch-learn-hamburg/
In the meantime, if you have any questions please contact tina@zifornd.com
Kind regards
Your Zifo Team!
**Event Categories:** Zifo Event
---
### [Lab of the Future USA | 2026](https://zifo.com/event/lab-of-the-future-usa-2026/)
**Published:** February 13, 2026
**Author:** Zifo_user
**Event Categories:** Industry Event
---
### [2026 BPD Cell and Gene Therapy Symposium](https://zifo.com/event/2026-bpd-cell-and-gene-therapy-symposium/)
**Published:** March 12, 2026
**Author:** tina
**Event Categories:** Industry Event
---
### [SLAS 2026 International Conference & Exhibition](https://zifo.com/event/slas-2026-international-conference-exhibition/)
**Published:** February 9, 2026
**Author:** Zifo_user
**Event Categories:** Industry Event
---
### [Analytica 2026 | Germany](https://zifo.com/event/analytica-2026-germany/)
**Published:** February 13, 2026
**Author:** Zifo_user
**Event Categories:** Industry Event
---